<SEC-DOCUMENT>0001493152-21-031510.txt : 20211215
<SEC-HEADER>0001493152-21-031510.hdr.sgml : 20211215
<ACCEPTANCE-DATETIME>20211215112553
ACCESSION NUMBER:		0001493152-21-031510
CONFORMED SUBMISSION TYPE:	424B1
PUBLIC DOCUMENT COUNT:		21
FILED AS OF DATE:		20211215
DATE AS OF CHANGE:		20211215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genenta Science S.p.A.
		CENTRAL INDEX KEY:			0001838716
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L6

	FILING VALUES:
		FORM TYPE:		424B1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-260923
		FILM NUMBER:		211493505

	BUSINESS ADDRESS:	
		STREET 1:		OLGETTINA, NO. 58
		CITY:			MILAN
		STATE:			L6
		ZIP:			20132
		BUSINESS PHONE:		39-02-2643-6639

	MAIL ADDRESS:	
		STREET 1:		OLGETTINA, NO. 58
		CITY:			MILAN
		STATE:			L6
		ZIP:			20132

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Genenta Science S.r.l.
		DATE OF NAME CHANGE:	20210104
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B1
<SEQUENCE>1
<FILENAME>form424b1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 12pt Georgia; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: bold 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: red"><P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Filed
                                            Pursuant to Rule 424(b)(1) <BR>
                                            File No. 333-260923</B></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>333-261653</B></P>



<P STYLE="font: bold 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: red"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">PROSPECTUS</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: red">&nbsp;</P>

<P STYLE="font: bold 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt">3,120,114
</FONT><FONT STYLE="font-size: 14pt">Ordinary Shares</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: red"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 12pt Georgia"><B><IMG SRC="logo_001.jpg" ALT="" STYLE="height: 113px; width: 500px"></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 14pt"><B>(Including 2,400,000
Ordinary Shares in the Form of American Depositary Shares)</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 1.5in"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">This is a public offering of 3,120,114 ordinary
shares with no par value, or ordinary shares, of Genenta S.p.A., which consists of (i) an initial public offering of 2,400,000
ordinary shares in the form of American Depositary Shares, or ADSs, each representing one of our ordinary shares, which we refer to as
the &ldquo;ADS offering,&rdquo; and (ii) a concurrent offering of 720,114 ordinary shares exclusively offered to existing shareholders
in Italy, as a mitigant for the exclusion of pre-emptive rights as resolved by the general shareholders meeting of the company in accordance
with Italian corporate law and our by-laws, which we refer to as the &ldquo;Reserved Offering&rdquo;. We refer in this prospectus to
the ADS offering and the Reserved Offering collectively as the &ldquo;offering.&rdquo; Ordinary shares may be offered directly or in
the form of ADSs, which likewise may be evidenced by American Depositary Receipts, or ADRs.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">No
public market currently exists for the ADSs or ordinary shares. We refer to the ADSs,
including the underlying ordinary shares and the ordinary shares being offered hereby, collectively, as the &ldquo;securities.&rdquo;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
</FONT><FONT STYLE="font: 10pt Georgia">ADSs have been approved for listing on the Nasdaq Capital Market, or Nasdaq, under
the symbol &ldquo;GNTA,&rdquo; subject to official notice of issuance.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; and a &ldquo;foreign private issuer&rdquo; under applicable U.S. federal securities
laws and are eligible for reduced public company reporting requirements. See &ldquo;Prospectus Summary&mdash;Implications of Being
an Emerging Growth Company&rdquo; and &ldquo;Prospectus Summary&mdash;Implications of Being a Foreign Private Issuer&rdquo; for
additional information.</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 1.5in"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Investing
in our securities involves a high degree of risk, including the risk of losing your entire investment. See &ldquo;Risk Factors&rdquo;
beginning on page 12 of this prospectus for a discussion of information that should be considered in connection with an investment
in our securities.</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Neither
the Securities and Exchange Commission nor any state or foreign securities commission has approved or disapproved of these securities
or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 1.5in"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Georgia, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Georgia, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Georgia, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Per security</TD><TD STYLE="font: bold 10pt Georgia, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Georgia, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Georgia, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="font: bold 10pt Georgia, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Georgia, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia, Times, Serif; width: 64%; text-align: left">Initial public offering price of ADSs - ADS
    Offering</TD><TD STYLE="font: 10pt Georgia, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Georgia, Times, Serif; width: 14%; text-align: right">11.50</TD><TD STYLE="font: 10pt Georgia, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Georgia, Times, Serif; width: 14%; text-align: right">27,600,000</TD><TD STYLE="font: 10pt Georgia, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Georgia, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Georgia, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">Offering price of ordinary shares - Reserved Offering (1)</TD><TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: right">11.50</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: right">8,281,311</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Georgia, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Georgia, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">Total offering proceeds to us (before expenses, underwriting
    discounts and commissions, and advisory fees)</TD><TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: right">35,881,311</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Georgia, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Georgia, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">Underwriting discounts and commissions on ADSs (1)</TD><TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: right">0.805</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: right">1,932,000</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Georgia, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Georgia, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">Total offering proceeds to us (before expenses and advisory
    fees)(2)</TD><TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: right">33,949,311</TD><TD STYLE="font: 10pt Georgia, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: bold 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt; width: 2in"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 8pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 8pt Georgia; vertical-align: top">
<TD STYLE="font: 8pt Georgia; width: 0"></TD><TD STYLE="font: 8pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 8pt"><SUB>(1)</SUB></FONT></TD><TD STYLE="font: 8pt Georgia; text-align: left"><P STYLE="font: 8pt Georgia, Times, Serif; margin: 0">We have agreed to reimburse the underwriters for certain expenses. Underwriting
discounts and commissions at a reduced rate apply to certain investors. See &ldquo;Underwriting&rdquo; beginning on page 191 of this
prospectus for additional disclosure regarding underwriter compensation and offering expenses.</P>
<FONT STYLE="font: 8pt Georgia"></FONT></TD></TR><TR STYLE="font: 8pt Georgia; vertical-align: top">
<TD STYLE="font: 8pt Georgia">&nbsp;</TD><TD STYLE="font: 8pt Georgia">&nbsp;</TD><TD STYLE="font: 8pt Georgia; text-align: left">&nbsp;</TD></TR>
                                                 <TR STYLE="font: 8pt Georgia; vertical-align: top">
<TD STYLE="font: 8pt Georgia">&nbsp;</TD><TD STYLE="font: 8pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 8pt"><SUB>(2)</SUB></FONT></TD><TD STYLE="font: 8pt Georgia; text-align: left">Certain
                                            of our existing shareholders in Italy are expected to purchase ordinary shares directly from
                                            us concurrently with the closing of this offering for which we will not incur any underwriting
                                            discount or commission but will owe an advisory fee to the underwriters. See &ldquo;Underwriting&rdquo;
                                            beginning on page 191 of this prospectus for additional disclosure regarding underwriter
                                            compensation and offering expenses</TD></TR>
                                                 </TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have granted the underwriters an option for a period of 30 days from the date of this prospectus to purchase up to an additional 360,000
ADSs to cover over-allotments, if any.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Delivery
of the ADSs will be made on or about December 17,  2021, subject to customary closing conditions.</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Sole
</I></B></FONT><FONT STYLE="font: 10pt Georgia"><B><I>Book-Running Manager</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font-family: Georgia; vertical-align: top">
    <TD STYLE="font-family: Georgia; text-align: center; width: 100%"><FONT STYLE="font-family: Georgia; font-size: 18pt; background-color: white"><B>Roth
    Capital Partners</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><B><I>Lead Manager</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 18pt; background-color: white"><B>Maxim
    Group LLC</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Georgia"></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
date of this prospectus is December 15, 2021</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">TABLE
OF CONTENTS</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Georgia; width: 0.5in; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">Prospectus
    Summary</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Risk
    Factors</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">12</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">Cautionary
    Note Regarding Forward-Looking Statements</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">68</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">Use
    of Proceeds</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">70</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">Dividend
    Policy</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">72</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">Capitalization</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">73</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">Dilution</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">74</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><FONT STYLE="font-size: 10pt"><A HREF="#ar_001">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></FONT></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">76</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">Business</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">92</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#S_001"><FONT STYLE="font-size: 10pt">Management</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">137</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#S_002"><FONT STYLE="font-size: 10pt">Beneficial
    Ownership of Principal Shareholders and Management</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">146</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#S_003"><FONT STYLE="font-size: 10pt">Related
    Party Transactions</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">147</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#S_004"><FONT STYLE="font-size: 10pt">Description
    of Share Capital and Governing Documents</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">150</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Georgia"><A HREF="#c_021"><FONT STYLE="font-family: Georgia; font-size: 10pt">Description of American Depositary Shares</FONT></A></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">161</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#S_005"><FONT STYLE="font-size: 10pt">Comparison
    of Italian Law and Delaware Law</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">169</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#S_006"><FONT STYLE="font-size: 10pt">Taxation</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">184</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#S_007"><FONT STYLE="font-size: 10pt">Underwriting</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">191</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#S_008"><FONT STYLE="font-size: 10pt">Expenses</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">197</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#S_009"><FONT STYLE="font-size: 10pt">Legal
    Matters</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">197</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#S_010"><FONT STYLE="font-size: 10pt">Experts</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">197</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#S_011"><FONT STYLE="font-size: 10pt">Enforceability
    of Civil Liabilities</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">197</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia"><A HREF="#S_012"><FONT STYLE="font-size: 10pt">Where
    You Can Find Additional Information</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">198</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A HREF="#ab_001">Index
    of Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">F-1</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>You
should rely only on the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us
or to which we have referred you. We have not authorized anyone to provide you with information that is different. We are offering
to sell our securities, and seeking offers to buy our securities, only in jurisdictions where offers and sales are permitted.
The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this
prospectus or any sale of our securities.</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">For
investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering
or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in
the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the
distribution of this prospectus.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are organized under the laws of Italy and our registered office and domicile is located in Milan, Italy. Under the rules of the
U.S. Securities and Exchange Commission, or the SEC, we are currently eligible for treatment as a &ldquo;foreign private issuer.&rdquo;
As a foreign private issuer, we will not be required to file periodic reports and financial statements with the SEC as frequently
or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended,
or the Exchange Act. Moreover, the chairman of the Board, the CEO and most of our directors are not residents of the United States,
and all or a substantial portion of the assets of such persons are located outside the United States. As a result, it may not
be possible for investors to effect service of process within the United States upon us or upon such persons or to enforce against
them judgments obtained in U.S. courts, including judgments in actions predicated upon the civil liability provisions of the federal
securities laws of the United States. We have been advised by our Italian counsel that there is doubt as to the enforceability
in Italy of original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely
predicated upon the federal and state securities laws of the United States. See &ldquo;Enforceability of Civil Liabilities&rdquo;
in this prospectus for additional information.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In May 2021, we changed the legal form of our company
under Italian law (the &ldquo;Corporate Conversion&rdquo;) from a limited liability company (societ&agrave; a responsabilit&agrave;
limitata, or S.r.l.) to a joint stock company (societ&agrave; per azioni, or S.p.A.). Unless otherwise indicated or the context otherwise
requires, all references in this prospectus to the terms &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company&rdquo;
and &ldquo;Genenta&rdquo; refer to Genenta Science S.p.A. after the transformation of Genenta Science S.r.l. to an Italian joint
stock company.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">All
trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience,
the trademarks and trade names in this prospectus are referred to without the &reg; and &trade; symbols, but such references should
not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their
rights thereto. We do not intend the use or display of other companies&rsquo; trademarks and trade names to imply a relationship
with, or endorsement or sponsorship of us by, any other companies.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
reporting currency and functional currency is the Euro. Unless otherwise expressly stated or the context otherwise requires, references
in this prospectus to &ldquo;dollars,&rdquo; &ldquo;USD&rdquo; or &ldquo;$&rdquo; mean U.S. dollars, and references to &ldquo;euros,&rdquo;
&ldquo;EUR&rdquo; or &ldquo;&euro;&rdquo; are to the European Union euros. U.S. dollar translations of EUR amounts presented in this
prospectus were done on different dates in accordance with the date as of such entry in our books and are derived from our audited financial
statements included elsewhere in this prospectus. U.S. dollar translations of EUR amounts presented in this prospectus that are not derived
from our audited financial statements included elsewhere in this prospectus are translated using the rate of &euro; 1.00 to $1.1309,
based on the euro foreign exchange reference rate provided by the European Central Bank on December 14, 2021.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">This
prospectus includes statistical, market and industry data and forecasts which we obtained from publicly available information
and independent industry publications and reports that we believe to be reliable sources. These publicly available industry publications
and reports generally state that they obtain their information from sources that they believe to be reliable, but they do not
guarantee the accuracy or completeness of the information. Although we believe that these sources are reliable, we have not independently
verified the information contained in such publications.</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></P>

<DIV STYLE="font-family: Georgia; padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="a_001"></A>PROSPECTUS
SUMMARY</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>This
summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you
should consider before investing in our securities. Before you decide to invest in our securities, you should read the entire
prospectus carefully, including the &ldquo;Risk Factors&rdquo; section and the financial statements and related notes appearing
at the end of this prospectus.</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
Company</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment
of solid tumors. We have developed a novel biologic platform which involves the <I>ex-vivo</I> gene transfer of a therapeutic
candidate into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly to
the tumor by infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Our technology is designed to turn
TEMs, which normally have an affinity for and travel to tumors, into a &ldquo;Trojan Horse&rdquo; to counteract cancer progression
and to prevent tumor relapse. Our technology is not target dependent, and therefore we believe it can be used as a treatment for
a broad variety of cancers.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
technology incorporates the use of a lentiviral vector (LVV) that combines a therapeutic transgene sequence, or payload, with
our proprietary platform. Our proprietary platform consists of (i) the Tie-2 promoter, that drives transgene sequence transcription
specifically in TEMs, and (ii) miRNA-126 target sequences to downregulate transgene expression post-transcription in those cells
where the Tie-2 promoter is active and the miRNA-126 is present. We believe there are many advantages to our approach:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Trojan
                                         Horse Mechanism of Action (&ldquo;MoA&rdquo;):</I> We use and modify TEMs, a subpopulation
                                         of tumor-associated myeloid cells, known to be involved in tumor growth and in the inhibition
                                         of immune system response, to allow the immune system to recognize the tumor and to deliver
                                         to the cancer site a chosen therapeutic.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; padding-bottom: 10pt"></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Select
                                         Regulation of Transgene Expression: </I>Our selected control of the chosen therapeutic
                                         gene expression is designed to avoid off-target and systemic toxicity.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; padding-bottom: 10pt"></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Potential
                                            Long-Term Effect: </I>Through the use of hematopoietic stem cells, our candidate is
                                            designed to be a &ldquo;<I>living therapy</I>&rdquo; that has the potential to break the
                                            cancer-induced immune tolerance and to establish a competent immune surveillance throughout
                                            the life of the patient.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; padding-bottom: 10pt"></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Agnostic
                                         Response</I>: In contrast to antigen-restricted chimeric antigen receptor T cells
                                         (CAR-T), our platform is not restricted to a pre-selected tumor antigen, nor any one
                                         tumor type. As such, it may be applied to a broad number of solid tumors and cancer subtypes,
                                         thereby overcoming one of the central unresolved challenges of immune-oncology cancer
                                         therapies.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Our lead product candidate, Temferon, was developed using
our platform and carries an interferon-alpha (IFN-&alpha;) payload. IFN-&alpha; is a well-known therapeutic that was previously administered
intravenously for treatment of various cancers but is currently rarely used due to its systemic toxicity. The Temferon-modified TEMs
express the transgene payload, IFN-&alpha;, in the tumor microenvironment resulting in the breakdown of tumor induced immune-tolerance.
As a result, the immune system can recognize the tumor, respond, and inhibit tumor growth. Because Temferon delivers the IFN-&alpha;
payload directly to the tumor, we believe it will demonstrate clinical activity without the side effect profile of systemic delivery
of IFN-&alpha;. In preclinical cancer mouse models treated with Temferon, both direct (anti-angiogenic, pro-apoptotic) and indirect
(immune response) effects were observed.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We are currently developing Temferon for the treatment of
glioblastoma multiforme (GBM) in patients with GBM who have an unmethylated MGMT gene promoter (uMGMT-GBM). GBM is the most common malignant
primary brain tumor accounting for more than half of all central nervous system (CNS) cancers, and unmethylated MGMT promoter status
is identified in approximately 60% of GBM patients. Patients suffering from GBM have limited, non-curative treatment options. Although
these treatments may improve survival, the prognosis for GBM patients remains poor with a median overall survival (mOS) of approximately
13 to 15 months and only 5.5% of patients estimated to be alive five years after diagnosis. With no curative treatments available and
such poor prognosis for patients, there remains a large, unmet medical need. We chose GBM among our first targets for clinical development
after considering the medical need, the active role that TEMs have in GBM pathology, and the high number of newly diagnosed uMGMT-GBM
patients potentially interested in participating in our study. As a result, we believe GBM offers a good profile for our initial proof
of concept trial in humans. We are currently conducting a Phase 1/2a dose-escalation clinical trial with Temferon in newly diagnosed
uMGMT-GBM patients in Italy. We intend to complete patient enrollment by the second quarter of 2022 and to use the preliminary
results of our Phase 1/2a clinical trial to support a Clinical Trial Application to conduct in Europe a multicenter Phase 2 trial in
uMGMT-GBM, which we currently intend to conduct primarily in Italy. As of November 15<SUP>th</SUP>, 2021, we have administered
Temferon to a total of 15 patients in clinical trials. The preliminary results to date show that Temferon was generally well tolerated
with no dose limiting toxicities identified so far.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<DIV STYLE="font-family: Georgia; padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We also intend to develop Temferon for the treatment of other
solid tumor indications, and locally advanced hepatocellular carcinoma (HCC) and intra-hepatic cholangiocarcinoma (ICC) are two indications
under consideration. HCC and ICC are gastrointestinal (GI) cancers affecting the digestive system. HCC is a primary malignancy of
the liver that occurs predominantly in patients with underlying chronic liver disease and cirrhosis. ICC is a biliary tract cancer and
represents approximately 3% of all GI malignancies. The prognosis for patients with locally advanced HCC or ICC remains poor with few
therapeutic options which have limited clinical benefits. While we are considering development of Temferon for these liver indications
for similar reasons as GBM (i.e. the high unmet need, TEMs&rsquo; role in HCC and ICC pathology, and the number of newly diagnosed patients
potentially eligible for our study), we are also evaluating development of Temferon for other solid tumor indications. If HCC and
ICC will be selected, we intend to submit a Clinical Trial Application (CTA) for conducting a Phase 1/2a study of Temferon to the
Italian Medicines Agency (Agenzia Italiana del Farmaco, or AIFA), the public institution responsible for the regulatory activity of pharmaceuticals
in Italy.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In addition to our Temferon programs being developed in uMGMT-GBM patients, or other solid tumor indications such as HCC and ICC, we have exclusive option rights to
license (i) Temferon for the treatment of additional indications, and (ii) other drug candidates that are currently in the preclinical
stage of development both as standalone treatments and as combination therapies.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">AGC Biologics&rsquo; facility in Milan, Italy, will continue
manufacturing LVV and Temferon to support Genenta&rsquo;s trials. For further larger studies we may use AGC&rsquo;s
60,000 square meter cell and gene therapy manufacturing facility located in Longmont, Colorado (U.S.), which AGC purchased from Novartis
in July 2021 or another US-based CMO.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Research
and Development Pipeline</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
portfolio of clinical and preclinical <I>ex-vivo</I> autologous gene cancer therapies is based on our technology platform,
which was originally developed in our founders&rsquo; laboratories at Ospedale San Raffaele, or OSR. Through our collaboration
with OSR, we have worldwide commercial rights to Temferon for the treatment of GBM, HCC and ICC, as well as exclusive option rights
to license all of our other programs. Specifically, we retain exclusive option rights to license (i) any platform improvements,
including our second-generation technology, which includes developments to enable the on/off regulation of the therapeutic transgene,
(ii) products for additional indications that utilize our platform technology but use different transgene payloads, and (iii)
combinations of our platform with therapies in the immuno-oncology (IO) field, such as immune checkpoint inhibitors (ICI), CAR-T
cell therapies and T cell receptor (TCR) therapies.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<DIV STYLE="font-family: Georgia; padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
current pipeline, with clinical and preclinical stage programs, is summarized below:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="chart_001.jpg" ALT="" STYLE="height: 303px; width: 650px"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: center"><I>*Genenta has options/rights on IP derived from
preclinical data generated at SR-Tiget laboratories.</I></P>

<P STYLE="margin: 0; font: 12pt Georgia, Times, Serif"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Strategy</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We are developing novel cancer therapeutics using our
autologous <I>ex-vivo</I> gene therapy platform, to initially address the unmet medical needs of GBM patients and patients
suffering from another solid cancer indication such as HCC and ICC. Ultimately, we hope to broaden our platform to
treat a wide variety of cancers by pursuing the following strategies:</P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Advance
development of our leading clinical-stage product candidate, Temferon in the U.S. </I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We are currently conducting a Phase 1/2a dose-escalation study
to primarily evaluate the safety and tolerability of Temferon in up to 21 uMGMT-GBM patients, following radiotherapy treatment. In the
fourth quarter of 2022, we intend to file the regulatory package required to initiate in Europe a multicenter Phase 2
trial in uMGMT-GBM, which we currently intend to conduct primarily in Italy, to evaluate the safety and efficacy of Temferon in up to
27 uMGMT-GBM patients (both newly diagnosed and with progressive disease) who have an unmethylated MGMT promoter where we intend to measure
progression free survival (PFS) and overall survival (OS) as endpoints. In advance of our CTA submission and although it is not required
for our European trial, we submitted a pre-IND meeting request to the FDA and received written responses from the Agency regarding future
possible Phase 2 clinical studies and drug product manufacturing as part of our development of long-term strategies following our European
trial. There cannot be any assurance that such meetings will lead to clinical and manufacturing strategies in the US in the future, which
is dependent on feedback from the FDA and advice from key opinion leaders and US partnering clinical centers, as well as the availability
of financial and other resources.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Extend</I></B></FONT><FONT STYLE="font: 10pt Georgia"><B><I>
our product pipeline across multiple indications</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
intend to extend our product pipeline by:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Identifying
                                            additional indications suitable for Temferon. We are in the planning stages for a second
                                            study using Temferon in another solid tumor indication and locally advanced HCC and ICC are
                                            under consideration. The Istituto Superiore di Sanit&agrave; (ISS), an independent
                                            committee with oversight from the Italian Ministry of Health, must issue a positive opinion
                                            regarding our CTA before AIFA will approve it. In addition to these indications, we believe
                                            there may be additional cancer indications which actively recruit TEMs to proliferate for
                                            which Temferon may be a suitable therapy.</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Using
                                         our platform with different transgene payloads. </I>Our platform technology is designed
                                         to enable us to use different transgene payloads to potentially achieve therapeutic
                                         outcomes in selected cancer indications. We are currently conducting preclinical studies
                                         for two therapeutics using our platform with different payloads targeting solid
                                         tumors.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Developing
                                         a second-generation platform that enables the &ldquo;on-demand&rdquo; release of the
                                         transgene payload</I>. We intend to develop a second-generation technology platform that
                                         allows the drug products to be switched on to exert the therapeutic effects and switched
                                         off if they are no longer needed, or to mitigate toxicity. This technology may enable
                                         us to expand our treatment options to broader patient populations.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<DIV STYLE="font-family: Georgia; padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Exploring
                                         combination therapies. We will seek to enter into collaborations with other companies
                                         to explore combination studies of our therapeutics with other cancer therapies, such
                                         as ICI, CAR-T cell therapies and TCR therapies. We believe our product candidate, as
                                         a result of its MoA, has the potential to enhance the durability and efficacy
                                         of the existing therapies, thus abolishing the immune tolerance to the tumor.</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Exploiting
                                         in-licensing opportunities with OSR</I>. We intend to exploit in-licensing opportunities
                                         with OSR, a co-founding shareholder.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Develop
and maintain efficient manufacturing processes to support anticipated growth</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Currently, for Temferon manufacturing we rely on
AGC Biologics, a contract development and manufacturing organization (CDMO), at their cell and gene therapy facility located
in Milan (Italy). After the completion of our planned multicenter Phase 2 uMGMT- GBM study most likely to be conducted in Italy, to meet
our drug product supply needs for conducting larger trials we intend to enter into a supply agreement with a US-based CMO for the manufacturing
of our products. In July 2021 AGC Biologics purchased a 60,000 square meters cells and gene therapy manufacturing facility located in
Longmont, Colorado (U.S.).</P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Establish
a patient-centered infrastructure and strong relationships with key U.S. opinion leaders working in our disease area</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Since
cell and gene-based therapies are relatively new approaches in oncology, we intend to implement programs to improve
patient and physician education regarding the availability of gene therapy-based products for those cancers with a high unmet
medical need. To this end, we are discussing with Antonio Chiocca, MD, Professor Neurosurgeon-in-Chief and
Chairman, Department of Neurosurgery at Brigham and Women&rsquo;s Hospital in Boston, MA, Frederick Lang, MD,
Professor and Chairman of the Department of Neurosurgery at MD Anderson in Houston, TX, and David A. Reardon, MD,
Department of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Develop
opportunistic partnership(s) with pharmaceutical company(s)</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
may choose to partner with larger pharmaceutical companies whose core competencies and oncology strategies are in line with ours.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Our
Strengths </B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt; font-weight: normal"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We believe that our growing body of early clinical
data supporting the potential of our autologous <I>ex-vivo</I> gene therapy approach, coupled with our founders&rsquo;
expertise in the development, manufacturing and commercialization of gene and cell therapies, positions us well to provide potentially
transformative therapies through a single administration to patients suffering from a broad range of cancers. We believe our key
strengths include:</P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: normal 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Unique
                                         and valuable expertise.</I></B> We are conducting our clinical trials at OSR, a leading
                                         center for <I>ex-vivo</I> gene therapy for inherited diseases. OSR has treated more than
                                         121 patients worldwide (one of the highest number of patients treated with gene
                                         therapy for rare diseases in a research hospital) using an ex-vivo viral vector
                                         platform similar to the one we are developing for cancer treatment. Members of
                                         our executive leadership team have held senior positions at GSK, Merck, Annapurna-Adverum
                                         and other companies specializing in gene and cell therapies and rare diseases. We have
                                         partnered with academic institutions that are pioneers in autologous <I>ex-vivo</I> gene
                                         therapy and hold exclusive option rights to license additional patents and know-how to
                                         build our portfolio. Partnerships with leading academic institutions that are well recognized
                                         in the gene therapy field, such as SR-Tiget and OSR, are a core part of our research
                                         engine through which we are working to advance the clinical development of our product
                                         candidates and to identify new opportunities that we believe have comparably high probabilities
                                         of success in a preclinical setting. We believe our expertise, combined with our plan
                                         to leverage our relationships with leading academic institutions, will help expedite
                                         the commercialization of our lead clinical-stage product candidate and further expand
                                         our pipeline.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<DIV STYLE="font-family: Georgia; padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Deep
                                         pipeline with broad utility</I>.</B> We believe that the flexibility of our technology
                                         platform combined with our exclusive option rights to in-license additional programs,
                                         give us the ability to grow our pipeline by targeting a broad set of cancer diseases.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Durable
                                            therapeutic potential</I>.</B> <FONT STYLE="font-weight: normal">Preliminary interim clinical
                                            data collected from fifteen uMGMT- GBM patients following a single administration
                                            of Temferon displayed modified cells at 18 months, the last measured timepoint to date. </FONT></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Designed
                                            for tumor</I></B></FONT><FONT STYLE="font: 10pt Georgia"><B><I> restricted therapeutic
                                            payload delivery and release</I>.</B> <FONT STYLE="font-weight: normal">The design of our
                                            transgene expression cassette is intended to restrict payload expression to the tumor
                                            microenvironment. The local and tumor restricted therapeutic gene deployment approach is
                                            designed to focus the pleiotropic anti-tumor activities of the selected payload, by limiting
                                            the toxic manifestation that results from standard systemic administration of the payload.</FONT></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Agnostic
                                            approach.</I></B> <FONT STYLE="font-weight: normal">Our immune-gene therapy approach is designed
                                            to be a tumor-agnostic immunotherapy that does not rely on any specific target
                                            or tumor type, and we believe it could be successfully applied to a potentially broad range
                                            of cancers and immune contexts. </FONT></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt; font-weight: normal">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Solid
                                         tumors targeting.</I></B> <FONT STYLE="font-weight: normal">Our platform has the potential
                                         to efficiently target solid tumors. Solid tumors are difficult to treat, even by the
                                         most novel and leading-edge technologies such as ICIs and CAR-T cells. Our cellular carrier,
                                         TEMs, is spontaneously and actively recruited by growing tumors and is found in several
                                         human solid tumors, irrespective of location. </FONT></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Active
                                            and sustained tumor surveillance. </I></B>Our immune-gene therapy is designed to trigger
                                            the patient&rsquo;s own immune response that establishes an active immune surveillance. Our
                                            preclinical work, which used different cancer models (B-cell acute lymphoblastic leukemia
                                            - B-ALL and GBM), as well as preliminary data collected from our uMGMT-GBM patients
                                            suggests the occurrence of changes in the immune system.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Fine
                                            dose tuning.</I></B> Our platform holds promise to fine tune the dose to be administered
                                            based on individual patient characteristics.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Preliminary
                                         data indicate that our approach is feasible and well-tolerated.</I></B> Temferon has
                                         been well-tolerated in the limited number of patients treated to date. Our <I>ex-vivo
                                         </I>modification of the patient&rsquo;s own HSPCs and cryopreservation allow us to formulate
                                         the patient&rsquo;s drug product prior to administering the therapy.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>LVV
                                            as transgene payload delivery vehicles. </I></B>LVVs are particularly attractive for clinical
                                            applications due to their capacity to transfer large genes/payloads and their ability to
                                            efficiently transduce non-proliferating or slowly proliferating cells, such as hematopoietic
                                            stem and progenitor cells that allow a persistent gene expression in transduced cells. Moreover,
                                            LVVs have a potentially reduced risk of genotoxicity compared to gamma-retroviral
                                            vectors (gRV). A large number of patients have been treated both with other LVV gene
                                            therapy products approved for sale and with clinical-stage product candidates for rare diseases
                                            worldwide, and generally these therapies have been well tolerated. We believe that long-term
                                            extensive follow-up across multiple diseases, with vectors expressing different genes, demonstrates
                                            the potential safety of our LVV-based autologous <I>ex-vivo </I>gene therapy approach.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Applicability
                                         to a potentially large number of patients and indications</I></B>. We believe our autologous
                                         <I>ex-vivo</I> gene therapy approach has broad therapeutic potential across a large number
                                         of malignancies. The <I>ex-vivo</I> transduction of HSPCs allows for the potentially
                                         long-term production of a differentiated cellular carrier loaded with the therapeutic
                                         gene and the consequent distribution of the therapeutic payload throughout multiple organs
                                         and tissues containing solid tumors.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<DIV STYLE="font-family: Georgia; padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Company
History and Management Team</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
were founded in 2014 by San Raffaele Hospital (OSR) in Milan, a globally recognized premier research hospital for <I>ex-vivo </I>gene
therapy, with Pierluigi Paracchi (our CEO), Luigi Naldini (Chairman of our Executive Scientific Board) and Bernhard Gentner (a
member of our Executive Scientific Board), to develop potential ground-breaking cell and gene cancer therapies. We leverage
the vast experience in LVV technology of the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget). SR-Tiget, a joint venture
between OSR and Fondazione Telethon (Telethon), is a world leading cell and gene therapy research institution at the forefront
of developing therapies for rare diseases. SR-Tiget has a proven track record for successful collaborative clinical research programs
in <I>ex-vivo </I>gene therapy. Its research has resulted in a number of approved products, including Strimvelis, an <I>ex-vivo
</I>gammaretroviral vector-based gene therapy for adenosine deaminase severe combined immunodeficiency (ADA-SCID), and Libmeldy,
an <I>ex-vivo</I> gene therapy for the treatment of early-onset metachromatic leukodystrophy (MLD) patients, both marketed by
Orchard Therapeutics. Our platform was developed in the SR-Tiget laboratories of our founders, Prof. Naldini and Dr. Gentner,
and we hold exclusive rights and option rights, to certain intellectual property (IP) originating there.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Since
closing our first round of funding in May 2015, we have recruited a leading management team, established a manufacturing process
for our drug product candidate, completed preclinical activities (research and Good Laboratory Practice &ndash; GLP &ndash; grades),
engaged with Italian, European and U.S. Key Opinion Leaders (KOLs) to identify our clinical lead indications, and submitted our
first CTA (June 2018).</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt; font-weight: normal">Our
leadership team has a proven track record as biotech executives. Their expertise spans from finance and venture capital to medical
affairs, from scientific research to clinical drug product development and clinical trial management. For example, members of
our management team have been involved in the successful development of Ethical Oncology Science, which was acquired in 2013 for
over $400 million, and Strimvelis the first ever ex-vivo approved gene therapy product that was developed under the guidance
of Carlo Russo, our Chief Medical Officer and Head of Development (formerly Head of Development of R&amp;D Biopharm and Rare Disease
Units at GSK). Our management team members have played important roles in both large pharma companies such as Merck and GSK, and
biotech startups, such as Adverum, Annapurna, VaxInnate Corporation, OncoSec Medical, Biological Dynamics and GenMark Diagnostics.
We believe this multi-disciplinary competence, provides a unique blend for the development of innovative gene and cell therapy
products, and constitutes a fertile ground for alliances with industrial partners that could help us bring new therapies to patients.</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Risks
Associated with Our Business</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
business, and investing in our securities, are subject to numerous risks and uncertainties, as more fully described in the section
&ldquo;Risk Factors&rdquo; included elsewhere in this prospectus. You should read these risks before making a decision to invest
in our securities. If any of these risks actually occur, our business, financial condition or results of operations would likely
be materially adversely affected. In each case, the trading price of our securities would likely decline, and you may lose all
or part of your investment. The following is a summary of some of the principal risks we face:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
                                         have a limited operating history and have incurred significant losses since our inception.
                                         We have never generated revenue and will require significant additional funds, which
                                         may not be available on acceptable terms or at all. As a result, you could lose your
                                         entire investment.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
                                         lentiviral-based gene therapy product candidates are based on a novel technology that
                                         is in preliminary stages of evaluation, which makes it difficult to predict the
                                         time and cost of product candidate development or the likelihood of receiving required
                                         regulatory approvals. Our rights to the intellectual property underlying our novel technology
                                         derive solely from our license agreement with OSR and any failure to comply with the
                                         terms of such license agreement could have a material adverse effect on our intellectual
                                         property position and our ability to seek approval for and ultimately commercialize
                                         such product candidates.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Even
                                         if we do receive regulatory approvals for our product candidates, they may face commercialization
                                         issues from significantly larger oncology competitors, unfavorable pricing regulations
                                         or lack of acceptance by doctors, hospitals, patients and insurers. Our product candidates
                                         and the process for administering them may also cause undesirable side effects or have
                                         other properties that could delay or prevent their regulatory approval, limit their commercial
                                         potential or result in significant negative consequences following any potential marketing
                                         approval.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<DIV STYLE="font-family: Georgia; padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
                                         currently have very few employees and rely almost entirely on the efforts of third parties
                                         over which we have limited control and in certain cases are reliant on a sole supplier
                                         for our materials. Our contract research organizations, or CROs, may fail to observe
                                         the standards to which our studies must be conducted and our product candidates may not
                                         be approved as a result. Likewise, our contract manufacturing organizations, or
                                         CMOs, may not continue producing the needed materials for preclinical and clinical testing,
                                         whether as a result of their commitments to other customers or otherwise. Any failure
                                         of these third parties to meet our expectations would have a materially adverse effect
                                         on our product development efforts.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
                                         clinical trials for Temferon must be successful if we are to seek and obtain regulatory
                                         marketing application through the submission of a new Biological License Application
                                         (BLA) and marketing authorization application (MAA) with the U.S. Food and Drug Administration
                                         (FDA) and the European Medicines Agency (EMA), respectively. Advanced clinical trials
                                         are often not successful even if prior trials were successful, and even if we are able
                                         to conduct advanced clinical trials and those trials are successful, we may not obtain
                                         necessary regulatory approvals for Temferon or we may be unable to successfully commercialize
                                         our products even if we receive the necessary regulatory approvals.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
                                         ongoing COVID-19 pandemic could adversely impact our ongoing and planned clinical trials,
                                         operations and financial condition, and our overall generation of revenues may not succeed
                                         on the time frames we expect or at all.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
                                            Chief Executive Officer, directors and shareholders who own more than 5% of our outstanding
                                            ordinary shares before this offering currently own approximately 47.1% of our outstanding
                                            ordinary shares and will own approximately 39.03% of our ordinary shares upon the
                                            completion of this offering and will therefore be able to exert significant control over
                                            matters submitted to our shareholders for approval.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
                                         a public company following the conclusion of this offering, we will need to comply with
                                         extensive additional U.S. and Italian governmental and Nasdaq regulations, which will
                                         be expensive, and which will require significant management attention.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
                                         a company organized under the laws of Italy and whose shares are represented by ADSs,
                                         the rights of investors in the company following this offering will differ in several
                                         material respects from the rights of holders of shares of common stock of a US domestic
                                         company and may not afford investors the same protections.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Corporate
Information</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Genenta
was formed as an Italian limited liability company (societ&agrave; a responsabilit&agrave; limitata, or S.r.l.) in 2014. In May 2021,
we changed the legal form of our company under Italian law to a joint stock company (societ&agrave; per azioni, or S.p.A.).</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
principal executive offices are located at Via Olgettina No. 58, 20132 Milan, Italy. Our telephone number in Italy is +39.02.2643.6639.
Our website address is www.genenta.com. The information contained on, or that can be accessed through, our website is not part
of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Securities and Exchange Commission, or the SEC, also maintains an Internet website that contains reports, proxy and information
statements and other information regarding issuers that file electronically with the SEC. Our filings with the U.S. Securities
and Exchange Commission, or the SEC, will also be available to the public through the SEC&rsquo;s website at http://www.sec.gov.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<DIV STYLE="font-family: Georgia; padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Implications
of Being an &ldquo;Emerging Growth Company&rdquo;</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
qualify as an &ldquo;emerging growth company,&rdquo; as defined in Section 2(a) of the Securities Act of 1933, as amended, or
the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we are eligible
to, and intend to, take advantage of certain exemptions from various reporting requirements applicable to other public companies
that are otherwise applicable generally to public companies. These provisions include:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">only
                                         two years of audited financial statements in addition to any required unaudited interim
                                         financial statements with correspondingly reduced &ldquo;Management&rsquo;s Discussion
                                         and Analysis of Financial Condition and Results of Operations&rdquo; disclosure;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">reduced
                                         disclosure about our executive compensation arrangements;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">exemption
                                         from the auditor attestation requirement in the assessment of our internal control over
                                         financial reporting; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">an
                                         exemption from new or revised financial accounting standards until they would apply to
                                         private companies and from compliance with any new requirements adopted by the Public
                                         Company Accounting Oversight Board requiring mandatory audit firm rotation.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
could remain an &ldquo;emerging growth company&rdquo; for up to five years, or until the earliest of (a) the last day of the first
fiscal year in which our annual gross revenue exceeds $1.07 billion, (b) the date that we become a &ldquo;large accelerated filer&rdquo;
as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the
market value of our securities that is held by non-affiliates exceeds $700 million as of the last business day of our most recently
completed second fiscal quarter, or (c) the date on which we have issued more than $1 billion in nonconvertible debt during the
preceding three-year period. We may choose to take advantage of some but not all of these exemptions. We have taken advantage
of reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different from the
information you receive from other public companies in which you hold stock. We have elected to avail ourselves of the exemption
for the delayed adoption of certain accounting standards and, therefore, will not be subject to the same new or revised accounting
standards as other public companies that are not emerging growth companies.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Implications
of being a &ldquo;Foreign Private Issuer&rdquo;</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Upon
consummation of this offering, we will be subject to the information reporting requirements of the Exchange Act that are applicable
to &ldquo;foreign private issuers,&rdquo; and under those requirements we will file reports with the SEC. As a foreign private
issuer, we will not be subject to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange
Act, we will be subject to reporting obligations that, in certain respects, are less detailed and less frequent than those of
U.S. domestic reporting companies. For example, we will not be required to issue quarterly reports, proxy statements that comply
with the requirements applicable to U.S. domestic reporting companies, or individual executive compensation information that is
as detailed as that required of U.S. domestic reporting companies. We also will have four months after the end of each fiscal
year to file our annual report with the SEC and will not be required to file current reports as frequently or promptly as U.S.
domestic reporting companies. Our officers, directors and principal shareholders will be exempt from the requirements to report
transactions in our equity securities and from the short-swing profit liability provisions contained in Section 16 of the Exchange
Act. As a foreign private issuer, we will not be subject to the requirements of Regulation FD (Fair Disclosure) promulgated under
the Exchange Act. In addition, as a foreign private issuer, we will be permitted to follow certain home country corporate governance
practices instead of those otherwise required under the Nasdaq Stock Market rules for domestic U.S. issuers and will not be required
to be compliant with all Nasdaq Stock Market rules as of the date of our initial listing on Nasdaq as would domestic U.S. issuers
(see &ldquo;Risk Factors&mdash;Risks Related to this Offering and Ownership of Our Securities&rdquo;). These exemptions and leniencies
will reduce the frequency and scope of information and protections available to you in comparison to those applicable to a U.S.
domestic reporting company. We intend to take advantage of the exemptions available to us as a foreign private issuer during and
after the period we qualify as a </FONT>&ldquo;foreign private issuer.&rdquo;</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<DIV STYLE="font-family: Georgia; padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">THE
OFFERING</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 41%">Securities offered by us</TD>
    <TD STYLE="font: 10pt Georgia; width: 59%; text-align: left">3,120,114, including ADSs representing 2,400,000 ordinary
    shares</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Ordinary shares issued
    and outstanding prior to this offering</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">15,000,000</FONT><FONT STYLE="font: 10pt Georgia">
    ordinary shares</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Ordinary shares to
    be issued and outstanding after this offering</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left">18,120,114 ordinary shares (or 18,480,114 ordinary shares if the underwriters
    exercise their option to purchase additional ADSs within 30 days of the date of this prospectus from us in full) (includes ordinary
    shares represented by the ADSs)</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">Reserved Offering</P></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">At our request, 720,114
                                            ordinary shares covered by the registration statement of which this prospectus is part
                                            have been reserved for sale, at the initial public offering price, by the Company, directly
                                            or through agents, in the Reserved Offering to existing shareholders of the Company, as a
                                            mitigant for the exclusion of pre-emptive rights as resolved by the general shareholders
                                            meeting of the Company in accordance with Italian corporate law and our by-laws. The Reserved
                                            Offering will be effected in compliance with the laws of Italy, at the same price to investors
                                            as the offering of ADSs. We will receive the full proceeds from the Reserved Offering and
                                            will not pay any underwriting discounts or commissions with respect to ordinary shares that
                                            we sell in the Reserved Offering but have agreed to pay an advisory fee to the underwriters
                                            with respect to such sales. The offer and sale of ordinary shares in the Reserved Offering
                                            (i) is contingent upon the completion of the offering of ADSs and will commence and be consummated
                                            concurrently with such offering of ADSs, (ii) has been registered for purposes of the securities
                                            laws of the United States under the registration statement of which this prospectus is part,
                                            and (iii) is conducted in Italy under applicable exemptions from Italian and European regulations
                                            concerning prospectus.</P>
</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">The ADSs</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Each
                                   ADS represents one of our ordinary shares, with no par value. The ADSs may
                                   be evidenced by American Depositary Receipts, or ADRs. The depositary will hold in custody the ordinary
                                   shares underlying the ADSs and you will have the rights of an ADS holder as provided in the deposit
                                   agreement among us, the depositary and owners and holders of ADSs from time to time.</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">To better
        understand the terms of the ADSs, you should carefully read the &ldquo;Description of American Depository Shares&rdquo;
        section of this prospectus. We also encourage you to read the deposit agreement, which is incorporated by reference as an exhibit
        to the registration statement that includes this prospectus.</FONT></P></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Over-allotment option</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">We have granted to the underwriters
    an option exercisable for a period of 30 days after the date of this prospectus to purchase up to 360,000 additional ADSs
    from us solely to cover over-allotments, if any. If the underwriters exercise all or part of this option, it will purchase securities
    covered by the option at the public offering price per ADS, less the underwriting discounts and advisory fees. See &ldquo;Underwriting.&rdquo;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Use of proceeds</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
                                   estimate that the net proceeds from our issuance and sale of 3,120,114 securities in this offering
                                   will be approximately $32.3 million, and after deducting underwriting discounts and commissions
                                   and offering expenses payable by us. If the underwriters exercise the over-allotment option in full,
                                   we estimate that the net proceeds from this offering will be approximately $36.2 million, after
                                   deducting underwriting discounts and commissions and offering expenses payable by us. We currently
                                   expect to use the net proceeds from this offering:</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
        conduct a clinical trial in selected cancer patient populations;</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
        support the ongoing Temferon TEM-GBM 001 trial and its long term follow up;</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"></FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
        fund further preclinical research for the development of Temferon across broad cancer indications;</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
        fund Temferon manufacturing activities including LVV manufacturing, stability and process scalability studies,  and tech
        transfer activities; and</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;working
        capital and general corporate purposes.</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">See
        &ldquo;Use of Proceeds&rdquo; for additional information. See &ldquo;Use of Proceeds&rdquo; for additional
        information.</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<DIV STYLE="font-family: Georgia; padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 41%"><FONT STYLE="font-family: Georgia; font-size: 10pt">Depositary</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 59%; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
    Bank of New York Mellon</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Custodian</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The Bank of New York
    Mellon, as custodian, acting through an office located in the United Kingdom</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Proposed Nasdaq trading
    symbol and listing</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our</FONT><FONT STYLE="font: 10pt Georgia">
    ADSs have been approved for listing on the Nasdaq Capital Market under the symbol &ldquo;GNTA,&rdquo; subject to official
    notice of issuance.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Lock-up</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
    directors, executive officers, and certain shareholders have agreed with the underwriters not to offer for sale, issue, sell,
    contract to sell, pledge or otherwise dispose of any of our ordinary shares or securities convertible into ordinary shares
    for a period of 180 days following the date of this prospectus. See &ldquo;Underwriting.&rdquo;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Risk factors</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">You
    should read the &ldquo;Risk Factors&rdquo; section starting on page 12 of this prospectus for a discussion of factors to consider
    carefully before deciding to invest in our securities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">The number of our ordinary shares that are and will be outstanding
immediately before and after this offering as shown above is based on 15,000,000 ordinary shares, with no par value, outstanding as of
June 30, 2021, and excludes ordinary shares that are available for future issuance under our 2021-2025 Equity Incentive Plan.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Unless otherwise indicated, this prospectus reflects and assumes
no exercise by the underwriters of their over-allotment option or the warrants to purchase ADSs at an exercise price per share equal
to 125% of the initial public offering price per ADS or $14.375, that will be issued to the underwriters in connection with this offering
(the &ldquo;Underwriters&rsquo; Warrants&rdquo;).</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<DIV STYLE="font-family: Georgia; padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid"><P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">SUMMARY
FINANCIAL DATA</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We have derived the following summary statements of operations
data for the years ended December 31, 2020 and 2019, and the six months ended June 30, 2021 and 2020, and summary balance sheet
data as of June 30, 2021 from our audited and unaudited financial statements included elsewhere in this prospectus. Our
historical results are not necessarily indicative of the results that may be expected in the future. The following summary financial
data should be read in conjunction with &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
and our financial statements and related notes included elsewhere in this prospectus, and are qualified entirely by reference to such
financial statements.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Our financial statements included in this prospectus
are prepared and presented in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. </P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="text-indent: 0.5in; text-align: left; font: 12pt Georgia; margin: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; text-indent: 0.5in; text-align: left; margin: 0pt"><FONT STYLE="font: 12pt Georgia"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">Year Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">Six Months Ended</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">June 30,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">in Euros, except share data</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">(Unaudited)</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">Research and development expenses</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 11%; text-align: right">4,688,461</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 11%; text-align: right">3,702,982</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 11%; text-align: right">3,199,234</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 11%; text-align: right">2,072,129</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">901,765</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">921,520</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">842,236</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">404,885</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,590,226</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,624,502</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,041,470</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,477,014</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Loss from operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,590,226</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,624,502</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,041,470</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,477,014</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,966</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,331</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,679</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">559</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Foreign exchange loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,754</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,552</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,111</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,849</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,592,014</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,597,723</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,047,902</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,479,304</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Comprehensive loss:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right">(5,592,014</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right">(4,597,723</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right">(4,047,902</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right">(2,479,304</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Pro forma information (unaudited):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Pro forma net loss</TD><TD STYLE="padding-bottom: 2.5pt"></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(5,592,014</P></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt"></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(4,597,723</P></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,047,902</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,479,304</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Pro forma net loss per share - basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt"></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(0.38</P></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt"></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(0.36</P></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.27</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.17</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Weighted average pro forma number of shares outstanding - basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">14,539,534</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">12,651,158</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,772,610</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,420,904</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt; width: 2in"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Georgia">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 8pt"><SUB>(1)</SUB></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Georgia; font-size: 8pt">We have presented pro forma basic and diluted loss
    per share for the years ended December 31, 2020 and 2019 and the six months ended June 30, 2021 and 2020, which consists of
    our historical loss attributable to Genenta Science S.r.l., divided by the pro forma basic and diluted weighted average number of
    shares outstanding after giving effect to the Corporate Conversion. See Notes 2 and 10 to our interim financial statements
    and our Management Discussion and Analysis included elsewhere in this prospectus for additional information regarding the
    method used to calculate the pro forma basic and diluted loss per share and the pro forma weighted average number of shares used
    in the computation of the per share amounts. </FONT></TD></TR>
</TABLE>


<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia, Times, Serif; border-collapse: collapse; width: 90%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 8pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 8pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 8pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>As
    of<BR> June 30, 2021</B></FONT><P STYLE="font: 8pt Georgia, Times, Serif; margin: 0; text-align: center"></P> <P STYLE="margin: 0; font: 8pt Georgia, Times, Serif"><B>(Unaudited)</B></P> <FONT STYLE="font: 8pt Georgia"><B></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 8pt; font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">in Euros</TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Proforma </B></FONT><FONT STYLE="font: 8pt Georgia"><B></B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 8pt Georgia"><B>As Adjusted<SUP>(1)</SUP></B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Balance Sheet Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 16%; text-align: right">10,553,906</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 16%; text-align: right"><P STYLE="margin: 0">39,089,861</P></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,291,009</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,826,964</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total long-term liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,645</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,645</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,538,377</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(25,538,377</P></TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,601,054</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,137,009</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>













<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt; width: 2in"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">

<TR STYLE="font: 8pt Georgia; vertical-align: top">
<TD STYLE="text-align: left; font: 8pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 8pt"><SUB>(1)</SUB></FONT></TD><TD STYLE="font: 8pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 8pt">The
                                            as adjusted balance sheet data gives effect to the issuance and sale 3,120,114 securities,
                                            including ADSs, representing 2,400,000 ordinary shares, in this offering, after
                                            deducting the estimated underwriting discounts, estimated advisory fees and estimated offering
                                            expenses payable by us.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="a_002"></A>RISK
FACTORS</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>An
investment in our securities involves a high degree of risk. We operate in a dynamic and rapidly changing industry that involves
numerous risks and uncertainties. You should consider carefully the risks described below, as well as the financial or other information
included in this prospectus, including our financial statements and the related notes, before you decide to buy our securities.
The risks and uncertainties described below are not the only risks facing us. We may face additional risks and uncertainties not
currently known to us or that we currently deem to be immaterial. Any of the risks described below, and any such additional risks,
could materially adversely affect our business, financial condition or results of operations. In such case, you may lose all or
part of your original investment.</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Risks
Related to Our Financial Position and Capital Requirements</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
are a clinical-stage biopharmaceutical company with limited operating history, which may make it difficult for you to evaluate
the success of our business to date and to assess our future viability. </I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are an emerging biotechnology company with a limited operating history. Investment in biopharmaceutical product development is
highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product
candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially
viable. All of our product candidates are in early development and none have been approved for commercial sale. We have not demonstrated
an ability to successfully complete late-stage clinical trials, obtain regulatory approvals, manufacture our product candidates
at commercial scale or arrange for a third-party to do so on our behalf, conduct sales and marketing activities necessary for
successful commercialization, or obtain reimbursement in the countries of sale. We may encounter unforeseen expenses, difficulties,
complications, and delays in achieving our business objectives. Our short history as an operating company makes any assessment
of our future success or viability subject to significant uncertainty. If we do not address these risks successfully or are unable
to transition at some point from a company with a research and development focus to a company capable of supporting commercial
activities, then our business will be materially harmed.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
have incurred significant losses in every year since our inception. We expect to continue to incur losses over the next several
years and may never achieve or maintain profitability. </I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We have no products approved for commercial sale, have not
generated any revenue from commercial sales of our product candidates, and have incurred losses each year since our inception. Our losses
for the six months ended June 30, 2021 and 2020 were approximately &euro;4.0 million and &euro;2.5, respectively; and for the
years ended December 31, 2020 and 2019 were approximately &euro;5.6 million and &euro;4.6 million, respectively. As of June 30, 2021
and December 31, 2020, we had an accumulated deficit of approximately &euro;(25.5) million and &euro;(21.5) million, respectively.
Substantially all of our operating losses resulted from costs incurred in connection with our research and development activities,
including pre- and non-clinical development of our gene therapy product candidates, namely our leading product candidate Temferon, and
from general and administrative costs associated with our operations.</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
expect that it will be several years, if ever, before we have any product approved for commercial sale. We have funded our operations
to date primarily through proceeds from the private placement of ordinary shares to our founding shareholders. We expect to continue
to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will
increase substantially if, and as, we</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">continue
                                         the research and development of our gene therapy product candidates, including continuing
                                         and conducting preclinical studies and clinical trials of Temferon and conducting preclinical
                                         studies and clinical trials for any additional product candidates that we may pursue
                                         in the future;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="padding-bottom: 10pt; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">develop
                                         and obtain regulatory approval for registration studies for our current product candidate
                                         Temferon and any additional product candidates that we may pursue in the future;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">seek
                                         regulatory and marketing approvals for our product candidates that successfully complete
                                         clinical studies, if any, including obtaining orphan drug designation;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">establish
                                         a sales, marketing, and distribution infrastructure to commercialize any product candidates
                                         for which we may obtain marketing approval;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">industrialize
                                         our lentivirus <I>ex-vivo</I> gene therapy approach into a robust, scalable and, if approved,
                                         commercially viable process;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">maintain,
                                         protect, and expand our intellectual property portfolio;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">hire
                                         and retain qualified technical personnel, such as clinical, quality control, commercial
                                         and scientific personnel;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">expand
                                         our infrastructure and facilities to support our operations, including adding equipment
                                         and physical infrastructure to support our research and development; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">incur
                                         additional legal, accounting and other expenses associated with operating as a public
                                         company.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
have not generated revenue from product sales and may never be profitable.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with partners, to successfully
complete the development of, and obtain the regulatory approvals necessary to commercialize, our product candidates. We do not
anticipate generating revenues from product sales for the next several years, if ever, and our ability to do so depends heavily
on our success in many areas, including but not limited to:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">completing
                                         research and pre- and non-clinical development of our products candidates</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">seeking
                                         and obtaining regulatory and marketing approvals for product candidates for which we
                                         complete clinical studies, if any;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">establishing
                                         and maintaining supply and manufacturing processes and relationships with third parties
                                         that can provide adequate (in amount and quality) products and services, and at acceptable
                                         costs, to support clinical development and market demand for our product candidates,
                                         if marketing approval is received;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">negotiating
                                         favorable terms in any collaboration, licensing or other arrangements into which we may
                                         enter; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">obtaining
                                         market acceptance of our product candidates, if approved for marketing, as viable treatment
                                         options.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Even
if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant
costs associated with commercialization, with all associated risks and uncertainties. Therefore we cannot predict when, or if,
we will be able to achieve profitability. Additional clinical trials or delays in the initiation and completion of clinical trials
could cause our expenses to increase significantly and profitability to be further delayed.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital,
maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company
also could cause you to lose all or part of your investment.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><B><I>We will need additional capital in the future. Raising additional
capital by issuing securities may cause dilution to existing shareholders. Financing may not be available on acceptable
terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product candidate
development efforts or other operations. </I></B></P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font: 10pt Georgia"><B><I></I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
of June 30, 2021 and December 31, 2020, our cash and cash equivalents were approximately &euro;10.6 and &euro;15.5 million,
respectively. If we continue to use cash at our historical rates of use we will need significant additional financing, which we may
seek through a combination of private and public equity offerings, debt financings and collaboration, strategic alliance and licensing
arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership
interest will be diluted, and the terms of any such offerings may include liquidation or other preferences that may adversely affect
the then existing shareholders rights. Debt financing, if available, would result in increased fixed payment obligations, and we may
be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our
ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability
to conduct our business. If we raise additional funds through collaboration, strategic alliance or licensing arrangements with third
parties, we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable
to us. Even if we believe that we have sufficient funds for our current or future operating plans, we may seek additional capital if
market conditions are favorable or if we have specific strategic considerations.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
future funding requirements will depend on many factors, including but not limited to:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         scope, progress, results and costs of drug discovery, laboratory testing, pre- and non-clinical
                                         development and clinical trials for our product candidates, including Temferon;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         cost, timing and outcome of regulatory review of our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         costs of future activities, including product sales, marketing, manufacturing and distribution,
                                         for any of our product candidates for which we receive marketing approval;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         cost of preparing, filing and prosecuting patent and trademark applications, maintaining
                                         and enforcing our intellectual property rights and defending our intellectual property-related
                                         claims;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">any
                                         product liability or other lawsuits related to our products;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         expenses needed to attract and retain skilled personnel; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         costs associated with being a public company.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Any
additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability
to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available
in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings
or the rights of holders of our securities and the issuance of additional securities, whether equity or debt, by us, or the possibility
of such issuance, may cause the market price of our securities to decline.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more
of our research or development programs or the development or commercialization, if any, of any product candidates or be unable
to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our
business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Risks
Related to Product Development, Regulatory Approval and Commercialization</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Our
lentivirus ex-vivo gene transfer therapy product candidates are based on a novel technology, which makes it difficult to predict
the time and cost of product candidate development and likelihood of subsequently obtaining regulatory approval.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have concentrated our research and development efforts on our lentivirus <I>ex-vivo</I> gene transfer strategy approach, and our
future success is highly dependent upon our successful development of commercially viable gene therapy product candidates. There
can be no assurance that we will not experience problems or delays in developing new product candidates and that such problems
or delays will not cause unanticipated costs, or that any such development problems can be solved. Because lentivirus <I>ex-vivo
</I>gene transfer cell therapies represent a relatively new field of cellular immunotherapy and cancer treatment generally, developing
and commercializing our product candidates subjects us to a number of risks and challenges, including:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">obtaining
    regulatory approval for our product candidates, as the FDA, the EMA, the AIFA and other regulatory authorities have limited
    experience with lentivirus <I>ex-vivo</I> gene transfer therapies for cancer;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">developing
    and deploying consistent and reliable processes for engineering a patient&rsquo;s HSPCs <I>ex vivo </I>and infusing the engineered
    HSPCs back into the patient;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">sourcing
    clinical and, if approved, commercial supplies of the materials used to manufacture our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">developing
    programming modules with the desired properties, while avoiding adverse reactions;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">creating
    viral vectors capable of delivering multiple programming modules;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">developing
    a reliable and consistent <I>ex vivo</I> gene modification and manufacturing process;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">securing
    manufacturing capacity suitable for the manufacture of our product candidates in line with expanding enrollment in our clinical
    studies and our projected commercial requirements;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">minimizing
    and avoiding infection and contamination during production of product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">developing
    protocols for the safe administration of our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">educating
    medical personnel regarding our lentivirus <I>ex-vivo</I> gene transfer technologies and the potential side effect profile
    of each of our product candidates, such as potential adverse effects related to pyrexia and infections;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">establishing
    integrated solutions in collaboration with specialty treatment centers in order to reduce the burdens and complex logistics
    commonly associated with the administration of lentivirus <I>ex-vivo</I> gene transfer cell therapies;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">if
    and when we obtain any required regulatory approvals, establishing sales and marketing capabilities or partnerships to successfully
    launch and commercialize our product candidates and gaining market acceptance of a novel therapy; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    availability of coverage and adequate reimbursement from third-party payors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
may not be able to successfully develop our lentivirus <I>ex-vivo</I> gene transfer product candidates or our technology in a
manner that will yield products that are safe, effective, scalable or profitable. Additionally, because our technology involves
the genetic modification of patient cells <I>ex vivo</I>, we are subject to additional regulatory challenges and risks, including:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">regulatory
    requirements governing gene and cell therapy products have changed frequently and may continue to change in the future. To
    date, few CAR-T cell therapy products that involve the genetic modification of patient cells have been approved in the United
    States and/or the European Union, and no lentivirus <I>ex-vivo</I> gene transfer product candidates have been approved by
    any regulatory authority. In this regard, the European Commission has granted conditional marketing authorization for ZYNTEGLO;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">genetically
    modified products could lead to lymphoma, leukemia or other cancers, or other aberrantly functioning cells in the event of improper
    insertion of a gene sequence into a patient&rsquo;s chromosome, or due to other unknown causes;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">although
    our viral vectors are not able to replicate, there is a risk with the use of lentiviral vectors that they could lead to new
    or reactivated pathogenic strains of virus or other infectious diseases; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    FDA recommends a 15-year follow-up observation period for patients who receive treatment using gene therapies and guidance
    promulgated by the EMA requires a similar follow-up observation period for patients who receive cell therapeutic products,
    which has to be sufficient to observe the subjects for risks that may be due to the characteristics of the product, the nature
    and extent of the exposure, and the anticipated time of occurrence of delayed adverse reactions and could be as long as life-time,
    and we may need to adopt an observation period for our product candidates.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Moreover,
public perception and awareness of cell and gene therapy safety issues may adversely influence the willingness of subjects to
participate in clinical trials of our product candidates, or if approved, of physicians to prescribe our products. Physicians,
hospitals and third-party payors often are slow to adopt new products, technologies and treatment practices that require additional
upfront costs and training. Treatment centers may not be willing or able to devote the personnel and establish other infrastructure
required for the administration of lentivirus <I>ex-vivo</I> gene transfer cell therapies. Physicians may not be willing to undergo
training to adopt this novel and personalized therapy, may decide the therapy is too complex to adopt without appropriate training
and may choose not to administer the therapy. Based on these and other factors, hospitals and payors may decide that the benefits
of this new therapy do not or will not outweigh its costs.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Our
gene therapy product candidates and the process for administering our product candidates may cause undesirable side effects or
have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant
negative consequences following any potential marketing approval.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Following
treatment with our gene therapy product candidates, patients may experience changes in their health, including illnesses, injuries,
discomforts or a fatal outcome. It is possible that as we study and test Temferon or other product candidates in larger, longer
and more extensive clinical programs, or as use of our product candidates becomes more widespread if they receive regulatory approval,
illnesses, injuries, discomforts and other adverse events that were observed in earlier clinical trials, as well as conditions
that did not occur or went undetected in previous clinical trials, will be reported by patients. Gene therapies are also subject
to the potential risk that occurrence of adverse events will be delayed following administration of the gene therapy due to persistent
biological activity of the genetic material or other components of the vectors used to carry the genetic material. Many times,
additional safety risks, contraindications, drug interactions, adverse events and side effects are only detectable after investigational
products are tested in larger scale clinical trials or, in some cases, after they are made available to patients on a commercial
scale after approval. Moreover, as noted above the FDA generally requires a long-term follow-up of study subjects for potential
gene therapy-related adverse events for a 15-year period, including a minimum of five years of annual examinations followed by
ten years of annual queries, either in person or by questionnaire, of study subjects. If additional clinical experience indicates
that Temferon or any other product candidates or similar products developed by other companies has side effects or causes serious
or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate
has received regulatory approval, such approval may be revoked or limited.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif; text-indent: 0.5in">There have been several significant adverse side effects
in gene therapy treatments in the past, including reported cases of leukemia with the use of gammaretrovirus vector and patient deaths
in other clinical trials. There have been recent case reports of suspected unexpected serious adverse reactions (SUSARs) involving an
ex-vivo transduced lentivirus vector (LVV) gene therapy product, BlueBird Bio&rsquo;s elivaldogene autotemcel (&ldquo;Lenti-D&rdquo;),
involving two SUSARs for cases of acute myeloid leukemia (AML), and one case involving myelodysplastic syndrome.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif; text-indent: 0.5in">In July 2021, the European Medicines Agency&rsquo;s (EMA)
safety committee (Pharmacovigilance Risk Assessment Committee - PRAC) announced that there is no evidence the LVV used in both Lenti-D
and the EU-approved gene therapy Zynteglo spurred the AML cases.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif; text-indent: 0.5in">BlueBird Bio announced on August 9, 2021 that the SUSAR
involving myelodysplastic syndrome occurred in one patient treated with Lenti-D over a year previously, that this SUSAR &ldquo;is likely
mediated by Lenti-D lentiviral vector (LVV) insertion,&rdquo; and that &ldquo;[e]vidence currently available suggests that specific design
features of Lenti-D LVV likely contributed to this event.&rdquo; As a result of this SUSAR, the FDA has placed a clinical hold on BlueBird
Bio&rsquo;s Lenti-D phase 3 trial for cerebral adrenoleukodystrophy (CALD).</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Gene therapy is still a relatively new approach to disease
treatment and additional adverse side effects could develop. Possible adverse side effects that may occur with treatment with gene therapy
products include an immunologic reaction early after administration that could substantially limit the effectiveness of the treatment
or represent safety risks for patients. Another safety concern for gene therapies using viral vectors has been the possibility
of insertional mutagenesis by the vectors, leading to malignant transformation of transduced cells. While our lentivirus <I>ex-vivo </I>gene
transfer therapy approach is designed to avoid immunogenicity after administration, there can be no assurance that patients would not
create antibodies that may impair treatment. Our approach involves the use of integrating vectors which have the potential for genomic
disruption and therefore could interfere with other genes with adverse clinical effects. If any of our gene therapy product candidates
demonstrates adverse side effects, we may decide or be required to halt or delay clinical development of such product candidates.</P>
<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Potential
risks for gene therapy products can be identified, in addition to side effects caused by the product candidate itself, as part of the
entire process required for their manufacturing and administration. For Temferon manufacturing, each patient needs to be subjected to
a mobilization and harvesting process for hemapoietic stem progenitor cells (HSPCs) collection. This procedure is associated
with risks linked to the administration of mobilization agents. The conditioning regimen required for administering our product candidate
and the associated procedures can also cause adverse side effects. A gene therapy patient is generally administered with cytotoxic drugs
to remove stem cells from the bone marrow to create sufficient space for the modified stem cells to engraft and produce their progeny.
This procedure compromises the patient&rsquo;s immune system, and adverse events related to preconditioning have been observed in our
ongoing clinical trial. If in the future we are unable to demonstrate that such adverse events were caused by the conditioning regimens
used, or by their administration process or related procedure, the FDA, EMA or other regulatory authorities could order us to cease further
development of, or deny the approval of, Temferon or our other product candidates for any or all target indications. Even if we are able
to demonstrate that adverse events are not related to our drug product, such occurrences could affect the ability to enroll patients
to complete the clinical trial, or the commercial viability of any product candidates that obtain regulatory approval.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">To
date, Temferon has only been administered to a small number of human subjects in our ongoing Phase 1/2a study. Due to the lack of a broader
experience in human subjects, there is limited information available about the relationship of adverse events to administration of Temferon.
Adverse events experienced in our clinical trials and attributed to autologous stem cell transplant (ASCT), concomitant medications,
and disease progression have included febrile neutropenia and other infectious complications, venous thromboembolism, poor performance
status, liver enzyme elevation, brain abscess and hemiparesis. While most of these adverse events were managed with treatment and supportive
care, two GBM patients died (day +60 and +122) due to complications following the conditioning regimens.</FONT></P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Patient deaths and severe adverse effects caused by
any investigational product candidates could result in the delay, suspension, clinical hold or termination of clinical
trials by Sponsors, ethics committees and regulatory authorities. If we elect or are required to delay, suspend or terminate
any clinical trial of any product candidates that we develop, the commercial prospects of such product candidates will be harmed
and our ability to generate product revenue from any of these product candidates would be delayed or eliminated. Serious adverse
events observed in clinical trials could hinder or prevent market acceptance of the product candidate at issue. Any of these occurrences
may harm our business, prospects, financial condition and results of operations significantly.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Additionally,
if any of our product candidates receives marketing approval, the FDA could require us to adopt a Risk Evaluation and Mitigation
Strategy, or REMS, and other non-U.S. regulatory authorities could impose other specific obligations as a condition of approval
to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks
of the product for distribution to patients, a communication plan to health care practitioners, and restrictions on how or where
the product can be distributed, dispensed or used. Furthermore, if we or others later identify undesirable side effects caused
by Temferon or any of our other product candidates, several potentially significant negative consequences could result, including:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">regulatory
                                         authorities may suspend or withdraw approvals of such a product candidate;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">regulatory
                                         authorities may require additional warnings or limitations of use in product labeling;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">we
                                         may be required to change the way a product candidate is distributed, dispensed, or administered
                                         or conduct additional clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">we
                                         could be sued and held liable for harm caused to patients; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         reputation may suffer.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could significantly
harm our business, prospects, financial condition and results of operations.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
are evaluating Temferon in a Phase 1/2a clinical trial in newly diagnosed unmethylated MGMT gene promoter glioblastoma
tumor patients (TEM-GBM Study). To date, the TEM-GBM Study is ongoing and not complete. </I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We are at a very early stage of development for all of our
gene therapy product candidates. At this stage, only our lead product candidate Temferon has been authorized by the AIFA to be evaluated
in a Phase 1/2a clinical trial in Italy. A study testing Temferon in multiple myeloma study was also approved by AIFA, but we
closed the study due to lack of enrollment feasibility, rather than clinical events, as no multiple myeloma patients have been
treated with Temferon.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
order to commence a clinical trial in the United States, we will be required to seek FDA acceptance of an IND for each of our
product candidates, including Temferon. We cannot be sure any IND we submit to the FDA, or any similar clinical trial application
we submit in other countries, will be accepted. If we will be required by regulatory authorities to conduct additional preclinical
testing prior to filing an IND or similar application to clinically evaluate any of our product candidates, including Temferon,
this may result in delay in our product candidate development. The results of any such preclinical testing may not be positive
and may not support an application to study Temferon or any of our other product candidates in additional clinical trials.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">It
is possible that the FDA or EMA will not view our ongoing or planned trials as providing adequate support for future clinical
trials or for an application for marketing approval, for any one or more reasons, including elements of the design or execution
of the trials or safety concerns or other trial results. If we are unable to confirm or replicate the results of our trials in
larger patient group or if negative results are obtained, we would likely be further delayed or prevented from advancing further
clinical development of Temferon or any of our other product candidates.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Additionally,
the FDA or EMA may disagree with the sufficiency of our proposed reliance upon the preclinical, manufacturing or clinical data
generated by third-party academic-sponsored trials, or our interpretation of preclinical, manufacturing or clinical data from
our ongoing trials. If so, the FDA or EMA may require us to obtain and submit additional preclinical, manufacturing or clinical
data.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
need to complete our Phase 1/2a clinical trial for Temferon, as well as additional clinical trials in order to obtain regulatory
approvals to market Temferon. Carrying out later-stage clinical trials is a complicated process. We are a small organization with limited
experience in preparing, submitting and prosecuting regulatory filings, and we have not previously submitted a biologics license application,
or BLA, to the FDA for any product candidate.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, we have not yet conducted clinical trials of any our product candidates in the United States,  and we cannot be certain how many clinical trials of Temferon or any of
our other product candidates will be required or how such trials should be designed. Consequently, we may be unable to successfully
and efficiently execute and complete necessary clinical trials in a way that leads to a BLA submission and approval of Temferon
or any of our other product candidates. We may require more time and incur greater costs than our competitors and may not succeed
in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned
clinical trials, could prevent us from or delay us in commercializing Temferon.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
may encounter substantial delays in commencement and completion of clinical trials.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Before
obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical
studies to demonstrate the safety and efficacy of the product candidates in humans. Clinical development is a long, expensive
and uncertain process, and delay or failure can occur at any stage of any of our clinical trials. We cannot guarantee that any
clinical studies will be conducted or completed on schedule, if at all. Clinical trials can be delayed or prevented for a number
of reasons, including:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">delays
                                         in reaching a consensus with regulatory agencies on study design;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">changes
                                         in regulatory requirements and guidance that require amending or submitting new clinical
                                         protocols;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">difficulties
                                         obtaining regulatory approval to commence a clinical trial or complying with conditions
                                         imposed by a regulatory authority regarding the scope or term of a clinical trial;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">difficulties
                                         obtaining institutional review board, or IRB, approval to conduct a clinical trial at
                                         a prospective site;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">failure
                                         to perform in accordance with the FDA&rsquo;s good clinical practices, or GCP, or applicable
                                         regulatory guidelines in other countries;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">delays
                                         in reaching or failing to reach agreement on acceptable terms with prospective contract
                                         research organizations, or CROs, and trial sites, the terms of which can be subject to
                                         extensive negotiation and may vary significantly among different CROs and trial sites;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">failure
                                         by CROs, other third parties or us to adhere to clinical trial protocol and record keeping
                                         requirements;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">trial
                                         sites or patients dropping out of a study;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         occurrence of SAEs associated with the product candidate that are viewed to outweigh
                                         its potential benefits;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">insufficient
                                         or inadequate supply or quality of a product candidate or other materials necessary to
                                         conduct our clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">delays
                                         in the testing, validation, manufacturing and delivery of our product candidates to the
                                         clinical sites; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">if
                                         the FDA or the EMA or other regulatory authorities elect to enact policy changes, as
                                         a result of the COVID-19 pandemic or otherwise.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Clinical
trials may also be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may
be suspended or terminated by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, a data safety monitoring
board overseeing the clinical trial at issue or by other regulatory authorities due to a number of factors, including:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">failure
                                         to conduct the clinical trial in accordance with regulatory requirements or our clinical
                                         protocols;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">inspection
                                         of the clinical trial operations or trial sites by the FDA or other regulatory authorities;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">unforeseen
                                         safety issues (including those that result from the COVID-19 pandemic) or lack of effectiveness;
                                         and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">lack
                                         of adequate funding to continue the clinical trial.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Any
inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability
to generate revenues. This could result in increased costs, delays in advancing our product candidates, delays in testing the
effectiveness of our product candidates or termination of the clinical trials altogether.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In addition, if we make changes to our product candidates,
we may need to conduct additional studies to bridge our modified product candidates to earlier versions, this will increase the
costs and could delay our clinical development plan, or marketing approval for our product candidates. For example, among our
preclinical candidates we are developing a &ldquo;switchable&rdquo; system. This system has the potential to be
a &ldquo;switchable&rdquo; on/off system that may limit the long-term exposure to any selected therapeutic payloads, but
it requires further preclinical testing as well as additional manufacturing validation. Moreover, our platform is designed
to allow us to use other therapeutic payloads, other than IFN-&alpha;. This has the potential to open a multitude of
therapeutic indications but further preclinical testing as well as additional manufacturing validation are required. Any modification
of our product candidates will likely require updates to our clinical trial applications and INDs with the relevant regulatory
authorities, which may result in delay, suspension or termination of ongoing or future clinical trials pending our submission,
and the agencies&rsquo; review, of such updates. Clinical study delays could also shorten any periods during which we may have
the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do,
which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>The
results of preclinical studies, early-stage clinical trials, data obtained from real-world use, and published third-party studies
may not be indicative of results in future clinical trials and we cannot assure you that any clinical trials will lead to results
sufficient for the necessary regulatory approvals.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">The results of preclinical studies may not be predictive
of the results of clinical trials, and the results of any completed clinical trials, including studies derived from real-world
use and studies in published literature, or clinical trials we commence may not be predictive of the results of later-stage clinical
trials. Additionally, interim results and analyses from our ongoing clinical trials do not necessarily predict final results.
Moreover, preliminary data and analyses from our ongoing clinical trials may change as more patient data become available. In
general, we conduct interim analyses at pre-specified times, which do not include data subsequent to the cut-off
date and will not be available until the next planned interim analysis. From time to time, preliminary data and analyses might
be presented, typically by academic investigators at scientific conferences or in scientific publications. Interim data and analyses
are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or
more patient data become available to us. Interim and preliminary data/analyses also remain subject to audit and verification
procedures that may result in the final data being materially different from the preliminary data available to us or that we previously
published. As a result, preliminary and interim data/analyses should be viewed with caution until the final data are available.
Material adverse changes in the final data compared to the preliminary or interim data/analyses could significantly harm our business
prospects.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Indeed,
our product candidates may fail to show the desired safety and efficacy in clinical development despite demonstrating positive
results in preclinical studies or having successfully advanced through initial clinical trials. Later clinical trial results may
not replicate earlier clinical trials for a variety of reasons, including differences in trial design, different trial endpoints
(or lack of trial endpoints in exploratory studies), subject population, number of subjects, subject selection criteria, trial
duration, drug dosage and formulation and lack of statistical power in the earlier studies. Our company has limited experience
in designing and conducting clinical trials and we may be unable to design and execute a clinical trial to support regulatory
approval. There can be no assurance that any of our clinical trials will ultimately be successful or support further clinical
development of any of our product candidates. A number of companies in the pharmaceutical and biotechnology industries have suffered
significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks
in our clinical development could have a negative impact on our business. Any of our product candidates, including Temferon, may
fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies. Any such
failure would cause us to abandon the product candidate.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">Additionally, our ongoing clinical trial utilizes, and our planned clinical
trials may utilize, an &ldquo;open-label&rdquo; trial design. An &ldquo;open-label&rdquo; clinical trial is one where both the
patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved
drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may
do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic
effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be
subject to a &ldquo;patient bias&rdquo; where patients perceive their symptoms to have improved merely due to their awareness
of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &ldquo;investigator bias&rdquo;
where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received
treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label
trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label
clinical trial when studied in a controlled environment with a placebo or active control.</P>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical
trials of our product candidates.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Identifying
and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of
our clinical trials depends on our ability and on the speed at which we can recruit patients to participate in testing our product
candidates, as well as the completion of required follow-up periods. We may experience delays in our clinical trials if we encounter
difficulties in enrollment. Patients may be unwilling to participate in our gene therapy clinical trials because of negative publicity
from adverse events related to the biotechnology or gene therapy fields, the safety profile of our product candidate under study,
the perceived risks and benefits of the product candidate under study; the perceived risks and benefits of gene therapy-based
approaches to treatment of diseases, including any required pretreatment conditioning regimens, the existence of competitive clinical
trials for similar patient populations.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, we may not be able to identify, recruit and enroll a sufficient number of patients due to the existence of efficacious
alternative treatments, the size of the patient population and process for identifying subjects, the design of the trial protocol,
the exclusion/inclusion criteria that we are currently targeting may limit the pool of patients that may be enrolled in our ongoing
or planned clinical trials, the proximity and availability of clinical trial sites for prospective subjects and the patient referral
practices of physicians; the ability to obtain and maintain subject consent; the risk that enrolled subjects will drop out before
completion of the trial.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, the evolving COVID-19 pandemic may directly or indirectly impact the pace of enrollment in our clinical trials as patients
may avoid or may not be able to travel to healthcare facilities and physicians&rsquo; offices due to a health emergency and clinical
trial staff can no longer get to the clinic. Additionally, such facilities and offices have been and may continue to be required
to focus limited resources on non-clinical trial matters, including treatment of COVID-19 patients, thereby decreasing availability,
in whole or in part, for clinical trial services. See &ldquo;Risks Related to Our Business Operations &ndash; We face business
disruption and related risks resulting from the recent outbreak of COVID-19, which could have a material adverse effect on our
business and results of operations&rdquo; for additional information.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting studies
and obtaining regulatory approval of potential product candidates will be delayed.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
we experience delays in the commencement or completion or termination of any clinical trial of our product candidates, the commercial
prospects of our product candidates will be harmed, and our ability to generate product candidate revenue from any of these product
candidates could be delayed or prevented. In addition, any delays in completing our clinical trials will increase our costs, slow
down our product candidate development and approval process and jeopardize our ability to commence product candidate sales and
generate revenue. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition,
many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead
to the denial of regulatory approval of our product candidates.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>The
results of clinical trials conducted at clinical sites outside the United States may not be accepted by the FDA and the results
of clinical trials conducted at clinical sites in the United States may not be accepted by international regulatory authorities.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">To date our only ongoing recruiting
clinical trial has been conducted in Europe but we are planning to globally develop Temferon, including in the United
States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is
subject to certain conditions imposed by the FDA. For example, the clinical trial must be well-designed and conducted and
performed by qualified investigators in accordance with, GCPs, ethical principles such as or IRB or ethics committee approval
and informed consent. Generally, the subject population for any clinical trials conducted outside of the United States must
be representative of the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in
ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local
laws, FDA acceptance of the data will be dependent upon its determination that the trials were conducted consistent with all
applicable U.S. laws and regulations. There can be no assurance the FDA or international regulatory authorities will accept
data from trials conducted outside of the location in which each regulatory authority is based as adequate support of
a marketing application in a given jurisdiction. If the FDA does not accept the data from sites in our globally
conducted clinical trials, or if international regulatory authorities do not accept the data from our U.S. clinical trials,
it would likely result in the need for additional trials, which would be costly and time-consuming and could delay or
permanently halt the development of one or more of our product candidates.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
ability to successfully initiate, enroll and complete a clinical trial in any foreign country including the United States, is
subject to numerous risks unique to conducting business in foreign countries, including:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">difficulty
                                         in establishing or managing relationships with contract research organizations, or CROs,
                                         and physicians;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">different
                                         standards for the conduct of clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         absence in some countries of established groups with sufficient regulatory expertise
                                         for review of gene therapy protocols;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         inability to locate qualified local consultants, physicians and partners; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         potential burden of complying with a variety of laws, medical standards and regulatory
                                         requirements, including the regulation of pharmaceutical and biotechnology products and
                                         treatment.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Changes
in methods of product candidate manufacturing or formulation may result in additional costs or delay.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization,
it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along
the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended
objectives. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or delays
in transferring that process to commercial partners, which may prevent us from initiating, completing or expanding our clinical
trials or commercializing our products, if any, on a timely or profitable basis, if at all. For example, the anticipated transition
of our cell processing to a different commercial partner in the U.S., or to a commercial partner(s) relying on automated closed
system, if available, using all disposable supplies would require regulatory approvals, may not be successful or may experience
unforeseen delays, which may cause shortages or delays in the supply of our products available for clinical trials and future
commercial sales, if any. In addition, there is no assurance that products manufactured using a different commercial partner or
an automated closed system, if and when available, will achieve the same results observed to date in Temferon clinical and preclinical
and non-clinical studies. Any of these changes could cause our product candidates to perform differently and affect the results
of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes.
Such changes may also require additional testing such as comparability studies, FDA or EMA notification or FDA approval. This
could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical
trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and
generate revenue.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Even
if we complete the necessary preclinical and clinical studies, we cannot predict when or if we will obtain regulatory approval
to commercialize a product candidate and the approval may be for a more narrow indication than we seek.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We cannot commercialize a product until the appropriate
regulatory authorities have reviewed and approved the product candidate. Even if our product candidates demonstrate safety and
efficacy in preclinical and clinical studies, the regulatory agencies may not complete their review processes in a timely manner,
or we may not be able to obtain regulatory approval. Many companies in the pharmaceutical and biotechnology industries have suffered
significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage
clinical trials. Additional delays may result if an FDA Advisory Committee or other regulatory authority does not recommend
approval or recommends restrictions on approval. In addition, we may experience delays or rejections based upon additional
government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period
of product development, clinical studies and the review process. Regulatory agencies also may approve a product candidate
for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies.
In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization
of our product candidates. If we are unable to obtain necessary regulatory approvals, our business, prospects, financial condition
and results of operations may suffer.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
may seek designations for our product candidates with the FDA and other comparable regulatory authorities that are intended to
confer benefits such as a faster development process or an accelerated regulatory pathway, but there can be no assurance that
we will successfully obtain such designations. In addition, even if one or more of our product candidates are granted such designations,
we may not be able to realize the intended benefits of such designations.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
FDA, and other comparable regulatory authorities, offer certain designations for product candidates that are intended to encourage
the research and development of pharmaceutical and biotechnology products addressing conditions with significant unmet medical
need. These designations may confer benefits such as additional interaction with regulatory authorities, a potentially accelerated
regulatory pathway and priority review. There can be no assurance that we will successfully obtain such designation for Temferon.
In addition, while such designations could expedite the development or approval process, they do not change the standards
for approval. Even if we obtain such designations for one or more of our product candidates, there can be no assurance that we
will realize their intended benefits.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">For
example, we may seek a Breakthrough Therapy Designation from the FDA for one or more of our product candidates. A Breakthrough
Therapy Designation is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat
a serious or life-threatening disease or condition, if preliminary clinical evidence indicates that the therapy may demonstrate
substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment
effects observed early in clinical development. For therapies that have Breakthrough Therapy Designation, interaction and communication
between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing
the number of patients placed in ineffective control regimens. Therapies with Breakthrough Therapy Designation from the FDA are
also eligible for accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly,
even if we believe one of our product candidates meets the criteria for Breakthrough Therapy Designation, the FDA may disagree
and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy Designation for a product
candidate may not result in a faster development process, review or approval compared to therapies considered for approval under
conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product
candidates qualify for Breakthrough Therapy Designation, the FDA may later decide that such product candidates no longer meet
the conditions for qualification.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
may also seek Fast Track Designation from the FDA for some of our product candidates. If a therapy is intended for the treatment
of a serious or life-threatening condition and the therapy demonstrates the potential to address unmet medical needs for this
condition, the therapy sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this
designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance
that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development
process, review or approval compared to conventional FDA procedures, and receiving a Fast Track Designation does not provide assurance
of ultimate FDA approval. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported
by data from our clinical development program.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In addition, we may seek a regenerative medicine advanced
therapy, or RMAT, designation for some of our product candidates. An RMAT is defined as a cell therapy, therapeutic
tissue engineering products, human cell and tissue products, or any combination products using any such therapies or products.
Gene therapies, including genetically modified cells that lead to a durable modification of cells or tissues may meet the definition
of a regenerative medicine therapy. The RMAT program is intended to facilitate efficient development and expedite review of RMATs,
which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and for which preliminary clinical evidence indicates that the candidate has potential to address unmet medical needs for such disease
or condition. A new drug application or a BLA for an RMAT may be eligible for priority review or accelerated approval through
(1) surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit or (2) reliance upon data obtained
from a meaningful number of sites. Benefits of such designation also include early interactions with FDA to discuss any potential
surrogate or intermediate endpoint to be used to support accelerated approval. A regenerative medicine therapy that is granted
accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical
evidence, clinical studies, patient registries, or other sources of real world evidence, such as electronic health records; the
collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its
approval. RMAT designation is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates
meets the criteria for designation as a regenerative medicine advanced therapy, the FDA may disagree and instead determine not
to make such designation. In any event, the receipt of RMAT designation for a product candidate may not result in a faster development
process, review or approval compared to product candidates considered for approval under conventional FDA procedures and
does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as for RMAT designation,
the FDA may later decide that the biological products no longer meet the conditions for qualification.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
may seek a conditional marketing authorization in Europe for some or all of our current product candidates, but we may not be
able to obtain or maintain such designation.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">As part of its marketing authorization process, the
EMA may grant marketing authorizations for certain categories of medicinal products on the basis of less complete data than is
normally required, where the benefit of immediate availability of the medicine outweighs the risk inherent in the fact that
additional data are still required or in the interests of public health. In such cases, it is possible for the Committee
for Medicinal Products for Human Use, or CHMP, to recommend the granting of a marketing authorization, subject to certain specific
obligations to be reviewed annually, which is referred to as a conditional marketing authorization. This may apply to medicinal
products for human use that fall under the jurisdiction of the EMA, including those that aim at the treatment, the prevention,
or the medical diagnosis of seriously debilitating or life-threatening diseases and those designated as orphan medicinal products.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">A
conditional marketing authorization may be granted when the CHMP finds that, although comprehensive clinical data referring to
the safety and efficacy of the medicinal product have not been supplied, all the following requirements are met:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         risk-benefit balance of the medicinal product is positive;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         applicant will provide the comprehensive clinical data post-authorization;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">unmet
                                         medical needs will be fulfilled; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         benefit to public health of the immediate availability on the market of the medicinal
                                         product concerned outweighs the risk inherent in the fact that additional data is still
                                         required.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
granting of a conditional marketing authorization is restricted to situations in which only the clinical part of the application
is not yet fully complete. Incomplete preclinical or quality data may only be accepted if duly justified and only in the case
of a product intended to be used in emergency situations in response to public health threats. Conditional marketing authorizations
are valid for one year, on a renewable basis. The holder will be required to complete ongoing trials or to conduct new trials
with a view to confirming that the benefit-risk balance is positive. In addition, specific obligations may be imposed in relation
to the collection of pharmacovigilance data.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Granting
a conditional marketing authorization allows medicines to reach patients with unmet medical needs earlier than might otherwise
be the case and will ensure that additional data on a product is generated, submitted, assessed and acted upon. Although we may
seek a conditional marketing authorization for one or more of our product candidates by the EMA, the CHMP may ultimately not agree
that the requirements for such conditional marketing authorization have been satisfied and hence delay the commercialization of
our product candidates.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
may be unable to obtain orphan drug designation for our product candidates and, even if we obtain such designation, we may not
be able to realize the benefits of such designation, including potential marketing exclusivity of our product candidates, if approved.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Regulatory authorities in some jurisdictions, including
the United States and EU, may designate drugs for relatively small patient populations as &ldquo;orphan drugs.&rdquo; Under the
Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition,
which is generally defined as a patient population of fewer than 200,000 individuals in the United States or a patient population
of 200,000 or more individuals in the United States, but for which there is no reasonable expectation that the cost of
developing the drug will be recovered from sales in the United States. In the EU, the European Commission grants orphan drug designation
to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically
debilitating condition affecting not more than five in 10,000 persons in the EU community. Additionally, designation is granted
for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and
chronic condition and when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify
the necessary investment in developing the drug or biologic product. In either case, the applicant for orphan designation must
also demonstrate that no satisfactory method of diagnosis, prevention, or treatment for the condition has been authorized (or,
if a method exists, the new product would be a significant benefit to those affected compared to the product available).</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
we request orphan drug designation (or the international equivalent) for Temferon or any of our other product candidates, there
can be no assurances that the FDA or international regulatory authorities will grant any of our product candidates such designation.
This designation of a product candidate as an orphan product does not mean that any regulatory agency will accelerate regulatory
review of, or ultimately approve, that product candidate, nor does it limit the ability of any regulatory agency to grant orphan
drug designation to product candidates of other companies that treat the same indications as our product candidates prior to our
product candidates receiving exclusive marketing approval.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Generally, if a product candidate with an orphan drug
designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug
may be entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application
for the same drug for the same indication for that time period, except in limited circumstances. If another sponsor receives such
approval before we do (regardless of our orphan drug designation), we will be precluded from receiving marketing approval for
our product for the applicable exclusivity period. The applicable period is seven years in the United States and ten years in
the EU. The exclusivity period in the EU can be reduced to six years if a drug no longer meets the criteria for orphan drug designation
or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be revoked
if any regulatory agency determines that the request for designation was materially defective or if the manufacturer is unable
to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Even
if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate
from competition because different drugs can be approved for the same indication. Even after an orphan drug is approved, the FDA
may subsequently approve another drug for the same condition if the FDA concludes that the latter drug is not the same drug or
is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the EU,
marketing authorization may be granted to a similar medicinal product for the same orphan indication if:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         second applicant can establish in its application that its medicinal product, although
                                         similar to the orphan medicinal product already authorized, is safer, more effective
                                         or otherwise clinically superior;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         holder of the marketing authorization for the original orphan medicinal product consents
                                         to a second orphan medicinal product application; or</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         holder of the marketing authorization for the original orphan medicinal product cannot
                                         supply sufficient quantities of orphan medicinal product.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Even
if we obtain and maintain regulatory approval for a product candidate, our products will remain subject to ongoing regulatory
oversight. </I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Even if we obtain any regulatory approval for our product
candidates, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising,
promotion, sampling, record-keeping and submission of safety and other post-market information. Any regulatory approvals that
we receive for our product candidates also may be subject to a REMS, limitations on the approved indicated uses for which the
product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing,
including Phase 4 clinical trials, and surveillance to monitor the quality, safety and efficacy of the product. For example, as
noted above in the United States, the holder of an approved BLA is obligated to monitor and report adverse events and any failure
of a product to meet the specifications in the BLA. FDA guidance advises that patients treated with some types of gene therapy
undergo follow-up observations for potential adverse events for as long as 15 years. The holder of an approved marketing application
also must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product
labeling or manufacturing process.</P>

<P STYLE="font: 12pt Georgia; margin: 0 0 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif; text-indent: 0.5in">We must comply with requirements
concerning advertising and promotion for any product candidates for which we obtain marketing approval. Promotional communications
with respect to therapeutics are subject to a variety of legal and regulatory restrictions and continuing review by the FDA or
comparable foreign regulatory authorities, Department of Justice, Department of Health and Human Services&rsquo;, or HHS, Office
of Inspector General, state attorneys general, members of Congress, and the public. When the FDA or comparable foreign regulatory
authorities issue regulatory approval for a product candidate, the regulatory approval is limited to those specific uses and indications
for which a product is approved. If we are not able to obtain FDA or comparable foreign regulatory authority approval for desired
uses or indications for our current product candidates and any future product candidates, we may not market or promote them for
those indications and uses, referred to as off-label uses, and our business, financial condition, results of operations, stock
price and prospects will be materially harmed. We also must sufficiently substantiate any claims that we make for our products,
including claims comparing our products to other companies&rsquo; products, and must abide by the FDA or a comparable foreign
regulatory authority&rsquo;s strict requirements regarding the content of promotion and advertising.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif; text-indent: 0.5in">While physicians may choose
to prescribe products for uses that are not described in the product&rsquo;s labeling and for uses that differ from those tested
in clinical trials and approved by the regulatory authorities, we and any third parties engaged on our behalf are prohibited from
marketing and promoting the products for indications and uses that are not specifically approved by the FDA or comparable foreign
regulatory authorities. Regulatory authorities in the United States generally do not restrict or regulate the behavior of physicians
in their choice of treatment within the practice of medicine. Regulatory authorities do, however, restrict communications by biopharmaceutical
companies concerning off-label use.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">If we are found to have impermissibly promoted any
of our current product candidates and any future product candidates, we may become subject to significant liability and government
fines. The FDA and other agencies actively enforce the laws and regulations regarding product promotion, particularly those prohibiting
the promotion of off-label uses, and a company that is found to have improperly promoted a product may be subject to significant
sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and
has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent
decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</P>
<P STYLE="font: 12pt Georgia; margin: 0 0 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0 0 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In the European Union, the advertising and promotion
of our products are subject to European Union laws governing promotion of medicinal products, interactions with physicians, misleading
and comparative advertising, and unfair commercial practices. In addition, other legislation adopted by individual European
Union Member States may apply to the advertising and promotion of medicinal products. These laws require that promotional materials
and advertising for medicinal products are consistent with the product&rsquo;s Summary of Product Characteristics, or SmPC, as
approved by the competent authorities. The SmPC is the document that provides information to physicians concerning the safe and
effective use of the medicinal product. It forms an intrinsic and integral part of the marketing authorization granted for the
medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion.
The off-label promotion of medicinal products is prohibited in the European Union. The applicable laws at European Union level
and in the individual European Union Member States also prohibit the direct-to-consumer advertising of prescription-only medicinal
products. Violations of the rules governing the promotion of medicinal products in the European Union could be penalized by administrative
measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the
general public, and may also impose limitations on our promotional activities with health care professionals.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections
by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or GMP, requirements and
adherence to commitments made in the BLA or foreign marketing application. If we, or a regulatory authority, discover previously
unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility
where the product is manufactured or disagrees with the promotion, marketing or labeling of that product, a regulatory authority
may impose restrictions relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of
the product from the market or suspension of manufacturing.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
we fail to comply with applicable regulatory requirements, a regulatory authority may:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">issue
                                         an untitled letter or warning letter that we are in violation of the law;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">seek
                                         an injunction or impose administrative, civil or criminal penalties or monetary fines;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">suspend
                                         or withdraw regulatory approval;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">suspend
                                         any ongoing clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">refuse
                                         to approve BLA or comparable foreign marketing application (or any supplements thereto)
                                         submitted by us or our strategic partners;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">restrict
                                         the marketing or manufacturing of the product;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">seize
                                         or detain the products or require the withdrawal of the product from the market;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">refuse
                                         to permit the import or export of the products; or</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">refuse
                                         to allow us to enter into supply contracts, including government contracts.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Any
government investigation of alleged violations of law could require us to expend significant time and resources in response and
could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize
our product candidates and adversely affect our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, the FDA&rsquo;s policies, and those of the EMA and other regulatory authorities, may change and additional government
regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict
the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either
in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements
or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained
and we may not achieve or sustain profitability, which would materially and adversely affect our business, financial condition,
results of operations and prospects.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Both
marketing authorization holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the
EMA and the competent authorities of the individual European Union Member States both before and after grant of the manufacturing
and marketing authorizations. This includes control of compliance with GMP rules, which govern quality control of the manufacturing
process and require documentation policies and procedures. We and our third-party manufacturers would be required to ensure that
all of our processes, quality systems, methods, and equipment are compliant with GMP. Failure by us or by any of our third-party
partners, including suppliers, manufacturers, and distributors to comply with European Union laws and the related national laws
of individual European Union Member States governing the conduct of clinical trials, manufacturing approval, marketing authorization
of medicinal products, both before and after grant of marketing authorization, and marketing of such products following grant
of authorization may result in administrative, civil, or criminal penalties. These penalties could include delays in or refusal
to authorize the conduct of clinical trials or to grant marketing authorization, product withdrawals and recalls, product seizures,
suspension, or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing,
or clinical trials, operating restrictions, injunctions, suspension of licenses, fines, and criminal penalties. operating restrictions,
injunctions, suspension of licenses, fines, and criminal penalties.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, European Union legislation related to pharmacovigilance, or the assessment and monitoring of the safety of medicinal
products, provides that EMA and the competent authorities of the European Union Member States have the authority to require companies
to conduct additional post-approval clinical efficacy and safety studies. The legislation also governs the obligations of marketing
authorization holders with respect to additional monitoring, adverse event management and reporting. Under the pharmacovigilance
legislation and its related regulations and guidelines, we may be required to conduct a burdensome collection of data regarding
the risks and benefits of marketed products and may be required to engage in ongoing assessments of those risks and benefits,
including the possible requirement to conduct additional clinical trials, which may be time-consuming and expensive and could
impact our profitability. Non-compliance with such obligations can lead to the variation, suspension or withdrawal of marketing
authorization or imposition of financial penalties or other enforcement measures.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><B><I>We do not have sales, distribution, and marketing capabilities.
If we are unable to develop these capabilities or enter into agreements with third parties to market and sell Temferon and our
other product candidates, we will be unable to generate any product revenue.</I></B></P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font: 10pt Georgia"><B><I></I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
currently have no sales, distribution or marketing organization. To successfully commercialize any of our current or future product
candidates, if approved, we will need to develop these capabilities, either on our own or with others. The establishment and development
of our own commercial team or the establishment of a contract sales force to market any product candidate we may develop will
be expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully
develop this capability. We may enter into collaborations regarding any approved product candidates with other entities to utilize
their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms,
if at all. If any future collaborators do not commit sufficient resources to commercialize our product candidates, or we are unable
to develop the necessary capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business.
We compete with many companies that currently have extensive, experienced and well-funded sales, distribution and marketing operations
to recruit, hire, train and retain marketing and sales personnel. We also face competition in our search for third parties to
assist us with the sales and marketing efforts of our product candidates, if approved. Without an internal team or the support
of a third-party to perform marketing and sales functions, we may be unable to compete successfully against these more established
companies.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Even
if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians,
patients, third-party payors and others in the medical community necessary for commercial success.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
commercial success of Temferon will depend upon the acceptance of each product by the medical community, including physicians,
patients and third-party payors. The degree of market acceptance of any approved product will depend on a number of factors, including:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         efficacy and safety of the product;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         potential advantages of the product compared to available therapies;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         convenience and ease of administration compared to alternative treatments;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">limitations
                                         or warnings, including use restrictions contained in the product&rsquo;s approved labeling;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">distribution
                                         and use restrictions imposed by the FDA, the EMA or other regulatory authority or agreed
                                         to by us as part of a mandatory or voluntary risk management plan;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">availability
                                         of alternative treatments, including competitive products expected to be commercially
                                         launched in the near future;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">pricing
                                         and cost effectiveness in relation to alternative treatments;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">if
                                         the product is included under physician treatment guidelines as a first-, second,- or
                                         third-line therapy;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         strength of sales, marketing and distribution support;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         availability of third-party coverage and adequate reimbursement and the willingness of
                                         patients to pay out-of-pocket in the absence of coverage by third-party payors;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         strength of sales, marketing and distribution support;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         willingness of patients to pay for drugs out of pocket in the absence of third-party
                                         coverage; and</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         willingness of the target patient population to try new therapies and of physicians to
                                         prescribe these therapies.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
Temferon is approved but does not achieve an adequate level of acceptance by physicians, third party payors and patients, we may
not generate sufficient revenue from the product, and we may not become or remain profitable. In addition, our efforts to educate
the medical community and third-party payors on the benefits of the product may require significant resources and may never be
successful.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, we may choose to collaborate with third parties that have direct sales forces and established distribution systems,
either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If
we enter into arrangements with third parties to perform sales, marketing and distribution services for our products, the resulting
revenues or the profitability from these revenues to us are likely to be lower than if we had sold, marketed and distributed our
products ourselves. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully
commercialize any of our product candidates that receive regulatory approval. Depending on the nature of the third-party relationship,
we may have little control over such third parties, and any of these third parties may fail to devote the necessary resources
and attention to sell, market and distribute our products effectively. If we are not successful in commercializing our product
candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer,
and we may incur significant additional losses.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Even
if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations or
third-party coverage and reimbursement policies, any of which could harm our business.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
ability to commercialize any product candidates successfully will depend, in part, on the extent to which coverage and reimbursement
for these products and related treatments will be available from government health administration authorities, private health
insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance
organizations, decide which medications they will pay for and impact reimbursement levels.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Obtaining
and maintaining adequate reimbursement for our products may be difficult. We cannot be certain if and when we will obtain an adequate
level of reimbursement for our products by third party payors. Even if we do obtain adequate levels of reimbursement, third-party
payors, such as government or private healthcare insurers, carefully review and increasingly question the coverage of, and challenge
the prices charged for, drugs. Reimbursement rates from private health insurance companies vary depending on the company, the
insurance plan and other factors. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government
authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular
medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from
list prices and are challenging the prices charged for drugs. We may also be required to conduct expensive pharmacoeconomic studies
to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and reimbursement
are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product
candidate for which we obtain marketing approval, and the royalties resulting from the sales of those products may also be adversely
impacted.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">There
may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes
for which the drug is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for
reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research,
development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient
to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical
setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into
existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government
healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries
where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and adequate reimbursement
rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect
on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country
to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional
costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be reimbursed.
In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign
markets, prescription drug pricing remains subject to continuing governmental control, including possible price reductions, even
after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but
then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively
impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder
our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.
There can be no assurance that our product candidates, if they are approved for sale in the United States or in other countries,
will be considered medically necessary or cost-effective for a specific indication, or that coverage or an adequate level of reimbursement
will be available.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in
obtaining regulatory approval of our product candidates in other jurisdictions. Our failure to obtain regulatory approval in international
jurisdictions would prevent our product candidates from being marketed abroad, and any approval we are granted for our product
candidates in the United States would not assure approval of product candidates in foreign jurisdictions.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements
of other countries regarding clinical trial design, safety and efficacy. The research, testing, manufacturing, labeling, approval,
sale, marketing and distribution of drugs are subject to extensive regulation by the FDA in the United States and other regulatory
authorities in other countries. These regulations differ from country to country. Even if we obtain and maintain regulatory approval
of our product candidates in one jurisdiction, such approval does not guarantee that we will be able to obtain or maintain regulatory
approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative
effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate,
comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the
product candidate in those countries.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Approval procedures vary among jurisdictions and
can involve requirements and administrative review periods different from those in the United States, including additional non-clinical
studies or clinical trials as investigations conducted in one jurisdiction may not be accepted by regulatory authorities in
other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before
it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject
to approval. These regulatory procedures can result in substantial delays in such countries. In other countries, product approval
depends on showing superiority to an approved alternative therapy. This can result in significant expense for conducting complex
clinical trials.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Approval
of a product candidate in the United States by the FDA does not ensure approval of such product candidate by the EMA or other
regulatory authorities in other countries or jurisdictions, and approval by the EMA or another regulatory authority does not ensure
approval by regulatory authorities in other foreign countries or by the FDA. Sales of our product candidates outside of the United
States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants
marketing approval for a product candidate, comparable regulatory authorities of foreign countries also must approve the manufacturing
and marketing of the product candidates in those countries. Approval procedures vary among jurisdictions and can involve requirements
and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical
studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement
before it can be approved for sale in that country. In some cases, the price that we intend to charge for our products, if approved,
is also subject to approval. We intend to submit an MAA to the EMA for approval of our product candidates in the European Union
but obtaining such approval from the European Commission following the opinion of EMA is a lengthy and expensive process. Even
if a product candidate is approved, the FDA or the European Commission may limit the indications for which the product may be
marketed, require extensive warnings on the product labeling or require expensive and time consuming additional clinical trials
or reporting as conditions of approval. Regulatory authorities in countries outside of the United States and the European Union
also have requirements for approval of product candidates with which we must comply prior to marketing in those countries. Obtaining
foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties
and costs for us and could delay or prevent the introduction of our product candidates in certain countries.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Finally,
we do not have any products approved for sale in any jurisdiction, including international markets, and we do not have experience
in obtaining regulatory approval. If we, or any third parties with whom we work, fail to comply with regulatory requirements in
United States or international markets or to obtain and maintain required approvals or if regulatory approvals in international
markets are delayed, our target market may be reduced and our ability to realize the full market potential of our products will
likely be harmed. The inability to meet continuously evolving regulatory standards for approval may result in our failing to obtain
regulatory approval to market our current product candidates, which could significantly harm our business, results of operations
and prospects.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Additionally,
on June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the EU, commonly referred to as &ldquo;Brexit.&rdquo;
On March 29, 2017, the country formally notified the EU of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty
and the withdrawal of the United Kingdom from the EU took effect on January 31, 2020. There was a transition period, during which
EU pharmaceutical law remained applicable in the United Kingdom, however this ended on December 31, 2020. Since a significant
proportion of the regulatory framework governing the development and commercialization of medicinal products in the United Kingdom
is derived from EU Directives and Regulations, Brexit, now that the transition period is over, could materially impact the regulatory
regime with respect to the approval of our product candidates in the United Kingdom or the EU, as United Kingdom legislation now
has the potential to diverge from EU legislation. Any delay in obtaining, or an inability to obtain, any regulatory approvals,
as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or
the EU and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we
may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or EU for our product candidates,
which could significantly and materially harm our business.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
operate in a rapidly changing industry and face significant competition, which may result in others discovering, developing or
commercializing products before or more successfully than we do. </I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
development and commercialization of new biopharmaceutical products is highly competitive and subject to rapid and significant
technological advancements. We face competition from major multi-national pharmaceutical companies, biotechnology companies and
specialty pharmaceutical companies with respect to our current and future product candidates that we may develop and commercialize
in the future. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products
or are pursuing the development of product candidates for the treatment of cancer. Smaller or early-stage companies may also prove
to be significant competitors, particularly through collaborative arrangements with large, established companies. Potential competitors
also include academic institutions, government agencies and other public and private research organizations. Our competitors may
succeed in developing, acquiring or licensing technologies and products that are more effective, more effectively marketed and
sold or less costly than any product candidates that we may develop, which could render our product candidates noncompetitive
and obsolete.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Many
of our competitors, either alone or with their strategic collaborators, have substantially greater financial, technical and human
resources than we do. Accordingly, our competitors may be more successful than we are in obtaining approval for treatments and
achieving widespread market acceptance, which may render our treatments obsolete or noncompetitive. Mergers and acquisitions in
the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of
our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel
and establishing clinical study sites and patient registration for clinical studies, as well as in acquiring technologies complementary
to, or necessary for, our programs.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more
effective, have fewer or less severe side effects, are more convenient or are less expensive or better reimbursed than any products
that we may commercialize. Our competitors also may obtain EMA, FDA or other regulatory approval for their products more rapidly
than we do, which could result in our competitors establishing a strong market position for either the product or a specific indication
before we are able to enter the market.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 24.5pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Our
product candidates may face competition sooner than anticipated from biosimilar products. </I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Even if we are successful in achieving regulatory approval
to commercialize a product candidate faster than our competitors, our product candidates may face competition from biosimilar products.
In the United States, our product candidates are regulated by the FDA as biologic products and we intend to seek approval for these
product candidates pursuant to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an
abbreviated pathway for the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes
legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &ldquo;interchangeable&rdquo;
based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved
by the FDA until 12 years after the original branded product was approved under a BLA. The law is complex and is still being interpreted
and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">There is a risk that any exclusivity we may be afforded
if any of our product candidates are approved as a biologic product under a BLA could be shortened due to congressional action,
the results of recent litigation, or otherwise, or that the FDA will not consider our product candidates to be reference
products for competing products, potentially creating the opportunity for generic or biosimilar competition sooner than anticipated.
Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in
a way that is similar to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number
of marketplace and regulatory factors that are still developing. In addition, a competitor could decide to forego the biosimilar
approval path and submit a full BLA after completing its own preclinical studies and clinical trials. In such cases, any exclusivity
to which we may be eligible under the BPCIA would not prevent the competitor from marketing its product as soon as it is approved.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, critics of the 12-year exclusivity period in the biosimilar pathway law will likely continue to seek to shorten the
data exclusivity period and/or to encourage the FDA to interpret narrowly the law&rsquo;s provisions regarding which new products
receive data exclusivity. In December 2019, the US agreed to remove from the United States-Mexico-Canada Agreement a requirement
for at least 10 years of data exclusivity for biologic products. Also, the FDA is considering whether subsequent changes to a
licensed biologic would be protected by the remainder of the reference product&rsquo;s original 12-year exclusivity period (a
concept known in the generic drug context as &ldquo;umbrella exclusivity&rdquo;). If the FDA were to decide that umbrella exclusivity
does not apply to biological reference products or were to make other changes to the exclusivity period, this could expose us
to biosimilar competition at an earlier time. There also have been, and may continue to be, legislative and regulatory efforts
to promote competition through policies enabling easier generic and biosimilar approval and commercialization, including efforts
to lower standards for demonstrating biosimilarity or interchangeability, limit patents that may be litigated and/or patent settlements
and implement preferential reimbursement policies for biosimilars.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In Europe, the European Commission has granted marketing
authorizations for several biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar
approvals issued over the past few years. In the EEA, innovative medicinal products generally receive eight years of data exclusivity
and an additional two years of marketing exclusivity. Data exclusivity prevents biosimilar applicants from referencing the innovator&rsquo;s
preclinical and clinical trial data when applying for a biosimilar marketing authorization, during a period of eight years from
the date on which the reference product was first authorized in the EEA. During the additional two-year period of market exclusivity,
biosimilar marketing authorization can be submitted, and the innovator&rsquo;s data may be referenced, but no biosimilar product
can be marketed until the expiration of the market exclusivity period. This 10-year marketing exclusivity period may be extended
to 11 years if, during the first eight of those 10 years, the marketing authorization holder obtains an approval for one or more
new therapeutic indications that bring significant clinical benefits compared with existing therapies. However, even if an
innovative medicinal product gains the prescribed period of data exclusivity, another company may market another version of the
product if such company obtained marketing authorization based on an application with a complete independent data package of pharmaceutical
tests, preclinical tests and clinical trials. In addition, companies may be developing biosimilar products in other countries
that could compete with our products, if approved.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
competitors are able to obtain marketing approval for biosimilars referencing our product candidates, if approved, such products
may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences.
Such competitive products may be able to immediately compete with us in each indication for which our product candidates may have
received approval.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 24.5pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>If
product liability lawsuits are brought against us, we may incur substantial liabilities, even if we have appropriate insurance
policies, and we may be required to limit commercialization of our product candidates. </I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing,
marketing and use of biopharmaceutical and biotechnology products. Currently, we have no products that have been approved for
marketing or commercialization; however, the use of our product candidates in clinical trials, and the sale of these product candidates,
if approved, in the future, may expose us to liability claims. Product liability claims may be brought against us or our partners
by participants enrolled in our clinical trials, patients, health care providers, biotechnology and pharmaceutical companies,
our collaborators or others using, administering or selling any of our future approved products. If we cannot successfully defend
ourselves against any such claims, we may incur substantial liabilities, even if we have product liability or such other applicable
insurance policies in effect. We may not be able to maintain adequate levels of insurance for these liabilities at reasonable
cost and/or reasonable terms. Excessive insurance costs or uninsured claims would add to our future operating expenses and adversely
affect our financial condition. As a result of such lawsuits and their potential results, we may be required to limit commercialization
of our product candidates. Regardless of the merits or eventual outcome, liability claims may result in:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">decreased
                                         demand for our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">termination
                                         of clinical trial sites or entire trial programs;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">injury
                                         to our reputation and negative media attention;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">product
                                         recalls or increased warnings on product labels;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">withdrawal
                                         of clinical trial participants;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">costs
                                         of to defend the related litigation;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">diversion
                                         of management and our resources;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">substantial
                                         monetary awards to, or costly settlements with, clinical trial participants, patients
                                         or other claimants;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">higher
                                         insurance premiums;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">loss
                                         of initiation of investigations by regulators or other authorities; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         inability to successfully commercialize our product candidates, if approved.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Gene
therapies are novel, complex and difficult to manufacture. We could experience production problems that result in delays in our
development or commercialization programs or otherwise adversely affect our business.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Biological
products are inherently difficult to manufacture, and gene therapy products are complex biological products, the development and
manufacture of which necessitates substantial expertise and capital investment.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Temferon
is individually manufactured for each patient using complex processes in specialized facilities. Our production process requires
a variety of raw materials, some of which are highly specialized, including the viral vector that encodes for the therapeutic
payload. Some of these raw materials have limited and, in some cases, sole suppliers. Even though we plan to have back-up supplies
of raw materials whenever possible, we cannot be certain such supplies will be sufficient if our primary sources are unavailable.
A shortage of a critical raw material or a technical issue during manufacturing may lead to delays in clinical development or
commercialization of our product candidates.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Our product candidate, Temferon, is being studied for GBM
patients with unmethylated MGMT status, as determined by a laboratory test. If approved for use only in uMGMT-GBM patients, use of such
a laboratory test would be required for each patient before treatment with Temferon. There are several currently-marketed, CE-marked
tests for uMGMT status in the EU, one or more of which may be used in our clinical trials and which we would expect to be used in clinical
practice upon approval of Temferon. If a regulatory authority were, however, to deem that no currently-available tests are appropriate
for use with Temferon, or if appropriate tests were to become commercially unavailable, we might be required to develop and obtain regulatory
approval for our own version of such a companion diagnostic test, or work with another entity to develop such a test, in which case we
could experience significant delays in obtaining regulatory approval or interruptions in our ability to market Temferon.</P>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Several factors could cause production interruptions,
including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption
in utility services, human error or disruptions in the operations of our suppliers. We have limited experience manufacturing our
product candidates. We have contracted with a third party CMO for the manufacture of our viral vectors and drug product for clinical
trials. We expect this CMO will be capable of providing sufficient quantities of our viral vectors and gene therapy products to
meet the anticipated scales for our clinical trials, in due course, and commercial demands, if approved. However, to meet our projected
needs for further commercial manufacturing and large scale clinical trials, third parties with whom we currently work might need
to increase their scale and frequency of production, and we will likely need to secure alternate suppliers or develop our own capabilities.
We believe that there are alternate sources of supply that can satisfy our requirements, although we cannot be certain that identifying
and establishing relationships with such sources, if necessary, would not result in significant delay or material additional costs.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, two vaccines for COVID-19 were granted Emergency Use Authorization by the FDA in late 2020, and more are likely to be
authorized in the coming months. The resultant demand for vaccines and potential for manufacturing facilities and materials to
be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult to obtain
materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">All
manufacturers of pharmaceutical products must comply with strictly enforced requirements and complex regulations. Any failure
by our CMO to adhere to or document compliance to such regulatory requirements could lead to a delay or interruption in the availability
of our product candidate for clinical trials or result in sanctions, including clinical holds, fines, injunctions, civil penalties,
delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of raw materials, product candidates or
products, operating restrictions and criminal prosecutions, any of which could have significant adverse consequences on us. Our
potential future dependence upon others for the manufacture of our gene therapies may also adversely affect our future profit
margins and our ability to commercialize any product candidates that receive regulatory approval on a timely and competitive basis.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Delays
in obtaining regulatory approval of our or our CMOs&rsquo; manufacturing process and facility or disruptions in our manufacturing
process may delay or disrupt our commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Before we can begin to commercially manufacture our
viral vector or product candidates in our own facility, or the facility of a CMO, we must obtain regulatory approval from the
FDA for our manufacturing processes and for the facility in which manufacturing is performed. A manufacturing authorization must
also be obtained from the appropriate European Union regulatory authorities. In addition, we must pass a pre-approval inspection
of our or our CMOs manufacturing facility by the FDA and other relevant regulatory authorities before any of our gene therapy
product candidates can obtain marketing approval. Since March 2020, foreign and domestic inspections by FDA have largely
been on hold with FDA announcing plans in July 2020 to resume prioritized domestic inspections. Should FDA determine that an inspection
is necessary for approval of a marketing application and an inspection cannot be completed during the review cycle due to restrictions
on travel, FDA has stated that it generally intends to issue a complete response letter. Further, if there is inadequate information
to make a determination on the acceptability of a facility, FDA may defer action on the application until an inspection can be
completed. In 2020, several companies announced receipt of complete response letters due to the FDA&rsquo;s inability to complete
required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy
measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. In order to obtain
approval, we will need to ensure that all of our processes, quality systems, methods, equipment policies and procedures are compliant
with GMP, and perform extensive audits of vendors, contract laboratories, CMOs and suppliers. If any of our vendors, contract
laboratories, CMOs or suppliers is found to be out of compliance with GMP, we may experience delays or disruptions in manufacturing
while we work with these third parties to remedy the violation or while we work to identify suitable replacement vendors. The
GMP requirements govern quality control of the manufacturing process and documentation policies and procedures. In complying with
GMP, we will be obligated to expend time, money and effort in production, record keeping and quality control to assure that the
product meets applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject
to possible regulatory action and may not be permitted to sell any products that we may develop.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Failure
to comply with ongoing regulatory requirements could cause us to suspend production or put in place costly or time-consuming remedial
measures.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
regulatory authorities may, at any time following approval of a product for sale, audit the manufacturing facilities for such
product. If any such inspection or audit identifies a failure to comply with applicable regulations, or if a violation of product
specifications or applicable regulations occurs independent of such an inspection or audit, the relevant regulatory authority
may require remedial measures that may be costly or time-consuming to implement and that may include the temporary or permanent
suspension of a clinical trial or commercial sales or the temporary or permanent closure of a manufacturing facility. Any such
remedial measures imposed upon our CMO or us could harm our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
our CMOs or we fail to comply with applicable GMP regulations, FDA and foreign regulatory authorities can impose regulatory sanctions
including, among other things, refusal to approve a pending application for a new product candidate or suspension or revocation
of a pre-existing approval. Such an occurrence may cause our business, financial condition, results of operations and prospects
to be harmed.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Additionally,
if supply from any CMO or us is delayed or interrupted, there could be a significant disruption in the clinical or commercial
supply of our product candidates. We have agreements in place with our CMO pursuant to which we are collaborating on GMP manufacturing
processes and analytical methods for the manufacture and release of our viral vectors and drug product. Therefore, if we are unable
to enter into an agreement with our CMO to manufacture clinical or commercial material for our product programs, or if our agreement
with our CMOs were terminated, we would have to find suitable alternative manufacturers. This could delay our or our collaborators&rsquo;
ability to conduct clinical trials or commercialize our current and future product candidates. The regulatory authorities also
may require additional clinical trials and other nonclinical and or analytical evaluations if a new manufacturer is relied upon
for clinical or commercial production. Switching manufacturers may involve substantial costs, require significant comparability
studies and could result in a delay in our desired clinical and commercial timelines.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Any
contamination in our manufacturing process, shortages of materials or failure of any of our key suppliers to deliver necessary
components could result in interruption in the supply of our product candidates and delays in our clinical development or commercialization
schedules.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Given
the nature of biologics manufacturing, there is a risk of contamination in our manufacturing processes. Any contamination could
materially adversely affect our ability to produce product candidates on schedule and could, therefore, harm our results of operations
and cause reputational damage.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Some
of the materials required in our manufacturing process are derived from biologic sources. Such materials are difficult to procure
and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically
derived substances in the manufacture of our product candidates could adversely impact or disrupt the commercial manufacturing
or the production of clinical material, which could materially and adversely affect our development timelines and our business,
financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Patients&rsquo;
cellular source material must be transported from the clinical collection site to the manufacturing facility and the cryopreserved
drug product must be returned to the clinical site for administration into the patient using controlled temperature shipping containers.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Once
collected from the patient, the cellular source material must be transported to the manufacturing facility using a shipping container
that maintains the material at a required temperature and be delivered typically within three days of collection. While we intend
to use reputable couriers and agents for the transport of such materials, if the shipping container is opened or damaged such
that the required temperature is not maintained, the cellular source material may be adversely impacted and it may not be feasible
to manufacture a drug product for the patient. Similarly, if a shipment is delayed due to adverse weather, misrouting, other events
or held up at a customs point, the cellular source material may not be delivered within a time window that will allow for its
use for the successful manufacture of a drug product. Similarly, the patient&rsquo;s autologous drug product must be returned
to the clinical site for administration into the patient using a specialized shipping container that maintains the material at
a very low temperature for a period of typically up to ten days. While we intend to use reputable couriers and agents for the
transport of our drug products, if the shipping container is opened or damaged such that the very low temperature is not maintained,
the drug product may be adversely impacted and it may be unsuitable for administration to the patient or harmful. Similarly, if
a shipment is delayed due to adverse weather, misrouting, held up at a customs point or other events, and is not delivered to
the clinical site within the time period that the very low temperature is maintained, the drug product may be unsuitable for administration
to the patient or harmful.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Our
gene therapies are for autologous use only. Therefore, if a drug product is administered to the wrong patient, the patient could
suffer harm.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
gene therapies are autologous, so they must be administered back only to the patient from which the cellular source material was
collected. While we implement specific identifiers, lot numbers and labels with cross checks for our products and operations from
collection of cellular source material, through manufacture of drug product, transport of product to the clinical site up to thawing
and administration of the product, it is possible that a product may be administered into the wrong patient. If an autologous
gene therapies were to be administered into the wrong patient, the patient could suffer harm, including experiencing a severe
adverse immune reaction and this event, should it happen, could adversely affect our business, financial condition, results of
operations and prospects.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Our
focus on developing our current product candidates may not yield any commercially viable products, and our failure to successfully
identify and develop additional product candidates could impair our ability to grow.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
part of our growth strategy, we intend to identify, develop and market additional product candidates beyond our existing product
candidate, namely Temferon. We may spend several years completing our development of any particular current or future product
candidates, and failure can occur at any stage. The product candidates to which we allocate our resources may not end up being
successful. Because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product
candidates or for indications that later prove to have greater commercial potential than Temferon or our other product candidates.
Our spending on current and future research and development programs may not yield any commercially viable product candidates.
If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights
to that product candidate through strategic collaborations, licensing or other arrangements in cases in which it would have been
more advantageous for us to retain sole development and commercialization rights to such product candidate. If any of these events
occur, we may be forced to abandon our development efforts with respect to a particular product candidate or fail to develop a
potentially successful product candidate.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, certain of our current or future product candidates may not demonstrate in patients any or all of the pharmacological
benefits we believe they may possess or compare favorably to existing, approved therapies. We have not yet succeeded and may never
succeed in demonstrating efficacy and safety of our product candidates or any future product candidates in preclinical studies,
clinical trials or in obtaining marketing approval thereafter and, therefore, may not result in the discovery and development
of commercially viable products.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
we are unsuccessful in our development efforts, we may not be able to advance the development of our product candidates, commercialize
products, raise capital, expand our business or continue our operations.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Risks
Related to Our Reliance on Third Parties</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
utilize, and expect to continue to utilize, third parties to conduct some or all aspects of our vector production and product
manufacturing for the foreseeable future, and these third parties may not perform satisfactorily.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
currently rely on our CMO for the production of our viral vectors and product candidate for our ongoing clinical trials and
preclinical studies. For future clinical trials we intend to utilize materials manufactured by GMP-compliant CMOs. If our partners
do not successfully carry out their contractual duties, meet expected deadlines or manufacture our viral vector and product candidates
in accordance with regulatory requirements or if there are disagreements between us and our CMO, we will not be able to complete,
or may be delayed in completing, the clinical trials required to support approval of our product candidates or the FDA, EMA or
other regulatory agencies may refuse to accept our clinical or preclinical data. In such instances, we may need to enter into
an appropriate replacement third-party relationship, which may not be readily available or available on acceptable terms, which
would cause additional delay or increased expense prior to the approval of our product candidates and would thereby have a negative
impact on our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have partnered with a commercial GMP-compliant CMO and intend to utilize viral vectors and gene therapy products manufactured
by such CMO for our future clinical trials and products for which we obtain marketing approval. There is no assurance that our
CMO, or any other future third-party manufacturer that we engage, will be successful in producing any or all of our viral vector
or product candidates, that any such product will, if required, pass the required comparability testing, or that any materials
produced by any other third-party manufacturer that we engage will have the same effect in patients that we have observed to date.
We believe that our manufacturing network will have sufficient capacity to meet demand for our clinical and existing and expected
initial commercial needs, but there is a risk that if supplies are interrupted or result in poor yield or quality, it would materially
harm our business. Additionally, if the gene therapy industry were to grow, we may encounter increasing competition for the raw
materials and consumables necessary for the production of our product candidates. Furthermore, demand for CMO GMP manufacturing
capabilities may grow at a faster rate than existing manufacturing capacity, which could disrupt our ability to find and retain
third-party manufacturers capable of producing sufficient quantities of our viral vectors or product candidates for future clinical
trials or to meet expected initial commercial demand.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
certain circumstances, our current CMO is entitled to terminate their engagements with us. If we need to enter into alternative
arrangements, it could delay our development activities. Our reliance on our CMO for certain manufacturing activities will reduce
our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations.
In addition to our current CMO, we may rely on additional third parties to manufacture ingredients of our viral vectors and or
drug product in the future and to perform quality testing, and reliance on these third parties entails risks including:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">reduced
                                         control for certain aspects of manufacturing activities;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">termination
                                         or nonrenewal of manufacturing and service agreements with third parties in a manner
                                         or at a time that is costly or damaging to us; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">disruptions
                                         to the operations of our third-party manufacturers and service providers caused by conditions
                                         unrelated to our business or operations, including the bankruptcy of the manufacturer
                                         or service provider.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Any
of these events could lead to clinical trial delays or failure to obtain regulatory approval, or impact our ability to successfully
commercialize any of our product candidates. Some of these events could be the basis for FDA, EMA or other regulatory authority
action, including injunction, recall, seizure or total or partial suspension of product manufacture.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
rely on third parties to conduct our preclinical and clinical studies and perform other tasks for us. If these third parties do
not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not
be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
do not expect to independently conduct all aspects of our lentiviral vector protocol development, research and preclinical and
clinical testing. We currently rely, and plan to continue to rely, upon third-party CROs to monitor and manage data for our ongoing
preclinical and clinical programs. Pursuant to the OSR License Agreement, we agreed to use OSR as the primary site in any preclinical
study or clinical trial (including all phases thereof) relating to any licensed products in the field of use, subject to OSR maintaining
any required quality standards and providing its services on customary and reasonable terms and consistent with then-applicable
market standards. We rely on these parties, including OSR, for execution of our preclinical and clinical studies, but we can only
control limited aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted
in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve
us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with current GMP, Good Clinical
Practices, or GCP, and Good Laboratory Practices, or GLP, which are regulations and guidelines enforced by the FDA, the Competent
Authorities of the Member States of the EEA, and comparable foreign regulatory authorities for all of our product candidates in
clinical development. Regulatory authorities enforce these regulations through periodic inspections of study sponsors, principal
investigators, study sites and other contractors. If we or any of our CROs or vendors fail to comply with applicable regulations,
the clinical data generated in our clinical studies may be deemed unreliable and the FDA, the EMA or other comparable regulatory
authorities may require us to perform additional clinical studies before approving our marketing applications. We cannot assure
you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical studies
comply with GCP regulations. In addition, our clinical studies must be conducted with product candidates which are produced under
GMP regulations. These risks may be heightened as a result of the evolving COVID-19 pandemic due to difficulties in recruiting
study subjects during times of travel restriction, delays in obtaining required regulatory inspections, and potential unavailability
of our CROs due to their involvement with COVID-related development activities. Our failure to comply with these regulations may
require us to repeat clinical studies, which would delay the regulatory approval process.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
and our collaborators and contract manufacturers are subject to significant regulation with respect to manufacturing our product
candidates. The manufacturing facilities on which we rely may not meet regulatory requirements and have limited capacity.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Contract
manufacturers and their facilities are required to comply with extensive regulatory requirements, including ensuring that quality
control and manufacturing procedures conform to GMPs. These GMP regulations cover all aspects of manufacturing relating to our
product candidates and components used in clinical studies. These regulations govern manufacturing processes and procedures (including
record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational product
candidates and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or
to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing.
We, our collaborators or our contract manufacturers must supply all necessary documentation in support of an BLA or MAA on a timely
basis and must adhere to GLP and GMP regulations enforced by the FDA and other regulatory authorities through their facilities
inspection program. The facilities and quality systems of some or all of our collaborators and third-party contractors must pass
a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product
candidates or any of our other potential product candidates. In addition, the regulatory authorities may, at any time, audit or
inspect a manufacturing facility involved with the preparation of our product candidates or our other potential product candidates
or the associated quality systems for compliance with the regulations applicable to the activities being conducted. We do not
control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with
the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the product
candidates may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory
authority, if ever. Moreover, if our contract manufacturers fail to achieve and maintain high manufacturing standards, in accordance
with applicable regulatory requirements, or there are substantial manufacturing errors, this could result in patient injury or
death, product shortages, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or
other problems that could seriously harm our business.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
are dependent on a limited number of suppliers and, in some instances, a sole supplier, for some of our components and materials
used in our product candidates.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
currently depend on a limited number of suppliers and, in some instances, a sole supplier, for some of the components and equipment
necessary for the production of our viral vectors and drug product. We cannot be sure that these suppliers will remain in business,
or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce
these materials for our intended purpose. Our use of a sole or a limited number of suppliers of raw materials, components and
finished goods exposes us to several risks, including disruptions in supply, price increases, late deliveries and an inability
to meet customer demand. There are, in general, relatively few alternative sources of supply for these components, and in some
cases, no alternatives. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial
sale. Establishing additional or replacement suppliers for these components could take a substantial amount of time and it may
be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any supplier or
manufacturing location could lead to supply delays or interruptions which would damage our business, financial condition, results
of operations and prospects.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
we are required to switch to a replacement supplier, the manufacture and delivery of our viral vectors and product candidates
could be interrupted for an extended period, adversely affecting our business. Establishing additional or replacement suppliers
may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified
and may require additional regulatory authority approval, which could result in further delay. For example, the FDA or EMA could
require additional supplemental data, manufacturing data and comparability data up to and including clinical trial data if we
rely upon a new supplier. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the
conduct of additional clinical trials. While we seek to maintain adequate inventory of the components and materials used in our
product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components
or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to conduct our clinical
trials and, if our product candidates are approved, to meet the demand of our customers and cause them to cancel orders.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, as part of the FDA&rsquo;s approval of our product candidates, the FDA must review and approve the individual components
of our production process, which includes raw materials, the manufacturing processes and facilities of our suppliers. Some of
our current suppliers have not undergone this process nor have they had any components included in any product approved by the
FDA.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
reliance on these suppliers subjects us to a number of risks that could harm our reputation, business, and financial condition,
including, among other things:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         interruption of supply resulting from modifications to or discontinuation of a supplier&rsquo;s
                                         operations;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">delays
                                         in product shipments resulting from uncorrected defects, reliability issues, or a supplier&rsquo;s
                                         variation in a component;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">a
                                         lack of long-term supply arrangements for key components with our suppliers;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         inability to obtain adequate supply in a timely manner, or to obtain adequate supply
                                         on commercially reasonable terms;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">difficulty
                                         and cost associated with locating and qualifying alternative suppliers for our components
                                         in a timely manner;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">production
                                         delays related to the evaluation and testing of products from alternative suppliers,
                                         and corresponding regulatory qualifications;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">a
                                         delay in delivery due to our suppliers prioritizing other customer orders over ours;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 53.45pt; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 53.45pt; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">damage
                                         to our reputation caused by defective components produced by our suppliers;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">increased
                                         cost of our warranty program due to product repair or replacement based upon defects
                                         in components produced by our suppliers; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">fluctuation
                                         in delivery by our suppliers due to changes in demand from us or their other customers.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
any of these risks materialize, costs could significantly increase and our ability to conduct our clinical trials and, if our
product candidates are approved, to meet demand for our products could be impacted.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Any
collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability
to develop and commercialize our current and potential future product candidates.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
may seek collaboration arrangements with biotechnology or pharmaceutical companies for the development or commercialization of
our current and potential future product candidates. We may enter into these arrangements on a selective basis depending on the
merits of retaining commercialization rights for ourselves as compared to entering into selective collaboration arrangements with
other biotechnology or pharmaceutical companies for each product candidate, both in the United States and internationally. We
will face, to the extent that we decide to enter into collaboration agreements, significant competition in seeking appropriate
collaborators. Moreover, collaboration arrangements are complex and time consuming to negotiate, document and implement. We may
not be successful in our efforts to establish and implement collaborations or other alternative arrangements should we so choose
to enter into such arrangements. The terms of any collaborations or other arrangements that we may establish may not be favorable
to us.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Disagreements
between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays
in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration
arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Collaborations
with biotechnology or pharmaceutical companies and other third parties often are terminated or allowed to expire by the other
party. Any such termination or expiration could adversely affect us financially and could harm our business reputation.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Our
reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover
them or that our trade secrets will be misappropriated or otherwise disclosed.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Because
we rely on third parties to develop and manufacture our product candidates, we must, at times, share trade secrets with them.
We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material
transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators,
advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically
limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual
provisions employed when working with third parties, the need to share trade secrets and other confidential information increases
the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others,
or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how
and trade secrets, a competitor&rsquo;s discovery of our trade secrets or other unauthorized use or disclosure would impair our
competitive position and may have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, these agreements typically restrict the ability of our collaborators, advisors, employees and consultants to publish
data potentially relating to our trade secrets. Our principal investigators, physicians and academic collaborators typically have
rights to publish data, provided that we are notified in advance and may delay publication for a specified time in order to secure
our intellectual property rights arising from the collaboration. Despite our efforts to protect our trade secrets, our competitors
may discover our trade secrets, either through breach of these agreements, independent development or publication of information
including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication.
A competitor&rsquo;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Risks
Related to Intellectual Property</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
depend on license agreements with OSR to permit us to use patents and patent applications, as well as to exploit specific OSR
know-how. Termination of these rights or the failure to comply with obligations under these agreements could materially harm
our business and prevent us from developing or commercializing our product candidates (Temferon in particular).</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">We are party to a license agreement with
OSR under which we were granted rights to patents and patent applications, as well as proprietary technologies, that are important
and necessary to our business, including our Temferon based product candidates. Our rights to use these patents and patent
applications and employ the inventions claimed in these licensed patents, as well as the exploitation of OSR proprietary technology,
are subject to the continuation of, and our compliance with, the terms of our license agreement.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
license agreement with OSR imposes upon us various diligence, payment and other obligations, including the following:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         obligation to pay OSR various milestone payments in the aggregate amount of up to &euro;10
                                         million related to the Lympho-Hematopoietic Indication of each Licensed Product and up
                                         to &euro;53 million related to each Solid Cancer indication, contingent upon
                                         our achievement of certain late-stage regulatory and sales milestones with respect to
                                         use of Temferon for GBM, and additional amounts for milestones with other solid cancer
                                         indications upon exercising those rights.</FONT> However, starting with the fifth
                                         Solid Cancer indication, the first two related milestone payments totaling &euro;7.0
                                         million are reduced to &euro;3.5 million.</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         obligation to pay OSR royalties based on net sales of each licensed product that we commercialize
                                         under the agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         obligation to pay a percentage of income derived from sublicensees for each licensed
                                         product sublicensed under the agreement.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         obligation to pay fees associated with the prosecution, maintenance, or filing of the
                                         patents and patent applications we have licensed.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
we fail to comply with any of our obligations under the OSR license agreement, or we are subject to a bankruptcy or dissolution,
OSR may have the right to terminate the license agreement, in which event we would not be able to market any product candidates
covered by the license.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
do not currently own any patents, and we are heavily reliant upon license from OSR to certain patent rights that are important
or necessary to the development of our technology and product candidates, including the patents relating to Temferon. Our license
is exclusive only to specific fields of use, namely: GBM, solid liver cancer and any lympho-hematopoietic indication. Although
we have exclusive option rights to license additional fields of use, or indications, upon the payment of additional fees to OSR,
there is no guarantee that we will be in a position to do so within the time period specified to exercise such right. As a result,
we may not be able to prevent competitors from developing and commercializing competitive products.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We do not control the prosecution, maintenance, or
filing of the patents and patent applications that are licensed to us under the OSR license agreement (unless OSR chooses
i) not to file and/or prosecute certain patent applications, or  ii) to abandon such patent application and issued patents,
in which cases we have the right to &ndash; at our expense &ndash; file, prosecute and/or maintain such patent applications), or
the enforcement of these patents and patent applications against infringement by third parties. Thus, these patents and
patent applications were not drafted by us or our attorneys, and we do not control or have any input into the prosecution of
these patents and patent applications. We cannot be certain that drafting or prosecution of the patents and patent
applications licensed to us has been conducted in compliance with applicable laws and regulations or will result in valid and
enforceable patents. OSR controls the preparation, filing and prosecution of patent applications, and is responsible for
maintaining the patents, covering technology that we license.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Pursuant
to our license, we are required to file an IND regarding Temferon for GBM prior to February 2022. If we fail to comply with the
obligations under our license agreement, including as a result of COVID-19 impacting our operations or due to lack of funds, or
if we use the licensed intellectual property in an unauthorized manner, we may be required to pay damages and our licensors may
have the right to terminate the license. If our license agreement is terminated, we may not be able to develop, manufacture, market
or sell the product candidates covered by our agreement and those being tested or approved in combination with such products.
Such an occurrence could materially adversely affect the value of the product candidates being developed under any such agreement.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Disputes
may arise regarding intellectual property subject to, and any of our rights and obligations under, any license or other strategic
agreement, including:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    scope of rights granted under the license agreement and other interpretation-related issues;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    extent to which our technology and processes infringe, misappropriate or violate the intellectual property of the licensor
    that is not subject to the license agreement;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
    diligence obligations under the license agreement and what activities satisfy those diligence obligations;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    sublicensing of patent and other rights to third parties under any such agreement or collaborative relationships;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by
    our licensors and us and our partners; and</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    priority of invention of patented technology.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, the agreements under which we license intellectual property or technology to or from third parties are complex, and
certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation
disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or
technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which
could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes
over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements
on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
business also would suffer if any current or future licensors fail to abide by the terms of the license, if the licensors fail
to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid
or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Moreover, our licensors may own or
control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their
merit, that we are infringing, misappropriating or otherwise violating the licensor&rsquo;s rights.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, if we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the
existing intellectual property rights we have, we may have to seek alternative options, such as developing new product candidates
with design-around technologies, which may require more time and investment, or abandon development of the relevant research programs
or product candidates and our business, financial condition, results of operations and prospects could suffer.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
have been granted licenses in certain fields of use to patent applications. There can be no assurance that any of the patent applications
that we have licenses to will result in issued patents. As a result, our ability to protect our proprietary technology in the
marketplace may be limited.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have been granted licenses in certain fields of use to patent applications in many countries worldwide. These applications cover
a range of areas including: applications relating, in general terms, to the use of gene vectors comprising a miRNA target sequence,
and the use of gene vectors comprising an interferon-alpha transgene operably linked to a miRNA-130a or miRNA-126 target sequence.
Unless and until the pending patent applications are issued, their protective scope is impossible to determine. It is also impossible
to predict whether or how many of the patent applications will result in issued patents. Even if pending applications are issued,
they may be issued with coverage significantly narrower than what is currently sought.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Our
proprietary position for our product candidates currently depends in part upon licenses to patents protecting methods of use,
which may not prevent a competitor or other third party from using the same product candidate for another use.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Composition
of matter patent claims on the active pharmaceutical ingredient, or API, in pharmaceutical drug products are generally considered
to be the favored form of intellectual property protection for pharmaceutical products, as such patents generally provide protection
without regard to any particular method of use, manufacture or formulation of the API used. Method of use patent claims protect
the use of a product for the specified method and dosing. These types of patent claims do not prevent a competitor or other third
party from making and marketing an identical API for an indication that is outside the scope of the method claims or from developing
a different dosing regimen. Moreover, even if competitors or other third parties do not actively promote their product for our
targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products off-label,
or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method of use patents,
the practice is common and such infringement is difficult to prevent or prosecute.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><B><I>Even</I></B><B><I> if patents are issued based on patent applications
to which we have been granted a license, because the patent positions of pharmaceutical and biotechnology products are
complex and uncertain, we cannot predict the scope and extent of patent protection for our product candidates.</I></B></P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font: 10pt Georgia"><B><I></I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Any
patents that may be issued based on patent applications that we have been granted licenses to will not ensure sufficient protection
with respect to our activities for a number of reasons, including without limitation the following:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">any
                                         issued patents may not be broad or strong enough to prevent competition from other gene
                                         therapy products including identical or similar products;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">if
                                         patents are not issued or if issued patents expire, there would be no protections against
                                         competitors making generic equivalents;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">there
                                         may be prior art of which we are not aware that may affect the validity or enforceability
                                         of a patent claim;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">there
                                         may be other patents existing, now or in the future, in the patent landscape for Temferon,
                                         or any other product candidates that we seek to commercialize or develop, if any, that
                                         will affect our freedom to operate;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">if
                                         patents that we have been granted licenses to are challenged, a court could determine
                                         that they are not valid or enforceable;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">a
                                         court could determine that a competitor&rsquo;s technology or product does not infringe
                                         patents that we have been granted licenses to;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">patents
                                         to which we have been granted licenses could irretrievably lapse due to failure
                                         to pay fees or otherwise comply with regulations, or could be subject to compulsory licensing;
                                         and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">if
                                         we encounter delays in our development or clinical trials, the period of time during
                                         which we could market our products under patent protection would be reduced.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Obtaining
and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and patent protection could be reduced or eliminated for noncompliance with these requirements.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Periodic
maintenance fees on any issued patent are due to be paid to the United States Patent and Trademark Office (USPTO) and foreign
Intellectual Property Offices in several stages over the term of the patent. Maintenance fees are also due for pending patent
applications in some countries. The USPTO and various foreign governmental patent agencies require compliance with a number of
procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent
lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are
situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial
or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse
of a patent or patent application include, but are not limited to, failure to respond to office actions within prescribed time
limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might
be able to enter the market, which would have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>The
life of patent protection is limited, and third parties could develop and commercialize products and technologies similar or identical
to ours and compete directly with us after the patent licensed to us expires, which could materially and adversely affect our
ability to commercialize our products and technologies. </I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
life of a patent and the protection it affords is limited. For example, in the United States, if all maintenance fees are timely
paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. In Europe,
the expiration of an invention patent is 20 years from its filing date. Even if we successfully obtain patent protection for an
approved drug candidate, it may face competition from generic or biosimilar medications. Manufacturers of generic or biosimilar
drugs may challenge the scope, validity or enforceability of the patents underlying our technology in court or before a patent
office, and the patent holder may not be successful in enforcing or defending those intellectual property rights and, as a result,
we may not be able to develop or market the relevant product candidate exclusively, which would materially adversely affect any
potential sales of that product.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Given
the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such
drug candidates might expire before or shortly after such drug candidates are commercialized. As a result, the patents and patent
applications licensed to us may not provide us with sufficient rights to exclude others from commercializing products similar
or identical to ours. Even if we believe that the patents involved are eligible for certain (and time-limited) patent term
extensions, there can be no assurance that the applicable authorities, including the FDA and the USPTO, and any equivalent regulatory
authority in other countries, will agree with our assessment of whether such extensions are available, and such authorities may
refuse to grant extensions to such patents, or may grant more limited extensions than requested. For example, depending upon the
timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of the U.S.
patents licensed to us may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration
Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as
compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining
term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those
claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not
be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review
process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise
failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could
be less than requested. If we are unable to obtain patent term extension or term of any such extension is less than requested,
our competitors may obtain approval of competing products following our patent expiration, and our business could be harmed. Changes
in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value
of our patents or narrow the scope of our patent protection.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
patents and pending patent applications licensed to us for our product candidates are expected to expire on various dates as described
in &ldquo;Business&mdash;Intellectual Property.&rdquo; Upon the expiration, we will not be able to assert such licensed patent
rights against potential competitors, which would materially adversely affect our business, financial condition, results of operations
and prospects.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 24.5pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
may need to license intellectual property from third parties, and such licenses may not be available or may not be available on
commercially reasonable terms or at all. </I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">There
may be intellectual property rights existing now, or in the future, relevant to Temferon, or any other product candidates that
we seek to commercialize or develop, if any, that may affect our ability to commercialize such product candidates. Although the
Company is not aware of any such intellectual property rights, a</FONT><FONT STYLE="font: 10pt Georgia"> third-party may hold
intellectual property rights, including patent rights, that are important or necessary to the development or manufacture of our
product candidates. Even if all our main product candidates are covered by patents, it may be necessary for us to use the patented
or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain
a license from these third parties. Such a license may not be available on commercially reasonable terms, or at all, and we could
be forced to accept unfavorable contractual terms. In that event, we may be required to expend significant time and resources
to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology,
all of which may not be feasible on a technical or commercial basis. If we are unable to do so, our business could be harmed.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies
may pursue strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary.
These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical
development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to
assign or license rights to us. We also may be unable to license or acquire third party intellectual property rights on terms
that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights
to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have
to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business,
financial condition, results of operations, and prospects.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and
unsuccessful.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition to the possibility of litigation relating to infringement claims asserted against it, we may become a party to other
patent litigation and other proceedings, including <I>inter partes</I> review proceedings, post-grant review proceedings, derivation
proceedings declared by the USPTO and similar proceedings in foreign countries, regarding intellectual property rights with respect
to our current or future technologies or product candidates or products. Pursuant to the OSR License Agreement, OSR has the right
to enforce the patents at its own expense. However, if OSR fails to do so, we have the right to enforce the licensed patents in
the field of use, at our expense. The cost to us of any patent litigation or other proceeding, even if resolved in our favor,
could be substantial. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively
than we can because of their substantially greater financial resources. Patent litigation and other proceedings may also absorb
significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings
could impair our ability to compete in the marketplace.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Competitors may infringe or otherwise violate our intellectual
property, including patents that may issue to or be licensed by us. As a result, we may be required to file claims in an effort
to stop third-party infringement or unauthorized use. Any such claims could provoke these parties to assert counterclaims against
us, including claims alleging that we infringe their patents or other intellectual property rights, and/or that any of our
IP, including licensed IP, is invalid and/or unenforceable. This can be prohibitively expensive, particularly for a company
of our size, and time-consuming, and even if we are successful, any award of monetary damages or other remedy we may receive may
not be commercially valuable. In addition, in an infringement proceeding, a court may decide that our asserted intellectual property
is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that
our intellectual property does not cover its technology. An adverse determination in any litigation or defense proceedings could
put our intellectual property at risk of being invalidated or interpreted narrowly and could put our patent applications at risk
of not issuing.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
the breadth or strength of our patent or other intellectual property rights is compromised or threatened, it could allow third
parties to exploit and, in particular, commercialize our technology or products or result in our inability to exploit
and/or commercialize our technology and products without infringing third-party intellectual property rights. Further, third
parties may be dissuaded from collaborating with us.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Interference
or derivation proceedings brought by the USPTO or its foreign counterparts may be necessary to determine the priority of inventions
with respect to our patent applications, and we may also become involved in other proceedings, such as re-examination proceedings,
before the USPTO or its foreign counterparts. Due to the substantial competition in the pharmaceutical space, the number of such
proceedings may increase. This could delay the prosecution of our pending patent applications or impact the validity and enforceability
of any future patents that we may obtain. In addition, any such litigation, submission or proceeding may be resolved adversely
to us and, even if successful, may result in substantial costs and distraction to our management.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation, even if some jurisdictions
have specific rules so as to maintain confidentiality during the proceedings. Moreover, intellectual property law relating
to the fields in which we operate is still evolving and, consequently, patent and other intellectual property rights in
our industry are subject to change and are often uncertain. We may not prevail in any of these suits or other efforts to protect
our technology, and the damages or other remedies awarded, if any, may not be commercially valuable. During the course of this
type of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments.
If securities analysts or investors perceive these results to be negative, the market price for our common stock could be significantly
harmed.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Intellectual
property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Litigation
or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive
and time consuming and is likely to divert significant resources from our core business, including distracting our technical and
management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required
in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised
by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions
or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it
could have a substantial adverse effect on the price of our common stock and negatively impact our ability to raise additional
funds. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for
development activities or any future sales, marketing or distribution activities.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors
may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial
resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able
to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights.
Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse
effect on our ability to compete in the marketplace.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Any
trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business. </I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
expect to rely on trademarks, including Temferon, as one means to distinguish any of our product candidates that are approved
for marketing from the products of our competitors. Other than Temferon, which we have registered in the EU and the U.S., we have
not yet selected trademarks for our product candidates and have not yet begun the process of applying to register trademarks for
any other of our product candidates. Once we select trademarks and apply to register them, our trademark applications may not
be approved. Third parties may oppose our trademark applications, or otherwise challenge our use of the trademarks. In the event
that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand
recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our
trademarks and we may not have adequate resources to enforce our trademarks.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, any proprietary name we propose to use with our clinical-stage product candidates or any other product candidate in
the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark.
The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other
product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional
resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not
infringe the existing rights of third parties and be acceptable to the FDA. The EMA may also object to our proposed proprietary
product name that infringes the existing rights of third parties.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets
of interest and our business may be adversely affected. Over the long term, if we are unable to establish name recognition based
on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.
Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other
intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely
affect our business, financial condition, results of operations and growth prospects.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
may not be able to enforce intellectual property rights throughout the world.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Filing, prosecuting, and defending patent
applications and issued patents on product candidates in all countries throughout the world would be prohibitively expensive,
and intellectual property rights that we have been granted licenses to in some countries outside the United States and Italy can
be less extensive than those in the United States and Italy. In addition, the laws of some foreign countries do not protect intellectual
property to the same extent as laws in the United States and Italy. Consequently, we may not be able to seek to prevent third
parties from practicing inventions that are the subject of patents that we have been granted licenses to in all countries outside
the United States and Italy, or from selling or importing products made using inventions that are the subject of patents that
we have been granted licenses to in and into the United States or other jurisdictions. Competitors, for example, may use technologies
that are the subject of patents that we have been granted licenses to in jurisdictions where we have not licensed patents to develop
their own products and further, may export otherwise infringing products to territories where we have been granted licenses to
patents, but enforcement is not as strong as that in the United States and Italy.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Many companies have encountered significant problems
in protecting and defending intellectual property in foreign jurisdictions. The legal systems of certain countries, particularly
certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly
those relating to pharmaceutical and biotechnology products, which could make it difficult for us to stop the infringement of
patents that we have been granted licenses to or marketing of competing products in violation of our proprietary rights generally.
To date, we have not sought to enforce any issued patents in these foreign jurisdictions. Proceedings to enforce patent rights
that we have been granted licenses to in foreign jurisdictions could result in substantial costs and divert our efforts and attention
from other aspects of our business, could put patents that we have been granted licenses to at risk of being invalidated or interpreted
narrowly and patent applications that we have been granted licenses to at risk of not issuing and could provoke third parties
to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded,
if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries, particularly developing
countries. Certain countries in Europe and developing countries, including China and India, have compulsory licensing laws under
which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited
remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially
diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce
intellectual property rights that we have been granted licenses to around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>If
we are unable to maintain effective proprietary rights for our product candidates, we may not be able to compete effectively in
our markets.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition to the protection afforded by any issued patents to which we have been granted licenses and future patents that may be
granted, our license agreement with OSR provides rights to access know-how, or trade secrets. We seek to preserve the integrity
and confidentiality of our data, trade secrets and intellectual property by maintaining physical security of our premises and
physical and electronic security of our information technology systems, as well as by entering into confidentiality agreements.
Agreements or security measures may be breached or could expire, and we may not have adequate remedies for any breach and/or
expiration. In addition, our trade secrets may otherwise become known or be independently discovered
by competitors.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
cannot provide any assurances that trade secrets and other confidential proprietary information will not be disclosed in violation
of confidentiality agreements or that competitors will not otherwise gain access to trade secrets or independently develop substantially
equivalent information and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally,
if the steps taken to maintain trade secrets and intellectual property are deemed inadequate, we may have insufficient recourse
against third parties for misappropriating any trade secret.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Third
parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which
would be uncertain and could have a material adverse effect on the success of our business.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
commercial success depends upon our ability to develop, manufacture, market and sell our platform technology without infringing
the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical
industries. While no such judicial litigation has been brought against us and we have not been held by any court to have
infringed a third party&rsquo;s intellectual property rights, we cannot guarantee that our technology or use of our technology
does not infringe third-party patents. It is also possible that we have failed to identify relevant third-party patents or applications.
For example, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed
outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are
published approximately 18 months after the earliest filing, which is referred to as the priority date in cases where priority
is claimed. Therefore, patent applications covering our technology could have been filed by others without our knowledge. Additionally,
pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could
cover our technology.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
March 2013, the United States transitioned to a &lsquo;first to file&rsquo; system in which the first inventor to file a patent
application will be entitled to the patent. Third parties are allowed to submit prior art prior to the issuance of a patent by
the USPTO and may become involved in post-grant review or derivation proceedings for applications filed on or after March 16,
2013, interference proceedings for applications filed before March 16, 2013, <I>ex parte</I> reexamination, or <I>inter partes
</I>review challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding
or litigation could reduce the scope of, or invalidate, our patent rights, which could adversely affect our competitive position
with respect to third parties. We may become party to, or threatened with, future adversarial proceedings or litigation regarding
intellectual property rights with respect to our technology, including <I>inter partes</I> review, interference, or derivation
proceedings before the USPTO and similar bodies in other countries. Third parties may assert infringement claims against us based
on existing intellectual property rights and intellectual property rights that may be granted in the future.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are aware of issued patents in the United States that cover the lentiviral vectors used in the manufacture of our product candidates.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
we are found to infringe a third party&rsquo;s intellectual property rights, we could be required to obtain a license from such
third party to continue developing and marketing our technology. However, we may not be able to obtain any required license on
commercially reasonable terms or at all. Any inability to secure licenses or alternative technology could result in delays in
the introduction of our products or lead to prohibition of the manufacture or sale of products by us. Even if we were able to
obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We
could be forced, including by court order, to cease commercializing the infringing technology. In addition, we could be found
liable for monetary damages, including treble damages and attorneys&rsquo; fees if we are found to have willfully infringed a
patent. A finding of infringement could prevent us from commercializing our technology or force us to cease some of our business
operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade
secrets of third parties could have a similar negative impact on our business.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade
secrets, inventions or intellectual property rights of their current or former employers or claims asserting ownership
of what we regard as intellectual property that we have been granted licenses to.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Certain
of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants
and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that
these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information,
of any such individual&rsquo;s current or former employer. Litigation may be necessary to defend against these claims. If we fail
in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel.
Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management. Our licensors may face similar risks, which could have an adverse impact on intellectual property that is licensed
to us.</FONT></P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In this respect, our key people Mr. Luigi Naldini
and Mr. Bernhard Gentner are also employees of Ospedale San Raffaele, and have been appointed, according to a consultancy agreement,
as directors of our scientific committee for the purpose of designing and developing the preclinic research and clinic experimentation
program in the area of cancers (Prof. Naldini) and mieloma (Dr. Gentner) gene therapy. The relevant consultancy agreements do
not set forth any specific representation and warranty in our favor that their activities do not infringe any third-party&rsquo;s
intellectual property rights (in particular, of OSR). In this respect, Mr. Naldini and Mr. Gentner have executed a statement whereby
they have declared that their consultancy activities in our favor have been carried out by the same without infringing upon the
intellectual property rights of OSR. OSR is not part of this statement and, therefore, OSR could in any case address claims against
us with respect to an infringement of its intellectual property right by Mr. Naldini and Mr. Gentner in relation to their activity
in our favor.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>There
may be claims challenging the inventorship of patents and other intellectual property that we have been granted licenses to. </I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">There
may be claims that former employees, collaborators or other third parties have an interest in patents or other intellectual property
that we have been granted licenses to as an inventor or co-inventor. For example, we may have inventorship disputes arise from
conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary
to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying
monetary damages, there may be a loss of valuable intellectual property rights to us or our licensors, such as exclusive ownership
of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even
if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management
and other employees. In addition, we may receive less revenue from future products if any of our employees successfully claim
for compensation for their work in developing intellectual property, which in turn could impact our future profitability.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><B><I>Under applicable employment laws, we may not be able to prevent
our employees or key consultants, after the termination of their relationship with us or - with reference to key consultants -
during the same, to perform competitive activity in favor of other companies nor to enforce covenants not to compete and therefore
may be unable to prevent our competitors from benefiting from the expertise of such employees or consultants. In addition,
employees and consultants may be entitled to seek compensation for their inventions irrespective of their agreements with us.</I></B></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">To date, we have not entered into non-competition agreements
with our current employees in order to prevent them, after the termination of their employment, to perform competitive activity in favor
of other employers. Therefore, we cannot exclude that, after the termination of the employment, such employers may benefit from the expertise
of our current employees developed while working for us. We sometimes enter into non-competition agreements with certain key consultants.
These agreements prohibit key consultants, if they cease working for us, from competing directly with us or working for our competitors
or clients for a limited period of time. We may be unable to enforce these agreements under the laws of the jurisdictions in which our
consultants work and it may be difficult for us to restrict our competitors from benefitting from the expertise our former consultants
developed while working for us. Under Italian law, a non-competition agreement could be invalidated if, for example, the geographic scope
of the non-competition agreement is too broad, or, alternatively, such an agreement could be deemed by an Italian court to be an occupation
ban. Such actions would make enforcing our non-competition agreements more challenging and could make it easier for our competitors to
employ or benefit from the expertise of our key consultants. In addition, we cannot exclude that our current independent consultants
may perform activities &ndash;during their relationship with us- which could result in competition / conflict with our activity (e.g.,
in case they perform their activity for the benefit of other employers or companies). Lastly, with reference to the key consultants with
whom no non-competition agreement has been entered into, we cannot exclude that, after the termination of their relationship with us
or during the same, other employers or companies may benefit from the expertise of such consultants developed while working for
us.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In addition, under Italian law, in case of inventions developed
by our employees, which were developed while performing their employment activities, but outside the performance of their contractual
duties, the rights to the inventions belong to us but we are required to compensate the employees for the rights to their respective
inventions. With regard to independent consultants, Italian law provides that, save for the case in which the inventive activity of the
same has been set forth as the subject of the consulting agreement and compensated for this purpose, the rights to economically exploit
the original contributions and inventions realized in the execution of the consulting agreement will belong to consultant.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 35.45pt">To date, both the employment agreements and consultancy
agreements do not provide any specific compensation related to the inventive activity.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">As a consequence, employees and independent consultants
may ask for a fair compensation due to such inventions and, with regard to independent consultants, the failure to pay a fair compensation
could prevent us from obtaining rights on their inventions, and this could have a material adverse effect on our operations and ability
to effectively compete.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Intellectual
property rights do not necessarily address all potential threats. </I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have
limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">any
    product candidates we may develop will eventually become commercially available in generic or biosimilar product forms;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">others
    may be able to make products that are similar to any product candidates we may develop or utilize similar technology but that
    are not covered by the claims of the patents that we may own or license now or in the future;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">we,
    or any future license partners or collaborators, might not have been the first to make the inventions covered by the issued
    patent or pending patent application that we own or license now or in the future;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">we,
    or any future license partners or collaborators, might not have been the first to file patent applications covering certain
    of our or their inventions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">others
    may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our
    intellectual property rights;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">it
    is possible that pending patent applications currently licensed or those to which we may enter into a license regarding in
    the future will not lead to issued patents;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">it
    is possible that there are prior public disclosures that could invalidate the issued patents that have been licensed to us,
    or parts of such issued patents;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">it
    is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with
    claims covering our product candidates or technology similar to ours;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">issued
    patents to which we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our
    competitors;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    claims of patent applications, if and when issued, may not cover our product candidates;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
    competitors might conduct research and development activities in countries where we do not have patent rights and then use
    the information learned from such activities to develop competitive products for sale in our major commercial markets;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    laws of foreign countries may not protect our proprietary rights or the proprietary rights of license partners or current
    or future collaborators to the same extent as the laws of the United States;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    inventors of our patent applications may become involved with competitors, develop products or processes that design around
    our patents, or become hostile to us or the patents or patent applications on which they are named as inventors;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">we
    engage in scientific collaborations and will continue to do so in the future, and our collaborators may develop adjacent or
    competing products that are outside the scope of our patents;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">any
    product candidates we develop may be covered by third parties&rsquo; patents or other exclusive rights;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    patents of others may harm our business;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">we
    may not develop additional proprietary technologies that are patentable; and</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">we
    may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third-party may subsequently
    file a patent covering such intellectual property.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Should
any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations,
and prospects. The patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex
legal, technical and factual questions and have in recent years been the subject of much litigation. As a result, the issuance,
scope, validity, enforceability and commercial value of our patents, including those patent rights licensed to us by third parties,
are highly uncertain.</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Risks
Related to Our Business Operations</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>As
a company currently with substantial operations outside of the United States, our business is subject to economic, political,
regulatory and other risks associated with international operations. </I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
a company with substantial operations in Italy, our business is subject to risks associated with conducting business outside the
United States. Many of our suppliers and clinical trial relationships are located outside the United States. Accordingly, our
future results could be harmed by a variety of factors, including:</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">economic
    weakness, including inflation, or political instability in particular non-U.S. economies and markets;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">differing
    and changing regulatory requirements for product approvals;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">differing
    jurisdictions could present different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">potentially
    reduced protection for intellectual property rights;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">difficulties
    in compliance with different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance
    with a wide variety of foreign laws, treaties and regulations;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">changes
    in non-U.S. regulations and customs, tariffs and trade barriers;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">foreign
    exchange risks and currency controls;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">changes
    in a specific country&rsquo;s or region&rsquo;s political or economic environment;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">trade
    protection measures, import or export licensing requirements or other restrictive actions by governments;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">differing
    reimbursement regimes and price controls in certain non-U.S. markets;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">negative
    consequences from changes in tax laws;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">compliance
    with tax, employment, immigration and labor laws for employees living or traveling abroad, including, for example, the variable
    tax treatment in different jurisdictions of options granted under our share incentive plans;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">workforce
    uncertainty in countries where labor unrest is more common than in the United States;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">litigation
    or administrative actions resulting from claims against us by current or former employees or by employees of third
    party contractors or consultants, individually or as part of class actions, including: (i) claims of wrongful terminations
    and payment of the related damages, (ii) discrimination, (iii) misclassification, (iv) claims for salary
    differences or for a different classification according to national collective bargaining agreement, (v) claims for
    the payment of social security charges or severance benefits, (vi) claims from suppliers&rsquo; employees or external
    consultants such as, by way of example, claims for reclassification as employees, rather than independent contractors, or, as indicated
    above, requests for payment of salary / social security charges, (vii) any sanctions due to the above-mentioned obligations,
    (viii) or other violations of labor law or other alleged conduct;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">difficulties
    associated with staffing and managing international operations, including differing labor relations;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">production
    shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; vertical-align: top; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">business
    interruptions resulting from geo-political actions, including war and terrorism, health epidemics, or natural disasters including
    earthquakes, typhoons, floods and fires.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
manage our business through a small number of employees, key consultants and third-party contractors.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
key people include our Chief Executive Officer and current Vice Chairman, Pierluigi Paracchi, who co-founded our company in 2014
along with Luigi Naldini, our Executive Scientific Board Chairman, and Bernhard Gentner, a member of our Executive Scientific Board.
Our other key people include Carlo Russo, our Chief Medical Officer &amp; Head of Development, Richard Slansky, our Chief Financial Officer,
and Stefania Mazzoleni, our Scientific Project Manager and Communications Officer. With the exception of Ms. Mazzoleni, our key
personnel are not (currently) engaged as full-time employees. Dr. Russo shall become a full-time employee after
this offering and Mr. Slansky has signed an agreement to become a full-time employee at the earlier of the conclusion of this offering
or November 1, 2021, whichever is earlier. We expect that some of our key personnel and other personnel that join us after
the completion of this offering will be engaged as full-time employees in the immediate future. Our future growth and success depend
on our ability to recruit, retain, manage, and motivate our employees and key consultants. The loss of the services of our Chief
Executive Officer or any of our key personnel or the inability to hire or retain experienced management personnel could adversely affect
our ability to execute our business plan and harm our operating results. Although we expect to enter into employment agreements with
management, these agreements will likely be terminable at will with notice.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, laws and regulations on executive compensation, including legislation in our home country, Italy, may restrict our ability
to attract, motivate and retain the required level of qualified personnel.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Because
of the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain
qualified scientific and technical consultants. In particular, the loss of one or more of our key personnel could be
detrimental to us if we cannot recruit suitable replacements in a timely manner. Recruiting and retaining other qualified
employees, consultants and advisors for our business, including scientific and technical personnel, will also be critical to
our success. There is currently a shortage of skilled executives in our industry, which is likely to continue. As a result,
competition for skilled personnel, including in gene therapy research and vector manufacturing, is intense and the turnover
rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous
pharmaceutical and biotechnology companies for individuals with similar skill sets. In addition, failure to succeed in
preclinical or clinical trials may make it more challenging to recruit and retain qualified personnel. The inability to
recruit or the loss of the services of any executive, key employee, consultant or advisor may impede the progress of our
research, development and commercialization objectives. We do not currently carry &ldquo;key person&rdquo; insurance on the
lives of members of senior management. The competition for qualified personnel in the biotechnology and pharmaceutical fields
is intense. Due to this intense competition, we may be unable to attract and retain qualified personnel necessary for the
development of our business or to recruit suitable replacement personnel.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
face business disruption and related risks resulting from the recent outbreak of the COVID-19 pandemic, which could have a material
adverse effect on our business and results of operations.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
December 2019, a novel strain of coronavirus, COVID-19, was identified in Wuhan, China. This virus continues to spread globally
and, as of February 2021, has spread to over 200 countries and territories, including Italy and the United States. The spread
of COVID-19 from China to other countries has resulted in the World Health Organization declaring the outbreak of COVID-19 as
a &ldquo;pandemic,&rdquo; or a worldwide spread of a new disease. Many countries around the world have imposed quarantines and
restrictions on travel and mass gatherings to slow the spread of the virus. Authorities around the world have and may continue
implementing similar restrictions on businesses and individuals in their jurisdictions. While COVID-19 is still spreading and
the final implications of the pandemic are difficult to estimate at this stage, it is clear that it has affected the lives of
a large portion of the global population, including significant infections in Italy and the United States.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
operations and business have experienced disruption due to the unprecedented conditions surrounding the COVID-19 pandemic spreading
throughout Italy and the world. There can be no assurance we will be able to enact any remedial measures that will enable us to
avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally
or in our sector in particular. In addition, the impact of COVID-19 may cause delays to our preclinical studies and future clinical
trials, and may make it difficult for us to enroll patients to clinical trials.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">It
is not possible at this time to estimate the full impact that the COVID-19 pandemic, the continued spread of COVID-19, and
any additional measures taken by governments, health officials or by us in response to such spread, could have on our
business, including the timing of our future clinical trials, results of operations and financial condition. The COVID-19
pandemic and mitigation measures have also negatively impacted global economic conditions, which, in turn, could adversely
affect our business, including the timing of our future clinical trials, results of operations and financial condition. We
continue to monitor our operations and government recommendations. A significant reduction in our workforce and our
compliance with instructions imposed by Italian and other European authorities may harm our ability to continue operating our
business and materially and adversely affect our operations and financial condition. Therefore, there can be no assurances
that we will be able to immediately comply with all government regulations and we may be subject to authorities&rsquo;
inspections which may result, in case of non-compliance, in the application of sanctions (in the worst case, even the
suspension of work activity). Moreover, we cannot foresee whether the Italian or other European authorities or the U.S.
federal government will impose further restrictive instructions, which if implemented may lead to significant changes. The
spread of COVID-19 may also result in the inability of our suppliers to deliver components or raw materials on a timely
basis. The extent to which COVID-19 impacts our business, results of operations and financial condition will depend on future
developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the
severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. See &ldquo;<I>Risks Related to
Product Development, Regulatory Approval and Commercialization &ndash; We may find it difficult to enroll patients in our
clinical trials. Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates</I>&rdquo;
for additional information.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
will need to significantly increase the size of our organization, and we may experience difficulties in managing growth.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
currently have a very limited number of employees. If we are successful in executing our business strategy and in order to commercialize
our products, if approved, we will need to substantially increase our operations, including expanding our employee base of managerial,
operational and financial personnel. Any future growth will impose significant added responsibilities on members of management,
including the need to identify, recruit, maintain and integrate additional employees. To that end, we must be able to:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">manage
                                         our clinical trials and the regulatory process effectively;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">develop
                                         our administrative, accounting and management information systems and internal controls;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">hire
                                         and train additional qualified personnel; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">integrate
                                         current and additional management, administrative, financial and sales and marketing
                                         personnel.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Our
employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities,
including non-compliance with regulatory standards and requirements and insider trading. </I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners.
Misconduct by these parties could include intentional failures to comply with the regulations of the FDA, EMA or of other foreign
regulatory authorities, provide accurate information to the FDA, EMA and other foreign regulatory authorities, comply with healthcare
fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose
unauthorized activities to us. in particular, sales, marketing and business arrangements in the healthcare industry are subject
to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices.
These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission,
customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information
obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation.
We plan to adopt a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee
misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply
with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves
or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant
fines or other sanctions.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health
information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial
penalties.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations
may be directly or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without
limitation, the federal Anti-Kickback Statute, the federal False Claims Act and physician sunshine laws and regulations. These
laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient
privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our
ability to operate include:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly
                                         and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly,
                                         to induce, or in return for, the purchase or recommendation of an item or service reimbursable
                                         under a federal healthcare program, such as the Medicare and Medicaid programs;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">federal
                                         civil and criminal false claims laws and civil monetary penalty laws, which prohibit,
                                         among other things, individuals or entities from knowingly presenting, or causing to
                                         be presented, claims for payment from Medicare, Medicaid or other third-party payors
                                         that are false or fraudulent;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created
                                         new federal criminal statutes that prohibit executing a scheme to defraud any healthcare
                                         benefit program and making false statements relating to healthcare matters;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">HIPAA,
                                         as amended by the Health Information Technology and Clinical Health Act, and its implementing
                                         regulations, which imposes certain requirements relating to the privacy, security and
                                         transmission of individually identifiable health information;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         federal physician sunshine requirements under the Patient Protection and Affordable Care
                                         Act, as amended by the Health Care and Education Reconciliation Act, or the PPACA, requires
                                         manufacturers of drugs, devices and medical supplies to report annually to the U.S. Department
                                         of Health and Human Services information related to payments and other transfers of value
                                         to physicians, other healthcare providers and teaching hospitals and ownership and investment
                                         interests held by physicians and other healthcare providers and their immediate family
                                         members and applicable group purchasing organizations;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">state
                                         law equivalents of each of the above federal laws, such as anti-kickback and false claims
                                         laws that may apply to items or services reimbursed by any third-party payor, including
                                         commercial insurers; state laws that require biotechnology and pharmaceutical companies
                                         to comply with the biotechnology and pharmaceutical industries&rsquo; voluntary compliance
                                         guidelines and the relevant compliance guidance promulgated by the federal government,
                                         or otherwise restrict payments that may be made to healthcare providers and other potential
                                         referral sources; state laws that require drug manufacturers to report information related
                                         to payments and other transfers of value to physicians and other healthcare providers
                                         or marketing expenditures; and state laws governing the privacy and security of health
                                         information in certain circumstances, many of which differ from each other in significant
                                         ways and may not have the same effect, thus complicating compliance efforts; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">European
                                         and other foreign law equivalents of each of the laws, including reporting requirements
                                         detailing interactions with and payments to healthcare providers, and the European General
                                         Data Protection Regulation, or GDPR, which became effective in May 2018 and contains
                                         new provisions specifically directed at the processing of health information, higher
                                         sanctions and extra-territoriality measures intended to bring non-EU companies under
                                         the regulation, including companies like us that conduct clinical trials in the EU; we
                                         anticipate that over time we may expand our business operations to include additional
                                         operations in the EU and with such expansion, we would be subject to increased governmental
                                         regulation in the EU countries in which we might operate, including the GDPR and all
                                         relevant data protection rulings and further legislation.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare
reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently
increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations,
prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude
that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud
and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any
other related governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative
penalties, including, without limitation, damages, fines, imprisonment, disgorgement, exclusion from participation in government
funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight and reporting obligations if
we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with these
laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities
with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to similar actions,
penalties and sanctions. Efforts to ensure that our business arrangements comply with applicable healthcare laws and regulations,
as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert
a company&rsquo;s attention from the business.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Healthcare
legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
industry is highly regulated and changes in law may adversely impact our business, operations or financial results. The PPACA
is a sweeping measure intended to, among other things, expand healthcare coverage within the United States, primarily through
the imposition of health insurance mandates on employers and individuals and expansion of the Medicaid program. Several provisions
of the law may affect us and increase certain of our costs.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, other legislative changes have been adopted since the PPACA was enacted. These changes include aggregate reductions
in Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, following passage of the
Bipartisan Budget Act of 2018, will remain in effect through 2027 unless additional Congressional action is taken. In January
2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare
payments to several types of providers and increased the statute of limitations period for the government to recover overpayments
to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding,
which could have a material adverse effect on our customers and, accordingly, our financial operations.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
anticipate that the PPACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous
coverage criteria and an additional downward pressure on the reimbursement our customers may receive for our products. Further,
there have been, and there may continue to be, judicial and Congressional challenges to certain aspects of the PPACA. For example,
the U.S. Tax Cuts and Jobs Act of 2017, or TCJA, includes a provision repealing, effective January 1, 2019, the tax-based shared
responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or
part of a year that is commonly referred to as the &ldquo;individual mandate.&rdquo; Additional legislative and regulatory changes
to the PPACA, its implementing regulations and guidance and its policies, remain possible. However, it remains unclear how any
new legislation or regulation might affect the prices we may obtain for any of our product candidates for which regulatory approval
is obtained. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments
from private payers. The implementation of cost containment measures or other healthcare reforms may prevent us from being able
to generate revenue, attain profitability or commercialize our products.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, the delivery of healthcare in the European Union, including the establishment and operation of health services and the
pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National
governments and health service providers have different priorities and approaches to the delivery of health care and the pricing
and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states
have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with
ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay
marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize
any products for which we obtain marketing approval.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are currently unable to predict what additional legislation or regulation, if any, relating to the health care industry may be
enacted in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would
have on our business. The pendency or approval of such proposals or reforms could result in a decrease in the price of our securities
or limit our ability to raise capital or to enter into collaboration agreements for the further development and potential commercialization
of our products.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>The
use of any of our product candidates could result in product liability or similar claims that could be expensive, damage our reputation
and harm our business.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
business exposes us to an inherent risk of potential product liability or similar claims. The biotechnology and pharmaceutical
industries has historically been litigious, and we face financial exposure to product liability or similar claims if the use of
any of our products were to cause or contribute to injury or death. There is also the possibility that defects in the design or
manufacture of any of our products might necessitate a product recall. Although we plan to maintain product liability insurance,
the coverage limits of these policies may not be adequate to cover future claims. In the future, we may be unable to maintain
product liability insurance on acceptable terms or at reasonable costs and such insurance may not provide us with adequate coverage
against potential liabilities. A product liability claim, regardless of merit or ultimate outcome, or any product recall could
result in substantial costs to us, damage to our reputation, customer dissatisfaction and frustration and a substantial diversion
of management attention. A successful claim brought against us in excess of, or outside of, our insurance coverage could have
a material adverse effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Our
internal information technology systems, or those of our third-party vendors, collaborators or other contractors or consultants,
may fail or suffer security breaches or other unauthorized or improper access, which could result in a significant disruption
of our product development programs, give rise to significant liability, subject us to costly and protracted litigation, cause
significant reputational harm and impact our ability to operate our business effectively. </I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are increasingly dependent upon information technology systems, infrastructure, and data to operate our business. In the ordinary
course of business, we collect, store, and transmit confidential information (including but not limited to intellectual property,
proprietary business information, and personal information). It is critical that we do so in a secure manner to maintain the confidentiality
and integrity of such information. We also have outsourced elements of our operations to third parties, and as a result we manage
a number of third-party vendors and other contractors and consultants who have access to our confidential information.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
internal information technology systems and those of our current and any future third-party vendors, collaborators and other contractors
or consultants may be vulnerable to a variety of disruptive elements, including data breaches, cyber-attacks by malicious third
parties (including the deployment of computer viruses, harmful malware, ransomware, denial-of-service attacks, social engineering,
and other means to affect service reliability and threaten the confidentiality, integrity, and availability of information), unauthorized
access, natural disasters, terrorism, war, telecommunication and electrical failures and persons with access to systems inside
our organization. In particular, the risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion,
including by computer hackers and cyber terrorists, has generally increased as the number, intensity, and sophistication of attempted
attacks and intrusions from around the world have increased. We may not be able to anticipate all types of security threats, and
we may not be able to implement preventive measures effective against all such security threats. Because the techniques used by
cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including
outside groups such as external service providers, organized crime affiliates or terrorist organizations, we and our partners
may be unable to anticipate these techniques or implement adequate preventative measures. Further, we do not have any control
over the operations of the facilities or technology of third parties that collect, process and store personal data on our behalf.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">While
we have not experienced any significant system failure, accident or security breach to date, if such an event were to occur and
cause interruptions in our operations or a loss of, or damage to, our data or applications, or those of our third-party vendors
and other collaborators, contractors and consultants, it could result in a disruption of our development programs and our business
operations, whether due to a loss of our trade secrets or other confidential, personal or proprietary information, significant
delays or setbacks in our research, or other similar disruptions. For example, the loss of clinical trial data from completed
or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover
or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data
or applications, or inappropriate disclosure of confidential, personal or proprietary information, we could incur significant
liability, our competitive position could be harmed, our reputation could be damaged, and the further development and commercialization
of our product candidates could be delayed.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Unauthorized
disclosure of sensitive or confidential data, including personal information, whether through a breach of computer systems, systems
failure, employee negligence, fraud or misappropriation, or otherwise, or unauthorized access to or through our information systems
and networks, whether by our employees or third parties, could result in negative publicity, damage to our reputation and/or compel
us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective
action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information.
The costs related to significant security breaches or disruptions could be material. If the information technology systems of
our third-party vendors and other collaborators, contractors and consultants become subject to disruptions or security breaches,
we may be exposed to material liability and have insufficient recourse against such third parties and we may have to expend significant
resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature
from occurring. Any of the foregoing could adversely affect our business, financial condition, results of operations or prospects.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>We
or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business
continuity and disaster recovery plans may not adequately protect us from a serious disaster.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Earthquakes
or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results
of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us
from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities
of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible
for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have
in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may
incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly
when taken together with our lack of earthquake insurance, could have a material adverse effect on our business, financial condition,
results of operations and prospects.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Unsuccessful
compliance with certain European privacy regulations could have an adverse effect on our business and reputation.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
collection and use of personal health data in the EU is governed, as of May 2018, by the General Data Protection Regulation 2016/679
(GDPR) as implemented by European Data Protection Board (EDPB) guidelines and EU Member States national legislations. General
EU data protection rules impose several requirements relating to the consent of the individuals to whom the personal data relates,
the information provided to the individuals, notification of data processing obligations to the competent national data protection
authorities and the security and confidentiality of the personal data. The GDPR also extends the geographical scope of EU data
protection law to non-EU entities under certain conditions, tightens existing EU data protection principles and creates new obligations
for companies and new rights for individuals. Failure to comply with the requirements of the GDPR, the EDPB guidelines and the
related national data protection laws of the EU Member States may result in fines and other administrative penalties. The GDPR
introduces new data protection requirements in the EU and substantial fines for breaches of the data protection rules, including
violation of articles 44 to 49 GDPR related to transfer of personal data to a recipient in a non-EU country. The GDPR regulations
impose additional responsibility and liability in relation to personal data that we process, and we intend to put in place additional
mechanisms ensuring compliance with these and/or new data protection rules. In addition, other jurisdictions, including Italy,
</FONT>have implemented regulations similar to GDPR. With regard to Italian legislation, the national Privacy and Data Protection
Code has been amended according to GDPR provisions (Legislative Decree n. 196/2003 as amended and updated by Legislative Decree
n. 101/2018) and imposes additional fines and administrative penalties in relation to the processing of health data and processing
of data for scientific research purposes. Moreover, European data protection background is constantly changing under the drive
of the European Data Protection Board (EDPB) on the correct interpretation and application of GDPR and the ruling activity of
the Court of Justice of the European Union (see, for instance, the recent CJEU case C-3111/18, also known as Schremes II which
invalidated the EU-US Privacy Shield Framework for transfer of data to United States).</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company is compliant with most recent legislative changes in European data protection rules, adopting Data Processing Agreements
containing Standard Contractual Clauses with all partners based in the United States and (for the transition period until June
2021) in the United Kingdom. However, changes</FONT><FONT STYLE="font: 10pt Georgia"> to these European privacy regulations
(and similar regulations in other jurisdictions) and unsuccessful compliance may be onerous and adversely affect our business,
financial condition, prospects, results of operations and reputation.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Risks
Related to this Offering and Ownership of Our Securities</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><B><I>An active trading market for the ADSs may not develop and you may
not be able to resell the ADSs at or above the initial offering price, or at all. </I></B></P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Georgia"><B><I></I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">This
offering constitutes the initial public offering of the ADSs, and no public market has previously existed for the ADSs. Any delay
in the commencement of trading of the ADSs on Nasdaq would impair the liquidity of the market for the ADSs and make it more difficult
for holders to sell the ADSs. There can be no assurance that an active trading market for the ADSs will develop or be sustained
after this offering is completed. The lack of an active trading market may also reduce the fair market value of the ADSs. The
initial offering price was determined by negotiations among the lead underwriters and us. Among the factors considered in determining
the initial public offering price were our future prospects and the prospects of our industry in general, our revenue, net income
and certain other financial and operating information in recent periods, and the market prices of securities and certain financial
and operating information of companies engaged in activities similar to ours. However, there can be no assurance that, following
the completion of this offering, the ADSs will trade at a price equal to or greater than the initial public offering price.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
management will have broad discretion as to the use of the net proceeds from this offering and may not use the proceeds effectively.</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
currently intend to use the net proceeds of this offering for working capital and general corporate purposes, possible in licensing
of additional intellectual property and product candidates, and next generation product development. See &ldquo;Use of Proceeds.&rdquo;
However, our management will have broad discretion in the application of the net proceeds. Our shareholders may not agree with
the manner in which our management chooses to allocate the net proceeds from this offering. The failure by our management to apply
these funds effectively could have a material adverse effect on our business, financial condition and results of operation. Pending
their use, we may invest the net proceeds from this offering in a manner that does not produce income. The decisions made by our
management may not result in positive returns on your investment and you will not have an opportunity to evaluate the economic,
financial or other information upon which our management bases its decisions.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">If you
purchase the securities in this offering, you will incur immediate and substantial dilution in the book value of the securities.</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Because
the price per security being offered is substantially higher than our net tangible book value per ADS or ordinary share, you will suffer
substantial dilution in the net tangible book value of any ADSs or ordinary shares you purchase in this offering. After giving effect
to the sale by us of securities in this offering, based on the public offering price of $11.50 per security, after deducting underwriting
discounts, estimated advisory fees and offering expenses payable by us, our as adjusted net tangible book value of the securities would
be approximately &euro;40.1 million, or approximately $2.51 per ADS or ordinary share, as of June 30, 2021. If you purchase
ADSs or ordinary shares in this offering, you will suffer immediate and substantial dilution of our as adjusted net tangible book value
of approximately $8.99 per ADS or ordinary share. As a result of this dilution, investors purchasing shares in this offering may
receive significantly less than the purchase price paid in this offering in the event of liquidation. See &ldquo;Dilution&rdquo; for
additional information.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">ADS
representing a substantial percentage of our outstanding ordinary shares may be sold in this offering, which could cause the price
of the ADSs to decline.</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">We may sell in this offering securities
representing 2,400,000 ADSs and 720,114 ordinary shares, or approximately 21%, of our outstanding securities
as of June 30, 2021. This sale and any future sales of a substantial number of ADSs in the public market, or the perception that
such sales may occur, could materially adversely affect the price of the ADSs. We cannot predict the effect, if any, that market
sales of those ADSs or the availability of those ADSs for sale will have on the market price of the ADSs. While the securities sold
to non-affiliates in this offering will be freely tradable in the public market, substantially all of the securities owned prior to
this offering are expected to be subject to lock-up agreements with the underwriters that restrict the ability of these shareholders
to transfer our securities held by them for at least six months from the date of this prospectus. These outstanding securities that
are subject to lock-up agreements are expected to become eligible for unrestricted sale upon expiration of the lock-up period. In
addition, securities issued or issuable upon exercise of options and warrants vested as of the expiration of the lock-up period will
be eligible for sale at that time. Sales of securities by these shareholders could have a material adverse effect on the trading
price of the ADSs.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
do not know what the trading price of the ADSs will be following this offering and as a result it may be difficult for you to
sell the ADSs.</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
trading price of the ADSs is likely to be volatile. The following factors, in addition to other risk factors described in this
section, may have a significant impact on the market price of the ADSs:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">adverse
                                         results or delays in pre- and non-clinical studies or clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">reports
                                         of adverse events in other gene therapy products or clinical studies of such products;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">inability
                                         to obtain additional funding;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">inability
                                         to obtain the approvals necessary to commence clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">unsatisfactory
                                         results of clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">announcements
                                         of regulatory approval or the failure to obtain it, or specific label indications or
                                         patient populations for its use, or changes or delays in the regulatory review process;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">announcements
                                         of therapeutic innovations or new products by us or our competitors;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">adverse
                                         actions taken by regulatory authorities with respect to our clinical trials, manufacturing
                                         supply chain or sales and marketing activities;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">changes
                                         or developments in laws or regulations applicable to the treatment of cancer tumors,
                                         or any other indication that we may seek to develop;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">any
                                         adverse changes to our relationship with manufacturers or suppliers;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">any
                                         intellectual property infringement actions in which we may become involved;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">announcements
                                         concerning our competitors or the biotechnology and pharmaceutical industries in general;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">achievement
                                         of expected product sales and profitability or our failure to meet expectations;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         commencement of, or involvement in, litigation;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">any
                                         major changes in our board of directors or management;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         ability to recruit and retain qualified regulatory, research and development personnel;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">legislation
                                         in the United States relating to the sale or pricing of biotechnology or gene therapy
                                         products;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         depth of the trading market in the ADSs;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">termination
                                         of the lock-up agreements or other restrictions limiting our ability or that of any of
                                         our existing shareholders to sell our securities (or any other securities that we may
                                         issue, if any) after this offering;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">economic
                                         weakness, including inflation, or political instability in particular foreign economies
                                         and markets;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">business
                                         interruptions resulting from a local or worldwide pandemic, such as COVID-19, geopolitical
                                         actions, including war and terrorism, or natural disasters;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         granting or exercise of employee stock options or other equity awards;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">disputes
                                         or other developments relating to proprietary rights, including patents, litigation matters
                                         and our ability to obtain patent protection for our technologies;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">additions
                                         or departures of key scientific or management personnel;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">significant
                                         lawsuits, including patent or stockholder litigation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">changes
                                         in investors&rsquo; and securities analysts&rsquo; perception of the business risks and
                                         conditions of our business.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, the stock market in general, and the Nasdaq Stock Market in particular, have experienced extreme price and volume fluctuations
that have often been unrelated or disproportionate to the operating performance of small companies. Broad market and industry
factors may negatively affect the market price of the ADSs, regardless of our actual operating performance. Further, a systemic
decline in the financial markets and related factors beyond our control may cause our ADS price to decline rapidly and unexpectedly.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Holders
of ADSs may not receive the same distributions or dividends as those we make to the holders of our ordinary shares, and, in some
limited circumstances, you may not receive dividends or other distributions on our ordinary shares and you may not receive any
value for them, if it is illegal or impractical to make them available to you.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Depositary for the ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on ordinary
shares or other deposited securities underlying the ADSs, after deducting its fees and expenses and subject to the terms of the
deposit agreement. You will receive these distributions in proportion to the number of ordinary shares the ADSs represent. However,
in accordance with the limitations set forth in the deposit agreement the Depositary is not responsible if it decides that it
is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make
a distribution to a holder of ADSs if it consists of securities that require registration under the Securities Act, but that are
not properly registered or distributed under an applicable exemption from registration. In addition, conversion into U.S. dollars
from foreign currency that was part of a dividend made in respect of deposited ordinary shares may require the approval or license
of, or a filing with, any government or agency thereof, which may be unobtainable. In these cases, the Depositary may determine
not to distribute such property and hold it as &ldquo;deposited securities&rdquo; or may distribute the net cash proceeds from
the sale of the dividends. We have no obligation to register under U.S. securities laws any ADSs, ordinary shares, rights or other
securities received through such distributions. We also have no obligation to take any other action to permit the distribution
of ADSs, ordinary shares, rights or anything else to holders of ADSs. In addition, the Depositary may withhold from such dividends
or distributions its fees and an amount on account of taxes or other governmental charges to the extent the Depositary believes
it is required to make such withholding. This means that you may not receive the same distributions or dividends as those we make
to the holders of our ordinary shares, and, in some limited circumstances, you may not receive any value for such distributions
or dividends if it is illegal or impractical for us to make them available to you. These restrictions may cause a material decline
in the value of the ADSs.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Holders
of ADSs must act through the Depositary to exercise voting rights relating to the ordinary shares.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Holders
of the ADSs do not have the same rights of our shareholders and may only exercise the voting rights with respect to the underlying ordinary
shares in accordance with the provisions of the Deposit Agreement. When a shareholder meeting is convened, holders of ADSs may not receive
sufficient notice of a shareholder meeting to permit them to cancel their ADSs and withdraw ordinary shares to allow them to directly
cast their vote with respect to any specific matter. In addition, the Depositary and its agents may not be able to send voting instructions
to holders of ADSs or carry out their voting instructions in a timely manner. We will make all reasonable efforts to cause the Depositary
to extend voting rights to holders of the ADSs in a timely manner, but we cannot assure holders that they will receive the voting materials
in time to ensure that they can instruct the Depositary to vote the ordinary shares underlying their ADSs. Furthermore, the Depositary
and its agents will not be responsible for any failure to carry out any instructions to vote, for the manner in which any vote is cast
or for the effect of any such vote. As a result, holders of the ADSs may not be able to exercise their right to vote and they may lack
recourse if the ordinary shares underlying their ADSs are not voted as they requested. In addition, in the capacity as a holder
of ADSs, they will not be able to call a shareholder meeting.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>ADSs
holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could augur less
favorable results to the plaintiff(s) in any such action.</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
deposit agreement governing the ADSs representing our shares provides that owners and holders of ADSs, including those who purchase
the ADSs in a secondary transaction, irrevocably waive the right to a trial by jury in any legal proceeding arising out of or
relating to the deposit agreement, our shares or the ADSs or the transactions contemplated thereby, including claims under federal
securities laws, against us or the depositary to the fullest extent permitted by applicable law. If this jury trial waiver provision
is prohibited by applicable law, an action could nevertheless proceed under the terms of the deposit agreement with a jury trial.
To our knowledge, the enforceability of a jury trial waiver under the federal securities laws has not been finally adjudicated
by a federal court. However, we believe that a jury trial waiver provision is generally enforceable under the laws of the State
of New York, which govern the deposit agreement, by a court of the State of New York or a federal court in New York, which have
non-exclusive jurisdiction over matters arising under the deposit agreement, applying such law. In determining whether to enforce
a jury trial waiver provision, New York courts and federal courts will consider whether the visibility of the jury trial waiver
provision within the agreement is sufficiently prominent such that a party has knowingly waived any right to trial by jury. We
believe that this is the case with respect to the deposit agreement, our shares and the ADSs and the transactions contemplated
thereby. In addition, New York courts will not enforce a jury trial waiver provision in order to bar a viable setoff or counterclaim
sounding in fraud or one which is based upon a creditor&rsquo;s negligence in failing to liquidate collateral upon a guarantor&rsquo;s
demand, or in the case of an intentional tort claim (as opposed to a contract dispute), none of which we believe are applicable
in the case of the deposit agreement, our shares or the ADSs or the transactions contemplated thereby. No condition, stipulation
or provision of the deposit agreement or ADSs serves as a waiver by any owner or holder of ADSs or by us or the depositary of
compliance with any provision of the federal securities laws. If you or any other owner or holder of ADSs brings a claim against
us or the depositary in connection with matters arising under the deposit agreement, our shares or the ADSs or the transactions
contemplated thereby, you or such other owner or holder may not be entitled to a jury trial with respect to such claims, which
may have the effect of limiting and discouraging lawsuits against us and/or the depositary, lead to increased costs to bring a
claim, limited access to information and other imbalances of resources between such owner or holder and us, or limit such holder&rsquo;s
ability to bring a claim in a judicial forum that such holder finds favorable. If a lawsuit is brought against us and/or the depositary
under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted
according to different civil procedures and may augur different results than a trial by jury would have had, including results
that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims,
the judge or justice hearing such claims, and the venue of the hearing.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 24.5pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have identified material weaknesses in our internal control over financial reporting and, if our remediation of the material weaknesses
is not effective or if we identify additional material weaknesses in the future, we may not be able to accurately or timely report
our financial results, or prevent fraud, and investor confidence in our Company and the market price of our shares may be adversely
affected.</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
a public company, we will be required to maintain internal control over financial reporting and to report any material weaknesses
in such internal control. Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our
internal control over financial reporting. A material weakness is a deficiency or combination of deficiencies in internal control
over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements
will not be prevented or detected on a timely basis.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">To date, we have had limited financial and accounting
personnel, which has resulted in a limited segregation of duties to fully execute our accounting processes and address our internal
control over financial reporting. In connection with the audits of our financial statements as of and for the years ended December
31, 2020 and 2019, we identified certain material weaknesses in our internal control over financial reporting, including but not
limited to our lack of adequate staff to: (i) process financial information in a timely manner; (ii) analyze and
account for complex, non-routine transactions - including those subject to our critical accounting policies; and, (iii)
maintain adequate segregation of duties; and, the lack of documentation related to our internal control over financial reporting
including our policy over related party relationships and transactions.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
plan to take steps to address the internal control deficiencies that contributed to the material weaknesses, including the following:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">hiring
                                         of additional finance and accounting personnel with prior experience working for finance
                                         departments and technical accounting experience, supplemented by third-party resources;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">documenting
                                         and formally assessing our accounting and financial reporting policies and procedures;
                                         and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">increasing
                                         the use of third-party consultants in assessing significant accounting transactions and
                                         other technical accounting and financial reporting issues, preparing accounting memoranda
                                         addressing these issues and maintaining these memoranda in our corporate records.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">While
we believe that these efforts will improve our internal control over financial reporting, the implementation of these measures
is ongoing and will require validation and testing of the design and operating effectiveness of internal controls over a sustained
period of financial reporting cycles. We cannot assure you that the measures we have taken to date, and are continuing to implement,
will be sufficient to remediate the material weaknesses we have identified or avoid potential future material weaknesses. If the
steps we take do not correct the material weaknesses in a timely manner, we will be unable to conclude that we maintain effective
internal control over financial reporting. Accordingly, there could continue to be a reasonable possibility that these deficiencies
or others could result in a misstatement of our accounts or disclosures that would result in a material misstatement of our financial
statements that would not be prevented or detected on a timely basis.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">Our management and independent registered public accounting firm did
not perform an evaluation of our internal control over financial reporting during any period in accordance with the provisions
of the Sarbanes-Oxley Act. Had we and our independent registered public accounting firm performed an evaluation of our internal
control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional control deficiencies
amounting to material weaknesses may have been identified. If we identify new material weaknesses in our internal control over
financial reporting, if we are unable to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner,
if we are unable to assert that our internal control over financial reporting is effective, or if our independent registered public
accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, we may
be late with the filing of our periodic reports, investors may lose confidence in the accuracy and completeness of our financial
reports and the market price of our common stock could be negatively affected. As a result of such failures, we could also become
subject to investigations by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities,
and become subject to litigation from investors and stockholders, which could harm our reputation, financial condition or divert
financial and management resources from our core business.</P>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
may be subject to securities litigation, which is expensive and could divert management attention.</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
the past, companies that have experienced volatility in the market price of their shares have been subject to securities class
action litigation. We may be the target of this type of litigation in the future. Litigation of this type could result in substantial
costs and diversion of management&rsquo;s attention and resources, which could seriously hurt our business. Any adverse determination
in litigation could also subject us to significant liabilities.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><B><I>Our Chief Executive Officer, directors and shareholders who own more than
5% of our outstanding ordinary shares before this offering currently own approximately 47.14% of our outstanding ordinary shares and
will own approximately 39.03% of our ordinary shares upon the completion of this offering. They will therefore be able to exert
significant control over matters submitted to our shareholders for approval.</I></B></P>
<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">After this offering, our Chief Executive Officer and directors,
and shareholders who own more than 5% of our outstanding ordinary shares before this offering will, in the aggregate, beneficially own
approximately 39.03% of our ordinary shares (assuming no exercise of the underwriters&rsquo; over-allotment option). This significant
concentration of share ownership may adversely affect the trading price for the ADSs because investors often perceive disadvantages in
owning securities in companies with controlling shareholders. As a result, these shareholders, if they acted together, could significantly
influence or even unilaterally approve matters requiring approval by our shareholders, including the election of directors and the approval
of mergers or other business combination transactions. The interests of these shareholders may not always coincide with our interests
or the interests of other shareholders. Also, the concentration of our beneficial ownership may have the effect of delaying, deterring
or preventing a change in our control, or may discourage bids for our shares at a premium over the market price of the shares. The significant
concentration of share ownership may adversely affect the trading price of our ordinary shares due to investors&rsquo; perception that
conflicts of interest may exist or arise.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
we were to be characterized as a &ldquo;passive foreign investment company&rdquo; for U.S. tax purposes, U.S. holders of the ADSs
could have adverse U.S. income tax consequences.</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In general, we will be treated as a passive foreign investment
company, or a PFIC, for U.S. federal income tax purposes in any taxable year in which either (1) at least 75% of our gross income is &ldquo;passive
income&rdquo; or (2) on average at least 50% of our assets by value produce passive income or are held for the production of passive income.
Passive income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities
and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive income also includes
amounts derived by reason of the temporary investment of funds, including those raised in a public offering. In determining whether a
non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly,
at least a 25% interest (by value) is taken into account. We have not made the formal analysis necessary to determine whether or not we
are currently a PFIC or whether we have ever been a PFIC, although preliminarily it appears we may have been a PFIC at certain points
in the past. The tests for determining PFIC status depend, in part, on the application of complex U.S. federal income tax rules, which
are subject to differing interpretations. In addition, whether any corporation will be a PFIC for any taxable year depends on the assets
and income of such corporation over the course of each such taxable year and, as a result, it is difficult to make accurate projections
of future income and assets which are relevant to this determination for the current taxable year or any future period. If we are a PFIC
in any taxable year during which a U.S. taxpayer holds the ADSs, such U.S. taxpayer would be subject to certain adverse U.S. federal income
tax rules. In particular, if the U.S. taxpayer did not make an election to treat us as a &ldquo;qualified electing fund,&rdquo; or QEF,
or make a &ldquo;mark-to- market&rdquo; election, then &ldquo;excess distributions&rdquo; to the U.S. taxpayer, and any gain realized
on the sale or other disposition of the ADSs by the U.S. taxpayer: (1) would be allocated ratably over the U.S. taxpayer&rsquo;s holding
period for the ADSs; (2) the amount allocated to the current taxable year and any period prior to the first day of the first taxable year
in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of the other taxable years would be subject
to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest charge for the deemed
deferral benefit would be imposed with respect to the resulting tax attributable to each such other taxable year. In addition, if the
U.S. Internal Revenue Service, or the IRS, determines that we are a PFIC for a year with respect to which we have determined that we were
not a PFIC, it may be too late for a U.S. taxpayer to make a timely QEF or mark-to-market election. U.S. taxpayers that have held the
ADSs during a period when we were a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC in subsequent years, subject
to exceptions for U.S. taxpayer who made a timely QEF or mark-to-market election. A U.S. taxpayer can make a QEF election by completing
the relevant portions of and filing IRS Form 8621 in accordance with the instructions thereto. U.S. taxpayers that hold the ADSs are strongly
urged to consult their tax advisors about the PFIC rules, including tax return filing requirements and the eligibility, manner, and consequences
to them of making a QEF or mark-to-market election with respect to the ADSs in the event that we are a PFIC. See &ldquo;Taxation &mdash;U.S.
Federal Income Tax Consequences&mdash;Passive Foreign Investment Companies&rdquo; for additional information.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or
if they adversely change their recommendations or publish negative reports regarding our business or our securities, our ADS price
and trading volume could decline.</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
trading market for the ADSs will be influenced by the research and reports that industry or securities analysts may publish about
us, our business, our market or our competitors. We do not have any control over these analysts and we cannot provide any assurance
that analysts will cover us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation
regarding our securities, or provide more favorable relative recommendations about our competitors, our ADS price would likely
decline. If any analyst who may cover us were to cease coverage of our Company or fail to regularly publish reports on us, we
could lose visibility in the financial markets, which in turn could cause our ADS price or trading volume to decline.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have not paid, and do not intend to pay, dividends on our ordinary shares and, therefore, unless our traded securities appreciate
in value, our investors may not benefit from holding our securities.</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have never declared or paid cash dividends on our ordinary shares. We do not anticipate paying any cash dividends on our ordinary
shares in the foreseeable future. Consequently, investors may need to rely on sales of their ADSs after price appreciation, which
may never occur, as the only way to realize any future gains on their investment. Investors seeking cash dividends should not
purchase the ADSs. Moreover, Italian law imposes certain restrictions on our ability to declare and pay dividends. In particular,
Italian law prohibits distributing dividends other than from net income or distributable reserves set forth in a company&rsquo;s
statutory accounts approved by a meeting of shareholders and after the establishment of certain compulsory reserves. In addition,
if losses from previous fiscal years have reduced a company&rsquo;s capital, dividends may not be paid until the capital is reconstituted
or its stated amount is reduced by the amount of such losses. The application of these restrictions limits our ability to make
distributions to holders of our shares See &ldquo;Dividend Policy&rdquo; and &ldquo;Description of Share Capital and Governing
Documents&mdash;Dividends and Other Distributions&rdquo; for additional information.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
requirements associated with being a public company will require significant company resources and management attention.</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Following
this offering, we will become subject to the reporting requirements of the Exchange Act, Nasdaq listing requirements and other
applicable securities rules and regulations. The Exchange Act requires that we file periodic reports with respect to our business
and financial condition and maintain effective disclosure controls and procedures and internal control over financial reporting.
In addition, subsequent rules implemented by the SEC and the Nasdaq Stock Market may also impose various additional requirements
on public companies. As a result, we will incur additional legal, accounting and other expenses that we did not incur as a nonpublic
company, particularly after we are no longer an &ldquo;emerging growth company&rdquo; as defined in the JOBS Act. In the period
following this offering, we estimate that these expenses will be at least several hundred thousand dollars annually. Further,
the need to establish the corporate infrastructure demanded of a public company may divert management&rsquo;s attention from implementing
our development plans. We have made changes to our corporate governance standards, disclosure controls and financial reporting
and accounting systems to meet our reporting obligations. The measures we take, however, may not be sufficient to satisfy our
obligations as a public company, which could subject us to delisting of our securities, fines, sanctions and other regulatory
action and potentially civil litigation.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>The
JOBS Act allows us to postpone the date by which we must comply with some of the laws and regulations intended to protect investors
and to reduce the amount of information we provide in our reports filed with the SEC, which could undermine investor confidence
in our Company and adversely affect the market price of the ADSs.</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">For
so long as we remain an &ldquo;emerging growth company&rdquo; as defined in the JOBS Act, we intend to take advantage of certain
exemptions from various requirements that are applicable to public companies that are not &ldquo;emerging growth companies&rdquo;
including:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         provisions of the Sarbanes-Oxley Act requiring that our independent registered public
                                         accounting firm provide an attestation report on the effectiveness of our internal control
                                         over financial reporting;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Section
                                         107 of the JOBS Act, which provides that an &ldquo;emerging growth company&rdquo; can
                                         take advantage of the extended transition period provided in Section 7(a)(2)(B) of the
                                         Securities Act for complying with new or revised accounting standards. This means that
                                         an &ldquo;emerging growth company&rdquo; can delay the adoption of certain accounting
                                         standards until those standards would otherwise apply to private companies. We are electing
                                         to delay such adoption of new or revised accounting standards. As a result of this election,
                                         our financial statements may not be comparable to companies that comply with the
                                         public company effective date;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">any
                                         rules that may be adopted by the Public Company Accounting Oversight Board requiring
                                         mandatory audit firm rotation or a supplement to the auditor&rsquo;s report on the financial
                                         statements; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         ability to furnish two rather than three years of income statements and statements of
                                         cash flows in various required filings.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
intend to take advantage of these exemptions until we are no longer an &ldquo;emerging growth company.&rdquo; We will remain an
emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the date
of the completion of this offering, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which
we are deemed to be a large accelerated filer, as defined in the rule under the Exchange Act, and (2) the date on which we have
issued more than $1.0 billion in non-convertible debt during the prior three-year period.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
cannot predict if investors will find our securities less attractive because we may rely on these exemptions. If some investors
find our securities less attractive as a result, there may be a less active trading market for the ADSs, and our ADS price may
be more volatile and may decline.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
a foreign private issuer, we are permitted, and intend, to follow certain home country corporate governance practices instead
of otherwise applicable SEC and Nasdaq requirements, which may result in less protection than is accorded to investors under rules
applicable to domestic U.S. issuers.</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
status as a foreign private issuer exempts us from compliance with certain SEC laws and regulations and certain regulations of
the Nasdaq Stock Market, including the proxy rules, the short-swing profits recapture rules, and certain governance requirements
such as independent director oversight of the nomination of directors and executive compensation. In addition, we will not be
required under the Exchange Act to file current reports and financial statements with the SEC as frequently or as promptly as
U.S. domestic companies whose securities are registered under the Exchange Act and we will generally be exempt from filing quarterly
reports with the SEC. Furthermore, as a foreign private issuer, we are also not subject to the requirements of Regulation FD (Fair
Disclosure) promulgated under the Exchange Act. These exemptions and leniencies will reduce the frequency and scope of information
and protections to which you are entitled as an investor. See &ldquo;Management &ndash; Differences between Italian Laws and Nasdaq
Requirements&rdquo; for additional information.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt; font-style: normal; font-weight: normal"></FONT><FONT STYLE="font-family: Georgia; font-size: 10pt">As
a foreign private issuer, we are permitted, and intend, to phase-in our compliance with certain Nasdaq Listing Rules, as permitted
by Nasdaq Listing Rule 5615(b)(1), instead of otherwise having to be in compliance with such rules as of the date of our initial
listing on Nasdaq, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers
and if we do not obtain compliance within the allotted time, we could become subject to delisting by Nasdaq.</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
accordance with Nasdaq Listing Rule 5615(b)(1), as a foreign private issuer, we are permitted, and intend, to phase-in our compliance
with certain Nasdaq Listing Rules, instead of otherwise having to be in compliance with such rules as of the date of our initial
listing on Nasdaq. For instance, although we are a foreign private issuer and have opted into following our home country rules,
which are the laws of the Italy, in lieu of following certain Nasdaq Listing Rules, we are still required to have an audit committee
that satisfies Nasdaq Listing Rule 5605(c)(3) and ensure that such audit committee members meet the independence requirement in
Nasdaq Listing Rule 5605(c)(2)(A)(ii), provided, however, that in light of Nasdaq Listing Rule 5615(b)(1), we have up to one year
from the date of our listing to have an audit committee and members who meet such requirements. This phased-in period of compliance
may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers and if we do not obtain
compliance within the allotted time, we could become subject to delisting by Nasdaq.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><B><I>We may become taxable in a jurisdiction other than Italy and this
may increase the aggregate tax burden on us.</I></B></P>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Since
incorporation, we have, on a continuous basis, had our place of effective management in Italy. We are therefore a tax
resident of Italy under Italian tax law. However, we may become subject to limited income tax liability in other countries
with respect to our operations in other countries, for example, the United States, due to the existence of a permanent
establishment or a permanent representative. The applicable tax laws or interpretations thereof may change. We have our place
of effective management in Italy and, as such, we believe we are tax residents in Italy, although that determination is
largely a matter of fact and degree based on all the circumstances, rather than a question of law, which facts and degree may
also change. Changes to applicable laws or interpretations thereof and changes to applicable facts and circumstances (for
example, a change of board members or the place where board meetings take place), may result in us becoming a tax resident of
a jurisdiction other than Italy. As a consequence, our overall effective income tax rate and income tax expense could
materially increase, which could have a material adverse effect on our business, results of operations, financial condition
and prospects. However, if there is a double tax treaty
between Italy and the respective other country, double taxation of income may be avoided and the detrimental tax
effects mitigated by the application of the treaty.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Risks
Related to Italian Law and Our Operations in Italy</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are an Italian corporation. The rights of our shareholders may be different from the rights of shareholders in companies governed
by the laws of U.S. jurisdictions.</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt; font-style: normal; font-weight: normal">We
are an Italian corporation. Our corporate affairs are governed by our articles of association and by the laws governing companies incorporated
in Italy. The rights of our shareholders and the responsibilities of members of our board of directors may be different from the rights
and obligations of shareholders and directors of companies governed by the laws of U.S. jurisdictions. While performing its duties, our
board of directors is required by Italian law to act with the diligence required by the nature of their assignment and by their specific
expertise. Italian corporate law limits the ability of our shareholders to challenge resolutions made or other actions taken by our board
of directors in court. Our shareholders generally are not permitted to file a suit to reverse or void a decision or an action taken by
our board of directors, except for those decisions that are detrimental to their rights. If a board resolution has not been taken in
accordance with the Italian law or the company&rsquo;s articles of association, only the board of statutory auditors and the absent or
dissenting members of the board of directors may challenge it within 90 days of such resolution. However, the shareholders may, where
they represent the thresholds provided for by Italian law, bring corporate liability action against our directors where they have acted
in violation of their duties of conduct. The individual shareholder may also take action for compensation for the damage directly caused
to them by the director&rsquo;s conduct. Under Italian law, shareholders&rsquo; claims against a member of our board of directors for
breach of their duties of conduct must be filed in Milan, Italy, as the place where the company was incorporated. See &ldquo;Share Capital
Description and Governing Documents&rdquo; and &ldquo;Comparison of Delaware Law and Italian Law&rdquo;. </FONT></P>

<P STYLE="text-indent: 0.5in; font: italic 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Our
shares are not listed in Italy, our home jurisdiction. As a result, our shareholders will not benefit from certain provisions
of Italian law that are designed to protect shareholders in a public takeover offer or a change-of-control transaction and may
not be protected in the same degree in a public takeover offer or a change-of-control transaction as are shareholders of certain
U.S. companies or in an Italian company listed in Italy.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Because
the ADSs will be listed exclusively on Nasdaq and not in Italy&rsquo;s stock exchange, our shareholders will not
benefit from the protection afforded by certain provisions of Italian law that are designed to protect shareholders in the event
of a public takeover offer or a change-of-control transaction. For example, Article 120 of the Italian Financials&rsquo; Consolidated
Act and its implementing provisions require investors to disclose their interest in the relevant listed company if they reach,
exceed or fall below certain ownership thresholds. Similarly, the Italian takeover regime imposes a duty on any person or group
of persons who acquires more than the 30% of a company&rsquo;s voting rights (or the 25% if such company is not a small-medium
enterprise, where there is no other shareholder holding a higher stake) to make a mandatory offer for all of the company&rsquo;s
outstanding listed equity securities. In addition, the Italian takeover regime imposes certain restrictions and obligations on
bidders in a voluntary public takeover offer that are designed to protect shareholders. However, these protections are applicable
only to issuers that list their equity securities in Italy and, because the ADSs will be listed exclusively on Nasdaq,
will not be applicable to us. Furthermore, since Italian law restricts our ability to implement rights plans or U.S.-style &ldquo;poison
pills,&rdquo; our ability to resist an unsolicited takeover attempt or to protect minority shareholders in the event of a change
of control transaction may be limited. Therefore, our shareholders may not be protected in the same degree in a public takeover
offer or a change-of-control transaction as are shareholders in certain U.S. companies or in an Italian company listed in Italy.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
process of seeking to raise additional funds is cumbersome, subject to the verification of an Italian notary public in compliance
with our bylaws and applicable law and may require prior approval of our shareholders at an extraordinary shareholder meeting.</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are incorporated under the laws of the Republic of Italy. The principal laws and regulations that apply to our operations, those
of Italy and the European Union, are different from those of the United States. With some exceptions, in order to issue new equity
or debt securities convertible into equity, we must increase our authorized capital. In order to do so, our board of directors
must meet and resolve to recommend that our shareholders approve an amendment to our bylaws increasing our capital. The holders
of the majority of our outstanding shares must then approve that amendment at an extraordinary shareholder meeting duly called.
These meetings take time to call and it might be very difficult to get a majority of the holders of all outstanding shares to
vote in favor of the proposed resolution. In addition, an Italian notary public must verify that the capital increase is in compliance
with our bylaws and with applicable Italian law. Further, under Italian law, our existing shareholders and any holders of convertible
securities have preemptive rights (except in specific cases) to acquire any such shares pro-rated on their percentage interest
in our company, and on the same terms as approved for such capital increase. Alternatively, our shareholders can delegate the
power to increase our capital to the board of directors, but the board&rsquo;s right to exercise such power, if delegated, will
expire after five years. If the board does not approve a capital increase by the end of those five years, our board and shareholders
would need to meet again to re-delegate this authority.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">With
respect to shareholder resolutions approving a capital increase, Italian law provides that in the absence of meeting minutes,
or in the event of the impossibility or illegality of the resolution, any interested person may, for a period of 180 days following
the filing of the shareholder resolution with the competent Register of Companies, challenge such resolution. If a shareholder
meeting was not called to approve the capital increase, the relevant resolution should be considered invalid and, any interested
person may challenge the capital increase for a period of 90 days following the approval of the financial statements referring
to the year during which the shareholder resolution has been, also partially, executed. In addition, once our shareholders authorize
a capital increase, all those authorized shares that have been subscribed need to be entirely paid-up before the shareholders
may perform/execute a new capital increase. These restrictions could limit our ability to issue new equity or convertible debt
securities on a timely basis.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Italian
law places restrictions on the amount of debt securities that we may issue relative to our equity to the extent that such debt
securities are not listed on regulated markets or do not otherwise provide the holder of such securities the right to purchase
or convert the same into our shares.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Under Italian law, we may issue debt securities in an amount
not to exceed twice the sum of our capital, our legal reserve and any other disposable reserves appearing on our latest Italian GAAP
balance sheet approved by our shareholders, unless the debt securities are listed on regulated markets or provide the holder of such
securities the right to purchase or convert the same into our shares, in which case such restrictions do not apply. The legal reserve
is a reserve to which we allocate 5% of our Italian GAAP net income each year until it equals at least 20% of our capital. One of the
other reserves that we maintain on our balance sheet is a &ldquo;share premium reserve,&rdquo; meaning amounts paid for our ordinary
shares in excess of the amount of such ordinary shares that is allocated to the capital. At December 31, 2020, the sum of our capital,
legal reserves and other reserves on our unaudited Italian GAAP financial statements was &euro; 18.3 million. If, in the future,
we issue debt securities that are not listed on regulated markets or do not provide the holder of the securities the right to purchase
or convert the same into our shares, until such debt securities are repaid in full, we may not voluntarily reduce our capital or allocate
our reserves (such as by declaring dividends) if it results in the aggregate of the capital and reserves being less than half of the
outstanding amount of the debt. In such a case, if our equity is reduced by losses or otherwise such that the amount of the outstanding
debt securities is more than twice the amount of our equity, some legal scholars are of the opinion that the ratio must be restored through
a recapitalization of our company. If our equity is reduced, we could recapitalize by issuing new shares or having our shareholders contribute
additional capital to us, although there can be no assurance that we would be able to find purchasers of new shares or that any of our
current shareholders would be willing to contribute additional capital.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>If
we suffer losses that reduce our capital to less than &euro;50,000, we would need to recapitalize, change our form of entity or
be liquidated.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT><P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Italian
                                            law requires us to reduce our shareholders&rsquo; equity and, in particular, our capital,
                                            to reflect on-going losses, in certain cases of losses exceeding 1/3 of the capital of the
                                            company. Also, as an S.p.A., we are also required to maintain a minimum capital of &euro;50,000.
                                            At December 31, 2020, our Italian GAAP capital was &euro;37,056; however, in May 2021,
                                            it was increased to &euro;50,000 due to the exercise of options on &euro;715 Quota B plus
                                            a quotaholder action at a special meeting which converted the Company from an S.r.l. to an
                                            S.p.A. and increased the share capital. If we suffer losses from operations that reduce
                                            our capital to less than &euro;50,000, then we must either increase our capital (which we
                                            could do by issuing new shares or having our shareholders contribute additional capital to
                                            our company) to at least &euro;50,000 (or convert the form of our company into an S.r.l.
                                            but such conversion would not be applicable since the S.r.l. form is not consistent with
                                            being listed pursuant to Italian law). If we do not take these steps, our company could be
                                            liquidated.</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
apply our operational losses against our legal reserves and capital. If our capital is reduced more than one-third as a result
of losses, our board of directors must call a shareholder meeting as soon as possible. The shareholders should take appropriate
measures, which may include, inter alia, reducing the legal reserves and capital by the amount of the remaining losses, or carrying
the losses forward for up to one year. If the shareholders vote to carry the losses forward up to one year, and the losses are
still more than one-third of the amount of the capital at the end of the year, then we must reduce our capital by the amount of
the losses.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Italian
labor laws could impair our flexibility to restructure our business.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
Italy, our employees are protected by various laws which afford them consultation rights with respect to specific matters regarding
their employers&rsquo; business and operations, including the downsizing or closure of facilities and employee terminations. In
particular, among other applicable Italian laws: (i) Laws no. 604/1966, 300/1970 and 92/2012 regulate the individual
dismissals; (ii) Law no. 223/1991, concerns the collective dismissal procedure; (iii) Law no. 428/1990 as amended by legislative
decree no. 18/2001, provides for the information and consultation procedure in case of a transfer of the undertaking or a part
thereof; (iv) Legislative decree no. 25/2007, introduces a general right to information and consultation for employees and (v)
Legislative Decree no. 23/2015 regulates the consequences of individual dismissals with specific reference to the employees hired
starting from March 7, 2015. In addition, due to COVID-19 emergency, various government decrees have introduced a specific
ban on dismissals for objective reasons and collective dismissal procedures. These laws and the collective bargaining agreements
to which we are subject could impair our flexibility if we need to restructure our business.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Purchasers
of our Ordinary Shares and ADSs may be exposed to increased transaction costs as a result of the Italian financial transaction
tax or the proposed European financial transaction tax.</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">On
February 14, 2013, the European Commission adopted a proposal for a directive on the financial transaction tax (&ldquo;EU FTT&rdquo;)
to be implemented under the enhanced cooperation procedure by eleven Member States initially (Austria, Belgium, Estonia, France,
Germany, Greece, Italy, Portugal, Slovenia, Slovakia and Spain). Following Estonia&rsquo;s formal withdrawal on March 16, 2016,
ten Member States are currently participating in the negotiations on the proposed directive. Member States may join or leave the
group of participating Member States at later stages and, subject to an agreement being reached by the participating Member States,
a final directive will be enacted. The participating Member States will then implement the directive in local legislation. If
the proposed directive is adopted and implemented in local legislation, investors in Ordinary Shares and ADSs may be exposed to
increased transaction costs.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Italian financial transaction tax (the &ldquo;IFTT&rdquo;) applies with respect to trades entailing the transfer of (i) shares
or equity-like financial instruments issued by companies resident in Italy, such as the Ordinary Shares; and (ii) securities representing
the shares and financial instruments under (i) above (including depositary receipts such as the ADSs), regardless of the residence
of the issuer. The IFTT may also apply to the transfer of Ordinary Shares and ADSs by a U.S. resident. The IFTT does not apply
to companies having an average market capitalization lower than &euro;500 million in the month of November of the year preceding
the year in which the trade takes place. In order to benefit from this exemption, companies whose securities are listed on a foreign
regulated market, such as the Company, need to be included on a list published annually by the Italian Ministry of Economy and
Finance. The Company is in the process of starting the relevant procedures to be included in such list by the end of 2020. For
so long as the Company is not included in such list, investors in the Ordinary Shares and ADSs may be exposed to increased transaction
costs. See &ldquo;Taxation.&rdquo;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="a_003"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Some
of the statements made under &ldquo;Prospectus Summary,&rdquo; &ldquo;Risk Factors,&rdquo; &ldquo;Use of Proceeds,&rdquo; &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; &ldquo;Business&rdquo; and elsewhere in this
prospectus constitute forward- looking statements. In some cases, you can identify forward-looking statements by terminology such
as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential&rdquo; &ldquo;intends&rdquo; or &ldquo;continue,&rdquo;
or the negative of these terms or other comparable terminology.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Forward-looking
statements include, but are not limited to, statements about:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         timing, progress and results of preclinical studies and clinical trials for our programs
                                         and product candidates, including statements regarding the timing of initiation and completion
                                         of studies or trials and related preparatory work, the period during which the results
                                         of the trials will become available and our research and development programs;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         interactions with the regulatory bodies, key opinion leaders and partnering clinical
                                         centers that may result in changes to clinical trials and manufacturing programs;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         timing, scope or likelihood of regulatory filings and approvals;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         ability to develop and advance product candidates into, and successfully complete, clinical
                                         studies;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         expectations regarding the size of the patient populations for our product candidates,
                                         if approved for commercial use;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         implementation of our business model and our strategic plans for our business, product
                                         candidates and technology;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         commercialization, marketing and manufacturing capabilities and strategy;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         pricing and reimbursement of our product candidates, if approved;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         scalability and commercial viability of our manufacturing methods and processes;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         rate and degree of market acceptance and clinical utility of our product candidates,
                                         in particular, and gene therapy, in general;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         ability to establish or maintain collaborations or strategic relationships or obtain
                                         additional funding;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         competitive position;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         scope of protection we and/or our licensors are able to establish and maintain for intellectual
                                         property rights covering our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">developments
                                         and projections relating to our competitors and our industry;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         expectations related to the use of proceeds from this offering;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         estimates regarding expenses, future revenue, capital requirements and needs for additional
                                         financing;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         ability to remediate the material weaknesses that we and our independent registered public
                                         accounting firm identified and avoid any findings of material weaknesses or significant
                                         deficiencies in the future;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia; width: 0.25in"></TD><TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         impact of laws and regulations;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
                                         ability of our management team to lead the development of our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         expectations regarding the time during which we will be an emerging growth company under
                                         the JOBS Act; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
<TD STYLE="font: 10pt Georgia"></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">our
                                         expectations regarding the impact of the COVID-19 pandemic, including on our planned
                                         clinical trials, operations and financial position.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Forward-looking
statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking
statements on assumptions and assessments made by our management in light of their experience and their perception of historical
trends, current conditions, expected future developments and other factors they believe to be appropriate.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">These
statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause
our or our industry&rsquo;s actual results, levels of activity, performance or achievements to be materially different from those
anticipated by the forward-looking statements. We discuss many of these risks in this prospectus in greater detail under the heading
&ldquo;Risk Factors&rdquo; and elsewhere in this prospectus. You should not rely upon forward-looking statements as predictions
of future events.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the
forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this prospectus.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="a_004"></A>USE
OF PROCEEDS</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">We estimate that the net proceeds to us in this
offering will be approximately $32.3 million, after deducting the estimated underwriting discounts, estimated advisory fees
and estimated offering expenses payable by us, based on 720,114 ordinary shares being sold in the Reserved Offering
and 2,400,000 ADS being sold in the public offering. If the underwriters exercise their option to purchase
additional ADSs in full, we estimate that the net proceeds to us from this offering will be approximately $36.2 million,
after deducting the estimated underwriting discounts and estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">We currently expect that we will use the net proceeds
from this offering, together with our existing cash and cash equivalents, as follows:</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">approximately
                                            $5.3 million to complete our current Temferon TEM-GBM 001 trial, which is expected to enroll
                                            its last patient in the second quarter of 2022, and has been designed to establish
                                            clinical proof of concept and determine a therapeutic dosage of Temferon that is safe and
                                            well tolerated for patients in order to advance our GBM clinical program to Phase 2;</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font: 10pt Georgia; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>&#9679;</TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">approximately
                         $0.6 million to support long-term monitoring of the patients in the Temferon TEM-GBM 001 trial required by applicable
                         regulations, which is expected to run through 2029;</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font: 10pt Georgia; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>&#9679;</TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">approximately
                              $1.0 million to fund preclinical research performed in the laboratories of our founders, Professor Naldini
                              and Dr. Gentner at OSR. The aims of the research programs include the development of Temferon across a
                              broad range of cancer indications, second generation switchable Temferon, additional payloads and combination
                              therapies. We have exclusive licensing options extending over the scope of supported research pursuant to existing arrangements;
                              </FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font: 10pt Georgia; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>&#9679;</TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">approximately
                              $11.2 million to conduct an Italian clinical Phase 2 synthetic controlled study of Temferon in approximately
                              thirty (30) uMGMT-GBM patients expected to take place from early 2023 to late 2025, with the objectives
                              of safety, tolerability and efficacy of a single dose compared to matched patients in the synthetic arm
                              receiving standard of care. The results of this study could help us develop an adaptive study design for
                              the registration of Temferon in newly diagnosed GBM patients;</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font: 10pt Georgia; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>&#9679;</TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">approximately
                              $7.2 million to fund Temferon manufacturing activities for the Phase 2 trial, including LVV manufacturing,
                              stability and process scalability studies and technology transfer activities; and,</FONT></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font: 10pt Georgia; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>&#9679;</TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
                              remainder to fund ongoing business development activities, general and administrative expenses, the costs
                              of operating as a public company, working capital, and other general corporate purposes.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">We envision the future development of Temferon for
the treatment of other solid tumor indications and we have already identified locally advanced hepatocellular carcinoma (HCC) and intra-hepatic
cholangiocarcinoma (ICC) as appropriate additional target indications; however, the funding of this future development is not expected
to be covered by the net proceeds we will receive from this offering. We expect additional capital would need to be raised, either through
additional equity financings through future offerings of the Company&rsquo;s ADSs, a strategic funding event or an alternative funding
strategy to begin work on these other solid tumor indications.</P>


<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">It is difficult to predict the cost and timing required
to complete such trials due to, among other factors; the final study design, the timeline for regulatory agency approval, the rate of
enrollment of patients, and/or the timing and costs of manufacturing and supplying our product candidates for our planned trials. Furthermore,
we estimated our budget for European clinical trial activities currently planned by referencing the rates we are paying to sites and
third-party vendors involved in our ongoing programs in Italy, and subsequently applying an adjustment to those rates. Our estimated
rates may change as a result of discussions with regulatory bodies, key opinion leaders and partnering clinical centers. We may also
use a portion of the net proceeds to in-license, acquire or invest in additional businesses, technologies, products and/or assets. Therefore,
we cannot predict with certainty all of the particular uses of the net proceeds from the offering or the actual amounts that we will
spend on the uses set forth above.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">As a result, we believe that the expected net proceeds
from this offering, together with our existing cash and cash equivalents, will be sufficient to enable us to fund the development of
Temferon through Phase 2 and our other operating expenses until 2025. While we have based this estimate on assumptions that we believe to be reasonable, there can be no assurance that those assumptions will
not be proven wrong by future events, including the ongoing effects of the COVID 19 pandemic and related issues. Therefore we could deplete our available capital resources
more quickly than we currently expect.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">This expected use of net proceeds from this
offering represents our intentions based upon our current plans and business conditions, which could change in the future as our
plans and business conditions evolve. We may also use a portion of the net proceeds to in-license, acquire, or invest in additional
businesses, technologies, products, or assets. We may invest or raise additional capital to begin a new Temferon clinical program in
a second solid tumor indication. We cannot predict with certainty all of the particular uses for the net proceeds to be received
upon the closing of this offering or the amounts that we will actually spend on the uses set forth above. Predicting the cost
necessary to develop product candidates can be difficult and the amounts and timing of our actual expenditures may vary
significantly depending on numerous factors, many of which are beyond our control, including the progress of our development, the
status of and results from clinical trials, the availability of manufacturing capabilities, any collaborations that we may enter
into with third parties for our product candidates and any unforeseen cash needs. As a result, although we currently intend to focus
on the development of Temferon in uMGMT-GBM in a clinical Phase 2 trial to be performed in Italy, we will retain broad discretion
over the allocation of the net proceeds from this offering.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Pending our use of the net proceeds from this offering, we
may invest the net proceeds in a variety of capital preservation investments, including short-term, investment grade, and interest-bearing
instruments and government securities.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="a_005"></A>DIVIDEND
POLICY</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have never declared or paid any cash dividends on our ordinary shares and do not anticipate paying any cash dividends in the foreseeable
future. Payment of cash dividends, if any, in the future will be at the discretion of our shareholders, upon proposal by our board
of directors, and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions,
capital requirements, business prospects and other factors our board of directors may deem relevant.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
Italian law, Italian companies are required to furnish certain information to the Italian tax authorities regarding the identity
of non-resident shareholders in connection with the payment of dividends. Shareholders are required to provide their Italian tax
identification number, if any, or alternatively, in the case of legal entities, their name, country of establishment and address,
or in the case of individuals, their name, address and place and date of birth, or in the case of partnerships, the information
required for individuals with respect to one of their representatives. Payment of dividends may be subject to Italian withholding
taxes. See &ldquo;Taxation&mdash;Italy Tax Considerations&rdquo; for additional information. However, beneficial U.S. holders
are entitled to a reduction of the withholding taxes applicable to dividends paid to them under the income tax convention for
the avoidance of double taxation between the United States and Italy, which was signed on August 25, 1999 and went into effect
on December 16, 2009 (the &ldquo;Income Tax Convention&rdquo;); provided, however, that conditions set out in the Income Tax Convention
are met and subject to the applicable anti-avoidance provisions contained therein. In order for you to benefit from that reduction,
we are required to furnish certain information about you to the Italian tax authorities and, therefore, any claim by you for those
benefits would need to be accompanied by the required information.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia"><A NAME="a_007"></A><FONT STYLE="font-size: 10pt">CAPITALIZATION</FONT></FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
following table sets forth our cash and cash equivalents and our capitalization as of June 30, 2021:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; text-indent: 0in; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; text-indent: 0in; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">on
    an actual basis;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt">on an as
    adjusted basis to give effect to the issuance and sale of 3,120,114 securities (720,114 ordinary shares and 2,400,000
    ADSs) in this offering, after deducting estimated underwriting discounts, estimated advisory fees and estimated offering
    expenses payable by us, and to the application of the net proceeds as described in &ldquo;Use of Proceeds,&rdquo; as if the sale of
    the securities had occurred on June 30, 2021.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">You
should read this table in conjunction with the sections titled &ldquo;Selected Financial Data&rdquo; and &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and our financial statements and related notes
included elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="text-align: center; font-family: Georgia; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-family: Georgia; text-align: center"><P STYLE="font: 10pt Georgia; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>As
                                         of</B></FONT></P> <P STYLE="font: 10pt Georgia; margin-top: 0; margin-bottom: 0; text-align: center"><B>June
                                            30, 2021</B></P></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-family: Georgia; font-weight: bold; font-style: italic; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt">in
    Euros, except share data</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-family: Georgia; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">Actual</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-family: Georgia; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Proforma
                                            </B></FONT><FONT STYLE="font: 8pt Georgia"><B>As</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Adjusted</B></FONT></P></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia">(Unaudited)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font-family: Georgia; width: 62%; text-align: left"><FONT STYLE="font-family: Georgia">Cash and cash equivalents</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Georgia; width: 15%; text-align: right">10,553,906</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Georgia; width: 15%; text-align: right">39,089,861</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Shareholders&rsquo; deficit:</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">Ordinary shares, with no par value, 59,700,000 shares authorized:
    15,000,000 shares issued and outstanding; 18,120,114 shares, pro forma</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right">37,139,431</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right">65,675,386</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Accumulated deficit</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: right">(25,538,377</TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: right">(25,538,377<FONT STYLE="font-family: Georgia"></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Total  (deficit) equity</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right">11,601,054</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right">40,137,009</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Total capitalization</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: right">11,601,054</TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: right">40,137,009</TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">The number of our securities to be outstanding immediately
after this offering is 18,120,114 based on 15,000,000 ordinary shares outstanding as of June 30, 2021, after the Corporate Conversion,
plus 720,114 ordinary shares and 2,400,000 ADSs sold in this offering and excludes:</P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left">ordinary shares that are available
for future issuance under our 2021-2025 Equity Incentive Plan;</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">ordinary shares issuable upon
    exercise of the Underwriters&rsquo; Warrants; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left">&#9679;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left">ordinary shares and/or debentures convertible into ordinary shares issuable by
    the board of directors in connection with certain events such as the acquisition of stocks, assets or convertible notes and certain
    private placements and/or public offerings.</TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="a_008"></A>DILUTION</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">If you invest in our securities, your interest will be diluted
immediately to the extent of the difference between the public offering price per security you will pay in this offering and the pro
forma net tangible book value per security after the offering. At June 30, 2021, we had net tangible book value of approximately &euro;11.6
million, corresponding to a net tangible book value of approximately &euro;0.77 per ordinary share or $0.87 per ordinary share
(using the ratio of one ordinary share to one ADS). Net tangible book value per ordinary share or per ADS represents the amount of our
total tangible assets less our total liabilities, divided by 15.0 million, the total number of ordinary shares outstanding at June 30,
2021, or 15.0 million, the total number of ADSs that would represent such total number of shares based on an ordinary share-to-ADS ratio
of one-to-one.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">After
giving pro forma effect to the Corporate Conversion and the sale of the securities offered by us in this offering and after deducting
the estimated underwriting discounts, estimated advisory fees and estimated offering expenses payable by us, our pro forma estimated
net tangible book value at June 30, 2021 would have been approximately &euro;40.1 million, representing &euro;2.22 per
security or $2.51 per security. This represents an immediate increase in pro forma net tangible book value of &euro;1.44
per security or $1.64 per security to existing shareholders and an immediate dilution in pro forma net tangible book value
of &euro;7.95 per security or $8.99 per security to purchasers of ADSs or ordinary shares in this offering. Dilution for
this purpose represents the difference between the price per security paid by these purchasers and pro forma net tangible book value
per security immediately after the completion of this offering.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
following table illustrates this dilution on a per security basis to purchasers of securities in this offering:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 64%; text-align: left; text-indent: 0; padding-left: 0"><FONT STYLE="font-family: Georgia">Public
    </FONT><FONT STYLE="font-family: Georgia">offering price per security,  set forth on
    the cover page of this prospectus</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 14%; text-align: right"></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">$</FONT></TD><TD STYLE="font-family: Georgia; width: 14%; text-align: right">11.50</TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Historical net tangible book value (deficit)
    per security as of June 30, 2021</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">$</FONT></TD><TD STYLE="font-family: Georgia; text-align: right">0.87</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left; text-indent: 0; padding-left: 0"><FONT STYLE="font-family: Georgia">Increase in
    net tangible book value per security attributable to new investors in this offering</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">$</FONT></TD><TD STYLE="font-family: Georgia; text-align: right">1.64</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Pro forma as adjusted net tangible book value
    per security after offering</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"></TD><TD STYLE="padding-bottom: 1pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-family: Georgia; text-align: right">2.51</TD><TD STYLE="padding-bottom: 1pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Dilution in tangible book value per security
    to new investors</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Georgia; text-align: right"></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Georgia; text-align: right">8.99</TD><TD STYLE="padding-bottom: 2.5pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Percentage of dilution in net tangible book
    value per security for new investors</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right">78</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
the underwriters exercise their over-allotment option in this offering in full, the pro forma net tangible book value per security after
this offering would be $2.67 per security, and the dilution in pro forma as adjusted net tangible book value per security to new
investors purchasing securities in this offering would be $8.83 per security, after deducting estimated underwriting discounts,
estimated advisory fees and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
following table summarizes, on an as adjusted basis as of June 30, 2021, the differences between the number of securities acquired from
us, the total amount paid and the average price per security paid by the existing holders of our ordinary shares and by investors in
this offering and based upon the public offering price of $11.50 per security.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-family: Georgia; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">Shares</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">Total
    Consideration</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">Average Price
    Per Ordinary</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">Number</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">Percent</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">Amount</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">Percent</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">Share</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Existing shareholders&nbsp;</FONT></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: right"><FONT STYLE="font-family: Georgia; font-size: 10pt">15,000,000</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-size: 10pt">83</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: right"><FONT STYLE="font-size: 10pt">37,990,193</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Georgia; text-align: right"><FONT STYLE="font-size: 10pt">51</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: right"><FONT STYLE="font-size: 10pt">2.53</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Georgia; text-align: left; padding-bottom: 1.5pt; width: 31%"><FONT STYLE="font-family: Georgia; font-size: 10pt">New
    investors</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left; width: 1%"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right; width: 10%"><FONT STYLE="font-size: 10pt">3,120,114</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left; width: 1%"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left; width: 1%"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right; width: 10%"><FONT STYLE="font-size: 10pt">17</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 2.5pt; text-align: left; width: 1%"><FONT STYLE="font-family: Georgia; font-size: 10pt">%</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left; width: 1%"><FONT STYLE="font-family: Georgia; font-size: 10pt">$</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right; width: 10%"><FONT STYLE="font-size: 10pt">35,881,311</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left; width: 1%"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left; width: 1%"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right; width: 10%"><FONT STYLE="font-size: 10pt">49</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 2.5pt; text-align: left; width: 1%"><FONT STYLE="font-family: Georgia; font-size: 10pt">%</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: left; width: 1%"><FONT STYLE="font-family: Georgia; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right; width: 10%"><FONT STYLE="font-size: 10pt">11.50</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">18,120,114</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Georgia; text-align: right"><FONT STYLE="font-family: Georgia; font-size: 10pt">100</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">%</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">$</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 10pt">73,871,504</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Georgia; text-align: right"><FONT STYLE="font-family: Georgia; font-size: 10pt">100</FONT></TD><TD STYLE="font: 10pt Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">%</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"></TD></TR>
</TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">The number of our securities to be outstanding immediately
after this offering is 18,120,114 based on 15.0 million ordinary shares outstanding as June 30, 2021, 720,114 ordinary
shares and 2,400,000 ADSs sold in this offering and excludes:</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; text-indent: 0in; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; text-indent: 0in; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left">ordinary shares that are available for future issuance under
our 2021-2024 Equity Incentive Plan; </TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; text-indent: 0in">ordinary shares issuable upon exercise of the Underwriters&rsquo;
    Warrants; and</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; text-indent: 0in">&#9679;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; text-indent: 0in"><P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">ordinary
                                            shares and/or debentures convertible into ordinary shares issuable by the board of directors
                                            in connection with certain events such as the acquisition of stocks, assets or convertible
                                            notes and certain private placements and/or public offerings.</P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
the representative of the underwriters exercises the over-allotment option to purchase additional ADSs in full in this offering, the
number of securities held by new investors will increase from 3,120,114, or 17% to 3,480,114, or 19% of the
total number of securities outstanding after this offering and the percentage of ordinary shares held by existing shareholders will decrease
from 83% to 81% of the total securities outstanding.</FONT></P>

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><A NAME="ar_001"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><I>The
following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in
this prospectus. This discussion and other parts of the prospectus contain forward-looking statements based upon current expectations
that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated
in these forward-looking statements as a result of several factors, including those set forth under &ldquo;Risk Factors&rdquo; and elsewhere
in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><I>Prior
to this offering, we were a limited liability company, but the change in incorporation did not affect the financial information herein
presented, except for the transformation of our quotas into ordinary shares. As such the historical financial statements will not be
retrospectively adjusted.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
are a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of
solid tumors. We have developed a novel biologic platform which involves the <I>ex-vivo</I> gene transfer of a therapeutic candidate
into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly to the tumor by infiltrating
monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Our technology is designed to turn TEMs, which normally have an affinity for
and travel to tumors, into a &ldquo;Trojan Horse&rdquo; to counteract cancer progression and prevent tumor relapse. Because our technology
is not target dependent, we believe it can be used for treatment across a broad variety of cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Since
our inception in 2014, we have devoted substantially all of our resources to organizing and staffing our company, business planning,
raising capital, acquiring or discovering product candidates and securing related intellectual property rights, conducting discovery,
research and development activities for our programs and planning for eventual commercialization. We do not have any products approved
for sale and have not generated any revenue from product sales. To date, we have funded our operations with proceeds from the sales of
equity securities, which through December 31, 2020, aggregated gross cash proceeds of approximately &euro;33.6 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
do not have any products approved for sale, have not generated any revenue from commercial sales of our product candidates, and have
incurred net losses each year since our inception. Our ability to generate product revenue sufficient to achieve profitability will depend
heavily on the successful development and eventual commercialization of one or more of our current or future product candidates and programs.
Our net losses for the six months ended June 30, 2021 and 2020 were approximately &euro;4.0 million and approximately &euro;2.5 million,
respectively. Our net losses for the years ended December 31, 2020 and 2019 were approximately &euro;5.6 million and approximately &euro;4.6
million, respectively. At June 30, 2021 and December 31, 2020, we had an accumulated deficit of approximately &euro;25.5 million and
&euro;21.5 million. Substantially all of our operating losses resulted from costs incurred in connection with our research and development
activities, including preclinical and clinical development of our gene therapy product candidates, namely our leading product candidate
Temferon, and from general and administrative costs associated with our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
expect to continue to incur significant expenses for at least the next several years as we advance our product candidates from discovery
through preclinical development and clinical trials and seek regulatory approval of our product candidates. In addition, if we obtain
marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing,
marketing, sales and distribution. We may also incur expenses in connection with the in-licensing or acquisition of additional product
candidates. Furthermore, we expect to continue incurring additional costs associated with operating as a public company, including significant
legal, accounting, investor relations and other expenses.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">As
a result, for our long-term strategy, we will need substantial additional funding to support our continuing operations and pursue our
growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations
with proceeds from outside sources, with most of such proceeds to be derived from sales of equity securities, including the net proceeds
from our IPO and follow-on offerings. We also plan to pursue additional funding from outside sources, including but not limited to our
entry into or expansion of new borrowing arrangements; research and development incentive payments, government grants, pharmaceutical
companies and other corporate sources; and our entry into potential future collaboration agreements with pharmaceutical companies or
other third parties for one or more of our programs. We may be unable to raise additional funds or enter into such other agreements or
arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed,
we may have to significantly delay, scale back or discontinue the development and eventual commercialization of one or more of our product
candidates or delay our pursuit of potential in-licenses or acquisitions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability,
mainly due to the numerous risks and uncertainties associated with product development and related regulatory filings, which we expect
to make in multiple jurisdictions. When we are eventually able to generate product sales, those sales may not be sufficient to become
profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue
our operations at planned levels and be forced to reduce or terminate our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">As
of June 30, 2021, we had cash and cash equivalents of approximately &euro;10.6 million. We believe that our existing cash and cash equivalents
as of June 30, 2021 will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months.
We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than
we expect. See &ldquo;&mdash;Liquidity and Capital Resources.&rdquo; To finance our continuing operations, we will need to raise additional
capital, which cannot be assured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>COVID-19 Update</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">As
of the date of this filing, the global healthcare community continues to respond to the COVID-19 pandemic, including the recent emergence
of the &ldquo;delta variant.&rdquo; In February 2020, the COVID-19 pandemic commenced in Italy. Regulatory guidance was issued in March
and updated in April 2020 relating to the management of clinical trials during the pandemic. As the global healthcare community continues
to respond to the COVID-19 pandemic, many hospitals, including our clinical sites, temporarily paused elective medical procedures, including
dosing of new patients in clinical trials of our investigational gene therapies. While dosing of new patients and data collection from
enrolled patients has resumed at clinical sites, the extent to which clinical activities continue to be delayed or interrupted will depend
on future developments that are highly uncertain. We have not experienced significant interruptions related to COVID-19, although one
patient tested positive for COVID-19 and had to delay treatment with Temferon. We may find it difficult to enroll patients in our clinical
trials, which could delay or prevent us from proceeding with clinical trials of our product candidates. We continue to closely monitor
this rapidly evolving situation and the potential impact on us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Components of Operating
Results</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Revenue</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
have not generated any revenue since inception and do not expect to generate any revenue from the sale of products in the near future
until we obtain regulatory approval of, and commercialize, our product candidates.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Operating Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Our
current operating expenses consist of two components &ndash; research and development expenses, and general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Research and Development
Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
expense research and development costs as incurred. These expenses consist of costs incurred in connection with the development of our
product candidates, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">license
    fees and milestone payments incurred in connection with our license agreements;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">expenses
    incurred under agreements with contract research organizations, or CROs, contract manufacturing organizations, or CMOs, as well as
    investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">manufacturing
    scale-up expenses and the cost of acquiring and manufacturing preclinical and, in due course, clinical trial materials and commercial
    materials, including manufacturing validation batches;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">employee-related
    expenses, including salaries, social security charges, related benefits, severance indemnity in case of termination of employees&rsquo;
    relationships, travel and stock-based compensation expense for employees engaged in research and development functions and consulting
    fees;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">costs
    related to compliance with regulatory requirements; and</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">facilities
    costs, depreciation and other expenses, which include rent and utilities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Our
research and development expenses are tracked on a program-by-program basis for our product candidates and consist primarily of external
costs, such as fees paid to outside consultants, CROs, CMOs, and central laboratories in connection with our preclinical development,
process development, manufacturing and clinical development activities. Our research and development expenses by program also include
fees incurred under license agreements, as well as option agreements with respect to licensing rights. We do not allocate employee costs
or facility expenses, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple
programs and, as such, are not separately classified. We primarily use internal resources to oversee research and discovery activities
as well as for managing our preclinical development, process development, manufacturing, and clinical development activities. These employees
work across programs, and therefore, we do not track their costs by program. We elected to present the research and development credit
net of the related research and development expenditure on the statements of operations and comprehensive loss. However, not all of our
research and development expenses are allocated by program:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Six Months Ended</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="5" STYLE="text-align: right"><P STYLE="text-align: center; margin-top: 0; font: 10pt Georgia, Times, Serif; margin-bottom: 0">(Unaudited)</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Direct research and development expenses by program:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left; padding-left: 10pt">TEM-GBM (including TEM-LT)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">1,692,458</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">948,019</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">TEM-MM</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,609</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">173,680</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">TEM-HC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Unallocated costs:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Personnel (including share-based compensation)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">401,380</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">318,833</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Consultants and other third parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">760,831</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">354,599</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Materials &amp; supplies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">312,844</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">243,892</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Travel &amp; entertainment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,445</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,106</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total research and development expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,199,234</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,072,129</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Year Ended December 31,</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2020</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2019</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Direct research and development expenses by program:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 56%">TEM-GBM</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">3,353,369</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">1,853,929</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">TEM-MM</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">190,764</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">769,146</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Option fee &ndash; second indication <SUP>1</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Unallocated costs:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Personnel (including share-based compensation)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">472,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">753,238</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Consultants and other third party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,035</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,736</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Materials &amp; supplies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,151</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Travel &amp; entertainment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,466</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133,573</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,127</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">55,209</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total research and development expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,688,461</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,702,982</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><SUP>1
</SUP>Although the second indication is currently liver cancer, the Company has the right to change the indication.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Research
and development activities are central to our business model. Product candidates in later stages of clinical development generally have
higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage
clinical trials. We expect that our research and development expenses will increase substantially over the next several years, particularly
as we increase personnel costs, including stock-based compensation, contractor costs and facilities costs, as we continue to advance
the development of our product candidates. We also expect to incur additional expenses related to milestone and royalty payments payable
to third parties with whom we have entered into license agreements to acquire the rights to our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
successful development and commercialization of our product candidates is highly uncertain. At this time, we cannot reasonably estimate
or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any
of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. This uncertainty
is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development
    activities;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    impact of the COVID-19 pandemic on our preclinical development activities, clinical trials and other research and development activities;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">establishing
    an appropriate safety profile with IND-enabling studies;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">successful
    patient enrollment in, and the design, initiation and completion of, clinical trials;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">establishing
    and maintaining clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">development
    and timely delivery of commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">obtaining,
    maintaining, defending and enforcing patent claims and other intellectual property rights;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">significant
    and changing government regulation;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">qualifying
    for, and maintaining, adequate coverage and reimbursement by the government and other payors for any product candidate for which
    we obtain marketing approval;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">launching
    commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">addressing
    any competing technological and market developments; and</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">maintaining
    a continued acceptable safety profile of the product candidates following approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical
trials. We may elect, or be forced by regulatory authorities, to discontinue, delay or modify clinical trials of some product candidates
or focus on others. Any changes in the outcome of any of these variables with respect to the development of our product candidates in
preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these
product candidates. For example, if the EMA, FDA or another regulatory authority were to delay our planned start of clinical trials or
require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience significant delays
in enrollment in or treatment as part of any of our ongoing and planned clinical trials for any reason, including as a result of the
ongoing COVID-19 pandemic, we could be required to expend significant additional financial resources and time on the completion of clinical
development of that product candidate. Identifying potential product candidates and conducting preclinical testing and clinical trials
is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results
required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial
success.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>General and Administrative
Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">General
and administrative expenses consist primarily of salaries and consulting fees, related benefits, travel and stock-based compensation
expense for personnel in executive, finance and administrative functions. General and administrative expenses also include professional
fees for legal, consulting, accounting, and audit services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued
research activities and development of our product candidates. We also anticipate that we will continue to incur additional accounting,
audit, legal, regulatory, compliance, director and officer insurance costs as well as investor and public relations expenses associated
with being a public company. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate
an increase in payroll and other expense as a result of our preparation for commercial operations, especially as it relates to the sales
and marketing of our product candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Other Income (Expense)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Other
income (expense) consists primarily of interest income/(expense), foreign exchange income/(loss) and, for the year ended December 31,
2019, an award given to the Company by international institutions for the successful results achieved in clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Income taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
are subject to taxation in Italy. Taxes are recorded on an accrual basis. They therefore represent the allowances for taxes paid or to
be paid for the year, calculated according to the current enacted rates and applicable laws. Due to the tax loss position reported, no
income taxes were due for the six months ended June 30, 2021 and 2020 and the years ended December 31, 2020 and 2019 or the interim periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">As
of each reporting date, we consider existing evidence, both positive and negative, that could impact our view regarding to future realization
of deferred tax assets. We believe that it is more likely than not that the benefit for deferred tax assets will not be realized. In
recognition of this uncertainty, a full valuation allowance was applied to the deferred tax assets. Future realization depends on our
future earnings, if any, the timing and amount of which are uncertain as of June 30, 2021. In the future, should management conclude
that it is more likely than not that the deferred tax assets are partially or fully realizable, the valuation allowance would be reduced
to the extent of such expected realization and the amount would be recognized as a deferred income tax benefit in our statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">There
are open statutes of limitations for Italian tax authorities to audit our tax returns. There have been no material income tax-related
interests or penalties assessed or recorded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">There
is no liability related to uncertain tax positions reported in our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
line with the legislation in force until December 31, 2019, companies in Italy that invested in eligible research and development activities,
regardless of the legal form and economic sector in which they operate, could benefit from a tax credit up to 50% of the increase of
annual research and development expenses compared to the median expense for the years 2012-2014, which could be used as compensation
in order to reduce most taxes payable, including income tax or regional tax on productive activities, as well as of social security contributions.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The 2020
Italian Budget Law established that: (i) the tax credit due is up to 12% of the research and development costs incurred (up to a maximum
of &euro; 3.0 million); (ii) the actual support of eligible expenditure and its correspondence with the accounting documents must
result from a specific certification issued by the person responsible for the legal audit; (iii) the tax credit due can only be used
as compensation in three equal annual instalments. The 2021 Italian Budget Law established that: (i) the tax credit due is up to 20%
of the costs incurred (up to a maximum of &euro; 4.0 million); (ii) the tax credit can be used for 2021 and 2022 fiscal years;
(iii) it is necessary to have, besides the audit report, a technical report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Comparison of the
Six Months Ended June 30, 2021 to the Six Months Ended June 2020</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
following table summarizes our results of operations for the six months ended June 30, 2021 and 2020:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six-Months Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">(Unaudited)</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 56%; text-align: left">Research and development</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">3,199,234</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">2,072,129</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">842,236</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">404,885</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,041,470</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,477,014</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,041,470</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,477,014</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,679</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">559</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Foreign exchange loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,111</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,849</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total other income (expense), net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,432</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,290</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,047,902</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,479,304</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Income taxes (Note 5)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,047,902</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,479,304</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,047,902</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,479,304</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss per share and pro forma information (unaudited):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Loss and pro forma loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,047,902</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,479,304</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Loss per share and pro forma loss per share - basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.27</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.17</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average and pro forma weighted average number of shares outstanding - basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,772,610</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,420,904</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We have
presented actual and pro forma basic and diluted loss per share at June 30, 2021 and 2020, respectively, which consists of our historical
loss attributable to Genenta Science S.r.l. (and subsequently as of June 18, 2021 Genenta Science S.p.A.), divided by the weighted average
and pro forma basic and diluted weighted average number of ordinary shares outstanding, on an &ldquo;as converted&rdquo; basis (similar
to a stock split transaction) using the same conversion rate of 300 common shares per weighted average quota percentage of ownership
during the six months ended June 30, 2021 and 2020, respectively, after giving effect to the Corporate Conversion. See our disclosures
in this prospectus for additional information regarding the method used to calculate the pro forma basic and diluted loss per ordinary
share and the pro forma weighted average number of ordinary shares used in the computation of the per share amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Research and Development
Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Research
and development expenses were approximately &euro;3.2 million for the six months ended June 30, 2021, as compared to approximately
&euro;2.1 million for the six months ended June 30, 2020. The increase of approximately &euro;1.1 million was primarily due to the
increase of approximately &euro;1.3 million related the Company&rsquo;s GMB research and clinical activities (including personnel
costs and related stock option exercise expenses), partially offset by &euro;0.2 million related to the decrease of MM research and
clinical related expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>General and Administrative
Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">General
and administrative expenses were approximately &euro;0.8 million for the six months ended June 30, 2021, as compared to approximately
&euro;0.4 million for the six months ended June 30, 2020. The increase of approximately &euro;0.4 million of general and administrative
expenses was primarily due to &euro;0.2 million of accounting, legal and consulting fees and &euro;0.2 million of compensation
expense (including stock-based compensation and social costs).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Other Income</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Other
income was approximately &euro;2,700 for the six months ended June 30, 2021, as compared to approximately &euro;600 for the six months
ended June 30, 2020. The increase of approximately &euro;2,100 was primarily due to the number of awards granted to the Company in 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Foreign Exchange Loss</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Foreign
exchange loss was approximately &euro;9,100 for the six months ended June 30, 2021, as compared to approximately &euro;2,800 for the
six months ended June 30, 2020. The increase of approximately &euro;6,300 was primarily due to the net of exchange rate gains and losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Loss</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Our
loss was approximately &euro;4.0 million for the year six months June 30, 2021, as compared to approximately &euro;2.5 million for the
six months ended June 30, 2020. The increase of approximately &euro;1.5 million was primarily due to the increased spending related to
our overall research and clinical activities and to the increased spending related to advisory and consulting expenses related to our
fundraising activities.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Comparison of the
Year Ended December 31, 2020 to the Year Ended December 31, 2019</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
following table summarizes our results of operations for the years ended December 31, 2020 and 2019:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="5" STYLE="text-align: center"><FONT STYLE="font: 10pt Georgia, Times, Serif">(in Euros)</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 56%; text-align: left">Research and development</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">4,688,461</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">3,702,982</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">901,765</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">921,520</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,590,226</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,624,502</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,590,226</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,624,502</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,966</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,331</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Finance expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,754</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,552</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total other income (expense), net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,788</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,779</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,592,014</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,597,723</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Income tax benefit (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,592,014</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,597,723</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right">(5,592,014</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right">(4,597,723</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Pro forma information (unaudited):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Pro forma net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(5,592,014</P></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(4,597,723</P></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Pro forma net loss per share - basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(0.38</P></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(0.36</P></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average pro forma number of shares outstanding - basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">14,539,534</P></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">12,651,158</P></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have presented pro forma basic and diluted loss per share at December 31, 2020 and 2019, respectively, which consists of our historical
loss attributable to Genenta Science S.r.l., divided by the pro forma basic and diluted weighted average number of ordinary shares outstanding,
on an &ldquo;as converted&rdquo; basis, after giving effect to the Corporate Conversion, which occurred on June 18, 2021. See our disclosures
in this prospectus for additional information regarding the method used to calculate the pro forma basic and diluted loss per ordinary
share and the pro forma weighted average number of ordinary shares used in the computation of the per share amounts.</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">
We did not present basic and diluted loss per share for the years ended December 31, 2020 and 2019 in our audited Statements of Operations,
since we were an S.r.l. at the time and maintained classes of quota (similar to membership interests in a limited
liability company in the United States) rather than shares, which it now has post-conversion to an S.p.A.,(similar to a C-corporation
in the United States). The quotas represented percentage ownership in us and not actual shares. We did not believe
that representing loss per quota was meaningful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Research and Development
Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Research
and development expenses were approximately &euro;4.7 million for the year ended December 31, 2020, as compared to approximately &euro;3.7
million for the year ended December 31, 2019. The increase of approximately &euro;1.0 million was primarily due to the increase of approximately
&euro;1.6 million related the Company&rsquo;s GBM research and clinical activities partially offset by &euro;0.6 million related to the
decrease of MM related expenses. In addition, we exercised our option with OSR for our second cancer indication, which triggered an option
fee of &euro;0.5 million; however, this was offset by a decrease of &euro;0.3 million of personnel costs and &euro;0.2 million of other
research, development, and clinical related expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>General and Administrative
Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">General
and administrative expenses were approximately &euro;0.9 million for the year ended December 31, 2020, as compared to approximately &euro;0.9
million for the year ended December 31, 2019. The general and administrative expenses remained essentially flat due to our ability to
control expenses and focus our resources on research, development, and clinical activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Other Income</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Other
income was approximately &euro;6,000 for the year ended December 31, 2020, as compared to approximately &euro;36,000 for the year ended
December 31, 2019. The decrease of approximately &euro;30,000 was primarily due to the awards granted to the Company in 2019, i.e., the
Company won two international prizes for its results on research programs in 2019 without a corresponding award in 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Finance Expense</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Finance
expense was approximately &euro;7,800 for the year ended December 31, 2020, as compared to approximately &euro;9,600 for the year ended
December 31, 2019. The increase of approximately &euro;1,800 was primarily due to small exchange rate gains and losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Loss</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Our
loss was approximately &euro;5.6 million for the year ended December 31, 2020, as compared to approximately &euro;4.6 million for the
year ended December 31, 2019. The increase of approximately &euro;1.0 million was primarily due to the increased spending related to
our GBM research and clinical activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Liquidity and Capital
Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Since
our inception, we have not generated any revenue and have incurred significant operating losses and negative cash flows from our operations.
We have funded our operations to date primarily with proceeds from the sales of quotas. Through June 30, 2021, we had received gross
cash proceeds of approximately &euro;33.6 million from sales of our quotas. As of June 30, 2021, we had approximately &euro;10.6
million in cash and cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
table below presents our cash flows for the periods indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(in Euros)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Six Months Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>For the Year Ended</B></FONT></P> <P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>December 31,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(Unaudited)</P></TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2021</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="width: 11%; border-bottom: Black 1.5pt solid; text-align: right">(4,690,869</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="width: 11%; border-bottom: Black 1.5pt solid; text-align: right">(1,943,466</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="width: 11%; border-bottom: Black 1.5pt solid; text-align: right">(6,044,581</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="width: 11%; border-bottom: Black 1.5pt solid; text-align: right">(2,490,187</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,727</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(13,194</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20,871</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(216,741</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">136</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,389,316</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,768,202</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net (decrease) increase in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right">(4,911,337</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right">(1,956,524</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right">(4,676,136</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right">12,278,015</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,465,243</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,141,379</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,141,379</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,863,364</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,553,906<FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,184,855</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,465,243</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">20,141,379</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Operating Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">During
the six months ended June 30, 2021 and 2020, operating activities used approximately &euro;4.7 million and &euro;1.9 million, respectively
of cash and cash equivalents, resulting from our loss of approximately &euro;4.0 million and by cash used for changes in our operating
assets and liabilities of approximately &euro;1.1 million and partially offset non-cash charges of approximately &euro;0.5 million.
The net changes in our operating assets and liabilities were primarily due to an increase in payment of related party research and clinical
accrued expenses as well as an increase of prepaid and other current assets mainly related to a VAT (value added tax) receivable. The
non-cash charges primarily included approximately &euro;0.5 million of stock-based compensation expense and a deminimus amount of depreciation
and retirement benefit obligation expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">During
the year ended December 31, 2020, operating activities used approximately &euro;6.0 million of cash and cash equivalents, resulting from
our net loss of approximately &euro;5.6 million and by cash used for changes in our operating assets and liabilities of approximately
&euro;0.9 million and partially offset non-cash charges of approximately &euro;0.5 million. The net changes in our operating assets and
liabilities were primarily due to an increase in payment of related party research and clinical accrued expenses as well as an increase
of prepaid and other current assets mainly related to a VAT (value added tax) receivable. The non-cash charges primarily included approximately
&euro;0.5 million of stock-based compensation expense and a deminimus amount of depreciation and retirement benefit obligation expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">During
the year ended December 31, 2019, operating activities used approximately &euro;2.5 million of cash and cash equivalents, resulting from
our net loss of approximately &euro;4.6 million partially offset by cash provided by changes in our operating assets and liabilities
of approximately &euro;1.4 million and non-cash charges of approximately &euro;0.7 million. The net changes in our operating assets and
liabilities were primarily due to an increase in accruals and liabilities linked to the clinical trials made in cooperation with Ospedale
San Raffaele and the related clinical manufacturers. The non-cash charges relate primarily to approximately &euro;0.7 million of share-based
compensation expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Financing Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">During
the six months ended June 30, 2021 and 2020, cash flow from financing activities were &euro;(216,741) and &euro;136,
respectively, consisting of cash proceeds from the exercise of options on our class B quota. &euro;172 class B quota
was repurchased from Drs. Naldini and Gentner at nominal value, cancelled, and allocated to the option plan as available for grant.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">During
the year ended December 31, 2020, net cash provided by financing activities was approximately &euro;1.4 million, primarily consisting
of net cash proceeds from the sale of our class E quota, which raised net proceeds of approximately &euro;1.4 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">During
the year ended December 31, 2019, net cash provided by financing activities was approximately &euro;14.8 million, consisting of net cash
proceeds received from the rounds of equity fundraising that occurred in 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Current Outlook</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
have financed our operations to date primarily through proceeds from sales of our quotas to our founding quota holders and other third-party
investors. We have incurred losses and generated negative cash flows from operations since inception in 2014. To date we have not generated
revenue, and we do not expect to generate significant revenues from the sale of our product candidates in the near future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">As
of June 30, 2021, our cash and cash equivalents were approximately &euro;10.6 million. Our primary cash obligations relate to payments
to OSR pursuant to our license agreement and other providers of clinical trial related services. We believe that our existing cash and
cash equivalents will be sufficient to fund our projected cash requirements through the fourth quarter of 2022. Therefore, we will require
significant additional financing in the future to fund our operations. As we continue to assess the effects of the COVID-19 pandemic,
we do believe that it is possible that the COVID- 19 pandemic may make financing opportunities scarcer or more difficult or, if such
funds are available to us, that such additional financing may not be available in an amount that is sufficient to meet our needs. Our
failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and
could force us to delay, reduce or terminate our planned clinical trials or other operations, or grant rights to develop and commercialize
product candidates that we would otherwise prefer to develop and commercialize ourselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We currently
anticipate that we will require approximately &euro;5.2 million for research and development activities over the course of the
next twelve months. We also anticipate that we will require approximately &euro;3.1 million for operational expenditures over
such twelve-month period, which consists primarily of expenditures for supporting preclinical studies required for obtaining approval
to conduct such clinical studies for our product candidates, general and administration labor costs, and fundraising activities. In light
of our financial condition, we reduced our operating expenses, including for those purposes listed above, before the start of the COVID-19
pandemic. There can be no assurance that the analysis that we have undertaken or remedial measures that have been enacted will enable
us to avoid part or all of any impact from the spread of COVID-19 or its consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">This
expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions, which
could change in the future as our plans and business conditions evolve. We may also use a portion of the net proceeds to in-license,
acquire, or invest in additional businesses, technologies, products or assets. We cannot predict with certainty all of the particular
uses for the net proceeds to be received upon the closing of this offering or the amounts that we will actually spend on the uses set
forth above. Predicting the cost necessary to commercialize approved products and develop product candidates can be difficult and the
amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development,
our plans to develop our in-house drug product and vector manufacturing capabilities, the status of and results from clinical trials,
any collaborations that we may enter into with third parties for our product candidates and any unforeseen cash needs. As a result, our
management will retain broad discretion over the allocation of the net proceeds from this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Based
on our planned use of the net proceeds from this offering and our existing cash, we estimate that such funds will be sufficient to fund
our operations and capital expenditure requirements into 2024. We have based this estimate on assumptions that may prove to be wrong,
and we could use our available capital resources sooner than we currently expect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
addition, our operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional
funds sooner than planned. Our future capital requirements will depend on many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    length of the COVID-19 pandemic and its impact on our planned clinical trials, operations and financial condition;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    progress and costs of our preclinical studies, clinical trials and other research and development activities;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    scope, prioritization and number of our clinical trials and other research and development programs;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">any
    cost that we may incur under in- and out-licensing arrangements relating to our product candidate that we may enter into in the future;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    costs and timing of obtaining regulatory approval for our product candidates;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    costs of, and timing for, amending current manufacturing agreements for production of sufficient clinical and commercial quantities
    of our product candidates, or entering into new agreement with existing or new CMOs;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities
    internally; and</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    costs of acquiring or undertaking the development and commercialization efforts for additional, future therapeutic applications of
    our product candidates and the magnitude of our general and administrative expenses.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Until
we can generate significant revenues, if ever, we expect to satisfy our future cash needs through our existing cash, cash equivalents
and short-term deposits, the net proceeds from this current offering, loans, debt or equity financings. We cannot be certain that additional
funding will be available to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope
of, or eliminate research or development plans for, or commercialization efforts with respect to, one or more applications of our product
candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Critical Accounting
Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Our
financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of
our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates
on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates
under different assumptions or conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
believe that the accounting policies described below are critical in order to understand the judgements and estimates used in the financial
statements and to fully understand and evaluate our financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Accrued Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">As
part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses.
This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been
performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not
yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed,
on a pre-determined schedule or when contractual milestones are met; however, some require advanced payments. We make estimates of our
accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time.
We periodically confirm the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated
accrued research and development expenses include fees paid to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">vendors,
    including central laboratories, in connection with preclinical development activities, especially, OSR, a co-founding quotaholder,
    significant related party vendor and a leading center for ex-vivo gene therapy for inherited diseases;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">CROs
    and investigative sites in connection with preclinical and clinical studies; and</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">CMOs
    in connection with drug substance and drug product formulation of preclinical and clinical trial materials.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant
to quotes and contracts with multiple research institutions and CROs that conduct and manage preclinical studies and clinical trials
on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven
payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in
a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and
the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed
and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies
from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be
materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the
actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular
period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Share-based compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">To reward
the efforts of employees, directors, and certain consultants to promote our growth, our Board of Directors has historically approved,
during its existence, various share-based awards, although no share-based awards were granted during the year ended December 31, 2020;
however, during the six months ended June 30, 2021, the Board granted fully vested options on &euro;169 quota B. In addition, the Board
accelerated the vesting of other stock options on &euro;546 quota B that were previously granted. This amounted to a total of
&euro;715 quota B that were exercised prior to the Corporate Conversion. All options were awarded with an exercise price of &euro;1 per
quota and, when exercised, were first converted to Quota B of Genenta Science S.r.l. and then to ordinary shares giving effect to our
Corporate Conversion to Genenta Science S.p.A. All options have now been granted and there were no outstanding options as of June 30,
2021. The Board is implementing a new stock option plan (the Company&rsquo;s &ldquo;Equity Incentive Plan 2021&ndash;2025&rdquo;) based
on a maximum of 2.7 million of new ordinary shares (i.e., common stock) or 10% of the number of shares outstanding after the next round
of financing. The new stock option plan will be implemented by the Compensation and Nominating Committee of the Board of Directors after
the next round of financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
measure share-based awards granted to employees and directors based on the fair value on the date of the grant and recognize compensation
expense for those awards over the requisite service period, which is the vesting period of the respective award. Forfeitures are accounted
for as they occur. The measurement date for option awards is the date of the grant. We classify share-based compensation expense in our
statements of operations and comprehensive loss in the same manner in which the award recipient&rsquo;s payroll costs are classified
or in which the award recipient&rsquo;s service payments are classified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">With
the adoption of Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2018-07, Compensation&mdash;Stock Compensation (Topic 718): Improvements
to Nonemployee Share-Based Payment Accounting (&ldquo;ASU 2018-07&rdquo;) on January 1, 2019, the measurement date for non-employee awards
is the date of the grant. The compensation expense for non-employees is recognized, without changes in the fair value of the award, over
the requisite service period, which is the vesting period of the respective award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Quota B valuations
(Pre-Conversion to S.p.A.)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
fair value of the Quota B of Genenta Science S.r.l. underlying our stock-based compensation grants prior to our Corporate Conversion
has historically been determined by our board of directors, with input from management and third-party valuations. We believe that the
board of directors has the relevant experience and expertise to determine the fair value of the Quota B, when also securing third-party
assistance. Given the absence of a public trading market of our equity, and in accordance with the American Institute of Certified Public
Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, the board of directors exercised
reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of our
equity at each grant date. These factors include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">valuations
    of the Quota B equity performed by third-party specialists;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    price of our equity to third-party, arms-length, sophisticated, and qualified investors, which was used in the OPM backsolve model;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    prices, rights, preferences, and privileges of our Quota C, D, and E preferred equity classes relative to those of our equity;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">lack
    of marketability of the Quota B;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">lack
    of voting rights of the Quota B;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">current
    business conditions and projections;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">hiring
    of key personnel and the experience of management;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">our
    stage of development;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    timing, progress and results of our preclinical studies and clinical trials for our programs and product candidates; including statements
    regarding the timing of initiation and completion of trials or studies and related preparatory work, the period during which the
    results of the trials will become available and our research and development programs;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">likelihood
    of achieving a liquidity event, such as an initial public offering, a merger or acquisition given prevailing market conditions, or
    other liquidation events for us;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    market performance of comparable publicly traded companies; and</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    European, U.S. and global capital market conditions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
valuing the Quota B, the board of directors determined the equity value of our business using various valuation methods. The board of
directors engaged a third-party valuation firm who performed analyses in accordance with the guidance outlined in the American Institute
of Certified Public Accountants&rsquo; Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as
Compensation. Our option valuations were prepared using an option pricing method (&ldquo;OPM&rdquo;), which used market approaches to
estimate our enterprise value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
OPM treats each equity class as a call options on the total equity value of a company, with exercise prices <I>(i.e.</I>, breakpoints)
based on the value thresholds at which the allocation among the various holders of a company&rsquo;s securities changes. A discount was
considered for Lack of Marketability (&ldquo;DLOM&rdquo;), which is an amount or percentage that is deducted from the value in order
to reflect the absence of a viable market. The DLOM was then applied to arrive at an indication of value for the option. Also, considered
in the valuation was volatility and the fact that the Quota B did not carry voting rights. The expected volatility used in the OPM is
based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Application
of our approach involved the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding
the selection of comparable companies, and the expected timing of an initial public offering (&ldquo;IPO&rdquo;) or other liquidity event.
Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact the valuations at each
valuation date and may have a material impact on the valuation of the Quota B, and consequently, our share-based compensation expense
could be materially different. For valuations after the completion of an initial public offering, the board of directors will determine
the fair value of each share of underlying equity shares based on the closing price of the shares as reported on the date of grant.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On
June 18, 2021, all Quota B were converted, with all other classes of Quota, into ordinary common stock based essentially on their ownership
percentages. All previous rights and privileges of the classes of quotaholders were cancelled and all owners received their pro rata
ownership in the same class of ordinary common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Research and development
tax credit receivables</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
account for our research and development tax credit receivable in accordance with IAS 20 <I>Accounting for Government Grants and Disclosure
of Government Assistance</I>. The receivable is recognized when there is reasonable assurance that: (1) the recipient will comply with
the relevant conditions and (2) the grant will be received. We elected to present the credit net of the related expenditure on the statements
of operations and comprehensive loss. While these tax credits can be carried forward indefinitely, we recognized an amount which reflects
management&rsquo;s best estimate of the amount that is reasonably assured to be realized or utilized in the foreseeable future based
on historical benefits realized, adjusted for expected changes, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Emerging Growth Company
Status</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
are an &ldquo;emerging growth company.&rdquo; Under the JOBS Act, an emerging growth company can delay adopting new or revised accounting
standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably
elected to avail ourselves of this exemption from new or revised accounting standards, and, therefore, will not be subject to the same
new or revised accounting standards as public companies that are not emerging growth companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Off-Balance Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
have not engaged in any off-balance sheet arrangements, such as the use of unconsolidated subsidiaries, structured finance, special purpose
entities or variable interest entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
do not believe that our off-balance sheet arrangements and commitments have or are reasonably likely to have a current or future effect
on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures
or capital resources that is material to investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Quantitative and Qualitative
Disclosure About Market Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial
position due to adverse changes in financial market prices and rates. Our current investment policy is to invest available cash in bank
deposits with banks that have a credit rating of at least A-. Accordingly, a substantial majority of our cash and cash equivalents is
held in deposits that bear interest. Given the current low rates of interest we receive, we will not be adversely affected if such rates
are reduced. Our market risk exposure is primarily a result of foreign currency exchange rates, which is discussed in detail in the following
paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Foreign Currency Exchange
Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Our
results of operations and cash flow are not subject to significant fluctuations due to changes in foreign currency exchange rates. As
discussed above, most of our liquid assets and our expenses are denominated in EUR. Changes of 5% and 10% in the USD/EUR exchange rate
would not have significantly increased/decreased our operating expenses. As we continue to grow our business, our results of operations
and cash flows might be subject to fluctuations due to changes in foreign currency exchange rates, which could adversely impact our results
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
do not hedge our foreign currency exchange risk. In the future, we may enter into formal currency hedging transactions to decrease the
risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may
not adequately protect us from the material adverse effects of such fluctuations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="a_010"></A>BUSINESS</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Overview</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment
of solid tumors. We have developed a novel biologic platform that involves the <I>ex-vivo</I> gene transfer of a therapeutic candidate
into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly to the tumor by
infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Our technology is designed to turn TEMs, which
normally have an affinity for and travel to tumors, into a &ldquo;Trojan Horse&rdquo; to counteract cancer progression
and to prevent tumor relapse. Our technology is not target dependent, and therefore we believe it can be used as a treatment for
a broad variety of cancers.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
technology incorporates the use of a lentiviral vector (LVV) that combines a therapeutic transgene sequence, or payload, with
our proprietary platform. Our proprietary platform consists of (i) the Tie-2 promoter, that drives transgene sequence transcription
specifically in TEMs, and (ii) miRNA-126 target sequences to downregulate transgene expression post-transcription in those cells
where the Tie-2 promoter is active and the miRNA-126 is present. We believe there are many advantages to our approach:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Trojan
    Horse Mechanism of Action (&ldquo;MoA&rdquo;):</I> We use and modify TEMs, a subpopulation of tumor-associated myeloid cells,
    known to be involved in tumor growth and in the inhibition of immune system response, to allow the immune system to recognize
    the tumor and to deliver to the cancer site a chosen therapeutic.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Select
    Regulation of Transgene Expression: </I>Our selected control of the chosen therapeutic gene expression is designed to avoid
    off-target and systemic toxicity.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif"><I>Potential
                                            Long-Term Effect:</I> Through the use of hematopoietic stem cells, our therapeutic
                                            candidate is designed as a &ldquo;<I>living therapy</I>&rdquo; intended to break the cancer-induced
                                            immune tolerance and to establish a competent immune surveillance throughout the life of
                                            the patient.</P></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Agnostic
    Response</I>: In contrast to antigen-restricted CAR-T cells, our platform is not restricted to a pre-selected tumor antigen,
    nor any one tumor type. As such, it may be applied to a broad range of solid tumors and cancer subtypes, which would overcome
    one of the central unresolved challenges of immune-oncology cancer therapies.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Our lead product candidate, Temferon, was developed using
our platform and carries an interferon-alpha (IFN-&alpha;) payload. IFN-&alpha; is a well-known therapeutic that was previously administered
intravenously for treatment of various cancers, but it is currently rarely used because of its systemic toxicity. The Temferon<B>-</B>modified
TEMs express the transgene payload, IFN-&alpha;, in the tumor microenvironment resulting in the breakdown of tumor induced immune-tolerance.
As a result, the immune system can recognize the tumor, respond, and inhibit tumor growth. Because Temferon is designed to deliver
the IFN-&alpha; payload directly to the tumor, we believe it will demonstrate clinical activity without the side effect profile of systemic
delivery of IFN-&alpha;. In preclinical mouse cancer models treated with Temferon both direct (anti-angiogenic, pro-apoptotic)
and indirect (immune response) effects were observed.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We are currently developing Temferon for the treatment of
glioblastoma multiforme (GBM) in patients who have an unmethylated MGMT gene promoter (uMGMT-GBM). GBM is the most common malignant primary
brain tumor, accounting for more than half of all central nervous system (CNS) cancers. Patients suffering from GBM have limited, non-curative
treatment options. Although these treatments may improve survival, the prognosis for GBM patients remains poor, with a median overall
survival (mOS) of approximately 13 to 15 months and only 5.5% of patients estimated to be alive 5 years after diagnosis. With no curative
treatments available and such poor prognosis for patients, there remains a large, unmet medical need. We chose uMGMT-GBM among our first
targets for clinical development after considering the medical need, the active role that TEMs have in GBM pathology, and the high number
of newly diagnosed uMGMT-GBM patients potentially interested in participating in our study. As a result, we believe uMGMT-GBM offers
a good profile for our initial proof of concept trial in humans. We are currently conducting a Phase 1/2a clinical trial with Temferon
in newly diagnosed uMGMT-GBM patients in Italy. We anticipate completing enrollment and patient dosing by the second quarter of 2022.
We intend to use the preliminary results of our Phase 1/2a clinical trial to support a Clinical Trial Application to conduct in EU a
multicenter Phase 2 trial in uMGMT-GBM, which we currently intend to conduct primarily in Italy. As of November 15<SUP>th</SUP>,
2021, we have dosed a total of 15 patients. The preliminary results show that Temferon has been generally well tolerated, with no dose
limiting toxicities identified so far.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We also intend to develop Temferon for the treatment of other
solid tumor indications, and locally advanced hepatocellular carcinoma (HCC) and intra-hepatic cholangiocarcinoma (ICC) are under
consideration. HCC and ICC are gastrointestinal (GI) cancers affecting the digestive system. HCC is a primary malignancy of the liver
that occurs predominantly in patients with underlying chronic liver disease and cirrhosis. ICC is a biliary tract cancer and represents
approximately 3% of all GI malignancies. The prognosis for patients with locally advanced HCC or ICC remains poor, with few therapeutic
options, having limited clinical benefits. While we are considering development of Temferon for these liver indications for similar reasons
as GBM (i.e. the high unmet need, TEMs&rsquo; role in HCC and ICC pathology, and the number of newly diagnosed patients potentially eligible
for our study), we are also evaluating development of Temferon for other solid tumor indications.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In addition to our Temferon programs that target uMGMT-GBM
or other solid tumor indications such as HCC and ICC, we have exclusive option rights to license (i) Temferon for the treatment of
additional indications, and (ii) other drug candidates that are currently in the preclinical stage of development both as standalone
treatments and as combination therapies.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">AGC Biologics facility in Milan, Italy, will continue
manufacturing LVV and Temferon to support Genenta&rsquo;s trials. For further larger studies we may use AGC&rsquo;s 60,000 square
meter cell and gene therapy manufacturing facility located in Longmont, Colorado (U.S.), which AGC purchased from Novartis in July
2021 or another US-based CMO.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
were founded in 2014 by San Raffaele Hospital (Ospedale San Raffaele or OSR) in Milan, a globally recognized premier research
hospital for <I>ex-vivo</I> gene therapy, with Pierluigi Paracchi (our CEO), Luigi Naldini (Chairman of our Executive Scientific
Board) and Bernhard Gentner (a member of our Executive Scientific Board), to develop potential ground-breaking cell and
gene cancer therapies. We leverage the vast experience in LVV technology of the San Raffaele Telethon Institute for Gene Therapy
(SR-Tiget), a world leading cell and gene therapy research institution on the forefront of developing therapies for rare diseases
that is a joint venture between OSR and Fondazione Telethon (Telethon). SR-Tiget has a proven track record for successful collaborative
clinical research programs in <I>ex-vivo </I>gene therapy that give rise to approved products, including Strimvelis, an <I>ex-vivo
</I>gammaretroviral vector-based gene therapy for adenosine deaminase severe combined immunodeficiency (ADA-SCID), and Libmeldy,
an <I>ex-vivo</I> gene therapy for the treatment of early-onset metachromatic leukodystrophy (MLD) patients, both marketed by
Orchard Therapeutics. Our platform was developed in the SR-Tiget laboratories of our founders, Prof. Naldini and Dr. Gentner and
we hold exclusive rights, and exclusive option rights, to certain intellectual property originating there.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Since
closing our first round of funding in May 2015, we have recruited a leading management team, established a manufacturing process
for our drug product candidate, completed  preclinical activities (research and Good Laboratory Practice &ndash; GLP &ndash; grades),
engaged with Italian, European and U.S. Key Opinion Leaders (KOLs) to identify our clinical lead indications and submitted our
first CTA.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
leadership team has a proven track record as biotech executives. Their expertise span from finance and venture capital to medical
affairs, scientific research, clinical drug product development and clinical trial management and conduction. For example, members
of our management team have been involved in the successful development of Ethical Oncology Science, which was acquired in 2013
for over $400 million, and Strimvelis the first ever approved <I>ex-vivo</I> gene therapy product that was developed under the
guide of Carlo Russo, our Chief Medical Officer and Head of Development (formerly Head of Development of the Biopharm Unit and
Head of Research &amp; Development of the Rare Disease Unit at GSK). Our management team members have played important
roles in both large pharma companies such as Merck and GSK, and life science startups, such as Adverum, Annapurna, VaxInnate
Corporation, OncoSec Medical, Biological Dynamics and GenMark Diagnostics. We believe this multi-disciplinary competence, provides
a unique blend for the development of innovative gene and cell therapy products, and constitutes a fertile ground for alliances
with industrial partners that could help us bring new therapies to patients.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Research
and Development Pipeline</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
portfolio of clinical and preclinical <I>ex-vivo</I> autologous gene cancer therapies is based on our technology platform, which
was originally developed in our founders&rsquo; laboratories at OSR. Through our collaboration with OSR, we have worldwide commercial
rights to Temferon (though our current trademark rights to Temferon are limited to the US and Europe) for the treatment of GBM, HCC and ICC, as well as exclusive option
rights to license all of our other programs. Specifically, we retain exclusive option rights to license (i) any platform improvements,
including our second-generation technology, which includes developments to enable the on/off regulation of the therapeutic transgene,
(ii) products for additional indications that utilize our platform technology but use different transgene payloads, and (iii)
combinations of our platform with therapies in the immuno-oncology (IO) field, such as ICI, CAR-T cell therapies and TCR therapies.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
current pipeline, with clinical and preclinical stage programs, is summarized below:</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="chart_002.jpg" ALT="" STYLE="height: 312px; width: 670px"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Georgia"><I>*Genenta
has options/rights on IP derived from preclinical data generated at SR-Tiget laboratories.</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Strategy</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We are developing novel cancer therapeutics using our autologous
<I>ex-vivo</I> gene therapy platform, to initially address the unmet medical needs of uMGMT-GBM patients and patients suffering
from another solid cancer indication such as HCC and ICC, but ultimately, we hope to broaden our platform to treat a wide variety of
cancers by pursuing the following strategies:</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Advance
development of our leading clinical-stage product candidate, Temferon in the U.S. </I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We are currently conducting a Phase 1/2a dose-escalation study
in Italy to primarily evaluate the safety and tolerability of Temferon in up to 21 uMGMT-GBM patients who have an unmethylated
MGMT promoter, following radiotherapy treatment. We plan to initiate in Europe a multicenter Phase 2 trial in uMGMT-GBM,
which we currently intend to conduct primarily in Italy to evaluate the safety and efficacy of Temferon in up to 27 uMGMT-GBM
patients who have an unmethylated MGMT promoter where we intend to measure progression free survival (PFS) and overall survival (OS)
as endpoints. In advance of our CTA submission and not required for our European trial, we have submitted a pre-IND meeting request
to the FDA and received written responses from the Agency in the third quarter of 2021 regarding the proposed Phase 2 clinical study design and drug product
manufacturing strategy. The plans for the Phase 2 clinical study and drug product manufacturing strategy will be informed by the Agency comments.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Extend
</I></B></FONT><FONT STYLE="font: 10pt Georgia"><B><I>our product pipeline across multiple indications</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
intend to expand our product pipeline by:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Identifying
    additional indications suitable for Temferon. We are in the planning stages for a second study using Temferon in a second solid
    tumor indication and locally advanced HCC and ICC are under consideration. The Istituto Superiore di Sanit&agrave;
    (ISS), an independent committee with oversight from the Italian Ministry of Health, must issue a positive opinion regarding our
    CTA before AIFA will approve it and we may start patient&rsquo;s recruitment. In addition to HCC and ICC, we believe
    there may be additional cancer indications which actively recruit TEMs to proliferate for which Temferon may be a suitable therapy.</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Using
    our platform with different transgene payloads</I>. Our platform technology is designed to enable us to use different
    transgene payloads to potentially achieve therapeutic outcomes in selected cancer indications. We are currently conducting
    preclinical studies for two therapeutics using our platform with different payloads targeting solid tumors.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Developing
    a second-generation platform that enables the &ldquo;on-demand&rdquo; release of the transgene payload</I>. We intend to develop
    a second-generation technology platform that allows the drug products to be switched on to exert the therapeutic effects and
    switched off if they are no longer needed, or to mitigate toxicity. This technology may enable us to expand our treatment
    options to broader patient populations.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Exploring
    combination therapies</I>. We will seek to enter into collaborations with other companies to explore combination studies of
    our therapeutics with other cancer therapies, such as ICI, CAR-T cell therapies and TCR therapies. We believe our product,
    as a result of its MoA, has the potential to enhance the durability and efficacy of the existing therapies, thus  abolishing the immune tolerance to the tumor.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Exploiting
    in-licensing opportunities with OSR</I>. We intend to exploit in-licensing opportunities with OSR, a co-founding shareholder.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Develop
and maintain efficient manufacturing processes to support anticipated growth</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">To meet our drug product supply needs for conducting
larger trials after the completion of our planned Phase 2 uMGMT-GBM study in Europe, we intend to enter into a supply
agreement with a US-based CMO for the manufacturing of our products. Currently, Temferon, is manufactured by AGC Biologics, a
leading global contract development and manufacturing organization (CDMO), which is headquartered in Italy and specializes in the
manufacturing of viral vectors and genetically engineered cells. Their facility is certified by AIFA. AGC Biologics facility in
Milan, Italy, will continue manufacturing LVV and Temferon to support Genenta&rsquo;s trials. For further larger studies we may
use AGC&rsquo;s 60,000 square meter cell and gene therapy manufacturing facility located in Longmont, Colorado (U.S.), which AGC
purchased from Novartis in July 2021 or another US-based CMO.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Establish
a patient-centered infrastructure and strong relationships with key U.S. opinion leaders working in our disease area</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Since
cell and gene-based therapies are relatively new approaches in oncology, we intend to implement programs to improve patient
and physician education regarding the availability of gene therapy-based products for those cancers with a high unmet medical
need. To this end, we are discussing with Antonio Chiocca, MD, Professor Neurosurgeon-in-Chief and Chairman, Department
of Neurosurgery at Brigham and Women&rsquo;s Hospital in Boston, MA, Frederick Lang, MD, Professor and Chairman
of the Department of Neurosurgery at MD Anderson in Houston, TX, and David A. Reardon, MD, Department of Medical Oncology at
Dana-Farber Cancer Institute in Boston, MA. </FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Develop
opportunistic partnership(s) with pharmaceutical company(s)</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
may choose to partner with larger pharmaceutical companies whose core competencies and oncology strategies are in line with ours.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Our
Strengths </B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt; font-weight: normal">We
believe that our growing body of early clinical data evidencing the potential of our autologous <I>ex-vivo</I> gene therapy
approach, coupled with our founders&rsquo; expertise in the development, manufacturing and commercialization of gene and cell
therapies, positions us well to provide potentially transformative therapies through a single administration to patients suffering
from a broad range of cancers. We believe our key strengths include:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Unique
    and valuable expertise.</I></B> We are conducting our clinical trials at OSR, a leading center for <I>ex-vivo</I> gene therapy
    for inherited diseases. OSR has treated more than 121 patients worldwide (one of the highest number of patients treated
    with gene therapy for rare diseases in a research hospital), using an ex-vivo viral vector platform similar to the
    one we are developing for cancer treatment. Members of our executive leadership team have held senior positions at GSK,
    Merck, Annapurna-Adverum and other companies specializing in gene and cell therapies and rare diseases. We have partnered
    with academic institutions that are pioneers in autologous <I>ex-vivo</I> gene therapy and hold exclusive option rights to
    license additional patents and know-how to build our portfolio. Partnerships with leading academic institutions well recognized
    in the gene therapy field, such as SR-Tiget and OSR, are a core part of our research engine through which we are working to
    advance the clinical development of our product candidates and to identify new opportunities that we believe have comparably
    high probabilities of success in a preclinical setting. We believe our expertise, combined with our plan to leverage our relationships
    with leading academic institutions, will help expedite the commercialization of our lead clinical-stage product candidate
    and further expand our pipeline.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Deep
    pipeline with broad utility</I>.</B> We believe that the flexibility of our technology platform combined with our exclusive
    option rights to in-license additional programs, gives us the ability to grow our pipeline by targeting a broad set of cancer
    diseases.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: bold 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Durable
    therapeutic potential</I>.</B> <FONT STYLE="font-weight: normal">Preliminary interim clinical data collected from twelve treated uMGMT-GBM
    patients following a single administration of Temferon displayed modified cells at 18 months, the last measured timepoint to
    date. </FONT></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: bold 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Designed
    for tumor restricted therapeutic payload delivery and release</I>.</B> <FONT STYLE="font-weight: normal">The design of our transgene
    expression cassette is intended to restrict payload expression to the tumor microenvironment. The local and tumor restricted therapeutic
    gene deployment approach is designed to focus the pleiotropic anti-tumor activities of the selected payload, by limiting the toxic
    manifestation that results from standard systemic administration of the payload.</FONT></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: bold 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Agnostic
    approach.</I></B> <FONT STYLE="font-weight: normal">Our immune-gene therapy approach is designed to be a tumor-agnostic immunotherapy
    that does not rely on any specific target or tumor type, and we believe it could be successfully applied to a potentially broad range
    of cancers and immune contexts.</FONT></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: bold 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Solid
    tumors targeting.</I></B> <FONT STYLE="font-weight: normal">Our platform has the potential to efficiently target solid tumors.
    Solid tumors are difficult to treat, even by the most novel and leading-edge technologies such as ICIs and CAR-T cells. Our
    cellular carrier, TEMs, is spontaneously and actively recruited by growing tumors and is found in several human solid tumors,
    irrespective of location. </FONT></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Active
    and sustained tumor surveillance. </I></B>Our immune-gene investigational therapy is designed to trigger the patient&rsquo;s own
    immune response and establish an active immune surveillance. Our preclinical work, which used different cancer models (B-cell acute
    lymphoblastic leukemia - B-ALL and GBM) as well as preliminary data collected from our uMGMT-GBM patients, suggests the occurrence
    of changes in the immune system.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Fine dose tuning. </I></B>Our
    platform holds promise to fine tune the dose to be administered based on individual patient characteristics.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Preliminary
    data indicate that our approach is feasible and well-tolerated.</I></B> Temferon has been well-tolerated in the limited number
    of patients treated to date. Our <I>ex-vivo</I> modification of the patient&rsquo;s own HSPCs and cryopreservation allow us
    to formulate the patient&rsquo;s drug product prior to administering the therapy.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>LVV
    as transgene payload delivery vehicles. </I></B>LVVs are particularly attractive for clinical applications due to their capacity
    to transfer large genes/payloads and their ability to efficiently transduce non-proliferating or slowly proliferating cells, such
    as hematopoietic stem and progenitor cells that allow a persistent gene expression in transduced cells. Moreover, LVVs have a potentially
    reduced risk of genotoxicity compared to gamma-retroviral vectors (gRV). A large number of patients have been treated both with other
    LVV gene therapy products approved for sale and with clinical-stage LVV gene therapy product candidates for rare diseases worldwide,
    and generally these therapies have been well tolerated. We believe that long-term extensive follow-up across multiple diseases, with
    vectors expressing different genes, demonstrates the potential safety of our LVV-based autologous <I>ex-vivo </I>gene therapy approach.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Applicability
    to a potentially large number of patients and indications</I></B>. We believe our autologous <I>ex-vivo</I> gene therapy approach
    has broad therapeutic potential across a large number of malignancies. The <I>ex-vivo</I> transduction of HSPCs allows for
    the potentially long-term production of a differentiated cellular carrier loaded with the therapeutic gene and the consequent
    distribution of the therapeutic payload throughout multiple organs and tissues containing solid tumors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Status
of Current IO Treatments </B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Despite
new therapeutic approaches and new drugs having been developed or approved, substantial unmet need remains for many of the most common
cancers. Immuno-oncology therapies seek to work in conjunction with the patient&rsquo;s own immune system to recognize and attack cancer
cells selectively, without affecting normal cells, or to deliver immune system components that prevent the spread of cancer. Immuno-oncology
therapy is recognized as an important type of cancer treatment in addition to more established options such as surgery, chemotherapy,
targeted therapy and radiation therapy. Indeed, the number of IO therapeutics in development worldwide grew 233% from 2017 to 2020.
IO therapeutics, which rely on the natural activity of the immune system to fight cancers in various ways, are grouped, by the
Cancer Research Institute, in five main classes reported in the tables below.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="pg80-149_002.jpg" ALT="" STYLE="height: 339px; width: 670px"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="pg80-149_003.jpg" ALT="" STYLE="height: 209px; width: 670px"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Current
Limitations of IO Approaches</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Despite
significant advances, the clinical application of immunotherapy for cancer patients still faces challenges, including:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Development
    of tumor resistance (positive selection of tumor cells bearing advantageous mutations);</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Dependence
    on specific targets;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Poor
    response for many patients;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Lack
    of a durable response;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Side
    effects;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Need
    for multiple dosing for most IO classes; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Inability
    to efficiently target many solid tumors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, manufacturing scalability of some IO approaches remains a challenge and significantly limits market penetration. The
table below reports some of the main limitations for each IO class.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>IO
    Class</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Limitations</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 1.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 0.1in"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD ROWSPAN="6" STYLE="font: 10pt Georgia; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Cell-based
    immunotherapies</I></B></FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Graft
    versus host disease (GVHD)</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Only
    a limited number of antigens may be targeted currently</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Inability
    to target multiple antigens at the same time</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Some
    antigens targeting may be ineffective</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
    majority of TILs within the tumor microenvironment are exhausted so even tumor-specific T cells are hypo-responsive</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">CAR-T</FONT><FONT STYLE="font: 10pt Georgia">
    cells can only recognize antigens that are naturally expressed on the cell surface, so the range of potential antigen targets
    is smaller than with TCRs</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Presence
    of target-negative tumor cells cause relapse in the long-term</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Limited
    penetration and distribution into solid tumor tissues</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD ROWSPAN="4" STYLE="font: 10pt Georgia; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Immunomodulators</I></B></FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Loss
    of self-tolerance (establishment of autoimmunity associated with failure of tumor rejection)</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Absence
    of reliable biomarkers and thresholds to identify the most likely responsive population</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Induction
    of overactive immune responses as well off-target responses against healthy cells</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Limited
    penetration and distribution into solid tumor tissues</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD ROWSPAN="2" STYLE="font: 10pt Georgia; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Vaccines</I></B></FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Absence
    of universal antigens (each individual&rsquo;s tumor is unique and has its own distinguishing antigens)</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Presence
    of a compromised/weak/immunosuppressed immune system</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD ROWSPAN="5" STYLE="font: 10pt Georgia; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Antibody-based
    targeted therapies</I></B></FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Limited
    penetration and distribution into solid tumor tissues (mAbs directed against tumor-specific antigens largely remain in the
    blood and no more than 20% of the administered dose typically interacts with the tumor)</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Low
    binding affinity between the antibody and its receptor</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Antibody
    uptake limit</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Competition
    for target binding between the therapeutic antibodies and a patient&rsquo;s antibodies</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Speed
    of diffusion through tumors is mAb size dependent (large tumor masses may be more difficult to treat by mAb therapy)</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD ROWSPAN="6" STYLE="font: 10pt Georgia; text-align: center; vertical-align: middle"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Oncolytic
    viruses</I></B></FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Development
    of neutralizing antibodies by the host, which limits the viral delivery to cancer sites and the therapeutic effect</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Limited
    penetration and distribution of the virus into tumor tissues</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Limited
    viral tropism and oncolysis capacity</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Tricky
    dosing strategies</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Induction
    of overactive immune responses as well off-target responses against healthy cells</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Risk
    of infection</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>IO
for Solid Tumors</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Despite
the success of IO therapies for some hematological cancers, significant gaps remain in the development of efficacious IO therapies
for solid tumors. There are still a number of challenges that IO therapies need to resolve to treat solid tumors including the
ability to target delivery of a therapeutic to the solid tumor and identification of suitable prominent cell surface targets.
Cell therapies have not been as successful in solid tumors in comparison to blood cancers mainly because of the absence
of a suitable prominent cell surface target and the high risk of toxicity when a potential solid tumor target is expressed, even
at a low level, on normal tissue. Even if targets for solid tumors with a suitable tumor-selectivity profile can be identified,
other factors may limit the activity of cell therapies, including limited cell-therapy penetration and distribution, low oxygen
concentration (hypoxia) barriers around cancers that may prevent T cell access to the tumor, expression by tumor cells of certain
checkpoint genes and an inability to target multiple antigens at the same time.</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">To
overcome the current limitations of IO therapies in solid tumors, a new, effective tumor therapeutic must:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.75in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">achieve
    a local and tumor-targeted delivery;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">maximize
    on-target effects;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">reach
    the desired therapeutic index;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">minimize
    the off-target side effects; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">potentially
    provide long term results.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Our
Platform</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
platform technology utilizes a novel mechanism of action that we believe has the potential to address the limitations
and challenges of current IO technologies. Through a single administration, our platform is designed to provide a broadly
applicable treatment to deliver a tumor-targeted therapeutic, including to solid tumors. It does so by exploiting a naturally
occurring cancer-induced biological process, allowing for the local delivery of the payload with a potentially durable response,
in a manner that we believe will limit systemic toxicity. The ability to deliver localized and tumor-targeted payloads,
by avoiding systemic or off-target toxicity, may also allow for the use of well-established immunotherapies, such as the immunomodulator
IFN-&alpha;, that has shown efficacy but has had limited therapeutic applications due to side effects associated
with its intravenous delivery.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Specifically,
we adapted an autologous <I>ex-vivo</I> gene therapy method to direct the patient&rsquo;s own hematopoietic stem and progenitor
cells (HSPCs) by loading them with an immunotherapeutic transgene sequence, or payload, that is able to counteract cancer progression
and prevent tumor relapse. We believe that by delivering a targeted therapeutic specific to cancer cells, we can reach
the desired on-target anti-tumor effect while reducing off-target side effects.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
platform technology employs the following key components:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.75in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">use
    of the patient&rsquo;s own autologous HSPCs;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">use
    of LVVs for <I>ex vivo</I> HSPCs transduction; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">payload
    delivery within the tumor microenvironment (TME) using specific tumor-associated myeloid cell (Tie2-expressing monocytes &ndash;
    TEMs). This &ldquo;cell-confined&rdquo; transgene expression is ensured by the selected promoter (Tie-2 promoter) and the
    imposed post-transcriptional regulation layer represented by a miRNA target sequence (miRNA-126 target sequences).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
image below illustrates the steps of our <I>ex-vivo</I> approach to transform patient&rsquo;s autologous HSPCs into a therapeutic
product.</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="pg80-147_004.jpg" ALT="" STYLE="height: 318px; width: 620px"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Illustration
of our ex-vivo approach (steps 1-2-3) and treatment process (step 4)</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">(1)
Patient&rsquo;s HSPCs are harvested by means of an apheresis process, and (2) <I>ex-vivo</I> modified by an LVV. The obtained
drug product is frozen and stored for clinical use (3). When needed, the therapeutic product may be thawed and infused back in
patient&rsquo;s blood stream (4). The engineered HSPCs will repopulate the entire hematopoietic system, giving rise to differentiated
progeny bearing the introduced modification<I>.</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>a)
HSPCs are the Source of the Delivery Vehicle for Our Gene Therapy Approach</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">By
re-introducing gene-modified HSPCs into the patient, we seek to take advantage of the self-renewing and multi-differentiation
capability of HSPCs to enable durable and potentially long-term effects following a single treatment. HSPCs are self-renewing
cells that can differentiate into all types of blood cells, including white blood cells, red blood cells and platelets. HSPCs
can be obtained directly from the bone marrow or from the patient&rsquo;s peripheral blood with the use of a mobilizing agent
that induces HSPCs to relocate from the bone marrow into the peripheral blood where they may be collected by apheresis. The advantages
of using a patient&rsquo;s own HSPCs include the absence of graft versus host disease (GVHD) that could occur using allogeneic
cells, and the potential long-term treatment durability of this approach.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>b)
Ex-vivo LVV based Transduction </I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">After
collection, a functional copy of the therapeutic gene is inserted into the patient&rsquo;s own HSPCs using a non-replicating LVV.
This is an <I>ex-vivo</I> process called transduction. We have chosen an <I>ex-vivo</I> gene therapy approach because it enables
us to optimize the quantity, or dose, of modified cells to be infused in each patient since we know, ahead of the administration,
the drug product characteristics.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
believe that LVVs are the first choice for <I>ex-vivo</I> gene therapy in humans because they can (i) carry large transgenes
that will allow us to expand the therapeutic options to a multitude of payloads without &ldquo;size&rdquo; limits and (ii)
efficiently transduce non-proliferating, or slowly proliferating cells, such as hematopoietic stem and progenitor cells. Most
importantly, there is already an abundance of safety data generated using these vectors to develop investigational products
currently under clinical testing, including CARs, TCRs, as well as commercial products such as Kymriah<SUP>&reg;</SUP> (CD-19
CAR-T, Novartis Pharma) and Zynteglo<SUP>&reg; </SUP>(&beta;-Thal, BlueBird Bio). With more than 100 clinical trials either
completed or in progress using LVVs worldwide, this delivery method accounts for more than a third of <I>ex-vivo</I> modified
gene therapy clinical trials.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Accordingly,
extensive clinical <I>ex-vivo</I> gene therapy studies, based on LVV gene transfer, have been performed in recent years by SR-Tiget for
the prevention and treatment of some severe inherited disorders, resulting in approved drugs, such as Libmeldy<SUP>TM</SUP>. These studies
have shown that LVVs constitute a valuable and safer alternative to gamma-retroviral vectors (gRV), enabling a more efficient gene transfer
into HSPCs and resulting in a robust and long-term transgene expression in their progeny. The studies also have demonstrated an alleviated
risk of genotoxicity because of the vector design.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Georgia, Times, Serif; text-indent: 0.5in">Differences exist between LVVs used for <I>ex-vivo </I>transduction
that could, in theory, lead to differences in the long-term safety profile of products, particularly in terms of genotoxic potential.
Use of strong promoters in conditions where a high pre-existing risk for hematologic malignancies exists, such as sickle cell disease
(SCD), could in the long-term (i.e. 5 years or more) contribute to the development of leukemia. There have been several significant
adverse side effects in gene therapy treatments involving an ex-vivo transduced lentivirus vector (LVV) gene therapy product, BlueBird
Bio&rsquo;s elivaldogene autotemcel (&ldquo;Lenti-D&rdquo;), involving two SUSARs for cases of acute myeloid leukemia (AML), and one
case involving myelodysplastic syndrome.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In February 2021, BlueBird Bio temporary suspended its
gene therapy clinical trials for SCD (HGB-206 and HGB-210) and the marketing of Zynteglo<SUP>&reg;</SUP> due to a suspected unexpected
serious adverse reaction (SUSAR) of acute myeloid leukemia (AML) in a SCD patient who received the product more than five years ago.
In July 2021, the European Medicines Agency&rsquo;s (EMA) safety committee (Pharmacovigilance Risk Assessment Committee - PRAC) announced
that there is no evidence the LVV used in both Lenti-D and the EU-approved gene therapy Zynteglo spurred the AML cases.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">BlueBird Bio announced on August 9, 2021 that the SUSAR
involving myelodysplastic syndrome occurred in one patient treated with Lenti-D over a year previously, that this SUSAR &ldquo;is likely
mediated by Lenti-D lentiviral vector (LVV) insertion,&rdquo; and that &ldquo;[e]vidence currently available suggests that specific design
features of Lenti-D LVV likely contributed to this event.&rdquo; As a result of this SUSAR, the FDA has placed a clinical hold on BlueBird
Bio&rsquo;s Lenti-D phase 3 trial for cerebral adrenoleukodystrophy (CALD).</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
believe that the intrinsic characteristics of the LVV we have selected as well as the properties of the promoter and control mechanisms,
combined with HSPCs&rsquo; ability to self-renew, allow for a stable integration of the modified gene into the HSPCs and their
related differentiated progeny, potentially achieving long-term safety and protection after only a single treatment.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>c)
Tumor-Targeted Payload Delivery</I></B></FONT></P>



<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
platform technology, used by all of our product candidates including Temferon, is designed to turn TEMs, which normally
have an affinity for and travel to tumors, into a &ldquo;Trojan Horse&rdquo; to deliver a tumor-targeted payload. The technology
ensures that the payload is only expressed in TEMs and not in other types of cells. The following key components make up our platform
technology: (i) a Tie-2 promoter that drives transgene sequence transcription specifically in TEMs, and (ii) a post-transcriptional
regulation layer represented by miRNA-126 target sequences that induces the downregulation of the transgene expression in those
cells where the Tie2 promoter is active and the miRNA-126 target sequence is present. This transcriptional / post-transcriptional
regulatory mechanism prevents off-target effects and allows the expression of the payload by the selected cellular carrier (TEMs).</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="pg80-147_005.jpg" ALT="" STYLE="height: 222px; width: 600px"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Our
transgene payload expression cassette consists of two key components: the Tie-2 promoter (RED) and miRNA-126 target sequences
(LIGHT BLUE)</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>(i)</I></B></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Tie-2
    promoter.</I></B> The Tie-2 promoter enables the transformation of TEMs into a &ldquo;Trojan Horse&rdquo;, to deliver the
    therapeutic payload within the tumor microenvironment. Tumor development and progression is a multi-step process leading to
    cancer growth. The so called &ldquo;angiogenic switch&rdquo; is one of the required steps and refers to a time-restricted
    event during tumor progression where the balance between pro- and anti-angiogenic factors tilts towards a pro-angiogenic outcome,
    resulting in the transition from a &ldquo;dormant&rdquo; avascularized tumor to an outgrowing vascularized cancer. It is well
    recognized that TEMs play an active role in this regard. Indeed, TEMs are actively recruited by proliferating tumors, through
    signals produced by the cancer cells or stromal/endothelial components, to promote the neo-vascularization and to contribute
    to the establishment of an immunosuppressive tumor microenvironment that leads to the failure in tumor eradication by the
    immune system. Amongst chemoattractant factors of monocytes, angiopoietins (Ang) play a crucial role. These are adhesion molecules
    and known vascular growth factors expressed by peritumoral blood vessels. One Ang in particular, Ang-2, attracts TEMs, which
    binds to the Tie-2 receptor. Expression of Ang-2 is upregulated by tumor hypoxia and may function as a chemoattractant for
    Tie2-expressing monocytes. Moreover, TEMs&rsquo; penetration into the tumor microenvironment in response to these stimuli
    cause Tie-2 receptor upregulation, which enhances the delivery of the payload to the tumor. Since TEMs recruitment is a naturally
    occurring event in the tumor development process and is a key aspect shared by several different cancers, we believe that
    our platform which enables the tumor targeted delivery of therapeutics represents a unique approach that may have broad applicability.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>(ii)</I></B></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>miRNA-126
    target sequences</I></B>. The miRNA-126 target sequence serves as a post-transcriptional regulation layer that allows the
    expression of the transgene payload only in cells where miRNA-126 is not expressed. In our case, because miRNA-126 is highly
    expressed in HSPCs but down-regulated in the differentiated progeny, it switches off transgene expression in the stem and
    progenitor cell compartment. Indeed, Tie2 is a weak promoter expressed, in the hematopoietic compartment, by Tie2-expressing
    monocytes and by hematopoietic stem cells (HSC). In HSC, it works as a membrane-bound receptor that keeps HSC cell-to-cell
    interaction and adhesion with the bone marrow niche and preserves the HSC quiescent/low proliferating state.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="pg80-149_006.jpg" ALT="" STYLE="height: 322px; width: 670px"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Post-transcriptional
control mechanism of transgene expression</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>A)
Transgene expression is allowed only in cells where miRNA-126 is not expressed; (1) mRNA is transcribed into the nucleus (2) the
transgene is then translated in the cytoplasm and released.</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>B)
In those cells expressing miRNA-126 the payload production is prohibited; (1) mRNA is transcribed into the nucleus (2) miRNA-126
recognizes its target sequences on the mRNA and forms double strands of RNA (3) that are degraded or block the translation process.</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="pg80-147_007.jpg" ALT="" STYLE="height: 197px; width: 670px"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Transgene
payload expression as the result of the transcriptional (promoter) and post-transcriptional regulation (miRNA-126 target sequence) imposed
by our expression cassette.</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
believe that combining our built-in post-transcriptional control mechanism (<I>miRNA-126 target sequences</I>), with TEMs designed
as a &ldquo;Trojan Horse&rdquo; allows our platform to restrict transgene expression and avoid systemic toxicity while reaching
the therapeutic index to drive efficacy.</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Our
Leading Product Candidate: Temferon</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
lead product candidate, Temferon, consists of genetically modified HSPCs which use our platform to deliver interferon-alpha (IFN-&alpha;),
within the tumor microenvironment via TEMs (HSPCs differentiated myeloid progeny). The IFN-&alpha; reduces angiogenesis, counteracts
tumor cells proliferation and breaks the established immune-tolerance, enabling the immune system to recognize the tumor. IFN-&alpha;
is a proven and known immunomodulatory molecule, or cytokine, that has limited clinical use due to the systemic toxicity associated with
its intravenous administration. Our technology is designed to protect the HSPCs from IFN-&alpha; mediated activation that could negatively
impact their repopulation capacity as reported in some studies of repeated systemic administration of high doses of IFN-&alpha;. We believe
that this protection technology, whereby we restrict payload expression to TEMs, and the release of IFN-&alpha; within the TME, has the
potential to provide efficacy without inducing systemic toxicity.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Because
TEMs are associated with the growth of numerous cancer types, including solid tumors, we believe that Temferon is tumor type and tumor
target agnostic and therefore may be used across a large variety of cancers. Currently, we are developing Temferon for uMGMT-GBM.</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="pg80-149_008.jpg" ALT="" STYLE="height: 340px; width: 650px"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Overview
of Temferon manufacturing process and mechanism of action. </I></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Patient&rsquo;s
<B>HSPCs</B> are harvested, (1) <B>ex-vivo</B> modified by <B>LVVs</B> (2) and re-introduced back in patient&rsquo;s blood stream
(3). Once recruited within the tumor microenvironment, TEMs release IFN-&alpha; that reduces angiogenesis, counteracts tumor cells
proliferation and enables the immune system to recognize the tumor.</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">GBM
is a solid tumor affecting the brain. We have chosen this indication due to the following factors:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>High
    unmet medical need.</I></B> The prognosis for GBM patients remains poor with few therapeutic options having limited clinical
    benefits.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Temferon&rsquo;s
    MoA targets TEMs which have an active role in uMGMT-GBM pathology.</I></B> GBMs are highly vascularized tumors that critically
    depend on the generation of tumor-associated blood vessels. Several studies demonstrate that infiltrating myeloid cells, including
    Tie2-expressing monocytes, contribute significantly to tumor angiogenesis, presumably by secreting pro-angiogenic factors and promoting
    malignant glioma growth by creating a local immunosuppressive microenvironment. Moreover, TEMs have been identified in the normal/tumor
    boundary from human biopsy samples of GBM patients who received treatment to reduce angiogenesis using the anti-VEGF treatment bevacizumab,
    and the Tie2 pathway has been implicated in the triggering of a bevacizumab-mediated VEGF-independent angiogenesis that explains
    the long-term refractoriness of GBMs to anti-VEGF treatment.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt; color: #111419"><B><I>Immunosuppressive
    tumor microenvironment.</I></B></FONT> <FONT STYLE="font-family: Georgia; font-size: 10pt">GBM is characterized by an immunosuppressive
    microenvironment that is mediated by tumor associated myeloid cells (including TEMs) that prevent the immune system from
    recognizing and rejecting the tumor. Our treatment approach is designed to exploit TEMS to deliver IFN-&alpha;
    to the tumor so that the immune system recognizes the tumor and halts tumor cell proliferation and recurrence.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Availability
    of a &ldquo;competent&rdquo; immune system.</I></B> Our approach relies on a patient&rsquo;s immune system being capable of providing
    an immune response upon recognition of the tumor. Therefore, we believe newly diagnosed uMGMT-GBM patients who have relatively
    &ldquo;competent&rdquo; immune systems, not yet damaged by repeated cycles of chemotherapies, are strong candidates for our candidate.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Compelling
    preclinical data.</I></B> Our preclinical studies, published in peer-reviewed papers, suggest that TEMs play an active role in uMGMT-GBM,
    and when used as a &ldquo;Trojan Horse,&rdquo; significantly shrink the tumor and to control disease progression. In more recent
    unpublished studies, we have also demonstrated, in a preclinical immunocompetent GBM mouse model, that treatment by Temferon resulted
    in a long-lasting immune response in surviving mice, even after repeated tumor challenge intended to replicate possible tumor recurrences.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Market Opportunity. </I></B>Based
    on currently available treatments, the global market size for all GBM is projected to grow to over $1.5 billion by 2026. We
    believe a novel therapeutic which demonstrates improvement over existing therapies would greatly increase the market size.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are discussing a second study using Temferon in a second solid tumor indication. Locally advanced HCC and ICC are the leading
indications under consideration and, as with GBM, these liver cancer indications have been selected for similar reasons as described
above.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Temferon for
uMGMT-GBM</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Disease
Overview</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">GBM
is the most common malignant primary brain tumor accounting for more than half of all central nervous system (CNS) cancers and for
which there is a high unmet medical need. The incidence rate is 3.20 per 100,000 persons with over 13,000 deaths per year in the
United States. This disease is lethal and left untreated, the median survival is three (3) months. The current standard of care
includes using a combination of surgery, radiation therapy, and chemotherapy for treatment. Although these treatments may improve
survival, the prognosis for GBM patients remains poor with a median overall survival (mOS) of approximately 13 to 15 months and only
5.5% of patients estimated to be alive 5 years after diagnosis. GBM may occur at any age, but 70% of cases are seen in patients
between 45 and 70 years of age (median 64 years). The disease often progresses rapidly (over 2 to 3 months). Neurological signs are
nonspecific as they result from intracranial hypertension and include headaches and vomiting, often associated with behavioral
changes or focal neurological deficits. Variants of GBM include secondary glioblastoma (20% of total diagnosed GBM), gliosarcoma
(2%) and giant cell glioblastoma (1%). We are not including these variants in our studies because they do not fully meet our
selection criteria discussed above.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Current
Treatment Landscape and Limitations</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
current standard of care for GBM includes surgery to remove the accessible tumor followed by radiation therapy (RTx), chemotherapy
with temozolomide (TMZ) and/or tumor treating fields (TTFields).</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Surgery
    </I></B>remains the mainstay of initial treatment. If the tumor is located in a resectable region of the brain, it is used
    to histologically confirm the diagnosis and level of tumor burden. For many patients, removal of the tumor also results in
    a decrease of tumor mass-associated symptoms. Although the extent of the surgical removal of the tumor is linked to longer
    survival, due to the invariably infiltrative nature of the disease, even the complete removal of the accessible tumor is not
    curative and most people with GBM later develop recurrent tumors either near the original site or at more distant locations
    within the brain. Additionally, as a possible consequence of surgical procedures, permanent brain damage may occur.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Radiation
    therapy </I></B>improves survival and is typically started approximately 3 to 4 weeks after surgery. RTx is performed daily
    for approximately 6 weeks. RTx induces the formation of neo-antigens and a pro-inflammatory response that are key aspects
    for immune system mediated disease control. However, the efficacy of RTx is impaired by hypoxia and by the negative effects
    of RTx on tumor infiltrating immune cells.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Chemotherapy.
    </I></B>Temozolomide, the current chemotherapeutic standard of care, is a DNA-alkylating agent that can cross the blood-brain
    barrier to reach therapeutic concentrations in the brain. The drug is administered every day during radiation therapy and
    then for six to 12 cycles after radiation as a maintenance therapy. Each cycle lasts 28 days, with TMZ given the first five
    days of each cycle, followed by 23 days of rest. TMZ adds a methyl group to DNA that, if unrepaired, leads to DNA strand breaks
    and cytotoxicity. More than one-third of glioblastomas are deficient in methylguanine methyltransferase (MGMT), a repair protein
    that removes the methyl group. This MGMT deficiency occurs through the methylation (silencing) of the MGMT gene promoter.
    Glioblastoma patients with a silenced MGMT gene who are treated with TMZ have a longer survival than those with an unmethylated
    MGMT. TMZ has several adverse side effects, including a cumulative bone marrow toxicity.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Tumor-Treating
    Fields (TTFields)</I></B>. The use of TTFields to extend temozolomide maintenance chemotherapy for newly diagnosed glioblastoma
    patients has recently been incorporated as a new standard of care. TTFields are applied via multiple electrodes that are directly
    fixed to the scalp. These low-intensity, alternating electrical fields interfere with cell division ultimately leading to
    cell cycle arrest, aneuploidy, and apoptosis. The most common TTFields-associated adverse events (AEs) are mild-to-moderate
    array-associated contact dermatitis.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><P STYLE="margin-top: 0; font: 10pt Georgia; padding-bottom: 0; text-align: left; margin-right: 0; margin-bottom: 0"><B>Experimental
                                         Treatments.</B> Along with the above-mentioned treatments, the addition of the
                                         antiangiogenic agent bevacizumab (BEV) to RTx and TMZ has been explored with mixed
                                         clinical results <FONT STYLE="color: #111419">BEV was tested both a first-line
                                         treatment together with RTx and concomitant TMZ administration in newly diagnosed
                                         glioblastoma patients, as well as in combination with RTx in recurrent GBM patients.
                                         </FONT>BEV was approved by the FDA as monotherapy for recurrent glioblastoma in 2009
                                         under the name Avastin&reg;. The EMA declined to approve BEV for recurrent glioblastoma
                                         due to the absence of a non-bevacizumab control arm, a modest overall survival increment
                                         versus historic controls, inadequate elucidation of true antitumor effect, and challenges
                                         with radiographic response assessment. More recently, an immune-checkpoint blocker nivolumab
                                         was tested in combination with TMZ and RTx in a Phase 3 trial in recurrent glioblastoma
                                         patients but showed minimal activity and no benefit in terms of mOS, resulting in failure
                                         to meet one of its primary endpoints, progression free survival (PFS).</P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0 0 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; text-indent: 0.5in; margin: 0 0 0 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Currently
available GBM surgical treatments have not been able to prevent GBM recurrence because of the infiltrative nature of this disease
and the absence of an effective immune system. A therapeutic able to cross the blood-brain barrier and selectively impact proliferation
of cancer cells independently from the region of the brain where the tumor resides would be a significant advancement.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Our
Solution</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
believe that our investigational product, Temferon, has the potential to address the world recognized GBM unmet need. Through
a single administration, we believe Temferon may be able to provide a long-lasting immune response, minimize systemic toxicity, counteract
cancer progression and prevent tumor relapse.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Temferon
utilizes our platform and <I>ex-vivo</I> gene therapy approach to introduce a functional copy of IFN-&alpha; which is Temferon&rsquo;s
transgene payload, into the patient&rsquo;s autologous HSPCs, resulting in a drug product that can then be reintroduced into the
patient as outlined above (<I>see &ldquo;Our Leading Product Candidate: Temferon&rdquo; and &ldquo;Our Platform&rdquo;</I>). Temferon
is designed to colonize the patient&rsquo;s bone marrow with the genetically modified HSPCs to continuously generate TEMs
containing the IFN-&alpha; payload. Since TEMs are recruited within the tumor microenvironment, IFN-&alpha; is released solely
at the targeted tumor, which may result in clinical activity without inducing systemic toxicity.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Once within the tumor microenvironment, IFN-&alpha;
is expected to act both <I>directly</I> by promoting cancer cell apoptosis and inhibiting vascularization and <I>indirectly
</I>by restoring the body&rsquo;s anti-tumor immune response, as follows:</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Direct
    Effects.</I></B> IFN-&alpha; suppresses tumor cell proliferation and promotes the apoptosis of tumor and stromal cells by
    induction of proapoptotic genes or repression of anti-apoptotic genes. Moreover, IFN-&alpha; inhibits angiogenesis by downregulating
    the expression of proangiogenic factors.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Indirect
    Effects.</I></B> IFN-&alpha; stimulates early innate immune responses and the subsequent adaptive immune response via multiple
    pathways and mechanisms, including: maturation and cross-priming capacity of dendritic cells (DCs); upregulation of the expression
    of tumor-associated surface antigens and MHC class I molecules on tumor cells and of MHC class I and II molecules on DCs;
    enhanced priming and survival of T cells; enhanced humoral immunity; increased cytotoxic activity of NK cells and macrophages;
    control of helper T cell population balance (Th1=Th2); immunoglobulin class switching of B cells; and the regulation of CD8+
    cytotoxic T-lymphocyte (CTL) responses.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
believe that through these immunomodulatory functions and based on our preclinical data, IFN-&alpha; increases tumor immunogenicity,
recruits and activates immune cells within the tumor milieu, breaks established tumor-induced immunotolerance and may induce tumor
rejection.</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="pg80-149_009.jpg" ALT="" STYLE="height: 336px; width: 670px"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Overview
of Temferon antitumor activity</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Once
recruited at the tumor site, instead of fostering tumor growth and inhibiting the immune systems, TEMs start to release IFN-&alpha;
that triggers cancer cell apoptosis and arms the immune cells to fight the cancer.</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Clinical
Development of Temferon in uMGMT-GBM</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Preclinical
Data</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have preclinical data, published in 2018, suggesting that TEMs play an active role in GBM disease. Further studies
published in 2008 showed that when TEMs were used as a &ldquo;Trojan Horse,&rdquo; as utilized by Temferon, the
GBM tumor volume decreased and the disease progression was controlled. In more recent, unpublished preclinical studies,
we have also demonstrated, in an immunocompetent GBM mouse model, that treatment with Temferon resulted in a long-term immune
response in surviving mice, even after repeated tumor challenge intended to replicate possible tumor recurrences.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="pg80-149_010.jpg" ALT="" STYLE="height: 340pt; width: 306pt"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: italic 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">Inhibition
of Human Gliomas in IFN-&alpha; Gene Therapy Treated Athymic Mice (De Palma et al., 2008).</FONT></P>

<P STYLE="font: italic 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>A-B)
</I></B><I>Glioma growth (mean tumor volume &plusmn; SEM, measured by MRI) in individual control and IFN-&alpha; gene therapy
treated mice (Tie2-IFN) at 3 weeks post tumor injection (PTI). Tumor volume and progression decreased in IFN-&alpha; gene therapy
treated mice. <B>C)</B> MRI images showing brain tumor growth at the indicated time points PTI in representative control (Ctrl)
and Tie2-IFN mice. Intracranial gliomas are indicated by arrows and dashed line. The tumor did not progress in Tie2-IFN mice.
<B>D)</B> Measurement of tumor necrotic fraction (mean necrotic fraction, &nbsp;&nbsp;% &plusmn; SEM) by MRI in individual Ctrl and Tie2-IFN
mice at 3 weeks PTI, evidencing cancer cell death. <B>E)</B> The Tie2-IFN tumors that grew sufficiently to be analyzed displayed
decreased cell proliferation and greater apoptosis (assessed by Ki-67 and cleaved caspase-3 immunostaining, respectively a proliferation
and an apoptosis marker) as compared to the control tumors. (Caspase-3 = Casp-3; green) and CD31 (marker of blood vessels; red)
TO-PRO-3 (TP3; nuclear staining, blue). Arrows show Ki-67+CD31+ or caspase-3+CD31+ (ECs; dashed line indicates tumor margin).</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Phase
1/2a Clinical Trial</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
the second quarter of 2019, we enrolled our first patient in a single-arm, open label, dose escalation, Phase 1/2a clinical trial,
in adult patients aged 18 to 70 years (&ldquo;TEM-GBM 001 study&rdquo;). The trial is being conducted at two clinical centers of excellence
located in Milan, Italy: (i) Istituto Nazionale Neurologico &ldquo;<I>Carlo Besta</I>&rdquo;, an internationally recognized leading center
in neuroscience, specializing in the diagnosis and treatment of neurological diseases in adults and children, and (ii) OSR, which has
a recognized expertise in complex and innovative diagnostic and therapeutic approaches in onco-hematological patients and in gene therapy
treatments.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
primary objective of the TEM-GBM 001 study is to evaluate the safety, tolerability, feasibility and biological activity of Temferon
in uMGMT-GBM patients with an unmethylated MGMT gene, who as a result of the gene, have a poor prognosis and are expected to not
respond to TMZ treatment. These patients are identified immediately after surgery, upon confirmation of the diagnosis and MGMT methylation
status. After enrollment, each patient is screened for eligibility, and if eligible subjected to the mobilization procedure to induce
HSPCs to exit from the bone marrow niche and to migrate into the peripheral blood where they are collected by leukapheresis. Immediately
after collection, each patient&rsquo;s HSPCs are sent to our CMO to be genetically modified and become Temferon. After Temferon administration,
each patient is followed for two years. The figure below depicts the different stages of TEM-GBM 001 study enrollment and treatment.</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="pg80-149_011.jpg" ALT="" STYLE="height: 230pt; width: 396pt"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>TEM-GBM
001 Study Design.</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our study aims to evaluate the short-term (up to
90 Days) and long-term (up to 2 years) tolerability and safety of five escalating doses of Temferon in up to 21 patients
with uMGMT-GBM and an unmethylated MGMT promoter, following first line radiotherapy.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Initially the study was designed with a dose escalation
phase in 15 patients assigned to 5 cohorts (Part A) to test three different escalating Temferon doses and two different conditioning regimens,
with the aim of determining the best Temferon engraftment associated with fewer side effects to be then applied to an expansion phase
(Part B) in six additional patients.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Patients in cohorts 1,
2 and 3 received Temferon dose escalation up to 2 x 10<SUP>6</SUP> CD34+ cells/kg (Dose Level 3) and 3 x 10<SUP>6</SUP> CD34+ cells/kg
as unmanipulated supporter HSPCs. Patients in Cohorts 4 and 5 were infused with Temferon Dose Level 3 but received 2 x 10<SUP>6</SUP>
CD34+ cells/kg and were conditioned with 2 different conditioning regimens (BCNU &amp; thiotepa for Cohort 4, also utilized in Cohort
1-3 and Busulfan &amp; thiothepa for Cohort 5). </FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on the results collected in the Part A of the study,
we have amended the study to add two additional dose escalation cohorts (numbers 6 and 7). The Clinical Protocol amendment was submitted
on July 20<SUP>th</SUP>, 2021 to the Italian Competent Authorities, and approved by AIFA in September 2021.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As per the submitted clinical protocol amendment, Cohorts
6 and 7 will recruit three patients each who will be conditioned with BCNU and thiotepa and will receive 2 x 10<SUP>6</SUP>/kg supporter
HSPCs and a Temferon dose of 3 x 10<SUP>6</SUP> cells/kg and (Cohort 6, Dose Level 4), and 4 x 10<SUP>6 </SUP>cells/kg (Cohort 7, Dose
Level 5), respectively.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The figure below represents the amended TEM-GBM
001 study scheme with interim and anticipated milestones. The study EudraCT Number is 2018-001404-11 and can be found at clinicaltrialsregister.eu/ctr-search/trial/2018-001404-11/IT.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt"><IMG SRC="drsaa_004.jpg" ALT="" STYLE="height: 384px; width: 670px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>TEM-GBM
001 Amended Study Design.</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Preliminary
Interim Results.</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We designed the TEM-GBM 001 study to: (i) obtain rapid accrual
of patients (ii) assess the safety profile of Temferon, (iii) identify the optimal dose, and (iv) measure the biological activity of Temferon
on those patients who progress to the point of requiring a second surgery.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We designed our study anticipating that patients receiving
lower doses of Temferon could progress to the point of needing a second surgery, which is often necessary in GBM patients. A second surgery
provides the only source of GBM specimens post treatment to evaluate the biological activity of Temferon and to evaluate its mechanism
of action in patients. We enrolled our first patient in April 2019 and as of November 15<SUP>th</SUP>, 2021, we had dosed 15 patients,
from cohort 1 to 5. We expect to complete the enrollment and the dosing of patients to be assigned to cohorts 6 and 7 by the end of the
second quarter of 2022.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Overview
of the current status of TEM-GBM 001 clinical development program</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><IMG SRC="drsa_011.jpg" ALT="" STYLE="height: 106px; width: 670px"></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">There have been no dose limiting toxicities identified in our
clinical study to date. All patients showed rapid engraftment and hematological recovery after administering the sub-myeloablative conditioning
regimens (Busulfan BCNU + Thiotepa or Busulfan and Thiothepa). Evidence of presence and persistence of Temferon-derived differentiated
cells is assessed by measuring the vector genomes in the DNA of peripheral blood and bone marrow cells (absolute number quantified by
ddPCR). The vector copy number (VCN) positive cells were present within 14 days post treatment and were detectable, albeit at lower levels,
in the long-term (up to 18 months, the last measured timepoint to date).</P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 12pt Georgia"><IMG SRC="drsa_012.jpg" ALT="" STYLE="height: 233px; width: 625px"></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: center"><I>Engineered myeloid cells persist in peripheral blood
for up to 18 months</I></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We also detected very low concentrations of IFN-&alpha; in
the plasma and cerebrospinal fluid, suggesting the transgene expression control mechanism may be working as intended by limiting systemic
IFN-a exposure.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Serious adverse events have mainly been attributed by the
Investigator to the effects of the conditioning regimen (pneumonia, pulmonary embolism, febrile neutropenia, fatigue, C.diff infection,
CMV reactivation, sepsis) or disease progression (worsening left hemiparesis, seizure, brain abscess, sudden death). Three instances
of elevated gamma glutamyl transferase (GGT) have been observed: two mild cases attributed to chemotherapy and HSPC harvesting, each
of which has resolved; and one case occurring at D+78 following Temferon administration, which was classified as a suspected unexpected
serious adverse reaction (SUSAR) possibly related to Temferon, and which has also resolved. Nine deaths have been reported to
date: seven at +241, +322, +340, +402, +478, +646 and +749 days after Temferon administration due to disease progression, and two
deaths at +60 and +122 days which the Investigator considered not related to Temferon but possibly related to complications
following the chronic steroid treatment and the conditioning regimens prior to Temferon administration.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">The last evaluable disease status as assessed by immunotherapy
response assessment for neuro-oncology (iRANO) criteria as of November 15<SUP>th</SUP>, 2021, the last evaluable time point for
all 15 treated patients (prior to death, where applicable), was as follows: six patients had shown stable disease (SD), two
patients had demonstrated partial response, seven patients had shown progressive disease (PD).
For reference, The iRANO guidelines specifically address interpretation of initial progressive imaging findings in the context of neuro-oncology
patients with a goal of decreasing the likelihood of premature discontinuation of potentially beneficial therapies while ensuring maximum
patient safety. iRANO empirically stipulates a three-month window for confirmation of progression on follow-up imaging, and further advises
that progressive imaging changes beyond six months after immunotherapy initiation are more likely true tumor progression.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">So far, eight out of the nine patients from the first
three cohorts and one patient in cohort 4 progressed. The PD occurred after a median of + 123 days (range 83&ndash;239
days) following administration of Temferon. Two patients of cohort 3 progressed before Temferon administration (11 and 12 days before
Temferon administration). Preliminary analyses performed on the tumor specimens belonging to patients with PD who underwent a second
surgery (four patients) confirmed the presence of TEMs within the tumor, as assessed by flow cytometry, and an increased expression
of IFN-responsive gene signatures compared to diagnosis, as assessed by quantitative polymerase chain reaction (PCR) tests. We believe
that these findings suggest intra-tumor IFN-&alpha; release.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Of the four patients who underwent the second surgery, one
patient had a prior lesion, which was not removed during the first surgery. When this patient underwent the second surgery following treatment
with Temferon, it was observed that this lesion was stable and had not grown. In addition, this patient presented a relapsing progressing
lesion that had developed at the first surgery site. Both lesions were removed and biopsied at the second surgery. Notably, as assessed
by flow cytometry, the stable lesion had a higher proportion of T cells and TEMs within the myeloid infiltrate and as detected by quantitative
PCR a markedly increased IFN-response signature as compared to the relapse-progressing lesion.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We also analyzed the peripheral blood of the patients from
cohorts 1 to 3. In these patients, the peripheral blood showed, on two of the four subjects with samples at the first and
second surgery, a change in the T cell immune repertoire post treatment, revealing expansion of tumor-associated clones, which suggested
that changes in the immune system are occurring.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We believe these results align with our preclinical data and
suggest the immune activation effects of Temferon. Specifically, the preliminary interim results, including the tumor analysis conducted
after second surgery described above, provide biological evidence to support the hypothesis that cellular and molecular changes were
triggered by Temferon in uMGMT-GBM patients despite the low dose administered. We have yet to reach the maximum tolerated dose
of Temferon and as outlined in our study protocol, we will be increasing the dose in cohorts 6 and 7.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><I>TEM-GBM Clinical Development Plan</I></P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We plan to use the results of our TEM-GBM Phase 1/2a
study (NCT03866109) to support a Clinical Trial Application to be conducted in Europe, a multicenter Phase 2 study in uMGMT-GBM,
which we currently intend to conduct primarily in Italy. In advance of our CTA submission and not required for our European trial,
we have submitted a pre-IND meeting request to the FDA and received written responses from the Agency in the third quarter of 2021
regarding the proposed Phase 2 clinical study design and drug product manufacturing strategy. The plans for the Phase 2 clinical
study and drug product manufacturing strategy will be informed by the Agency comments. We intend to submit the CTA for a
Temferon Phase 2 study for uMGMT-GBM patients by the fourth quarter of 2022. The Phase 2 study will evaluate the safety,
tolerability, biological reprogramming of the tumor microenvironment in Temferon treated patients compared to the current standard
of care, with primary endpoints, of PFS and mOS. We are also working with our current CMO and potentially other CMOs based in the
U.S. to manufacture and to supply Temferon in the U.S. for our larger trials to be conducted after the completion of our Phase 2
study.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Key components of the anticipated clinical trial are as follows:</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Multicenter
    study evaluating Temferon for safety, tolerability and efficacy compared to the current standard of care;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Enrollment and treatment of
    up to 27 patients with newly diagnosed and recurrent uMGMT-GBM;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 0; text-align: left"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">PFS and
                                            mOS as co-primary study endpoints</P></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
study design as discussed with FDA at the Pre-IND meeting may be subject to modifications.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Second
Solid Tumor Indication</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are also evaluating liver cancers as a potential second solid tumor to be investigated. HCC and ICC are gastrointestinal cancers affecting
the digestive system. We chose to pursue these indications for similar reasons as the uMGMT-GBM indication, namely:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>High
    unmet medical need and market opportunity</I>.</B> The prognosis for patients with locally advanced HCC and ICC remains poor
    with few therapeutic options having limited clinical benefits.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt; color: #111419"><B><I>TEMs
    have an active role in HCC and ICC pathology.</I></B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Several
    third-party studies have shown that tumor infiltration by tumor associated myeloid cells, including TEMs, is a negative
    prognostic factor in HCC and ICC.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
    HCC, TEMs are the most abundant proportion of tumor associated myeloid cells. </FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Hepatitis
    B (HBV) infections and hepatitis C (HCV) infections, both of which predispose individuals to the development of chronic liver
    disease and the subsequent liver cancers, upregulate Ang-2 expression, further contributing to tumor angiogenesis and TEMs
    migration. </FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
    HCC, Ang-2 mRNA expression is significantly increased when compared to adjacent liver tissue and angiopoietins and tumor infiltrating
    TEMs appear to be associated with metastasis and recurrent disease.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">All
the above evidence highlights the role of TEMs in fostering liver cancer growth, by promoting angiogenesis. </FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt; color: #111419"><B><I>Pro-inflammatory
    and immunosuppressive tumor microenvironment.</I></B></FONT> <FONT STYLE="font-family: Georgia; font-size: 10pt">Both locally
    advanced HCC and ICC are characterized by a pro-inflammatory and immunosuppressive tumor microenvironment with TEMs playing
    a key role.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><B><I>IFN-&alpha; and liver tumors.</I></B> Chronic
    inflammation resulting from HBV and HCV infection are key contributors for the development of HCC or ICC. Before the introduction
    of antiviral agents in 2011, parenterally administered interferons, including IFN-&alpha;, were utilized as the standard
    of care in order to achieve viral clearance and/or suppression. The use of IFN-based regimens for HCV and HBV infections
    has been associated with a reduction in HCC risk. Evidence suggests that use of IFN-&alpha; as an adjuvant therapy
    in HCC patients after curative therapy may reduce the recurrence rates for up to 5 years, particularly in patients with concurrent
    HCV infection.</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt; color: #111419"><B><I>Available
    preclinical</I></B></FONT><B><I> <FONT STYLE="font-family: Georgia; font-size: 10pt">data.</FONT></I></B><FONT STYLE="font: 10pt Georgia">
    We have preclinical data, published in peer reviewed papers suggesting that TEMs used as a &ldquo;Trojan
    Horse&rdquo; for cancer that has metastasized to the liver were able to induce a statistically significant tumor shrinkage
    and control disease progression.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Market
    Opportunity.</I></B> Based on currently available treatments, the HCC and ICC combined global market value is projected to
    grow to over $2.6 billion by 2026. We believe a novel therapeutic which demonstrates improvement over existing therapies would
    greatly grow the market size.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Disease
Overview</I></B><I> </I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Liver
and intrahepatic bile duct cancers are upper gastrointestinal (GI) cancers that affect the digestive system. They are the fifth
most common cause of cancer deaths in men in the U.S., and the seventh most common cause of death in women. The American Cancer
Society (ACS) estimates that 42,230 new cases of liver cancer (including intrahepatic bile duct cancers) will
be diagnosed in 2021. Of these cases, approximately three-quarters were HCC, while less than one-quarter were
bile duct cancers (both intrahepatic and extrahepatic). We are developing Temferon to treat the two tumor types listed
below.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Hepatocellular
    carcinoma</I></B> (HCC) is a primary malignancy of the liver that occurs predominantly in patients with underlying chronic
    liver disease and cirrhosis. The incidence of HCC has been rising worldwide over the last 20&thinsp;years, with about eight
    new cases per 100,000 adults per year. The highest incidence of HCC occurs in Asia and Africa, where the endemically
    high prevalence of hepatitis B (HBV) and hepatitis C (HCV) strongly predisposes individuals to the development of chronic
    liver disease and the subsequent development of HCC. Patients with HCC have, when treated with the current standard of
    care, an expected median OS of only 11 months with approximately 10-40% of patients surviving 3 years. Up to 25% of HCC
    patients have no history of cirrhosis and do not present any risk factors for chronic liver disease, such as HBV and HCV.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: italic bold 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: italic bold 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Cholangiocarcinoma
    <FONT STYLE="font-style: normal; font-weight: normal">is a biliary tract cancer and represents approximately 3% of all GI
    malignancies. Of this 3%, ICC accounts for 5% to 10% of those cases. The incidence is 2.1 per 100,000 person years. Despite
    surgery, the prognosis remains poor with disease recurrence and progression occurring in approximately two-thirds of patients
    and a 5-year survival rate of only 30%.</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: italic bold 12pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>HCC
Current Treatment Landscape and Limitations</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
general, HCC patients are asymptomatic in the early stages of the disease, and as a result, the diagnosis is usually obtained
in later stages of the disease when there are no curative therapies available. The implementation of surveillance, and the improvements
in imaging techniques, have enabled the diagnosis at earlier stages of HCC. In terms of first line treatment approaches, patients
with very early HCC are optimal candidates for surgical resection and liver transplantation but when these options are not suitable
due to tumor localization or the absence of a matched liver donor, local ablation through percutaneous ethanol injection or radiofrequency
are the available alternative treatments. For late-stage HCC, the transcatheter arterial chemoembolization (TACE) is the standard
of care.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Surgical
    Resection</I></B> is the recommended first line therapy for patients with a single HCC nodule, achieving the highest effectiveness
    in terms of disease control and overall survival. However, despite the accurate selection of patients with early tumors and
    the complete tumor removal, HCC patients are at high risk of tumor recurrence.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Percutaneous
    ethanol injection</I></B> (PEI) is an effective technique used for early-stage HCC with a low complication rate that induces
    the complete necrosis of small HCC lesions. However, PEI has limitations including the need for multiple treatment sessions
    (4-6) and a prolonged treatment time. Although generally well tolerated, PEI can result in death and rare instances of tumor
    seeding. PEI-treated lesions have a high rate of local recurrence (33% - 43%).</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Radiofrequency
    ablation</I></B> (RFA) has advantages compared to PEI including ease of performance, effectiveness similar to that of surgical
    resection, high safety, and low invasiveness. RFA is the first-choice post-surgery procedure for patients with early-stage
    HCC. However, despite the advantages of RFA, complete tumor ablation remains difficult to achieve in some specific liver sites.
    Many patients treated with RFA develop atrial fibrillation on long-term follow-up.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Transarterial
    chemoembolization</I></B> (TACE) is the current standard of care for patients with intermediate/late-stage HCC and who have
    relatively preserved liver function. TACE combines the &ldquo;tumor embolization&rdquo;, meaning the treatment blocks the
    vascular supply to a tumor accompanied by a local administration of chemotherapy. This permits high concentration of drugs
    in the tumor area, while simultaneously reducing systemic exposure. However, the technique is not standardized and there is
    no universal consensus as to TACE application in the clinical setting thereby limiting reliable comparison of results.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Sorafenib </I></B>has
    been the first line chemotherapy standard of care for patients with advanced unresectable hepatocellular carcinoma (HCC) since
    2007 and has also been found to be useful in association with TACE as an effective chemotherapeutic agent to prolong survival
    in inoperable HCCs. However, Sorafenib is associated with adverse events (AEs) such as hand-foot skin reaction, rash,
    upper and lower gastrointestinal distress (i.e. diarrhea), fatigue, and hypertension. Furthermore, a proportion of treated
    patients show no response to the drug.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>ICC
Current Treatment Landscape and Limitations</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Surgery
(radical excision) is the only treatment available for ICC. However, the disease will recur in 40&ndash;85% of patients
who have a median survival of 36 months. Neo-adjuvant approaches have largely been unsuccessful and adjuvant therapy (radiotherapy,
chemoradiotherapy or chemotherapy alone) is offered to patients only as a palliative solution. Based on a single, positive Phase
3 study, chemotherapy with gemcitabine and cisplatin is considered the standard of care and plays an established role as
a palliative care solution.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Our
Solution</I></B><I> </I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Similar
to Temferon for GBM, we believe that Temferon may overcome the current treatment limitations of HCC and ICC that are not curative/resolutive
by stopping/delaying disease progression.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0"><B><I>Clinical Development of Temferon in HCC and ICC</I></B></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Preclinical
Data</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
described in the study published by Giovanni Sitia&rsquo;s research group at OSR in collaboration with Luigi Naldini, our IFN-&alpha;
gene delivery platform was tested in a mouse model of liver metastases from colorectal cancer (CRC) resulting in a substantially
delayed or complete prevention of tumor growth with prolonged long-term survival. Our approach was also effective on pre-established
liver metastases that more closely mimics tumor treatment in human.</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="pg80-149_014.jpg" ALT="" STYLE="height: 369pt; width: 468pt"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: italic 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
vivo data on Tie2-IFN gene therapy platform in a mouse model of colorectal cancer (CRC) liver metastasis (Catarinella et.
al; 2016)</FONT></P>

<P STYLE="font: italic 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>IFN-&alpha;
gene therapy treatment impairs the metastatic growth in the liver CRC liver metastasis.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>CT26
and MC38 cell line panels: Percentage and tumor volume quantification measured by MRI analysis of mice injected with CT26 cells bearing
at least one CRC liver metastasis estimated by MRI analysis and Kaplan&ndash;Meier survival curves of the indicated groups. The inset
images show representative macroscopic photographs of the metastatic progression in the liver. Sham i.e., mice transplanted with non-transduced
HSPCs and intrasplenically injected with saline thereafter.</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><I>Second Solid Tumor</I><I> Study Design</I></P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">As with the TEM-GBM 001 study, we plan to propose to the Italian
regulatory bodies a non-randomized, open label, single center, Phase 1/2a, therapeutic-exploratory, prospective study, involving a single
injection of Temferon administration in up to 9 patients. The study will recruit and track patients at OSR.</P>

<P STYLE="font: 12pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Patients
will be administered Temferon following the same process as our TEM-GBM trial, namely: (i) HSPCs harvesting, (ii)
standard of care chemotherapy concomitant to Temferon manufacturing, (iii) administration of the conditioning regimen followed
by Temferon infusion, and (iv) 2-years of follow-up.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>Additional Pipeline Pre-Clinical Programs</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in">Our platform technology was designed to be flexible
so that it can be potentially adapted to treat a variety of cancers. We believe that Temferon lends itself to be used in combination
with a variety of current existing therapeutics to potentially enhance overall efficacy because its mechanism of action is intended to
abrogate tumor induced tolerance. Additionally, we are developing a second-generation platform which is designed to release our therapeutic
payload &ldquo;on demand&rdquo;. Finally, our proprietary platform is designed to control the expression of a potentially wide variety
of therapeutic payloads we may choose for different targets.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><B>Combination Treatment</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in">While therapies to treat several types of cancers,
such as ICI, CAR-T and TCR, are rapidly transforming the practice of medical oncology, clinical data point to the risk of late relapses
after treatment with these therapeutics. Thus, the data suggest that the durability of the response to these therapies remains a significant
challenge. We believe that due the potentially agnostic nature of Temferon, its potential activity, which includes the abrogation
of tumor induced tolerance, and its potentially synergistic mechanism of action, makes it an ideal candidate to be considered for combination
treatments. Specifically, Temferon may be a good candidate to be used in combination, for very aggressive tumors, with other immune-oncology
drugs, such as CAR-T and ICI, to extend the durability of the response in very aggressive tumors. We believe that this additional Temferon
application is supported by the promising results coming from the combination studies performed using Temferon with CAR-T, TCR and ICI
in our pre-clinical programs as discussed below.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in">In preclinical studies conducted in the laboratories
of our founders, Professor Luigi Naldini and Dr. Bernhard Gentner, Temferon was evaluated in combination with CAR T, TCR-edited T cells
directed against tumor-associated antigens and immune checkpoint blockers. The results showed promising additive-to-synergistic anti-tumor
activity in leukemia experimental models (Escobar et al., Nature Communication 2018), glioblastoma models, and multiple myeloma mouse
models (manuscripts in preparation). These results lead us to believe that IFN gene therapy might also boost the efficacy of other immunotherapies.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in">Specifically, in a leukemia mouse model, a CD19
CAR-T approach had detectable, but not significant effect on the tumor burden. However, when used in combination with Temferon, the combination
treatment resulted in a significant inhibition of the hematological malignancy with a significant fraction of CAR-T/Temferon treated
mice surviving at the latest timepoint of analysis. Similarly, the combination of IFN gene therapy to &alpha;-CTLA4, an immune check
point blocker, or adoptive T cell therapy, significantly improved the survival of the mice (Escobar et al., Nature Communication 2018).</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in">In a multiple myeloma mouse model, Temferon was
administered in combination with human TCR-edited T cells directed against NY-ESO1 and anti-myeloma drugs. The combination approach showed
promising additive-to-synergistic effects leading to more pronounced disease control compared to most single-agent regimens, and without
exacerbating hematologic or systemic toxicities (manuscript in preparation).</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10.5pt Arial, Helvetica, Sans-Serif; margin: 0"><B>Switchable Platform</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in">Our founders are developing a second-generation
platform designed to release the therapeutic payload &ldquo;on demand&rdquo; to allow in vivo control of its potential efficacy. Potential
advantages of this application include (i) broadening the clinical application to patient populations with more favorable pre-treatment
prognoses; (ii) control of long-term side effects that may arise from the chronic exposure to immunostimulatory molecules and (iii) the
ability to activate the immune system on demand to recognize tumors based on clinical need.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in">An inducible version of the IFN-<FONT STYLE="font-family: Symbol">a
</FONT>payload has been generated by fusing the protein with a destabilizing domain (DD), which targets the protein to proteasomal degradation,
unless a small molecule ligand binding to the DD and stabilizing it, is administered. The optimized fusion construct is delivered by
the TEM platform and the exogenous administration of the ligand switches on its secretion within the tumor. The results from experiments
performed in the laboratory of Professor Naldini with a glioblastoma mouse model showed similar anti-tumor activity of the inducible
and wild-type IFN payload. Moreover, the inducible construct allows switching of IFN release upon tumor clearance (manuscript to be submitted
for publication). We plan to use our second generation platform carrying an IFN-<FONT STYLE="font-family: Symbol">a</FONT> payload in
combination with CAR T cells to target glioblastoma-associated antigens or immune checkpoint blockers in an experimental tumor model
in mice.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><B>Other Payloads</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in">Our platform is designed to allow the control of
the expression of any payload we use. Similar to IFN-<FONT STYLE="font-family: Symbol">a</FONT>, there are several alternative payloads
with immunotherapeutic properties that were previously systemically delivered to patients, but were discontinued due to significant toxicity
that prevented the drug from reaching therapeutic dosages (e.g. TNF-<FONT STYLE="font-family: Symbol">a</FONT>). Because we believe that
our first- and second-generation platforms may overcome the limitations associated with systemic administration, we are testing them
with additional payloads such as IFN-<FONT STYLE="font-family: Symbol">g</FONT>, IL-12 and TNF-<FONT STYLE="font-family: Symbol">a</FONT>.
Because each payload triggers a unique biological response, we believe our platform may enable a personalized treatment approach unique
amongst the current treatment paradigms.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in">Additional immune activating cytokines have been
tested for TEM-mediated gene-based delivery to tumor models in mice. Current pre-clinical results suggest the feasibility and specificity
of tumor-targeted delivery of IFN-<FONT STYLE="font-family: Symbol">g</FONT> and TNF-<FONT STYLE="font-family: Symbol">a </FONT>and further
support our hypothesis that the specific transcriptional and microRNA regulated expression of the payload prevents toxicity. Data generated
in the laboratory of our founders in a leukemia model showed that IFN-<FONT STYLE="font-family: Symbol">g</FONT> but not TNF-<FONT STYLE="font-family: Symbol">a
</FONT>mediate anti-tumor activity when delivered <I>ex vivo</I>. Further <I>ex vivo</I> studies showed enhanced anti-tumor activity
upon combined delivery of two cytokines by the TEM-based platform.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in">Moreover, experiments conducted with our second-generation
inducible platform expressing IL-12 supported the hypothesis that our proprietary transcriptional and microRNA regulated expression of
the payload to may prevent toxicity. Indeed, IL-12 is a potent cytokine that must be kept within a therapeutic dose range to prevent
toxicity. Targeted delivery and anti-tumor activity of the new inducible payload are being investigated (abstracts to be presented at
EACR in June 2021; at ASGCT 2021 in May 2021; and manuscript to be submitted). The laboratory of Professor Naldini plans to test the
combination of TEM-mediated gene-based delivery of inducible Il-12 or additional inducible payloads with CAR-T, TCR and ICI in experimental
murine tumor models.</P>




<P STYLE="font: 12pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 12pt Georgia; text-align: left; margin: 0 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Biotechnology
and pharmaceutical industries put significant resources in developing novel and proprietary therapies for the treatment of cancer.
For the cell therapy field in particular, this results in rapidly advancing and changing technologies, intense competition and
a strong emphasis on intellectual property. While we believe that our leading product candidate, Temferon and our scientific expertise
in the field of cell and gene therapy provide us with competitive advantages, we face potential competition from various sources,
including larger and better-funded pharmaceutical, specialty pharmaceutical and biotechnology companies, as well as from academic
institutions, governmental agencies and public and private research institutions.</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Manufacturing</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
manufacturing process for our autologous cell and gene therapy approach requires the following steps:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.75in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">HSPCs
    harvesting in a specialized clinical center (leukapheresis)</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Shipping
    of apheresis bag/s to the selected contract manufacturing organization (CMO)</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">CD34+
    cells enrichment</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Ex-vivo
    </I>transduction of CD34+ cells with our LVV,</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Cryopreservation,
    characterization and release by a Qualified Person of the obtained drug product.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
LVV manufacturing needed for the <I>ex-vivo</I> transduction process, as well as steps from 3 to 5, are conducted by the CMO.
The figure below delineates the steps and the timeline for manufacturing Temferon.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="drsa_003.jpg" ALT="" STYLE="height: 304px; width: 630px"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Overview
of Temferon manufacturing Process</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We have entered into agreements with AGC Biologics to manufacture
our LVV and drug product for our ongoing clinical programs in Italy. AGC Biologics is a leading global contract development and manufacturing
organization (CDMO), providing world-class development and manufacture of mammalian and microbial-based therapeutic proteins of plasmid
DNA (pDNA) and recently with the acquisition of Molecular Medicine S.p.A. (&ldquo;MolMed&rdquo;), of viral vectors and genetically engineered
cells. MolMed S.p.A. is recognized as the leading cell and gene therapy CDMO focused on research, development, production and clinical
validation of cell and gene therapies for the treatment of cancer and rare diseases. Indeed, Strimvelis, the first ever market approved
<I>ex-vivo</I> gene therapy for children, was developed and is still currently manufactured by AGC Biologics (former MolMed). Accordingly,
Orchard Therapeutics (NasdaqGS: ORTX) in July 2020 renewed their collaboration agreement with AGC which will continue to
support activities related to the development and manufacturing of vectors and drug products for several of Orchard&rsquo;s investigational
<I>ex-vivo </I>hematopoietic stem cell (HSC) gene therapies in the upcoming years, including the recent EU market authorized gene therapy
drug <I>Libmeldy.</I></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: sp1 -->
<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="pg80-149_016.jpg" ALT="" STYLE="height: 408px; width: 650px"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>AGC
Biologics Headquarters and Capabilities</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Georgia"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Our agreement with AGC (MolMed) establishes agreed-upon
timelines for purchase order submissions and manufacturing date changes/cancellation. The supply agreement also sets milestones both
during the clinical phase and any future commercial phase of our product candidates and for technology transfer if required, as well
as customary termination provisions, allowing for termination by a party upon the other party&rsquo;s uncured material breach or upon
the other party&rsquo;s insolvency. AGC Biologics facility in Milan, Italy, will continue manufacturing LVV and Temferon to support
Genenta&rsquo;s trials. For further larger studies we may use AGC&rsquo;s 60,000 square meter cell and gene therapy manufacturing facility
located in Longmont, Colorado (U.S.), which AGC purchased from Novartis in July 2021 or another US-based CMO.</P>

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Intellectual
Property</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
goal is to obtain, maintain and enforce patent protection for our product candidates, formulations, processes, methods and any
other proprietary technologies, preserve our trade secrets, and operate without infringing on the proprietary rights of other
parties, both in the United States and in other countries. Our policy is to actively seek to obtain, where appropriate, the broadest
intellectual property protection possible for our current product candidates and any future product candidates, proprietary information
and proprietary technology through a combination of contractual arrangements and patents, both in the United States and abroad.
However, patent protection may not afford us with complete protection against competitors who seek to circumvent our patents.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
also depend upon the skills, knowledge, experience and know-how of our management and research and development personnel, as well
as that of our advisors, consultants and other contractors. To help protect our proprietary know-how, which is not patentable,
and for inventions for which patents may be difficult to enforce, we currently rely and will in the future rely on trade secret
protection and confidentiality agreements to protect our interests. To this end, we require all of our employees, consultants,
advisors and other contractors to enter into confidentiality agreements that prohibit the disclosure of confidential information
and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important
to our business.</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Temferon</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Temferon is protected by the following patents families
that contain both issued and/or pending patent applications. While the following patent families are jointly owned by OSR and
Fondazione Telethon (Telethon), as set forth in our December 15, 2014 license agreement with OSR (described below), Telethon
granted OSR a worldwide exclusive license, with the right to sublicense, its rights in the patent families pursuant to a separate
cooperation agreement between OSR and Telethon. As described below, we have a worldwide exclusive license, from OSR, to the
following patent families (including the U.S. and European family members indicated) in the fields of: GBM, solid liver cancer
(LC) and any lympho-hematopoietic indication:</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Focus
    / Family</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Georgia; width: 15%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>U.S.</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Georgia; width: 15%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>E.U.</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Georgia; width: 15%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Expiration</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: center"><P STYLE="text-align: left; font: 10pt Georgia, Times, Serif; margin: 0">Gene Vector comprising mi-RNA</P>

<P STYLE="text-align: left; font: 10pt Georgia, Times, Serif; margin: 0">(composition and method of treatment claims)</P>

<P STYLE="text-align: left; margin: 0; font: 10pt Georgia, Times, Serif">PCT/IB2006/002266 (WO 2007/000668).</P>
</TD>
    <TD STYLE="text-align: center; font-family: Georgia">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><P STYLE="font: 10pt Georgia, Times, Serif; text-align: left; margin: 0">USP 10,000,757*</P>

<P STYLE="text-align: left; font: 10pt Georgia, Times, Serif; margin: 0">USP 9,556,438</P>

<P STYLE="font: 10pt Georgia, Times, Serif; text-align: left; margin: 0">USSN 16/004,394</P>

<P STYLE="text-align: left; margin: 0; font: 10pt Georgia, Times, Serif">(pending)</P></TD>
    <TD STYLE="text-align: center; font-family: Georgia">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left">EP 2002003 B1</TD>
    <TD STYLE="text-align: center; font-family: Georgia">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left">5/26/2026*</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-family: Georgia">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font-family: Georgia">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center; font-family: Georgia">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">Gene Vector comprising mi-RNA</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">(composition and method of treatment claims)</P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">PCT/IB2010/001166 (WO / 2010/125471)</P>
</TD>
    <TD STYLE="font-family: Georgia">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">USP 10,287,579</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">USP 9,951,328</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">USSN 16/384,571</P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(pending)</P>
</TD>
    <TD STYLE="font-family: Georgia">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">EP 2424571 B1<BR>
                                            EP 20167404.1<BR>
                                            (pending)</P></TD>
    <TD STYLE="font-family: Georgia">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">4/30/2030</P></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Monocyte
                                   Cell (Tie-2) activation process (composition claims)</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt">USP
        7,833,789</FONT></P></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">USP
    7,833,789</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">10/5/2027</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Methods
for Genetic Modification of Stem Cells </FONT></P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(method of treatment claims)</P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font: 10pt Georgia"></FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt">PCT/IB2014/065594
        (WO 2015/059674)</FONT></P></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt">USP
                                         10,617,721*</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt">USSN
16/827,708</FONT></P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(pending)</P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font: 10pt Georgia"></FONT></P></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt">EP
                                         3060670 B1</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt">EP
19185334&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(pending)</P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font: 10pt Georgia"></FONT></P></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">10/24/2034*</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">Vector Production</P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(composition and method of treatment claims)</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">PCT/IB2015/055286 (WO 2016/009326)</P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font: 10pt Georgia"></FONT></P></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">USP 10,912,824</FONT></P>
                                                     <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">17/143,953</P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(pending)</P></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">EP
    3169788</FONT>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">(pending)</P>
<FONT STYLE="font: 10pt Georgia"></FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">7/13/2035</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">Type 1 Interferon Gene Therapy</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">(method of treatment claims)</P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">PCT/EP2018/060238 (WO 2018/193119)</P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font: 10pt Georgia"></FONT></P></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">USSN 16/604,484 </FONT></P>
                                                     <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Georgia">(pending)</FONT></P></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">EP
    18724470.2</FONT>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">(pending)</P>
<FONT STYLE="font: 10pt Georgia"></FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">4/20/2038**</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">*
Later expiration for certain U.S. patents pursuant to patent term adjustment (35 U.S.C. &sect;154(b)).</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in">** Application pending, anticipated expiration
based on 20 year patent term.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Our technology incorporates the use of a lentiviral
vector (LVV) that combines a therapeutic transgene sequence, or payload, with our proprietary platform. Our proprietary platform
consists of (i) the Tie-2 promoter, that drives transgene sequence transcription specifically in TEMs, and (ii) miRNA-126 target
sequences to downregulate transgene expression post-transcription in those cells where the Tie-2 promoter is active and the miRNA-126
is present. Intellectual property protection for our proprietary platform includes an exclusive license to all issued patents
and pending applications (if any) in the PCT/IB2006/002266 (WO 2007/000668) and PCT/IB2010/001166 (WO / 2010/125471) families,
as well as trade secrets. As discussed below, we have the option to license exclusively USP 7,833,789 and issued
patents and pending applications (in the PCT/IB2014/065594 and PCT/IB2015/055286 patent families we have not yet exercised
the option rights), and improvements, for other indications (fields of use) and other product candidates.</P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition to patents and patent applications that we have been granted licenses to, we may also rely on unpatented trade secrets,
know-how, and continuing technological innovation to develop and maintain our competitive position. We seek to protect know-how
and trade secrets through an active program of legal mechanism including invention assignments, confidentiality agreements, material
transfer agreements, research collaborations and licenses to protect our product candidates. These agreements may be breached,
and we may not have adequate remedies for any breach. In addition, trade secrets may otherwise become known or be independently
discovered by competitors. To the extent that our employees, consultants, scientific advisors or other contractors use intellectual
property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.
For a more comprehensive discussion of the risks related to our intellectual property, please see &ldquo;Risk Factors &mdash;
Risks Related to Our Intellectual Property.&rdquo;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Collaboration
/ Licensing</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>License
Agreement with Ospedale San Raffaele</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Effective
December 15, 2014, we entered into a license agreement with OSR (OSR License Agreement) pursuant to which OSR granted us an exclusive,
royalty-bearing, non-transferrable (except with the prior written consent of OSR) worldwide license, subject to
certain retained rights, to certain patents, patent applications and existing know-how for (1) the use in the field(s) of IFN
gene therapy by lentiviral based-HSPC gene transfer with respect to (a) any Lympho-Hematopoietic Indication and/or (b) any Solid
Cancer Indication that we exercise a future option (discussed below); and (2) certain products developed during the license term
for use in the aforementioned field(s) consisting of any lentivirals vector regulated by miR126 and/or miR130 and/or other miRs
with the same expression pattern as miR126 and miR130 in hematopoietic cells for the expression of IFN under the control of a
Tie2 promoter. Lympho-Hematopoietic Indications mean any indication related to lympho-hematopoietic malignancies and Solid Cancer
Indication means any solid cancer indication (e.g., without limitation, breast, pancreas, colon cancer), wherein each affected
human organ being considered as a specific Solid Cancer Indication.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
rights retained by OSR, and extending to its affiliates, include the right to use the licensed technology for internal research
within the field(s) of use, and the right to use the licensed technology for any use outside the field(s) of use, but subject
to the options described below. In addition, we granted OSR a perpetual, worldwide, royalty-free, non-exclusive license
to any improvement generated by us with respect to the licensed technology, to conduct internal research within the field of use
directly, or in or with the collaboration third parties; and, for any use outside the field of use, in which case the license
is sublicenseable by OSR. Finally, the world-wide rights for the field of use granted to us regarding the Lentigen know-how are
non-exclusive and cannot be sublicensed due to a pre-existing nonexclusive sublicense to these rights between OSR and GlaxoSmithKline
Intellectual Property Development Limited.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
stated, we have an exclusive option to (i) certain additional patents and patent applications, and OSR improvements at
no additional cost, which could be useful for the development and/or commercialization of licensed products in the field of use;
and (ii) any Solid Cancer Indication to be included as part of the field of use, on an indication-by-indication basis,
subject to the payment of specified option fees and milestone payments.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
consideration, we paid OSR an upfront fee of &euro;250,000, and we agreed to pay OSR royalties on a single digit percentage of
the net sales of each licensed product. The royalty may be reduced upon the introduction of generic competition or patent stacking,
but in no event would the royalty be less than half of what it would have otherwise been, but for the generic competition or patent
stacking. We also agreed to pay OSR a royalty of our net sublicensing income for each licensed product and to pay OSR certain
milestone payments upon the achievement of certain milestone events, such as the initiation of different phases of clinical trials
of a licensed product, MAA approval by a major EU country, BLA acceptance by the FDA, the first commercial sale of a licensed
product in the United States and certain EU countries, and achievement of certain net sales levels.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
part of the license, we agreed to use OSR as the primary site in any preclinical study or clinical trial (including all phases
thereof) relating to any licensed products in the field of use, subject to OSR maintaining any required quality standards and
providing its services on customary and reasonable terms and consistent with then-applicable market standards. We are also obligated
to carry out our development activities using highly skilled professionals and sufficient level of resources and, specifically,
to invest (a) at least &euro;5,425,000 with respect to the development of the licensed products, and (b) at least &euro;2,420,000
with respect to the manufacturing of such licensed products (subject to certain adjustments).</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">OSR
maintains control of the preparation, prosecution and maintenance of the patents licensed. We are obligated to pay those
costs unless additional licensees benefit from these rights, in which case the cost will be shared <I>pro rata</I>. OSR controls
enforcement of the patents and know-how rights, at its own expense. In the event that OSR fails to file suit to enforce such rights
after notice from Genenta, we have the right to enforce the licensed technology within the field of use. Both us and OSR
must consent to settlement of any such litigation, and all monies recovered will be shared equally between the parties after reimbursement
for costs, or failing a bona fide agreement between us and OSR, on a 50% - 50% basis.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">The OSR License expires upon the expiry of the &ldquo;Royalty
Term&rdquo; for all licensed products in all countries, unless terminated earlier. The Royalty Term begins on the first commercial
sale of a licensed product and ends upon the later of the (a) expiration of the commercial exclusivity for such product (wherein
the commercial exclusivity refers to any remaining valid licensed patent claims covering such licensed product, or any remaining
regulatory data exclusivity for such licensed product), and (b) 10 years from the first commercial sale of such licensed product.
The parties may terminate the agreement in the event the other party breaches its obligations therein, which termination shall
become effective 60 business days following written notice thereof to the breaching party. The breaching party shall have the
right to cure such breach or default during such 60 business days. OSR may terminate the agreement for failure to pay in the event
that we fail to pay any of the upfront payment, sublicensing income or milestone payments within 30 days of due dates for each.
In addition, OSR may terminate our rights as to certain fields of use for our failure to develop (a) with respect to a solid cancer
indication, upon third anniversary of the date we exercised such option, if we have not filed an IND with respect to such optioned
solid cancer indication specifically, as to GBM, we are required to file an IND regarding Temferon for GBM prior to February
2022, or (b) with respect to a lympho-hematopoietic indication, on the earlier of (i) the fifth anniversary of the initiation
(first patient dosed) of the first human clinical trial for a licensed product in any lympho hematopoietic indication or solid
cancer indication if a patient has not been dosed with a licensed product in a Phase 3 clinical trial and (ii) September 1, 2025.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
March 2017, the OSR License Agreement was amended to provide us with additional exclusive option to expand the license to include the
use of lentiviral based-HSPC gene therapy platform to use tumor necrosis factor (TNF) as an alternative payload (rather than IFN) and
for the use of that product alone or in combination with other products and committed to spend &euro;500,000 on such product should the
option be exercised. We have until September 30, 2022 to exercise this option, upon the payment of specified option fees, as
further amended by the third amendment to the OSR License Agreement described below.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">In February 2019, we entered into a second amendment
to the OSR License Agreement, whereby we exercised an option with respect to GBM as the first solid cancer indication. We agreed to pay
OSR a GBM option fee of &euro;1.0 million upon the dosing of the tenth patient in a specified clinical trial of GBM. We also agreed to
extend the period to exercise the option rights set forth by the license agreement until September 30, 2021. This date has been extended
to September 30, 2022 pursuant to the fourth amendment to the to the OSR License Agreement described below.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
December 2020, we entered into a third amendment to the OSR License Agreement, whereby the GBM option fee included in the second amendment
was reduced to &euro;500,000 pursuant to an agreement to enter into a sponsored research agreement (SRA) within forty-five (45) days
(and later amended to seventy (70) days) from the effective date of the third amendment (discussed below) in relation to research programs
aimed at further studies regarding Temferon, with all intellectual property generated by such SRA being owned by OSR/Telethon subject
to the grant by OSR to us of exclusive option rights with respect to such intellectual property. With the third amendment we also exercised
an option with respect to a second solid cancer indication, namely solid liver cancer (LC). We agreed to pay OSR an LC option fee of
&euro;500,000 upon the earlier of (i) June 30, 2021 and (ii) the enrollment of the first patient within the Phase I clinical study for
an LC licensed product. Under the terms of the third amendment, if we are unable to obtain regulatory approval to initiate human clinical
trial with respect to solid liver cancer within nine (9) months from the third amendment effective date, we have the right, at no additional
cost, to convert the option exercise for the second solid liver cancer indication to an alternative indication. In addition, pursuant
to the third amendment, the option period for us to exercise an option with respect to any other solid cancer indication is extended
until the second anniversary of the third amendment effective date, or December 23, 2022. The aggregate amount paid to date under the
OSR License Agreement is &euro;0.75 million. In addition, &euro;0.5 million is currently due under the OSR License Agreement. Future
potential payments that are not yet considered probable under this agreement include &euro;53 million relating to GBM, &euro;47.5 million
relating to LC and &euro;0.3 million relating to the license fee option for the third indication, if exercised. In addition, the OSR
agreement was amended to extend the exclusive option as to Alternative Payload/Competing Product to September 30, 2022, as noted above.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
February 2021, we entered into a Sponsored Research Agreement (&ldquo;SRA&rdquo;) with OSR to conduct certain research projects
related to Temferon. Unless terminated earlier or extended by mutual agreement, the SRA ends upon the earlier of (a) the date
of completion of all activities relating to the sponsored research and (b) December 31, 2022. The total consideration to be
paid by the Company under the SRA will be &euro;1.0 million with payments scheduled quarterly over 2021 and 2022. The aggregate
amount paid in 2021 to date under the SRA is &euro;0.25 million.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">In September 2021, the OSR License Agreement was amended to extend the exclusive
option. Specifically, if Genenta is not able to obtain approval of the Regulatory Authorities to initiate a human clinical trial in any
country with respect to solid liver cancer on or before September 30, 2022, then Genenta has the right, at no additional cost, to convert
the option exercise for the second Solid Cancer Indication to an indication other than solid liver cancer. We now have until September
30, 2022 to exercise this option.</P>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Know-How
License Agreement with Fondazione Telethon</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
February 2016, we entered into a Know-How License Agreement with Telethon (Telethon License Agreement). Telethon granted us a
non-exclusive, perpetual, sublicensable (through multiple tiers), royalty-bearing, worldwide license to use its manufacturing
know-how in the research and development, sale and export of any product, which is defined therein as any lentiviral vector regulated
by miRNA 126 and/or miRNA 130 and/or other miRNAs with the same expression pattern as miRNA 126 and/or miRNA 130 in hematopoietic
cells for the expression of any anticancer protein under the control of a Tie2 promoter or INF under the control of any promoter
other than Tie2 for any cancer indication. As consideration for the license, we agreed to pay Telethon a royalty equal to a low
single digit percentage of any actual payments (excluding taxes) to any CMO for the manufacturing of any product using the licensed
know-how. The royalty payments must be made for eight (8) years from the effective date, or until February 2, 2024. The parties
may terminate the agreement in the event the other party breaches its obligations therein, which termination shall become effective
sixty (60) business days following written notice thereof to the breaching party.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Government
Regulation; Coverage, Reimbursement, Pricing</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Government
authorities in the United States, at the federal, state and local levels, and in other countries and jurisdictions, including
the EU, extensively regulate, among other things, the research, development, testing, manufacture, sales, pricing, reimbursement,
quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval
monitoring and reporting, and import and export of biopharmaceutical products. The processes for obtaining marketing approvals
in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations
and other regulatory authorities, require the expenditure of substantial time and financial resources.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Approval
and Regulation of Drugs in the United States</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
the United States, drug products are regulated by the FDA under the Federal Food, Drug, and Cosmetic Act (&ldquo;FDCA&rdquo;)
and other laws, including, in the case of biologics, the Public Health Service Act (&ldquo;PHSA&rdquo;). Drug products
are also subject to other federal, state and local statutes and regulations. A failure to comply with any applicable requirements
during the product development, approval, or post-approval periods may lead to administrative or judicial sanctions, including,
among other things, the imposition by the FDA or an institutional review board (&ldquo;IRB&rdquo;) of a hold on clinical trials,
refusal to approve pending marketing applications or supplements, withdrawal of approval, warning letters, product recalls, product
seizures, total or partial suspension of production or distribution, injunctions, fines, or administrative, civil and/or criminal
investigation, penalties or prosecution.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
the United States, all of our product candidates are regulated by the FDA as biologics. Biologics require the submission of a
BLA and approval by the FDA prior to being marketed in the United States. Manufacturers of biologics may also be subject to state
and local regulation.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
steps required before a biologic may be marketed in the United States generally include:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">completion
    of preclinical studies, animal studies and formulation studies, performed in accordance with the FDA&rsquo;s good laboratory
    practices (&ldquo;GLP&rdquo;) requirements, and applicable requirements for the humane use of laboratory animals or other
    applicable regulations;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">submission
    to the FDA of an application for an investigational new drug application (&ldquo;IND&rdquo;), which must become effective
    before human clinical trials may commence;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">approval
    of the protocol and related documentation by an independent IRB or ethics committee at each clinical trial site before each
    trial may be initiated;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">performance
    of adequate and well-controlled clinical trials under protocols submitted to the FDA and reviewed and approved by each IRB,
    conducted in accordance with the FDA&rsquo;s good clinical practices (&ldquo;GCPs&rdquo;) requirements and any additional
    requirements for the protection of human research subjects and their health information to establish the safety, purity and
    potency of the biologic for each targeted indication;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">preparation
    of and submission to FDA of a biologics license application (&ldquo;BLA&rdquo;) for marketing approval that includes sufficient
    evidence of establishing the safety, purity, and potency of the proposed biological product for its intended indication, including
    from results of nonclinical testing and clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">a
    determination by the FDA within 60 days of its receipt of a BLA to accept and file the application;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">satisfactory
    completion of an FDA pre-license inspection of the manufacturing facility or facilities where the biological product is produced
    to assess compliance with current good manufacturing practices (&ldquo;cGMPs&rdquo;) to assure that the facilities, methods
    and controls are adequate to preserve the biological product&rsquo;s identity, strength, quality and purity;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">satisfactory
    completion of an FDA Advisory Committee review, if applicable;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">potential
    FDA audit of the preclinical study and clinical trial sites that generated the data in support of the BLA in accordance with
    any applicable expedited programs or designations;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">payment
    of user fees for FDA review of the BLA (unless a fee waiver applies);</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">FDA
    review and approval, or licensure, of the BLA to permit commercial marketing of the product for particular indications for
    use in the U.S.;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">satisfactory
    completion of an FDA inspection of the manufacturing facilities at which the biologic is produced to assess compliance with
    current Good Manufacturing Practices (&ldquo;cGMP&rdquo;) and to assure that the facilities, methods and controls are adequate;
    and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">FDA
    review and approval of the BLA.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Preclinical
</I></B></FONT><FONT STYLE="font: 10pt Georgia"><B><I>Studies and the IND Process</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">Before testing any biological product candidate
in humans, the product candidate enters the preclinical testing stage. Preclinical studies include laboratory evaluation
of a product&rsquo;s biological characteristics, chemistry, formulation and toxicity, as well as animal studies to assess the
characteristics and potential safety and efficacy of the product candidate. The conduct of the preclinical studies must comply
with federal regulations and requirements, including, as applicable, GLP and the Animal Welfare Act.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Prior
to commencing an initial clinical trial in humans with a product candidate in the U.S., an IND must be submitted to the FDA and
the FDA must allow the IND to proceed. An IND is an exemption from the FD&amp;C Act that allows an unapproved product candidate
to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA allowance that such investigational
product may be administered to humans in connection with such trial. Such authorization must be secured prior to interstate shipment
and administration. In support of a request for an IND, the clinical trial sponsor must submit the results of the preclinical
tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical
protocol, to the FDA as part of the IND. An IND must become effective before human clinical trials may begin. Once submitted,
the IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the IND on a full or partial clinical
hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before
the clinical trial or part of the study can begin. Submission of an IND therefore may or may not result in FDA authorization to
begin a clinical trial. The FDA also may impose clinical holds on a sponsor&rsquo;s IND at any time before or during clinical
trials due to, among other considerations, unreasonable or significant safety concerns, inability to assess safety concerns, lack
of qualified investigators, a misleading or materially incomplete investigator brochure, study design deficiencies, interference
with the conduct or completion of a study designed to be adequate and well-controlled for the same or another investigational
product, insufficient quantities of investigational product, lack of effectiveness, or non-compliance. If the FDA imposes a clinical
hold, studies may not recommence without FDA authorization and then only under terms authorized by the FDA.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Clinical
Trials</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">Clinical trials involve the administration of
the product candidate to healthy volunteers or patients under the supervision of qualified investigators. Clinical trials are
subject to extensive regulation and must be conducted in compliance with (i) federal regulations, (ii) GCP standards, which set
safeguards to protect the rights and health of patients and establish standards for conducting, recording data from, and reporting
results of clinical trials, and (iii) protocols detailing, among other things, the objectives of the trial, subject
selection and exclusion criteria, the parameters and criteria to be used in monitoring safety, and the effectiveness
criteria to be evaluated, if any. Foreign studies conducted under an IND generally must meet the same requirements that apply
to studies being conducted in the United States. The informed written consent of each study patient must be obtained before the
patient may begin participation in the clinical trial. The study protocol, study plan, and informed consent forms for each clinical
trial must be reviewed and approved by an IRB for each clinical site, and the study must be conducted under the auspices of an
IRB for each trial site. Investigators and IRBs must also comply with FDA regulations and guidelines, including those regarding
oversight of study patient informed consent, complying with the study protocol and investigational plan, adequately monitoring
the clinical trial, and timely reporting of adverse events. An IRB can suspend or terminate approval of a clinical trial at
its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&rsquo;s
requirements or if the product candidate has been associated with unexpected serious harm to patients.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
clinical trial program for a product candidate is generally divided into three phases. Although the phases are usually conducted
sequentially, they may overlap or be combined. The three phases are as follows:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Phase 1</I>. Phase
1 involves the initial introduction of a product candidate into humans. Phase 1 clinical trials are typically conducted in healthy
human subjects, but in some situations are conducted in patients with the target disease or condition. These clinical trials are
generally designed to evaluate the safety, metabolism, pharmacokinetic (&ldquo;PK&rdquo;) properties and pharmacologic actions
of the product candidate in humans, the side effects associated with increasing doses and, if possible, to gain early evidence
of effectiveness. During Phase 1 clinical trials, sufficient information about the product candidate&rsquo;s PK properties and
pharmacological effects may be obtained to inform and support the design of Phase 2 clinical trials.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Phase
    2</I>. Phase 2 includes the controlled clinical trials conducted to obtain initial evidence of effectiveness of the product
    candidate for a particular indication(s) in patients with the target disease or condition, to determine dosage tolerance and
    optimal dosage, and to gather additional information on possible adverse side effects and safety risks associated with the
    product candidate. Phase 2 clinical trials are typically well-controlled, closely monitored, and conducted in a limited patient
    population; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Phase
    3</I>. Phase 3 clinical trials are clinical trials conducted in an expanded patient population at geographically dispersed
    clinical trial sites. They are performed after preliminary evidence suggesting effectiveness of the product candidate has
    been obtained and are intended to further evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk
    relationship of the product candidate and to provide an adequate basis for regulatory approval.  In most cases, the FDA requires two adequate and well controlled
    Phase 3 clinical trials to demonstrate the efficacy of the product candidate, although a single Phase 3 clinical trial with
    other confirmatory evidence may be sufficient in certain instances.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
August 2018, the FDA released a draft guidance entitled &ldquo;Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite
Development of Oncology Drugs and Biologics,&rdquo; which outlines how developers can utilize an adaptive trial design commonly
referred to as a seamless trial design in early stages of oncology biological product development (i.e., the first-in-human clinical
trial) to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information
to support the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials
can potentially bring efficiency to biological product development and reduce developmental costs and time.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to
gain more information about the product. These post-approval clinical trials, sometimes referred to as Phase 4 clinical trials,
may also be made a condition to approval of the BLA. Failure to exhibit due diligence regarding conducting required Phase
4 clinical trials could result in withdrawal of approval for products.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Concurrent
with clinical trials, companies usually complete additional animal studies and also must develop additional information about
the chemistry and physical characteristics of the biological product as well as finalize a process for manufacturing the product
in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents
with use of biological products, the PHSA, emphasizes the importance of manufacturing control for products whose attributes cannot
be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate
and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the
final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted
to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">During
all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities,
clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be
submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected
adverse events, any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk
for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed
in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor
determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening
suspected adverse reaction within seven calendar days after the sponsor&rsquo;s initial receipt of the information.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
decision to suspend or terminate development of a product candidate may be made by either a health authority body, such as the
FDA, by an IRB, or by a company for various reasons and during any phase of clinical trials. The FDA may order the temporary or
permanent discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial either
is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. In
some cases, clinical trials are overseen by a data safety monitoring board (&ldquo;DSMB&rdquo;), which is an independent group
of qualified experts organized by the trial sponsor to evaluate at designated points in time whether or not a trial may move forward
and/or should be modified. These decisions are based on unblinded access to data from the ongoing trial and generally involve
determinations regarding the benefit-risk ratio for study patients and the scientific integrity and validity of the clinical trial.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, there are requirements for the registration of certain clinical trials of product candidates on public registries, such
as <U>www.clinicaltrials.gov</U>, and the submission of certain information pertaining to these trials, including clinical trial
results, after trial completion.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Assuming
successful completion of all required testing in accordance with all applicable regulatory requirements, a sponsor submits extensive
information about the product candidate to the FDA in the form of a BLA to request marketing approval for the product candidate
in specified indications.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Biologics
License Applications</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
order to obtain approval to market a biologic in the United States, a BLA  must be submitted to the FDA that provides data
establishing the safety and effectiveness of the product candidate for the proposed indication. The BLA includes all relevant
data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well
as positive findings, together with detailed information relating to the product&rsquo;s chemistry, manufacturing, controls and
proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness
of a product candidate, or from a number of alternative sources, including studies initiated by investigators. To support marketing
approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the product
candidate to the satisfaction of the FDA.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
the Prescription Drug User Fee Act (&ldquo;PDUFA&rdquo;), as amended, the fees payable to the FDA for reviewing an original BLA,
as well as annual program fees for approved products, can be substantial, subject to certain limited deferrals, waivers and reductions
that may be available. The FDA has 60 days from receipt of a BLA to determine whether the application will be accepted for filing
based on the agency&rsquo;s threshold determination that it is sufficiently complete to permit substantive review. The FDA may
refuse to accept for filing any BLA that it deems incomplete or not properly reviewable at the time of submission, in which case
the BLA will have to be updated and resubmitted. The FDA&rsquo;s PDUFA review goal (which is not a legal requirement) is to review
90% of priority BLA applications within six months of filing and 90% of standard applications within 10 months of filing, but
the FDA can and frequently does extend this review timeline to consider certain later-submitted information or information intended
to clarify or supplement information provided in the initial submission. The FDA may not complete its review or approve a BLA
within these established goal review times. The FDA reviews the BLA to determine, among other things, whether the proposed product
is safe, pure, and potent for its intended use, and whether the product is being manufactured in compliance with cGMP to ensure
its continued safety, purity and potency. The FDA may also refer applications for novel product candidates which present difficult
questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review,
evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound
by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">Before approving a BLA, the FDA will inspect
the facilities at which the product is manufactured or the facilities that are significantly involved in the product development
and distribution process, and will not approve the product candidate unless cGMP compliance is satisfactory and the manufacturing
processes and facilities are adequate to assure consistent production of the product within required specifications. Additionally,
before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP requirements.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
the Pediatric Research Equity Act, certain BLAs must include an assessment, generally based on clinical trial data, of the safety
and effectiveness of the biological product in relevant pediatric populations. The FDA may waive or defer the requirement for
a pediatric assessment, either at a company&rsquo;s request or by its own initiative, including waivers for certain products not
likely to be used in a substantial number of pediatric patients. Unless otherwise required by regulation, products
with orphan drug designation are exempt from these requirements for orphan-designated indications with no formal waiver process
required.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">After
the FDA evaluates the BLA and the manufacturing facilities, the FDA may issue either an approval letter or a complete response
letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional
testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed
to the FDA&rsquo;s satisfaction in a resubmission of the BLA, the FDA may issue an approval letter. The FDA&rsquo;s PDUFA review
goal is to review such resubmissions within two or six months of receipt, depending on the type of information included. Notwithstanding
the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the
regulatory criteria for approval and deny approval of a resubmitted BLA. FDA approval of any application may include many delays
or never be granted. An approval letter authorizes commercial marketing of the product candidate with specific prescribing information
for specific indications. As a condition of BLA approval, the FDA may require a risk evaluation and mitigation strategy (&ldquo;REMS&rdquo;)
to help ensure that the benefits of the product outweigh the potential risks. REMS can include Medication Guides, communication
plans for healthcare professionals, and also may include elements to assure safe use (&ldquo;ETASU&rdquo;). ETASU can include,
but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances,
special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and
profitability of the biologic. Moreover, product approval may require substantial post-approval testing and surveillance to monitor
the biologic&rsquo;s safety, purity, or potency, which can be costly.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Changes
to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing
processes or facilities, require submission and FDA approval of a new BLA or a supplemental BLA before the change can be implemented.
A supplemental BLA for a new indication typically requires clinical data similar to that in the original application, and the
FDA generally uses the same procedures and actions in reviewing a supplemental BLA as it does in reviewing a new BLA.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Product
approvals may be withdrawn if compliance with regulatory standards is not maintained or if safety or manufacturing problems occur
following initial marketing. For example, quality control and manufacturing procedures must conform, on an ongoing basis, to cGMP
requirements, and the FDA periodically inspects manufacturing facilities to assess compliance with cGMP. Accordingly, manufacturers
must continue to spend time, money and effort to maintain cGMP compliance. In addition, new or modified government requirements,
including from new legislation, may be established that could delay or prevent regulatory approval of our product candidates under
development or affect our ability to maintain product approvals we have obtained.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><B><I>Regulation of Companion Diagnostics.</I></B></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">For drugs and therapeutic biologics where the use of a
specific diagnostic test is essential for the safe and effective use of the therapeutic product, such as when the use of a product is
limited to a specific patient subpopulation that can be identified by using the test, regulatory authorities may require, as a condition
of approval, that a relevant &ldquo;companion diagnostic&rdquo; test also be approved or cleared for the appropriate indication. This
general policy approach may be inapplicable in cases where the drug or therapeutic biologic is intended to treat a serious or life-threatening
condition for which no satisfactory alternative treatment exists and the benefits from the use of a product with an unapproved companion
diagnostic device are so pronounced as to outweigh the risks from the lack of an approved companion diagnostic. Companion diagnostics
are generally regulated as medical devices by regulatory authorities and relevant statutes and regulations govern, among other things,
medical device design and development, preclinical and clinical testing, premarket regulatory review, manufacturing, labeling, storage,
advertising and promotion, sales and distribution, export and import, and post-market surveillance.</P>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Orphan
Drug Designation</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">The FDA may grant orphan drug designation
to biologics intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States
or a disease or condition that affects 200,000 or more individuals in the United States but there is no reasonable expectation
that the cost of developing and making the biologic would be recovered from sales in the United States. Orphan drug designation
must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent
and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten
the duration of the regulatory review and approval process.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
the United States, orphan drug designation entitles a party to financial incentives, such as opportunities for grant funding
towards clinical trial costs, tax credits for certain research and user fee waivers under certain circumstances. In addition,
if a company receives the first FDA approval of a drug or biologic for the indication for which it has orphan drug designation,
the product is entitled to seven years of orphan exclusivity, which means the FDA may not approve any other application
for the &ldquo;same&rdquo; drug or biologic for the same indication for a period of seven years, except in limited circumstances,
such as a showing of clinical superiority over the product with orphan exclusivity. The FDA can revoke a product&rsquo;s orphan
drug exclusivity under certain circumstances, including when the product sponsor is unable to assure the availability of sufficient
quantities of the product to meet patient needs. Orphan drug exclusivity does not prevent the FDA from approving a different drug
or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">In the EEA, the criteria for designating an
&ldquo;orphan medicinal product&rdquo; are similar in principle to those in the United States. Under Article 3 of Regulation (EC)
141/2000, a medicinal product may be designated as an orphan medicinal product if it meets the following criteria: (a) it
is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating conditions; (b)
either such condition that affects no more than five in 10,000 people in the E.U.; or without the benefits derived
from orphan status, it must be unlikely that the marketing of the medicine would generate sufficient return in the E.U. to justify
the investment needed for its development; and, (c) there exists no satisfactory method of diagnosis, prevention or
treatment of the condition concerned, or, if such a method exists, the medicinal product would be of significant benefit to those
affected by the condition. The application for orphan designation must be submitted to the EMA and approved by the European Commission
before an application is made for marketing authorization for the product. Once designated, orphan medicinal product designation
also entitles a party to financial incentives such as reduction of fees or fee waivers. Moreover, ten years of market exclusivity
is granted, if the product continues to be designated as an orphan medicinal product upon grant of the marketing authorization.
During this ten-year period, with a limited number of exceptions, neither the competent authorities of the E.U. Member States,
the EMA, or the European Commission are permitted to accept applications or grant marketing authorization for other similar medicinal
products with the same therapeutic indication. A &ldquo;similar medicinal product&rdquo; is defined as a medicinal product
containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended
for the same therapeutic indication. However, marketing authorization may be granted to a similar medicinal product with the
same orphan indication during the ten-year period with the consent of the marketing authorization holder for the original orphan
medicinal product or if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities. Marketing
authorization may also be granted to a similar medicinal product with the same orphan indication if this latter product is demonstrated
to be safer, more effective or otherwise clinically superior to the original orphan medicinal product. This period of market exclusivity
may be reduced to six years if, at the end of the fifth year, it is established that the orphan designation criteria
are no longer met, including where it can be demonstrated on the basis of available evidence that the product is sufficiently
profitable not to justify maintenance of market exclusivity.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Expedited
Programs in the United States and Other Jurisdictions</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
the United States, the FDA has various programs, including fast track designation, breakthrough therapy designation, accelerated
approval and priority review, that are intended to expedite or simplify the process for the development and FDA review of drugs
and biologics that are intended for the treatment of serious or life-threatening diseases or conditions. A product may be granted
fast track designation if it is intended for the treatment of a serious or life-threatening condition and demonstrates the potential
to address unmet medical needs for such condition. Fast track designation applies to the combination of the product and the specific
indication for which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate the drug or biologic
as a fast track product at any time during the clinical development of the product. With fast track designation, the sponsor may
be eligible for more frequent opportunities to obtain the FDA&rsquo;s feedback. Another benefit of fast track designation, for
example, is that the FDA may consider for review sections of the marketing application on a rolling basis before the complete
application is submitted if certain conditions are satisfied, including an agreement with the FDA on the proposed schedule for
submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review. Even
if a product candidate receives fast track designation, the designation can be rescinded and provides no assurance that a product
will be reviewed or approved more expeditiously than would otherwise have been the case, or that the product will be approved
at all.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
the FDA&rsquo;s breakthrough therapy program, a sponsor may seek FDA designation of its product candidate as a breakthrough therapy
if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or
life-threatening disease or condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement
over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early
in clinical development. Breakthrough therapy designation comes with all of the benefits of fast-track designation. The
FDA may take other actions appropriate to expedite the development and review of the product candidate, including holding meetings
with the sponsor and providing timely advice to, and interactive communication with, the sponsor regarding the development program.
Even if one or more of our product candidates receives breakthrough therapy designation, the designation can be rescinded and
provides no assurance that a product will be reviewed or approved more expeditiously than would otherwise have been the case,
or that the product will be approved at all.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">A
product candidate may be eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness
in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may
receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials
establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or
on the basis of an effect on an intermediate clinical endpoint other than survival or irreversible morbidity or mortality, that
is reasonably likely to predict irreversible morbidity or mortality or other clinical benefit, taking into account the severity,
rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the
FDA generally requires that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled
post-marketing clinical trials to verify the clinical benefit in relationship to the surrogate endpoint or ultimate outcome in
relationship to the clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval
of promotional materials, which could adversely impact the timing of the commercial launch of the product. The FDA may withdraw
approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the
predicted clinical benefit of the product.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; text-align: left; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The FDA may grant
priority review designation to a product candidate, which sets the user fee target date for FDA action on the application at six
months from FDA filing. Priority review may be granted where a product is intended to treat a serious or life-threatening disease
or condition and, if approved, has the potential to provide a safe and effective therapy where no satisfactory alternative therapy
exists or a significant improvement in safety or efficacy compared to available therapy. If criteria are not met for priority
review, the standard FDA review period is ten months from FDA filing. Priority review designation does not change the scientific/medical
standard for approval or the quality of evidence necessary to support approval.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Under the 21st
Century Cures Act, a drug is eligible for regenerative medicine advanced therapy (&ldquo;RMAT&rdquo;) designation if (i)
the drug is a regenerative medicine therapy, which is defined by FDA to include cell therapy, therapeutic tissue engineering product,
human cell and tissue product, any combination product using such therapies or products, and certain human gene therapies and
xenogeneic cell products, except for human cells, tissues, and cellular and tissue-based products (&ldquo;HCT/P&rsquo;s&rdquo;)
that are regulated solely under Section 361 of the Public Health Service Act and part 1271 of Title 21, Code of Federal Regulations;
(ii) the drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (iii) preliminary
clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition. An RMAT
designation include all the benefits of the fast track and breakthrough therapy designation programs, including early interactions
with FDA, and the potential to support accelerated approval and address post-approval requirements. An RMAT designation request
should be submitted with the IND or after and, ideally, no later than the end-of-phase 2 meeting. Even if a product candidate
receives RMAT designation, the designation can be rescinded and provides no assurance that a product will be reviewed or approved
more expeditiously than would otherwise have been the case, or that the product will be approved at all.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Under the
centralized procedure in the EEA, the maximum timeframe for the evaluation of a marketing authorization application is 210
days (excluding &lsquo;&lsquo;clock stops,&rsquo;&rsquo; when additional written or oral information is to be provided by the
applicant in response to questions asked by the CHMP). Clock stops may extend the timeframe of evaluation of a marketing
authorization application considerably beyond 210 days. Accelerated evaluation might be granted by CHMP in exceptional cases,
when a medicinal product is expected to be of a major public health interest, which should be justified and assessed on a
case-by-case basis. In this circumstance, EMA ensures that the opinion of CHMP is given within 150 days (excluding clock
stops).</FONT></P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B><I>Expanded Access to an Investigational
Drug for Treatment Use</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Expanded access,
also called &ldquo;compassionate use,&rdquo; is the use of investigational new drug products outside of clinical trials to treat
patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative
treatment options. The FDA regulations allow access to investigational drugs under an IND by the sponsor or the treating physician
for treatment purposes on a case-by-case basis for individual patients, intermediate-size patient populations, and larger populations
for use of the drug under a treatment protocol or Treatment IND Application.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The suitability
of treating a patient or a group of patients under expanded access is determined by the following: if patient(s) have a serious
or immediately life-threatening disease or condition, there is no comparable or satisfactory alternative therapy to diagnose,
monitor, or treat the disease or condition, the potential patient benefit justifies the potential risks of the treatment and the
potential risks are not unreasonable in the context or condition to be treated, and the expanded use of the investigational drug
for the requested treatment will not interfere with the initiation, conduct or completion of clinical investigations that could
support marketing approval of the product candidate or otherwise compromise the potential development of the product candidate.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Sponsors</FONT><FONT STYLE="font-size: 10pt">
of one or more investigational drugs for the treatment of a serious disease(s) or condition(s) make publicly available their policies
for evaluating and responding to requests for expanded access for individual patients. This provision requires drug companies
to make publicly available their policies for expanded access for individual patient access to products intended for serious diseases.
Sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 study or
15 days after the drug receives breakthrough therapy, fast track, or regenerative medicine advanced therapy designation.
Additionally, in 2018 the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for
certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are
undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling
in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug
manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B><I>U.S. market exclusivity</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">A biological
product can obtain pediatric market exclusivity in the U.S. Pediatric exclusivity, if granted, adds six months to existing exclusivity
periods, including some regulatory exclusivity periods tied to patent terms. This six-month exclusivity, which runs from the end
of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance
with an FDA-issued &ldquo;Written Request&rdquo; for such a study.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The Biologics Price
Competition and Innovation Act of 2009 (&ldquo;BPCIA&rdquo;), created an abbreviated approval pathway for biological products
shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product. This amendment to the PHSA attempts
to <FONT STYLE="font-family: Georgia">minimize duplicative testing. Biosimilarity, which requires that there be no clinically
meaningful differences between the biological product and the reference product in terms of safety, purity, and potency,
can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that
a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same
clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic
may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative
to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structure
of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation
that are still being worked out by the FDA.</FONT></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>&nbsp;</I></B></FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">FDA will not accept
an application for a biosimilar or interchangeable product based on the reference biological product until four years after the
date of first licensure of the reference product, and FDA will not approve an application for a biosimilar or interchangeable
product based on the reference biological product until 12 years after the date of first licensure of the reference product. &ldquo;First
licensure&rdquo; typically means the initial date the particular product at issue was licensed in the U.S. Date of first licensure
does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure
is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological
product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure
of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system,
delivery device or strength, or for a modification to the structure of the biological product that does not result in a change
in safety, purity, or potency. The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government
proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may
impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate implementation
and impact of the BPCIA is subject to significant uncertainty.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B><I>Post-approval requirements</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Rigorous and extensive
FDA regulation of biological products continues after approval, particularly with respect to cGMP requirements, as well as requirements
relating to record keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising
and promotion of the product. Manufacturers of products are required to comply with applicable requirements in the cGMP regulations,
including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements
applicable to biological products, include reporting of cGMP deviations that may affect the identity, potency, purity and overall
safety of a distributed product, record keeping requirements, reporting of adverse effects, reporting updated safety and efficacy
information, and complying with electronic record and signature requirements. After a BLA is approved, the product also may be
subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on
each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the
manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history
of manufacture of the lot and the results of all of the manufacturer&rsquo;s tests performed on the lot. The FDA also may perform
certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer. In addition,
the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of
biological products.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">As</FONT><FONT STYLE="font-size: 10pt">
a condition of BLA approval, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to
further assess and monitor the product&rsquo;s safety and effectiveness after commercialization. Regulatory approval of oncology
products often requires that patients in clinical trials be followed for long periods to determine the overall survival benefit
of the product. In addition, as a holder of an approved BLA, a company would be required to report adverse reactions and production
problems to the FDA, to provide updated safety and efficacy information, and to comply with requirements concerning advertising
and promotional labeling for any of its products.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Manufacturers must
comply with the FDA&rsquo;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the
prohibition on promoting products for uses or in patient populations that are not described in the product&rsquo;s approved labeling
(known as &ldquo;off-label use&rdquo;), industry-sponsored scientific and educational activities, and promotional activities involving
the internet. Discovery of previously unknown problems with a product or failure to comply with applicable regulatory requirements
</FONT><FONT STYLE="font-size: 10pt">after approval may result in serious and extensive restrictions on a product or the manufacturer
or holder of an approved BLA, as well as lead to potential market disruptions. These restrictions may include suspension of product
manufacturing until the FDA is assured that quality standards can be met, continuing oversight of manufacturing by the FDA under
a &lsquo;&lsquo;consent decree,&rsquo;&rsquo; which frequently includes the imposition of costs and continuing inspections over
a period of many years, as well as possible withdrawal of the product from the market. Other potential consequences include interruption
of production, issuance of warning letters or other enforcement letters, refusal to approve pending BLAs or supplements to approved
BLAs, product seizure or detention, product recalls, fines, and injunctions or imposition of civil and/or criminal penalties.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In addition, changes
to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval
before being implemented. FDA regulations also require investigation, correction, and reporting of any deviations from cGMP and
impose reporting and documentation requirements upon a company and any third-party manufacturers that a company may decide to
use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to
maintain compliance with cGMP and other aspects of regulatory compliance.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Biological product
manufacturers and other entities involved in the manufacture and distribution of approved biological products are required to
register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the
FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time,
money, and effort in the area of production and quality control to maintain cGMP compliance.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Newly discovered or developed
safety or effectiveness data may require changes to a product&rsquo;s approved labeling, including the addition of new warnings
and contraindications, and also may require the implementation of other risk management measures, such as additional post-market
clinical trials to assess new safety risks or distribution-related or other restrictions under a REMS. In addition, changes
to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes
to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review
and approval.</FONT></P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Patent
Term Restoration and Extension</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Depending
upon the timing, duration and specifics of the FDA approval of our product candidates, some of our U.S. patents may be eligible
for limited patent term extension. The provisions of the Drug Price Competition and Patent Term Restoration Act, informally known
as the Hatch-Waxman Act, permit a patent restoration term of up to five years as compensation for patent term lost during product
development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent
beyond a total of 14 years from the product&rsquo;s approval date. The patent term restoration period is generally one-half the
time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA
and the approval of that application. Only one patent applicable to an approved product is eligible for the extension and the
application for the extension must be submitted prior to the expiration of the patent. The United States Patent and Trademark
Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the
future, we may apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond
its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing
of the relevant BLA.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Many
other countries also provide for patent term extensions or similar extensions of patent protection for biologic products. For
example, in Japan, it may be possible to extend the patent term for up to five years and in Europe, it may be possible to obtain
a supplementary patent certificate that would effectively extend patent protection for up to five years.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Health
Care Laws and Regulations</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Health
care providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted
marketing approval. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable
fraud and abuse, anti-kickback, false claims laws, patient privacy laws and regulations and other health care laws and regulations
that may constrain business and/or financial arrangements. Restrictions under applicable federal and state health care laws and
regulations include the following:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting,
    offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either
    the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may
    be made, in whole or in part, under a federal health care program such as Medicare and Medicaid;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which
    prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, directly or indirectly,
    to the federal government, claims for payment that are false, fictitious or fraudulent or knowingly making, using or causing
    to made or used a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal laws
    that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health
    care benefit program or making false statements relating to health care matters;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">HIPAA,
    as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective implementing regulations,
    including the Final Omnibus Rule published in January 2013, which impose obligations, including mandatory contractual terms,
    with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material
    fact or making any materially false statement in connection with the delivery of or payment for health care benefits, items
    or services;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    FCPA which prohibits companies and their intermediaries from making, or offering or promising to make improper payments to
    non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    federal transparency requirements known as the federal Physician Payments Sunshine Act, under the PPACA, which requires certain
    manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid
    Services within the United States Department of Health and Human Services, information related to payments and other transfers
    of value made by that entity to physicians and teaching hospitals, as well as ownership and investment interests held by physicians
    and their immediate family members; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">analogous
    state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to health care
    items or services that are reimbursed by non-government third-party payors, including private insurers.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Further,
some state laws require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines
and the relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information
related to payments to physicians and other health care providers or marketing expenditures. Additionally, some state and local
laws require the registration of pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern
the privacy and security of health information in some circumstances, many of which differ from each other in significant ways
and often are not preempted by HIPAA, thus complicating compliance efforts.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Pharmaceutical
Insurance Coverage and Health Care Reform</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing
the prescribed services generally rely on third-party payors to reimburse all or part of the associated health care costs. Significant
uncertainty exists as to the coverage and reimbursement status of drug products approved by the FDA and other government authorities.
Thus, even if a product candidate is approved, sales of such product will depend, in part, on the extent to which third-party
payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and
managed care organizations, provide coverage and establish adequate reimbursement levels for, the product. The process for determining
whether a payor will provide coverage for a drug product may be separate from the process for setting the price or reimbursement
rate that the payor will pay for the drug product once coverage is approved. Third-party payors are increasingly challenging the
prices charged, examining the medical necessity and reviewing the cost-effectiveness of medical products and services and imposing
controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary,
which might not include all of the approved products for a particular indication.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
order to secure coverage and reimbursement for any product candidate that might be approved for sale, a company may need to conduct
expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition
to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered
medically necessary or cost effective. A decision by a third-party payor not to cover a product candidate could reduce physician
utilization once the product candidate is approved. Additionally, a payor&rsquo;s decision to provide coverage for a drug product
does not imply that an adequate reimbursement rate will be approved. Further, one payor&rsquo;s determination to provide coverage
for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of
coverage and reimbursement can differ significantly from payor to payor.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
containment of health care costs also has become a priority of federal, state and foreign governments and the prices of products
have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including
price controls, restrictions on reimbursement and requirements for substitution of generic drug products. Adoption of price controls
and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures,
could further limit a company&rsquo;s revenue generated from the sale of any approved drug products. Coverage policies and third-party
reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more drug
products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement
rates may be implemented in the future.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">There
have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical
products, limiting coverage and reimbursement for drugs and biologics and other medical products, government control and other
changes to the health care system in the United States.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
March 2010, the United States Congress enacted the PPACA, which, among other things, included changes to the coverage and payment
for drug products under government health care programs. The PPACA effected the following changes of importance to our potential
product candidates:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">established
    an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic
    agents, apportioned among these entities according to their market share in certain government healthcare programs;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">expanded
    eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals
    with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&rsquo;s Medicaid
    rebate liability;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">expanded
    manufacturers&rsquo; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded
    and generic drugs and revising the definition of &ldquo;average manufacturer price&rdquo; for calculating and reporting Medicaid
    drug rebates on outpatient prescription drug prices;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">addressed
    a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that
    are inhaled, infused, instilled, implanted or injected;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">expanded
    the types of entities eligible for the 340B drug discount program;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">established
    the Medicare Part D coverage gap discount program by requiring manufacturers to provide a 70% point-of-sale discount off of
    the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for
    the manufacturers&rsquo; outpatient drugs to be covered under Medicare Part D; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">established
    a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness
    research, along with funding for such research.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Other
legislative changes have been proposed and adopted in the United States since the PPACA was enacted. In August 2011, the Budget
Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit
Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was
unable to reach required goals, thereby triggering the legislation&rsquo;s automatic reduction to several government programs.
This included aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April
2013 and, due to subsequent legislative amendments, will remain in effect through 2027 unless additional congressional action
is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things,
further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and
increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Since
enactment of the PPACA, there have been numerous legal challenges and congressional actions to repeal and replace provisions of
the law. For example, with enactment of the TCJA, which was signed by the President on December 22, 2017, Congress repealed the
&ldquo;individual mandate.&rdquo; The repeal of this provision, which requires most Americans to carry a minimal level of health
insurance, will become effective in 2019. According to the Congressional Budget Office, the repeal of the individual mandate will
cause 13 million fewer Americans to be insured in 2027 and premiums in insurance markets may rise. Additionally, on January 22,
2018, the President signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain
PPACA-mandated fees, including the so-called &ldquo;Cadillac&rdquo; tax on certain high cost employer-sponsored insurance plans,
the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt
medical devices. Further, the Bipartisan Budget Act of 2018, among other things, amended the PPACA, effective January 1, 2019,
to increase from 50% to 70% the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare
Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &ldquo;donut hole&rdquo;. Congress
will likely consider other legislation to replace elements of the PPACA during the next congressional session.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
presidential </FONT><FONT STYLE="font: 10pt Georgia">administration has also taken executive actions to undermine or delay
implementation of the PPACA. In January 2017, the President signed an Executive Order directing federal agencies with authorities
and responsibilities under the PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the
PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or
manufacturers of pharmaceuticals or medical devices. In October 2017, the President signed a second Executive Order allowing for the
use of association health plans and short-term health insurance, which may provide fewer health benefits than the plans sold through
the PPACA exchanges. At the same time, the presidential administration announced that it will discontinue the payment of
cost-sharing reduction, or CSR, payments to insurance companies until Congress approves the appropriation of funds for such CSR
payments. The loss of CSR payments is expected to increase premiums on certain policies issued by qualified health plans under the
PPACA. A bipartisan bill to appropriate funds for CSR payments was introduced in the Senate, but the future of that bill is
uncertain. In addition, the Centers for Medicare &amp; Medicaid Services has recently proposed regulations that would give states
greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of
relaxing the essential health benefits required under the PPACA for plans sold through such marketplaces.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Further,
there have been several recent U.S. congressional inquiries and proposed and enacted federal and state legislation designed to,
among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient
programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products.
At the federal level, the presidential administration&rsquo;s budget proposal for fiscal year 2019 contained further drug
price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example,
measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to
negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. While any proposed
measures will require authorization through additional legislation to become effective, Congress and the presidential
administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug
costs.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">At
the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to
control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly
using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription
drug and other health care programs.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Review
and Approval of Medicinal Products in Europe</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">In order to market any medicinal product outside
of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions
regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial
sales and distribution of medicinal products. Whether or not it obtains FDA approval for a product candidate, an applicant will
need to obtain the necessary approvals by the comparable non-U.S. regulatory authorities before it can commence clinical trials
or marketing of the product in those countries or jurisdictions. Some countries outside of the United States have a similar process
that requires the submission of a CTA much like the IND prior to the commencement of human clinical trials. In the E.U., for example,
a CTA must be submitted to the national competent authorities of the E.U. Member States where the clinical trial is conducted
and to an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a
country&rsquo;s requirements, clinical trial development may proceed.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">In April 2014, the E.U. adopted a new Clinical
Trials Regulation (EU) No 536/2014, which is set to replace the current Clinical Trials Directive 2001/20/EC. It will overhaul
the current system of approvals for clinical trials in the E.U. Specifically, the new regulation, which will be directly applicable
in all Member States (meaning that no national implementing legislation in each E.U. Member State is required), aims at simplifying
and streamlining the approval of clinical trials in the E.U. For instance, the new Clinical Trials Regulation provides for a
streamlined application procedure via a single entry point and strictly defined deadlines for the assessment of clinical trial
applications. It is expected that the new Clinical Trials Regulation will come into effect following confirmation of full functionality
of the Clinical Trials Information System, the centralized EU portal and database for clinical trials foreseen by the new Clinical
Trials regulation, through an independent audit, which is currently expected to occur in December 2021.</P>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Clinical
Trial Regulations in Italy</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
the E.U. and EU-member country legislation, any application for marketing authorization must be accompanied by the results of
clinical trials conducted in accordance with applicable regulations. A unified regulation on clinical trial procedures has been
approved (EU Reg. 536/2014), but is not yet effective. The currently applicable rule is EU Directive 2001/20, as implemented in
the various EU member countries from time to time through national laws and regulations.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are currently conducting or planning Phase I/II clinical trials on Temferon in Italy, in accordance with the specific regulations applicable
to such early-phase trials. As discussed elsewhere in this prospectus, we are currently conducting our TEM-GBM 001 study on UMGMT-GBM
patients and plan to start new ones on hepatic tumor (HCC and IHC) in the near future by means of appropriate application to the
Italian Regulatory Authority (&ldquo;AIFA&rdquo;).</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
applicable Italian regulation is the Decree of April 27, 2015 of the Ministry of Health, providing a precise sequence of approvals
for the start of Phase I studies and subsequent amendments to the related protocols. According to such Decree, an initial request
must be submitted to AIFA seeking a technical-scientific opinion of Istituto Superiore di Sanit&agrave; (ISS), acting on behalf
of AIFA, on the admissibility of the request. Upon the favorable opinion of ISS, AIFA issues an authorization to proceed with
the planned study, and the rules generally governing the conduct of clinical trials (Legislative Decree 211 of June 24, 2003,
implementing in Italy EU Directive 2001/20, Decree of December 17, 2004 of the Ministry of Health for non-profit studies, plus
procedural rules such as the Decree of December 21, 2007, so called &ldquo;CTA decree&rdquo;, for the prescribed formats), are
of application.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Based
on the AIFA approval, the Independent Ethics Committees (&ldquo;IECs&rdquo;) of the research centers participating in the trial
issue their opinions on the conduct of the study, having evaluated the study protocol and all other relevant documentation such
as the informed consent form (&ldquo;ICF&rdquo;), the insurance policy underwritten by the sponsor, the information and consent
form for data protection purposes. The IEC of the Coordinating Center issues first its opinion &ndash; the so-called <I>Parere
Unico</I>, lit. &ldquo;sole opinion&rdquo; (&ldquo;PU&rdquo;) - and then the IECs of the other participating centers accept or
refuse the PU in its entirety (they may seek amendment to the ICF on the basis of local operating circumstances).</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">All
documents pertaining to each specific step of the procedure, in the right sequence, must be loaded on the online database of Aifa
(&ldquo;Osservatorio sulle Sperimentazioni Cliniche&rdquo;, or OsSC); the OsSC system provides certain controls to make sure that
e.g. no IEC opinion can be loaded before the pertinent AIFA approval, or that the opinions of the participating sites cannot be
loaded before the PU is loaded. It may occur however that, due to calendar mismatches in the calendars of IEC meeting (usually
held on a monthly basis), an approval may precede by a few days a &ldquo;prior&rdquo; one (typically, the PU or the AIFA approval):
in such cases the IEC approval is issued under reservation (&ldquo;<I>con riserva</I>&rdquo;) and can be loaded in advance accordingly,
under the assumption that the documents subjected to evaluation - protocol (updated) version, ICF and the rest &ndash; coincide
exactly.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Marketing
Authorization Application for Biologic Medicinal Products</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">To obtain regulatory approval to commercialize
a new drug in the EEA (comprising the E.U. Member States plus Iceland, Liechtenstein and Norway, we must submit a marketing
authorization application.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">In the E.U., a marketing authorization for a
medicinal product can be obtained through a centralized, mutual recognition, decentralized procedure, or national procedure (single
country). The centralized procedure is mandatory for certain medicinal products, including orphan medicinal products, those
produced by biotechnology, advanced therapy medicinal products (gene therapy, somatic cell therapy and tissue-engineered products)
and those with a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, autoimmune
and other immune dysfunctions, viral diseases or diabetes, and is optional for certain other products, including medicinal
products with a new active substance for other indications, and products that are a significant therapeutic, scientific
or technical innovation, or whose authorization would be in the interest of public health.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in">Under the centralized procedure, the
applicant can submit a single application for marketing authorization to the EMA which will provide a positive opinion regarding
the application if it meets certain quality, safety, and efficacy requirements. Based on the opinion of the EMA, the European
Commission takes a final decision to grant a centralized marketing authorization which permits the marketing of a product throughout
the EEA. Under the centralized procedure, the maximum timeframe for the evaluation of a marketing authorization application
is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response
to questions asked by the EMA Committee for Medicinal Products for Human Use (&ldquo;CHMP&rdquo;)). Clock stops may extend
the timeframe of evaluation of a marketing authorization application considerably beyond 210 days. Where the CHMP gives a positive
opinion, it provides the opinion together with supporting documentation to the European Commission, who make the final decision
to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&rsquo;s recommendation. Accelerated assessment
might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of major public health interest,
particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of a marketing authorization application
under the accelerated assessment procedure is 150 days, excluding clock stops, but it is possible that the CHMP may revert to
the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated
assessment.</P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in">Now that the United Kingdom (which comprises
Great Britain and Northern Ireland) has left the E.U., Great Britain will no longer be covered by centralized marketing authorizations
(under the Northern Irish Protocol, centralized marketing authorizations will continue to be recognized in Northern Ireland).
All medicinal products with a current centralized marketing authorization were automatically converted to Great Britain marketing
authorizations on January, 1 2021. For a period of two years from January 1, 2021, the Medicines and Healthcare products Regulatory
Agency, or MHRA, the United Kingdom medicines regulator, may rely on a decision taken by the European Commission on the approval
of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain marketing authorization.
A separate application will, however, still be required.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in">For other countries outside of the E.U., such as the
United Kingdom and countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials,
product licensing, pricing and reimbursement vary from country to country. Internationally, clinical trials are generally required
to be conducted in accordance with cGCPs, applicable regulatory requirements of each jurisdiction and the medical ethics principles
that have their origin in the Declaration of Helsinki. If we fail to comply with applicable foreign regulatory requirements, we
may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products,
operating restrictions and criminal prosecution.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><I>Advertising, Promotion and Compliance</I></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In the E.U., the advertising and promotion of our products
will also be subject to E.U. laws and E.U. Member States&rsquo; national laws governing promotion of medicinal products, interactions
with physicians, misleading and comparative advertising and unfair commercial practices. These laws require that promotional materials
and advertising in relation to medicinal products comply with the product&rsquo;s Summary of Product Characteristics (&ldquo;SmPC&rdquo;),
as approved by the competent authorities. The SmPC is the document that provides information to physicians concerning the safe
and effective use of the medicinal product. The SmPC forms an intrinsic and integral part of the marketing authorization granted
for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label
promotion and is prohibited in the E.U. The applicable laws at the E.U. level and in the individual E.U. Member States also prohibit
the direct-to-consumer advertising of prescription-only medicinal products. Violations of the rules governing the promotion of
medicinal products in the E.U. could be penalized by administrative measures, fines and imprisonment. As the United Kingdom
medicinal products legislation is still largely based on EU legislation, the promotion of prescription-only medicines to the public
and promotion of medicinal products not in compliance with the SmPC are both also prohibited under United Kingdom law.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">During all phases of development (pre- and post-marketing),
failure to comply with applicable regulatory requirements may result in administrative or judicial sanctions. These penalties could
include the imposition of a clinical hold on trials, refusal to approve pending applications, withdrawal of an approval, warning
letters, product recalls, product seizures, total or partial suspension of production or distribution, product detention or refusal
to permit the import or export of products, injunctions, fines, civil penalties or criminal prosecution. Any agency or judicial
enforcement action could have a material adverse effect on us.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><I>Regulatory Data Protection in the EEA</I></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In the EEA, innovative medicinal products approved
on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and
an additional two years of market exclusivity pursuant to Directive 2001/83/EC. Regulation (EC) No 726/2004 repeats this entitlement
for medicinal products authorized in accordance the centralized authorization procedure. Data exclusivity prevents applicants
for authorization of generics or biosimilars of these innovative products from referencing the innovator&rsquo;s data when
applying for a generic or biosimilar marketing authorization for a period of eight years from the date on which the innovator&rsquo;s
product was first authorized in the EEA. During an additional two-year period of market exclusivity, a generic or biosimilar
marketing authorization can be submitted and authorized, and the innovator&rsquo;s data may be referenced, but no generic
or biosimilar medicinal product can be placed on the EU market until the expiration of the market exclusivity. The overall
10-year period will be extended to a maximum of 11 years if, during the first eight years of those 10 years, the marketing authorization
holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their
authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if an innovative
medicinal product gains the prescribed period of data exclusivity, another company may market another version of the product
if such company obtained a marketing authorization based on a marketing authorization application with a complete
independent data package of pharmaceutical tests, preclinical tests and clinical trials.</P>
<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Periods
of Authorization and Renewals</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">A marketing authorization
has an initial validity for five years in principle. The marketing authorization may be renewed after five years on the basis
of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the relevant Member State. To
this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the
file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted,
at least six months before the marketing authorization ceases to be valid. The European Commission or the competent authorities
of the EEA Member States may decide, on justified grounds relating to pharmacovigilance, to proceed with one further five-year
period of marketing authorization. Once subsequently definitively renewed, the marketing authorization shall be valid for an unlimited
period. Any authorization which is not followed by the actual placing of the medicinal product on the EEA market (in case
of centralized procedure) or on the market of the authorizing EEA Member State within three years after authorization ceases
to be valid (the so-called sunset clause).</FONT></P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Pediatric Studies and Exclusivity</I></FONT></P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Prior to obtaining a
marketing authorization in the EEA, applicants must demonstrate compliance with all measures included in an EMA-approved
PIP covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or
a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures
are laid down in Regulation (EC) No 1901/2006, commonly referred to as the Pediatric Regulation. This requirement also applies
when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized.
The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of
the medicine for children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may
also grant waivers when development of a medicine for children is not needed or is not appropriate, such as for diseases that
only affect an adult population. Before a marketing authorization application can be filed, or an existing marketing
authorization can be amended, the EMA must determine that a company actually complied with the agreed studies and measures
listed in each relevant PIP, unless the EMA has granted: (i) a product-specific waiver, (ii) a class waiver or (iii) a deferral
for one or more of the measures included in the PIP. If an applicant obtains a marketing authorization in all EEA Member
States, or a marketing authorization granted in the centralized procedure by the European Commission, and the study results
of the pediatric clinical trials conducted in accordance with the PIP are included in the drug product information, even
when negative, the medicine is then eligible for an additional six-month period of qualifying patent protection through extension
of the term of the Supplementary Protection Certificate. In the case of orphan medicinal products, a two year extension of
the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically
available when data in compliance with the PIP are developed and submitted.</FONT></P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><I>Regulatory Requirements after a Marketing
Authorization has been Obtained</I></FONT></P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In case an authorization
for a medicinal product in the EEA is obtained, the holder of the marketing authorization is required to comply with a
range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include:</FONT></P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Compliance
    with the EU&rsquo;s stringent pharmacovigilance or safety reporting rules must be ensured. These rules can impose post-authorization
    studies and additional monitoring obligations.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
    manufacturing of authorized medicinal products, for which a separate manufacturer&rsquo;s license is mandatory, must also
    be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive
    2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice, or EU cGMP.
    These requirements include compliance with EU cGMP standards when manufacturing medicinal products and APIs, including the
    manufacture of API outside of the EU with the intention to import the API into the EU.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
    marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed
    toward the prescribers of drugs and/or the general public, are strictly regulated in the EU notably under Directive 2001/83EC,
    as amended, and E. Member State laws. Direct-to-consumer advertising of prescription medicines is prohibited across the EU.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Brexit
and the Regulatory Framework in the United Kingdom</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">On June 23, 2016, the electorate in the United
Kingdom voted in favor of Brexit. Thereafter, on March 29, 2017, the country formally notified the EU of its intention to withdraw
pursuant to Article 50 of the Lisbon Treaty. The withdrawal of the United Kingdom from the EU took effect on January 31, 2020,
however, there was a transition period until December 31, 2020 during which EU laws, including in respect of medicinal products,
continued to be applicable in the United Kingdom. Since the regulatory framework for pharmaceutical products in the United
Kingdom covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial
sales and distribution of pharmaceutical products is derived from EU Directives and Regulations, Brexit could materially
impact the future regulatory regime which applies to drug products and the approval of product candidates in the United Kingdom,
now that the United Kingdom legislation has the potential to diverge from EU legislation. It remains to be seen how Brexit
will impact regulatory requirements for product candidates and approved drug products in the United Kingdom in the long term.
The MHRA, the United Kingdom&rsquo;s medicines and medical devices regulator, has recently published detailed guidance for industry
and organizations to follow from January 1, 2021 now the transition period is over, which will be updated as the United Kingdom&rsquo;s
regulatory position on medicinal products evolves over time.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>General
Data Protection Regulation</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
collection, use, disclosure, transfer or other processing of personal data of individuals in the EU, including personal health
data, is governed by the GDPR, which became effective on May 25, 2018. After effectiveness of GDPR, the European data protection
law background has been constantly implemented through the activity of the European Data Protection Board (EDPB) concerning the
correct interpretation and application of GDPR, as well as through the ruling of the Court of Justice of the European Union (CJEU).
The GDPR and EU Member States national data protection legislation, including Italy, are wide-ranging in scope and impose
numerous requirements on companies that process personal data, including requirements relating to processing health and other
sensitive data, obtaining consent of the individuals to whom the personal data relates, providing notice to individuals regarding
data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification
of data breaches, and taking certain measures when engaging third party processors. The GDPR also imposes strict rules on the
transfer of personal data to countries outside the EU, including the United States and now &ndash; after Brexit &ndash; the
United Kingdom, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential
fines of up to &euro;20 million or 4% of annual global revenues, whichever is greater. </FONT>Concerning the transfer of (pseudonymized)
personal data to the United States, the recent CJEU case C-3111/18, also known as Schremes II, invalidated the European Commission&rsquo;s
adequacy decision for the EU-U.S. Privacy Shield Framework, on which the majority of U.S. companies relied to conduct trans-Atlantic
trade in compliance with EU data protection rules. The decision reinforced the importance of data protection to global commerce
and imposed EU companies trading with US companies or organizations to rely the transfer of personal data on other legal basis
or appropriate safeguards provided for in the GDPR, such as Standard Contractual Clauses (SCC), Binding Corporate Rules (BCR)
or derogations for specific situations. Regarding the transfer of personal data to United Kingdom, the EU / UK agreement regulating
the transition period after Brexit (&ldquo;Statement on the end of the Brexit transition period&rdquo;) provides that, until June
2021, &ldquo;all data flows of personal data between stakeholders subject to GDPR and UK organizations will not be considered
as transfers to a third country&rdquo;, thus implying the adoption of appropriate legal basis and safeguards provided for in the
GDPR for any communication of personal data to a third party, such as Data Processing Agreement containing Standard Contractual
Clauses.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia">The GDPR also confers a private right of
action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and
obtain compensation for damages.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Compliance
with the GDPR and all relevant EU data protection rules will be a rigorous and time-intensive process that may increase
our cost of doing business.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Pricing
Decisions for Approved Drug Products</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be
marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that
compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology
assessments, in order to obtain reimbursement or pricing approval. For example, the EU provides options for the EU Member States
to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control
the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead
adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU
Member States allow companies to fix their own prices for drug products, but monitor and control prescription volumes and issue
guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required
on pharmaceuticals and these efforts could continue as countries attempt to manage health care expenditures, especially in light
of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general,
particularly with respect to prescription products, has become intense. As a result, increasingly high barriers are being erected
to the entry of new drug products. Political, economic and regulatory developments may further complicate pricing negotiations,
and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States,
and parallel trade, i.e., arbitrage between low-priced and high-priced EU Member States, can further reduce prices. There can
be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable
reimbursement and pricing arrangements for any drug products, if approved in those countries.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt; font-style: normal">Employees
and consultants</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">As of September 15, 2021, we had four
full-time employees, all located in Milan, Italy and we rely on consultants and a large number of collaborators at SR-TIGET and OSR.
Our full-time employees and consultants are engaged in clinical, research and development, product development and quality assurance
activities. We consider our relationship with our employees to be good.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt; font-style: normal">Property
and Facilities</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
corporate headquarters is located in Milan, Via Olgettina 58 within San Raffaele Hospital, Italy, where we lease approximately 51 square
meters of office space (3 offices). The lease commenced in January 2020 and has a 6-year initial term. It will expire on December 1,
2025 and may be renewed for additional 6 years. We also have an office in a co-working space located in Alexandria Center -
LaunchLabs, 430 East 29<SUP>th</SUP> Street, New York, NY. We believe that our existing facilities are adequate for our near-term
needs, and we believe that suitable additional or alternative office will be available as required in the future on commercially reasonable
terms.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt; font-style: normal">Legal
Proceedings</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">From
time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We
are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse
effect on our business and have not been notified of any claims in respect thereof, other than as set forth below:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">By letter dated February 25, 2019, Theravectys notified
the Company of the possible infringement by Genenta of Theravectys&rsquo; exclusive license to patents no. EP 1071804 (and
of the corresponding US patent US 6,682,907), EP 1224314, and EP 1222300 (and of the corresponding US patent US 7,968,332)
granted from the owner of the patents Institut Pasteur. Theravectys requested Genenta engage in discussions as to possible
contractual arrangements including the opportunity to either enter into (i) a manufacturing and supply agreement; or (ii) a non-exclusive
license for Genenta&rsquo;s use of the technologies allegedly protected under the patent(s). Each of these patents is now expired,
having each reached the end of it its patent term on April 23, 2019 for EP1071804 and October 10, 2020 for EP 1224314, and EP
1222300.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">To date, Genenta has not engaged in any such
discussions with Theravectys nor has Genenta received any further claim/request from Theravectys in relation to
the above.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="S_001"></A>MANAGEMENT</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Executive
Officers and Directors</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
following table sets forth the name, age as of the date of this prospectus, and position of the individuals who will serve as directors
and executive officers of Genenta Science S.p.A. following the Corporate Conversion in May 2021 and the closing of this offering.
The following also includes certain information regarding the individual experience, qualifications, attributes and skills of our directors
and executive officers as well as brief statements of those aspects of our directors&rsquo; backgrounds that led us to conclude that
they are qualified to serve as directors:</FONT></P>

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; font: 10pt Georgia; width: 25%; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Georgia; vertical-align: bottom; width: 7%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; font: 10pt Georgia; width: 37%; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Position</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; font: 10pt Georgia; width: 25%; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Year
    elected or appointed</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Stephen Squinto,
    Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">65</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Chairman of the Board of Directors(1)(2)</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">2021</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Pierluigi Paracchi</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">48</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Chief Executive Officer, Vice Chairman of the
    Board of Directors and General Manager *</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">2014</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Richard B. Slansky</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">64</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">2021</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Carlo Russo, M.D.</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">68</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Chief Medical Officer,
    Head of Development</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">2021</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Roger Abravanel</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">75</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Director(1)(2)</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">2017</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Daniela Bellomo,
    Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center">53</TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia">2019</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Guido Guidi</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">68</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Director(1)(2)</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">2017</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Luca Guidotti</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center">60</TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia">2018</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia">Anthony Marucci</TD>
    <TD STYLE="font: 10pt Georgia">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: center">59</TD>
    <TD STYLE="font: 10pt Georgia">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Director(1)</FONT></TD>
    <TD STYLE="font-family: Georgia">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia">2021</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Stefania Mazzoleni,
    Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">40</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Scientific Project
    Manager and Communications Officer</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia">2016</TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">*
Role of General Manager effective upon listing</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Independent
    Director (as defined under Nasdaq Stock Market rules)</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Member
    of the Compensation, Nomination and Governance Committee</FONT></TD></TR>
</TABLE>
<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
directors above were elected at the Company&rsquo;s general shareholders&rsquo; meeting held on May 20, 2021, for a three-year
term. The board of directors consists of 7 (seven) members.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
board of directors&rsquo; term will expire with the Shareholders&rsquo; Meeting called to approve the financial statements for
the year ending December 31, 2023.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Following the expiration of the above board of directors,
future members will be appointed by means of a slate voting mechanism: slates may be submitted by the shareholders representing, individually
or collectively with other shareholders joining in the submission of the slate, at least 6% of share capital eligible to vote at the
shareholders&rsquo; meeting at which directors are to be elected, such eligibility to be established by filing an appropriate certification
to that effect. The board of directors will be appointed as follows: (a) candidates for election as directors equal to the number of
seats on the board of directors minus 1 (one) will be drawn from the slate that has obtained the highest number of votes cast on the
shareholders&rsquo; meeting (the Majority Slate), based on the progressive order in which they are listed on the slate, while (b) the
first candidate listed on the slate that receives the second greatest number of votes cast (the Minority Slate) will be elected as director
so long as the Minority Slate has no connection in any way, whether directly or indirectly, with the shareholders who have submitted
or voted the Majority Slate.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Each shareholder and shareholders belonging to the same
group shall not submit, or contribute to submit, or cast their vote for more than one slate, including through a nominee. Each candidate
may only be listed on a single slate or, otherwise, will be ineligible for election if named on multiple slates.</P>


<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">For additional information concerning the slate voting
mechanism, see &ldquo;Description of Share Capital and Governing Documents&rdquo; &ndash; &ldquo;Board of Directors&rdquo;.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Management</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Pierluigi
Paracchi, Chief Executive Officer, Vice Chairman of the Board of Directors and General Manager</I></FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Mr.
Paracchi has over 15 years of combined experience as an investor and director of life science companies, including as Founder and CEO
of Quantica SGR and in senior roles at Ax&ograve;n Capital, Sofinnova Partners and AurorA Science. He was also a board member and investor
in Ethical Oncology Science, which was acquired in 2013 for a total deal of $470 million. Pierluigi Paracchi is a member of the
Assobiotec Steering Committee, the Italian Association for the development of biotechnology. He also serves on the Board of Directors
of the autoimmune disease and cancer company Altheia Science, as non-executive Chairman at medical device company Lipogems International
and is a venture partner with AurorA Science, an independent biotech investment vehicle.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Richard
B. Slansky, Chief Financial Officer</I></FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Mr.
Slansky is a senior financial executive with more than 30 years of experience as Chief Financial Officer in various biopharmaceutical,
diagnostic and life science companies, including OncoSec Medical, Biological Dynamics and GenMark Diagnostics. His experience
spans across public and private healthcare and technology companies at various stages of growth, pre-revenue to commercial. He
has been responsible for strategic vision and oversight of financial and operational teams, organizational leadership and creating
maximum stakeholder value. He also serves on the Board of Directors of several private companies, including Nuclear RNA Networks,
an early-stage RNA gene transcription therapeutics company.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Carlo
Russo, M.D., Chief Medical Officer &amp; Head of Development</I></FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">Dr. Russo has extensive experience as a biotech executive
focused on medical affairs and research and development. He has served as Head of Development of GSK&rsquo;s R&amp;D Biopharm
and Rare Disease Units and the Cardiovascular Metabolic Center. Previously, Dr. Russo served as an Executive VP and CMO of Adverum,
CMO &amp; Head of Research &amp; Development of Annapurna and President and CEO of VaxInnate Corporation, among
other senior roles. Dr Russo holds a number of senior positions at research institutions, including Cornell University Medical
College, Columbia University and Scripps Research Institute. He holds his MD and Board Certification in Hematology from the University
of Genoa Medical School and is the author of more than 70 scientific publications.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Stefania
Mazzoleni, Ph.D., Scientific Project Manager and Communications Officer</I></FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">Dr. Mazzoleni manages and oversees the scientific development of parallel immuno-gene
therapy studies in oncology indications and provides scientific support for investor interactions. Dr. Mazzoleni has more than
15 years&rsquo; experience in life science research and development, oncology and project management, including over 4
years of drug development and cell and gene therapy experience acquired while working at various academic institutions (San Raffaele
Hospital, National Institute of Molecular Genetics) and pharmaceutics (Nerviano Medical Sciences). Dr. Mazzoleni received a MSc
in Medical Biotechnology in 2005, holds a PhD in Molecular and Cellular Biology from San Raffaele Vita-Salute University,
has a second level vocational Master&rsquo;s in Pharmacy and Pharmaceutical Oncology and is a member of the European Academy of
Tumor Immunology.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Board
of Directors</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Stephen
Squinto, Ph.D., Chairman of the Board of Directors</I></FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Dr. Squinto has more than 25 years&rsquo; experience in the
biotech industry and is an Executive Partner of the healthcare investment company OrbiMed Advisors. He was previously CEO of the gene
therapy company, Passage Bio, and co-founded Alexion Pharmaceuticals, where he served as Chief Global Operations Officer and Global Head
of Research, and held several senior leadership positions at Regeneron Pharmaceuticals. Dr Squinto currently serves on the Board of Directors
of several biotech and healthcare companies and has received numerous honors and awards from academic and professional organizations
for his scientific work.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Roger
Abravanel, Director</I></FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Mr.
Abravanel worked at McKinsey &amp; Company for 34 years as a consultant for Italian and multinational corporations in Europe,
the United States and the Far East, and is now an emeritus director. He is a former board member of Luxottica, COFIDE, Teva and
Admiral, is currently Chairman of the INSEAD&rsquo;s advisory group in Italy and is the author of several best-selling business
books.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Daniela
Bellomo, Ph.D., Director</I></FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Dr.
Bellomo is Head of Business Development at San Raffaele Hospital, where she oversees technology transfer, development and value
generation of  research in biotech, medical technology and digital health. Dr. Bellomo is a board member of San Raffaele&rsquo;s
spin off Genespire and has previously been on the boards of Parco Tecnologico Padano and BiovelocITA, as well as an advisor to
several life science start-ups, venture capital and incubators in the biotech and medical technology field.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Guido Guidi,
Director</I></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Mr. Guidi has 35 years of experience in top global roles in
large pharmaceuticals companies, managing up to 7,000 employees and a turnover of more than &euro;7 billion. He was previously Head of
Pharma EU at Novartis, Head of Oncology at Novartis EU, overseeing major products including Cosentyx, Entresto, Lucentis, Gilenya, Xolair,
Ultibro, Seebri, Galvus and Exforge.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Luca Guidotti,
MD, PhD., Director</I></FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Dr.
Guidotti is an experimental pathologist renowned internationally in the field of viral hepatitis. Dr. Guidotti spent more than
20 years as a Faculty of the Scripps Research Institute in La Jolla, California and he currently serves as Deputy Scientific Director
of San Raffaele Hospital, Milan. He has published works in prestigious scientific journals including Cell, Nature, Science, Nature
Medicine, Journal of Clinical Investigation and Journal of Experimental Medicine.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Georgia; margin: 0pt 0; text-align: left"><B>Anthony Marucci, Director</B></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in">Mr. Marucci is a seasoned life sciences
and public company leader who has raised $1.7 billion in capital in multiple organizations over his 30 years&rsquo; experience.
He is currently President and CEO of Celldex Therapeutics, the company he co-founded in 2004 and which develops targeted therapeutics,
including immunotherapies and other targeted biologics. Prior to founding Celldex, he was Treasurer at Medarex, from which Celldex
was spun out, and he holds an MBA from Columbia University and a MHL from Brown University. </P>

<P STYLE="font: 12pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Executive
Scientific Board</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Luigi
Naldini, M.D., Ph.D., Chairman of the Executive Scientific Board</I></FONT></P>

<P STYLE="font: bold 12pt Georgia; text-indent: 0.5in; margin: 0 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Professor
Naldini is a deeply experienced scientist and academic, considered by many to be the father of lentiviral gene therapy. Dr. Naldini
is Professor of Cell and Tissue Biology and Cell and Gene Therapy at the Vita-Salute San Raffaele University School of Medicine
in Milan, and Director of the San Raffaele-Telethon Institute for Gene Therapy and of the Division of Regenerative Medicine, Stem
Cells &amp; Gene Therapy at the San Raffaele Scientific Institute. He has previously served as President of the European Society
of Gene and Cell Therapy and a member of the Board of Directors and Advisory Council of the American Society of Gene and Cell
Therapy. Dr. Naldini is also a scientific advisor on EMEA and WHO committees for the evaluation of novel gene transfer medicines
and has authored more than 250 scientific publications.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Bernhard
Gentner, M.D., Member of the Executive Scientific Board</I></FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Dr.
Gentner is a physician scientist, serving as Group Leader of the Translational Stem Cell and Leukemia Research Unit at the San
Raffaele-Telethon Institute for Gene Therapy in Milan and Staff Hematologist in the Hematology and Bone Marrow Transplantation
Unit of San Raffaele Hospital. Dr. Gentner completed his MD studies at the University of Heidelberg, Germany, the MD Anderson
Cancer Center and Baylor College of Medicine, Houston, USA. He completed his internal medicine training at Erlangen University
Hospital, Germany and his hematology training at San Raffaele Vita-Salute University and has authored more than 30 scientific
publications.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><B>Strategic Advisors</B></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Advisors to the Company include:</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Gaurav Shah, M.D.: co-founder of Rocket Pharma (NASDAQ:
    RCKT) and serves as its Chief Executive Officer and Corporate Board Member. Prior to this role Dr. Shah was a Global Program Head
    in the Cell &amp; Gene Therapies Unit at Novartis, where he had strategic oversight of 12 functions and helped spearhead pivotal
    trials with CART-19 for patients with leukemia and lymphoma.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Brad Loncar: Founder and Chief Executive Officer at Loncar
    Investments. Mr. Loncar is a biotech investor, index provider, and creator of two Nasdaq-listed exchange traded funds. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Alexander Ross: Distinguished Visiting Professor at The University
    of Bologna Business School and a Board Partner at Amplo, a global venture capital firm. He is the author of New York Times&ndash;bestselling
    <I>The Industries of the Future</I> and Former Senior Advisor for Innovation to the US Secretary of State (2009-2013).</FONT><FONT STYLE="font: 10pt Georgia, Times, Serif">
    </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Family
Relationships</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">There
are no family relationships among our executive officers and directors.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Arrangements
Concerning Election of Directors and Members of Management</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">There
are no arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our directors
or members of senior management were selected as such.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Compensation</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
following table presents in the aggregate all compensation we paid to all of our directors and senior management as a group for
the year ended December 31, 2020. The table does not include any amounts we paid to reimburse any of such persons for costs incurred
in providing us with services during this period. We are not required to provide the compensation, on an individual basis, of
our executive officers and directors under Italian law. As a matter of Italian law, the compensation of directors is established
at the time of their appointment or by the shareholders&rsquo; meeting. The compensation of the managing directors shall be established
by the board of directors, with the opinion of the board of statutory auditors. Our bylaws provides that the shareholders&rsquo;
meeting may determine a total amount for the compensation of the directors, including managing directors.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">All
amounts reported in the table below reflect the cost to the Company, in thousands of Euros, for the year ended December 31, 2020.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: center"><P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Salary,
                                         Bonuses</B></FONT></P> <P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P> <P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>and
                                         Related</B></FONT></P> <P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P> <P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Benefits</B></FONT></P></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: center"><P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Pension,</B></FONT></P> <P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P> <P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Retirement</B></FONT></P> <P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P> <P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>and
                                         Other</B></FONT></P> <P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P> <P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Similar</B></FONT></P> <P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P> <P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Benefits</B></FONT></P></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: center"><P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Share</B></FONT></P> <P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P> <P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Based</B></FONT></P> <P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P> <P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Compensation</B></FONT></P></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 49%; text-align: left"><FONT STYLE="font-family: Georgia">All directors and senior management
    as a group, consisting of 9 persons</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left">&euro;</TD><TD STYLE="font-family: Georgia; width: 13%; text-align: right"><FONT STYLE="font-family: Georgia">617,904</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left">&euro;</TD><TD STYLE="font-family: Georgia; width: 13%; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 13%; text-align: right"><FONT STYLE="font-family: Georgia">460,194&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Differences
between Italian Laws and Nasdaq Requirements</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Sarbanes-Oxley Act, as well as related rules subsequently implemented by the SEC, requires foreign private issuers, such as us,
to comply with various corporate governance practices. In addition, following the listing of the ADSs on Nasdaq, we will be required
to comply with the Nasdaq Stock Market Rules. Under those rules, we may elect to follow certain corporate governance practices
permitted under Italian law in lieu of compliance with corresponding corporate governance requirements otherwise imposed by the
Nasdaq Stock Market Rules for U.S. domestic registrants.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
accordance with Italian law and practice and subject to the exemption set forth in Rule 5615 of the Nasdaq Stock Market Rules,
as a foreign private issuer, we have elected to rely on home country governance requirements and certain exemptions thereunder
rather than the Nasdaq Stock Market Rules, with respect to the following requirements:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font-family: Georgia; width: 0.25in"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Composition
    of the board of directors</I>. Italian law does not require that the majority of our board of directors consist of independent
    directors. Our board of directors therefore may include fewer independent directors than would be required if we were subject
    to Nasdaq Listing Rule 5605(b)(1). In addition, we will not be subject to Nasdaq Listing Rule 5605(b)(2), which requires that
    independent directors must regularly have scheduled meetings at which only independent directors are present.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif"><FONT STYLE="font-size: 10pt">Quorum.
                                         In accordance with Italian law quorum requirements generally applicable to general meetings
                                         of shareholders are set forth in the Italian Civil Code (see &ldquo;Description of
                                         Share Capital and Governing Documents&rdquo;&mdash;&ldquo;Meeting of shareholders&rdquo;)
                                         therefore our bylaws may not provide a specific regulation of them. Our practice
                                         thus varies from the requirement of Nasdaq Listing Rule 5620(c), which requires an issuer
                                         to provide in its bylaws for a generally applicable quorum, and that such quorum may
                                         not be less than one-third of the outstanding voting stock.</FONT></P></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">According
    to Italian law, the management report and the annual financial statements shall be communicated to Company&rsquo;s auditor
    and to the board of statutory auditors at least 30 days prior to the general meeting of shareholders convened for its approval.
    The board of statutory auditors must report to the shareholders&rsquo; meeting on the results of the financial year and on
    the activities carried out in the performance of its duties, and make observations and proposals regarding the financial statements
    and their approval. The financial statements, together with the reports of the directors, statutory auditors and Company&rsquo;s
    auditors, must remain deposited at the Company&rsquo;s registered office for the 15 days preceding the shareholders&rsquo;
    meeting called to approve them.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Proxy
    Solicitations</I>. Under Italian law shareholders may appoint attorneys-in-fact by delivering in writing appropriate power
    of attorney to represent them in an ordinary or extraordinary shareholders&rsquo; meeting of the Company. Our directors,
    auditors and employees may not be proxies. Italian law does not have a specific regulatory regime for the solicitation of
    proxies in private companies; thus our practice will vary from the requirement of Nasdaq Listing Rule 5620(b), which sets
    forth certain requirements regarding the solicitation of proxies.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Share
    Issuances</I>. Pursuant to Italian law, prior to this offering, we will opt out of shareholder approval requirements by way of including
    authorized and conditional share capital (see &ldquo;Description of Share Capital and Governing Documents&mdash;General &mdash;Authorization
    of shares&rdquo;) for the issuance of securities in connection with certain events such as the acquisition of stock, assets or
    convertible notes, certain private placements and/or public offering. To this extent, our practice varies from the requirements
    of Nasdaq Listing Rule 5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in
    connection with such events.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Audit Committee</I>.
    US companies listed on Nasdaq are required to have an audit committee that satisfies the requirements of Rule 10A-3 under
    the Exchange Act and certain additional requirements set by the Nasdaq. In particular, all members of this committee must
    be independent and the committee must adopt a written charter. The committee&rsquo;s prescribed responsibilities include (i)
    the appointment, compensation, retention and oversight of the external auditors; (ii) establishing procedures for handling
    &ldquo;whistle blower&rdquo; complaints regarding accounting, internal accounting controls, or auditing matters; (iii) engaging
    independent counsel and other advisers, as it determines necessary to carry out its duties and (iv) determine appropriate
    funding for payments to the external auditor, advisors employed by the audit committee and other necessary administrative
    expenses of the audit committee. A company must also have an internal audit function, which may be outsourced, except to the
    independent auditor. We follow the &ldquo;traditional&rdquo; model of corporate governance for Italian companies and accordingly
    have established  a board of statutory auditors established
    in accordance with Italian law which performs substantially the same functions, (see &ldquo;Description of Share Capital and
    Governing Documents&rdquo; &ndash; Statutory auditors&rdquo;) and is accordingly exempt from the audit committee requirements
    established by Rule 10A-3 and Nasdaq rules. The Company&rsquo;s reliance on such exemption is based on the circumstance that
    the Company&rsquo;s board of statutory auditors meets the following requirements set forth in Exchange Act Rule 10A-3(c)(3):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.75in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    board of statutory auditors is established and selected pursuant to Italian law expressly permitting such a board;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    board of statutory auditors is required under Italian law to be separate from the Company&rsquo;s board of directors;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    board of statutory auditors is not elected by management of the Company and no executive officer of the Company is a member
    of the board of statutory auditors;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Italian
    law provides for standards for the independence of the board of statutory auditors from the Company and its management;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    board of statutory auditors, in accordance with applicable Italian law and the Company&rsquo;s governing documents, is responsible,
    to the extent permitted by Italian law, for the appointment, retention and oversight of the work (including, to the extent
    permitted by law, the resolution of disagreements between management and the auditor regarding financial reporting) of any
    registered public accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit,
    review or attest services for the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
reliance on Rule 10A-3(c)(3) does not, in our opinion, materially adversely affect the ability of its board of statutory auditors
to act independently and to satisfy the other requirements of Rule 10A-3.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Compensation, Nomination and Governance Committee</I>. Italian law does not require the appointment of a Compensation, Nomination and Governance Committee as required by the Nasdaq Listing Rules. As a matter of Italian law applicable to Italian stock corporations whose shares are not listed on a regulated market in the European Union and under our bylaws, the compensation of executive directors, including the CEO, is determined by the board of directors, after consultation with the board of statutory auditors, while the Company&rsquo;s shareholders, according to Italian law and our bylaws, may determine a total amount for the compensation of the directors, including managing directors. Compensation of the Company&rsquo;s executive officers is determined by board of directors or by the CEO, if duly empowered. Nevertheless, although not required under Italian law, the Company intend to establish a Compensation, Nomination and Governance Committee.</FONT></P>
                                                     <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Georgia">&nbsp;</FONT></P></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Code of Business</I>.
    Conduct and Ethics. Pursuant to Italian law, prior to this offering, we will adopt an &ldquo;Organization and Operational
    Model&rdquo; as required by Italian Legislative Decree of June 8, 2001, No. 231 (relating to administrative responsibility)
    that we expect will consist of: (i) a Code of Etichs; (ii) operating procedures and reporting systems applicable to all of
    our directors, officers and employees, which may not comply with the requirements of Nasdaq Listing Rule 5610.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Committees
of the Board of Directors</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
currently follow the historical Italian corporate governance system, with a board of directors (<I>consiglio di amministrazione</I>)
and a separate board of statutory auditors (<I>collegio sindacale</I>) with supervisory functions. The two boards are separate
and no individual may be a member of both corporate bodies. Both the members of the board of directors and the members of the
board of statutory auditors owe duties of loyalty and care to the Company.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Statutory
Auditors</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">During 2020, the Company&rsquo;s statutory auditors received
approximately &euro;35,000 in compensation in the aggregate for their services to the Company.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">At the Company&rsquo;s annual general shareholders&rsquo;
meeting held on May 20, 2021, the following individuals were elected or re-appointed to the Company&rsquo;s board of statutory
auditors for a three-year term. The board consists of three members, one of which is the chairman, and two alternates. The board of statutory
auditors&rsquo; term will therefore expire with the Shareholders&rsquo; Meeting called to approve the financial statements for the year
ending December 31, 2023.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Georgia; text-align: center; width: 22%; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Georgia; vertical-align: bottom; width: 6%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Georgia; text-align: center; width: 41%; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Position</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Georgia; text-align: center; width: 25%; vertical-align: bottom"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>Year
    elected or re-appointed</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Carlo-Alberto Nicchio</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">46</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Chairman of the Board
    of Statutory Auditors</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia">2021</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Cesare Lazzaroni</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">70</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Statutory auditor</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia">2021</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Jacopo Doveri</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">48</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Statutory auditor</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia">2021</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Lorenzo Gianluigi Grossi</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">55</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Alternate auditor</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia">2021</TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Alessandro Arpiani</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center">37</TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Alternate auditor</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia">2021</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Following the expiration of the above board of statutory
auditors, future members will be appointed by means of a slate voting mechanism: slates may be submitted by the shareholders representing,
individually or collectively with other shareholders joining in the submission of the slate, at least 6% of share capital eligible to
vote at the shareholders&rsquo; meeting at which auditors are to be elected, such eligibility to be established by filing an appropriate certification
to that effect. According to the Company&rsquo;s bylaws, the board of statutory auditors will be appointed as follows: (a) candidates
for election as auditors equal to two statutory auditors and one alternate auditor will be drawn from the slate that has obtained the
highest number of votes on the shareholders meeting (the Majority Slate), based on the progressive order in which they are listed, while
(b) the remaining statutory auditor (who will act as President of the board of statutory auditors) and alternate auditor will be drawn
from the slate that has obtained the second greatest number of votes cast (the Minority Slate) so long as the Minority Slate has no connection
in any way, whether directly or indirectly, with the shareholders who have submitted or voted the Majority Slate.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt; color: windowtext">Each
shareholder and shareholders belonging to the same group shall not submit, or contribute to submit, or to cast their
vote for more than one slate, including through a nominee.</FONT> <FONT STYLE="font-family: Georgia; font-size: 10pt">
</FONT><FONT STYLE="font: 10pt Georgia"><FONT STYLE="color: windowtext">Each candidate may only be listed on single slate
or, otherwise, will be ineligible for election </FONT></FONT>if named in multiple slates.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"><FONT STYLE="color: windowtext"> </FONT></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">For additional information concerning the slate voting
mechanism, see &ldquo;Description of Share Capital and Governing Documents&rdquo; &ndash; &ldquo;Board of Statutory auditors&rdquo;.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company relies on an exemption from the Rule 10A-3 requirements provided by Rule 10A-3(c)(3) of the Exchange Act for foreign private
issuers with a board of statutory auditors established in accordance with local law or listing requirements and subject to independence
requirements under local law or listing requirements. See &ldquo;&mdash; <I>Differences between Italian Laws and Nasdaq Requirements</I>&rdquo;
for more information.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Additional
Board Committees</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Although Italian law does not require that we adopt a Compensation,
Nomination and Governance Committee, in connection with the Corporate Conversion, we have established a Compensation, Nomination
and Governance Committee according to Nasdaq Listing Rule 5615(a)(3). The members of our compensation, nomination and governance committee
include Stephen Squinto, Roger Abravanel and Guido Guidi. The compensation, nomination and governance committee will assist our board
of directors in overseeing our cash compensation and equity award recommendations for our executive officers along with the rationale
for such recommendations, as well as summary information regarding the aggregate compensation provided to our executive officers.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><B><I>Equity Incentive Plan</I></B></P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><I>2021 &ndash; 2025 Equity Incentive Plan</I></P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">On May 20, 2021, our shareholders meeting approved
a capital increase to allow for issuance of up to 2,700,000 ordinary shares to the service of a four-year employees&rsquo;
share option plan (the &ldquo;2021-2025 Equity Incentive Plan&rdquo;) to be adopted by the board of directors. The purpose of
the 2021-2025 Equity Incentive Plan is to motivate and reward performance of our employees, directors, non-employee directors
and consultants, and in the best interests of the Company and our shareholders.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">On May 20, 2021 our board of directors approved the
specific terms (e.g., regulation) of our 2021 &ndash; 2025 Equity Incentive Plan which will become effective upon the effectiveness
of the registration statement of which this prospectus is part. Under Italian law, we do not need to obtain the approval of the specific
terms of our equity incentive plans by our shareholders. Except where the context indicates otherwise, reference hereunder to our ordinary
shares shall be deemed to include a number of ADSs equal to the number of ordinary shares.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Plan
Administration. </I>Our 2021 &ndash; 2025 Equity Incentive Plan is administered by our board of directors in consultation with
the Compensation, Nomination and Governance Committee, unless and until the board delegates administration to this latter.
The board of directors has the authority to take all actions and make all determinations under the 2021 &ndash; 2025 Equity Incentive
Plan, to interpret the 2021 &ndash; 2025 Equity Incentive Plan and award agreements and to adopt, amend and repeal rules for
the administration of the 2021 &ndash; 2025 Equity Incentive Plan as it deems advisable, subject to certain limitations imposed
under the 2021 &ndash; 2025 Equity Incentive Plan, and other applicable laws and stock exchange rules.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Eligible
Participants</I>. The board of directors jointly with the Compensation, Nomination and Governance Committee will be able to offer
equity awards at its discretion under the 2021 &ndash; 2025 Equity Incentive Plan to:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">any employees
    of us or any of our subsidiaries;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">any
    </FONT><FONT STYLE="font: 10pt Georgia">non-employee directors serving on our board of directors;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">any consultants
    to us or any of our subsidiaries (the &ldquo;Eligible Participants&rdquo;).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><I>Grant of Awards; Shares Available for Awards.</I> The 2021
&ndash; 2025 Equity Incentive Plan provides for the grant of options to purchase up to a maximum of 2.7 million ordinary
shares (<I>i.e.</I> approximately 10% of the issued share capital of the Company upon this offering on a fully diluted basis)
in the future upon written exercise notice. This number is subject to adjustment in the event of a split-up, share dividend or other
change in our capitalization. If any award expires, is cancelled, or is terminated, unexercised or is forfeited, the number of shares
subject thereto is again available for grant under the 2021 &ndash; 2025 Equity Incentive Plan.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
number of stock options to be granted to executives and directors cannot be determined at this time as the grant of stock options
and/or restricted shares is dependent upon various factors such as hiring requirements and job performance.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><I>Terms of exercise &ndash; Stock Options</I>.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">Options may be granted to selected Eligible
Participants (the &ldquo;Optionee&rdquo;) on such terms and conditions as the board of directors may determine; provided,
however, that the exercise price of an option may not be less than the fair market value of a Company share as of the grant date
as determined by the board of directors, or the Compensation, Nomination and Governance Committee, in its reasonable discretion
and the term of the option my not exceed three years from the grant date.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Vesting</I>.
The vesting conditions for stock options granted under the 2021 &ndash; 2025 Equity Incentive Plan are set forth in the applicable
award documentation.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Termination
of Service and Change in Control</I>. In the event of termination of an Optionee&rsquo;s employment or service without
cause or an Optionee&rsquo;s resignation for just cause (as defined in the 2021 &ndash; 2025 Equity Incentive Plan) following
a change in control of the company (as defined in the 2021 &ndash; 2025 Equity Incentive Plan), any awards outstanding to the
Optionee (unless otherwise provided in the award agreement) will immediately vest, and options will become fully exercisable
during the twelve (12) months following the Change in Control of the Company, or until the date of expiration of the applicable option, if earlier. In the event of a change in control
that involves a merger, acquisition or other corporate transaction, any outstanding award not assumed, substituted, replaced or continued
in connection with the transaction will immediately vest, and options will become fully exercisable and upon the effectiveness
of such corporate transaction, the 2021 &ndash; 2025 Equity Incentive Plan and all awards will automatically terminate.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Amendment
and Termination</I>. Within the limitation of the 2021 &ndash; 2025 Equity Incentive Plan, the board of directors or
the Compensation, Nomination and Governance Committee may amend, suspend or terminate the 2021 &ndash; 2025 Equity Incentive
Plan, at any time and for any reason. The suspension or termination of the 2021 &ndash; 2025 Equity Incentive Plan, or any
amendment thereof, shall not affect any option previously granted under the <FONT STYLE="letter-spacing: 0.05pt">2021 &ndash; 2025</FONT>
Equity Incentive Plan. No option shall be granted under the <FONT STYLE="letter-spacing: 0.05pt">2021 &ndash; 2025 </FONT>Equity Incentive
Plan after its suspension or termination. An amendment of the 2021 &ndash; 2025 Equity Incentive Plan shall be subject to the approval
of the Company&rsquo;s shareholders only to the extent required by </FONT><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">applicable
laws or regulations.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><I>Right to amend options</I>. The board of directors at
any time, and from time to time, may amend the terms of any one or more options; provided, however, that the rights under any option
shall not be impaired by any such amendment unless (i) the Company requests the consent of the optionee and (ii) the optionee consents
in writing.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>2021-
2025 Chairman Sub-Plan </I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
2021 &ndash; 2025 Chairman Sub-Plan allows for the grant of options to our chairman of the board of directors, Mr. Squinto. In particular,
Mr. Squinto is entitled to receive options to subscribe: (i) no. 147,783 shares at a price equal to &euro;6.38 each upon listing; and
(ii) no. 73,892 shares at a price equal to &euro;6.38 each, during the year starting from the first anniversary of the listing.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Except
for the above,</FONT><FONT STYLE="font: 10pt Georgia"> the 2021 &ndash; 2025 Chairman Sub-Plan provides for identical terms and
conditions under our 2021 &ndash; 2025 Equity Incentive Plan.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Accelerated
Vesting of Existing Options Represented by Class B Quotas</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">The following table summarizes, as of the date of this
prospectus, previously outstanding options subject to accelerated vesting upon the occurrence of a liquidity event. Prior
to the consummation of the Corporation Conversion all such options were converted into Quota B and then subsequently
converted into our ordinary shares.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 80%">
<TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="text-align: center; font-family: Georgia; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia; font-size: 8pt">Name</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">Class
    B quotas<BR> Underlying Options<BR> Awarded</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">Exercise
    Price<BR> (&euro;/Share)</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 60%"><FONT STYLE="font-family: Georgia">Roger Abravanel<SUP></SUP></FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 16%; text-align: right"><FONT STYLE="font-family: Georgia">82</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 16%; text-align: center">1</TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">Guido Guidi<SUP></SUP></FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">82</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: center">1</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">Luca Guidotti<SUP></SUP></FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">82</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: center">1</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Carlo Russo</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">300</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: center">1</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right">546</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: center">1</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="S_002"></A>BENEFICIAL
OWNERSHIP OF PRINCIPAL SHAREHOLDERS AND MANAGEMENT</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
following table sets forth information regarding beneficial ownership of our ordinary shares as of December 12, 2021 by:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">each
    person, or group of affiliated persons, known to us to be the beneficial owner of more than 5% of our outstanding ordinary
    shares;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">each
    of our directors and executive officers; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">all
    of our directors and executive officers as a group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC, and includes voting or investment power with respect to ordinary shares.
Percentage of shares beneficially owned before this offering is based on 15,000,000 shares outstanding on December 12, 2021. The
number of ordinary shares deemed outstanding after this offering includes the ordinary shares being offered for sale in this offering
but assumes no exercise by the representative of the underwriters of the over-allotment option.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Except
as indicated in footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with
respect to all shares shown to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise
noted below, each beneficial owner&rsquo;s address is: c/o Genenta Science S.p.A., Via Olgettina no. 58, 20132 Milan, Italy.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font: 12pt Georgia, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 12pt Georgia, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 8pt Georgia, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>No. of Shares</B></FONT></P> <P STYLE="font: 8pt Georgia, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Beneficially</B></FONT></P> <P STYLE="font: 8pt Georgia, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Owned</B></FONT></P> <P STYLE="font: 8pt Georgia, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Prior to this</B></FONT></P> <P STYLE="font: 8pt Georgia, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Offering</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; font: 12pt Georgia, Times, Serif">&nbsp;</TD><TD STYLE="font: 12pt Georgia, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 12pt Georgia, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 8pt Georgia, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percentage</B></FONT></P> <P STYLE="font: 8pt Georgia, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Owned</B></FONT></P> <P STYLE="font: 8pt Georgia, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Before this</B></FONT></P> <P STYLE="font: 8pt Georgia, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Offering<SUP>(1)</SUP></B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; font: 12pt Georgia, Times, Serif">&nbsp;</TD><TD STYLE="font: 12pt Georgia, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 12pt Georgia, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 8pt Georgia, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percentage</B>&nbsp;</FONT></P> <P STYLE="font: 8pt Georgia, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Owned</B></FONT></P> <P STYLE="font: 8pt Georgia, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>After this</B>&nbsp;</FONT></P> <P STYLE="font: 8pt Georgia, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Offering<SUP>(3)</SUP></B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; font: 12pt Georgia, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia, Times, Serif; font-weight: bold; text-align: left">Directors and executive officers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">Stephen Squinto</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 42%; font-family: Georgia, Times, Serif; text-align: left">Pierluigi Paracchi</TD><TD STYLE="width: 2%; font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-family: Georgia, Times, Serif; text-align: right">2,275,516</TD><TD STYLE="width: 1%; font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-family: Georgia, Times, Serif; text-align: right">15.17</TD><TD STYLE="width: 1%; font-family: Georgia, Times, Serif; text-align: left">%</TD><TD STYLE="width: 2%; font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-family: Georgia, Times, Serif; text-align: right">12.56</TD><TD STYLE="width: 5%; font-family: Georgia, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">Roger Abravanel</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">73,729</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">*&nbsp;</FONT></TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%<SUP>(4)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">Daniela Bellomo</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">16,357</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">*&nbsp;</FONT></TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">Guido Guidi</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">61,553</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">*&nbsp;</FONT></TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">Luca Guidotti</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">49,469</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">*&nbsp;</FONT></TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">Anthony Marucci</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">Richard B. Slansky</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">19,947</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">*&nbsp;</FONT></TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia, Times, Serif">Carlo-Russo</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">598,417</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">3.99</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">3.30</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">Luigi Naldini</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">1,386,145</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">9.24</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">7.65</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">Bernard Gentner</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">692,871</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">4.62</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">3.82</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia, Times, Serif; font-style: italic; text-align: left">All directors and executive officers as a group (11 persons)</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">5,174,004</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">34.49</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">28.57</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia, Times, Serif">5% Shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">Ospedale San Raffaele</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">1,896,730</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">12.64</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">10.47</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia, Times, Serif"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Spafid<SUP>(2)</SUP></FONT></TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">3,404,688</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">22.70</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD><TD STYLE="font-family: Georgia, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Georgia, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: right">18.79</TD><TD STYLE="font-family: Georgia, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">* Less than
1%.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt; width: 2in"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><SUB>(1)</SUB></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The percentages shown are based
    on 15,000,000 ordinary shares issued and outstanding as of December 12, 2021.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in; text-align: left"><FONT STYLE="font-family: georgia; font-size: 10pt"><SUB>(2)</SUB></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><P STYLE="font: 10pt Georgia, Times, Serif; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0">Spafid
                                            is a public limited liability company established under the laws of Italy, having its registered
                                            office at Via Filodrammatici no. 10, 20121 Milan, Italy, and having its principal place of
                                            business at Foro Buonaparte no. 10, 20121 Milan, Italy, registered under number 00717010151,
                                            that acts pursuant to Italian Law 23 November 1939 no. 1966 on &ldquo;fiduciary Activity&rdquo;.
                                            Spafid is indicated as Owner Entity because identified as formal owner of the shares. As
                                            Fiduciary Company, according to Italian Rules, Spafid operates on behalf of Beneficial Owner
                                            of Fiduciary Mandate. Shares of Spafid are wholly owned by Mediobanca &ndash; Banca di Credito
                                            Finanziario S.p.A., a leading Italian investment bank. In such a capacity of Fiduciary
                                            company, Spafid owns no. 3,404,688 ordinary shares of the Company on behalf of no.
                                            43 beneficial owners (&ldquo;fiducianti&rdquo;).</P>
</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: left">(3)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">The percentages shown are based on 18,120,114 securities issued and outstanding
    after this offering.</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: left">(4)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Includes 2,450 ordinary shares that Mr. Abravanel intends to purchase in the Reserved
    Offering.</TD></TR>
</TABLE>


<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: georgia; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left">Although the shares of the Company owned by Spafid represent 22.70%
of the Company&rsquo;s share capital: (i) the average shareholding owned through Spafid in the Company&rsquo;s share capital by each
beneficial owner is equal to 0.53%; while (ii) the maximum shareholding owned through Spafid in the Company&rsquo;s share capital by
a single beneficial owner is equal to 2.30%. Spafid exercises - and will exercise - the relevant voting rights in the shareholders&rsquo;
meeting of the Company according to voting instructions provided for by each beneficial owner.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Record
Holders</FONT></P>

<P STYLE="text-indent: 0.5in; font: italic bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
of December 12, 2021, there was a total of 68 holders of record of our ordinary shares, none of which had, to the best of our
knowledge, a registered address in the United States.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are not controlled by another corporation, by any foreign government or by any natural or legal persons except as set forth herein,
and there are no arrangements known to us which would result in a change in control of the Company at a subsequent date.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="S_003"></A>RELATED
PARTY TRANSACTIONS</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Agreements
with OSR</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We have a longstanding relationship with OSR. Dr. Guidotti,
a member of our Board of Directors, currently serves as Deputy Scientific Director of OSR. On June 4, 2015, we entered into a
service agreement with OSR to provide certain services (accounting/bookkeeping and rent of spaces, the latter with an addendum
effective from January 1, 2016) free of charge. Beginning in January 2020, we engaged a third-party provider to perform these
services. We determined that the value of these services provided in 2019 and in prior years were not material to our financial
statements. Beginning January 1, 2020, we entered into a six-year lease agreement for the use of office space in the OSR building.
We paid OSR annual rent of &euro;13,400 in 2020 with a security deposit of &euro;3,350.</P>
<P STYLE="font: 10pt Georgia; text-indent: 0.5in; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We entered into a license agreement with
OSR effective December 15, 2014, pursuant to which OSR granted us an exclusive, royalty-bearing, non-transferable,
worldwide license, subject to certain retained rights, to certain patents, patent applications and existing know-how in
exchange for certain ongoing payment obligations. See &ldquo;Business &mdash; Collaboration/Licensing.&rdquo; In February 2021, we entered into a Sponsored Research
Agreement (&ldquo;SRA&rdquo;) with OSR to conduct certain research projects related to Temferon. The total
consideration to be paid by the Company under the SRA will be &euro;1.0 million with payments scheduled quarterly during 2021
and 2022.</P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Employment,
Consulting and Services Agreements</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Dr. Russo is currently a party to a Service Agreement
dated July 2017 through an affiliated company, XDG BioMed LLC, which, as amended, provides for fixed annual fees of &euro;300,000 gross
and a discretionary annual variable gross remuneration up to a minimum amount of &euro;50,000, tax included. We entered into consulting
agreements in October 2015 and April 2016 with Prof. Naldini and Dr. Gentner, which, as amended, provided for gross annual fees of &euro;50,000
and &euro;30,000, respectively. These agreements renew automatically each year.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We entered into a directorship
agreement with Mr. Paracchi in December 2019, which provides for a gross annual salary of &euro;250,000 and a discretionary
&euro;50,000 gross performance bonus payment to be approved by the Board of Directors. Such agreement will be terminated by
the parties for mutual consent upon signature of the below employment agreement.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Proposed
New Employment Agreements</I></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We intend to enter into new employment agreements with each
of Mr. Paracchi, Dr. Russo and Mr. Slansky effective upon the consummation of this offering, and in the case of Mr. Slansky, the earlier
of the consummation of this offering or November 1, 2021, whichever is earlier. The forms of such proposed employment agreements have
been filed as exhibits to the registration statement of which this prospectus forms a part. Pursuant to such proposed employment agreements,
Mr. Paracchi, Dr. Russo and Mr. Slansky are entitled to gross annual base salaries of &euro;420,000, $500,000 and $300,000, respectively,
which is subject to annual review by and at the sole discretion of the Compensation, Nomination and Governance Committee of our board
of directors. Mr. Paracchi is also eligible to receive an annual cash bonus of up to 20% of base salary, and Dr. Russo
and Mr. Slansky are eligible to receive an annual cash bonus of up to 30% of base salary, provided that such individual
achieves performance targets determined by the Compensation, Nomination and Governance Committee of the board of directors.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">The proposed employment agreements of Dr. Russo and
Mr. Slansky, are governed by US Law and include the following terms and conditions, among others:</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-indent: 0.5in"><P STYLE="font: 12pt Georgia, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font: 10pt Georgia, Times, Serif"><I>(a)</I></FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Georgia, Times, Serif">each proposed
    employment agreement has a term commencing on the date of consummation of this offering and continuing until terminated (i) upon
    death of the employee, (ii) upon disability, (iii) for cause or good reason, (iv) without cause, or (v) voluntarily. The employment
    agreement also contains, among other things, the following material provisions: (i) reimbursement for all reasonable travel and other
    out-of-pocket expenses incurred in connection with such individual&rsquo;s employment; (ii) paid vacation leave; (iii) health benefits;
    and (iv) a severance payment equal to twelve (12) months of base salary and a prorated portion of the applicable cash bonus upon
    termination by such individual for just cause or by the Company without cause (each as defined in the relevant agreement), with restrictive
    covenants applicable for a corresponding period after termination.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-left: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Georgia, Times, Serif"><I>(b)</I></FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">in the event
    such individual is terminated three months prior to or one year after a Change of Control (as defined in the agreement)
    by the Company for any reason other than cause or by such individual for good reason, then the executive shall be entitled to receive
    a cash payment equal to a multiple of such individual&rsquo;s then-current annual base salary determined by the time elapsed
    since the commencement of the agreement (in the case of Dr. Russo) or two times such salary (in the case of Mr. Slansky). Such
    payment shall be in lieu of the severance payment described above.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">The proposed employment agreement of Mr. Paracchi is governed
by Italian Law and include the following terms and conditions, among others:</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-indent: 0.5in">

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><I>(a)</I></FONT></TD>
    <TD><P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0pt">the duties of general manager (<I>direttore generale</I>)
    with direct report to the Board of Directors of the Company;</P>
    <P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><I>(b)</I></FONT></TD>
    <TD><P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0pt">reimbursement of reasonable expenses incurred in
    the performance of work duties, health benefits and, subject to the approval of the board of directors, a grant of an equity award
    under an equity incentive plan to be adopted after the offering;</P>
    <P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><I>(c)</I></FONT></TD>
    <TD STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">in
    case of Change of Control (as defined in the relevant agreement), in the event of termination not for &ldquo;cause&rdquo; by the
    Company or of resignation for &ldquo;cause&rdquo; by the executive (such terms as understood in accordance with &nbsp;Article 2119
    of the Italian Civil Code), the executive shall be entitled to receive a cash payment equal to three&nbsp;times such individual&rsquo;s
    then-current annual base salary (such indemnity will replace any indemnity provided for by the applicable National Collective Labour
    Agreement in case of termination);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><I>(d)</I></FONT></TD>
    <TD><P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0pt">non-competition and non-solicitation obligations
    of the executive for a 12 months period after the termination of the employment in consideration for compensation equal to 12 months
    after termination at the executive&rsquo;s then-current monthly base salary for each obligation;</P>
    <P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0pt">Such agreement has a term commencing on the date
    of consummation of this offering and continuing until terminated, among other things, (a) upon death of the executive, (b) for just
    cause, (c) with objective or subjective reason, (d) by resignation of the executive, or (e) voluntarily by mutual agreement between
    the parties.</P>
    <P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0pt"><I>Proposed New Consultancy Agreements</I></P>
    <P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">Each of Messrs. Squinto and Marucci have entered
    into consultancy agreements in connection with their appointment to the board of directors in order to support the development and
    growth of the Company. The agreements provide for gross compensations of $25,000 (Mr. Squinto) and $11,875 (Mr. Marucci) per quarter
    (pro rated for partial quarters). The consultant will be fully and solely responsible for the payment of all tax and/or social security
    charges and will not be entitled to expenses reimbursement. These agreements have a term of three years, but are subject to termination
    at the option of either party by written notice given at least 15 days prior to each anniversary of the date of effectiveness of
    the agreement).</P>
    <P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; margin: 0pt; font: 10pt Georgia, Times, Serif">In addition, Messrs. Alexander Ross, Brad Loncar and
Gaurav Shah have entered into consultancy agreements for the activity of support the development and the growth of the Company in the
US market. All agreements provide for a gross compensation of USD 30,000 for the 12-months&rsquo; period of duration of the agreements
and a specific no-conflict clause towards the Company.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><B><I>Indemnification Agreements&nbsp;</I></B></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">On or before the time of effectiveness of this registration
statement, an indemnification agreement with our directors and executive officers will be&nbsp;entered into. The indemnification agreement
requires us to indemnify our directors and executive officers to the fullest extent permitted by law, save for a limited number of instances,
including when (i) officers and directors&rsquo; acts or omissions constituted willful misconduct or gross negligence, (ii) officers
and directors did not act in good faith, for a purpose which they reasonably believed to be in, or not opposed to, the best interests
of the Company and (iii) officers and directors are held liable towards the Company.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Insofar as indemnification of liabilities arising under
the Securities Act may be permitted to executive officers and board members or persons controlling us pursuant to the foregoing provisions,
we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act
and is therefore unenforceable</P>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Issuances
of Share Capital</I></B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Since
our founding, we have obtained equity financing in an aggregate amount of approximately &euro;33.6 million in four separate rounds
based on the credentials and reputation of our founders and management team and our relationship with SR-TIGET, OSR, and Telethon Institute
for Gene Therapy.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">Upon its organization in July 2014, the
Company was capitalized with &euro;11,650 through the issuance of the following quotas:</P>

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 80%">
<TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="text-align: center; font-family: Georgia; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia; font-size: 8pt">Name</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">Quotas
    (&euro;)</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">Aggregate
    Purchase Price<BR> (&euro;)</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 60%; text-align: left"><FONT STYLE="font-family: Georgia">Ospedale San Raffaele</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 16%; text-align: right"><FONT STYLE="font-family: Georgia">4,754.37</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 16%; text-align: right"><FONT STYLE="font-family: Georgia">1,500</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Pierluigi Paracchi</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">5,703.84</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">10,000</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Luigi Naldini</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">794.53</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">100</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Bernhard Gentner</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">397.26</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">50</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
quotas held by Mr. Paracchi and OSR, on the one hand, and by Prof. Naldini and Dr. Gentner, on the other
hand, were converted into class A and B quotas, respectively, in connection with our first round of equity
financing approved by shareholders on December 23, 2014 (which resolution has been subsequently amended and restated), as follows:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>issuance of a maximum of &euro;6,237.50 of class B quotas to Prof. Naldini and Dr.
    Gentner, directors, employees and other individuals in recognition of their contributions to the Company&rsquo;s
    growth; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>issuance of   class C quotas (including class C quotas issuable upon conversion of
    convertible notes) for an aggregate amount equal to &euro;10.0 million.</TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">The class C quotas were offered on the basis of
a pre-money valuation of the Company of &euro;20.0 million with assistance from Banca Esperia, the formerly
Private Bank of Mediobanca, and purchased by accredited investors, including entrepreneurs, managers, and
family offices, including affiliates of the Ferrari family, which controls FIS Holding, one of the leading
manufacturers of pharmaceuticals in Europe, and an early investor in Advanced Accelerator Application (NASDAQ: AAAP)
(&ldquo;AAAP&rdquo;), a biotech company later acquired by Novartis (NYSE: NVS) for $3.9 billion.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In connection with the class C quota offering,
Roger Abravanel (former McKinsey &amp; Company director and board member of TEVA) joined the Company&rsquo;s board of directors.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">On June 27, 2017, our shareholders approved the
issuance of  class D quotas for an aggregate amount equal to &euro;7.0 million on the basis of a pre-money
valuation of the Company of &euro;45.0 million. The class D quotas were purchased by Italian, British, and
Swiss private investors, family offices, and angel investors, including FIDIM S.r.l., the holding company for
the Rovati family, former owner of Rottapharm, which was acquired in 2014 by Meda/Mylan for $2.2 billion)
(&ldquo;FIDIM&rdquo;), some other early investors in AAAP, and Mr. Giuseppe Vita, former Chairman of
Schering-Plough.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In connection with the class D quota offering, Guido Guidi,
then Head of Novartis in Europe joined the Company&rsquo;s board of directors. During his tenure as Head of Novartis&rsquo; Oncology
Europe division, Mr. Guidi led the development and launch of a number of highly successful products, such as Cosentyx, Entresto, Lucentis,
Gilenya, Xolair, Ultibro, Seebri, Galvus, Exforge, Zometa, Femara and Glivec. At that time, Kenneth C. Anderson, Kraft Family Professor
of Medicine at Harvard Medical School,  President Elect of the American Society of Hematology, and Director of the Lebow Institute
for Myeloma Therapeutics and the Jerome Lipper Myeloma Center at DanaFaber Cancer Institute, joined the Company&rsquo;s Scientific Advisory
Board.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In August 2019, our shareholders approved the
issuance of  class E quotas for an aggregate amount equal &euro;17.1 million, subscribed for &euro;15.1 million,
on the basis of a pre-money valuation of the Company of &euro;70.0 million. The lead investor in the class E
quota offering was Qianzhan Investment Management, a Shanghai based private company active in private equity and
venture capital investments, and FIDIM. Qianzhan was an early investor in Tencent Music (NASDAQ: TME) and in
pharmaceutical and biotech companies in China and in the U.S.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">In July 2020, our shareholders approved
the issuance of an additional of class E quotas for an aggregate amount equal to &euro; 1.5 million  on the
basis of a pre-money valuation of the Company of &euro;90.0 million. The lead investor was GM
Investimenti, a private company controlled by Giuseppe Miroglio, former CEO and current Chairman of Miroglio
Group.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
tables below set forth the aggregate number of class B and D quotas issued and subscribed by related parties
as part of the offerings described above. No related parties purchased class C or E quotas.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 80%">
<TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="text-align: center; font-family: Georgia; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia; font-size: 8pt">Name</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">Class
    B Quotas (&euro;)</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">Aggregate
    Purchase Price<BR> (&euro;)</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 60%; text-align: left"><FONT STYLE="font-family: Georgia">Luigi Naldini</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 16%; text-align: right"><FONT STYLE="font-family: Georgia">2,795</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 16%; text-align: right"><FONT STYLE="font-family: Georgia">2,795</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Bernhard Gentner</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">1,396.5</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">1,396.5</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Carlo Russo</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">1,200</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">1,200</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Roger Abravanel</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">74</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">74</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Guido Guidi</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">55</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">55</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Luca Guidotti</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">42</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">42</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Stefania Mazzoleni</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">30</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">30</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 80%">
<TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="text-align: center; font-family: Georgia; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia; font-size: 8pt">Name</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">Class
    D Quotas (&euro;)</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">Aggregate
    Purchase Price<BR> (&euro;)</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 60%; text-align: left"><FONT STYLE="font-family: Georgia">Roger Abravanel</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 16%; text-align: right"><FONT STYLE="font-family: Georgia">28.81</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 16%; text-align: right"><FONT STYLE="font-family: Georgia">50,000</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Guido Guidi</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">17.29</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">30,000</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="S_004"></A>DESCRIPTION
OF SHARE CAPITAL AND GOVERNING DOCUMENTS</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">The following description summarizes important terms of our
capital stock and certain provisions of our articles of association and by-laws, each of which will be in effect upon the closing of
this offering. Copies of these documents will be filed with the SEC as exhibits to our registration statement, of which this prospectus
forms a part. The description of our capital stock reflects the completion of the Corporate Conversion that occurred in May 2021.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">As of the date of filing of this prospectus our authorized
capital stock is equal to Euro 50,000 represented by 15,000,000 ordinary shares with no par value.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">No preference shares are designated, issued or outstanding.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
following is a summary of certain information concerning our ordinary shares and bylaws (<I>Statuto</I>), as well as Italian law
provisions applicable to companies like ours whose shares are not listed in a &ldquo;regulated market&rdquo; within the European
Union, as in effect at the date of this prospectus. The summary contains such information as we consider material regarding the
ordinary shares but does not purport to be complete and is qualified in its entirety by reference to our bylaws or Italian law,
as the case may be.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
Italian law, most of the procedures regulating our Company, including certain rights of shareholders, are contained in our bylaws.
Amendments to our bylaws must be approved at an extraordinary meeting of shareholders, as described below.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Authorization
of shares</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Our shareholders may authorize the issuance of additional
shares at any time at an extraordinary shareholders&rsquo; meeting. However, the newly issued shares may not be purchased before all
the outstanding shares (i.e., the shares already subscribed) are entirely paid for. Moreover, although Italian law generally provides
shareholders with preemptive rights when new shares are issued for cash, it is possible, in certain case, for general meeting to exclude
or limit preemptive rights. Such an exclusion of preemptive rights must be illustrated by the directors with a specific report which
sets out the reasons for the exclusion or limitation of the pre-emptive right, or, if the exclusion derives from a contribution in kind,
the reasons for such contribution in kind, and in any case the criteria adopted for determining the issue price. On May 20, 2021, our shareholders approved or delegated our board of directors to approve &mdash; several capital increases. In particular, the shareholders&rsquo; meeting unanimously resolved, <I>inter alia</I></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font-family: Georgia; vertical-align: top">
    <TD STYLE="font-family: Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">t<FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">o
                                            increase the share capital against payment in one or more instalments on a divisible basis,
                                            with the exclusion of the pre-emptive rights under Article 2441, paragraph 5, of Italian
                                            Civil Code, up to a maximum amount of &euro; 115 million (including share premium), with allocation
                                            to capital of &euro; 0.10 per share, by issuance of a maximum of 11.5 million new ordinary shares
                                            with no par value and with regular dividend entitlement, to the service of our initial public
                                            offering, granting authority to the board of directors to implement the proposed capital
                                            increase in one or more tranches, in the amounts quoted above, within the time limit of December
                                            31, 2021, of which a maximum number of 10 million ordinary shares against a countervalue
                                            of &euro; 100 million (including share premium), shall be issued to the service of the initial
                                            public offering; while a maximum number of 1.5 million ordinary shares (subject to the maximum
                                            limit of 15% of the number of shares actually used to the service of our initial public offering)
                                            against a countervalue of &euro; 15 million (including share premium), shall be issued to the
                                            service of potential exercise of the over-allotment option (greenshoe);</FONT></P></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: top">
    <TD STYLE="font-family: Georgia; text-align: left">&nbsp;</TD>
    <TD STYLE="font-family: Georgia; text-align: left">&#9679;</TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><P STYLE="margin: 0">to grant to the board of directors the
                                            authority to approve the issuance of a maximum number of 0.5 million warrants to be granted
                                            free of charge to the Underwriters and to increase the share capital, on a divisible
                                            basis, to the service of warrants exercised by the Underwriters, by maximum par values of
                                            &euro;5,000,000 (including share premium), with allocation to capital of &euro;0.10 per share,
                                            by issuance of a further maximum number of 500,000 ordinary shares (subject to the maximum
                                            limit of 4% of the ADSs to service our initial public offering as well as criteria set forth
                                            in agreements executed by the Company in relation to our initial public offering), all represented
                                            by ADSs, to be issued by no later than December 31, 2021, <FONT STYLE="font-family: Georgia, Times, Serif">being
                                            it specified that, if such increase is not fully subscribed within that time limit, the increase
                                            shall remain valid within the limits of the subscriptions collected; being it further specified
                                            that such capital increase shall be implemented, pursuant to the warrants regulation, by
                                            the board of directors duly authorized to set the issue price and the portions to be allocated
                                            to capital and to share premium; and</FONT></P>

</TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: top">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&#9679;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">to grant to the board
                                            of directors the authority, in accordance with Article 2443 of Italian Civil Code, to further
                                            increase the share capital against payment, in one or more instalments on a divisible basis,
                                            up to a maximum amount of &euro;300,000,000 (including share premium), by issuance of
                                            a maximum number of 30,000,000&nbsp;new ordinary shares with no par value and with regular
                                            dividend entitlement, also with the exclusion of pre-emptive rights or free of charge, in
                                            accordance with Article 2441, paragraphs 4, 5 and 8, of Italian Civil Code for a five-year
                                            period, also in support of third-party grants of participating interests and/or industrial
                                            and intellectual property rights and similar intangible assets (such as patents, marks and
                                            know-how) which can be granted and held by the board of directors itself in accordance to
                                            the scope of the corporate purpose, in addition to the authority, pursuant to Article 2420-<I>ter
                                            </I>of Italian Civil Code, to issue convertible debentures in one or more instalments, convertible
                                            into ordinary shares, within the same aggregate maximum amount of &euro;300,000,000 (including
                                            share premium), with consequent capital increase to the service of the conversion, also with
                                            the exclusion of pre-emptive rights in accordance with Article 2441, paragraphs 4, 5 and
                                            8 of Italian Civil Code, likewise for a period of five years.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Form
and transfer of shares</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
ordinary shares are not represented by share certificates (<I>certificati azionari) as they are dematerialised (azioni</I><I>
 dematerializzate</I>). The ownership of the shares, their transfer, the related rights and restrictions on the shares (if any)
results from the electronical register managed by an intermediary (banks and other financial institutions). The entitlement to
exercise the rights attached to the shares is then proven by the exhibition of certifications or communications to the issuer
made by the intermediary, pursuant to its own accounting records, in favor of the subject entitled to the right.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">There
are no limitations on the right to own or vote our ordinary shares, which applies to non-Italian residents and foreign residents
except for Golden Power&rsquo;s rules and Antitrust rule (see Section &ldquo;Notification of Acquisition of Shares&rdquo;). There
are no provisions in our articles of association or bylaws that would have the effect of delaying, deferring or preventing a change
of control of our Company and that would operate only with respect to a merger, acquisition or corporate restructuring involving
our Company. There are no provisions in our bylaws governing the ownership threshold which shareholder ownership must be disclosed.
There are no provisions discriminating against any existing or prospective holder of our ordinary shares as a result of such shareholder
owning a substantial number of our shares. There are no sinking fund provisions or provisions providing for liability for further
capital calls by our Company.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Dividend
rights</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
payment of any annual dividend must be proposed by our board of directors to the shareholders and is subject to the approval of
our shareholders at the annual ordinary shareholders&rsquo; meeting. Before dividends may be paid out of our unconsolidated net
income in any year, we must allocate an amount equal to 5% of the Italian GAAP net income to our legal reserve until such reserve
is at least equal to 20% of our corporate capital. If a loss in our corporate capital occurs, we may not pay dividends until the
capital is reconstituted or reduced by the amount of such losses. We may pay dividends out of available retained earnings from
prior years, provided that after such payment, we will have a legal reserve at least equal to the legally required minimum of
20% of the corporate capital. We may not approve or pay dividends until this minimum (i.e., 20% of the capital) is met. If the
minimum is met, the board of directors could propose the issuance of a dividend to the shareholders and the shareholders&rsquo;
resolution might approve that issuance. The shareholders&rsquo; resolution will specify the manner and the date for dividend payment.
Any dividends which shareholders do not collect within five years of the date on which they become payable will be forfeited by
those shareholders and come back to us. The board of directors may not approve interim dividends at times between our annual ordinary
shareholders&rsquo; meetings.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Governance
</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
Nasdaq rules, the Company is permitted, as a listed foreign private issuer, to adhere to the corporate governance rules of our
home country in lieu of certain Nasdaq corporate governance rules.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Corporate
governance rules for Italian corporations (<I>societ&agrave; per azioni</I>) like the Company provide that the Company can be managed
by a board of directors (<I>consiglio di amministrazione</I>) and a separate board of statutory auditors (<I>collegio sindacale</I>)
with supervisory functions concerning the compliance of the by-laws and Italian laws. The two boards are separate and no individual may
be a member of both boards. Both the members of the board of directors and the members of the board of statutory auditors owe duties
of loyalty and care to the Company. As required by Italian law, an external auditing firm (<I>societ&agrave; di revisione</I>) is in
charge of auditing the Company&rsquo;s financial statements. The members of the Company&rsquo;s board of directors and board of statutory
auditors, as well as the external auditor, are directly and separately appointed by shareholders&rsquo; resolution at the shareholders&rsquo;
meetings.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Board
of directors</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
board of director consists of seven members (see &ldquo;Management&rdquo; for additional information). Our board of
directors is elected at an ordinary shareholders&rsquo; meeting for the period established at the time of election but in any case, for
no longer than three fiscal years. Our directors, who may but are not required to be shareholders, may be reappointed for successive
terms.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Following the expiration of the term of directors currently
in office, future members of the board of directors will be elected by means of a slate voting mechanism. Slates may be submitted by
shareholders representing, individually or collectively with other shareholders joining in the submission of the slate, at least 6% of
the share capital eligible to vote at the shareholders&rsquo; meeting at which directors are to be elected, such eligibility to be established
by filing with the Company a certification to that effect. The board of directors shall be elected as follows: (a) candidates for election
as directors equal to the total number of seats on the board of directors minus one shall be drawn from the slate that has obtained the
highest number of votes cast at the shareholders meeting (the Majority Slate), in the order in which their name is listed on the Majority
Slate, (b) the first candidate listed on the slate that receives the second greatest number of votes cast (the Minority Slate) shall
be elected as director so long as none of the shareholders joining in the submission of the Minority Slate has any connection whatsoever,
whether directly or indirectly, with the shareholders who have submitted or voted the Majority Slate.</P>


<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Each shareholder and shareholders belonging to the same
group shall not submit, or join in submitting, or cast their vote for more than one slate, including through a nominee or agent. Each
candidate for election as director may only be listed on single slate and will be ineligible for election if named on multiple slates.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In the event that the Majority Slate does not contain a
sufficient number of candidates to fill the number of vacancies on the board of directors to be filled as provided under clause (a) above,
all candidates listed in the Majority Slate shall be elected as directors and the remaining directors shall be elected from the Minority
Slate according to the order in which they are listed in such slate. The voting procedure according to slates described above shall be
applicable only in case of election of the entire board of directors at the same shareholders&rsquo; meeting. In the event of a tie between
slates, a new vote shall be taken and the candidates obtaining the largest number of votes shall be elected without regard to the slate
on which they are listed or application of the slate voting mechanism. Should a single slate be submitted, the shareholders eligible
to vote at the meeting shall cast their vote on such slate and, so long as more votes are cast for such slate than votes cast against
such slate, all the members of the board of directors shall be elected from that slate in accordance with applicable law at the time.
If no slates are submitted, or a single slate is submitted and such slate does not obtain the requisite number of votes, or the number
of directors to be elected on the basis of the slates submitted is less than the full number of directors to be elected, or the entire
board of directors is not to be elected at the same shareholders&rsquo; meeting, or in case it is otherwise not possible for any reason
to elect the board of directors in accordance with the provisions set out in our by-laws, the members of the board of directors shall
be elected at the shareholders&rsquo; meeting in accordance with generally applicable procedures and required majorities under applicable
law, without application of the slate voting mechanism.</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
board of directors has all ordinary and extraordinary powers to manage our affairs as it deems advisable for the achievement of
our corporate purposes, except for the actions reserved, by applicable law or the bylaws, to a vote of the shareholders at an
ordinary or extraordinary shareholders&rsquo; meeting.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
we cannot repay our creditors, and a court determines that our directors did not perform their duties regarding the preservation
of our assets, the court may find our directors liable to our creditors. However, the judgement on the director&rsquo;s diligence
in carrying out his or her mandate should never cover the management choices or the manner and circumstances of such choices,
even if the same entail significant economic risks, but should cover only the diligence shown by the director in appreciating
in advance the risk margins connected with the transaction to be undertaken, and therefore, the possible omission of those precautions,
assessments and information normally required for a decision of that type, implemented in those circumstances and with those methods.
Directors are liable to the company&rsquo;s creditors when their improper management conduct impairs the company&rsquo;s assets
in such a way that the same may not be sufficient to satisfy creditors&rsquo; claims.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">If a chairman (<I>presidente</I>) has not already been
elected by the shareholders, the board of directors must appoint one. The board of directors may appoint a vice-chairman. The chairman
of the board of directors is the legal representative of the Company. Our board of directors may delegate certain powers to one or more
managing directors (<I>amministratori delegati</I>), determine the nature and scope of the powers delegated to each such managing director
and revoke such delegation at any time. Any managing director shall report to the board of directors and the board of statutory auditors
at least every 180 days on the Company&rsquo;s business and the principal business carried out by the Company or by its subsidiaries.
Our board of directors may also appoint one or more general managers (<I>direttori generali</I>) who must report directly to the board
and may delegate authority for specific matters or categories of matters to employees of the Company or persons unaffiliated with the
Company. The general managers may be employees, and the board of directors may delegate certain powers to general managers that the board
has not already delegated to managing directors or an executive committee, subject to the following limitations: under Italian law, the
board of directors may not delegate to officers or employees of the Company certain responsibilities, including the preparation and approval
of draft financial statements, the approval of merger and de-merger plans to be presented to shareholders&rsquo; meetings, increases
in the amount of our share capital or the issuance of convertible debentures (if any of such powers has been delegated to our board of
directors by our shareholders at an extraordinary shareholders&rsquo; meeting).</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">The board of directors may establish one or more committees
with advisory, deliberative or oversight functions in accordance with applicable laws and regulations in whatsoever applicable jurisdiction,
as well as with codes of conduct and corporate governance best practices. If one or more committees are established, their composition,
powers and operation shall be as determined by the board of directors.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
Italian law, the members of the board of directors must perform the duties imposed on them by law and company&rsquo;s bylaws with
the degree of diligence that is required by the nature of their office and pursuant to their specific level of competence.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Meetings of our board of directors are called with
no less than four days&rsquo; notice or, in case of urgency, at least one day&rsquo;s notice given by registered letter
or e-mail sent by the chairman, the deputy chairman or a managing director. Statutory auditors are normally required to attend meetings
of the board of directors, but if a meeting has been duly called, the board of directors may validly take action at the meeting
even if the board of statutory auditors does not participate. If the meeting has not been duly called, the meeting is nevertheless
validly constituted if all of the directors in office and all of the statutory auditors are in attendance.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Meetings
of our board of directors may be held in person, or by audio-conference or video-conference, in Italy and in any member state of the
European Union or the United States. The quorum for meetings of our board of directors is a majority of the directors in office.
Resolutions are adopted by the vote of the majority of the directors in attendance at a meeting at which a quorum is met.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">Our directors are not subject to the non-compete obligations provided by Italian
law. As a result, our directors may (i) be equity holders in competing companies, including entities where they have unlimited liability,
(ii) exercise in person or on behalf of third parties activities in competition with that of the Company, and (iii) be elected as directors
of, or act as general managers (<I>direttori generali</I>) in, competing companies.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia">Under
Italian law, directors having any interest in a proposed transaction must disclose their interest to the board of directors and
to the board of statutory auditors, even if such interest is not in conflict with the Company&rsquo;s interest in the same transaction.
The interested director is not required to abstain from voting on the resolution approving the transaction, but the resolution
must state explicitly the reasons for, and the benefit to us of, the approved transaction. If these provisions are not complied
with, or if the transaction would not have been approved without the vote of the interested director, the resolution may be challenged
by a director or by our board of statutory auditors if the approved transaction may be prejudicial to us. A director having any
interest in a proposed transaction that he or she has authority to approve must solicit prior board approval of such transaction.
The interested director may be held liable for damages to us resulting from a resolution adopted in breach of the above rules.
Finally, directors may be held liable for damages to us if they illicitly profit from insider information or corporate opportunities.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
board of directors may transfer the Company&rsquo;s registered office within Italy, set up and eliminate secondary offices and, if the
company&rsquo;s bylaws (as in our case) so provide, approve mergers by absorption into the Company of any subsidiary in which the Company
holds at least 90% of the issued share capital. Our board of directors may also approve the issuance of shares or convertible debentures
and reductions of the Company&rsquo;s share capital in the case of withdrawal of a shareholder if so authorized by the Company&rsquo;s
extraordinary shareholders&rsquo; meeting.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left">

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Under Italian law, directors may be removed from office at
any time by the vote of shareholders at any shareholders&rsquo; meeting. Whilst the removal is immediately effective within the
company, it is effective <I>vis-&agrave;-vis</I> third parties only upon entry of the relevant resolution in the companies register.
The resolution of the shareholders&rsquo; meeting in favor of a liability suit against a director and the occurrence of causes of ineligibility
constitute just cause for removal. If the removal of a director occurs without just cause, such director may have a claim
for damages against us. These damages may include, but are not limited to, compensation that would otherwise have been paid to the director
for the remainder of his or her term and damage to his or her reputation. Directors may resign at any time by written notice to the
board of directors and to the chairman of the board of statutory auditors. The board of directors must appoint substitute
directors to fill vacancies arising from the removal or resignation of any director, subject to the approval of the board
of statutory auditors, to serve until the next shareholders&rsquo; meeting. If, at any time, more than half of the members of
our board of directors appointed by the shareholders&rsquo; meeting of the Company resign, such resignation is ineffective until the
majority of the new board of directors has been appointed. In such a case, the remaining members of the board of directors (or the board
of statutory auditors if all members of the board of directors have resigned or cease to be directors) must promptly call a
shareholders&rsquo; meeting to elect new directors.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Our Compensation, Nomination and Governance Committee will
recommend the compensation of our directors to the board of directors, which in turn will make recommendations to our shareholders.
Under Italian law, our shareholders determine the compensation of our directors relating to basic board service, such as annual fees
for serving on the board and/or fees for attending board meetings. The board of directors, after consultation with the
board of statutory auditors, may determine the remuneration of directors that serve on the various board committees and/or perform management
or other special services for the Company, such as managing directors and general directors. Our directors are entitled
to reimbursement for expenses incurred in connection with their service as directors, such as travel expenses to attend board
meetings.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Statutory
auditors</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
board of statutory auditors (<I>Collegio Sindacale</I>) is elected by the shareholders and must be comprised of individuals qualified
to act in such capacity under Italian law. Statutory auditors are elected for a term of three fiscal years, they may be re-elected for
successive terms and may be removed only for cause and with the approval of a competent court. Each member of the board of statutory
auditors must provide evidence that such individual is qualified to act in such capacity under Italian law and meets certain professional
standards.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
Italian law, at least one standing statutory auditor and one substitute statutory auditor must be chosen among persons registered
with the Register of Auditors established with the Italian Ministry of Justice. The other statutory auditors shall be chosen among those
registered with any register established by decree of the Ministry of Justice or among University professors in economics or law, if
they are not registered with the Register of Auditors. The following persons may not serve as statutory auditors:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">a
    person legally incapacitated, bankrupt, or disqualified from holding public or an executive office under Italian law;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    spouse, parent or relative-in-law of a director of the company or an affiliate of the company; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">a person</FONT><FONT STYLE="font: 10pt Georgia">
    whose independence may be impaired due to an employment or consulting relationship or any other economic relationship with the company
    or an affiliate of the company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
bylaws currently provides that the board of statutory auditors shall consist of three standing statutory auditors and two alternate
auditors (who will automatically replace a statutory auditor who resigns or is otherwise unable to serve).</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Following the expiration of the members of the board of
statutory auditors currently in office, future members will be elected by means of a slate voting mechanism: slates may be submitted
by shareholders representing, individually or collectively with other shareholders joining in the submission of the slate, at least 6%
of share capital eligible to vote at the shareholders&rsquo; meeting at which auditors are to be elected, such eligibility to be established
by filing with the Company an appropriate certification to that effect. The slates of candidates shall be split into two sections, one
for candidates for the position of statutory auditor and one for candidates for the position of alternate auditor. According to the Company&rsquo;s
bylaws, the board of statutory auditors will be elected as follows: (a) two statutory auditors and one alternate auditor shall be drawn
from the slate that has obtained the highest number of votes on the shareholders meeting (the Majority Slate), in the order in which
their name is listed in the Majority Slate, and(b) the remaining statutory auditor (who will act as President of the board of statutory
auditors) and alternate auditor shall be drawn from the slate that receives the second greatest number of votes cast (the Minority Slate)
so long as none of the shareholders joining in the submission of the Minority Slate has any connection whatsoever, whether directly or
indirectly, with the shareholders who have submitted or voted the Majority Slate.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">Each shareholder and shareholders belonging to the same group shall not submit,
or contribute join in submitting, or cast their vote for more than one slate, including through a nominee or agent. Each candidate for
election as statutory auditor or alternate auditor may only be listed on single slate and will be ineligible for election if named on
multiple slates.</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In the event that the Majority Slate does not contain a
sufficient number of candidates to fill the number of vacancies on the board of statutory auditors to be filled as provided under paragraph
(a) above, all candidates listed in the Majority Slate shall be elected statutory auditors and the remaining statutory auditors shall
be drawn from the Minority Slate according to the order in which they are listed in such slate. The voting procedure according to slates
provided above shall be applicable only in case of election of the entire board of statutory auditors. In the event of a tie between
slates, a new vote shall be taken and the candidates obtaining the largest number of votes shall be elected without regard to the slate
on which they are listed or application of the slate voting mechanism. Should a single slate be submitted, the shareholders eligible
to vote at the meeting shall cast their vote on such slate and, so long as more votes are cast for such slate than votes cast against
such slate, all the members of the board of statutory auditors shall be elected from that slate in accordance with applicable law at
the time. If no slates are submitted, or a single slate is submitted and such slate does not obtain the requisite number of votes, or
the number of statutory auditors to be elected on the basis of the slates submitted is less than the full number of statutory auditors
to be elected, or the board of statutory auditors is not to be entirely elected, or it is otherwise not possible for any reason to elect
the board of statutory auditors in accordance with the provisions of this title, the members of the board of statutory auditors shall
be elected at the shareholders&rsquo; meeting in accordance with generally applicable procedures and required majorities under applicable
law, without application of the slate voting mechanism.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">In the event of the resignation or removal termination of a member of the board
of statutory auditors who was drawn from the Majority Slate or from the Minority Slate, as the case may be, alternate statutory auditors
drawn from the same slate shall fill the vacancy, with older alternates being seated before younger alternates, subject to compliance
with the requirements of our bylaws regarding the composition of the board of statutory auditors</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
board of statutory auditors is required, among other things, to verify that we:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">comply
    with applicable laws and our bylaws;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">respect
    principles of good governance; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">maintain
    adequate organizational structure, internal controls and administrative and accounting system.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
board of statutory auditors is required to meet at least once every ninety days and is expected to attend meetings of our board of directors
and our shareholders. In case a statutory auditor, without just cause, does not attend the shareholders&rsquo; meetings or does not attend
two consecutive meetings of the board of directors or of the board of statutory auditors during the same fiscal year, such statutory
auditor shall automatically be removed from office. Our statutory auditors may decide to call a shareholders&rsquo; meeting, ask
for information about our management from our directors, carry out inspections and verifications at our offices and exchange information
with our external auditors. Any shareholder may submit a complaint to our board of statutory auditors regarding facts that the shareholder
believes should be investigated and if shareholders collectively representing 5% of our corporate capital, or 2% of the corporate capital
should our company be classified as an Open Company (as defined in Section &ldquo;Applicable Laws&rdquo;), submit such
a complaint, our board of statutory auditors must promptly undertake an investigation and present its findings and any recommendations
to a shareholders&rsquo; meeting (which must be convened immediately if the complaint appears to have a reasonable basis and there is
an urgent need to take action). Our board of statutory auditors may report serious breaches of directors&rsquo; duties to a competent
court which then may take such actions as inspecting the company&rsquo;s operations, removing directors, appointing temporary administrators
to manage the company or any other actions that the court feels is necessary to preserve the value of our company for our creditors and
shareholders.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>External
auditor</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">Mayer Hoffman McCann, P.C. remains the PCAOB-registered,
independent registered public accounting firm for the purposes of all of our filings in the United States; however, <FONT STYLE="font-family: Georgia; font-size: 10pt">Italian
law requires us to appoint an external auditor or a firm of external auditors (<I>revisore legale dei conti</I>), each of them qualified
to act in such capacity under Italian law, to verify during the fiscal year that our accounting records are correctly kept and accurately
reflect our activities, and to audit our financial statements for statutory filings.This is separate and apart from the work of Mayer
Hoffman McCann, P.C. The Italian external auditor&rsquo;s opinion on the financial statements must be published in Italy.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Italian external auditor is appointed for a three-year term by the vote of our shareholders at an ordinary shareholders&rsquo;
meeting. Once appointed, the shareholders may remove the auditors only for cause and with the approval of the board of statutory auditors
and of a competent court. Following removal, the Company and the external auditor or auditing firm must timely inform the Italian Ministry
of Economics and Finance, explaining the reasons justifying the removal. In case we are considered an Open Company, such communication
must be notified also to Consob.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">On May 20, 2021, our shareholders appointed Kreston GV Italy
&ndash; Audit S.r.l., subject to the effective listing of the Company on the Nasdaq Capital Market, as our Italian external auditors
for three-year term expiring at the time of the annual shareholders meeting to approve the financial statement for the financial year
ending on December 31, 2023.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Meetings
of shareholders</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Shareholders
are entitled to attend and vote at ordinary and extraordinary shareholders&rsquo; meetings. Votes may be cast personally or by proxy.
Shareholders&rsquo; meetings may be called by the board of directors (or by the board of statutory auditors) and must be
called if requested by holders of at least 10% of the outstanding shares. Shareholders are not entitled to request that a meeting of
shareholders be convened to vote on issues which as a matter of law fall within the authority of the board of directors. If the
shareholders&rsquo; meeting is not called despite a shareholders&rsquo; request and such refusal is unjustified, a competent court
may call the meeting.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
may hold meetings of shareholders at our registered office, or elsewhere within Italy and any member state of the European Union or in the
United States. Our bylaws provides that </FONT><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">shareholders&rsquo;
meetings, both ordinary and extraordinary, shall be called by notice published in the Italian daily newspaper &ldquo;Il Sole 24
Ore&rdquo; at least 15 days prior to the date of the meeting or otherwise given by our Company, provided that so long as the Company
is allowed by applicable Italian law, by sending, either in the alternative or in addition to the foregoing published notice, a
notice to the shareholders, to the members of the board of directors and to the members of the board of statutory auditors, by: (a)
registered mail with return receipt requested; (b) e-mail with electronic acknowledgment of receipt; as long as the notice is
received by the addressee at least eight calendar days before the date set for the meeting with evidence thereof as provided
above. The notice shall also be posted on our Company&rsquo;s web site.</FONT> <FONT STYLE="font-family: Georgia; font-size: 10pt">However,
if the above procedures are not complied with, the shareholders&rsquo; meeting will still be deemed validly held if all outstanding
shares are represented, all other holders having the right to vote are present and a majority of the board of directors and the
board of statutory auditors are in attendance; provided that in such event, any shareholder or other participant present may
object to the discussion of items with respect to which he/she does not deem to have been adequately informed.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
must convene an ordinary shareholders&rsquo; meeting at least once a year. Our annual stand-alone financial statements are prepared
by the board of directors and submitted for approval to the ordinary shareholders&rsquo; meeting, which must be convened within
120 days after the end of the fiscal year to which such financial statements relate. This term may be extended by up to 180 days
after the end of the fiscal year, as long as the Company continues to be bound by law to draw up financial statements or if particular
circumstances concerning our structure or our purposes so require. At ordinary shareholders&rsquo; meetings, our shareholders
also appoint the external auditors, approve any distribution of dividends that have been proposed by our board of directors, elect
our board of directors and statutory auditors, determine their remuneration and vote on any business matter for which resolution
or authorization is entrusted to the shareholders by law.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
may call extraordinary shareholders&rsquo; meetings to vote upon spin-offs, split-ups, dissolutions, appointment of receivers
and similar extraordinary actions. We may also call extraordinary shareholders&rsquo; meetings to vote upon proposed amendments to our
bylaws, issuance of convertible debentures, mergers and de-mergers and capital increases and reductions, if such actions may not
be authorized by the board of directors without shareholder approval. The board of directors has the authority to transfer our
registered office within Italy, authorize, on a non-exclusive basis, amendments to our bylaws that are required by law, authorize mergers
by absorption to our subsidiaries in which we hold all or at least 90% of the outstanding shares, if the Company&rsquo;s bylaws
(as in our case) so provide, authorize reductions of our share capital in case of withdrawal of a shareholder and indicate who among
the directors is our legal representative. If the shareholders authorize the issuance of shares or other securities at an extraordinary
meeting, they may delegate the power to make specific issuances to the board of directors.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Once
our shareholders have authorized the issuance of securities, the securities that have been subscribed must be fully paid for before
the shareholders may authorize the issuance of additional securities, unless the shareholders meet and vote to cancel those authorized
but unsubscribed securities.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
notice of our shareholders&rsquo; meeting may specify two or more meeting dates for an ordinary or extraordinary shareholders&rsquo;
meeting.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
quorum for an ordinary meeting of our shareholders on the first call, also in the event we are considered an Open Company, is at
least 50% of the outstanding ordinary shares, while on second call there is no quorum requirement. In either case, resolutions may
be adopted with the majority of ordinary shares in attendance or represented at the meeting. The quorum for an
extraordinary shareholders&rsquo; meeting is more than half of the outstanding ordinary shares on the first call and more than
one-third of the outstanding shares on second call. Extraordinary shareholders&rsquo; meeting resolutions may be adopted with
the majority of the outstanding ordinary shares on first call and at least two-thirds of the holders of shares in attendance or
represented at the meeting on second call. In the event we are considered an Open Company, the quorum for an extraordinary
shareholders&rsquo; meeting is, on first call, the majority of at least two-thirds of the shares present or represented at such
meeting, provided that a quorum of at least half of the share capital is attending; on second call, the majority of at least
two-thirds of the  shares present or represented at such meeting, provided that a quorum of more than one-third of the
share capital is attending. In addition, certain matters (such as, for example, a change in our corporate purpose, the
transfer of our registered office outside Italy or our liquidation prior to the date set forth in our bylaws) must be adopted by
shareholders representing more than one-third of the outstanding ordinary shares (not just the ordinary shares in attendance or
represented at the meeting).</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Shareholders
are entitled to one vote per ordinary share. Neither Italian law nor our bylaws limit the right of non-resident or foreign owners
to hold or vote their shares. Shareholders do not need to present their share certificates (due to the fact that our shares are
not represented by share certificates) but the entitlement to attend the meetings is then proven by exhibition of the certificate
or communication to the Company made by the intermediary (banks and other financial institutions) which manages the electronical
register whereby ownership of the shares, their transfer, the related rights and restrictions on shares (if any) are recorded.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Shareholders
may appoint proxies or attorneys-in-fact by delivering in writing the proxies to represent them in an ordinary or extraordinary
shareholders&rsquo; meeting. Our directors, auditors and employees may not be proxies. Italian law provides that no proxy may represent
more than twenty shareholders prior to the company &ldquo;seeking access to the risk capital market.&rdquo; It is unsettled whether listing
shares on a stock exchange outside of the European Union constitutes &ldquo;seeking access to the risk capital market&rdquo; for
this purpose.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Preemptive
rights</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to Italian law, holders of outstanding ordinary shares
and convertible debentures are entitled to subscribe for newly issued ordinary shares or convertible debentures in proportion
to their holdings at the time that the shareholders authorize the capital increase for those issuances, unless those issuances
are for non-cash considerations. Those who exercise their preemptive rights, provided they make such request simultaneously, have
a pre-emption right on the purchase of shares and debentures convertible into shares that have not been subscribed. Preemptive
rights may be excluded or limited by resolution of the shareholders at an extraordinary shareholders&rsquo; meeting, or by the
board of directors if the bylaws delegate such power to the board of directors (including the power to exclude or limit the preemptive
right), and provided that such exclusion or limitation is in the interest of the company, or if the shares are to be paid by means of
contributions in kind. According to Italian law proposals to increase share capital with exclusion or limitation of preemptive rights
must be accompanied by a report of the board of directors setting forth the reasons for the exclusion or limitation of
pre-emptive rights, or, if the exclusion derives from a contribution in kind, the reasons for such contribution in kind, and the
report must in all cases set forth the criteria adopted for determining the issue price. The report must be communicated by
the board of directors to the board of statutory auditors and to the external auditor at least 30 days prior to the date
set for the shareholders&rsquo; meeting. Within 15 days, the board of statutory auditors must express its opinion on the fairness
of the issue price of the shares. The opinion of the board of statutory auditors and, only in the case of contributions in kind,
the sworn report of an expert appointed by a competent court or documentation provided by Italian law, must remain deposited
at the Company&rsquo;s registered office during the 15 days prior to the shareholders&rsquo; meeting and until the latter
has passed a resolution. The resolution shall determine the issue price of the shares on the basis of of shareholders&rsquo; equity,
taking into account, in the case of shares listed on regulated markets, also the trend in prices over the last six months. The foregoing
procedure shall apply also in case of capital increase delegated to the board of directors.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Preference
shares; other securities</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Italian
law permits us to issue preference shares with limited voting rights, other classes of equity securities with different economic
and voting rights, shares with economic rights related to the results of the corporate activity in a specific sector,
&ldquo;participation instruments&rdquo; with limited economic and voting rights against the contribution, by shareholders or third-parties,
of work or services, as well as &ldquo;participation instruments&rdquo; in favor of employees.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
bylaws allow us to issue shares without voting rights, with voting rights limited to particular subjects, with voting rights
subject to the occurrence of particular conditions not merely arbitrary or with multiple voting rights (each multiple voting right
share may have a maximum of three votes). According to Italian law, the total value of such shares may not exceed half of the
share capital. Our bylaws also provides that, in relation to the quantity of shares held by the same party, the voting right may
be limited to a maximum extent or may be staggered.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&ldquo;Participation
instruments&rdquo; may include convertible equity and/or &ldquo;hybrid&rdquo; instruments that confer on the holder the right
to vote on specific matters and/or grants economic rights, to be determined at the time of the issuance of such instruments, or
management rights, such as the right to appoint, in accordance with the procedures established by the bylaws, an independent member
of the board of directors or a statutory auditor.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
bylaws currently allow us to issue these securities. We may also issue convertible and non-convertible debt securities. In order
to issue convertible debt securities, our board of directors would need to recommend to our shareholders that they approve the
issuance of particular securities in connection with a capital increase, and the shareholders would need to vote to approve such
an issuance and capital increase at an extraordinary meeting. The board of directors would also need to recommend, and the shareholders
would need to approve by vote at the extraordinary meeting, specific terms of the securities. The shareholders may vote at the
extraordinary shareholders&rsquo; meeting to delegate authority to the board of directors to issue those securities from time
to time, but not for more than five years from the date of the extraordinary shareholders&rsquo; meeting.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Debt-equity
ratio</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Italian
law provides that we may not issue debt securities for an amount exceeding twice the value of the sum of our equity capital, our
legal reserve and any other disposable reserves appearing on the latest balance sheet approved by our shareholders. The board
of statutory auditors must certify compliance with such limitation. This limitation may be exceeded if the debt securities issued
in excess are intended for subscription by professional investors subject to prudential supervision pursuant to special laws.
In the event of subsequent circulation of the debt security, whoever transfers them is liable for the solvency of the company
vis-&agrave;-vis buyers who are not professional investors. The rules indicated above do not apply in case we intend to issue
debt securities to be listed on regulated markets or multilateral trading systems or which have attached the right to purchase
or subscribe shares. The legal reserve is a reserve to which we are required to allocate 5% of our Italian GAAP net income each
year until it equals at least 20% of our equity capital. One of the other reserves that we maintain on our balance sheet is a
&ldquo;share premium reserve&rdquo;, meaning amounts paid for our ordinary shares in excess of the amount of such ordinary shares
that is allocated to stated capital (<I>valore nominale</I>). Until our outstanding debt securities are repaid in full, we may
not voluntarily reduce our equity capital or distribute our reserves (such as by declaring dividends) in the event the aggregate
of the capital plus reserves, after giving effect to such reduction, is less than half of the outstanding amount of the debt securities.
If our equity capital is reduced by losses or otherwise such that the amount of the outstanding debt securities is more than twice
the amount of our equity capital, we cannot distribute profits to our shareholders until the ratio between the amount of our debt
securities and our equity capital plus reserves is restored. If our equity capital is reduced, we could recapitalize by means
of issuing new shares or having our current shareholders contribute additional capital to our company, although there can be no
assurance that we would be able to find purchasers for new shares or that any of our current shareholders would be willing to
contribute additional capital. The legal requirements regarding the ratio of debt securities to equity capital plus reserves do
not apply to issuances of debt securities to professional investors (as defined by Italian law). However, in such a case, should
the professional investors transfer such debt securities to third parties not qualified as professional investors, the former
remains liable for the payment of such securities.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Reduction
of equity by losses</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Italian
law requires us to reduce our shareholders&rsquo; equity in certain situations. Our shareholders&rsquo; equity has three main components:
capital, legal reserves and other shareholders&rsquo; equity (such as share premium and retained earnings). We first apply our losses
from operations against our shareholders&rsquo; equity other than legal reserves and capital. If additional losses remain and, after
the legal reserves, our corporate capital is reduced by more than one-third, our board of directors must call a shareholders&rsquo; meeting
as soon as possible. The shareholders should take appropriate measures, which may include, among others, either reducing the legal
reserves and capital by the amount of the remaining losses, or carrying the losses forward for up to one year. If the shareholders vote
to elect to carry the losses forward for up to one year, and the losses are still more than one-third of the amount of the capital
at the end of the year, then we must reduce our capital by the amount of the losses.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have no present intention to enter into any such transaction and no such transaction is currently in effect.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Liquidation
rights</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Pursuant
to Italian law and subject to the satisfaction of the claims of all creditors, our shareholders are entitled to a distribution
in liquidation that is equal to an amount resulting from the division of the positive liquidation balance by the number of shares
(to the extent available out of our net assets). Preferred shareholders and holders of &ldquo;participating certificates&rdquo;
typically do not participate in the distribution of assets of a dissolved corporation beyond their established contractual preferences.
Once the rights of preferred shareholders and holders of participating certificates and the claims of all creditors have been
fully satisfied, holders of ordinary shares are entitled to the distribution of any remaining assets.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Purchase
of shares by us (Treasury Stocks)</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are permitted to purchase our outstanding shares, subject to certain conditions and limitations provided for by Italian law. We
may only purchase the shares out of profits available for dividends or out of distributable reserves, in each case as appearing
on the latest shareholder-approved financial statements; in lack, the shares in excess must be cancelled and the corporate capital
must be reduced accordingly. Further, we may only repurchase fully paid-in shares. Such purchases and the conditions thereto must
be authorized by our shareholders by vote at an ordinary shareholders&rsquo; meeting and the authorization may be issued for a
period not exceeding the term of eighteen (18) months.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">A
corresponding reserve equal to the purchase price of such shares must be created in the balance sheet, and such reserve is not
available for distribution, unless such shares are sold or cancelled. Shares purchased and held by us may be resold only pursuant
to a resolution of our shareholders adopted at an ordinary shareholders&rsquo; meeting. The voting rights attaching to the shares
held by us or our subsidiaries cannot be exercised, but the shares can be counted for quorum purposes in shareholders&rsquo; meetings.
Dividends and other rights, including pre-emptive rights, attaching to such shares will accrue to the benefit of other shareholders.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
foregoing limitations do not apply in case we purchase our shares: (i) by giving execution to shareholders&rsquo; meeting resolution
authorizing capital reduction through repurchase or cancellation; (ii) for free, to the extent they are fully paid-in; (iii) as
a consequence of universal succession, merger or demerger; (iv) on occasion of foreclosures authorized to satisfy a credit of
our company, to the extent they are fully paid-in.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
long as such shares remain the property of the company, the right to profits and the right of option are attributed proportionally
to the other shares. The right to vote is suspended, but such shares are nevertheless taken into account for the purposes of calculating
the majority and the quorum required for the constitution and for the resolutions of the shareholders&rsquo; meetings</FONT>.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company does not hold any of its shares.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Notification
of the acquisition of shares</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
accordance with Italian antitrust laws, the Italian Antitrust Authority could prohibit, if certain threshold requirements are
met, the acquisition of control in a company which would thereby create or strengthen a dominant position in the domestic market
or a significant part thereof and which would result in the elimination or substantial reduction, on a lasting basis, of competition,
provided that certain turnover thresholds are exceeded. However, if the turnover of the acquiring party and the company to be
acquired exceed certain other monetary thresholds, the antitrust review of the acquisition falls within the exclusive jurisdiction
of the European Commission.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In addition, if we fall under the scope of the Law Decree
No. 21 of March 15, 2012 (so-called Italian <I>&ldquo;Golden Power&rdquo; regulations</I>), as subsequently amended and supplemented,
(i) certain resolutions of the Company and, if specific thresholds requirements are met, (ii) certain third-party investors&rsquo; purchases
of our shares may be subject to <I>ad hoc </I>notifications to the Italian Government and this latter may object to the transaction thereof.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Georgia, Times, Serif; text-indent: 0.5in">In particular, in such cases the Government would have,
<I>among others</I>:</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I></I></P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Georgia, Times, Serif; text-indent: 0.5in">(i) the power to veto or to impose specific
conditions with respect to the acquisition of certain shareholdings by any foreign entity outside the European Union with respect
to companies having assets and business in sectors of strategic importance; and</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(ii) the power to veto or impose specific conditions
with regard to the adoption of specific corporate resolutions, acts or transactions by the same companies.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia"></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Minority
shareholders&rsquo; rights; withdrawal rights</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Shareholders&rsquo;
resolutions which are not adopted in conformity with applicable law or our bylaws may be challenged (with certain limitations and exceptions)
within 90 days of such resolution (or, if such resolution is subject to registration or filing with the Italian Company Register,
within ninety days of its registration or filing) by absent, dissenting or abstaining shareholders representing individually or in the
aggregate at least 5% of our share capital (as well as by our board of directors or our board of statutory auditors). Shareholders not
reaching this threshold or shareholders not entitled to vote at our meetings may only claim damages arising from the challenged resolution.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Dissenting
or absent shareholders may withdraw from the company as a result of shareholders&rsquo; resolutions approving, among other things, material
modifications of our corporate purpose or of the voting rights of our ordinary shares, our transformation from a share corporation into
a different legal entity or the transfer of our registered seat outside Italy. In such a case, our other shareholders would have a pre-emptive
right to purchase the shares of the withdrawing shareholder. Should no shareholder exercise that pre-emptive right, the shares must be
offered to third parties or, in the absence of any third party wishing to buy them, they will be purchased by us by using the available
reserves. In the event that no reserve is available, our equity capital must be reduced accordingly. Any repurchase of such shares by
us must be on terms authorized by our board of directors, upon consultation with our board of statutory auditors and our external auditor,
having regard to our net asset value, our prospective earnings and the market value of our ordinary shares, if any. Under Italian law,
we may set forth different criteria in our bylaws for the consideration to be paid to withdrawing shareholders. We have not done so as
of the date of this prospectus.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Any
</FONT><FONT STYLE="font: 10pt Georgia">shareholder may bring to the attention of the board of statutory auditors facts or acts which
such shareholder deems wrongful. If such shareholders represent at least 5% of our share capital, or in case we are considered an Open
Company 2% of the same, our board of statutory auditors must investigate without delay and report its findings and recommendations at
our shareholders&rsquo; meeting. Shareholders representing more than 10% of our share capital, or, in case we are considered an Open
Company one-twentieth, have the right to report to the competent court serious breaches of the duties of the directors which may be prejudicial
to us or to our subsidiaries. In addition, shareholders representing at least 20% of our share capital may commence derivative suits
before the competent court against our directors, statutory auditors and general managers. We may waive or settle the suit unless shareholders
holding at least 20% of the shares vote against such waiver or settlement. We will reimburse the legal costs of such action in the event
that the claim of such shareholder is successful and the court does not award such costs against the relevant directors, statutory auditors
or general managers.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Applicable
Laws</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
of the date of this prospectus and upon completion of this offering, the Company is and will be governed by the corporate
laws of Italy, and is and will be legally considered and treated, according to the Italian Civil Code, as a private company being our
shares not listed on a regulated market in Italy or within the European Union.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">It should be noted that under Italian corporate
law, while joint-stock companies are all the same type of legal entity, there is a distinction between those companies
that do not have access to the capital markets (<I>Private Companies</I>) and companies that have such access. This latter category
comprises both companies listed on European regulated markets (<I>Public Companies</I>) and companies whose securities are not listed
on such markets, insofar as they have completed a significant distribution of their securities among the public (so-called &ldquo;<I>emittenti
aventi strumenti finanziari diffusi tra il pubblico in maniera rilevante</I>&rdquo;), according to the relevant provisions set forth
in Italian Financials&rsquo; Consolidated Act and its implementing provisions (<I>Open Companies</I>).</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Pursuant
to Article 2-bis of the Issuer&rsquo;s Regulation implemented by Consob (<I>Regolamento emittenti</I>), Open Companies must meet
the following requirements:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">having
    at least 500 shareholders in addition to the majority shareholders who hold at least 5% of the outstanding share capital; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD><FONT STYLE="font: 10pt Georgia, Times, Serif">exceeding at least two out of the following three thresholds:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">total assets side of &euro;4.4
    million;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">total revenues of &euro;8.8 million;
    and,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">an average of 50 employees during the year.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">If, following completion of this offering, we issue financial
instruments widely distributed among the public, the regulation relating to Open Companies could apply to us.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Stock
Exchange Listing</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have reserved the symbol &ldquo;GNTA&rdquo; for purposes of listing the ADSs on the Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><B>Registrar of Shares</B></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
share register is currently kept by Spafid S.p.A., which acts as registrar. The share register reflects
only record owners of our ordinary shares.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 163; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="c_021"></A><B>DESCRIPTION
OF AMERICAN DEPOSITARY SHARES</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Bank of New York Mellon, as depositary, will register and deliver American Depositary Shares, also referred to as ADSs. Each ADS
will represent one share (or a right to receive one share) deposited with The Bank of New York Mellon, as custodian, acting through
an office located in the United Kingdom. Each ADS will also represent any other securities, cash or other property that may be
held by the depositary. The deposited shares together with any other securities, cash or other property held by the depositary
are referred to as the deposited securities. The depositary&rsquo;s office at which the ADSs will be administered and its principal
executive office are located at 240 Greenwich Street, New York, New York 10286.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">You
may hold ADSs either (A) directly (i) by having an American Depositary Receipt, also referred to as an ADR, which is a certificate
evidencing a specific number of ADSs, registered in your name, or (ii) by having uncertificated ADSs registered in your name,
or (B) indirectly by holding a security entitlement in ADSs through your broker or other financial institution that is a direct
or indirect participant in The Depository Trust Company, also called DTC. If you hold ADSs directly, you are a registered ADS
holder, also referred to as an ADS holder. This description assumes you are an ADS holder. If you hold the ADSs indirectly, you
must rely on the procedures of your broker or other financial institution to assert the rights of ADS holders described in this
section. You should consult with your broker or financial institution to find out what those procedures are.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Registered
holders of uncertificated ADSs will receive statements from the depositary confirming their holdings.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. Italian law governs shareholder
rights. The depositary will be the holder of the shares underlying the ADSs. As a registered holder of ADSs, you will have ADS
holder rights. A deposit agreement among us, the depositary, ADS holders and all other persons indirectly or beneficially holding ADSs
sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the
ADSs.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
following is a summary of the material provisions of the deposit agreement. For more complete information, you should read
the entire deposit agreement and the form of ADR. Directions on how to obtain copies of those documents are provided under
the heading &ldquo;Where You Can Find More Information.&rdquo;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Dividends
and Other Distributions</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>How
will you receive dividends and other distributions on the shares?</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
depositary has agreed to pay or distribute to ADS holders the cash dividends or other distributions it or the custodian receives
on shares or other deposited securities, upon payment or deduction of its fees and expenses. You will receive these distributions
in proportion to the number of shares the ADSs represent.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Cash</I>.
The depositary will convert any cash dividend or other cash distribution we pay on the shares into U.S. dollars, if it can do
so on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government
approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only
to those ADS holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the
ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Before
making a distribution, any withholding taxes, or other governmental charges that must be paid will be deducted. See &ldquo;Taxation.&rdquo;
The depositary will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If
the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some of the value
of the distribution.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Shares</I>.
The depositary may distribute additional ADSs representing any shares we distribute as a dividend or free distribution. The depositary
will only distribute whole ADSs. It will sell shares which would require it to deliver a fraction of an ADS (or ADSs representing
those shares) and distribute the net proceeds in the same way as it does with cash. If the depositary does not distribute additional
ADSs, the outstanding ADSs will also represent the new shares. The depositary may sell a portion of the distributed shares (or
ADSs representing those shares) sufficient to pay its fees and expenses in connection with that distribution.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 164; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Rights
to purchase additional shares</I>. If we offer holders of our securities any rights to subscribe for additional shares or any
other rights, the depositary may (i) exercise those rights on behalf of ADS holders, (ii) distribute those rights to ADS holders
or (iii) sell those rights and distribute the net proceeds to ADS holders, in each case after deduction or upon payment of its
fees and expenses. To the extent the depositary does not do any of those things, it will allow the rights to lapse. In that case,
you will receive no value for them. The depositary will exercise or distribute rights only if we ask it to and provide satisfactory
assurances to the depositary that it is legal to do so. If the depositary will exercise rights, it will purchase the securities
to which the rights relate and distribute those securities or, in the case of shares, new ADSs representing the new shares, to
subscribing ADS holders, but only if ADS holders have paid the exercise price to the depositary. U.S. securities laws may restrict
the ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or certain
ADS holders, and the securities distributed may be subject to restrictions on transfer.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Other
Distributions</I>. The depositary will send to ADS holders anything else we distribute on deposited securities by any means it
thinks is legal, fair and practical. If it cannot make the distribution in that way, the depositary has a choice. It may decide
to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what
we distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required
to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal
to make that distribution. The depositary may sell a portion of the distributed securities or property sufficient to pay its fees
and expenses in connection with that distribution. U.S. securities laws may restrict the ability of the depositary to distribute
securities to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders.
We have no obligation to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation
to take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that you
may not receive the distributions we make on our shares or any value for them if it is illegal or impractical for us to make them
available to you.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Deposit,
Withdrawal and Cancellation</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>How
are ADSs issued?</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
depositary will deliver ADSs if you or your broker deposits shares or evidence of rights to receive shares with the custodian.
Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary
will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person
or persons that made the deposit.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>How
can ADS holders withdraw the deposited securities?</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">You
may surrender the ADSs to the depositary for the purpose of withdrawal. Upon payment of its fees and expenses and of any taxes
or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will deliver the shares and any other deposited
securities underlying the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at
your request, risk and expense, the depositary will deliver the deposited securities at its office, if feasible. However, the
depositary is not required to accept surrender of ADSs to the extent it would require delivery of a fraction of a deposited share
or other security. The depositary may charge you a fee and its expenses for instructing the custodian regarding delivery of deposited
securities.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>How
do ADS holders interchange between certificated ADSs and uncertificated ADSs?</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">You
may surrender your ADR to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel
that ADR and will send to the ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated
ADSs. Upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange
of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to the ADS holder an ADR evidencing those
ADSs.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 165; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Voting
Rights</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>How
do you vote?</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">ADS
holders may instruct the depositary how to vote the number of deposited shares their ADSs represent. If we request the depositary
to solicit your voting instructions (and we are not required to do so), the depositary will notify you of a shareholders&rsquo;
meeting and send or make voting materials available to you. Those materials will describe the matters to be voted on and explain
how ADS holders may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date
set by the depositary. The depositary will try, as far as practical, subject to the laws of Italy and the provisions of our articles
of association or similar documents, to vote or to have its agents vote the shares or other deposited securities as instructed
by ADS holders. If we do not request the depositary to solicit your voting instructions, you can still send voting instructions,
and, in that case, the depositary may try to vote as you instruct, but it is not required to do so.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Except by instructing the depositary as described above,
you will not be able to exercise voting rights unless you surrender <FONT STYLE="font-style: normal; font-weight: normal">the
</FONT>ADSs and withdraw the shares. However, you may not know about the meeting enough in advance to withdraw the shares. In
any event, the depositary will not exercise any discretion in voting deposited securities and it will only vote or attempt to
vote as instructed.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your
shares. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the
manner of carrying out voting instructions. This means that you may not be able to exercise voting rights and there may be nothing
you can do if your shares are not voted as you requested.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
order to give you a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to Deposited
Securities, if we request the Depositary to act, we agree to give the depositary notice of any such meeting and details concerning
the matters to be voted upon at least 45 days in advance of the meeting date.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Fees
and Expenses</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Georgia; text-align: center; vertical-align: top; width: 55%"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B><I>Persons
    depositing or withdrawing shares or ADS holders must pay:</I></B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Georgia; padding-bottom: 1.5pt; vertical-align: top; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Georgia; text-align: center; vertical-align: bottom; width: 43%"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B><I>For:</I></B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">$5.00
    (or less) per 100 ADSs (or portion of 100 ADSs)</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Issuance of ADSs, including
    issuances resulting from a distribution of shares or rights or other property. Cancellation of ADSs for the purpose
    of withdrawal, including if the deposit agreement terminates</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">$.05
    (or less) per ADS</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Any
    cash distribution to ADS holders</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">A
    fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited
    for issuance of ADSs</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Distribution
    of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to
    ADS holders</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">$.05
    (or less) per ADS per calendar year</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Depositary
    services</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Registration
    or transfer fees</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Transfer
    and registration of shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw
    shares</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Expenses
    of the depositary</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Cable
    (including SWIFT) and facsimile transmissions (when expressly provided in the deposit agreement)Converting foreign currency
    to U.S. dollars</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Taxes
    and other governmental charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock
    transfer taxes, stamp duty or withholding taxes</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
    necessary</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Any
    charges incurred by the depositary or its agents for servicing the deposited securities</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
    necessary</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 166; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs
for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to
investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees.
The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing
investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its
fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to
ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until
its fees for those services are paid.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">From
time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment
and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from
the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers,
foreign currency dealers or other service providers that are owned by or affiliated with the depositary and that may earn or share
fees, spreads or commissions.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
depositary may convert currency itself or through any of its affiliates, or the custodian or we may convert currency and pay U.S.
dollars to the depositary. Where the depositary converts currency itself or through any of its affiliates, the depositary acts
as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue,
including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other
things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the
rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary
makes no representation that the exchange rate used or obtained by it or its affiliate in any currency conversion under the deposit
agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined
will be the most favorable to ADS holders, subject to the depositary&rsquo;s obligation to act without negligence or bad faith.
The methodology used to determine exchange rates used in currency conversions made by the depositary is available upon request.
Where the custodian converts currency, the custodian has no obligation to obtain the most favorable rate that could be obtained
at the time or to ensure that the method by which that rate will be determined will be the most favorable to ADS holders, and
the depositary makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect
losses associated with the rate. In certain instances, the depositary may receive dividends or other distributions from the us
in U.S. dollars that represent the proceeds of a conversion of foreign currency or translation from foreign currency at a rate
that was obtained or determined by us and, in such cases, the depositary will not engage in, or be responsible for, any foreign
currency transactions and neither it nor we make any representation that the rate obtained or determined by us is the most favorable
rate and neither it nor we will be liable for any direct or indirect losses associated with the rate.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Payment
of Taxes</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">You will be responsible for any taxes or other governmental
charges payable on the ADSs or on the deposited securities represented by any of the ADSs. The depositary may refuse to register
any transfer of the ADSs or allow you to withdraw the deposited securities represented by the ADSs until those taxes or other charges
are paid. It may apply payments owed to you or sell deposited securities represented by the ADSs to pay any taxes owed and you
will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number
of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid
the taxes.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Tender
and Exchange Offers; Redemption, Replacement or Cancellation of Deposited Securities</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
depositary will not tender deposited securities in any voluntary tender or exchange offer unless instructed to do so by an ADS
holder surrendering ADSs and subject to any conditions or procedures the depositary may establish.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 167; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
deposited securities are redeemed for cash in a transaction that is mandatory for the depositary as a holder of deposited securities,
the depositary will call for surrender of a corresponding number of ADSs and distribute the net redemption money to the holders
of called ADSs upon surrender of those ADSs.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
there is any change in the deposited securities such as a sub-division, combination or other reclassification, or any merger,
consolidation, recapitalization or reorganization affecting the issuer of deposited securities in which the depositary receives
new securities in exchange for or in lieu of the old deposited securities, the depositary will hold those replacement securities
as deposited securities under the deposit agreement. However, if the depositary decides it would not be lawful and practical to
hold the replacement securities because those securities could not be distributed to ADS holders or for any other reason, the
depositary may instead sell the replacement securities and distribute the net proceeds upon surrender of the ADSs.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
there is a replacement of the deposited securities and the depositary will continue to hold the replacement securities, the depositary
may distribute new ADSs representing the new deposited securities or ask you to surrender your outstanding ADRs in exchange for
new ADRs identifying the new deposited securities.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
there are no deposited securities underlying ADSs, including if the deposited securities are cancelled, or if the deposited securities
underlying ADSs have become apparently worthless, the depositary may call for surrender of those ADSs or cancel those ADSs upon
notice to the ADS holders.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Amendment
and Termination</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>How
may the deposit agreement be amended?</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We may agree with the depositary to amend the deposit
agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes
and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar
items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after
the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing
to hold <I>the </I>ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>How
may the deposit agreement be terminated?</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
depositary will initiate termination of the deposit agreement if we instruct it to do so. The depositary may initiate termination
of the deposit agreement if</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Georgia">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">60
    days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted
    its appointment;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">we
    delist the ADSs from an exchange in the United States on which they were listed and do not list the ADSs on another exchange
    in the United States or make arrangements for trading of ADSs on the U.S. over-the-counter market;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 75pt; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Georgia">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">we
    delist our shares from an exchange outside the United States on which they were listed and do not list the shares on another
    exchange outside the United States;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    depositary has reason to believe the ADSs have become, or will become, ineligible for registration on Form F-6 under the Securities
    Act of 1933;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 75pt; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">we
    appear to be insolvent or enter insolvency proceedings;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">all
    or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">there
    are no deposited securities underlying the ADSs or the underlying deposited securities have become apparently worthless; or</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">there
    has been a replacement of deposited securities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 168; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
the deposit agreement will terminate, the depositary will notify ADS holders at least 90 days before the termination date. At
any time after the termination date, the depositary may sell the deposited securities. After that, the depositary will hold the
money it received on the sale, as well as any other cash it is holding under the deposit agreement, unsegregated and without liability
for interest, for the pro rata benefit of the ADS holders that have not surrendered their ADSs. Normally, the depositary will
sell as soon as practicable after the termination date.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">After
the termination date and before the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited
securities, except that the depositary may refuse to accept a surrender for the purpose of withdrawing deposited securities or
reverse previously accepted surrenders of that kind that have not settled if it would interfere with the selling process. The
depositary may refuse to accept a surrender for the purpose of withdrawing sale proceeds until all the deposited securities have
been sold. The depositary will continue to collect distributions on deposited securities, but, after the termination date, the
depositary is not required to register any transfer of ADSs or distribute any dividends or other distributions on deposited securities
to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties under the deposit agreement
except as described in this paragraph.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Limitations
on Obligations and Liability</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Limits
on our Obligations and the Obligations of the Depositary; Limits on Liability to Holders of ADSs</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the
liability of the depositary. We and the depositary:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">are
    only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith, and the
    depositary will not be a fiduciary or have any fiduciary duty to holders of ADSs;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">are
    not liable if we are or it is prevented or delayed by law or by events or circumstances beyond our or its ability to prevent
    or counteract with reasonable care or effort from performing our or its obligations under the deposit agreement;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">are
    not liable if we or it exercises discretion permitted under the deposit agreement;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">are
    not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made
    available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages
    for any breach of the terms of the deposit agreement;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">have
    no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf
    or on behalf of any other person;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">may
    rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the
    proper person;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">are
not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the
    depositary has no duty to make any determination or provide any information as to our tax status, or any liability for any
    tax consequences that may be incurred by ADS holders as a result of owning or holding ADSs or be liable for the inability
    or failure of an ADS holder to obtain the benefit of a foreign tax credit, reduced rate of withholding or refund of amounts
    withheld in respect of tax or any other tax benefit.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 169; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Requirements
for Depositary Actions</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Before
the depositary will deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of shares, the depositary
may require:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">payment
    of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties
    for the transfer of any shares or other deposited securities;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">satisfactory
    proof of the identity and genuineness of any signature or other information it deems necessary; and</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">compliance
    with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer
    documents.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer
books are closed or at any time if the depositary or we think it advisable to do so.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Your
Right to Receive the Shares Underlying the ADSs</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">ADS
holders have the right to cancel their ADSs and withdraw the underlying shares at any time except:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">when
    temporary delays arise because: (i) the depositary has closed its transfer books or we have closed our transfer books; (ii)
    the transfer of shares is blocked to permit voting at a shareholders&rsquo; meeting; or (iii) we are paying a dividend on
    our shares;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">when
    you owe money to pay fees, taxes and similar charges; or</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">when
    it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or
    to the withdrawal of shares or other deposited securities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">This
right of withdrawal may not be limited by any other provision of the deposit agreement.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Direct
Registration System</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
the deposit agreement, all parties to the deposit agreement acknowledge that the Direct Registration System, also referred to
as DRS, and Profile Modification System, also referred to as Profile, will apply to the ADSs. DRS is a system administered by
DTC that facilitates interchange between registered holding of uncertificated ADSs and holding of security entitlements in ADSs
through DTC and a DTC participant. Profile is a feature of DRS that allows a DTC participant, claiming to act on behalf of a registered
holder of uncertificated ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its nominee and to deliver
those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior authorization from the ADS holder
to register that transfer.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement
understand that the depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS
holder in requesting registration of transfer and delivery as described in the paragraph above has the actual authority to act
on behalf of the ADS holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the
parties agree that the depositary&rsquo;s reliance on and compliance with instructions received by the depositary through the
DRS/Profile system and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the
depositary.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 170; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Shareholder
communications; inspection of register of holders of ADSs</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited
securities that we make generally available to holders of deposited securities. The depositary will send you copies of those communications
or otherwise make those communications available to you if we ask it to. You have a right to inspect the register of holders of
ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or the ADSs.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Jury
Trial Waiver</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
deposit agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they
may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any
claim under the U.S. federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the court
would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case
law.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">You
will not, by agreeing to the terms of the deposit agreement, be deemed to have waived our or the depositary&rsquo;s compliance
with U.S. federal securities laws or the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 171; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="S_005"></A>COMPARISON
OF ITALIAN LAW AND DELAWARE LAW</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
following comparison table summarizing the most significant differences in shareholder rights between the applicable provisions
of the Delaware General Corporation Law and the corporate laws of Italy, also taking into account those main differences existing
between the Private Companies and Open Companies.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">It
should be considered that this is only a general summary of certain provisions applicable to companies in Delaware and Italy.
Certain Delaware and Italian companies may be permitted to exclude certain of the provisions summarized below in their charter
documents.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>DELAWARE
    CORPORATE LAW</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>ITALIAN
    CORPORATE LAW</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Mergers
    and similar arrangements</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
    the Delaware General Corporation Law, with certain exceptions, a merger, consolidation, sale, lease or transfer of all or
    substantially all of the assets of a corporation must be approved by the board of directors and a majority of the outstanding
    shares entitled to vote thereon. A shareholder of a Delaware corporation participating in certain major corporate transactions
    may, under certain circumstances, be entitled to appraisal rights pursuant to which such shareholder may receive cash in the
    amount of the fair value of the shares held by such shareholder (as determined by a court) in lieu of the consideration such
    shareholder would otherwise receive in the transaction. The Delaware General Corporation Law also provides that a parent corporation,
    by resolution of its board of directors, may merge with any subsidiary of which it owns at least 90.0% of each class of capital
    stock without a vote by the shareholders of such subsidiary. Upon any such merger, dissenting shareholders of the subsidiary
    would have appraisal rights.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">Under Italian law, a merger requires the approval of more than half of the share
capital at an extraordinary shareholders&rsquo; meeting of each company which is part to the merger. The merger may only be adopted after
the expiry of a period of sixty (60) days from the filing of the merger resolution and the related documents with the companies&rsquo;
register. This time limit, in particular, is intended to allow the company&rsquo;s creditors, subject to limited exceptions, to file
an opposition to the merger, provided however that if such an opposition is deemed groundless and the company has given adequate financial
assurances, the competent court may nevertheless decide that the merger shall take place notwithstanding the opposition.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">Italian law also provides for simplified forms of merger (with less documentation
needed) in cases where the merger is carried out by combining wholly-owned subsidiaries and subsidiaries which are at least 90%
owned. In both cases the decision to merge is delegated to the board of directors, provided that the company&rsquo;s bylaws (as
in our case) so provide. The delegation of powers to the board of directors does not, in any event, release it from the
obligation to file and/or publish, as the case may be, the merger plan in order to inform shareholders of the merger and to postpone
consummation for 30 days from the filing/publication of the merger plan, unless the shareholders waive their right.
 Shareholders of the &ldquo;acquiring&rdquo; company representing at least 5% of the share capital may request the decision on the
merger to be taken by the extraordinary shareholders&rsquo; meeting. In such a case the authority to approve the merger shifts to
the extraordinary shareholders&rsquo; meeting, as provided for the non-simplified procedure.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Georgia"></FONT></P></TD></TR>
</TABLE>



<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 172; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>DELAWARE
    CORPORATE LAW</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>ITALIAN
    CORPORATE LAW</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Shareholders&rsquo;
    suits</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Class
    actions and derivative actions generally are available to shareholders of a Delaware corporation for, among other things,
    breach of fiduciary duty, corporate waste and actions not taken in accordance with applicable law. In such actions, the court
    has discretion to permit the winning party to recover attorneys&rsquo; fees incurred in connection with such action.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">Shareholders may bring to the attention of the board of statutory auditors facts
or acts which such shareholder deems wrongful. If such shareholders represent 5% of our share capital, or 2% should the company
be classified as an Open Company, the board of statutory auditors must investigate without delay and report its findings and recommendations
at a shareholders&rsquo; meeting.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">If there is a well-founded suspicion that the directors, in breach of their duties,
have committed serious irregularities in the management of the company&rsquo;s business that may cause damage to the company,
shareholders representing, in Private Companies, one-tenth of the share capital or, in Open Companies, one-twentieth of the share
capital can report the facts to a competent court. The court, having heard the directors and the statutory auditors, may order
an investigation of the matter. The court will not order an investigation and will delay legal proceedings for a fixed period
if the shareholders replace the directors and the statutory auditors and the new directors and auditors take action without delay to
ascertain whether wrongdoing has been committed and, if so, to remedy it, report to the court their findings and the actions undertaken
by them. If the reported wrongdoing did occur or if the investigations fail to address the matters at issue, the court may order appropriate
provisional measures and call a shareholders&rsquo; meeting to adopt appropriate resolutions. In the most serious cases, the court can
replace directors and the statutory auditors and appoint a receiver, determining his or her powers and duration of office.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">Liability claims against directors and general managers may be brought
either by the shareholders through resolutions approved at a shareholders&rsquo; meeting, by the board of statutory auditors
(following a resolution passed with the favorable vote of two thirds of its members) or directly by shareholders representing a specified
percentage of the share capital.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">With reference to resolutions to be adopted at a shareholders&rsquo; meeting,
a resolution concerning the liability of directors may be approved at a meeting for that purpose or at the meeting called
to approve the financial statements. Unless otherwise provided for in the bylaws, resolution shall require approval by standard
majority. Claims against directors are subject to a five year statute of limitations from the date of termination of
the director&rsquo;s office and can be waived or settled upon resolution approved by the shareholder, unless shareholders
representing at least one-fifth of the share capital, in Private Companies such as ours, or, in Open Companies, one-twentieth
of the share capital, vote against the resolution. The legal costs of such action shall be borne by the company unless
the court orders the directors, statutory auditors or general managers to pay them.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0">Shareholders representing a certain percentage of the share capital may bring claims against directors. In
case of a Private Company such as ours, the percentage required is one-fifth of the share capital, while for an Open Company
the percentage is one-fortieth of the share capital.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Georgia"></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 173; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->170<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>DELAWARE
    CORPORATE LAW</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>ITALIAN
    CORPORATE LAW</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Dissenters&rsquo;
    rights</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Any
    shareholder of a Delaware corporation has the right to dissent from any plan of merger or consolidation to which the corporation
    is a party, except that, unless the certificate of incorporation provides otherwise, a shareholder shall not have the right
    to dissent from any plan of merger or consolidation, with respect to shares of a class or series that are listed on a national
    securities exchange or held of record, by not less than 2,000 holders on the record date fixed to determine the shareholders
    entitled to vote upon the plan of merger or consolidation. A dissenting shareholder has a right to appraisal of its shares.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left">Under Italian law, shareholders&rsquo; resolutions which are not adopted in compliance
    with applicable law or the bylaws may be challenged (with certain limitations and exceptions) within 90 days of
    such resolution (or, if such resolution is subject to registration or filing with the Italian Company Register, within 90
    days of its registration or filing) by shareholders who did not attend the meeting, dissented or abstained representing, individually
    or in the aggregate, at least 5% of the share capital in case of a Private Company such as ours, or for an Open Company, at
    least one per thousand of the share capital, as well as by the board of directors or the board of statutory
    auditors. Shareholders who do not meet the threshold or are not otherwise entitled to vote at our meetings may only claim
    damages arising from the resolution. Alongside the challenge to the resolution, an urgent application may also be filed to suspend
    the implementation of the resolution being challenged, in order to preserve the rights of challengers.
    Dissenting or absent shareholders may withdraw from the company as a result of shareholders&rsquo; resolutions approving,
    among other things, material modifications to the corporate purpose, the rights attached to ordinary shares (e.g., voting
    rights and/or economic rights related to ordinary shares), conversion from a share corporation into a different legal entity or a
    transfer of the registered office outside of Italy. Under any such circumstances, non-withdrawing shareholders would have
    pre-emptive rights to purchase the shares of the withdrawing shareholders. Should no shareholder exercise its pre-emptive
    rights, the shares must be offered to third parties. If no third-party desires to purchase the shares, the Company must purchase
    them out of available reserves. In the event that there are no reserves available, the company must reduce its
    capital accordingly. According to Italian law, the liquidation value of any such shares must be on terms determined by the
    board of directors, after consultation with the board of statutory auditors and the external auditor, after careful consideration
    of the company&rsquo;s net asset value, prospective earnings and the market value of the ordinary shares. Under Italian
    law, a company may include provisions in its bylaws governing the criteria for determining the liquidation value of
    shares in the event of withdrawal. We have not done so as of the date of this offering.</TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 174; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->171<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>DELAWARE
    CORPORATE LAW</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>ITALIAN
    CORPORATE LAW</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Shareholder
    vote on board and management compensation</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
    the Delaware General Corporation Law, the board of directors has the authority to fix the compensation of directors, unless
    otherwise restricted by the certificate of incorporation or bylaws.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under Italian Law, the compensation
    of directors is established at the time of appointment or by resolution adopted at as shareholders&rsquo; meeting. The compensation
    of the chief executive officers shall be established by the board of directors, with input from the board of statutory auditors.
    If the bylaws so provide, the shareholders&rsquo; meeting may determine a total amount for the compensation of all directors,
    including the chief executive officer.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Annual
    vote on board renewal</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Unless
    otherwise specified in the certificate of incorporation or bylaws of the corporation, directors shall be elected by a plurality
    of votes of the shareholders on a date and at a time designated by or in the manner provided in the bylaws. Re-election is
    possible.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The board of directors is elected
    by resolution adopted at the annual shareholders&rsquo; meeting of the Company for the period established at the time
    of election but in no case for longer than three fiscal years. Directors may, but are not required to be, shareholders
    and may be reappointed for successive terms.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Indemnification
    of directors and executive management and limitation of liability</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD ROWSPAN="2" STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
                                         Delaware General Corporation Law provides that a certificate of incorporation may contain
                                         a provision eliminating or limiting the personal liability of directors, officers, employees
                                         or agents of the corporation for monetary damages for breach of a fiduciary duty as a
                                         director, except no provision in the certificate of incorporation may eliminate or limit
                                         the liability of a director for:</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;any
        breach of a director&rsquo;s duty of loyalty to the corporation or its shareholders;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;acts
        or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;statutory
        liability for unlawful payment of dividends or unlawful share purchase or redemption; or</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;any
        transaction from which the director derived an improper personal benefit.</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">A
        Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any proceeding,
        other than an action by or on behalf of the corporation, because the person is or was a director or officer, against liability
        incurred in connection with the proceeding if the director or officer acted in good faith and in a manner reasonably believed
        to be in, or not opposed to, the best interests of the corporation; and the director or officer, with respect to any criminal
        action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Unless
        ordered by a court, any foregoing indemnification is subject to a determination that the director or officer has met the
        applicable standard of conduct:</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;by
        a majority vote of the directors who are not parties to the proceeding, even though less than a quorum;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;by
        a committee of directors designated by a majority vote of the eligible directors, even though less than a quorum;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;by
        independent legal counsel in a written opinion if there are no eligible directors, or if the eligible directors so direct;
        or</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;by
        the shareholders.</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Moreover,
        a Delaware corporation may not indemnify a director or officer in connection with any proceeding in which the director
        or officer has been adjudged to be liable to the corporation unless and only to the extent that the court determines that,
        despite the adjudication of liability but in view of all the circumstances of the case, the director or officer is fairly
        and reasonably entitled to indemnity for those expenses which the court deems proper.</FONT></P></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Italian
                                   law requires directors and members of any committee designated by the board of directors to perform
                                   their duties with the degree of diligence required by the nature of their office and according to
                                   their specific level of competence. Liability should never arise from business judgments under the
                                   circumstances, even if the decisions made entail significant economic risks, but be attributable only
                                   to lack of diligence by the director in appreciating in advance the risk involved in the transaction
                                   to be undertaken, and therefore, the omission of possible precautions, assessments or the lack of
                                   information normally required for a decision of that type, taken under those circumstances and in
                                   that manner. Directors are liable to the company&rsquo;s creditors when their improper management
                                   conduct impairs the company&rsquo;s assets and prevents the company from satisfying creditors&rsquo;
                                   claims. If the company cannot repay its creditors, and a court determines that the directors did not
                                   adequately perform their duties relating to the preservation of assets, the court may find directors
                                   liable.</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 175; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->172<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>DELAWARE
    CORPORATE LAW</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>ITALIAN
    CORPORATE LAW</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Directors&rsquo;
    fiduciary duties</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">A
                                         director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders.
                                         This duty has two components: the duty of care and the duty of loyalty.</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
        duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise
        under similar circumstances. Under this duty, a director must inform himself of, and disclose to shareholders, all material
        information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act
        in a manner he reasonably believes to be in the best interests of the corporation. He must not use his corporate position
        for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of
        the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling
        shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been
        made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the
        corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties.</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">Should
        such evidence be presented concerning a transaction by a director, a director must prove the procedural fairness of the
        transaction, and that the transaction was of fair value to the corporation.</FONT></P></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under Italian law, directors
    must perform their duties and responsibilities with the degree of diligence required by the nature of their tasks
    and according to their level of competence.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 176; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->173<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>DELAWARE
    CORPORATE LAW</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>ITALIAN
    CORPORATE LAW</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Shareholder
    action by written consent</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">A
    Delaware corporation may, in its certificate of incorporation, eliminate the right of shareholders to act by written consent.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
    Italian law, shareholders may not act without a meeting.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Special/extraordinary
    meetings of shareholders</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
    Delaware law, special meetings of shareholders may be called by the board of directors or by such person or persons as may
    be authorized by the certificate of incorporation or the bylaws.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under Italian law, a shareholders&rsquo;
    meeting, both ordinary and extraordinary, may be called by the board of directors and must be called if requested by holders
    of at least 10% of the share capital in the case of a Private Company, as is our case, or for an Open Company, at least 5%
    of the share capital, unless in either case the bylaws establish a lower threshold. Shareholders are not entitled
    to request that a meeting of shareholders be convened to vote on issues which as a matter of law are within the authority
    of the board of directors. If a request by the shareholders for a meeting is rejected by the board of directors,
    and such refusal is unjustified, the meeting may be called by a competent court.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Shareholder
    proposals </I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">A
    shareholder of a Delaware corporation has the right to put any proposal before the annual meeting of shareholders, provided
    it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors
    or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special
    meetings.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">Registered holders of the Company&rsquo;s ordinary shares are entitled to attend
and vote at all ordinary and extraordinary shareholders&rsquo; meetings.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">When shareholders representing at least 10% of the share capital in
the case of a Private Company, as is our case, or for an Open Company, at least 5% of the share capital, unless
in either case the bylaws establish lower threshold, request the board of directors to call a meeting of shareholders, they
must set out in their request the proposals to be discussed.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Georgia"></FONT></P></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Cumulative
    voting</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
    the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation&rsquo;s
    certificate of incorporation provides for it.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under Italian law, shareholders
    are not entitled to elect directors through cumulative voting. Directors are elected by a majority of the votes cast by the
    shareholders entitled to vote in person or by proxy at an ordinary meeting of shareholders at which the relevant quorum is met.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Board
    action by written consent</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
    Delaware law, any action required or permitted to be taken at any meeting of the board of directors may be taken without a
    meeting if all members of the board consent to the action in writing or by electronic transmission, and the writing or electronic
    transmission is filed with the minutes of proceedings of the board, unless otherwise restricted by the certificate of incorporation
    or bylaws.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
    Italian law, directors of a corporation may not act without a meeting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 177; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->174<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: center"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 8pt"><B>DELAWARE CORPORATE LAW</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: center"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 8pt"><B>ITALIAN CORPORATE LAW</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 8pt"><I>Removal of directors</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Unless there is cumulative voting or there is a classified board, generally a director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">Under Italian law, a director may be removed from office at any time by the
    vote of shareholders at an ordinary shareholders&rsquo; meeting. The removal is immediately effective against third parties only
    upon entry of the relevant resolution in the Companies Register.</P>
    <P STYLE="font: 12pt Georgia, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">A resolution approved at a shareholders&rsquo; meeting of claim for liability
    against a director or the occurrence of causes of ineligibility to serve under applicable law constitute just cause for removal.</P>
    <P STYLE="font: 12pt Georgia, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">If the removal of a director is without just cause, the director
    may have a claim for damages against the company. These damages may include, but are not limited to, compensation that would
    otherwise have been paid to the director for the remainder of his or her term and damage to his or her reputation.</P>
    <P STYLE="font: 12pt Georgia, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">Directors may resign at any time by written notice to the board of directors
    and to the chairman of the board of statutory auditors. The board of directors, subject to the approval of the board of statutory
    auditors, must appoint substitute directors to fill any vacancies caused by removal or resignation of directors, and the substitute
    will serve until the next ordinary shareholders&rsquo; meeting. If, at any time, more than half of the members of the
    board of directors elected by shareholders resign, such resignation is ineffective until a majority of the new board
    of directors has been elected. In such a case, the remaining members of the board of directors (or the board of statutory
    auditors if all the members of the board of directors have resigned or ceased to be directors) must promptly call an ordinary shareholders&rsquo;
    meeting to elect new directors.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 8pt"><I>Transactions with interested shareholders or directors</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">The Delaware General Corporation Law generally prohibits a Delaware corporation from engaging in certain business combinations with an &ldquo;interested shareholder&rdquo; for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or group who or which owns or owned 15.0% or more of the corporation&rsquo;s outstanding voting shares within the past three years.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">Italian law provides that a resolution approved at a shareholders&rsquo;
    meeting with the vote of shareholders who have, directly or indirectly, a conflict of interest with the company may be challenged.</P>
    <P STYLE="font: 12pt Georgia, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">Under Italian law, a director having a personal interest in
    a proposed transaction must disclose his or her interest to the board of directors and to the board of statutory auditors, even if
    such interest does not conflict with the company&rsquo;s interest in the transaction. The interested director is not required
    to abstain from voting on the resolution approving the transaction, but the resolution must explicitly state the reasons for the
    approved transaction and the benefit of the transaction to the company. If these provisions are not complied with, or if the
    transaction would not have been approved without the vote of the interested director, the resolution may be challenged within 90
    days by any director or by the board of statutory auditors on grounds that the approved transaction would be prejudicial to the
    company. An authorized representative of the company having any interest in a proposed transaction that he or she has
    authority to approve must solicit prior board approval before consenting to such transaction. An interested director may be
    held liable for damages to the company resulting from a resolution adopted in breach of the above requirements. Finally,
    a director may be held liable for illicitly profiting from insider information or a corporate opportunity.</P></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 178; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->175<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>DELAWARE
    CORPORATE LAW</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>ITALIAN
    CORPORATE LAW</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Dissolution;
    winding up</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Unless
    the board of directors of a Delaware corporation approves the proposal to dissolve, dissolution must be approved by shareholders
    holding 100.0% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors
    may it be approved by a simple majority of the corporation&rsquo;s outstanding shares. Delaware law allows a Delaware corporation
    to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated
    by the board.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under Italian law, and subject
    to the satisfaction of the claims of all creditors, upon liquidation shareholders are entitled to a distribution that is equal to
    a per share amount equal to positive liquidation balance divided by the number of shares outstanding.
    Asset distribution to preferred shareholders and holders of &ldquo;participating certificates&rdquo; upon corporate dissolution is
    typically provided by established contractual preferences. Once the rights of preferred shareholders and holders of participating
    certificates have been fully satisfied, holders of ordinary shares are entitled to any remaining assets.</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Variation
    of rights of shares</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">A
    Delaware corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of
    such class, unless the certificate of incorporation provides otherwise.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">Italian law allows the Company to issue preference shares with limited voting rights,
other classes of equity securities with different economic and voting rights, shares with economic rights related to the results of the
corporate activity in a specific sector, &ldquo;participation instruments&rdquo; (<I>strumenti finanziari partecipativi</I>) with limited
economic and voting rights against the contribution, by shareholders or third parties, of work or services, as well as &ldquo;participation
instruments&rdquo; in favor of employees.</P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 179; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->176<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>DELAWARE
    CORPORATE LAW</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>ITALIAN
    CORPORATE LAW</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Amendment
    of governing documents</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">A
    Delaware corporation&rsquo;s governing documents may be amended with the approval of a majority of the outstanding shares
    entitled to vote, unless the certificate of incorporation provides otherwise.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
                                   Italian law, the charter documents consist of articles of association and bylaws. An amendment to
                                   these documents requires the approval of shareholders at an extraordinary shareholders&rsquo; meeting
                                   with the following majorities for a Private Company, such as ours: on the first call, more than half
                                   of the share capital, and on the second call, at least two-thirds of the shares present or represented
                                   at the meeting, provided that a quorum of more than one-third of the share capital is present or represented.
                                   Certain matters (such as a change in business purpose or corporate form, demergers, mergers, the
                                   transfer of the registered office outside Italy, liquidation prior to the term set forth in its bylaws,
                                   extension of the company&rsquo;s term, the revocation of liquidation and the issuance of special categories
                                   of shares) must be approved by the extraordinary shareholders&rsquo; meeting pursuant to the same
                                   requirements.</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">For an Open Company, according to Italian law, such resolutions are adopted,
on the first call, by a majority of at least two-thirds of the shares present or represented at such meeting, provided
that a quorum of at least half of the share capital is present or represented; on the second call, by a majority of at
least two-thirds of the shares present or represented at such meeting, provided that a quorum of more than one-third of the share
capital is present or represented; on the third and subsequent calls, by a majority of at least two-thirds of the shares present
or represented at such meeting, provided that a quorum of at least one-fifth of the share capital is present or represented.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">Under Italian law, a shareholder who has not participated in a resolution amending
the bylaws that involves a change in the rights attached to its shares has the right to withdraw from the company.</P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 180; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->177<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>DELAWARE
    CORPORATE LAW</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>ITALIAN
    CORPORATE LAW</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Inspection
    of Books and Records</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Shareholders
    of a Delaware corporation, upon written demand under oath stating the purpose thereof, have the right during the usual hours
    for business to inspect for any proper purpose, and to obtain copies of list(s) of shareholders and other books and records
    of the corporation and its subsidiaries, if any, to the extent the books and records of such subsidiaries are available to
    the corporation.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">Under Italian law, our shareholders may review the report of the board of directors
on the management of the company and the report of the statutory auditors and external auditor on the financial
statements during the 15 days prior to the ordinary shareholders&rsquo; meeting called to approve those financial statements.
The report remains on file at the company&rsquo;s office and is also filed with the Companies&rsquo; Register of Milan and made
publicly available. Moreover, any shareholder is entitled to examine the ledger of the minutes of the shareholders&rsquo; meeting at
any time.</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0">For an Open Company, insofar as the ownership of the share capital may vary on a daily basis and transfers are
electronically registered by intermediaries (banks and financial institutions), the record holder shall be determined according to certifications
or communications to the company from intermediaries, based to their own accounting records.</P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font: 10pt Georgia"></FONT></P></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Payment
    of dividends</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
                                         board of directors may approve a dividend without shareholder approval. Subject to any
                                         restrictions contained in its certificate of incorporation, the board may declare and
                                         pay dividends upon the shares of its capital stock either:</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;out
        of its surplus, or</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 21.5pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;in
        case there is no such surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the
        preceding fiscal year.</FONT></P></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">Under Italian law, any
                                            payment of dividends must be proposed by the board of directors to the
                                            shareholders and is subject to shareholder approval at the annual ordinary shareholders&rsquo;
                                            meeting. Before dividends may be paid out of profits in any year, the company must
                                            allocate an amount equal to 5% of the net profit to a legal reserve until such reserve
                                            is at least equal to 20% of the corporate capital. If the corporate capital
                                            is reduced as a result of accumulated losses, the company may not pay dividends until
                                            the capital is reconstituted or reduced by the amount of such losses. The company
                                            may distribute reserves constituting earnings retained from prior years, provided
                                            that after such payment the company must have a legal reserve at least equal to the
                                            legally required minimum of 20% of corporate capital. If the minimum requirement
                                            of a reserve equal to 20% of corporate capital is met, the board of directors
                                            could propose the payment of a dividend and the shareholders approve it, the
                                            shareholders&rsquo; resolution must specify the manner and date of dividend payment.
                                            Any dividends which shareholders do not collect within five years of the payment date
                                            will be forfeited and the money returned to the company. The board of directors
                                            may not approve dividends during the period between annual ordinary shareholders&rsquo;
                                            meetings.</P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 181; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->178<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>DELAWARE
    CORPORATE LAW</B></FONT></TD>
    <TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>ITALIAN
    CORPORATE LAW</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Return
    of Capital</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Delaware
    law provides that corporations may return capital by dividend, redemption or repurchase subject to certain solvency tests.
    Shareholder approval is not required for these transactions so long as the corporation meets the solvency tests.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left">Under Italian law, a company
                                   are permitted to purchase outstanding shares, subject to certain conditions and limitations (so-called
                                   &ldquo;<I>azioni proprie</I>&rdquo;). A company may only purchase shares out of profits available
                                   for dividends or out of distributable reserves, in each case as appearing on the latest financial
                                   statements approved by shareholders. Further, the company may only repurchase fully
                                   paid-in shares. Such purchases and the conditions thereto must be authorized by the shareholders
                                   at an ordinary shareholders&rsquo; meeting and the approval may not be for a period
                                   exceeding 18 months. Shares purchases in excess of the amount approved by shareholders
                                   must be sold within one year of the date of purchase and, if not sold, must be cancelled and
                                   the corporate capital must be reduced accordingly. Similar limitations apply with respect to purchases
                                   of shares by subsidiaries.</P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left">A reserve equal to the purchase price of such shares must be created
        on the balance sheet, and such reserve is not available for dividends, unless the shares are sold or cancelled.
        Shares purchased and held by the company may be resold only pursuant to a resolution adopted at an ordinary shareholders&rsquo;
        meeting. The voting rights attaching to the shares held by the company or its subsidiaries cannot be exercised,
        but the shares can be counted for quorum purposes. Dividends and other rights, including pre-emptive rights, attaching to such
        shares, will accrue to the benefit of other shareholders.</P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left">The foregoing limitations do not apply in case the company
        purchases shares: (i) pursuant to a shareholder resolution approved at a shareholders&rsquo; meeting authorizing
        a capital reduction through repurchase or cancellation; (ii) without consideration, to the extent the shares
        are fully paid-in; (iii) as a consequence of merger or demerger; (iv) by foreclosure to satisfy a debt owed to
        the company, to the extent the shares are fully paid-in.</P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
        long as such shares remain the property of the company, the right to profits and the right of option are attributed proportionally
        to the other shares. The right to vote is suspended, but such shares are nevertheless taken into account for the purposes
        of calculating the majority and the quora required for the constitution and for the resolutions of the shareholders&rsquo;
        meetings.</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 182; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->179<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>DELAWARE
    CORPORATE LAW</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>ITALIAN
    CORPORATE LAW</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Creation
    and issuance of new shares</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Shareholder
                                         approval is required to authorize capital stock in excess of that provided in the charter.
                                         The corporation must file a certificate of amendment to its certificate of incorporation
                                         before the creation of additional authorized shares may become effective.</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
        board of directors may, without shareholder consent, authorize capital stock to be issued for consideration consisting
        of cash, any tangible or intangible property or any benefit to the corporation, or any combination thereof.</FONT></P></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left">Under Italian law, the issuance of
                                   any shares, ordinary or otherwise, requires an amendment to the bylaws to increase the share
                                   capital, which must be recommended to the shareholders by the board of directors
                                   and approved by the shareholders at an extraordinary shareholders&rsquo; meeting. The board
                                   of directors shall then be authorized to issue the securities according to the terms
                                   and conditions approved by shareholders. Alternatively, the shareholders can delegate
                                   the power to increase the share capital to the board of directors, but the board&rsquo;s right
                                   to exercise such power for up to five years. If the board does not approve a capital increase
                                   within five years, the authority expires automatically. With respect to shareholders&rsquo;
                                   resolutions approving capital increases, Italian law provides that in the absence of meeting minutes
                                   or in the event of the impossibility or illegality of the resolution, any interested person may challenge
                                   such resolution for a period of 180 days following the filing of the shareholders&rsquo; resolution
                                   with the Register of Companies. If a shareholders&rsquo; meeting was not properly held to approve
                                   the capital increase, the relevant resolution should be considered invalid, and any interested person
                                   may challenge the capital increase for a period of 90 days following the approval of the financial
                                   statements for the year during which the capital increase was executed in whole or
                                   in part. Finally, once shareholders authorize a capital increase, all the new authorized
                                   shares that have been subscribed must be paid-up in full before a new capital increase may
                                   be executed.</P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left">By means of shareholders&rsquo; extraordinary resolution, the
        company can also increase its corporate capital (without requesting contributions from its shareholders) by
        allocating to capital its available reserves and other funds registered in its financial statements (so-called
        &ldquo;<I>aumento di capitale gratuito</I>&rdquo;). In this case, the newly issued shares must have the same characteristics
        as those previously issued, and they must be placed to the shareholders proportionally to their shareholdings in the company.</P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 183; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->180<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>DELAWARE
    CORPORATE LAW</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>ITALIAN
    CORPORATE LAW</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Option
    Rights</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
    Delaware law, shareholders do not possess option rights with respect to the issuance of additional securities by the corporation,
    unless the certificate of incorporation provides otherwise.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left">Under Italian law, shareholders and
                                   holders of convertible debentures are entitled to subscribe for newly issued ordinary shares
                                   or convertible debentures in proportion to their holdings at the time of authorization of the issuance,
                                   except in the case of contributions in kind. Those who exercise such option right, provided they
                                   make such request at the same time, have a further pre-emption right with respect
                                   to shares and debentures convertible into shares that have not been subscribed. The option
                                   rights may be excluded or limited by a shareholders&rsquo; resolution approved at an extraordinary
                                   meeting of the shareholders, if such exclusion or limitation is in the interest of the company,
                                   or if the shares are to be paid for by means of a contribution in kind.</P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">According
        to Italian law proposals to increase the share capital with the exclusion or limitation of pre-emptive rights
        must be accompanied by a report of the board of directors setting forth the reasons for the exclusion
        or limitation, or, if the exclusion derives from a contribution in kind, the reasons for such contribution in kind, and in all
        cases the criteria adopted for determining the issue price. The report must be communicated by the directors to the board
        of statutory auditors and to the external auditor at least 30 days prior to the date of the shareholders&rsquo;
        meeting at which the capital increase is to be approved. Within 15 days, the board of statutory auditors must express
        its opinion on the fairness of the issue price of the new shares. The opinion of the board of statutory auditors and,
        only in the case of contribution in kind, the sworn report of the expert appointed by a competent court or the documentation
        provided by Italian law, must be available at the company&rsquo;s registered office during the 15 days prior to
        the shareholders&rsquo; meeting. Such terms may be waived by unanimous consent of the shareholders. The shareholders&rsquo;
        resolution shall determine the issue price of the shares on the basis of shareholders&rsquo; equity, taking into account,
        in the case of shares listed on a regulated market, also the trend in prices over the last six months. The foregoing
        procedure shall apply also in case of capital increase delegated to the board of directors.</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 184; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->181<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>DELAWARE
    CORPORATE LAW</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>ITALIAN
    CORPORATE LAW</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Debt-equity
    ratio</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
    Delaware law, there are no restrictions on the amount of debt securities that a corporation may issue.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left">Under Italian law, a company
                                   may issue debt securities in an amount not to exceed twice the sum of its corporate capital,
                                   plus legal reserves and any other disposable reserves appearing on the latest
                                   balance sheet approved by the shareholders. The board of statutory auditors must certify compliance
                                   with such limitation. This limitation may be exceeded if the debt securities issued in excess are
                                   intended for subscription by professional investors subject to regulatory supervision pursuant
                                   to special laws. In the event of subsequent circulation of the debt security, whoever transfers them
                                   is liable for the solvency of the company vis-&agrave;-vis buyers who are not professional investors.
                                   The rules indicated above do not apply in case we intend to issue debt securities to be listed on
                                   regulated markets or multilateral trading systems or which have attached the right to purchase or
                                   subscribe shares.</P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left">The legal reserve is a reserve to which a company must
        allocate 5% of its net income each year until it equals at least 20% of the corporate capital. Another reserve
        is a &ldquo;share premium reserve,&rdquo; which reflects the amount paid for ordinary shares in excess of the amount allocated
        to corporate capital. Until its outstanding debt securities are repaid in full, a company may not voluntarily reduce
        its corporate capital or distribute reserves (such as by declaring dividends) if, by doing so, it fails to meet the
        limitation indicated above. In the event of mandatory capital reduction, or if reserves reduce as a consequence of losses, the
        company may not distribute dividends until the aggregate of corporate capital and reserves, following such reduction
        of capital and/or distribution of reserves, is equal or exceeding half of the outstanding principal amount of debt
        securities. If our equity is reduced by losses or otherwise, such that the principal amount of outstanding debt securities
        is more than twice the amount of the company&rsquo;s equity, the company cannot pay dividends to shareholders
        until the minimum ratio between the amount of debt securities and our capital and reserves is restored. Some legal scholars
        are of the opinion that the ratio must be restored by a recapitalization of the company. If equity is reduced, a company
        could recapitalize by means of issuing new shares or having current shareholders contribute additional capital, although
        there can be no assurance that we would be able to find purchasers for new shares or that any of our current shareholders would
        be willing to contribute additional capital. These provisions regarding the ratio of debt securities to corporate capital
        and reserves do not apply to the issuance of debt securities to professional investors (as defined by Italian law). However,
        professional investors who transfer such debt securities issued by us to third parties not qualified as professional investors
        would remain liable to our third-party investors for the payment of such securities.</P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 185; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->182<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>DELAWARE
    CORPORATE LAW</B></FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 49%; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><B>ITALIAN
    CORPORATE LAW</B></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Georgia"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt"><I>Reduction
    of equity by losses</I></FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD COLSPAN="3" STYLE="font: 10pt Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under Delaware law,
    shareholder equity in a corporation is reduced by losses and may become negative.</FONT></TD>
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia"><P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Italian
                                   law requires a company to reduce its shareholders&rsquo; equity in certain situations.
                                   Shareholders&rsquo; equity has three main components: capital, legal reserves and other shareholders&rsquo;
                                   equity (such as any premium paid for the shares over the nominal value and any retained earnings).
                                   Losses from operations are first offset against shareholders&rsquo; equity other than
                                   legal reserves and corporate capital. If additional losses remain and, after setting aside
                                   legal reserves, corporate capital is reduced by more than one-third as a result of losses, the
                                   board of directors must call a shareholders&rsquo; meeting as soon as possible. The shareholders,
                                   having received an updated report on the company&rsquo;s financial situation accompanied
                                   by a report of the board of statutory auditors, should take appropriate measures, which
                                   may include, among others<I>,</I> reducing the legal reserves and corporate capital
                                   by the amount of the remaining losses, or carrying the losses forward up to one year. If the shareholders
                                   vote to carry the losses forward up to one year, and the losses are still more than one-third of the
                                   amount of corporate capital at the end of that year, then the company must reduce its
                                   corporate capital by the amount of the losses suffered. An S.p.A. like us must have
                                   a corporate capital of at least &euro;50,000. If the amount of the losses would reduce our corporate
                                   capital to less than &euro;50,000, then:</FONT></P>
        <P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 22pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;we
        would need to increase our capital, which we could do by issuing new shares or having our shareholders contribute additional
        capital to our company, although there can be no assurance that we would be able to find purchasers for new shares or
        that any of our current shareholders would be willing to contribute additional capital;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 22pt; text-align: left; text-indent: -13.5pt"></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 22pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 22pt; text-align: left; text-indent: -13.5pt"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0 0 0 22pt; text-indent: -13.5pt"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0 0 0 22pt; text-indent: -13.5pt"></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 22pt; text-align: left; text-indent: -13.5pt">&#9679;&nbsp;&nbsp;&nbsp;our shareholders
would need to convert our company to an &ldquo;S.r.l.&rdquo;, a private limited liability company, which has a lower capital requirement
of &euro;10,000. Such arrangement would, however, prevent the Company to remain listed on Nasdaq since the S.r.l. form is not
consistent with being listed pursuant to Italian law; or</P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 22pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font: 12pt Georgia"></FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 22pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 22pt; text-align: left; text-indent: -13.5pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;&nbsp;&nbsp;&nbsp;if
        neither of these options are pursued, our shareholders or, if the directors do not convene a shareholders&rsquo; meeting,
        a court of competent jurisdiction, at the instance of individuals shareholders, could appoint a liquidator, who need not
        be an Italian citizen, to liquidate our company.</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">EXCHANGE
CONTROLS</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">No
exchange control consent is required in Italy for the transfer of dividends or other distributions with respect to shares of an
Italian company or proceeds from the sale thereof to persons outside of Italy.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 186; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->183<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="S_006"></A>TAXATION</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>The
following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition
of our ordinary shares. You should consult your own tax advisor concerning the tax consequences of your particular situation,
as well as any tax consequences that may arise under the laws of any state, local, foreign, including Italian, or other taxing
jurisdiction.</I></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Italy
Tax Considerations</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>General</I></B>.
Under Italian law, financial instruments issued by an Italian company are subject to the same tax regime as are shares, provided
that their remuneration is entirely represented by participation in the economic results of the issuer. Pursuant to Article 10(3)
of the Income Tax Convention, the tax regime of dividends applies to income from corporate rights of an Italian company, which
is subject to the same taxation treatment as income from shares under the laws of Italy.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Income
Tax Withholding on Dividends</I></B>. We do not anticipate making any distributions on our ordinary shares in the foreseeable
future. However, if we were to make distributions on our ordinary shares, we would generally be required under Italian law, except
as otherwise discussed below, to apply a definitive withholding tax on payments made to holders of our ordinary shares who are
not residents of Italy for tax purposes.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Notably,
dividends paid to beneficial owners who are not Italian residents and do not have a permanent establishment in Italy are generally
subject to a 26 percent substitute tax rate. Therefore, the amount of the dividends that the holders of ADRs or holders of equity
shares not residing in Italy will initially receive will be net of such Italian substitute tax.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">All
non-Italian resident owners of equity shares or ADRs may benefit from reduced withholding tax settled in the relevant anti-double
tax treaty undersigned between Italy and the country of residence for tax purposes of the owners of equity shares or ADRs. The
reduced withholding tax rate under the relevant anti-double tax treaty will be applicable provided that the non-resident owners
of the equity shares or ADRs are able to produce the documentation attesting the requirements to be eligible for the application
of the relevant anti-double tax treaty.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
Italian law, US owners can claim, in accordance with Presidential Decree No. 600 of October 16, 1973, Article 27(3), a refund
of up to eleven-twenty-sixths (<I>i.e. </I>11/26) of the Italian withholding tax withheld on dividends upon presenting evidence
to the Italian tax authorities that income taxes have been fully paid on the dividends in the country of residence of the US owners
in an amount at least equal to the total refund claimed. US holders should consult an independent tax advisor concerning the availability
of this refund, which has traditionally become payable only after extensive delays.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Under
the double tax treaty in force between Italy and the United States of America (&ldquo;US/Italy Income Tax Treaty&rdquo;),
if the payee is the beneficial owner of the payment, dividends paid to US owners will be subject to Italian withholding tax at
a reduced rate of: 1) 5%, if the beneficiary is a company owning at least 25% of the payer&rsquo;s voting shares (for at least
12 months preceding the dividend distribution); 2) 15% in any other case. The aforementioned regime (both 1 and 2) is applicable
only if the payee does not carry out an entrepreneurial activity in Italy through a permanent establishment or performs independent
personal services through a fixed place situated therein.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Companies
or entities subject to corporation tax and resident in States that are European Union Member States or participants in the EEA
(included in the list provided for by Italian Ministerial Decree, September 4, 1996, amended and supplemented by Ministerial Decree
March 23, 2017) may be entitled to a reduced tax rate of 1.2% on dividends distributed. The pensions funds established in an EU
Member State or EEA country may be entitled to a reduced tax rate of 11% or, under certain conditions, to exemption from Italian
taxation on dividends.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Income
Tax on Capital Gains</I>.</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
a general rule, gains from shares in Italian companies, under custody in Italy, could give rise to a taxable income for the non-resident
transferor.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 187; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->184<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Capital
Gains exempt from taxation in Italy</I> - &ldquo;Non-qualified shareholdings&rdquo; are those which are below 2% of the voting
rights and 5% of the capital of an exchange-listed company. Gains from the disposal of non-qualified share investments in Italian
listed companies by non-Italian residents are not subject to Italian income tax under domestic rule.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Capital
Gains subject to tax in Italy</I> - &ldquo;Qualified shareholdings&rdquo; in a listed company are those representing more than
the 2% of the voting rights or more than the 5% of the capital of an exchange-listed company. Capital gains from the disposal
of a qualified shareholding in a listed company are subject to a withholding tax of 26% under the domestic rule.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
&ldquo;qualified shareholding&rdquo; thresholds must be verified over a 12-month monitoring period, starting from the day on which
the investor has held at least a qualifying stake, either actual or potential (this rule aimed at preventing that a buy/sale kind
of trading resulting in an overall disposition of over 2% in 12 months may result in a qualifying gain having to be declared even
when the investor has never owned an actual or potential qualifying stake). As a consequence, all trades cumulatively carried
out in a 12-month period should be considered. More in details: (i) until the investor holds a qualifying shareholding at any
point in time, trades are not relevant for capital gain purposes, even if the overall amount disposed in a 12-month period exceeds
the relevant thresholds; and (ii) starting from the day when the taxpayer holds a qualifying shareholding, all the trades carried
out in any consecutive 12 months give rise to qualified capital gains if the overall amount disposed of exceeds one of the relevant
thresholds.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">However
please be informed that in accordance with rules stated in the anti-double tax treaty, in force between Italy and the country
of residence for tax purposes of the transferor, is possible to claim the benefit of exemption of the 26% taxation on capital
gains. In principle, and more in details, the art. 13 of the OECD model convention basically states that the capital gain is only
taxed in the transferor&rsquo;s country of tax residence. The Italy &ndash; U.S.A. anti-double treaty tax convention states a
taxation criterion in line with the above. In the light of the above and upon conditions that all the requirements relevant for
the application of the Italy &ndash; U.S.A. anti-double treaty tax convention are met, an US investor may benefit from the fully
exemption of taxation in Italy.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Furthermore,
save for any applicable anti-avoidance provision, pursuant to the Income Tax Convention, a US owner will not be subject to Italian
capital gain tax or to Italian individual or corporate income tax unless such US owner has a permanent establishment or fixed
base in Italy to which the owner&rsquo;s ordinary shares is effectively connected. To this end, US owners selling ordinary shares
and claiming benefits under the Income Tax Convention may be required to produce appropriate documentation establishing that the
above-mentioned conditions have been met.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Estate
and Gift Tax</I>. Inheritance and gift taxes, which were abolished in 2001, have been re-introduced in the Italian system by Law Decree
No. 262 of October 3, 2006 (converted into law, with amendments, by Law Decree No. 286 of November 24, 2006), as amended. Such taxes
will apply to the overall net value of the relevant assets, at the following rates, depending on the relationship between the testate
(or donor) and the beneficiary (or donee): (a) 4%, if the beneficiary (or donee) is the spouse or a direct ascendant or descendant (such
rate only applying on the net asset value exceeding, for each person, &euro;1.0 million); (b) 6%, if the beneficiary (or donee)
is a brother or sister (such rate only applying on the net asset value exceeding, for each person, &euro;0.1 million); (c) 6%
if the beneficiary (or donee) is another relative within the fourth degree or a direct relative-in-law as well as an indirect relative-in-law
within the third degree; and (d) 8% if the beneficiary is a person other than those mentioned under (a), (b) and (c), above. If the beneficiary
has a serious disability recognized under applicable law, inheritance and gift taxes will apply to its portion of the net asset value
exceeding &euro;1.5 million.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Transfer
tax</I>. In connection with the Italian stamp duty tax on the transfer of shares, according to article 37 of Law No. 248 of December
31, 2007, converted with amendments into Law No. 31 of February 28, 2008, the stamp duty has been abolished with regard to contracts
having as their object the transfer of shares. In certain cases the relevant transfer acts would be subject to the registration
tax at a flat amount equal to &euro;200.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Communications
Stamp Duty</I>. A stamp duty has been introduced under article 19 of Law Decree No. 201 of December 6, 2011, converted into Law
No. 214 of December 22, 2011, to be imposed on communications (issued by banks and financial intermediaries) to clients relating
to securities, even where the deposit of such securities is not mandatory (although certain entities are excluded). The amount
of the stamp duty is based on the market value of the securities or, in the absence of a market value, on the nominal amount or
the amount payable on redemption. As a general comment, the stamp duty rate is 0.2% on a yearly <I>pro-rata temporis</I> basis
(from January 1 up to December 31). The minimum amount is fixed of &euro; 34,20 up to a maximum amount of &euro;14,000. The communication
is deemed to be sent to clients at least once a year, even where there is no obligation to issue any such communication.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 188; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->185<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Financial
Transaction Tax</I>. Law 228 of December 24, 2012, Article 1(491 &ndash; 500) introduced the Italian Financial Transaction Tax
applicable (i) to the transfer of shares and other participative financial instruments issued by companies resident in Italy (&ldquo;Italian
Equity&rdquo;) and securities representing Italian Equity, regardless of the country where the issuer has its residence (together
with Italian Equity are referred to as &ldquo;Qualifying Equity&rdquo;); (ii) on the basis of the &ldquo;value of the transaction&rdquo;;
(iii) regardless of the place where the transaction is concluded and of the State where the parties have their residence; (iv)
to transactions on &ldquo;regulated markets and on multilateral trading facilities&rdquo; with a reduced rate; (v) to over-the-counter
transactions with a full rate.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
taxable event, triggering Italian Financial Transaction Tax, is the transfer of ownership of Qualifying Equity. Securities representing
Italian Equity are in scope of the Italian Financial Transaction Tax, regardless of the State where the issuer has its residence.
This provision is aimed at including in the scope of the Italian Financial Transaction Tax, American Depository Receipts (&ldquo;ADRs&rdquo;),
Global Depository Receipts (&ldquo;GDRs&rdquo;) and any other certificate of deposit, where the underlying securities are Italian
Equity.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
value of the transaction is determined on the basis of the net balance of the transactions settled daily, calculated for each
taxpayer with reference to the number of securities traded under the transactions settled in the same day and relating to the
same financial instrument.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
calculation is made by the financial intermediary responsible for the payment of the tax, i.e., the one receiving the order to
execute the transaction directly from the purchaser or final counterparty.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Italian Financial Transaction Tax is due by the person in whose favor the transfer of ownership of the Qualifying Equities occurs.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
tax rate applicable is 0.20% while the reduced rate for transactions on &ldquo;regulated markets and on multilateral trading facilities&rdquo;
is 0.10%.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
tax shall be paid by the 16th day of the month following the one in which the relevant triggering event occurs.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Italian Financial Transaction Tax does not apply to the transfer of ownership of Italian Equity where the issuing companies are
listed in regulated markets and have a market capitalization below 500 million Euros. Such exclusion also applies to the transfer
of ownership of securities representing Italian Equity.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">U.S. Federal
Income Tax Consequences</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">THE
FOLLOWING SUMMARY IS INCLUDED HEREIN FOR GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL
OR TAX ADVICE. EACH U.S. HOLDER SHOULD CONSULT WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES
OF THE PURCHASE, OWNERSHIP AND SALE OF ADSS, INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND POSSIBLE
CHANGES IN THE TAX LAWS.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Subject
to the limitations described in the next paragraph, the following discussion summarizes the material U.S. federal income tax consequences
to a &ldquo;U.S. Holder&rdquo; arising from the purchase, ownership and sale of the ADSs. For this purpose, a &ldquo;U.S. Holder&rdquo;
is a holder of ADSs that is: (1) an individual citizen or resident of the United States, including an alien individual who is
a lawful permanent resident of the United States or meets the substantial presence residency test under U.S. federal income tax
laws; (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) or a partnership (other than
a partnership that is not treated as a U.S. person under any applicable U.S. Treasury regulations) created or organized under
the laws of the United States or the District of Columbia or any political subdivision thereof; (3) an estate, the income of which
is includable in gross income for U.S. federal income tax purposes regardless of source; (4) a trust if a court within the United
States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have authority
to control all substantial decisions of the trust; or (5) a trust that has a valid election in effect to be treated as a U.S.
person to the extent provided in U.S. Treasury regulations.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 189; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->186<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">This
summary is for general information purposes only and does not purport to be a comprehensive description of all of the U.S. federal
income tax considerations that may be relevant to a decision to purchase the ADSs. This summary generally considers only U.S.
Holders that will own the ADSs as capital assets. This summary does not consider the U.S. federal tax consequences to a
person that is not a U.S. Holder, nor does it describe the rules applicable to determine a taxpayer&rsquo;s status as a U.S. Holder.
This summary is based on the provisions of the Internal Revenue Code of 1986, as amended, or the Code, final, temporary and proposed
U.S. Treasury regulations promulgated thereunder, administrative and judicial interpretations thereof,  and the U.S./Italy Income Tax Treaty, all as in effect as of the date hereof and all of which are subject to change,
possibly on a retroactive basis, and all of which are open to differing interpretations. We will not seek a ruling from the IRS
with regard to the U.S. federal income tax treatment of an investment in the ADSs by U.S. Holders and, therefore, can provide
no assurances that the IRS will agree with the conclusions set forth below.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">This
discussion does not address all of the aspects of U.S. federal income taxation that may be relevant to a particular U.S. holder
based on such holder&rsquo;s particular circumstances and in particular does not discuss any estate, gift, generation-skipping,
transfer, state, local, excise or foreign tax considerations. In addition, this discussion does not address the U.S. federal income
tax treatment of a U.S. Holder who is: (1) a bank, life insurance company, regulated investment company, or other financial institution
or &ldquo;financial services entity;&rdquo; (2) a broker or dealer in securities or foreign currency; (3) a person who acquired
our securities in connection with employment or other performance of services; (4) a U.S. Holder that is subject to the U.S. alternative
minimum tax; (5) a U.S. Holder that holds our securities as a hedge or as part of a hedging, straddle, conversion or constructive
sale transaction or other risk-reduction transaction for U.S. federal income tax purposes; (6) a tax-exempt entity; (7) real estate
investment trusts or grantor trusts; (8) an expatriate or a former long-term resident of the United States; or (9) a
U.S. Holder having a functional currency other than the U.S. dollar. This discussion does not address the U.S. federal income
tax treatment of a U.S. Holder that owns, directly or constructively, at any time, securities representing 10% or more of the
voting power or value of our shares. Additionally, the U.S. federal income tax treatment of partnerships (or other
pass-through entities) or persons who hold securities through a partnership or other pass-through entity are not addressed.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Each
prospective investor is advised to consult his or her own tax adviser for the specific tax consequences to that investor of purchasing,
holding or disposing of our securities, including the effects of applicable state, local, foreign or other tax laws and possible
changes in the tax laws.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Taxation
of Dividends Paid on Ordinary Shares</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
do not intend to pay dividends in the foreseeable future. In the event that we do pay dividends, and subject to the discussion
under the heading &ldquo;Passive Foreign Investment Companies&rdquo; below and the discussion of &ldquo;qualified dividend income&rdquo;
below, a U.S. Holder, other than certain U.S. Holders that are U.S. corporations, will be required to include in gross
income as ordinary income the amount of any distribution paid on ordinary shares (including the amount of any Italy tax withheld
on the date of the distribution), to the extent that such distribution does not exceed our current and accumulated earnings and
profits, as determined for U.S. federal income tax purposes. The amount of a distribution which exceeds our earnings and profits
will be treated first as a non-taxable return of capital, reducing the U.S. Holder&rsquo;s tax basis for the ordinary shares to
the extent thereof, and then capital gain. We do not expect to maintain calculations of our earnings and profits under U.S. federal
income tax principles and, therefore, U.S. Holders should expect that the entire amount of any distribution generally will be
reported as dividend income.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
general, preferential tax rates for &ldquo;qualified dividend income&rdquo; and long-term capital gains are applicable for U.S.
Holders that are individuals, estates or trusts. For this purpose, &ldquo;qualified dividend income&rdquo; means, inter alia,
dividends received from a &ldquo;qualified foreign corporation.&rdquo; A &ldquo;qualified foreign corporation&rdquo; is a corporation
that is entitled to the benefits of a comprehensive tax treaty with the United States which includes an exchange of information
program. The IRS has stated that the Italy/U.S. Tax Treaty satisfies this requirement and we believe we are eligible for the
benefits of that treaty.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 190; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->187<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, our dividends will be qualified dividend income if our ordinary shares are readily tradable on Nasdaq or another established
securities market in the United States. Dividends will not qualify for the preferential rates if we are treated, in the
year the dividend is paid or in the prior year, as a PFIC, as described below under &ldquo;Passive Foreign Investment Companies.&rdquo;
A U.S. Holder will not be entitled to the preferential rate: (1) if the U.S. Holder has not held our ordinary shares for at least
61 days of the 121 day period beginning on the date which is 60 days before the ex-dividend date, or (2) to the extent the U.S.
Holder is under an obligation to make related payments on substantially similar property. Any days during which the U.S. Holder
has diminished its risk of loss on our ordinary shares are not counted towards meeting the 61-day holding period. Finally, U.S.
Holders who elect to treat the dividend income as &ldquo;investment income&rdquo; pursuant to Code section 163(d)(4) will not
be eligible for the preferential rate of taxation.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
amount of a distribution with respect to our ordinary shares will be measured by the amount of the fair market value of any property
distributed, and for U.S. federal income tax purposes, the amount of any Italian taxes withheld therefrom. Cash distributions paid by
us in Euros will be included in the income of U.S. Holders at a U.S. dollar amount based upon the spot rate of exchange in effect
on the date the dividend is includible in the income of the U.S. Holder, and U.S. Holders will have a tax basis in such Euros
for U.S. federal income tax purposes equal to such U.S. dollar value. If the U.S. Holder subsequently converts the Euros into
U.S. dollars or otherwise disposes of it, any subsequent gain or loss in respect of such Euros arising from exchange rate fluctuations
will be U.S. source ordinary exchange gain or loss.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Taxation
of the Disposition of Ordinary Shares</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Except
as provided under the PFIC rules described below under &ldquo;Passive Foreign Investment Companies,&rdquo; upon the sale, exchange
or other disposition of our ordinary shares, a U.S. Holder will recognize capital gain or loss in an amount equal to the difference
between such U.S. Holder&rsquo;s tax basis for the ordinary shares in U.S. dollars and the amount realized on the disposition
in U.S. dollar (or its U.S. dollar equivalent determined by reference to the spot rate of exchange on the date of disposition,
if the amount realized is denominated in a foreign currency). The gain or loss realized on the sale, exchange or other disposition
of ordinary shares will be long-term capital gain or loss if the U.S. Holder has a holding period of more than one year at the
time of the disposition. Individuals who recognize long-term capital gains may be taxed on such gains at reduced rates of tax.
The deduction of capital losses is subject to various limitations.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Passive
Foreign Investment Companies</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Special
U.S. federal income tax laws apply to U.S. taxpayers who own shares of a corporation that is a PFIC. We will be treated as a PFIC
for U.S. federal income tax purposes for any taxable year that either:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; padding-bottom: 10pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">75%
    or more of our gross income (including our pro rata share of gross income for any company, in which we are considered to own
    25% or more of the shares by value), in a taxable year is passive; or</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">At
    least 50% of our assets, averaged over the year and generally determined based upon fair market value (including our pro rata
    share of the assets of any company in which we are considered to own 25% or more of the shares by value) are held for the
    production of, or produce, passive income.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">For
this purpose, passive income generally consists of dividends, interest, rents, royalties, annuities and income from certain commodities
transactions and from notional principal contracts. Cash is treated as generating passive income.</FONT><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">We have not made the formal analysis necessary to determine
whether or not we are currently a PFIC or whether we have ever been a PFIC, although preliminarily it appears we may have been a PFIC
at certain points in the past. The tests for determining PFIC status depend, in part, on the application of complex US federal income
tax rules, which are subject to differing interpretations. In addition, whether any corporation will be a PFIC for any taxable year depends
on the assets and income of such corporation over the course of each such taxable year and, as a result, it is difficult to make accurate
projections of future income and assets which are relevant to this determination for the current taxable year or any future period. Accordingly,
there can be no assurance that we currently are not or will not become a PFIC.</P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 191; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->188<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">If
we currently are or become a PFIC, each U.S. Holder who has not elected to mark the shares to market (as discussed below), would,
upon receipt of certain distributions by us and upon disposition of our ordinary shares at a gain: (1) have such distribution
or gain allocated ratably over the U.S. Holder&rsquo;s holding period for the ordinary shares, as the case may be; (2) the amount
allocated to the current taxable year and any period prior to the first day of the first taxable year in which we were a PFIC
would be taxed as ordinary income; and (3) the amount allocated to each of the other taxable years would be subject to tax at
the highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest charge for the deemed deferral
benefit would be imposed with respect to the resulting tax attributable to each such other taxable year. In addition, when shares
of a PFIC are acquired by reason of death from a decedent that was a U.S. Holder, the tax basis of such shares would not receive
a step-up to fair market value as of the date of the decedent&rsquo;s death, but instead would be equal to the decedent&rsquo;s
basis if lower, unless all gain were recognized by the decedent. Indirect investments in a PFIC may also be subject to these special
U.S. federal income tax rules.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
PFIC rules described above would not apply to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder has
held the ordinary shares while we are a PFIC, provided that we comply with specified reporting requirements. Instead, each U.S. Holder
who has made such a QEF election is required for each taxable year that we are a PFIC to include in income such U.S. Holder&rsquo;s pro
rata share of our ordinary earnings as ordinary income and such U.S. Holder&rsquo;s pro rata share of our net capital gains as long-term
capital gain, regardless of whether we make any distributions of such earnings or gain. In general, a QEF election is effective only
if we make available certain required information. The QEF election is made on a shareholder-by-shareholder basis and generally may be
revoked only with the consent of the IRS. </FONT></P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, the PFIC rules described above would not apply if we were a PFIC and a U.S. Holder made a mark-to-market election. A
U.S. Holder of our ordinary shares which are regularly traded on a qualifying exchange, including the Nasdaq Capital Market, can
elect to mark the ordinary shares to market annually, recognizing as ordinary income or loss each year an amount equal to the
difference as of the close of the taxable year between the fair market value of the ordinary shares and the U.S. Holder&rsquo;s
adjusted tax basis in the ordinary shares. Losses are allowed only to the extent of net mark-to-market gain previously included
income by the U.S. Holder under the election for prior taxable years.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">U.S.
Holders who hold our ordinary shares during a period when we are a PFIC will be subject to the foregoing rules, even if we cease
to be a PFIC. U.S. Holders are strongly urged to consult their tax advisors about the PFIC rules.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Tax
on Net Investment Income</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">U.S.
Holders who are individuals, estates or trusts will generally be required to pay a 3.8% Medicare tax on their net investment income
(including dividends on and gains from the sale or other disposition of our ordinary shares), or in the case of estates and trusts
on their net investment income that is not distributed. In each case, the 3.8% Medicare tax applies only to the extent the U.S.
Holder&rsquo;s total adjusted income exceeds applicable thresholds.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 192; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->189<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Information
Reporting and Withholding</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">A
U.S. Holder may be subject to backup withholding at a rate of 24% with respect to cash dividends and proceeds from a disposition
of ordinary shares. In general, backup withholding will apply only if a U.S. Holder fails to comply with specified identification
procedures. Backup withholding will not apply with respect to payments made to designated exempt recipients, such as corporations
and tax-exempt organizations. Backup withholding is not an additional tax and may be claimed as a credit against the U.S. federal
income tax liability of a U.S. Holder, provided that the required information is timely furnished to the IRS.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">A U.S. Holder with interests in &ldquo;specified
foreign financial assets&rdquo; (including, among other assets, our ordinary shares, unless such ordinary shares are held on such
U.S. Holder&rsquo;s behalf through a financial institution) may be required to file an information report with the IRS if the
aggregate value of all such assets exceeds $50,000 on the last day of the taxable year or $75,000 at any time during the taxable
year (or such higher dollar amount as may be prescribed by applicable IRS guidance); and may be required to file a Report of Foreign
Bank and Financial Accounts if the aggregate value of the foreign financial accounts exceeds $10,000 at any time during the calendar
year. You should consult your own tax advisor as to the possible obligation to file such information report.</P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 193; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->190<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="S_007"></A>UNDERWRITING</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left">Roth Capital Partners, LLC is acting as the representative
of the underwriters named below. We have entered into an underwriting agreement dated December 14, 2021 with the Representative.
Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to each underwriter named below, and each underwriter
named below has severally agreed to purchase, at the public offering price less the underwriting discount set forth on the cover page
of this prospectus supplement, the number of ADSs listed next to its name in the following table:</P>

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="text-align: center; font-family: Georgia; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia; font-size: 8pt">Underwriter</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 8pt">Number
    of ADSs</FONT></TD><TD STYLE="text-align: center; font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia; font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left; width: 78%"><FONT STYLE="font-family: Georgia">Roth Capital Partners, LLC</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left; width: 1%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right; width: 18%"><FONT STYLE="font-family: Georgia">1,920,000</FONT></TD><TD STYLE="font-family: Georgia; text-align: left; width: 1%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left">Maxim Group LLC</TD><TD STYLE="font-family: Georgia">&nbsp;</TD>
    <TD STYLE="font-family: Georgia; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia; text-align: right">480,000</TD><TD STYLE="font-family: Georgia; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">2,400,000</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
underwriters are committed to purchase all the ADSs offered by the Company, other than those covered by the over-allotment option
to purchase additional ADSs as described below. The obligations of the underwriters may be
terminated upon the occurrence of certain events specified in the underwriting agreement. Furthermore, the underwriting agreement
provides that the obligations of the underwriters to pay for and accept delivery of the ADSs offered by us in this prospectus are subject to various representations and warranties and other customary conditions specified in the underwriting
agreement, such as receipt by the underwriters of officers&rsquo; certificates and legal opinions.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act, and to
contribute to payments the underwriters may be required to make in respect thereof.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
underwriters are offering the ADSs subject to prior sale, when, as and if issued to and accepted by them, subject to approval
of legal matters by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right
to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have granted the underwriters an over-allotment option. This option, which is exercisable for up to 30 days after the date of this prospectus,
permits the underwriters to purchase up to an aggregate of 360,000 additional ADSs (equal to 15% of the total number of ADSs sold
in this offering) at the public offering price per share, less underwriting discounts and commissions, solely to cover over-allotments,
if any. If the Representative exercises this option in whole or in part, then the underwriters will be severally committed, subject to
the conditions described in the underwriting agreement, to purchase the additional ADSs in proportion to their respective commitments
set forth in the prior table.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Discounts,
Commissions and Reimbursement</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Representative has advised us that the underwriters propose to offer the ADSs to the public at the initial public offering price per
share set forth on the cover page of this prospectus. The underwriters may offer ADSs to securities dealers at that price less a concession
of not more than $0.4025 per ADS.
After the initial offering to the public, the public offering price and other selling terms may be changed by the Representative.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
following table summarizes the underwriting discounts and commissions, advisory fees payable to the underwriters and proceeds,
before expenses, to us assuming both no exercise and full exercise by the underwriters of their over-allotment option:</FONT></P>

<P STYLE="text-align: left; font: 12pt Georgia; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per ADS</TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Without Option</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">With Option</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 67%">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">11.50</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">35,881,311</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">40,021,311</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Underwriting discounts and commissions (public investors, 7%)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.805</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,932,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,221,800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Advisory fee (Reserved Offering, 4.5%)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.5175</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">372,659</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">372,659</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds, before expenses, to us</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10.695</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">33,576,652</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">37,426,852</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 194; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->191<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
underwriters have agreed that the maximum aggregate underwriting discounts and commissions shall not exceed 6.5% of the total gross proceeds
from the offering. In addition, we have also agreed to pay the reasonable and documented expenses of the underwriters relating
to the offering (including the costs of document preparation, production and distribution (such as printing and binding, and photocopies),
and third-party research and database services, and the reasonable fees and disbursements of independent counsel), up to an aggregate
of $470,000.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
estimate the expenses of this offering payable by us, not including underwriting discounts and commissions, will be approximately $1.4
million, including a $200,000 cash advisory fee payable to Roth if more than $5 million in gross proceeds are provided by
investors from the United States and the United Kingdom</FONT>.</P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company has granted to Roth Capital Partners, LLC and Maxim Group LLC a right of first refusal to act as underwriters in a future public
or private offering by the Company. This right of first refusal complies with FINRA Rule 5110(g)(6) and is deemed to have an underwriting
compensation value of 1% of the amount of this offering.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriters&rsquo;
</B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of this offering, we have agreed to issue to the Underwriters&rsquo; Warrants, or the Underwriters&rsquo; Warrants, to purchase
up to 26,080 ADSs equal to 4% of the total number of ADSs sold in this public offering to investors other than (i) non-US retail,
family office or institutional investors identified by the Company and mutually agreed with the Representative and (ii) existing investors
in the Company. The Underwriters&rsquo; Warrants will be exercisable at a per share exercise price equal to 125% of the public offering
price per ADS sold in this offering. The Underwriters&rsquo; Warrants are exercisable at any time and from time to time, in whole or
in part, during the four and one-half year period commencing six months from the deemed effective date of the registration statement
related to this offering. The Underwriters&rsquo; Warrants provide for customary antidilution provisions and contingent registration
rights in compliance with FINRA Rule 5110(g)(8)(D).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriters&rsquo; Warrants and the ADSs underlying the Underwriters&rsquo; Warrants have been deemed compensation by
the Financial Industry Regulatory Authority, or FINRA, and are therefore subject to a 180-day lock-up pursuant to FINRA Rule 5110(g)(1).
The holder, or permitted assignees under such rule, may not sell, transfer, assign, pledge, or hypothecate the Underwriters&rsquo;
Warrants or the ADSs underlying the Underwriters&rsquo; Warrants, nor will the holder engage in any hedging, short sale, derivative,
put, or call transaction that would result in the effective economic disposition of the Underwriters&rsquo; Warrants or the underlying
ADSs for a period of 180 days from the deemed effective date of the registration statement. Additionally, the Underwriters&rsquo;
Warrants may not be sold transferred, assigned, pledged or hypothecated for a 180-day period following the deemed effective date
of the registration statement except to any underwriter and selected dealer participating in the offering and their bona fide officers
or partners. The Underwriters&rsquo; Warrants will provide for adjustment in the number and price of the Underwriters&rsquo;
Warrants and the ADSs underlying such Underwriters&rsquo; Warrants in the event of recapitalization, merger, stock split or
other structural transaction, or a future financing undertaken by us.</FONT></P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Reserved
Offering/Directed</B></FONT><FONT STYLE="font: 10pt Georgia"><B> Share Program</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">At our request, 720,114 ordinary shares covered
by the registration statement of which this prospectus is part have been reserved for sale, at the initial public offering price, by
the Company, directly or through agents, in the Reserved Offering to existing shareholders of the Company, as a mitigant for the exclusion
of pre-emptive rights as resolved by the general shareholders meeting of the Company in accordance with Italian corporate law and our
by-laws. The Reserved Offering will be effected in compliance with the laws of Italy, at the same price to investors as the offering
of ADSs. We will receive the proceeds from the Reserved Offering minus an advisory fee payable to the underwriters equal to 4.5% of the
offering price of ordinary shares sold to existing shareholders. The offer and sale of ordinary shares in the Reserved Offering (i) is
contingent upon the completion of the offering of ADSs and will commence and be consummated concurrently with such offering of ADSs,
(ii) has been registered for purposes of the securities laws of the United States under the registration statement of which this prospectus
is part, and (iii) is conducted in Italy under applicable exemptions from Italian and European regulations concerning prospectus.</P>
<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 195; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->192<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Lock-Up
Agreements</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have agreed with the underwriters that we will not, without the prior consent of the Representative, for a period of 180 days following
the date of this prospectus, offer, sell, contract to sell, pledge, grant any option to purchase, purchase any option or contract to
sell, right or warrant to purchase, make any short sale, file a registration statement with respect to any ordinary shares or ADSs or
any securities that are convertible into or exercisable or exchangeable for ordinary shares or ADSs, or otherwise transfer or dispose
of (including entering into any swap or other agreement that transfers to any other entity, in whole or in part, any of the economic
consequences of ownership interest): (1) the ADSs and depositary shares representing our ordinary shares; (2) shares of our controlled
affiliates and depositary shares representing those shares; and (3) securities that are substantially similar to such ADSs or depositary
shares. We have also agreed to cause our stockholders at the time of the Corporate Conversion to abide by the restrictions of
the lock-up agreement. In addition, each of our directors and executive officers and each beneficial owner of 10% or more of the ADSs
or ordinary shares will abide by similar 180-day lock-up agreement with respect to their ordinary shares, ADSs, depositary shares representing
the ADSs and securities that are substantially similar to the ADSs or depositary shares representing our ordinary shares, subject to
customary exceptions for transfers among affiliates. The restrictions of our lock-up agreement do not apply to: (1) the issuance of securities
pursuant to our employee share incentive plan which is described in this prospectus, and (2) a transfer by us to our affiliate, provided
that such transfer is not a disposition for value and that such affiliate agrees to be bound in writing by the restrictions set forth
in the lock-up agreement to which we are subject. The exceptions also permit our executive officers and directors and other existing
security holders, subject to certain restrictions, to transfer ADSs, depositary shares representing the ADSs and securities that are
substantially similar to the ADSs or our ordinary shares: (i) as a bona fide gift or gifts, (ii) to the person&rsquo;s immediate family
or any trust, partnership or similar entity for the direct or indirect benefit of the person or their immediate family, (iii) by operation
of law, such as pursuant to a qualified domestic order or as required by a divorce settlement, (iv) as a distribution to the person&rsquo;s
limited partners or stockholders, (v) to the person&rsquo;s affiliates or any investment fund or other entity controlled or managed by
the person, or (vi) by will, other testamentary document or intestate succession upon death, including to the transferee&rsquo;s nominee
or custodian. Furthermore, during the lock-up period, our executive officers, directors, and other existing security holders may sell
ordinary shares purchased from us in the Reserved Offering and ADSs purchased from the underwriters or in the open market following this
offering, provided that such sales are not required to be reported in any public report or filing with the SEC or otherwise, and the
seller does not voluntarily effect any public filing or report regarding such sales during the lock-up period.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Indemnification</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have agreed to indemnify the several underwriters against certain liabilities, including certain liabilities under the Securities
Act. If we are unable to provide this indemnification, we have agreed to contribute to payments the underwriters may be required
to make in respect of those liabilities.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Some
of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial
dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary
fees and commissions for these transactions.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">No
Public Market</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Prior
to this offering, there has not been a public market for our securities in the U.S. and the public offering price for the ADSs
will be determined through negotiations between us and the underwriters. Among the factors to be considered in these negotiations will
be prevailing market conditions, our financial information, market valuations of other companies that we and the underwriters believe
to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
offer no assurances that the initial public offering price will correspond to the price at which the ADSs will trade in the public
market subsequent to this offering or that an active trading market for the ADSs will develop and continue after this offering.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 196; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->193<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Stock
Exchange</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">ADSs
have been approved for listing on the Nasdaq Capital Market under the symbol &ldquo;GNTA,&rdquo; subject to official notice
of issuance. </FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Electronic
Distribution</FONT></P>

<P STYLE="text-indent: 0.5in; font: bold 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">A
prospectus in electronic format may be made available on websites or through other online services maintained by one or more of
the underwriters of this offering, or by their affiliates. Other than the prospectus in electronic format, the information on
any underwriter&rsquo;s website and any information contained in any other website maintained by an underwriter is not part of
this prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by
us or any underwriter in its capacity as underwriter, and should not be relied upon by investors.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Stabilization</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering
transactions, penalty bids and purchases to cover positions created by short sales.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Stabilizing
transactions permit bids to purchase ADSs so long as the stabilizing bids do not exceed a specified maximum, and are engaged in
for the purpose of preventing or retarding a decline in the market price of the ADSs while the offering is in progress.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Over-allotment
transactions involve sales by the underwriters of ADSs in excess of the number of ADSs the underwriters are obligated to purchase.
This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short
position, the number of ADSs over-allotted by the underwriters is not greater than the number of ADSs that they may purchase in
the over-allotment option. In a naked short position, the number of ADSs involved is greater than the number of ADSs in the over-allotment
option. The underwriters may close out any short position by exercising their over-allotment option and/or purchasing ADSs in
the open market.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Syndicate
covering transactions involve purchases of ADSs in the open market after the distribution has been completed in order to cover
syndicate short positions. In determining the source of ADSs to close out the short position, the underwriters will consider,
among other things, the price of ADSs available for purchase in the open market as compared with the price at which they may purchase
ADSs through exercise of the over-allotment option. If the underwriters sell more shares than could be covered by exercise of
the over-allotment option and, therefore, have a naked short position, the position can be closed out only by buying ADSs in the
open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could
be downward pressure on the price of the ADSs in the open market that could adversely affect investors who purchase in the offering.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Penalty
bids permit the Representative to reclaim a selling concession from a syndicate member when the ADSs originally sold by that
syndicate member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">These
stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market
price of the ADSs or preventing or retarding a decline in the market price of the ADSs. As a result, the price of the ADSs in
the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the underwriters
make any representation or prediction as to the effect that the transactions described above may have on the price of the ADSs.
These transactions may be effected on Nasdaq in the over-the-counter market or otherwise and, if commenced, may be discontinued
at any time.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 197; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->194<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Certain
of the underwriters and their affiliates may in the future provide various investment banking, commercial banking and other financial
services for us and our affiliates for which they may in the future receive customary fees.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Offer
restrictions outside the United States</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities
offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus
may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in
connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances
that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this
prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution
of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered
by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Australia</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">This
prospectus is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian
Securities and Investments Commission and does not purport to include the information required of a disclosure document under
Chapter 6D of the Australian Corporations Act. Accordingly, (i) the offer of the securities under this prospectus is only made
to persons to whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act
under one or more exemptions set out in section 708 of the Australian Corporations Act, (ii) this prospectus is made available
in Australia only to those persons as set forth in clause (i) above, and (iii) the offeree must be sent a notice stating in substance
that by accepting this offer, the offeree represents that the offeree is such a person as set forth in clause (i) above, and,
unless permitted under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the securities
sold to the offeree within 12 months after its transfer to the offeree under this prospectus.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>China</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
information in this document does not constitute a public offer of the securities, whether by way of sale or subscription, in
the People&rsquo;s Republic of China (excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau
Special Administrative Region and Taiwan). The securities may not be offered or sold directly or indirectly in the PRC to legal
or natural persons other than directly to &ldquo;qualified domestic institutional investors.&rdquo;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>European
Economic Area</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
relation to each member state of the European Economic Area (each, a relevant member state), no securities have been offered or
will be offered pursuant to the offering described in this prospectus to the public in that relevant member state prior to the publication
of a prospectus in relation to the securities that has been approved by the competent authority in that relevant member state,
all in accordance with the Prospectus Regulation, except that offers of securities may be made to the public in that relevant
member state at any time:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&bull;
to qualified investors as defined under article 2(e) of the Prospectus Regulation;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font: 10pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font: 10pt Georgia">&bull; to fewer than 150
natural or legal persons (other than qualified investors as defined under article 2(e) of the Prospectus Regulation); or</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font: 10pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font: 10pt Georgia">&bull; in any
other circumstances falling within article 1(4) of the Prospectus Regulation, </FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font: 10pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">provided
that no such offer of securities shall require us or any underwriter to publish a prospectus pursuant to article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to article 23 of the Prospectus Regulation.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">For purposes of this provision,
the expression an &ldquo;offer to the public&rdquo; in relation to any securities in any relevant member state means the communication
in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable
an investor to decide to purchase or subscribe for any securities, and the expression &ldquo;Prospectus Regulation&rdquo; means
Regulation (EU) 2017/1129.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Israel</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
securities have not been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA, nor
have such securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public
in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with the offering
or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered
an opinion as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities
offered by this prospectus is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities
laws and regulations.</FONT></P>




<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Japan</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
securities have not been and will not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law
of Japan (Law No. 25 of 1948), as amended (the &ldquo;FIEL&rdquo;) pursuant to an exemption from the registration requirements
applicable to a private placement of securities to Qualified Institutional Investors (as defined in and in accordance with Article
2, paragraph 3 of the FIEL and the regulations promulgated thereunder). Accordingly, the securities may not be offered or sold,
directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan other than Qualified Institutional Investors.
Any Qualified Institutional Investor who acquires securities may not resell them to any person in Japan that is not a Qualified
Institutional Investor, and acquisition by any such person of securities is conditional upon the execution of an agreement to
that effect.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 198; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->195<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Switzerland</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&ldquo;SIX&rdquo;) or
on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the
disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure
standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange
or regulated trading facility in Switzerland. Neither this document nor any other offering material relating to the securities
may be publicly distributed or otherwise made publicly available in Switzerland.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Neither
this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss
regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised
by, the Swiss Financial Market Supervisory Authority (FINMA).</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">This
document is personal to the recipient only and not for general circulation in Switzerland.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>United
Arab Emirates</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Neither
this document nor the securities have been approved, disapproved or passed on in any way by the Central Bank of the United Arab
Emirates or any other governmental authority in the United Arab Emirates, nor has the Company received authorization or licensing
from the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates to market or
sell the securities within the United Arab Emirates. This document does not constitute and may not be used for the purpose of
an offer or invitation. No services relating to the securities, including the receipt of applications and/or the allotment or
redemption of such shares, may be rendered within the United Arab Emirates by the Company.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">No
offer or invitation to subscribe for securities is valid or permitted in the Dubai International Financial Centre.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>United
Kingdom</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Neither
the information in this document nor any other document relating to the offer has been delivered for approval to the Financial
Services Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets
Act 2000, as amended (&ldquo;FSMA&rdquo;) has been published or is intended to be published in respect of the securities. This
document is issued on a confidential basis to &ldquo;qualified investors&rdquo; (within the meaning of section 86(7) of FSMA)
in the United Kingdom, and the securities may not be offered or sold in the United Kingdom by means of this document, any accompanying
letter or any other document, except in circumstances which do not require the publication of a prospectus pursuant to section
86(1) FSMA. This document should not be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed
by recipients to any other person in the United Kingdom.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Any
invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with
the issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused
to be communicated in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to the Company.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience
in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets
Act 2000 (Financial Promotions) Order 2005 (&ldquo;FPO&rdquo;), (ii) who fall within the categories of persons referred to in
Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise
be lawfully communicated (together &ldquo;relevant persons&rdquo;). The investments to which this document relates are available
only to, and any invitation, offer or agreement to purchase will be engaged in only with, relevant persons. Any person who is
not a relevant person should not act or rely on this document or any of its contents.</FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Canada</B></FONT></P>

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are
permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations.
Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus
requirements of applicable securities laws. Securities legislation in certain provinces or territories of Canada may provide a
purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation,
provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities
legislation of the purchaser&rsquo;s province or territory. The purchaser should refer to any applicable provisions of the securities
legislation of the purchaser&rsquo;s province or territory for particulars of these rights or consult with a legal advisor. Pursuant
to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply
with the disclosure requirements of NI33-105 regarding underwriter conflicts of interest in connection with this offering.</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 199; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->196<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="S_008"></A>EXPENSES</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Set
forth below is an itemization of the total expenses, excluding underwriting discounts, expected to be incurred in connection with
the offer and sale of the ordinary shares by us. With the exception of the SEC registration fee and the FINRA filing fee, all
amounts are estimates:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%">
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 78%; text-align: left"><FONT STYLE="font-family: Georgia">SEC registration fee</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">$</FONT></TD><TD STYLE="font-family: Georgia; width: 18%; text-align: right">3,745</TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Nasdaq listing fee</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">$</FONT></TD><TD STYLE="font-family: Georgia; text-align: right">4,740</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">FINRA filing fee</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">$</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">6,560</P></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Printer fees and expenses</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">$</FONT></TD><TD STYLE="font-family: Georgia; text-align: right">15,000</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Legal fees and expenses</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">$</FONT></TD><TD STYLE="font-family: Georgia; text-align: right">875,000</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Accounting fees and expenses</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">$</FONT></TD><TD STYLE="font-family: Georgia; text-align: right">280,000</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Miscellaneous</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">$</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right">25,000</TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">$</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">1,210,045</P></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="S_009"></A>LEGAL
MATTERS</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Certain
legal matters concerning this offering will be passed upon for us by Loeb &amp; Loeb LLP, New York, New York. Certain legal matters
with respect to the legality of the issuance of the securities offered by this prospectus will be passed upon for us by Giovannelli
e Associati, Studio Legale, Italy. Certain legal matters related to the offering will be passed upon for the underwriters by Goodwin
Procter LLP, New York, New York. LCA Studio Legale, Italy is representing the underwriters with respect to certain matters of
Italian law.</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="S_010"></A>EXPERTS</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in">The financial statements of Genenta for its fiscal years ended December 31, 2020 and 2019 included herein have
been audited by Mayer Hoffman McCann P.C., independent registered public accounting firm, as set forth in their report thereon. Such
financial statements are included in this prospectus and registration statement in reliance upon such report given on the authority
of such firm as experts in accounting and auditing. The address of Mayer Hoffman McCann P.C. is 13500 Evening Creek Drive North
#450, San Diego, California, United States.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="S_011"></A>ENFORCEABILITY
OF CIVIL LIABILITIES</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
are incorporated under the laws of Italy and our registered office and domicile is located in Milan, Italy. Moreover, a majority
of our directors and executive officers are not residents of the United States, and all or a substantial portion of our assets
are located outside the United States. As a result, it may not be possible for investors to effect service of process within the
United States upon us or upon such persons or to enforce against them judgments obtained in U.S. courts, including judgments in
actions predicated upon the civil liability provisions of the federal securities laws of the United States.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have been advised by our Italian counsel that the recognition and enforcement of foreign judgements in Italy is regulated either
by (i) treaties or conventions, bilateral or multilateral, between Italy and the foreign country, whose court issued the judgement,
or (ii) Italian Law no. 218 of May 31, 1995 (the &ldquo;International Private Law Act&rdquo;). In this regard, the provisions
of the applicable treaties and conventions, if any, prevail on the provisions of the International Private Law Act. Indeed, Section
2 of the International Private Law Act states that the provisions of the International Private Law Act are &ldquo;<I>without prejudice
to the application of the international conventions binding on Italy</I>&rdquo;.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">That
said, Italian counsels advise us that there exist no treaties or other conventions in existence between the Republic of Italy
and the United States, or between the Republic of Italy and the US laws, relating to the recognition and enforcement of civil
judgments. There follows that a civil judgment of a court of New York or of a United States federal court applying New York law
will be recognized in Italy under the general provisions of the International Private Law Act.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 200; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->197<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-indent: 0.5in; font: 12pt Georgia; margin: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Section
64 of the International Private Law Act provides that a judgment issued in a foreign country is recognized in Italy, without any
proceedings (<I>i.e., </I>without a rehearing on the merits) being necessary, if all of the following conditions are met:</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">a)
the judge who issued the judgment had the power to decide the case pursuant to the principles on jurisdiction provided by Italian
law;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">b)
the writ of summons (or equivalent pleading) was duly served upon the defendant in compliance with the applicable provisions of
the <I>lex fori </I>(i.e., the application of the rules of the legal system to which the judge belongs);</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">c)
the parties entered an appearance, or their default was duly declared in compliance with the applicable provisions of the <I>lex
fori</I>;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">d)
the judgment to be recognized is a final judgment subject to no further appeal;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">e)
the judgment to be recognized does not contrast with a final judgment issued by an Italian Court;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">f)
there are no pending proceedings between the same parties and in relation to the same matter, which proceedings were commenced
prior to the commencement of the foreign proceedings; and</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">g)
the judgment to be recognized does not conflict with Italian public order.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">When
the foreign civil judgment must be enforced in Italy, the above-mentioned conditions must be verified by the Italian Court of
Appeal based in the area where the judgment must be executed, as indicated in Article 67 of the International Private Law Act.
The subsequent decision of the competent Court of Appeal constitutes the title to enforce the foreign decision. Whether these
requirements are met in respect of a judgment based upon the civil liability provisions of the United States securities laws,
including whether the award of monetary damages under such laws would constitute a penalty, is an issue for the court making such
decision.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Subject
to the foregoing, investors may be able to enforce in Italy judgments in civil and commercial matters that have been obtained
from U.S. federal or state courts. Nevertheless, we cannot assure you that those judgments will be recognized or enforceable in
Italy.</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><A NAME="S_012"></A>WHERE
YOU CAN FIND ADDITIONAL INFORMATION</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have filed with the SEC a registration statement on Form F-1 under the Securities Act relating to this offering of our ordinary
shares. This prospectus does not contain all of the information contained in the registration statement. The rules and regulations
of the SEC allow us to omit certain information from this prospectus that is included in the registration statement. Statements
made in this prospectus concerning the contents of any contract, agreement or other document are summaries of all material information
about the documents summarized, but are not complete descriptions of all terms of these documents. If we filed any of these documents
as an exhibit to the registration statement, you may read the document itself for a complete description of its terms.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically with
the SEC. Our filings with the SEC are also available to the public through the SEC&rsquo;s website at www.sec.gov.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Upon
completion of this offering, we will be subject to the information reporting requirements of the Exchange Act that are applicable
to foreign private issuers, and under those requirements will file reports with the SEC. Those other reports or other information
may be inspected without charge at the locations described above. As a foreign private issuer, we will be exempt from the rules
under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders
are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition,
we will not be required under the Exchange Act to file annual, quarterly and current reports and financial statements with the
SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. However, we
will file with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an
annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm, and will
submit to the SEC, on Form 6-K, unaudited quarterly financial information.</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
maintain a corporate website at www.genenta.com. Information contained on, or that can be accessed through, our website does not
constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.</FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 201; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->198<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><A NAME="ab_001"></A>INDEX TO FINANCIAL STATEMENTS</P>
<P STYLE="font: 12pt Georgia; margin: 0; text-align: center"></P>

<P STYLE="font: 12pt Georgia; margin: 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif; text-align: center">YEARS ENDED DECEMBER 31, 2020 AND 2019</P>
<P STYLE="font: 12pt Georgia; margin: 0; text-align: center"></P>

<P STYLE="font: 12pt Georgia; margin: 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><A HREF="#g_001">Report of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><A HREF="#ar_002">Statements of Operations and
    Comprehensive Loss</A> </FONT></TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><A HREF="#ar_003">Balance Sheets</A></FONT></TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Georgia; margin: 0pt 2.7pt 0pt 0; text-align: left"><A HREF="#ar_004">Statements of Changes in
    Quotaholders&rsquo; Equity</A></TD>
    <TD STYLE="font: 10pt Georgia; margin: 0pt; text-align: left">F-5</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><A HREF="#ar_005">Statements of Cash Flows</A></FONT></TD>
    <TD STYLE="font: 10pt Georgia; margin: 0pt; text-align: left">F-6</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><A HREF="#ar_006">Notes to the Financial Statements</A></FONT></TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font: 12pt Georgia"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: center">SIX MONTHS ENDED JUNE 30, 2021 AND 2020</P>

<P STYLE="font: 12pt Georgia, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><A HREF="#sad_001">Statements of Operations and Comprehensive Loss</A></FONT></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">F-28</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><A HREF="#sad_002">Balance Sheets</A></FONT></TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">F-29</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><A HREF="#sad_003">Statements of Changes in Quotaholders&rsquo; Equity</A></FONT></TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">F-30</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><A HREF="#sad_004">Statements of Cash Flows</A></FONT></TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">F-31</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><A HREF="#sad_005">Notes to the Financial Statements</A></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">F-</FONT><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font: 12pt Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 202; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT><P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt; text-transform: uppercase"><B><A NAME="g_001"></A>Report
                                         of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 2.7pt 0 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">To the
Board of Directors and Quotaholders of <B>Genenta Science S.r.l.</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 2.7pt 0 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Opinion on the
Financial Statements</B></FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
have audited the accompanying balance sheets of <B>Genenta Science S.r.l. </B>(the &ldquo;Company&rdquo;) as of December 31, 2020 and
2019, and the related statements of operations and comprehensive loss, changes in quotaholders&rsquo; equity, and cash flows for each
of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020,
in conformity with accounting principles generally accepted in the United States of America.</FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Basis for Opinion</B></FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">We have served
as the Company&rsquo;s auditor since 2020.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>/s/ Mayer Hoffman
McCann P.C.</I></FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">San Diego, California</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">April 22, 2021</FONT></P>


<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 203; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><A NAME="ar_002"></A></B></FONT><B><FONT STYLE="font-size: 10pt"><I>Genenta
Science S.r.l.</I></FONT></B></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Statements
of Operations and Comprehensive Loss</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Year
    Ended December 31,</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">2019</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">(in Euros)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Operating expenses</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; width: 68%; text-align: left"><FONT STYLE="font-family: Georgia">Research
    and development</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">4,688,461</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">3,702,982</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">General
    and administrative</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">901,765</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">921,520</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Total operating
    expenses</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">5,590,226</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">4,624,502</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Loss from operations</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">(5,590,226</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">(4,624,502</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Other income (expense)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Other income</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">5,966</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">36,331</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Finance
    expense</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(7,754</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(9,552</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Total other income
    (expense), net</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(1,788</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">26,779</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Loss</FONT><FONT STYLE="font-family: Georgia">
    before income taxes</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">(5,592,014</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">(4,597,723</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Income tax benefit
    (expense)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Net loss</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(5,592,014</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(4,597,723</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Comprehensive loss</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Total comprehensive loss</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">(5,592,014</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">(4,597,723</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>The accompanying
notes are an integral part of these financial statements.</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 204; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I><A NAME="ar_003"></A>Genenta
Science S.r.l.</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Balance
Sheets</B></FONT></P>

<P STYLE="font: 10pt Georgia; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">At
    December 31,</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2019</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">(in Euros)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; font-weight: bold"><FONT STYLE="font-family: Georgia">Assets</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; font-style: italic; text-align: left"><FONT STYLE="font-family: Georgia">Current assets</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; width: 68%; text-align: left"><FONT STYLE="font-family: Georgia">Cash
    and cash equivalents</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">15,465,243</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">20,141,379</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Prepaid expenses
    and other current assets</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">947,501</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">458,118</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Prepaid
    expenses and other current assets - related party</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">121,432</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; font-style: italic; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Total
    current assets</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">16,534,176</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">20,599,497</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; font-style: italic; text-align: left"><FONT STYLE="font-family: Georgia">Non-current assets</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Property and equipment,
    net</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">18,971</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Other asset- related
    party</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">3,350</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Other
    non-current assets</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">945,618</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">748,681</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; font-style: italic; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Total
    non-current assets</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">967,939</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">748,681</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Total
    assets</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">17,502,115</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">21,348,178</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; font-weight: bold; text-align: left"><FONT STYLE="font-family: Georgia">Liabilities and quotaholders&rsquo;
    equity</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; font-style: italic; text-align: left"><FONT STYLE="font-family: Georgia">Current liabilities</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Accounts payable</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">544,988</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">279,699</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Accounts payable
    - related party</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">10,027</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">292,741</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Accrued expenses</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">365,969</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">213,973</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Accrued expenses
    - related party</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">1,359,191</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">1,651,620</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Other
    current liabilities</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">53,243</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">48,000</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; font-style: italic; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Total
    current liabilities</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">2,333,418</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">2,486,033</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; font-style: italic; text-align: left"><FONT STYLE="font-family: Georgia">Long-term liabilities</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Retirement
    benefit obligation</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">17,388</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">11,332</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; font-style: italic; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Total
    long-term liabilities</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">17,388</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">11,332</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; font-style: italic; text-align: left"><FONT STYLE="font-family: Georgia">Commitments and
    contingencies (Note 13)</FONT></TD><TD STYLE="font-family: Georgia; text-align: center"></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; font-style: italic; text-align: left"><FONT STYLE="font-family: Georgia">Quotaholders&rsquo;
    equity</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Corporate capital</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">37,056</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">36,049</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Additional paid-in
    capital</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">36,604,728</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">34,713,225</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Accumulated
    deficit</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(21,490,475</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(15,898,461</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Total quotaholders&rsquo;
    equity</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">15,151,309</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">18,850,813</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia"><B>Total liabilities
    and quotaholders&rsquo; equity</B></FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia"><B>&euro;</B></FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia"><B>17,502,115</B></FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia"><B>&nbsp;</B></FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia"><B>&euro;</B></FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia"><B>21,348,178</B></FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia"><B>&nbsp;</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>The accompanying
notes are an integral part of these financial statements.</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 205; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I><A NAME="ar_004"></A>Genenta
Science S.r.l.</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Statement
of Changes in Quotaholders&rsquo; Equity</B></FONT></P>

<P STYLE="font: 10pt Georgia; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">(in
    Euros, except quotas)</FONT></TD><TD STYLE="font-family: Georgia; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Corporate<BR>
    capital</FONT></TD><TD STYLE="font-family: Georgia; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Additional<BR>
    paid-in<BR>
    capital</FONT></TD><TD STYLE="font-family: Georgia; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Accumulated<BR>
    deficit</FONT></TD><TD STYLE="font-family: Georgia; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 44%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Balance at January
    1, 2019</FONT></TD><TD STYLE="font-family: Georgia; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 10%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">29,179</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 10%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">19,202,381</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 10%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(11,300,738</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 10%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">7,930,822</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Capital increase, net of issuance costs</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">6,870</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">14,761,332</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">14,768,202</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Share-based compensation</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">749,512</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">749,512</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><P STYLE="font: 10pt Georgia; margin: 0"><FONT STYLE="font-family: Georgia">Net
                                         loss</FONT></P></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(4,597,723</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(4,597,723</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Balance at December 31, 2019</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">36,049</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">34,713,225</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(15,898,461</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">18,850,813</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Capital increase, net of issuance costs</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">1,007</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">1,431,309</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">1,432,316</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Share-based compensation</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">460,194</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">460,194</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><P STYLE="font: 10pt Georgia; margin: 0"><FONT STYLE="font-family: Georgia">Net
                                         loss</FONT></P></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(5,592,014</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(5,592,014</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Balance at December 31, 2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">37,056</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">36,604,728</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(21,490,475</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">15,151,309</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>The
accompanying notes are an integral part of these financial statements.</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 206; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I><A NAME="ar_005"></A>Genenta
Science S.r.l.</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Statements
of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Year-Ended
    </FONT><FONT STYLE="font-family: Georgia">December 31,</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2019</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">(in Euros)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; font-weight: bold; text-align: left"><FONT STYLE="font-family: Georgia">Cash flows from operating
    activities</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; width: 68%; text-align: left"><FONT STYLE="font-family: Georgia">Net loss</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">(5,592,014</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">(4,597,723</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Adjustments to reconcile net loss to
    net cash used in operating activities:</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Depreciation expense</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">1,900</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Retirement benefit
    obligation</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">6,056</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">4,867</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Share-based compensation</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">460,194</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">749,512</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Changes in operating assets and liabilities</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Prepaid expenses
    and other current assets</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">(454,082</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">151,091</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Other non-current
    assets</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">(200,287</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">(588,681</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Accounts payable</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">265,289</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">190,088</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Accounts payable
    - related party</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">(282,714</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">(217,670</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Accrued expenses</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">38,263</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">133,797</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Accrued expenses
    - related party</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">(292,429</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">1,666,295</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Other
    current liabilities</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">5,243</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">18,237</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Net cash used
    in operating activities</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(6,044,581</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(2,490,187</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; font-weight: bold; text-align: left"><FONT STYLE="font-family: Georgia">Cash flows from investing
    activities</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Purchases
    of property and equipment</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(20,871</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Net cash used
    in investing activities</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(20,871</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; font-weight: bold; text-align: left"><FONT STYLE="font-family: Georgia">Cash flows from financing
    activities</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Proceeds
    from the issuance of quotas</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">1,500,436</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">15,086,708</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left">Issuance costs</TD><TD STYLE="font-family: Georgia">&nbsp;</TD>
    <TD STYLE="font-family: Georgia; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia; text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(68,120</P></TD><TD STYLE="font-family: Georgia; text-align: left">)</TD><TD STYLE="font-family: Georgia">&nbsp;</TD>
    <TD STYLE="font-family: Georgia; text-align: left">&nbsp;</TD><TD STYLE="font-family: Georgia; text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">(318,506</P></TD><TD STYLE="font-family: Georgia; text-align: left">)</TD></TR>
    <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Georgia; padding-left: 10pt; text-align: left">Prepaid offering costs</TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: right"><P STYLE="margin: 0">(43,000</P></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Net cash provided
by financing activities</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">1,389,316</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">14,768,202</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; font-weight: bold; text-align: left"><FONT STYLE="font-family: Georgia">Net (decrease)
    increase in cash and cash equivalents</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">(4,676,136</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">12,278,015</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Cash and cash
    equivalents at beginning of year</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">20,141,379</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">7,863,364</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Cash
    and cash equivalents at end of year</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">15,465,243</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">20,141,379</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Non-cash
    financing activities: deferred offering costs accrued at year end</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">113,733</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>The accompanying
notes are an integral part of these financial statements.</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 207; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt; font-variant: small-caps"><B><I><A NAME="ar_006"></A>Genenta
Science S.r.l.</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt; font-variant: small-caps"><B>Notes
to the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>1.
Nature of business</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">Genenta Science S.r.l. (the &ldquo;Company&rdquo;) is an early-stage
company developing potential ground-breaking cell and gene cancer therapies. The Company is initially developing its clinical leading
product, Temferon, to treat glioblastoma multiforme (&ldquo;GBM&rdquo;), a solid tumor affecting the brain. The Company intends to start
a second clinical trial to study Temferon in liver cancers and is planning to expand its clinical trial on UMGMT-GBM indications
in the United States.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font: 10pt Georgia"></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Genenta
Science S.r.l. is an Italian limited liability company (societ&agrave; a responsabilit&agrave; limitata, or S.r.l.), which is
similar to a limited liability company in the United States. The Company was founded by San Raffaele Hospital (&ldquo;OSR&rdquo;),
in Milan, Italy, Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner and was incorporated in July 2014. The Company is organized
under the laws of Italy, with registered office in Milan. The corporate capital of an S.r.l. is called a &ldquo;quota.&rdquo;
A quota is a varying ownership or portion of subscribed capital in the S.r.l. Each quota has specific rights and value. (See Note
10. Quotaholders&rsquo; Equity.) The Company&rsquo;s reporting currency is Euros.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company is subject to risks and uncertainties common to early-stage clinical companies in the life-science and biotechnology industries,
including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals
for product candidates, development by competitors of new competing products, dependence on key personnel, protection of proprietary
technology, compliance with government regulations and the ability to secure additional capital to fund operations. The clinical
product candidates currently under development will require significant additional research and development efforts, including
regulatory approval and clinical testing prior to commercialization. These efforts require significant amounts of additional capital,
adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&rsquo;s product development
efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Liquidity
and Risks </I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia">The Company
has incurred recurring losses since its inception, including a net loss of &euro;5,592,014 and &euro;4,597,723 for the
years ended December 31, 2020 and 2019. In addition, as of December 31, 2020, the Company had an accumulated deficit of &euro;21,490,475.
The Company has primarily funded these losses through the proceeds from sales of convertible debt and quotas. Although the
Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects
that its existing cash and cash equivalents on hand as of December 31, 2020 of &euro;15,465,243 will be more than sufficient to
fund current planned operations and capital expenditure requirements for at least the next twelve months from the filing date
of these financial statements. However, the future viability of the Company is dependent on its ability to raise additional capital
to finance its operations. The Company&rsquo;s inability to raise capital as and when needed could have a negative impact on its
financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will
be achieved or that additional funding will be available on terms acceptable to the Company, or at all.</FONT></P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company has evaluated whether there are conditions and events considered in the aggregate that raise substantial doubt about the
Company&rsquo;s ability to continue as a going concern. The Company&rsquo;s business model, typical of biotechnology companies
developing new therapeutic products that have not reached a balanced income and financial position, features negative cash flows.
This is due to the fact that, at this stage, costs must be borne in relation to services and personnel, directly connected to
research and development activities, and return for these activities is not certain and, in any case, it is expected in future
years. Based on the accounting policies adopted, requiring full recognition of research and development costs in the statement
of operations and comprehensive loss in the year they are incurred, the Company has reported a loss since its inception, and expects
to continue to incur significant costs for research and development in the foreseeable future. There is no certainty that the
Company will become profitable in the future.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 208; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia">The Company
has primarily funded its operations with proceeds from several capital increases and at March 31, 2021, had approximately &euro;13.1
million of cash and cash equivalents. Therefore, management and the Board of Directors believe that the Company has adequate financial
resources to support business operations in the foreseeable future and for at least 12 months from the date of this report. Accordingly,
the accompanying financial statements have been prepared assuming that the Company will continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company will require additional capital to meet its long-term operating requirements. It expects to raise additional capital through,
among other things, the sale of equity or debt securities. If adequate funds are not available in the future, the Company may
be forced to delay, reorganize, or cancel research and development programs, or to enter into financing, licensing or collaboration
agreements with unfavorable conditions or waive rights to certain products which otherwise it would not have waived, resulting
in negative effects on the activity and on the economic, patrimonial and /or financial situation of the Company.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia">In
February 2020, the COVID-19 pandemic commenced in Italy. Regulatory guidance was issued in March and updated in April 2020 relating
to the management of clinical trials during the pandemic. As the global healthcare community continues to respond to the COVID-19
pandemic, many hospitals, including the Company&rsquo;s clinical sites, temporarily paused elective medical procedures, including
dosing of new patients in clinical trials of our investigational gene therapies. While dosing of new patients and data collection
from enrolled patients has resumed at clinical sites, the extent to which clinical activities continue to be delayed or interrupted
will depend on future developments that are highly uncertain. The Company has not experienced significant interruptions related
to COVID-19, although one patient tested positive for COVID-19 and had to delay treatment with Temferon&trade;. The Company may
find it difficult to enroll patients in its clinical trials, which could delay or prevent the Company from proceeding with clinical
trials of its product candidates. The Company continues to closely monitor this rapidly evolving situation and the potential impact
on the Company.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Basis
of presentation</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United
States of America (&ldquo;U.S. GAAP&rdquo;). Any reference in these notes to applicable guidance is meant to refer to the
authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (&ldquo;ASC&rdquo;)
and Accounting Standards Update (&ldquo;ASU&rdquo;) of the Financial Accounting Standards Board (&ldquo;FASB&rdquo;), unless otherwise
stated.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">A
summary of the significant accounting policies applied in the preparation of these financial statements is presented below, only
for the categories and headings now applicable and that might be applicable in the future based on the Company&rsquo;s business.
These policies have been consistently applied, unless otherwise stated.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>2.
Summary of significant accounting policies</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Use
of estimates</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts reported in the financial statements and the disclosures made in the accompanying notes. Estimates
and assumptions reflected in these financial statements include, but are not limited to, the accrual for research and development
expenses and related milestone payments, share-based compensation expense, valuation of Research &amp; Development (R&amp;D) tax
credits, the valuation of equity and the recoverability of the Company&rsquo;s net deferred tax assets and related valuation allowance.
Estimates are periodically reviewed considering changes in circumstances, facts and experience. Actual results may differ from
these estimates under different assumptions or conditions. Changes in estimates are recorded in the period in which they become
known. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant
to the financial statements are disclosed below.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Cash
and cash equivalents</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash
equivalents. In the cash flow statement cash and cash equivalents includes cash on hand, deposits held with banks, and other short-term
highly liquid investments. In the balance sheet, bank overdrafts, if any, are shown in current liabilities. Cash and cash equivalents
are detailed as follows:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 70%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">At
    December 31,</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2019</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">(in Euros)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 60%; text-align: left"><FONT STYLE="font-family: Georgia">Cash in bank</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 16%; text-align: right"><FONT STYLE="font-family: Georgia">15,462,805</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 16%; text-align: right"><FONT STYLE="font-family: Georgia">20,137,033</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Cash in hand
    &amp; prepaid cards</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">2,438</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">4,346</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">15,465,243</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">20,141,379</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 209; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Net </I></B></FONT><FONT STYLE="font: 10pt Georgia"><B><I>loss
per share</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Net
loss per share (&ldquo;EPS&rdquo;) is computed in accordance with U.S. GAAP. Basic EPS is computed by dividing net loss by the
weighted average number of common shares outstanding during the period. Diluted EPS reflects potential dilution and is computed by
dividing net loss by the weighted average number of common shares outstanding during the period increased by the number of
additional common shares that would have been outstanding if all potential common shares had been issued and were dilutive.
Historical EPS or QPS (quota per share) has not been included in these financial statements because the Company has determined it is
not a meaningful or material disclosure due to the Company&rsquo;s current capital structure. Net loss per share has not been
presented at December 31, 2020 and 2019, </FONT><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">since the
Company was an S.r.l. at the time and maintained classes of quota (similar to membership interests in a limited liability company in
the United States) rather than shares, which it now has post-conversion to an S.p.A.,(similar to a C-corporation in the United
States). The quotas represented percentage ownership in the Company and not actual shares. The Company did not believe that
representing loss per quota was a meaningful measurement.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Foreign currency
translation</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
reporting and functional currency of the Company is Euros. All amounts are presented in Euros unless otherwise stated. All amounts
disclosed in the financial statements and notes have been rounded to the nearest Euro unless otherwise stated. Foreign currency
transactions, if any, are translated into Euros using the exchange rates prevailing at the dates of the transactions or valuation
where items are re-measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the
translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in
the statement of operations. During the years ended December 31, 2020 and 2019, foreign exchange gains and losses were insignificant.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Emerging
growth company status</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company is an &ldquo;emerging growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act, or JOBS Act, and may
take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are
not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an &ldquo;emerging
growth company.&rdquo; Section 107 of the JOBS Act provides that an &ldquo;emerging growth company&rdquo; can take advantage of
the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company
has elected to use the extended transition period for complying with new or revised accounting standards and as a result of this
election, its financial statements may not be comparable to companies that comply with public company effective dates. The Company
may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of its initial
public offering (&ldquo;IPO&rdquo;) or such earlier time that it is no longer an &ldquo;emerging growth company.&rdquo;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 210; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Fair
value measurements</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Certain
assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that
would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for
the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used
to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets
and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value
hierarchy, of which the first two are considered observable and the last is considered unobservable:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%">
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Level 1 &mdash; Quoted
    prices in active markets for identical assets or liabilities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Level 2 &mdash; Observable
    inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted
    prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable
    or can be corroborated by observable market data.</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Level 3 &mdash; Unobservable
    inputs that are supported by little or no market activity that are significant to determining the fair value of the assets
    or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">To
the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination
of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is
greatest for instruments categorized in Level 3. A financial instrument&rsquo;s level within the fair value hierarchy is based
on the lowest level of any input that is significant to the fair value measurement.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
carrying values of the Company&rsquo;s research and development tax credits, VAT credits, accounts payable, accrued expenses and
other current liabilities approximate their fair values due to the short-term nature of these assets and liabilities.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Segment
information</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Operating
segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company
and its chief operating decision-maker view the Company&rsquo;s operations and manages its business in one operating segment,
which is the research and development in the pharmaceutical sector with a focus on developing novel therapeutics to treat cancer.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Tax
credit on investments in research and development</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
line with the legislation in force until December 31, 2020, companies in Italy that invest in eligible research and development
activities, regardless of the legal form and economic sector in which they operate, can benefit from a tax credit which can be
used in order to reduce most taxes payable, including income tax or regional tax on productive activities, as well as of social
security contributions and withholding taxes. The tax credit calculation methodology changed in 2020, and the credit was determined
as 12% of eligible expenses up to &euro;3.0 million. Up until December 31, 2019, the tax credit was up to 50% of the increase
of annual research and development expenses compared to the median expense for the years 2012-2014.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
eligible activities consist of fundamental research, industrial research, and experimental development as defined respectively
of the letters m), q) and j) of point 15, par. 1.3 of the Communication no. 198/2014 of the European Commission.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 211; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">To
determine the cost basis of the benefit, the following expenses are eligible:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%">
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Personnel costs.</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Depreciation charges,
    costs of the financial or simple lease and other expenses related to movable tangible assets and software used in research
    and development projects.</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Expenses for extra-euro
    research contracts concerning the direct execution of eligible research and development activities by the provider.</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Depreciation charges
    related to industrial privatives.</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Expenses for consultancy
    services and equivalent services related to research and development eligible activities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Expenses for materials,
    supplies, and other similar products used in the research and development projects.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company accounts for this receivable in accordance with International Accounting Standards (IAS) 20, <I>Accounting for Government
Grants and Disclosure of Government Assistance</I>. The receivable is recognized when there is reasonable assurance that: (1)
the recipient will comply with the relevant conditions and (2) the grant will be received. The Company elected to present it net
of the related expenditure on the statement of operations and comprehensive loss.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">While
these tax credits can be carried forward indefinitely, the Company recognized an amount which reflects management&rsquo;s best
estimate of the amount that is reasonably assured to be realized or utilized in the foreseeable future based on historical benefits
realized, adjusted for expected changes, as applicable. The tax credits are recorded as an offset to research and development
expenses in the Company&rsquo;s statement of operations and comprehensive loss.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Share-based
compensation</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">To
reward the efforts of employees, directors, and certain consultants to promote the growth of the Company, the Company&rsquo;s
Board of Directors has approved, during its existence, various share-based awards. All options have been awarded with an exercise
price of &euro;1 per quota and, when exercised, all options have been converted to Quota B. The options granted have the vesting
condition that the individual must remain in his/her role at least one year or as otherwise specified for each person.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company measures share-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes
compensation expense for those awards over the requisite service period, which is the vesting period of the respective award.
Forfeitures are accounted for as they occur. The measurement date for option awards is the date of the grant. The Company classifies
share-based compensation expense in its statements of operations and comprehensive loss in the same manner in which the award
recipient&rsquo;s payroll costs are classified or in which the award recipient&rsquo;s service payments are classified.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">With
the adoption of Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2018-07, Compensation&mdash;Stock Compensation (Topic 718):
Improvements to Nonemployee Share-Based Payment Accounting (&ldquo;ASU 2018-07&rdquo;) on January 1, 2019, the measurement date
for non-employee awards is the date of the grant. The compensation expense for non-employees is recognized, without changes in
the fair value of the award, over the requisite service period, which is the vesting period of the respective award.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 212; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Property
and equipment</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Property
and equipment are stated at cost, including any accessory and direct costs that are necessary to make the assets fit for use,
and adjusted by the corresponding accumulated depreciation. The depreciation recorded in the financial statements of operations
has been calculated on a straight line basis by taking into consideration the use, purpose and financial-technical duration
of the assets, on the basis of their estimated useful economic lives. The Company believes the above criteria to be represented
by the following estimated useful lives:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">-
Equipment &amp; Furniture: 15 years</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">-
Electronic office equipment: 10 years</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">-
Leasehold improvements: based on the length of the lease</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Ordinary
maintenance costs are entirely attributed to the statements of operations in the year in which they are incurred. Extraordinary
maintenance costs, the purpose of which is to extend the useful economic life of the asset, to technologically upgrade it and/or
to increase its productivity or safety for the purposes of the economic productivity of the Company, are attributed to the asset
to which they refer and depreciated on the basis of its estimated useful economic life. Amortization of leasehold improvements
is computed using the straight-line method based upon the terms of the applicable lease or estimated useful life of the improvements,
whichever is less.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Impairment
of long-lived assets</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
accordance with ASC Topic 360-10-20, &lsquo;&lsquo;Property, Plant and Equipment,&rsquo;&rsquo; the Company performs an impairment
test whenever events or circumstances indicate that the carrying value of long-lived assets with finite lives may be impaired.
Impairment is measured by comparing the carrying value of the long-lived assets to the estimated undiscounted pre-tax cash flows
expected to result from the use of such assets and their ultimate disposition. In circumstances where impairment is determined
to exist, the Company will write down the asset to its fair value based on the present value of estimated cash flows. To date,
no impairments have been identified by management for the years ended December 31, 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0; text-align: justify"><FONT STYLE="font-family: Georgia"><B><I>Deferred Offering Costs</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia">Deferred
public offering costs, which primarily consist of direct, incremental legal and accounting fees relating to the initial
public offering (IPO), are capitalized within prepaid expenses and other current assets. The deferred offering costs will be
offset against IPO proceeds upon the consummation of the offering. In the event the offering is terminated, deferred offering
costs will be expensed. The Company has incurred &euro;156,000 in IPO offering costs as of December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Recently
issued accounting pronouncements</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
December 2019, the FASB issued ASU 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes. The new standard intended
to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intra-period tax allocation,
the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside
basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws
or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. For non-public entities,
the standard is effective for annual periods beginning after December 15, 2021, with early adoption permitted. Adoption of the
standard requires certain changes to primarily be made prospectively, with some changes to be made retrospectively. The Company
is currently evaluating the impact that the adoption of ASU 2019-12 will have on its financial statements.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia">In
July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic
480), Derivatives and Hedging (Topic 815) (Part I) Accounting for Certain Financial Instruments with Down Round Features
(Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic
Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (&lsquo;&lsquo;ASU
2017-11&rsquo;&rsquo;). Part I applies to entities that issue financial instruments such as warrants, convertible debt or
convertible preferred stock that contain down-round features. Part II replaces the indefinite deferral for certain
mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of non-public entities
contained within ASC Topic 480 with a scope exception and does not impact the accounting for these mandatorily redeemable
instruments. For non-public entities, ASU 2017-11 is effective for annual reporting periods beginning after December 15,
2019, including interim periods within those fiscal years. The Company does not expect the adoption of ASU 2017-11 to have a
significant impact on its financial
position, results of operations, or cash flows.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia">In August
2018, the FASB issued No. ASU 2018-13, Fair Value Measurement (Topic 820)&mdash;Disclosure Framework (&lsquo;&lsquo;ASU 2018-13&rsquo;&rsquo;),
which improves the disclosure requirements for fair value measurements. For non-public entities, ASU 2018-13 is effective for
annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption
is permitted for any removed or modified disclosures. The Company is currently evaluating the impact that the adoption of ASU
2018-13 will have on its financial statements.</FONT><FONT STYLE="font-family: Georgia"> <FONT STYLE="font-size: 10pt">The
FASB issued authoritative guidance that amends guidance on reporting credit losses for financial assets, including available-for-sale
marketable securities and any other financial assets not excluded from the scope that result in a contractual right to receive
cash. For available-for-sale marketable securities, credit losses should be measured in a manner similar to current generally
accepted accounting standards; however, ASU 2016-13, Financial Instruments&mdash;Credit Losses (Topic 326): Measurement of Credit
Losses on Financial Instruments, will require that credit losses be presented as an allowance rather than as a write-down. For
non-public entities, the standard is effective for annual periods beginning after December 15, 2022, with early adoption permitted.
The Company is currently evaluating the impact that the adoption of ASU 2016-13 will have on its financial statements.</FONT></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 213; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>3. Research
and development</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Research
and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research
and development activities, including salaries, share-based compensation and benefits, facilities costs, third-party license fees,
certain milestone payments, and external costs of outside vendors and consultants engaged to conduct clinical development activities
and clinical trials, (e.g., contract research organizations or &ldquo;CROs&rdquo;), as well as costs to develop a manufacturing
processes, perform analytical testing and manufacture clinical trial materials, (e.g., contract manufacturing organizations or
&ldquo;CMOs&rdquo;). Non-refundable prepayments for goods or services that will be used or rendered for future research and development
activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related
services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered. In addition,
funding from research grants, if any, is recognized as an offset to research and development expense based on costs incurred on
the research program.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company yearly sustains a significant amount of research costs to meet its business objectives. The Company has various research
and development contracts, and the related costs are recorded as research and development expenses as incurred. When billing terms
under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates
of outstanding obligations as of period end to those third parties. Any accrual estimates are based on several factors, including
the Company&rsquo;s knowledge of the progress towards completion of the research and development activities, invoicing to date
under the contracts, communication from the research institution or other companies of any actual costs incurred during the period
that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates may be made in determining
the accrued balances at the end of any reporting period. Actual results could differ from the estimates made by the Company. The
historical accrual estimates made by the Company have not been materially different from the actual costs. (For further details
please refer to the Related Parties disclosure in Note 12 below.)</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>4.
General and administrative</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">General
and administrative costs consist primarily of salaries, share-based compensation, benefits and other related costs for personnel
and consultants in the Company&rsquo;s executive and finance functions, professional fees for legal, finance, accounting, auditing,
tax and consulting services, travel expenses and facility-related expenses, which include rent and maintenance of facilities and
other operating costs not otherwise included in research and development expense.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>5.
Income taxes</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company is subject to taxation in Italy, including the standard corporate income tax (&ldquo;IRES&rdquo;) and a regional business
tax (&ldquo;IRAP&rdquo;). Taxes are recorded on an accrual basis. They therefore represent the allowances for taxes paid or to
be paid for the year, calculated according to the current enacted rates and applicable laws. Due to the tax loss position reported,
no income taxes were due for the years ending December 31, 2020 and 2019. The Company is taxed in various countries where it has
permanent establishment, as applicable.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company uses the asset and liability method of accounting for deferred income taxes. Under this method, deferred tax assets and
liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and
the tax basis of assets and liabilities, measured at tax rates expected to be enacted at the time of their reversals. These temporary
differences primarily relate to net operating losses carried forward available to offset future taxable income.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 214; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
of each reporting date, the Company considers existing evidence, both positive and negative, that could impact its view with regards
to future realization of deferred tax assets. In consideration of the start-up status of the Company, a full valuation allowance
has been established to offset the deferred tax assets, as the related realization is currently uncertain. In the future, should
management conclude that it is more likely than not that the deferred tax assets are partially or fully realizable, the valuation
allowance will be reduced to the extent of such expected realization, and the corresponding amount will be recognized as income
tax benefit in the Company&rsquo;s statement of operations and comprehensive loss.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company recognizes tax liabilities from an uncertain tax position if it is more likely than not that the tax position will not
be sustained upon examination by the taxing authorities, based on the technical merits of the tax position. There are no uncertain
tax positions that have been recognized in the accompanying financial statements. The prior five (5) years&rsquo; tax returns
are potentially subject to audit.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">A
reconciliation of the Company&rsquo;s effective tax rate is summarized as follows:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 80%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia">At
    December 31,</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2019</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">(in Euros)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 64%; text-align: left"><FONT STYLE="font-family: Georgia">Income taxes at Italy statutory
    rate</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 14%; text-align: right"><FONT STYLE="font-family: Georgia">(1,342,083</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 14%; text-align: right"><FONT STYLE="font-family: Georgia">(1,103,454</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Permanent differences</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">3,750</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">11,370</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Change in valuation
    allowance</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">1,338,333</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">1,092,084</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Total provision
    expense for income taxes</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Significant
components of the Company&rsquo;s net deferred tax assets are summarized as follows:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 80%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia">At
    December 31,</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2019</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">(in Euros)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Deferred tax assets</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; width: 64%; text-align: left"><FONT STYLE="font-family: Georgia">Net
    operating loss carryforwards</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 14%; text-align: right"><FONT STYLE="font-family: Georgia">4,692,844</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 14%; text-align: right"><FONT STYLE="font-family: Georgia">3,192,643</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Other temporary
    differences</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">144,000</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Georgia">Allowance for corporate
    equity</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">210,620</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">178,972</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Total deferred tax assets</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">4,903,464</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">3,515,615</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Valuation
    allowance</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(4,903,464</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(3,515,615</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Net deferred
    tax assets</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Tax
loss carryforwards expire as follows:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 80%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia">At
    December 31,</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2019</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">(in Euros)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 64%; text-align: left"><FONT STYLE="font-family: Georgia">No expiration date</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 14%; text-align: right"><FONT STYLE="font-family: Georgia">5,487,085</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 14%; text-align: right"><FONT STYLE="font-family: Georgia">5,487,085</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">No expiration
    date - DL 98/2011</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">14,066,434</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">7,815,593</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">19,553,519</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">13,302,678</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
2011, the Italian tax authorities issued a set of rules that modified the previous treatment of tax loss carryforwards. According
to the DL 98/2011, at the end of 2011, all existing tax loss carryforwards will never expire but they can off-set only 80% of
the taxable income of the year. The rules do not affect the tax loss carryforwards that refer to the start-up period, defined
as the first three (3) years of operations starting from the inception of the Company.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 215; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>6.
Prepaid expenses and other current assets</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Prepaid
expenses and other current assets consist of the following:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 75%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">At
    December 31,</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2019</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">(in Euros)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 68%; text-align: left"><FONT STYLE="font-family: Georgia">Value Added Tax (VAT)</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">480,000</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">237,569</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Research and Development Tax Credit</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">280,631</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">192,020</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><P STYLE="font: 10pt Georgia; margin: 0"><FONT STYLE="font-family: Georgia">Deferred
                                         offering costs</FONT></P></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">156,261</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia"><P STYLE="font: 10pt Georgia; margin: 0"><FONT STYLE="font-family: Georgia">Advances to
                                     suppliers &ndash; related party</FONT></P></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">121,432</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right">-</TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Other</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">30,609</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Georgia; text-align: right">28,529</TD><TD STYLE="padding-bottom: 1.5pt; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">1,068,933</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">458,118</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Value
Added Tax (VAT) receivables are linked to purchases. Italian VAT (<I>Imposta sul Valore Aggiunto</I>) applies to the supply of
goods and services carried out in Italy by entrepreneurs, professionals, or artists and on imports carried out by anyone. Intra-Community
acquisitions are also subject to VAT under certain situations. The Italian standard VAT rate for 2020 and 2019 is 22%. Reduced
rates are provided for specifically listed supplies of goods and services. It is carried forward indefinitely and does not expire.
The Company reclassified to other non-current assets a portion of the receivable which is expected to be realized beyond 12 months.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia">Tax credits
on research and development represent a special tax relief offered to Italian companies operating in the research and development
sector and can be used to offset most taxes payable. Tax credits on research and development available were &euro;3.9 million
at December 31, 2020 and &euro;3.5 million at December 31, 2019, which can be carried forward indefinitely and does not expire.
However, given the start-up status of the Company and the fact that it will not be profitable in the foreseeable future which
limits the utilization of the credit, the Company recognized a receivable balance at December 31, 2020, that represents
the Company&rsquo;s best estimate of the amount of tax credit that can be used in offsetting taxes payable for 2021 and 2022,
which represents the current projected available cash to support operations. In 2019, the limitation on the Company&rsquo;s tax
credit was based on three years of cash available to support operations. In 2020 and 2019, the Company utilized &euro;280,631
and &euro;192,020 to offset certain taxes payable. The benefit recorded in 2020 and 2019 to offset research and development expenses
was &euro;265,834 and &euro;448,079, respectively. The Company reclassified to other non-current assets a portion of the
receivable which is expected to be realized beyond 12 months.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia">The remaining
balance is comprised of miscellaneous minor prepaid expenses and deferred offering costs.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 216; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>7. Property
and equipment, net</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Property
and equipment consist of the following:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 75%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">At
    December 31,</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2019</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">(in Euros)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 68%"><FONT STYLE="font-family: Georgia">Computer</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">16,196</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Furniture and
    fixtures</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">4,675</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <TD STYLE="font-family: Georgia; font-style: normal; font-weight: normal; text-align: left"><FONT STYLE="font-family: Georgia; font-style: normal; font-weight: normal">Total
    property and equipment</FONT></TD><TD STYLE="font-family: Georgia; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Georgia; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; font-style: normal; font-weight: normal; text-align: left"><FONT STYLE="font-family: Georgia; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-style: normal; font-weight: normal; text-align: right"><FONT STYLE="font-family: Georgia; font-style: normal; font-weight: normal">20,871</FONT></TD><TD STYLE="font-family: Georgia; font-style: normal; font-weight: normal; text-align: left"><FONT STYLE="font-family: Georgia; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Georgia; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; font-style: normal; font-weight: normal; text-align: left"><FONT STYLE="font-family: Georgia; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-style: normal; font-weight: normal; text-align: right"><FONT STYLE="font-family: Georgia; font-style: normal; font-weight: normal">-</FONT></TD><TD STYLE="font-family: Georgia; font-style: normal; font-weight: normal; text-align: left"><FONT STYLE="font-family: Georgia; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Less: accumulated
    depreciation</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">(1,900</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Property
    and equipment, net</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">18,971</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Georgia"><B>&nbsp;</B></FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia"><B>-</B></FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Georgia"><B>&nbsp;</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Property
and equipment consist of computers and furniture and fixtures of our office space in Milan. No disposals, nor impairments occurred
during the periods. Depreciation has been calculated by taking into consideration the use, purpose, and financial-technical duration
of the assets, based on their estimated economic lives. Property and equipment were entirely purchased in 2020.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Depreciation
expense for the year ended December 31, 2020 was &euro;1,900. There was no depreciation expense for the year ended December 31,
2019.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>8. Other
non-current assets</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Other
non-current assets consist of the long-term portion of the VAT receivable and R&amp;D tax credit, as follows:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 75%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">At
    December 31,</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2019</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">(in Euros)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 68%; text-align: left"><FONT STYLE="font-family: Georgia">Value Added Tax (VAT)</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">664,987</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">364,641</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Research and
    Development Tax Credit</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">280,631</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">384,040</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">945,618</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">748,681</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>9.
Retirement benefit obligation</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Employees
in Italy are entitled to Trattamento di Fine Rapporto (&ldquo;TFR&rdquo;), commonly referred to as an employee leaving indemnity,
which represents deferred compensation for employees in the private sector. Under Italian law, an entity is obligated to accrue
for TFR on an individual employee basis payable to each individual upon termination of employment (including both voluntary and
involuntary dismissal). The annual accrual is approximately 7% of total pay, with no ceiling, and is revalued each year by applying
a pre-established rate of return of 1.50%, plus 75% of the Consumer Price Index, and is recorded by a book reserve. TFR is an
unfunded plan. The costs of the retirement benefit obligation is accounted for under the provisions of ASC 715, <I>Compensation
&ndash; Retirement Benefits</I>. The amount of the obligation at December 31, 2020 and 2019 was &euro;17,388 and &euro;11,332,
respectively.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>10. Quotaholders&rsquo;
equity</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company is an S.r.l., which is an Italian limited liability company similar to a limited liability company in the United States.
The Articles of Incorporation, Shareholders&rsquo; Agreement and the By-laws of the Company provide for different quotas, which
represent the Company&rsquo;s corporate capital, rather than shares of stock as ownership.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 217; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Corporate
capital</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
an S.r.l., the Company&rsquo;s ownership is called &ldquo;corporate capital&rdquo; and &ldquo;quotas&rdquo; rather than shares,
stock or units.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company&rsquo;s capital is divided between the five quotas as summarized below at December 31, 2020 and 2019:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 90%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia">At
    December 31,</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia">At
    December 31,</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia">Quota</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia">2019</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia">Ownership
    %</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia">2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Georgia">Ownership
    %</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 22%; text-align: center"><FONT STYLE="font-family: Georgia">A</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 16%; text-align: right"><FONT STYLE="font-family: Georgia">10,458</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 16%; text-align: right"><FONT STYLE="font-family: Georgia">29</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">%</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 15%; text-align: right"><FONT STYLE="font-family: Georgia">10,458</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 15%; text-align: right"><FONT STYLE="font-family: Georgia">28</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">%</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">B</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">6,450</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">18</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">%</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">6,886</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">19</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">%</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">C</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">8,645</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">24</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">%</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">8,645</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">23</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">%</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">D</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">4,034</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">11</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">%</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">4,034</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">11</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">%</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">E</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">6,462</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">18</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">%</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">7,033</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">19</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">%</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; font-weight: bold; text-align: center; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Georgia">36,049</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Georgia">100</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Georgia">%</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Georgia">37,056</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Georgia">100</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Georgia">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The Company&rsquo;s
corporate capital at January 1, 2019 was &euro;29,179, consisting of quota A from founders, options converted to quota B, and
quotas C &amp; D from investment capital. Additional capital was raised in 2019 by the sale of quota E, along with options converted
to quota B, so corporate capital at December 31, 2019 was &euro;36,049. Additional capital was raised in 2020 by the sale of quota
E, so corporate capital at December 31, 2020 was &euro;37,056. </FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company currently has five (5) quotas:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%">
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><U>Quota A</U>. Quota
    A was reserved for certain founders. One of the founders has the right to appoint three (3) board members out of five (5),
    appoint the Chair from these three (3) persons and appoint one (1) member of the Board of Statutory Auditors. One other founder
    has the right to appoint two (2) board members out of five (5), appoint two (2) statutory auditors and appoint the Chair of
    the statutory auditors from the two (2) appointees. Quota A has voting rights.</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><U>Quota B</U>. Quota
    B has no voting rights, the same profit-sharing rights as Quota A and is priced at a nominal amount of &euro;1.00. The Company
    has historically utilized Quota B for its share-based compensation program offered to board members, employees, and consultants.
    Quota B is also held by certain co-founders. The Company&rsquo;s stock options are exercisable into Quota B for past and present
    board members, employees, and consultants.</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><U>Quota C</U>. Quota
    C has the right to appoint one (1) member of the Board of Statutory Auditors; specifically, the one (1) that a founder had
    the right to appoint. Investors received Quota C in the Company&rsquo;s first funding round (2014/2015) where approximately
    &euro;10 million was raised.</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><U>Quota D</U>. Investors
    received Quota D in the Company&rsquo;s second funding round (2017) where approximately &euro;7 million was raised.</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><U>Quota E</U>. Investors
    received Quota E in the Company&rsquo;s third funding round (through December 31, 2019) where approximately &euro;14.8 million
    was raised approximately (&euro;15.1 million gross, net of approximately &euro;0.3 million of financing fees). Investors
    received Quota E in the Company&rsquo;s second tranche of the third funding round (through December 31, 2020) where approximately
    &euro;1.4 million was raised (approximately &euro;1.5 million gross, net of approximately &euro;0.1 million of financing
    fees).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 218; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%">
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt"><U>Quotas A, C,
    D &amp; E</U>.</FONT><FONT STYLE="font: 10pt Georgia"> During a divestiture proceeding (meaning Quotas representing 100%
    of the corporate capital of the Company) or a dissolution of the Company, Quotas C, D &amp; E all have the same rights with
    respect to the proceeds of a divestiture, i.e., all three (3) quotas share the divestiture consideration equally (on a <I>pari
    passu</I> basis) up to the amount of their investment. If there is any consideration remaining after payment to quotas C,
    D &amp; E, then quota A shall be entitled to the amount remaining up to the amount of their investment. If proceeds of a divestiture
    are less than or equal to &euro;50 million, then any proceeds remaining after payment of quotas A, C, D &amp; E, shall be
    shared equally among quotas A, C, D &amp; E; however, if proceeds of a divestiture are greater than &euro;50 million, then
    any proceeds remaining after payment of quotas A, C, D &amp; E, shall be distributed to each quota separately
    according to a detailed formula specified in the Company&rsquo;s By-Laws, including quota B. Similar to a divestiture, net
    profits, if any, shall be distributed in the same manner to quotas A, B, C, D &amp; E, after deducting not less
    than five (5) percent for a legal reserve (up to where this reserve equals one-fifth of the quota capital). A, C, D, E have
    equal voting rights and the Company By-laws specify protective provisions for each class of quota for A, C, D &amp; E.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>11. Share-based
compensation</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Georgia"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company has granted options on its corporate capital to certain directors, officers, employees, and consultants, as an incentive
and as additional compensation. All options convert into Quota B when vested and exercised. All options have an exercise price
of &euro;1.00 per quota. Options generally vest over a one-to-three-year period and are exercised when vested. All options expire
on December 31, 2021, if not exercised. The Board of Directors approves any options granted and has authorized and granted 4,835
options to date. At December 31, 2019, there were no options available for grant, as all remaining authorized options were granted
in 2019; therefore, no options were granted in 2020.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company&rsquo;s quota option activity for the years ended December 31, 2020 and 2019 is represented by the following:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">Number
    of<BR>
    Options</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">Weighted<BR>
    Average<BR>
    Exercise Price</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">Weighted<BR>
    Average<BR>
    Remaining<BR>
    Contractual<BR>
    Term (Years)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">Aggregate<BR>
    Intrinsic<BR>
    Value</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-style: italic"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; font-style: italic; text-align: center"><FONT STYLE="font-family: Georgia">(in
    &euro;&rsquo;s)</FONT></TD><TD STYLE="font-family: Georgia; font-style: italic"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-style: italic"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; font-style: italic; text-align: center"><FONT STYLE="font-family: Georgia">(in
    &euro;&rsquo;s)</FONT></TD><TD STYLE="font-family: Georgia; font-style: italic"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 44%; text-align: left"><FONT STYLE="font-family: Georgia">Outstanding, vested and
    expected to vest as of December 31, 2019</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 10%; text-align: right"><FONT STYLE="font-family: Georgia">982</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 10%; text-align: right"><FONT STYLE="font-family: Georgia">1.00</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 10%; text-align: right"><FONT STYLE="font-family: Georgia">2.00</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 10%; text-align: right"><FONT STYLE="font-family: Georgia">1,056,316</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">Granted</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Vested and exercised</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">436</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">1.00</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">1.00</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">472,184</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Cancelled or
    forfeited</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Outstanding,
    vested and expected to vest as of December 31, 2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">546</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">1.00</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">1.00</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">584,132</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Exerciseable as of December 31, 2020</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company&rsquo;s share-based compensation expense for the years ended December 31, 2020 and 2019 is represented by the following
table:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 70%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">Year
    ended December 31,</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; font-weight: bold; text-align: right"><FONT STYLE="font-family: Georgia">2020</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; font-weight: bold; text-align: right"><FONT STYLE="font-family: Georgia">2019</FONT></TD><TD STYLE="font-family: Georgia; font-weight: bold"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 68%; text-align: left"><FONT STYLE="font-family: Georgia">Research &amp; development
    expense</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">21,804</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Research &amp; development expense -
    related party</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">326,400</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">581,949</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">General &amp;
    administrative expense</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">133,794</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">137,057</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">460,194</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">740,810</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">Unrecognized expense at December 31,</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">313,273</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">769,779</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 219; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company awarded eight options to a consultant on September 30, 2019 for assistance in raising additional Quota E capital for the
Company in 2019. The Company recorded the &euro;8,702, which was the fair value of the option as a charge to additional paid-in
capital. The weighted average grant date fair value of the options granted during 2019 was &euro;1,088. The Company&rsquo;s unrecognized
expense was &euro;313,273 and &euro;769,779 at December 31, 2020 and 2019, respectively, and will be expensed as the options
vest.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Quota
B Valuations</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
fair value of the Quota B underlying the Company&rsquo;s stock-based compensation grants has historically been determined by the
Company&rsquo;s board of directors, with input from management and third-party valuations. The Company believes that the board
of directors has the relevant experience and expertise to determine the fair value of its Quota B, when also securing third-party
assistance. Given the absence of a public trading market of the Company&rsquo;s equity, and in accordance with the American Institute
of Certified Public Accountants Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation, the
board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best
estimate of the fair value of the Company&rsquo;s equity at each grant date. These factors include:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%">
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">valuations of the
    Quota B equity performed by third-party specialists;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the price of the Company&rsquo;s
    equity to third-party, arms-length, sophisticated, and qualified investors, which was used in the OPM Backsolve Model;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the prices, rights,
    preferences, and privileges of the Company&rsquo;s Quota C, D, and E preferred equity classes relative to those of the Company&rsquo;s
    equity;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">lack of marketability
    of the Quota B;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">lack of voting rights
    of the Quota B;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">current business conditions
    and projections;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">hiring of key personnel
    and the experience of management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the Company&rsquo;s
    stage of development;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the timing, progress
    and results of the Company&rsquo;s pre-clinical studies and clinical trials for the Company&rsquo;s programs and product candidates;
    including statements regarding the timing of initiation and completion of trials or studies and related preparatory work,
    the period during which the results of the trials will become available and the Company&rsquo;s research and development programs;</FONT></TD></TR>

<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">likelihood of achieving
    a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions,
    or other liquidation events;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the market performance
    of comparable publicly traded companies; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">the European, U.S.
    and global capital market conditions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
valuing the Company&rsquo;s Quota B class of options, the board of directors determined the equity value of the Company&rsquo;s
business using various valuation methods. The board of directors engaged a third-party valuation firm who performed analyses in
accordance with the guidance outlined in the American Institute of Certified Public Accountants&rsquo; Accounting and Valuation
Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. The Company&rsquo;s option valuations were
prepared using an option pricing method (&ldquo;OPM&rdquo;), which used market approaches to estimate the Company&rsquo;s enterprise
value.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 220; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
OPM treats each equity class as a call options on the total equity value of a company, with exercise prices (i.e., breakpoints)
based on the value thresholds at which the allocation among the various holders of a company&rsquo;s securities changes. A discount
was considered for Lack of Marketability (&ldquo;DLOM&rdquo;), which is an amount or percentage that is deducted from the value
in order to reflect the absence of a viable market. The DLOM was then applied to arrive at an indication of value for the option.
Also, considered in the valuation was volatility and the fact that the Quota B class of equity did not carry voting rights. The
expected volatility used in the OPM is based upon the historical volatility of a number of publicly traded companies in similar
stages of clinical development.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Application
of the Company&rsquo;s approach involved the use of estimates, judgment, and assumptions that are highly complex and subjective,
such as those regarding the selection of comparable companies, and the expected timing of an initial public offering (&ldquo;IPO&rdquo;)
or other liquidity event. Changes in any or all of these estimates and assumptions or the relationships between those assumptions
impact the valuations at each valuation date and may have a material impact on the valuation of the Company&rsquo;s Quota B equity
class, and consequently, the Company&rsquo;s share-based compensation expense could be materially different.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>12. Related parties</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company&rsquo;s research and development expenses are a combination of third-party expenses and related party expenses, as detailed
below:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">For
    the Year Ended December 31, 2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">(In Euros)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Third
    Parties</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Related
    Parties</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 52%; text-align: left"><FONT STYLE="font-family: Georgia">Consultants &amp; other
    third parties</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">1,454,576</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">2,009,884</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">3,464,460</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Materials &amp; supplies</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">709,183</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">3,124</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">712,307</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Compensation (including share-based)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">145,700</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">326,400</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">472,100</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Travel &amp; entertainment</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">16,742</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">17,724</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">34,466</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Other</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">5,128</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">5,128</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">2,331,329</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">2,357,132</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">4,688,461</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">For
    the Year Ended December 31, 2019</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">(In Euros)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Third
    Parties</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Related
    Parties</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 52%; text-align: left"><FONT STYLE="font-family: Georgia">Consultants &amp; other
    third parties</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">74,518</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">2,036,870</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">2,111,388</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Compensation (including share-based)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">171,289</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">581,949</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">753,238</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Materials &amp; supplies</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">649,574</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">649,574</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Travel &amp; entertainment</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">97,063</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">36,510</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">133,573</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Other</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">55,209</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">55,209</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">1,047,653</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">2,655,329</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">3,702,982</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company recorded a research and development tax credit in the amount of &euro;265,834 and &euro;448,079 for the years ended December
31, 2020 and 2019, respectively, to offset Consultants and other third parties related research and development expenses.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 221; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company&rsquo;s general and administrative expenses are also a combination of third-party and related party expenses, as detailed
below:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 90%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">For
    the Year Ended December 31, 2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">(In Euros)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Third
    Parties</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Related
    Parties</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 46%; text-align: left"><FONT STYLE="font-family: Georgia">Compensation (including
    share-based)</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 14%; text-align: right"><FONT STYLE="font-family: Georgia">191,998</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 14%; text-align: right"><FONT STYLE="font-family: Georgia">298,628</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 14%; text-align: right"><FONT STYLE="font-family: Georgia">490,626</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Accounting, legal &amp; other professional</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">239,861</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">239,861</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Communication &amp; IT related</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">64,430</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">64,430</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Facility &amp; insurance related</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">24,685</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">14,402</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">39,087</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Consultants &amp; other third parties</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">59,648</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">1,495</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">61,143</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Other</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">6,618</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">6,618</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">587,240</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">314,525</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">901,765</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 90%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">For
    the Year Ended December 31, 2019</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">(In Euros)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Third
    Parties</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Related
    Parties</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 46%; text-align: left"><FONT STYLE="font-family: Georgia">Consultants &amp; other
    third parties</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 14%; text-align: right"><FONT STYLE="font-family: Georgia">375,201</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 14%; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 14%; text-align: right"><FONT STYLE="font-family: Georgia">375,201</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Compensation (including share-based)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">171,698</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">277,849</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">449,547</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Accounting, legal &amp; other professional</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">40,745</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">40,745</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Communication &amp; IT related</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">14,759</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">14,759</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Facility &amp; insurance related</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">13,630</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">13,630</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Other</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">22,336</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">5,302</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">27,638</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">638,369</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">283,151</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">921,520</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company&rsquo;s accounts payable to related parties are comprised as follows:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 80%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">At
    December 31,</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2019</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">(in Euros)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 68%; text-align: left"><FONT STYLE="font-family: Georgia">San Raffaele Hospital</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">4,085</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">283,115</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">XDG Biomed</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">5,942</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">9,626</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">10,027</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">292,741</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company&rsquo;s accrued expenses to related parties are comprised as follows:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 80%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">At
    December 31,</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2020</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">2019</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-family: Georgia; text-align: center"><FONT STYLE="font-family: Georgia">(in Euros)</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; width: 68%; text-align: left"><FONT STYLE="font-family: Georgia">San Raffaele Hospital</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">1,309,191</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; width: 12%; text-align: right"><FONT STYLE="font-family: Georgia">1,454,430</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Pierluigi Paracchi</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">25,000</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">50,000</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">XDG Biomed</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">25,000</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">147,190</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">1,359,191</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">1,651,620</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company has identified the following related parties:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Georgia; width: 100%">
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Pierluigi Paracchi
    (director and co-founder of the Company);</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Luigi Naldini (co-founder
    of the Company and executive scientific advisory board chairman);</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Carlo Russo (through
    XDG Biomed LLC- Chief Medical Officer);</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">Bernard Rudolph Gentner
    (co-founder of the Company and member of scientific advisory board); and,</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">San Raffaele Hospital
    (co-founder and main supplier of services).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 222; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
following is a description of the nature of the transactions between the Company and these related parties:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Pierluigi
Paracchi</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia">He is the Chief Executive
Officer and the Company&rsquo;s Vice-Chairman of the Board of Directors as well as co-founder. In addition to his annual remuneration
of &euro;250,000 for the year 2020 and &euro;201,980 for the year 2019, Mr. Paracchi also obtained a funding fee of &euro;185,510 in
2019 for the funding activity of the first financing as approved by the Board of Directors and by quotaholders at the Quotaholders&rsquo;
Meeting. This was recorded in additional paid-in capital as a direct reduction of proceeds. Mr. Paracchi was awarded a bonus of &euro;50,000
by the Board of Directors in July 2020. The bonus was accrued in the 2019 financial statements and paid in July 2020. At December 31,
2020, the Company also accrued a bonus of &euro;25,000 for the period July to December 2020: as per his Directorship agreement, Mr. Paracchi
is entitled to receive a bonus of up to &euro;50,000 to be approved by the Board of Directors each year to cover the period August 1st
to July 31st of each year. Such Directorship agreement will be terminated by the parties for mutual consent upon signature of the
employment agreement.</FONT></P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Luigi
Naldini/Bernard Rudolph Gentner</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">They
are co-founders of Genenta and part of the SAB &ndash; Scientific Advisory Board, with Dr. Naldini as Chairman, and Dr. Gentner
as a member. Dr. Naldini has an advisory agreement approved by the Board of Directors and performs the pre-clinical studies for
Genenta. In particular, the pre-clinical experiments are in solid tumor indications. The last agreement with Dr. Naldini is still
in effect and was signed on December 12, 2019. In 2020 and 2019, Dr. Naldini&rsquo;s compensation amounted to &euro;56,250 and
&euro;55,500, respectively. Dr. Gentner, like Dr. Naldini, oversees pre-clinical research related to the platform technology.
In addition, he analyzes clinical biological data. The last agreement with Dr. Gentner, which is still in force, was signed on
October 26, 2017. In 2020 and 2019, Dr. Gentner&rsquo;s compensation was &euro;18,750 and &euro;44,350, respectively.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>XDG Biomed
LLC</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia">This is the
LLC of Dr. Carlo Russo. Dr. Russo has a single contract signed by XDG and the Company that has been approved by the Board of Directors
and was subject to multiple amendments. In particular, Dr. Russo, via XDG, serves as the Company&rsquo;s Chief Medical Officer
and Head of Development. Dr. Russo is responsible for the clinical development of Temferon&trade;, the Company&rsquo;s gene therapy
platform. The applicable recurring fees are &euro;300,000 per year effective from August 1, 2019, (&euro;200,000 prior
to that date) plus a variable compensation of &euro;50,000 based on the results obtained and depending on the Company&rsquo;s
Board of Directors approval. In 2020, the Company incurred &euro;342,872. The Company accrued &euro;25,000 for a potential
bonus relating to the period of July to December 2020. The amounts owed at December 31, 2020 and 2019 are &euro;30,942 and &euro;156,816,
respectively. In 2019, the Company granted options on 1,000 class B quotas to Dr. Russo, of which 400 were exercised and converted
to class B quotas in 2019 and 300 were exercised and converted to class B quotas in 2020; the remaining 300 are
outstanding and will vest by the earlier of July 31, 2021 or the effectiveness of the Company&rsquo;s registration statement.
The fair value of the options based on the Company&rsquo;s valuation was &euro;1,084 per quota B. There were no options
granted in 2020.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>San
Raffaele Hospital - OSR</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left">San Raffaele Hospital (&ldquo;OSR&rdquo;)
is a co-founder of the Company and the Company is a corporate and research spin-off of OSR. OSR owns approximately 13% of the
Company, as of December 31, 2020. The Hospital is one of the leading biomedical research institutions in Italy and Europe, with
a 45-year history of developing innovative therapies and procedures. The Company has several contractual arrangements with OSR.
The Company has agreements to license technology, to perform research, pre-clinical and clinical activities, as well as to lease
facilities and obtain certain other support functions. The Company&rsquo;s headquarters is currently in an OSR facility.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 223 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>License
Agreement</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.45pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company has a License Agreement with OSR entered in December 2014, for the exclusive use of different patents. In particular, OSR granted
the Company an exclusive, world-wide, royalty bearing license under certain technology to conduct research and develop, make, use, import,
and sell licensed products. The License Agreement covers patents and patent applications, as well as proprietary technologies. The Company&rsquo;s
rights to use these patents and patent applications and to utilize the inventions claimed in these licensed patents are subject to the
continuation of, and the Company&rsquo;s compliance with, the terms of the License Agreement. </FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.45pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">Based
on the preclinical studies carried out by OSR, in particular by its SR-TIGET Institute (San Raffaele Telethon Institute for Gene Therapy),
on a specific gene therapy strategy with respect to lympho-hematopoietic indication and/or solid cancer indication, the Company decided
to develop a new therapy to treat cancer through a cell and gene therapy strategy. The &ldquo;Field of Use&rdquo; as defined in the License
Agreement is:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">Lympho-Hematopoietic
                                            Indication; and,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt">b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">Solid
                                            Cancer Indication.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
agreement provided for an upfront fee of &euro;250,000 (which was paid by the Company in 2015), plus future option fees are as follows:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">option fee on the first indication = &euro;1.0
    million (subsequently reduced to &euro;0.5 million);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">option fee on the second indication = &euro;0.5
    million;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">option fee on the third indication = &euro;0.3
    million; and,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">option fee on any additional indications =
    no license fee.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
addition, the Company would be obligated make payments on milestones depending on the Field of Use (as defined in the
agreement) and pay royalties of 4% of net sales of each Licensed Product (as defined in the agreement). For information
relating to the contingent milestones for these indications, please refer to Note 13 - Commitments and
Contingencies.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
February 2019, the Company and OSR entered into Amendment #2 of the License Agreement to conduct a clinical trial according to the protocol
TEM-GBM_001 and EudraCT 2018-001404-11 entitled: &ldquo;A phase I/IIa dose escalation study evaluating the safety and efficacy of autologous
CD34+ enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human interferon-&alpha;2
in patients with glioblastoma multiforme who have an unmethylated O-6-methylguanine-DNA methyltransferase gene promoter.&rdquo; In Amendment
#2, the Company and OSR also revised the license fee requirement for the first Solid Cancer indication (GBM). In relation to the GBM
trial, the Company and OSR agreed that the Company would be obligated to pay OSR the &euro;1.0 million Option Fee only in the event that
the Company was able to dose its tenth patient. Under this Amendment, the Company is also obligated to pay for the costs of the study-related
procedures performed on the patients recruited in the trial, according to periodic study reports delivered by OSR. The first GBM patient
was recruited in April 2019 and related clinical activity costs were recorded by the Company in the amount of &euro;1,145,202 in 2019. In 2020,
the comparable costs incurred and expensed for the glioblastoma program were &euro;989,556.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
December 2020, the Company and OSR entered into Amendment #3 of the License Agreement. The initial &euro;1.0 million license fee for
the first indication (i.e., GBM) would have become due when the tenth patient was dosed in the GBM trial; however, the license fee was
reduced to &euro;0.5 million, in exchange for the Company&rsquo;s agreement to exercise a second option for an additional Solid Cancer
indication (i.e., liver cancer) and an agreement to execute a Sponsored Research Agreement in February 2021. If the Company is not be
able to obtain approval from the competent authorities to initiate a human clinical trial in liver cancer on or before the expiration
of nine months (from December 2020), the Company has the right, at no additional costs, to convert the second solid cancer indication
(i.e., liver cancer) to an &ldquo;Alternate Indication,&rdquo; as defined in the agreement (i.e., to an indication other than liver cancer.)</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 224 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
summary, Amendment #3 to the license agreement amended the existing agreement as follows:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Georgia; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">reduction of option fee
    on the first solid cancer indication = &euro;0.5 million (accrued at December 31, 2019, since it was considered probable and paid in December 2020); plus,</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">commitment to enter into
    a Sponsored Research Agreement, which was executed in February 2021; and,</FONT></TD></TR>
  <TR STYLE="font: 10pt Georgia; vertical-align: top">
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Georgia; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">exercise of option
    fee on the second indication = &euro;0.5 million (accrued at December 31, 2020, to be paid by June 30, 2021.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">The Company has paid &euro;0.75 million to OSR, since inception under the license
agreement. No events have occurred or have been achieved (and none are considered probable) to trigger any contingent
payments under the license agreement as of December 31, 2020. For information relating to the contingency payments or future
milestones for these indications, please refer to Note 13 - Commitments and Contingencies.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">OSR may terminate the Company&rsquo;s rights as to certain fields of
use for the Company&rsquo;s failure to develop (a) with respect to a solid cancer indication, upon third anniversary of the date
the Company exercised such option, if the Company has not filed an IND with respect to such optioned solid cancer indication specifically,
as to GBM, the Company is required to file an IND regarding Temferon for GBM prior to February 2022, or (b) with respect to a
lympho-hematopoietic indication, on the earlier of (i) the fifth anniversary of the initiation (first patient dosed) of the first
human clinical trial for a licensed product in any lympho hematopoietic indication or solid cancer indication if a patient has
not been dosed with a licensed product in a Phase 3 clinical trial and (ii) September 1, 2025.</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Research
Funding Agreement</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.45pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
March 2019, the Company and OSR entered into a Research Funding Agreement to conduct a clinical trial according to the multiple myeloma
protocol, TEM-MM-101 and EudraCT 2018-001741-14, entitled &ldquo;A Phase I/II dose escalation study evaluating safety and activity of
autologous CD34+ enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human interferon-&alpha;2
in multiple myeloma patients with early relapse after intensive front-line therapy.&rdquo; This agreement required OSR to perform certain
clinical procedures and exploratory analyses on the study population, as per the protocol approved by the relevant competent authorities.
The Company was required to fund the costs of the study-related procedures performed on patients recruited in the Trial, according to
periodic study reports delivered by OSR. The first TEM-MM-101 trial patient was enrolled in August 2019, after the approval received
from national competent authorities.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 35.45pt">In 2019, the Company expensed &euro;130,589 for
the analysis performed by OSR for multiple myeloma and &euro;364,042 for the clinical procedures performed by OSR&rsquo;s Hematology
and Bone Transplant Unit for multiple myeloma. For the multiple myeloma program, the Company recorded expenses in 2020 of &euro;104,626;
however, the discussion to discontinue the program began in late 2020. The final decision to discontinue the program was reached
in early 2021, mainly due to the small number of&nbsp;eligible&nbsp;patients, the&nbsp;increasing competitive landscape, and the
faster progress and promising result on the concurrent solid tumor glioblastoma trial (TEM-GBM_001). No product indication was
exercised, and no milestones were achieved related to the multiple myeloma indication, and so no option fee or contingent payments
were due to OSR for this indication.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Sponsor
Research Agreement (SRA)</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">As
stated above, in exchange for a reduction in the first solid cancer indication (i.e., GBM) option fee from &euro;1.0 million
to &euro;0.5 million, the Company agreed to enter into a Sponsored Research Agreement (SRA) in December 2020. Under the SRA,
which was executed in February 2021, two sponsored research activities will be conducted for between &euro;0.5 million and
&euro;1.0 million. The first SRA payment was made in early 2021 in the amount of &euro;250,000.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Service
Agreement</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">A
service agreement to provide certain  services (accounting/bookkeeping and rent of spaces, the latter with an addendum
effective from January 1, 2016) free of charge was in place between the Company and OSR from 2014 to 2019. Beginning
in January 2020, a third-party provider was engaged by the Company to perform these services. The Company determined the value of these
services that were provided in 2019 and in prior years were not material to its financial statements.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">Beginning
January 1, 2020, the Company entered into a six-year lease agreement for the use of office space in the OSR building. The Company paid
OSR annual rent of &euro;13,400 in 2020 with a security deposit of &euro;3,350.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia, Times, Serif"></FONT></P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 225; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>13.
Commitments and contingencies</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company exercises considerable judgment in determining the exposure to risks and recognizing provisions or providing disclosure
for contingent liabilities related to pending litigations or other outstanding claims and liabilities. Judgment is necessary in
assessing the likelihood that a pending claim will succeed, or a liability will arise and to quantify the possible range of the
final settlement. Provisions are recorded for liabilities when losses are considered probable and can be reasonably estimated.
Because of the inherent uncertainties in making such judgments, actual losses may be different from the originally estimated provision.
Estimates are subject to change as new information becomes available, primarily with the support of internal specialists or outside
consultants, such as actuaries or legal counsel. Adjustments to provisions may significantly affect future operating results.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
following table summarizes our obligations by contractual maturity for years following December 31, 2020:</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%">
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="18" STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia">Payments
    by period</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom">
    <TD STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">(in
    Euros)</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">Less
    than a<BR>
    year</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">1
    to 3 years</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">4
    to 5 years</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-family: Georgia; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Georgia">More
    than<BR>
    5 years</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
    <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">Sponsored research agreement (SRA)
    with OSR</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left">&euro;<FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><P STYLE="font: 10pt Georgia; margin: 0"><FONT STYLE="font-family: Georgia">1,000,000</FONT></P></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; text-align: right"><P STYLE="font: 10pt Georgia; margin: 0"><FONT STYLE="font-family: Georgia">500,000</FONT></P></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia"></FONT>&euro;</TD><TD STYLE="font-family: Georgia; text-align: right"><P STYLE="font: 10pt Georgia; margin: 0"><FONT STYLE="font-family: Georgia">500,000</FONT></P></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia"></FONT>&euro;</TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; text-align: left">&euro;</TD><TD STYLE="font-family: Georgia; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; width: 35%; text-align: left"><FONT STYLE="font-family: Georgia">License option fee for liver
    cancer (or second cancer indication)</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 9%; text-align: right"><P STYLE="font: 10pt Georgia; margin: 0"><FONT STYLE="font-family: Georgia">500,000</FONT></P></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 9%; text-align: right"><FONT STYLE="font-family: Georgia">500,000</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 9%; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 9%; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 2%"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; width: 9%; text-align: right"><FONT STYLE="font-family: Georgia">-</FONT></TD><TD STYLE="font-family: Georgia; width: 1%; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Georgia; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">Operating leases</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right">80,400</TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia">13,400</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right">26,800</TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right">26,800</TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 1.5pt solid; text-align: right">13,400</TD><TD STYLE="font-family: Georgia; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Georgia; vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">Total</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">1,580,400</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">1,013,400</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Georgia">526,800</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right">26,800</TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Georgia">&euro;</FONT></TD><TD STYLE="font-family: Georgia; border-bottom: Black 2.5pt double; text-align: right">13,400</TD><TD STYLE="font-family: Georgia; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
above amounts include an option fee for the second cancer indication payable to OSR. Refer to the Related parties
- Note 12 for further information.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company entered into certain license agreements under which it is obligated to pay option license fees and to make contingent
milestone payments. The Company has not included future milestone and royalty payments in the table above because the payment
obligations under these agreements are contingent upon future events, such as the Company&rsquo;s achievement of specified milestones
or generating product sales, and the amount, timing and likelihood of such payments are unknown and are not yet considered probable.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company enters into contracts in the normal course of business with CMOs, CROs and other third parties for exploratory studies,
manufacturing, clinical trials, testing, and services (shipments, travel logistics, etc.). These contracts do not contain minimum
purchase commitments and, except as discussed below, are cancelable by the Company upon prior written notice. Payments due upon
cancellation consist only of payments for services provided or expenses incurred, including non-cancelable obligations of the
Company&rsquo;s vendors or third-party service providers, up to the date of cancellation. These payments are not included in the
table above as the amount and timing of such payments are not known.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>OSR
-</I></FONT><FONT STYLE="font: 10pt Georgia"><I> San Raffaele Hospital </I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
OSR agreements are non-cancelable, except in the case of breach of contract, and include total potential milestone payments of
up to &euro;10 million related to the Lympho-Hematopoietic Indication of each Licensed Product, and up to &euro;53 million related
to each Solid Cancer indication; however, starting with the fifth Solid Cancer indication, the first two related milestone payments
totaling &euro;7.0 million, are reduced to &euro;3.5 million. The milestones relate to certain events such as, dosing of the first
patient with a licensed product in Phase II and III of the trial, MAA (marketing authorization application) and NDA (new-drug
application) approval of the licensed product, the first commercial sale of the product in the US and major European countries,
and annual sales for the licensed product exceeding a certain amount in different territories.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 226; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><I>Multiple myeloma (MM)</I></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">As discussed in Note 12, the Company&rsquo;s MM
program was discontinued in early 2021 due to the relatively small number of eligible patients, and the highly competitive MM
landscape. No milestones were achieved with respect to the MM program, and as such no contingent payments were due under the agreement.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><I>Glioblastoma multiforme (GBM)</I></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">As discussed in Note 12, in December 2020, the
Company had one indication ongoing, glioblastoma multiforme. The Company&rsquo;s contingent liability for this first solid
cancer indication potentially payable to OSR was &euro;53 million.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif"><I>Liver cancer (LC)</I></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">In relation to the option exercised by the Company
for the second solid cancer indication, the Company and OSR agreed that the payment due in relation to the &ldquo;First patient
dosed with a Licensed Product in Phase I/II Clinical Trial,&rdquo; as stated in the agreement, was reduced to &euro;0.5
million rather than &euro;1.0 million. The reduction applied to the first license fee payment only. All the additional
contingent payments, other than the last contingent payment of &euro;5.0 million, remained a contingent liability
of the Company and potentially payable to OSR. Therefore, for the second solid cancer indication (liver cancer), the total potential
commitment of possible contingent payments could amount to &euro;47.5 million.</P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia">The agreements
also include a &euro;7.8 million commitment related to the development and manufacturing of licensed products, of which the Company
has incurred &euro;1.5 million of expense in 2020 compared to &euro;2.6 million of cumulative expense for
2019 and prior years.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia">In February
2021, the Company entered into a Sponsored Research Agreement (&ldquo;SRA&rdquo;) with OSR to conduct certain research
projects related to Temferon. The total consideration to be paid by the Company under the SRA will be &euro;1.0 million with payments
scheduled quarterly over 2021 and 2022. The Company made no payments under the SRA in 2020.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>AGC
Biologics (formerly MolMed) </I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
AGC Biologics agreement is non-cancelable, except in the case of breach of contract, and includes a potential milestone of &euro;0.3
million if a phase 3 study is approved by the relevant authority, as well as potential royalty fees between 0.5% and 1.0% depending
on the volume of annual net sales of the first commercial and named patient sale of the product. In the AGC Agreement, the Company
entrusts AGC with certain development activities that will allow the Company to carry out activities related to its clinical research
and manufacturing. The AGC agreement also includes a technology transfer fee of &euro;0.5 million related to the transfer of the
manufacturing know-how and &euro;1.0 million related to the marketability approval by regulatory authorities. The agreement is
a &ldquo;pay-as-you-go&rdquo; type arrangement with all services expensed in the period the services were performed. In February
2020, the Company entered into Amendment 4 to the Framework Service Agreement with AGC Biologics related to production and testing
of the Company&rsquo;s GBM trials, for a total amount of &euro;360,000. In March 2020, the Company entered into Amendment 5 to
the Framework Service Agreement with AGC Biologics related to production and testing of the Company&rsquo;s GBM trials, for a
total amount of &euro;259,000. In March 2020, the Company entered into Amendment 6 to the Framework Service Agreement with ACG
Biologics related to production and testing of the Company&rsquo;s GBM trials, for a total amount of &euro;41,000. In August 2020,
the Company entered into Amendment 7 to the Framework Service Agreement with ACG Biologics related to production and testing of
the Company&rsquo;s GBM trials, which provides the Company with an option to accelerate GBM production as stated in Amendment
5 at a 20% cost increase. In October 2020, the Company entered into Amendment 8 to the Framework Service Agreement with ACG Biologics
related to production and testing of the Company&rsquo;s GBM trials, for a total amount of &euro;17,000.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Adaptive
Biotechnologies</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia">The Adaptive
Biotechnologies agreement on exploratory analyses for trial endpoints is non-cancelable, except in the case of breach of contract,
and carries a total cost for the entire trial of &euro;0.2 million, of which approximately &euro;3,000 and approximately &euro;50,000
have been incurred as of December 31, 2020 and 2019, respectively.</FONT></P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Georgia">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 227; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt"><I>Biogazelle
NV</I></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Biogazelle NV agreement on exploratory analyses for trial endpoints is non-cancelable, except in the case of breach of contract,
and carries a total cost for the entire trial of &euro;106,000, of which &euro;28 thousand and &euro;6 thousand have been incurred
as of December 31, 2020 and 2019, respectively.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Operating leases</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">The
Company entered into a non-cancelable lease agreement for office space in January 2020. (See Footnote 12 &ndash; Related parties
under OSR for further information.)</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Legal
proceedings</I></B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia">The
Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or
not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of ASC
450, <I>Contingencie</I>s. The Company was notified by Theravectys of the possible infringement by the Company of
Theravectys&rsquo; exclusive license to patents no. EP 1071804, EP 1224314, and EP 1222300 granted from the owner of the
patents Institut Pasteur. Each of these patents is now expired, having each reached the end of it its patent term on April
23, 2019 for EP 1071804 and October 10, 2020 for EP 1224314, and EP 1222300. The Company considered the situation and
determined that the likelihood of a material adverse effect on its business is remote. To date, the Company has
not engaged in any such discussions with Theravectys nor has the Company received any further communication from Theravectys.
The Company expenses as incurred the costs related to its legal proceedings, if any.</FONT></P>
<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>14.
Subsequent events.</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Georgia; font-size: 10pt">In
February 2021, the Company entered into a Sponsored Research Agreement (&ldquo;SRA&rdquo;) with OSR to conduct certain research
projects related to Temferon. The total consideration to be paid by the Company under the SRA will be &euro;1.0 million with payments
scheduled quarterly over 2021 and 2022.</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0"><FONT STYLE="font-family: Georgia; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 228; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0pt 0pt 0; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 62.3pt; text-align: center"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><I><A NAME="sad_001"></A>Genenta
Science S.p.A.</I></B></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(formerly,
Genenta Science S.r.l.)</B></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Consolidated
Statements of Operations and Comprehensive Loss</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six-Months Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">(unaudited)</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left">Research and development </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 16%; text-align: right">3,199,234</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 16%; text-align: right">2,072,129</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">842,236</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">404,885</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,041,470</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,477,014</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,041,470</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,477,014</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,679</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">559</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Foreign exchange loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,111</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,849</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total other income (expense), net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,432</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,290</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,047,902</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,479,304</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Income taxes (Note 5)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,047,902</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,479,304</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,047,902</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,479,304</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss per share information (unaudited):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Loss </TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,047,902</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">-</P></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Loss per share - basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.27</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">-</P></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average number of shares outstanding - basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,772,610</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>The accompanying notes are
an integral part of these consolidated financial statements.</I></FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 229; Options: NewSection; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px"></FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 453pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><I><A NAME="sad_002"></A>Genenta
Science S.p.A.</I> </B></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(formerly,
Genenta Science S.r.l.)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 453pt; text-align: justify"></P>

<P STYLE="margin-right: 0pt; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Consolidated
Balance Sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 453pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">At June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">At December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(Unaudited)</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-left: 10pt">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">10,553,906</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">15,465,243</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Prepaid expenses and other current assets (Note 6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,549,766</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">947,501</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses and other current assets - related party (Note 12)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">121,432</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-bottom: 1.5pt">Total current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,103,672</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">16,534,176</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left">Non-current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Property and equipment, net (Note 7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,612</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,971</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Other asset- related party (Note 12)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,350</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other non-current assets (Note 8)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,163,375</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">945,618</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-bottom: 1.5pt">Total non-current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,187,337</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">967,939</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,291,009</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,502,115</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Liabilities and quotaholders&rsquo; and stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right">270,941</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&euro;</TD><TD STYLE="text-align: right">544,988</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable - related party (Note 12)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">88,392</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,027</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">418,571</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">365,969</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrued expenses - related party (Note 12)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">809,605</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,359,191</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">80,801</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">53,243</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-bottom: 1.5pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,668,310</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,333,418</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left">Long-term liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Retirement benefit obligation (Note 9)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,645</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,388</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-bottom: 1.5pt">Total long-term liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,645</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,388</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left">Commitments and contingencies (Note 13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left">Quotaholders&rsquo; and stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-style: italic; text-align: left">Corporate capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">37,056</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-style: italic; text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">36,604,728</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Common stock, no par value, 59,700,000 shares authorized and 15,000,000 shares
    issued and outstanding (unaudited) (Note 10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,139,431</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(25,538,377</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(21,490,475</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total quotaholders&rsquo; and stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,601,054</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,151,309</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and quotaholders&rsquo; and stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,291,009</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,502,115</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0 0pt 0 0; text-align: center"><I>The accompanying notes are an integral part of these <FONT STYLE="letter-spacing: -0.1pt">consolidated
</FONT>financial statements.</I></P>
<P STYLE="margin: 0pt 0pt 0pt 0; font-size: 10pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 230; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><I><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</I></FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><I><A NAME="sad_003"></A>Genenta
Science S.p.A.</I></B></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(formerly,
Genenta Science S.r.l.)</B></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Consolidated
Statement of Changes in Quotaholders&rsquo; and</B></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Stockholders&rsquo; Equity</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Corporate capital</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Additional paid-in capital</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Common shares outstanding</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Common stock, no par</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Accumulated deficit</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; padding-bottom: 1.5pt">Balance at December 31, 2019</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">36,049</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">34,713,225</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">(15,898,461</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="width: 6%; border-bottom: Black 1.5pt solid; text-align: right">18,850,813</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Capital increase from exercise of options on Quota B</P>
                                 <P STYLE="margin-top: 0; margin-bottom: 0">(Unaudited)&nbsp;</P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">136</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">136</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Share-based compensation</P>
                                 <P STYLE="margin-top: 0; margin-bottom: 0">(Unaudited)</P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,097</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">230,097</P></TD><TD STYLE="text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><P STYLE="margin-top: 0; margin-bottom: 0">Accumulated deficit</P>
                                                        <P STYLE="margin-top: 0; margin-bottom: 0">(Unaudited)</P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,479,304</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,479,304</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Balance at June 30, 2020 (Unaudited)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">36,185</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34,943,322</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(18,377,765</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">16,601,742</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Balance at December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">37,056</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">36,604,728</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(21,490,475</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,151,309</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">Capital increase from exercise of options on Quota B</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">(Unaudited)&nbsp;</P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">715</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">-</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">-</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">715</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">Share -based compensation</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">(Unaudited)</P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">497,104</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">497,104</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">Quota B repurchased</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">(Unaudited)</P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(172</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(172</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Corporate capital adjustment from Srl to SpA (Unaudited)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(37,599</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,279,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,599</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Capital increase related to SpA (Unaudited)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,401</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,720,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,401</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Conversion adjustment from Srl to SpA (Unaudited)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(37,089,431</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,089,431</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Accumulated deficit (Unaudited)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,047,902</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,047,902</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Balance at June 30, 2021 (Unaudited)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,000,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">37,139,431</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(25,538,377</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,601,054</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>The accompanying
notes are an integral part of these financial consolidated statements.</I></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 231; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 163.05pt; text-align: center; text-indent: -3.35pt">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 163.05pt; text-align: center; text-indent: -3.35pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><I><A NAME="sad_004"></A>Genenta
Science S.p.A.</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(formerly, Genenta
Science S.r.l.)</B></FONT></P>

<P STYLE="margin-right: 0pt; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Consolidated Statements
of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 11pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">Unaudited</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from operating activities </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left">Net loss </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 16%; text-align: right">(4,047,902</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 16%; text-align: right">(2,479,304</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Depreciation expense </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,086</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">566</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Retirement benefit obligation </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,256</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,014</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Share-based compensation </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">497,104</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,097</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Changes in operating assets and liabilities </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(263,548</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(61,337</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Other non-current assets </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(217,757</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,229</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accounts payable </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(274,047</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,769</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Accounts payable - related party </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,365</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">796,753</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accrued expenses </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,602</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,647</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Accrued expenses - related party </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(549,586</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(579,138</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other current liabilities </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">27,558</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,532</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,690,869</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,943,466</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from investing activities </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Purchases of property and equipment </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,727</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(13,194</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,727</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(13,194</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from financing activities </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from the exercise of stock options </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">715</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">136</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Quota B repurchased</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(172</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 11pt Georgia, Times, Serif">-</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid offering costs </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(217,284</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash provided (used in) by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(216,741</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">136</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net decrease in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,911,337</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,956,524</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of period </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,465,243</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,141,379</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of period </TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,553,906</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,184,855</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B></B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>The accompanying
notes are an integral part of these consolidated financial statements.</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 232; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt"><B><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><I><A NAME="sad_005"></A>Genenta
Science S.p.A.</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(formerly
Genenta Science S.r.l.)</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Notes to the Consolidated
Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin-right: 0pt; font: bold 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">1.</FONT> <FONT STYLE="font-size: 10pt">Nature of business</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Genenta
Science S.p.A. (formerly Genenta Science S.r.l.) (the &ldquo;Company&rdquo;) is an early-stage company developing first-in-class cell
and gene cancer therapies. The Company is initially developing its clinical leading product, Temferon&trade;, to treat glioblastoma multiforme
(&ldquo;GBM&rdquo;), a solid tumor affecting the brain. The Company intends to continue its clinical trials in Europe and eventually
start a second clinical trial to study Temferon&trade; in liver cancers, possibly in the United States.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Genenta
Science S.p.A. (formerly Genenta Science S.r.l. &ldquo;societ&agrave; a responsabilit&agrave; limitata,&rdquo; similar to a Limited Liability
Company in the United States) converted to an Italian corporation (&ldquo;societ&agrave; per azioni&rdquo;, or &ldquo;S.p.A.&rdquo;)
in June 2021, which is similar to a C corporation in the United States. The Company was founded by San Raffaele Hospital (&ldquo;OSR&rdquo;),
in Milan, Italy, Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner and was incorporated in July 2014. On May 20, 2021, the quotaholders
resolved that the Company converted from an S.r.l. to an S.p.A. and determined that the outstanding quota be converted to 15 million
common shares at no par value. (See Note 10. Quotaholder&rsquo;s and stockholder&rsquo;s equity.) New Bylaws have been adopted, two
new Board members were appointed and the existing Board of Directors and Board of Statutory Advisors were re-appointed. The registered
office remained located in Milan, Italy. The Company&rsquo;s reporting currency is Euros. In May 2021, the Company formed a wholly owned,
Delaware incorporated subsidiary, Genenta Science, Inc., intended for future operations in the United States. The Company&rsquo;s subsidiary
will operate in US Dollars.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
Company is subject to risks and uncertainties common to early-stage clinical companies in the life-science and biotechnology industries,
including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals
for product candidates, development by competitors of new competing products, dependence on key personnel, protection of proprietary
technology, compliance with government regulations and the ability to secure additional capital to fund operations. The clinical product
candidates currently under development will require significant additional research and development efforts, including regulatory approval
and clinical testing prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel
and infrastructure and extensive compliance-reporting capabilities. Even if the Company&rsquo;s product development efforts are successful,
it is uncertain when, if ever, the Company will realize revenue from product sales and profit from operations.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Liquidity and Risks</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company has incurred losses since its inception, including a net loss of &euro;4,047,902 and &euro;2,479,304 for the six-month
periods ended June 30, 2021 and 2020, respectively. In addition, at June 30, 2021, the Company had an accumulated deficit of &euro;25,538,377.
There is no certainty that the Company will become profitable in the future. The Company has primarily funded these losses through the
proceeds from sales of convertible debt and equity quotas, prior to the Company&rsquo;s conversion into an S.p.A.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company has evaluated whether there are conditions and events considered in the aggregate that raise substantial doubt about the Company&rsquo;s
ability to continue as a going concern. Although the Company has incurred recurring losses and expects to continue to incur losses for
the foreseeable future, the Company expects that its existing consolidated cash and cash equivalents on hand at September 27, 2021 of
approximately &euro;8.9 million will be sufficient to fund projected cash requirements through the fourth quarter of 2022. Therefore,
the Company will require significant additional financing in the future to fund operations. Accordingly, the accompanying financial
statements have been prepared assuming that the Company will continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 233; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
future viability of the Company is dependent on its ability to raise additional capital to finance its operations and the Company intends
to pursue financings in the US public market. The Company&rsquo;s inability to raise capital as and when needed could have a negative
impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating
plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Basis of presentation</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting
principles for interim financial information and with the instructions to Form 20-F and Article 10 of Regulation S-X promulgated by the
Securities and Exchange Commission (&ldquo;SEC&rdquo;). Accordingly, certain information and footnote disclosures normally included in
annual financial statements have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated
financial statements reflect all adjustments (including normal recurring adjustments and the elimination of intercompany accounts) considered
necessary for a fair statement of all periods presented. The results of operations of the Company for any interim periods are not necessarily
indicative of the results of operations for any other interim periods or for a full fiscal year. These unaudited interim condensed consolidated
financial statements for the six months ended June 30, 2021 and 2020 should be read in conjunction with the audited consolidated
financial statements and footnotes thereto for the years ended December 31, 2020 and 2019, included elsewhere herein.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">A
summary of the significant accounting policies applied in the preparation of these financial statements is presented below, only for
the categories and headings now applicable and that might be applicable in the future based on the Company&rsquo;s business. These policies
have been consistently applied, unless otherwise stated.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: bold 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-size: 10pt">2.</FONT> <FONT STYLE="font-size: 10pt">Summary of significant accounting policies</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: italic bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">Principles
of Consolidation</FONT></P>

<P STYLE="font: italic bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">The
accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany
accounts and transactions have been eliminated in consolidation.</FONT></P>

<P STYLE="font: italic 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 13.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">Use
of estimates</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the
reported amounts reported in the financial statements and the disclosures made in the accompanying notes. Estimates and assumptions reflected
in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and related
milestone payments, share-based compensation expense, valuation of Research &amp; Development (R&amp;D) tax credits, the valuation of
equity and the recoverability of the Company&rsquo;s net deferred tax assets and related valuation allowance. Estimates are periodically
reviewed considering changes in circumstances, facts and experience. Actual results may differ from these estimates under different assumptions
or conditions. Changes in estimates are recorded in the period in which they become known. The areas involving a higher degree of judgment
or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed below.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 234; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><B><I><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: italic bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Cash and cash equivalents</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents.
In the consolidated cash flow statements, cash and cash equivalents include: cash on hand, deposits held with banks, and other short-term
highly liquid investments. In the consolidated balance sheets, bank overdrafts, if any, are shown in current liabilities. Cash and cash
equivalents are detailed as follows:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-right: 0pt; margin-top: 0; margin-bottom: 0">At</P>
                                                                                <P STYLE="margin-right: 0pt; margin-top: 0; margin-bottom: 0">June 30,</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-right: 0pt; margin-top: 0; margin-bottom: 0">At</P>
                                                                                <P STYLE="margin-right: 0pt; margin-top: 0; margin-bottom: 0">December 31,</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Cash in bank</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">10,552,591</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">15,462,805</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash in hand &amp; prepaid cards</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,315</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,438</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,553,906</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,465,243</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Loss per share</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Loss
per share (&ldquo;EPS&rdquo;) is computed in accordance with US GAAP. Basic EPS is computed by dividing net loss by the weighted average
number of common shares outstanding during the period. Diluted EPS reflects potential dilution and is computed by dividing loss by the
weighted average number of common shares outstanding during the period increased by the number of additional common shares that would
have been outstanding if all potential common shares had been issued and were dilutive. Since the Company was an S.r.l. in previous periods,
QPS (quota per share) has not been included in the historical audited financial statements or the interim Statement of Operations
and Comprehensive Loss at June 30, 2020 because the Company determined it was not a meaningful or material disclosure due to the
Company&rsquo;s capital structure.
This calculation was applied, after the increase in capital to &euro;50,000 required to be an S.p.A. by Italian law. The Company&rsquo;s
stockholders authorized 59.7 million ordinary common shares. The Company has 15.0 million common shares issued and outstanding at June
30, 2021 with no outstanding options or warrants and 2.7 million common shares reserved for the Company&rsquo;s Equity Incentive Plan
2021&ndash;2025. Diluted EPS is not relevant at June 30, 2021, as there were no common share equivalents. (See Note 10. Quotaholders&rsquo;
and stockholders&rsquo; equity and Note 11. Share-based compensation.)</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Foreign currency
translation</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
reporting and functional currency of the Company is Euros. All amounts are presented in Euros unless otherwise stated. All amounts disclosed
in the consolidated financial statements and notes have been rounded to the nearest Euro unless otherwise stated. Foreign currency transactions,
if any, are translated into Euros using the exchange rates prevailing at the dates of the transactions or valuation where items are re-measured.
Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at period-end exchange
rates of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated statements of operations.
During the periods ended June 30, 2021 and 2020, foreign exchange gains and losses were insignificant.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Emerging growth
company status</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
Company is an &ldquo;emerging growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act, or JOBS Act, and may take
advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging
growth companies. The Company may take advantage of these exemptions until the Company is no longer an &ldquo;emerging growth company.&rdquo;
Section 107 of the JOBS Act provides that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period
afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition
period for complying with new or revised accounting standards and, because of this election, its consolidated financial statements may
not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up
until the last day of the fiscal year following the fifth anniversary of its initial public offering (&ldquo;IPO&rdquo;) or such earlier
time that it is no longer an &ldquo;emerging growth company.&rdquo;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 235; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><B><I><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: italic bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Fair value measurements</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Certain
assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value
must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair
value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are
considered observable and the last is considered unobservable:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Georgia, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Level
                                            1 &mdash; Quoted prices in active markets for identical assets or liabilities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 41pt; text-align: left; text-indent: -18.05pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Georgia, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Level
                                            2 &mdash; Observable inputs (other than Level 1 quoted prices), such as quoted prices in
                                            active markets for similar assets or liabilities, quoted prices in markets that are not active
                                            for identical or similar assets or liabilities, or other inputs that are observable or can
                                            be corroborated by observable market data.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 41pt; text-align: left; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Georgia, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Level
                                            3 &mdash; Unobservable inputs that are supported by little or no market activity that are
                                            significant to determining the fair value of the assets or liabilities, including pricing
                                            models, discounted cash flow methodologies and similar techniques.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">To
the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination
of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest
for instruments categorized in Level 3. A financial instrument&rsquo;s level within the fair value hierarchy is based on the lowest level
of any input that is significant to the fair value measurement.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
carrying values of the Company&rsquo;s research and development tax credits, VAT credits, accounts payable, accrued expenses and other
current liabilities approximate their fair values due to the short-term nature of these assets and liabilities.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Segment information</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Operating
segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its
chief operating decision-maker view the Company&rsquo;s operations and manages its business in one operating segment, which is the research
and development in the pharmaceutical sector with a focus on developing novel therapeutics to treat cancer.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Tax credit on investments
in research and development</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">In
line with the legislation in force until June 30, 2021, companies in Italy that invest in eligible research and development activities,
regardless of the legal form and economic sector in which they operate, can benefit from a tax credit which can be used in order to reduce
most taxes payable, including income tax or regional tax on productive activities, as well as social security contributions and payroll
withholding taxes. For eligible R&amp;D activities, the tax credit is equal to 20% (12% in FY 2020) of the eligible costs incurred, with
a maximum annual amount of &euro;4.0 million (&euro;3.0 million for FY 2020).</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 236; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px"></FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
eligible activities consist of fundamental research, industrial research, and experimental development as defined respectively of the
letters m), q) and j) of point 15, par. 1.3 of the Communication no. 198/2014 of the European Commission.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">To determine the
cost basis of the benefit, the following expenses are eligible:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Georgia, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Personnel
                                            costs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: -18.05pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Georgia, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Depreciation
                                            charges, costs of the financial or simple lease and other expenses related to movable tangible
                                            assets and software used in research and development projects;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Georgia, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Expenses
                                            for extra-euro research contracts concerning the direct execution of eligible research and
                                            development activities by the provider;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Georgia, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Depreciation
                                            charges;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: -18.05pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Georgia, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Expenses
                                            for consulting services and equivalent services related to eligible research and development
                                            activities; and,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Georgia, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Expenses
                                            for materials, supplies, and other similar products used in research and development projects.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
Company, by analogy, accounts for this receivable in accordance with International Accounting Standards (IAS) 20, <I>Accounting for Government
Grants and Disclosure of Government Assistance</I>. The receivable is recognized when there is reasonable assurance that: (1) the recipient
will comply with the relevant conditions; and, (2) the grant will be received. The Company has elected to present it net of the related
expenditure on the consolidated statements of operations and comprehensive loss.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">While
these tax credits can be carried forward indefinitely, the Company recognized an amount which reflects management&rsquo;s best estimate
of the amount that is reasonably assured to be realized or utilized in the foreseeable future based on historical benefits realized,
adjusted for expected changes, as applicable. The tax credits are recorded as an offset to research and development expenses in the Company&rsquo;s
consolidated statements of operations and comprehensive loss.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Share-based compensation</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">To
reward the efforts of employees, directors, and certain consultants and to promote the growth of the Company, the Company&rsquo;s Board
of Directors has approved, prior to the Company&rsquo;s conversion to an S.p.A., various share-based awards. All options have been awarded
with an exercise price of &euro;1 per quota and, when exercised, all options have been converted to Quota B. The options granted had
the vesting condition that the individual must remain in his/her role at least one year or as otherwise specified for each person. At
June 30, 2021, there were no outstanding options, as all options had been vested and/or accelerated and exercised prior to the Company&rsquo;s
conversion to an S.p.A.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company measures share-based awards granted to recipients based on the fair value on the date of the grant and recognizes compensation
expense for those awards over the requisite service period(s), which is the vesting period of the respective award. Forfeitures were
accounted for as they occurred. The measurement date for option awards was the date of the grant. The Company classifies share-based
compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&rsquo;s
payroll costs are classified or in which the award recipient&rsquo;s service payments are classified.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 237; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">With
the adoption of ASU No. 2018-07, Compensation&mdash; Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment
Accounting (&ldquo;ASU 2018-07&rdquo;) on January 1, 2019, the measurement date for non-employee awards is the date of the grant. The
compensation expense for non-employees is recognized, without changes in the fair value of the award, over the requisite service period,
which is the vesting period of the respective award.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Property
and equipment</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Property
and equipment are stated at cost, including any accessory and direct costs that are necessary to make the assets fit for use, and adjusted
by the corresponding accumulated depreciation. The depreciation rates recorded in the consolidated financial statements have been calculated
by taking into consideration the use, purpose, and financial-technical duration of the assets, on the basis of their estimated useful
economic lives. The Company believes the above criteria to be represented by the following depreciation rates:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Georgia, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Equipment
                                            &amp; Furniture: 15 years;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Georgia, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Electronic
                                            office equipment: 10 years; and,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Georgia, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Leasehold
                                            Improvements: based on the shorter of the life of the leasehold improvement or the remaining
                                            term of the lease.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Ordinary
maintenance costs are expensed to the consolidated statements of operations and comprehensive loss in the year in which they are incurred.
Extraordinary maintenance costs, the purpose of which is to extend the useful economic life of the asset, to technologically upgrade
it and/or to increase its productivity or safety for the purpose of economic productivity of the Company, are attributed to the asset
to which they refer and depreciated on the basis of its estimated useful economic life. Amortization of leasehold improvements is computed
using the straight-line method based upon the terms of the applicable lease or estimated useful life of the improvements, whichever is
less.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Impairment of long-lived
assets</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">In
accordance with ASC Topic 360-10-20, &lsquo;&lsquo;Property, Plant and Equipment,&rdquo; the Company performs an impairment test whenever
events or circumstances indicate that the carrying value of long- lived assets with finite lives may be impaired. Impairment is measured
by comparing the carrying value of the long-lived assets to the estimated undiscounted pre-tax cash flows expected to result from the
use of such assets and their ultimate disposition. In circumstances where impairment is determined to exist, the Company will write-down
the asset to its fair value based on the present value of estimated cash flows. To date, no impairments have been identified for the
periods ended June 30, 2021 and 2020.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Deferred Offering Costs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Deferred
public offering costs, which primarily consist of direct, incremental legal and accounting fees relating to fundraising activities (e.g.,
an initial public offering (IPO)), are capitalized within prepaid expenses and other current assets. The deferred offering costs will
be offset against proceeds from fundraising activities (e.g., an IPO) upon the consummation of an offering. In the event the fundraising
activities are terminated without raising capital, any deferred offering costs will be expensed. The Company has incurred &euro;373,545
in deferred offering costs for the six months ended June 30, 2021. (Also, see Note 6.)</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 238; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: italic bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Recently issued
accounting pronouncements</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">In
December 2019, the FASB issued ASU 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes. The new standard intended to simplify
the accounting for income taxes by eliminating certain exceptions related to the approach for intra-period tax allocation, the methodology
for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The
new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the
accounting for transactions that result in a step-up in the tax basis of goodwill. For non-public entities, the standard is effective
for annual periods beginning after December 15, 2021, with early adoption permitted. Adoption of the standard requires certain changes
to primarily be made prospectively, with some changes to be made retrospectively. The Company is currently evaluating the impact that
the adoption of ASU 2019-12 will have on its consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: bold 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-size: 10pt">3.</FONT> <FONT STYLE="font-size: 10pt">Research and development</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Research
and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and
development activities, including salaries, share- based compensation and benefits, facilities costs, third-party license fees, and external
costs of outside vendors and consultants engaged to conduct clinical development activities and clinical trials, (e.g., contract research
organizations [or &ldquo;CROs&rdquo;]), as well as costs to develop a manufacturing processes, perform analytical testing and manufacture
clinical trial materials, (e.g., contract manufacturing organizations [or &ldquo;CMOs&rdquo;]). Non-refundable prepayments for goods
or services that will be used or rendered for future research and development activities are recorded as prepaid expenses. Such amounts
are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that
the goods will be delivered, or the services rendered. In addition, funding from research grants, if any, is recognized as an offset
to research and development expense based on costs incurred on the research program.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
Company yearly sustains a significant amount of research costs to meet its business objectives. The Company has various research and
development contracts, and the related costs are recorded as research and development expenses as incurred. When billing terms under
these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of outstanding
obligations at period end to those third parties. Any accrual estimates are based on several factors, including the Company&rsquo;s knowledge
of the progress towards completion of the research and development activities, invoicing to date under the contracts, communication from
the research institution or other companies of any actual costs incurred during the period that have not yet been invoiced, and the costs
included in the contracts. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting
period. Actual results could differ from the estimates made by the Company. The historical accrual estimates made by the Company have
not been materially different from the actual costs. For further details, please refer to the Related Parties disclosures in Note 12
below.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: bold 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-size: 10pt">4.</FONT> <FONT STYLE="font-size: 10pt">General and administrative</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">General
and administrative costs consist primarily of salaries, share-based compensation, benefits and other related costs for personnel and
consultants in the Company&rsquo;s executive and finance functions, professional fees for legal, finance, accounting, auditing, tax and
consulting services, travel expenses and facility-related expenses, which include rent and maintenance of facilities and other operating
costs not otherwise included in research and development expense.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 239; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin-right: 0pt; font: bold 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-size: 10pt">5.</FONT> <FONT STYLE="font-size: 10pt">Income taxes</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company is subject to taxation in Italy, including the standard corporate income tax (&ldquo;IRES&rdquo;) and a regional business tax
(&ldquo;IRAP&rdquo;). Taxes are recorded on an accrual basis. They therefore represent the allowances for taxes paid or to be paid for
the year, calculated according to the current enacted rates and applicable laws. The Company is taxed in various countries where it has
permanent establishment, as applicable. Due to the tax loss position reported, no income taxes were due for the periods ending June 30,
2021 and 2020.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
Company uses the asset and liability method of accounting for deferred income taxes. Under this method, deferred tax assets and liabilities
are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets
and liabilities, measured at tax rates expected to be enacted at the time of their reversals. These temporary differences primarily relate
to net operating losses carried forward available to offset future taxable income.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">At
each reporting date, the Company considers existing evidence, both positive and negative, that could impact its view with regards to
future realization of deferred tax assets. In consideration of the start-up status of the Company, a full valuation allowance has been
established to offset the deferred tax assets, as the related realization is currently uncertain. In the future, should the Company conclude
that it is more likely than not that the deferred tax assets are partially or fully realizable, the valuation allowance will be reduced
to the extent of such expected realization, and the corresponding amount will be recognized as income tax benefit in the Company&rsquo;s
consolidated statements of operations and comprehensive loss.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 38.75pt"><FONT STYLE="font-size: 10pt">The
Company recognizes tax liabilities from an uncertain tax position if it is more likely than not that the tax position will not be sustained
upon examination by the taxing authorities, based on the technical merits of the tax position. There are no uncertain tax positions that
have been recognized in the accompanying consolidated financial statements. The prior five years of tax returns (2016-2020) are potentially
subject to audit.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 38.75pt"><FONT STYLE="font-size: 10pt">At
June 30, 2021 and 2020, the Company believes there are no significant differences with regards to its deferred tax assets and its relevant
components, compared to the computations of the preceding periods.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">In
2011, the Italian tax authorities issued a set of rules that modified the previous treatment of tax loss carryforwards. According to
the DL 98/2011, at the end of 2011, all existing tax loss carryforwards will never expire but they can off-set only 80% of the taxable
income of the year. The rules do not affect the tax loss carryforward that refer to the start-up period, defined as the first three years
of operations starting from the inception of the Company. The impact of the updated calculation of tax losses carryforward at June 30,
2021 and 2020 is deemed not significant with respect of the preceding periods. </FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 240; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="margin-right: 0pt; font: bold 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-size: 10pt">6.</FONT> <FONT STYLE="font-size: 10pt">Prepaid expenses and other current assets</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">Prepaid expenses
and other current assets consist of the following:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><P STYLE="margin-right: 0pt; margin-top: 0; margin-bottom: 0">At</P>
                                                                                <P STYLE="margin-right: 0pt; margin-top: 0; margin-bottom: 0">June 30,</P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><P STYLE="margin-right: 0pt; margin-top: 0; margin-bottom: 0">At</P>
                                                                                <P STYLE="margin-right: 0pt; margin-top: 0; margin-bottom: 0">December 31,</P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Value Added Tax (VAT)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">724,157</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">480,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research and development tax credit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">374,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">280,631</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">373,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,261</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Advances to suppliers- related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,432</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other prepaids</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">77,397</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">30,609</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,549,766</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,068,933</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Value
Added Tax (VAT) receivables are linked to purchases. Italian VAT (<I>Imposta sul Valore Aggiunto</I>) applies to the supply of goods
and services carried out in Italy by entrepreneurs, professionals, or artists and on imports carried out by anyone. Intra-Community acquisitions
are also subject to VAT under certain situations. The Italian standard VAT rate for 2021 and 2020 is 22%. Reduced rates are provided
for specifically listed supplies of goods and services. It is carried forward indefinitely and does not expire. The Company reclassified
to other non-current assets a portion of the receivable which is expected to be realized beyond 12 months.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Tax
credits on research and development represent a special tax relief offered to Italian companies operating in the research and development
sector and can be used to offset most taxes payable. The Company has a total research and development tax credit available to be used
of approximately &euro;4.2 million at June 30, 2021, and approximately &euro;3.9 million at December 31, 2020, which can be carried forward
indefinitely and does not expire. However, given the start-up status of the Company, and the fact that it will not be profitable in the
foreseeable future (which limits the utilization of the credit), the Company recognized a receivable balance that represents the Company&rsquo;s
best estimate of the amount of tax credit that can be used in offsetting taxes payable for 2022.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 35.95pt">During the six months ended June 30, 2021, the Company utilized
approximately &euro;204,000 to offset certain social contributions and taxes payable, while during the financial year 2020, the
Company utilized approximately &euro;281,000. The benefit recorded for the six months ended June, 2021 and 2020, to offset
research and development expenses was approximately &euro;204,000 and &euro;136,000, respectively. The Company reclassified to
other non-current assets as a portion of the receivable, which is expected to be realized beyond 12 months. The utilization rate of research
and development credit, in the periods following June 30, 2021, is projected in a consistent manner to previous periods.</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt">

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0 0 0 5pt; text-indent: 35.95pt">The amount of &euro;373,545 in &ldquo;deferred
offering costs&rdquo; in the chart above, mainly relate to legal fees incurred from fundraising activities (&euro;263,368) and
audit expenses (&euro;110,177). Fundraising deferred offering costs will be offset against the funding proceeds and reclassified
to common stock upon completion of the funding effort. If the funding is unsuccessful, the Company will expense all the related fundraising
costs. (See Note 2.) The amount of &euro;77,397 in &ldquo;other prepaids&rdquo; in the chart above, mainly relates to insurance expenses
(&euro;30,824) and various advance payments and operational prepaid expenses.</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: left; text-indent: 35.95pt">

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 41pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 41pt; text-align: justify"><FONT STYLE="font-size: 10pt">The remaining balance
is comprised of miscellaneous minor prepaid expenses.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 41pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 241; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: bold 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-size: 10pt">7.</FONT> <FONT STYLE="font-size: 10pt">Property and equipment, net</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Property
and equipment consist of the following:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-right: 0pt; margin-top: 0; margin-bottom: 0">At</P>
                                                                                <P STYLE="margin-right: 0pt; margin-top: 0; margin-bottom: 0">June 30,</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-right: 0pt; margin-top: 0; margin-bottom: 0">At</P>
                                                                                <P STYLE="margin-right: 0pt; margin-top: 0; margin-bottom: 0">December 31,</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%">Computer</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">22,740</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">16,196</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Furniture and fixtures</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,858</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,675</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,598</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,871</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,986</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,900</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">20,612</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,971</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Property
and equipment consist of computers and furniture and fixtures of our office space in Milan, Italy. There were no disposals, nor impairments
during the periods. Depreciation has been calculated by taking into consideration the use, purpose and financial-technical duration of
the assets, based on their estimated economic lives. No significant purchases occurred during the six months ended June 30, 2021.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: bold 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-size: 10pt">8.</FONT> <FONT STYLE="font-size: 10pt">Other non-current assets</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Other
non-current assets consist of the long-term portion of the VAT receivable and R&amp;D tax credit, as follows:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="margin-right: 0pt; margin-top: 0; margin-bottom: 0"><B>At</B></P>
                                               <P STYLE="margin-right: 0pt; margin-top: 0; margin-bottom: 0"><B>June 30,</B></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="margin-right: 0pt; margin-top: 0; margin-bottom: 0"><B>At</B></P>
                                                                                <P STYLE="margin-right: 0pt; margin-top: 0; margin-bottom: 0"><B>December 31,</B></P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2021</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2020</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: justify">Value Added Tax (VAT) <BR></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">975,215</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">664,987</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Research and development tax credit <BR></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">187,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">280,631</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">Other assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">827</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Other assets- related party <BR></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,350</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: justify">Total </TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,166,725</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">945,618</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Other
assets - related party include a security deposit of &euro;3,350 paid to Ospedale San Raffaele (&ldquo;OSR&rdquo;) as security guarantee
for the office lease contract. (See Note 13. Commitments and contingencies.)</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: bold 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-size: 10pt">9.</FONT> <FONT STYLE="font-size: 10pt">Retirement benefit obligation</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Employees
in Italy are entitled to Trattamento di Fine Rapporto (&ldquo;TFR&rdquo;), commonly referred to as an employee leaving indemnity, which
represents deferred compensation for employees in the private sector. Under Italian law, an entity is obligated to accrue for TFR on
an individual employee basis payable to each individual upon termination of employment (including both voluntary and involuntary dismissal).
The annual accrual is approximately 7% of total pay, with no ceiling, and is revalued each year by applying a pre-established rate of
return of 1.50%, plus 75% of the Consumer Price Index, and is recorded by a book reserve. TFR is an unfunded plan. The costs of the retirement
benefit obligation are accounted for under the provisions of ASC 715, <I>Compensation &ndash; Retirement Benefits</I>. The amount of
the obligation at June 30, 2021, and December 31, 2020 was &euro;21,645 and &euro;17,388, respectively.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0pt; font: bold 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-size: 10pt">10.</FONT> <FONT STYLE="font-size: 10pt">Quotaholders&rsquo; and stockholders&rsquo; equity</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company was an S.r.l., which is an Italian limited liability company similar to a limited liability company in the United States. The
Articles of Incorporation, Shareholders&rsquo; Agreement and the By-laws of the Company provided for different quotas, which represented
the Company&rsquo;s corporate capital, rather than shares of stock as ownership.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 242; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</FONT></P>

<P STYLE="font: 10pt/107% Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Corporate
capital</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">As
an S.r.l., the Company&rsquo;s ownership was called &ldquo;corporate capital&rdquo; and &ldquo;quotas&rdquo; rather than shares, stock
or units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company&rsquo;s capital was divided between the five quotas as summarized below at December 31, 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Georgia, Times, Serif; border-collapse: collapse; width: 60%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">At December&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Ownership</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Quota</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: justify">A</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 20%; text-align: right">10,458</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">28</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">B</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,886</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">C</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,645</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">D</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,034</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">E</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,033</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">37,056</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">100</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company had five (5) quotas:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Quota
    A. Quota A was reserved for certain founders. One of the founders had the right to appoint three (3) board members out of five (5),
    appoint the Chair from these three (3) persons and appoint one (1) member of the Board of Statutory Auditors. One other founder had
    the right to appoint two (2) board members out of five (5), appoint two (2) statutory auditors and appoint the Chair of the statutory
    auditors from the two (2) appointees. Quota A had voting rights.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Quota
    B. Quota B had no voting rights, the same profit-sharing rights as Quota A and was priced at a nominal amount of &euro;1.00. The
    Company had historically utilized Quota B for its share-based compensation program offered to board members, employees, and consultants.
    Quota B was also held by certain co-founders. The Company&rsquo;s stock options were exercisable into Quota B for past and present
    board members, employees, and consultants.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Quota
    C. Quota C had the right to appoint one (1) member of the Board of Statutory Auditors; specifically, the one (1) that a founder had
    the right to appoint. Investors received Quota C in the Company&rsquo;s first funding round (2014/2015) where approximately &euro;10
    million was raised.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Quota
    D. Investors received Quota D in the Company&rsquo;s second funding round (2017) where approximately &euro;7 million was raised.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Quota
    E. Investors received Quota E in the Company&rsquo;s third funding round (through December 31, 2019) where approximately &euro;14.8
    million was raised approximately (&euro;15.1 million gross, net of approximately &euro;0.3 million of financing fees). Investors
    received Quota E in the Company&rsquo;s second tranche of the third funding round (through December 31, 2020) where approximately
    &euro;1.4 million was raised (approximately &euro;1.5 million gross, net of approximately &euro;0.1 million of financing fees).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 243; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Quotas
A, C, D &amp; E. During a divestiture proceeding (meaning Quotas representing 100% of the corporate capital of the Company) or a dissolution
of the Company, Quotas C, D &amp; E all had the same rights with respect to the proceeds of a divestiture, i.e., all three (3) quotas
shared the divestiture consideration equally (on a pari passu basis) up to the amount of their investment. If there was any consideration
remaining after payment to quotas C, D &amp; E, then quota A was entitled to the amount remaining up to the amount of their investment.
If proceeds of a divestiture were less than or equal to &euro;50 million, then any proceeds remaining after payment of quotas A, C, D
&amp; E, were to be shared equally among quotas A, C, D &amp; E; however, if proceeds of a divestiture were greater than &euro;50 million,
then any proceeds remaining after payment of quotas A, C, D &amp; E, were to be distributed to each quota separately according to a detailed
formula specified in the Company&rsquo;s By-Laws, including quota B. Similar to a divestiture, net profits, if any, were to be distributed
in the same manner to quotas A, B, C, D &amp; E, after deducting not less than five (5) percent for a legal reserve (up to where this
reserve equals one-fifth of the quota capital). A, C, D, E had equal voting rights and the Company By-laws specify protective provisions
for each class of quota for A, C, D &amp; E.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">During
the six months ended June 30, 2021, two events occurred which together had a significant impact on the Company&rsquo;s equity:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">On April 1, 2021, the Board of Directors resolved
to grant to employees and non-employees stock options and accelerate the vesting of other stock options on &euro;715 quota B and &euro;172
quota B were repurchased at nominal value, cancelled, and allocated to the option plan as available for grant by Drs. Naldini and Gentner,
leaving a net equity increase of &euro;543 quota B. All quota B ownership has limited rights and carry a par value of &euro;1 per quota.
The Corporate Capital amount was &euro; 37,771 (&euro;37,056 corporate capital at December 31, 2020 + &euro;715 exercise of Quota
B options before the conversion).</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">On May 20, 2021, at a special Quotaholders&rsquo;
meeting in May 2021, the Quotaholders resolved to convert the Company from an S.r.l. to an S.p.A., which conversion became effective
on June 18, 2021. As consequence of the conversion, the Corporate Capital has been converted to ordinary common stock with no par value
and it was increased to &euro;50,000 to satisfy the minimum capital requirement to qualify as an S.p.A. This increase was an
adjustment from Additional Paid-in Capital to Common stock, no par value.</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 35.95pt">As a result of the Company conversion, the Corporate
Capital was reclassified as ordinary Common Stock no par value, combining the minimum capital amount of &euro;50,000 with
the Additional Paid-In Capital for a total of &euro;37,139,431. The outstanding quota of &euro;50,000 before the conversion
were all converted into 15 million shares of ordinary common stock no par value after the conversion at the same conversion rate of approximately
300 quota percentage of ownership. All preferences related to the quota classes were terminated and all stockholders now hold
ordinary common stock, no par value. All of shares outstanding after the conversion are held in ledger form. The Company adopted
a new Article of Association, appointed two new directors (including Mr. Squinto as Chairman) and re-appointed the existing members
of the Board of Directors and the existing Board of Statutory Auditors.</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt">

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Georgia, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1.4pt"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">11.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Share-based
                                            compensation</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
Company granted options on its Corporate Capital to certain directors, officers, employees, and consultants, as an incentive and
as additional compensation prior to the Company&rsquo;s conversion to an S.p.A. All options converted into Quota B when vested and exercised.
All options had an exercise price of &euro;1.00 per quota. Options generally vested over a one-to-three-year period and have been exercised
when vested.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">At
December 31, 2019, there were no options available for grant, as all remaining authorized options were granted in 2019; therefore, no
options were granted in 2020. However, in April 2021, &euro;172 of quota B shares were repurchased, cancelled and allocated to the option
plan as available for grant. The Board approved new option grants on &euro;169 of quota B and accelerated the vesting of options on &euro;546
quota B and all options were exercised. This totals &euro;715 quota B that were issued and exercised during the six months ended June
30, 2021.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 244; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Also,
in May 2021 as part of the conversion to an S.p.A., the shareholders adopted a medium-to long-term incentive plan, &ldquo;Equity Incentive
Plan 2021&ndash;2025,&rdquo; (the &ldquo;Plan&rdquo;) with the purpose of providing incentive and retention for key officers, directors,
employees and consultants with a view to developing the Company&rsquo;s business over the next few years. The Board of Directors and
the Board of Statutory Auditors reviewed a draft of the Plan. The Plan is intended to last four years and will have a maximum of 2,700,000
new ordinary common shares, or 10% of the total outstanding common shares of the Company. No grants were made under the Plan and the
Compensation Committee of the Board of Directors will administer the Plan.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">At
June 18, 2021, the date of the Company&rsquo;s conversion to an S.p.A., all stock options were granted, fully vested, exercised and converted
into ordinary common stock with no par value. At June 30, 2021, there were no outstanding stock options.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Number of Options on Quota</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Term (Years)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">Outstanding, vested and expected to vest as of January 1, 2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 11%; text-align: right">982</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">2</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 11%; text-align: right">1,056,316</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Vested and exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">436</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">472,184</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cancelled or forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Outstanding, vested and expected to vest as of December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">546</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">584,132</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Exercisable as of December 31, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">169</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">183,831</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Vested and exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">715</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">777,920</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Outstanding, vested and expected to vest as of June 30, 2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Exercisable as of June 30, 2021</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company&rsquo;s share-based compensation expense for the six months ended June 30, 2021 and 2020, is represented by the following table:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Research &amp; development expense</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">82,669</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 18%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research &amp; development expense - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">179,480</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">163,200</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">General &amp; administrative expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">234,955</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">66,897</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">497,104</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">230,097</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
weighted average fair value of the options granted during 2021 was &euro;1,088.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">For
the periods ended June 30, 2021 and 2020, the Company recorded &euro;497,104 and &euro;230,097, respectively as the fair value of the
stock options granted. There was no amount of unrecognized expense at June 30, 2021, since there were no outstanding stock options and
approximately &euro;540,000 of unrecognized expense at June 30, 2020.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 245; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><I>Quota
B Valuations</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
fair value of the Quota B underlying the Company&rsquo;s stock-based compensation grants had historically been determined by the Company&rsquo;s
board of directors, with input from management and third-party valuations. The Company believes that the board of directors has the relevant
experience and expertise to determine the fair value of its Quota B, when also securing third-party assistance. Given the absence of
a public trading market of the Company&rsquo;s equity, and in accordance with the American Institute of Certified Public Accountants
Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation, the board of directors exercised reasonable
judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company&rsquo;s
equity at each grant date. These factors include:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">valuations
    of the Quota B equity performed by third-party specialists;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    price of the Company&rsquo;s equity to third-party, arms-length, sophisticated, and qualified investors;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    prices, rights, preferences, and privileges of the Company&rsquo;s Quota C, D, and E preferred equity classes relative to those of
    the Company&rsquo;s equity;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">lack
    of marketability of the Quota B;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">lack
    of voting rights of the Quota B;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">current
    business conditions and projections;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">hiring
    of key personnel and the experience of management;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    Company&rsquo;s stage of development;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    timing, progress and results of the Company&rsquo;s pre-clinical studies and clinical trials for the Company&rsquo;s programs and
    product candidates; including statements regarding the timing of initiation and completion of trials or studies and related preparatory
    work, the period during which the results of the trials will become available and the Company&rsquo;s research and development programs;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">likelihood
    of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market
    conditions, or other liquidation events;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    market performance of comparable publicly traded companies; and</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">the
    European, U.S. and global capital market conditions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
valuing the Company&rsquo;s Quota B class of options, the board of directors determined the equity value of the Company&rsquo;s business
using various valuation methods. The board of directors engaged a third-party valuation firm who performed analyses in accordance with
the guidance outlined in the American Institute of Certified Public Accountants&rsquo; Accounting and Valuation Guide, Valuation of Privately-Held-Company
Equity Securities Issued as Compensation. The Company&rsquo;s option valuations were prepared using an option pricing method (&ldquo;OPM&rdquo;),
which used market approaches to estimate the Company&rsquo;s enterprise value.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
OPM treats each equity class as a call option on the total equity value of a company, with exercise prices (i.e., breakpoints) based
on the value thresholds at which the allocation among the various holders of a company&rsquo;s securities changes. A discount was considered
for Lack of Marketability (&ldquo;DLOM&rdquo;), which is an amount or percentage that is deducted from the value in order to reflect
the absence of a viable market. The DLOM was then applied to arrive at an indication of value for the option. Also, considered in the
valuation was volatility and the fact that the Quota B class of equity did not carry voting rights. The expected volatility used in the
OPM is based upon the historical volatility of a number of publicly traded companies in similar stages of clinical development.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 246; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Application
of the Company&rsquo;s approach involved the use of estimates, judgment, and assumptions that are highly complex and subjective, such
as those regarding the selection of comparable companies, and the expected timing of an initial public offering (&ldquo;IPO&rdquo;) or
other liquidity event. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact
the valuations at each valuation date and may have a material impact on the valuation of the Company&rsquo;s Quota B equity class, and
consequently, the Company&rsquo;s share-based compensation expense could be materially different.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: left; text-indent: 35.95pt"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0"><I>Weighted average shares</I></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-indent: 0.5in">As a result of the Company&rsquo;s conversion to an S.P.A., the Company was able to calculate
both a weighted average and pro forma weighted average number of shares outstanding. The calculation was performed by taking the number
of quota outstanding during a given period and weighting them for the number of days that number of quota were outstanding and then converting
the quota to common stock using the same conversion that was used at June 18, 2021. The quota carried different rights and privileges,
as indicated above, so the Company was not sure how all quota would be treated in a conversion; however, all classes of quota were treated
the same. Therefore, the conversion was straight forward. For the six months ended June 30, 2021 and 2020, there was a weighted average
of &euro;37,029.65 and &euro;35, 190.54 quota, respectively, which converted into 14,772,610 and 14,038.916 shares of the Company&rsquo;s
common stock, no par value, after the Corporate Capital adjustment.</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: left; text-indent: 35.95pt"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Georgia, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.45pt"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">12.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Related
                                            parties</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
Company&rsquo;s research and development expenses are a combination of third-party expenses, and related party expenses, as detailed
below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">For the Six Months Ended June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Third Parties</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">Related Parties</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Consultants &amp; other Services</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 11%; text-align: right">525,978</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 11%; text-align: right">1,541,526</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 11%; text-align: right">2,067,504</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Materials &amp; supplies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">717,905</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">717,905</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Compensation (including share-based)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">221,900</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">179,480</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">401,380</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Travel &amp; entertainment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,445</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,445</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,478,228</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,721,006</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,199,234</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Six Months Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Third Parties</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">Related Parties</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left">Consultants &amp; other Services</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 11%; text-align: right">383,901</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 11%; text-align: right">727,458</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 11%; text-align: right">1,111,359</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Materials &amp; supplies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">608,831</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">608,831</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Compensation (including share-based)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">155,633</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">163,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">318,833</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Travel &amp; entertainment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,106</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,106</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,181,471</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">890,658</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,072,129</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0pt"><FONT STYLE="font-size: 10pt">Research
and development (related party) expenses during the six months ended June 30, 2021, mainly relate to the clinical trial activity
done as per the agreement with the San Raffaele Hospital. This trial activity increased significantly from the second half of 2020 both
for number of patients enrolled in the trial and the number of patients subsequently dosed. (Also see <B><I>OSR &ndash; San Raffaele
Hospital</I></B> section below.)</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 247; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-size: 10pt"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company&rsquo;s general and administrative expenses are also a combination of third-party and related party expenses, as detailed below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: center; text-indent: 35.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><B>For the Six Months Ended <BR>
June 30,</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><B>Third Parties</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><B>Related Parties</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 52%"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Compensation (including share-based)</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&euro;</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">258,514</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&euro;</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">150,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&euro;</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">408,514</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Accounting, legal &amp; other professional</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">181,354</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">181,354</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Facility &amp; insurance related</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">1,712</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">7,197</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">8,909</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Consultants &amp; other third parties</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">127,988</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">127,988</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Other</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">115,471</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">115,471</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&euro;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">685,039</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&euro;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">157,197</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&euro;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">842,236</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: center; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: center; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">For the Six Months Ended <BR>
June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Third Parties</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Related Parties</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Compensation (including share-based)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 12%; text-align: right">116,329</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 12%; text-align: right">150,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 12%; text-align: right">266,329</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounting, legal &amp; other professional</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,863</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,863</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Communication &amp; IT related</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Facility &amp; insurance related</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,474</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,674</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Consultants &amp; other third parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">39,019</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">39,019</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">247,685</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">157,200</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">404,885</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: center; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company&rsquo;s accounts payable to related parties are comprised as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">At June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">At December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">San Raffaele Hospital</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 20%; text-align: right">88,193</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 20%; text-align: right">4,085</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">XDG Biomed</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,942</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Pierluigi Paracchi</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Naldini</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Genter</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">57</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">88,392</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,027</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Drs.
Naldini and Gentner outstanding balances represent the &ldquo;quotas&rdquo; reimbursement due to the Company as a result of the quota
repurchase.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 248; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Company&rsquo;s accrued expenses to related parties are comprised as follows:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 41pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">At June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">At December&nbsp;31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">San Raffaele Hospital</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 20%; text-align: right">809,605</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 20%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,309,191</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Pierluigi Paracchi</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">XDG Biomed</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">25,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">809,605</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,359,191</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 43.75pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 43.75pt; text-align: justify"><FONT STYLE="font-size: 10pt">No amounts
were due and recorded at June 30, 2021 to Mr. Paracchi and XDG Biomed, since their performance bonuses were paid in June 2021.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 43.75pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 43.75pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Company
has identified the following related parties:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Pierluigi
    Paracchi (director and co-founder of the Company);</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Luigi
    Naldini (co-founder of the Company and executive scientific advisory board chairman);</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Carlo
    Russo (through XDG Biomed LLC- Chief Medical Officer);</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Bernard
    Rudolph Gentner (co-founder of the Company and member of scientific advisory board); and,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">San
    Raffaele Hospital (co-founder and main supplier of services).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
following is a description of the nature of the transactions between the Company and these related parties:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Pierluigi
Paracchi</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Pierluigi
Parcchi, former President and Chairman of the Company prior to the conversion, is the Chief Executive Officer as well as co-founder.
His annual compensation amounts to of &euro;250,000 plus an annual performance bonus of &euro;50,000, maturing in the period July-June
of each year payable after Board of Directors approval. In 2020, the bonus was paid in July 2020. In 2021, the bonus was paid in June
2021. For the six months ended June 30, 2021 and 2020, the Company expensed &euro;150,000 each period, respectively, related to compensation
for Mr. Paracchi. At June 30, 2021 and the year ended December 31, 2020, the Company accrued &euro;0 and &euro;25,000, respectively,
related to compensation for Mr. Paracchi.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Luigi Naldini/Bernard
Rudolph Gentner</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Drs.
Naldini and Gentner are co-founders of Genenta and part of the SAB &ndash; Scientific Advisory Board, with Dr. Naldini as Chairman, and
Dr. Gentner as a member. Dr. Naldini has an advisory agreement approved by the Board of Directors and performs the pre-clinical studies
for the Company. In particular, the pre- clinical experiments are in solid tumor indications. The last agreement with Dr. Naldini was
signed in 2019 and it is still in force. The annual fee is &euro;50,000. During the six months ended June 30, 2020, he billed additional
fees for &euro;6,250. For the six months ended June 30, 2021 and 2020, the Company expensed &euro;25,000 and &euro;31,250, respectively,
related to Dr. Naldini. At June 30, 2021 and the year ended December 31, 2020, the Company did not accrue anything related to Dr. Naldini.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Dr.
Gentner, like Dr. Naldini, oversees pre-clinical research related to the platform technology. In addition, he analyzes clinical biological
data. The last agreement with Dr. Gentner, which is still in force, was signed in 2017. His annual fee is &euro;30,000. For the six months
ended June 30, 2021 and 2020, the Company expensed &euro;15,000 and &euro;22,950, respectively, related to Dr. Gentner. At June 30, 2021
and the year ended December 31, 2020, the Company did not accrue anything related to Dr. Gentner.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 249; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><B><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">XDG Biomed
LLC</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">This
is the LLC of Dr. Carlo Russo. Dr. Russo has a single contract signed by XDG and the Company that has been approved by the Board of Directors
and was subject to multiple amendments. In particular, Dr. Russo, via XDG, serves as the Company&rsquo;s Chief Medical Officer and Head
of Development. Dr. Russo is responsible for the clinical development of Temferon&trade;, the Company&rsquo;s gene therapy platform.
The applicable recurring fees are &euro;300,000 per year, plus a performance bonus of &euro;50,000 maturing for the period July-June
of each year and payable after Board of Directors approval. In 2020, the bonus was paid in July 2020. In 2021, the bonus was paid in
June 2021. For the six months ended June 30, 2021 and 2020, the Company expensed &euro;175,000 and &euro;175,000,
respectively, related to XDG Biomed. At June 30, 2021 and the year ended December 31, 2020, the Company accrued &euro;0 and &euro;25,000,
respectively, related to XDG Biomed.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">OSR &ndash;
San Raffaele Hospital</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">San
Raffaele Hospital (&ldquo;OSR&rdquo;) is a co-founder of the Company, and the Company is a corporate and research spin-off of OSR. At
June 30, 2021, OSR held 12.64% of the Company&rsquo;s common shares. OSR is one of the leading biomedical research institutions in Italy
and Europe, with a 45-year history of developing innovative therapies and procedures. The Company has agreements to license technology,
to perform research, pre-clinical and clinical activities, as well as to lease facilities and obtain certain other support functions.
The Company&rsquo;s headquarters is currently in an OSR facility.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt"><I>License
Agreement</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
Company has a License Agreement with OSR entered in December 2014, for the exclusive use of different patents. In particular, OSR granted
the Company an exclusive, world-wide, royalty bearing license under certain technology to conduct research and develop, make, use, import
and sell licensed products. The license agreement covers patents and patent applications, as well as proprietary technologies. The Company&rsquo;s
rights to use these patents and patent applications and to utilize the inventions claimed in these licensed patents are subject to the
continuation of, and the Company&rsquo;s compliance with, the terms of the license agreement.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Based
on the preclinical studies carried out by OSR, in particular by its SR-TIGET Institute (San Raffaele Telethon Institute for Gene Therapy),
on a specific gene therapy strategy with respect to lympho-hematopoietic indication and/or solid cancer indication, the Company decided
to develop a new therapy to treat cancer through a cell and gene therapy strategy. The &ldquo;Field of Use&rdquo; as defined in the License
Agreement is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Lympho-Hematopoietic
    Indication<SUP>1</SUP>; and,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Solid
    Cancer Indication.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
agreement provided for an upfront fee of &euro;250,000 (which was paid in 2015), future option fees are as follows:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">option
    fee on the first indication = &euro;1.0 million (subsequently reduced to &euro;0.5 million);</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">option
    fee on the second indication = &euro;0.5 million;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">option
    fee on the third indication = &euro;0.3 million; and,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&#9679;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">option
    fee on any additional indications = no license fee.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"><SUP>1</SUP> The Company
later amended the License agreement focusing on GBM options. The TEM-MM option fee has never been exercised and instead the related research
was abandoned in early 2021.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 250; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">In
addition, the Company would be obligated make payments on milestones depending on the Field of Use (as defined in the agreement) and
pay royalties of 4% of net sales of each Licensed Product (as defined in the agreement).</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">In
connection to the License Agreement, the Company engaged OSR to provide certain research activities regarding the Licensed Products in
the Field of Use, based on a mutually agreed study plan and utilizing the extensive resources at OSR. (See Note 13. Commitments and contingencies.)
In consideration of the research activities provided by OSR, the Company agreed to pay scientific collaboration research fees in advance.
In December 2014, the Company and OSR signed a Scientific Collaboration Agreement and subsequently modified the Agreement with Research
Addenda 1, 2 and 3 in 2016, 2017 and 2018, respectively. During the six months ended June 30, 2021 and 2020, there were no costs incurred
for the above activities.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
protocol TEM-GBM_001received approval by national Competent Authorities in September 2018 and recruited the first patient in April 2019.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-size: 10pt"><I>License
Agreement Amendment #2</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0; text-indent: 35.95pt">In February 2019, the Company and OSR entered into Amendment
#2 of the License Agreement to conduct a clinical trial according to the protocol TEM-GBM_001 and EudraCT 2018-001404-11 entitled: &ldquo;A
phase I/IIa dose escalation study evaluating the safety and efficacy of autologous CD34+ enriched hematopoietic progenitor cells genetically
modified with a lentiviral vector encoding for the human interferon-&alpha;2 in patients with GBMwho have an unmethylated O-6-methylguanine-DNA
methyltransferase gene promoter.&rdquo; In Amendment #2, the Company and OSR also revised the license fee requirement for the first Solid
Cancer indication (GBM). In relation to the GBM trial, the Company and OSR agreed that the Company would be obligated to pay OSR the
&euro;1.0 million Option Fee only in the event that the Company was able to dose its tenth patient. Under this Amendment, the Company
is also obligated to pay for the costs of the study-related procedures performed on the patients recruited in the trial, according to
periodic study reports delivered by OSR. The first GBM patient was recruited in April 2019 and related clinical activity costs were recorded
by the Company. During the six months ended June 30, 2021, the comparable costs incurred and expensed for the GBM program were approximately
&euro;0.8 million. During the six months ended June 30, 2020, the comparable costs incurred and expensed for the GBM program were approximately
&euro;0.5 million.</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt">

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">Under
this Amendment, the Company is obligated to cover the costs of the study-related procedures performed on the patients recruited in the
Trial, according to periodic study reports delivered by OSR.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-size: 10pt"><I>License
Agreement Amendment #3</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">In
December 2020, the Company and OSR entered into Amendment #3 of the License Agreement: The initial &euro;1.0 million payment in the event
of the tenth patient dosed in the GBM trial was reduced to &euro;0.5 million, in exchange for the Company&rsquo;s agreement to exercise
a second option for an additional Solid Cancer indication (possibly Liver Cancer) and an agreement to execute a Sponsored Research Agreement
in February 2021. Note: If the Company is not be able to obtain approval from the competent authorities to initiate a human clinical
trial on or before the expiration of nine months (from December 2020), the Company has the right, at no additional costs, to convert
this second solid cancer option to an &ldquo;Alternate Indication,&rdquo; i.e., an indication other than liver cancer.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">In
summary, the Amendment #3 formalized the new arrangement as follows:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">exercise
    of option fee on the first solid cancer indication = &euro;0.5 million (accrued in 2019, since it was considered probable, and paid
    in December 2020); plus,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">commitment
    to enter into a Sponsored Research Agreement by February 2021; and,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">exercise
    of option fee on the second indication = &euro;0.5 million (accrued at December 31, 2020 and was paid on June 30, 2021).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 251; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">At
June 30, 2021, no milestones were achieved related to any indication, as provided by License Agreement and subsequent amendments, therefore,
no payments were due to OSR. The Company has paid &euro;0.75 million to OSR, since inception under the license agreement. No events have
occurred or have been achieved (and none are considered probable) to trigger any contingent payments under the license agreement at December
31, 2020. For information relating to the contingency payments or future milestones for these indications, please refer to Note 13 -
Commitments and Contingencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">OSR
may terminate the Company&rsquo;s rights as to certain fields of use for the Company&rsquo;s failure to develop (a) with respect to a
solid cancer indication, upon third anniversary of the date the Company exercised such option, if the Company has not filed an IND with
respect to such optioned solid cancer indication specifically, as to GBM, the Company is required to file an IND regarding Temferon for
GBM prior to February 2022, or (b) with respect to a lympho-hematopoietic indication, on the earlier of (i) the fifth anniversary of
the initiation (first patient dosed) of the first human clinical trial for a licensed product in any lympho hematopoietic indication
or solid cancer indication if a patient has not been dosed with a licensed product in a Phase 3 clinical trial and (ii) September 1,
2025.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 41pt; text-align: left; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">During
the six months ended June 30, 2021, the Company recorded expenses for OSR for clinical trial in the amount of approximately &euro;1.3
million, while during the six months ended June 30, 2020, the expenses for clinical trials was approximately &euro;0.5 million. The
difference between the two periods is due to the increase of the trial activity in the second half of 2020, since a greater number of
patients were included in the trial and subsequently dosed.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 41pt; text-align: left; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">At
June 30, 2021, the total amount of expenses for the OSR clinical trial activity amounted to &euro;8.1 million and it includes the cost
for the exercise of the first and the second Solid Cancer indication Option fee.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-size: 10pt"><I>Research
Funding Agreement</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">In
March 2019, the Company and OSR entered a Research Funding Agreement to conduct a clinical trial according to the multiple myeloma protocol,
TEM-MM-101 and EudraCT 2018-001741-14, entitled &ldquo;A Phase I/II dose escalation study evaluating safety and activity of autologous
CD34+ enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human interferon-&alpha;2
in multiple myeloma patients with early relapse after intensive front-line therapy.&rdquo; This agreement required OSR to perform certain
clinical procedures and exploratory analyses on the study population, as per the protocol approved by the relevant competent authorities.
The Company was required to fund the costs of the study-related procedures performed on patients recruited in the Trial, according to
periodic study reports delivered by OSR. TEM-MM-101 received approval by national Competent Authorities in November 2018 and the first
TEM-MM-101 trial patient was enrolled in August 2019.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">For
the six months ended June 30, 2021 and 2020, the Company expensed &euro;0 and approximately &euro;65,000, respectively, for the analysis
performed by OSR for multiple myeloma and there were no clinical procedures performed by OSR&rsquo;s Hematology and Bone Transplant Unit
for multiple myeloma. The Company discontinued the multiple myeloma program in early 2021 due to the relatively small number of eligible
patients, and the highly competitive MM landscape. (See Note 13.)</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-size: 10pt"><I>Sponsor
Research Agreement (SRA)</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">As
stated above, in exchange for a reduction in the first Solid Cancer indication option fee from &euro;1.0 million to &euro;0.5 million,
the Company agreed to enter into a Sponsored Research Agreement (SRA). The Company and OSR executed the agreement in February 2021. Under
the SRA, sponsored research activities will be conducted for between &euro;0.5 million and &euro;1.0 million (minimum commitment &euro;0.5
million). The activities relate to:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 252; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Research
    1: Additional preclinical mouse model studies directed to identify Temferon effectors cells (transduced Tie2-expressing cells) and
    to test Temferon in combination with CAR-T in a GBM mouse model; and,</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&#9679;</TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Research
    2: Additional exploratory analyses, including single cell sequencing, to be conducted on samples collected from patients belonging
    to TEM-GBM_001 clinical trial aimed to deepen Temferon mechanism of action and get a broader insight on its biological activity in
    humans.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">For the six
months ended June 30, 2021, the Company paid and expensed &euro;375,000 related to the SRA. At June 30, 2021, the Company accrued &euro;125,000
related to the SRA.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><I>Operating leases</I></P>

<P STYLE="margin: 0; font: 10pt Georgia, Times, Serif">The Company entered into a non-cancelable lease agreement for office space
in January 2020.</P>
<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Georgia, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 1.4pt"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">13.</FONT></TD><TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Commitments
                                            and contingencies</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
Company exercises considerable judgment in determining the exposure to risks and recognizing provisions or providing disclosure for contingent
liabilities related to pending litigations or other outstanding claims and liabilities. Judgment is necessary in assessing the likelihood
that a pending claim will succeed, or a liability will arise and to quantify the possible range of the final settlement. Provisions are
recorded for liabilities when losses are considered probable and can be reasonably estimated. Because of the inherent uncertainties in
making such judgments, actual losses may be different from the originally estimated provision. Estimates are subject to change as new
information becomes available, primarily with the support of internal specialists or outside consultants, such as actuaries or legal
counsel. Adjustments to provisions may significantly affect future operating results.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
following table summarizes the Company obligations by contractual maturity at June 30, 2021:</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I></I></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Georgia, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Payments by period</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Less than a year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">1 to 3 years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">4 to 5 years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">More than 5 years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left">OSR operating leases and office rent</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 9%; text-align: right">33,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 9%; text-align: right">6,700</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 9%; text-align: right">26,800</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&euro;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">AGC</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">40,250</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,050</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">32,200</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">73,750</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,750</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">59,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&euro;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Company
has not included future milestone and royalty payments in the table above because the payment obligations under these agreements are
contingent upon future events, such as the Company&rsquo;s achievement of specified milestones or generating product sales, and the amount,
timing and likelihood of such payments are unknown and are not yet considered probable.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>CMOs and
CROs agreements</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
Company enters into contracts in the normal course of business with CMOs, CROs and other third parties for exploratory studies, manufacturing,
clinical trials, testing, and services (shipments, travel logistics, etc.). These contracts do not contain minimum purchase commitments
and, except as discussed below, are cancelable by the Company upon prior written notice. Payments due upon cancellation consist only
of payments for services provided or expenses incurred, including non- cancelable obligations of the Company&rsquo;s vendors or third-party
service providers, up to the date of cancellation. These payments are not included in the table above as the amount and timing of such
payments are not known.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 253; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><I><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>OSR - San
Raffaele Hospital</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
license agreement in place with OSR provides milestone payments and royalties. The OSR agreements are non-cancelable, except in the case
of breach of contract, and include total potential milestone payments of up to &euro;10 million related to the Lympho-Hematopoietic Indication
of each Licensed Product, and up to &euro;53 million related to each Solid Cancer indication (as defined in the agreement); however,
starting with the fifth Solid Cancer indication, the first two related milestone payments totaling &euro;7.0 million, are reduced to
&euro;3.5 million. The milestones relate to certain events such as, dosing of the first patient with a licensed product in Phase II and
III of the trial, MAA (marketing authorization application) and NDA (new-drug application) approval of the licensed product, the first
commercial sale of the product in the US and major European countries, and annual sales for the licensed product exceeding a certain
amount in different territories.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt"><I>Multiple
myeloma (MM)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">As
discussed in Note 12, the Company&rsquo;s MM program was discontinued in early 2021 due to the relatively small number of eligible patients,
and the highly competitive MM landscape. No milestones were achieved with respect to the MM program, and as such no contingent payments
were due under the agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt"><I>Glioblastoma
multiforme (GBM)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">As
discussed in Note 12, in December 2020, the Company had one indication ongoing, GBM. The Company&rsquo;s contingent liability for this
first solid cancer indication potentially payable to OSR was &euro;53 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt"><I>Liver
cancer (LC)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">In
relation to the option exercised by the Company for the second solid cancer indication, the Company and OSR agreed that the payment due
in relation to the &ldquo;First patient dosed with a Licensed Product in Phase I/II Clinical Trial,&rdquo; as stated in the agreement,
was reduced to &euro;0.5 million rather than &euro;1.0 million. The reduction applied to the first license fee payment only. All the
additional contingent payments, other than the last contingent payment of &euro;5.0 million, remained a contingent liability of the Company
and potentially payable to OSR. Therefore, for the second solid cancer indication (liver cancer), the total potential commitment of possible
contingent payments could amount to &euro;47.5 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The agreements
also include a &euro;7.8 million commitment related to the development and manufacturing of licensed products, of which the Company had
incurred &euro;1.5 million of expense during the six months ended June 30, 2020 compared to &euro;2.6 million of cumulative expense for
2019 and prior years. The Company has incurred approximately &euro;682,000 during the six months ended June 30, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><I>AGC
Biologics (formerly MolMed)</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
AGC Biologics agreement is non-cancelable, except in the case of breach of contract, and includes a potential milestone of &euro;0.3
million if a phase 3 study is approved by the relevant authority, as well as potential royalty fees between 0.5% and 1.0% depending on
the volume of annual net sales of the first commercial and named patient sale of the product. In the AGC Agreement, the Company entrusts
AGC with certain development activities that will allow the Company to carry out activities related to its clinical research and manufacturing.
The AGC agreement also includes a technology transfer fee of &euro;0.5 million related to the transfer of the manufacturing know-how
and &euro;1.0 million related to the marketability approval by regulatory authorities. The agreement is a &ldquo;pay-as-you-go&rdquo;
type arrangement with all services expensed in the period the services were performed. In February 2020, the Company entered into Amendment
4 to the Framework Service Agreement with AGC Biologics related to production and testing of the Company&rsquo;s GBM trials, for a total
amount of &euro;360,000. In March 2020, the Company entered into Amendment 5 to the Framework Service Agreement with AGC Biologics related
to production and testing of the Company&rsquo;s GBM trials, for a total amount of &euro;259,000. In March 2020, the Company entered
into Amendment 6 to the Framework Service Agreement with ACG Biologics related to production and testing of the Company&rsquo;s GBM trials,
for a total amount of &euro;41,000. In August 2020, the Company entered into Amendment 7 to the Framework Service Agreement with ACG
Biologics related to production and testing of the Company&rsquo;s GBM trials, which provides the Company with an option to accelerate
GBM production as stated in Amendment 5 at a 20% cost increase. In October 2020, the Company entered into Amendment 8 to the Framework
Service Agreement with ACG Biologics related to production and testing of the Company&rsquo;s GBM trials, for a total amount of &euro;17,000.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 254; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">In
the early 2020, the Company and AGC amended the Master Service Agreement for the fourth time to regulate some new production activities
for which the total estimated budget amounts to &euro;0.3 million. For the six months ended June 30, 2021, the Company is committed to
pay a total of &euro;40,250 relating to various stability timepoints, which will be realized and come due at different times through
2025.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Adaptive
Biotechnologies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
Adaptive Biotechnologies agreement on exploratory analyses for trial endpoints is non-cancelable, except in the case of breach of contract,
and carries a total cost for the entire trial of &euro;0.2 million, of which approximately &euro;20,000 and &euro;20,000 have been incurred
for the six months ended June 30, 2021 and 2020, respectively.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Biogazelle
NV</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
Biogazelle agreement on exploratory analyses for trial endpoints is a five-year agreement that can be withdrawn by each party with a
notice period of six months, or in case of breach. The Company shall compensate Biogazelle for any and all work (including but not limited
to work-in-progress) performed or commenced prior to the effective date of termination or expiration and reimburse Biogazelle for any
and all costs, expenses and consumables (including non-refundable) approved by the Company and incurred by Biogazelle prior to the effective
date of termination or expiration of this agreement. For the six months ended June 30, 2021 and 2020, the Company had incurred and paid
approximately &euro;14,000 and &euro;12,000, respectively. At June 30, 2021, there were no future commitment to Biogazelle identified
by the Company.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal">Operating
leases</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On
January 1, 2020, the Company began a six-year non-cancelable lease agreement for office space with OSR. Withdrawal is allowed
from the fourth year with a notice of 12 months. Since the annual rent amounts to &euro;13,400, at June
30, 2021, outstanding minimum payments amount to &euro;33,500 until January 1, 2023.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal">Legal
proceedings</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">The
Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential
loss amount or a potential range of loss is probable and reasonably estimable under the provisions of ASC 450, Contingencies. The Company
was notified by Theravectys of the possible infringement by the Company of Theravectys&rsquo; exclusive license to patents no. EP 1071804,
EP 1224314, and EP 1222300 granted from the owner of the patents Institut Pasteur. Each of these patents is now expired, having each
reached the end of it its patent term on April 23, 2019 for EP 1071804 and October 10, 2020 for EP 1224314, and EP 1222300. The Company
considered the situation and determined that the likelihood of a material adverse effect on its business is remote. To date, the Company
has not engaged in any such discussions with Theravectys nor has the Company received any further communication from Theravectys. The
Company expenses as incurred the costs related to its legal proceedings, if any.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 255; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Georgia, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><I><IMG SRC="fin_001.jpg" ALT="" STYLE="height: 65px; width: 280px">&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: italic 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal"></FONT></P>

<P STYLE="font: italic 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-weight: normal">Coronavirus
Pandemic</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; background-color: white">On
March 11, 2020, the World health Organization declared the outbreak of a coronavirus (COVID-19) pandemic. Significant uncertainties may
arise with respect to potential shutdowns of operations or government orders to cease activities due to emergency declarations, inability
to operate, or employee shortages, claims for business interruption insurance, etc. Although the Company has experienced minimal disruption
to date and still has staff working remotely from home, the Company</FONT> <FONT STYLE="font-size: 10pt">may find it difficult to enroll
patients in its clinical trials, which could delay or prevent the Company from proceeding with the clinical trials of its product candidates;
therefore, <FONT STYLE="background-color: white">the coronavirus pandemic may still have a significant impact on the future results of
the Company.</FONT></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-size: 10pt">14.</FONT> <FONT STYLE="font-size: 10pt">Subsequent events.</FONT></P>



<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
July 2021, the Company signed a financial advisory agreement with Roth Capital. The minimum commitment relates to some expenses to be
reimbursed by the Company up to US$50,000, or &euro;42,373, using the spot exchange rate at the time the agreement was signed. The agreement
also calls for the Company to pay Roth variable commission, estimated to average six percent of funds raised, if and when determined.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">In September
2021, the Company entered a new service agreement for shipment services with Marken. The budget provided through 2024 amounts to approximately
&euro;106,000, but the agreement can be withdrawal at any time with a reasonable but non-specific notice period.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">In
August and September 2021, the Company entered into two new purchase orders with AGC for a total amount of &euro;155,200 to be delivered
by the end of the year. The purchase orders with AGC are non-cancelable, except in the case of breach of contract, consistent with the
disclosure in Note 13 above.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">In
September 2021, the Company signed two purchase order with Cross NT amounting to &euro;141,006 to be executed in three years through
January 2024. Based on the Master Service Agreement in place with Cross NT, the Company can withdraw any task order with a notice period
of 60 business days.</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 256; Value: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 14pt"><B>3,120,114
</B></FONT><FONT STYLE="font: 14pt Georgia"><B>Ordinary Shares</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"><B>(including 2,400,000 Ordinary Shares in the form of American Depository
Shares)</B></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"><IMG SRC="logo_001.jpg" ALT="" STYLE="height: 113px; width: 500px">&nbsp;</P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 18pt"><B><I>Genenta
Science S.p.A.</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; margin-bottom: 3pt; width: 30%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 14pt">PROSPECTUS</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; margin-top: 3pt; width: 30%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Georgia; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B><I>Sole
</I></B></FONT><FONT STYLE="font: 10pt Georgia"><B><I>Book-Running Manager</I></B></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Georgia; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font-family: Georgia; vertical-align: top">
    <TD STYLE="font-family: Georgia; text-align: center; width: 100%"><FONT STYLE="font-family: Georgia; font-size: 18pt"><B>Roth
    Capital Partners</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Georgia, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><B><I>Lead Manager</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 18pt; background-color: white"><B>Maxim
    Group LLC</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 12pt Georgia"></FONT></P>

<P STYLE="font: 12pt Georgia; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Georgia; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Georgia">December 15<FONT STYLE="font-size: 10pt">,
2021</FONT></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Georgia; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Georgia; font-size: 10pt"><B>Through
and including January 8, 2022 (25 days after the date of this prospectus), all dealers that effect transactions in these
securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition
to the dealer&rsquo;s obligation to deliver a prospectus when acting as an underwriter and with respect to unsold allotment or subscription.</B></FONT></P>

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Georgia; font-size: 12pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 257; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Georgia; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Georgia; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo_001.jpg
<TEXT>
begin 644 logo_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !Q ?0# 2(  A$! Q$!_\0
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M=UXEUW1O#FDZEK^M7D-CI>C6-QJ.I7,N'6*TAC9F?RR&+EV4I#$JF2[G,=G
M)+B>-&_"CXF?%#7?B)\1]5^(9NM2T.^N"MAH;Z7J.HZ1J^AZ!ITL\6G>'[/6
M]-OH-0TZ6T9KNZUF2SETU+K7[_62UW+$R6UO]D?MM_&%G>S^$/AZ;S([=X]5
M\=3JS1I).T%O?:+X:M)$Q^]C6ZM-:U19MD(L9=.B61Y;AHZ_.AU4$!<MB.+
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M_5R(YXZ\*2?H>XP1D$4 345'YL8#,6(50I+E6"8;&TJY 5AR,E20.^*42(2
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MMF[F)+F!Y5V[XDD1I4W?=\R-27CST^=5YP.IQ0!:HJ+SHL@%PK$;@K H^"2
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MZ5^1?_!$)U/_  3J^$3#<0=;^(B A6/S2>,;X(#@<;MP.3@ 98D $C]<6E1
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MER7?@R/ECOD(#2MF1@&8@557;D D#=D#TR$&.N, \XP >>E6(#AS@<?,..Y
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M2M8<R&1%LM2M ^C>((X8WDD@LM&U*&&XNX+FVD^)XU550JNU$^8C&0$7+LP
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M:NVZM27M)MOF;YWS)Z7;O%K:[^9792[J$*LTLB1J@8 AY%Q'OSM50^QPIWD
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M_&NPDBE2\CUG3O$_CR/>4"[9_P"TK&_@62&38)%FF>)RC OERS'^OK_@F_\
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MV\4>FS7.GQ@'^BU',LK,JJX"C[[ !68221NB\[BT;1Y?*A<21E6;)"_SB?\
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MT>VT+PM\(_AGX>T:SMU@M=,TWP)X9MK2&-% 17CCTU3*$0!/G;<54!F)&:_
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MN34_"GPZND\B:3PG;P6J_P#"3>.W29) %\/175G!ITLML\!U>^M'8-Y)C?\
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M8X7'NH4Y]0><]OH_]D/2?!?B3XXV6E>)=01]2T31;OQ#X>TEG,,=_KEM-%%
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MZ]A)VBYL]4TZ>:QO8F8.!-:?NB0P#9'/YX?\%@%5?^";O[4^U57=X2\,,VT
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M)NKJ758[166#0_',4*7&HP21F-4BMO$\*7?B"PE$LIDU&#Q#;21V:II$6H?
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M=V.<8)/0')P0.H)&"<C&#D $XR"PQ L'#,K#T/!R06++]TLVT L1NVY (R:
M/\ZOX%_\%%_VV?V9K2T\-_#OXY^+[#0]+#PQ^!/&GV/QMX>L8XY/L[P6>A^)
M'UX:;"J6Z0XA6RMH6C>WC6%HI,_6\W_!>S_@H)<VOD0>)?A?;7/EO$NIQ_#;
MP]+<HXROF0(+B\TUW3HRI)*H=2KI%(KPI_9%\1OV4OV:?B]-+<_$[X#_  G\
M<W5Q*9I[WQ%X%\/7]_/*<DRSWSV NYI"S,QDEF=R3][@8\2B_P""8?\ P3ZA
MO?[03]D3X(&Z#!PTG@ZSFB5@ !MMI6>V4  ?*L(7N1DDD _AB^,W[7?[77[8
M^JPZ)\3_ (F_$'XHO=7YNM,\!:+#-!HL%U&S-N@\#^%HFLI;7<"PM[C3;E H
M7$F1FOU-_8!_X(:?&3XO>(O#WQ)_:OTF]^#WP@LY[74U\!73VT'Q.\>Q^1<*
M-.FT^+[6? VB7+3,-:N=>E?Q->I+Y5CI>G/(U[;?UQ?#KX"?!3X0P16_PN^%
M7@#P!'$'5'\*^%-%TBZ"2((VC%]:6<=Z(]GR+&+@(JDJJA20?5$@5#D-(>0<
M.[.HP-NU Y;8. <)CD9YR<M-K9[@<]X2\'Z#X&T#0/"?A73;'0O"_A?1[;0=
M T#3+9+;3M+TNQCBM["SM8_G=(+*U@2"%=Y8[YGF:5F0Q]1112 **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#Y:_::_;+_9\_9#\/67B'XZ^.;;
MPQ_;-R;+PQX=L;._\0>,O%MX,AH/#?A#1K:\U_5$@.W[=J,-C_8^FI*DVH:E
M;6Z74UM\$O\ \%J/AK!;_P!MWO[%_P"W]8>#@@,GBRZ^"7@W[#$QP?WEI;_%
M6XNTB5,O(Q02HH(:W\P%!X3X,O\ P9XU_P""Y_Q\B^/\ND3:]\,_@WX3TW]E
MW0?&LUNNBR&_L- O-7U+PO8ZO(EDWB9QK&NQZ7<Z9:7%VXNO$$[--<V<7V?^
M@'+J8R6<LT>(PSRPJS#&1)N>1MW.1FW++P&8Y+4 ?-/[,_[9W[._[7?A_4==
M^!7CZR\3S:$]K#XH\+7\%QH'C;PE<WC2);P>)?">K1VVKZ69'@N5BFE@:WNT
M@%QI\UY:7%K<3?2&J:UI^BZ?>:OJ]W9Z9I.F6<U_J>H:A>V]C:Z=90 R37E[
M<W;P6MM:PPJ\T\TUQ&(D4DJW6O&O#O[,?P)\&_&'Q'^T#X4^&OAGP_\ %[Q3
MX5B\(:_XPTFS&G3ZEHD-ZNH21SV%JT.DK>WMQ#:?VEJL=DFH7\5C8QWES-':
M0JOX[?\ !1OQ/XX_;#_;*^#'_!+_ , >)=2\(?#R_P##MM\7_P!J?Q%HDNR[
MU#PH%N[JS\#--(&@CCM-!TJSU6\CD@GL]2U#QCX360+#:7=I= 'N_P 0_P#@
MM[^R1X=\5:KX.^$WA'X]_M0:EHC&'5M7^ GP[L=:\(V%VDVR2U;Q'XO\3>#8
MM1!B62:VU'0+36=$O-@2'52/,>+LO@7_ ,%DOV.OC3XXLOACK<WQ+_9Z^(VJ
MW-K9Z-X3_:,\'V?@636;N\F6WM;6Q\1Z!K_C/P9'=7$\EO';6NH^);"XNGN8
M8[:.:9O*K[R^!WP)^$W[/?@?2/AQ\'O!&A^!_"FAV%O9P66D644-[=M HB:_
MU_5?GOO$&M7C1F74M6U*YN[RXNQ*99W'EJGAW[;'[#OP6_;3^%>N^ OB!H>E
M:9XNGL9F\"_%6VTBUO/%O@'Q,$6'1=5@9E@F\0:+]K,-KK_A?4-0AL=:T:6Z
MLEFL+I[74K$ ^Q);IA;RWGDO&([>6=HMHGFS;)YA1H8F"33I*DD21P7;1.R[
MHYI$=6KYF_90_:Z^$_[8_@/7?B+\'[?Q=%X=\/>+M;\"WZ^,M%MM U%=;T(6
MC7:6EA::AJ<<VFJMVJK=>:CL$/[K&&/8?LX?"7Q#\$?@?X#^%/BOXGZ_\9-6
M\%:$NB2_$+Q/IL&E:UK]E;@I817]FE_J\H33+&6'2K1[[4[_ %0V%C9QZAJ%
M]/')=3_D_P#\&_\ &)?V1OB6Q^4_\-#>/I J87]Z;719"^\?/EVP&&_:5 7&
M,Y /VA\=_$CP?\+O"VK^-OB#K^A^#O!GANPDOM=\3^(=4MM&T;3+6+RR9Y;V
M^,5HT(B\US#%<R7[M&EO9V-Y-(%7\K-2_P""V?[.^HW^H0?!WX%_M=?M":+I
M<\L=YXT^%/P<LF\'-#;9-Q+9:CXU\7>#]1N3MP]FSZ3;V>H#=]DOI,+O^=?B
M-I-Q_P %/_\ @I/XN_9W\6WFHS?L:_L/6UCK_P 1_"&D74MGI_Q3^+^KWD2>
M&-%\4W,%["\UO_:.E^,#9K C1VWACP3XALHXX-3\5V.MZ5^^/ACPKX6\$Z%I
MGA?P;X?TOPIX;T:VBL]+T'P]IMOI&D6%K"J+'#:V%A!!;1*JQH"RQAV .]FW
M-D ^(?V9/^"G/[*W[4_B2X^'WA'7O$WP\^+5L%=OA#\:?#K_  ^\>7$3+NSI
M<#7>K:#KMTB"1Y]*T+7M3UBT2-I+S3[:)HW?[]BNC( ?*9,MA0[ ,1N*Y( 8
M*ZE7$D3,'A8!) K,*_/']OK]@OP!^UO\-=6U70K!?"'[2/@RSF\1?!;XP: 8
M]&\8Z)XST</J6B:;<Z[$;2:YT?4[V"+3Y4O;AO[-2<7-C-;&-UEK?\$L_P!J
MS7?VO/V4=!\6^//(7XL_#WQ!K7PD^+HCACM3J'C'PDMA,GB+[!YEP;8>*_#V
MIZ3JU^A<QIJ]QJEK$0;1TA /;/@_^VG\%_C5=?M&0>')]=\.6O[+7Q$\1_#/
MXM:YX_M--\*>'M+USPI+J\&NZE9:O+JUY!<^'+"?0]0CGU6=;22/RU=K,1,S
MI\0^-_\ @N'^R=I&LZGHOPH\ ?M&_M+C27F2\\1_ KX9Z=K?@H-;,?/:W\5>
M*_%GA"PU" (/.M[S2DU"ROH6CFL;BXA=9#^4/[+O[-OC/]L7]MK]OOX(^*_$
M&H:-^R3X:_;;^-?Q4^.6AZ([:?J?Q3\1Z=\7OB3I7@?X;7NIV\L=Q!X?E+SZ
MQJ"6<2W4<5CBSGMM3NK2_M/ZM/A]\.? _P ,_#-AX1^'OA70?!/AG2X(;2RT
M+POI-GHFGVJ0(@1!%9HIFDB8NKS2R2/*S.9VFE,DL@!\=_L@?\%*?V;OVV+S
MQ!X=^$MWXHT'XA>$X(K[Q+\+_B7I-IX5\<Z;I+3V5K+K$-E8:EX@TK5;"VNK
MZWL+LZ5J]W<Z=J5WIMOJUMIT.HPW:_>XNB8PXA8DHS$*Z,JN 6$1926D8CKY
M"3#/W"XP3_/+_P % _!VA_LS?\%//^"=O[3GP^T^T\,:C\8OB%JOPC^*2:);
MK;P^);*[?0?">HW^M:>BI8WD]]X0\?2P2SR*SB_T'1]558M0TZ.YD_1[_@I?
M^U9??L??LC?$#XJ>&2L_C[4[W2/AM\,+8P></^$Z\67%Q:V=VZ>;$9TT#2;3
M7?$MS#"T,\EKHYABDBDQ(P O[4G_  4W_92_9(U>V\'_ !%\4ZQXG^*%Z(GL
M_A#\+M&?QK\1I8I@AA:[TU)].T;0)IHF:]M[3Q3KV@W5QIZ>;#$]W)#8R?)]
MK_P7;_9HTR^ME^*/P'_:]^"WAZ\OA:0>-?B)\)_#<?AF*(G O+MO#?Q!\0:T
ML+%HPL=CHVHW!#E_*$<<CKZQ_P $TOV!O"?[.7PVTOXL_$S3HO'W[5GQC@B\
M?_%7XI^+XX-?\1V&H>(T@UM/#/AZ]NT9]"L](CO8;'6I[0"_\2ZY#<:OJ5P]
MH-,T_3OTR\9>#/#'COP[J7A7QCH&A>*_#NLQ-:ZGH7BC3+76M'O;:;]W<13V
M5[%-$VZW:9(V 4Q,_F(R,H8 &%\+_BY\//C3X-T7XB?"SQ7HOCCP-XBMS<Z+
MXET"]%Y87>Q_)GLY#L22QU6SN@]O?:5?K;7MG(NR>)95GB@VO&OCKPI\.O#6
MK^,_'.OZ+X1\)>'K";5->\1^)-4M-(T;2-/ME+W$]]J-TZVENR@!84EFC%S(
M1%"[2E4;X*_8T_X)\:+^Q5\4/C9K_P +_BSXIE^"_P 6]3M-8\-_L]ZEI$=Q
MH/PTOT2V^T267BFZUS5=2UH6_EW6G:8YM-->STE[2RU*[UR[LSJ-Q\(?'73;
MS_@I=_P4@U#]D'6M2U&/]DO]C32]%\8?&O0=&O[BT'Q/^)=[;V=YIGA359[:
M5)C8P7%];6,HC>.>UM])\1&UGM=5N+.\M #Z!U/_ (+:_LX:GJM_8_!3X*?M
M8_M*:3I]S);R>,_@Q\(M/OO!=RL7W[K3]7\8^,/!]S?6BE7 N(--,<I7_1VF
M4[A[[^S9_P %1OV5?VF_%Z?#+P_JWB_X7_%V::6*T^$?QT\,M\./'>J>1&S3
M_P!A6\E]J^A:[<0.K++IVEZ]=:F88I[N"SFMTB>;[C\'^#_"O@+P]IWA/P7H
M&F>%/#&CVZVFD>'O#NGV^D:/IEHL<:Q06=E811V\2QJH&^)5\U]\DF^5I';X
MP_;P_8:^''[8OPSUBVFT^V\+_&[PY:'6_@]\8-%A.E^,_"GCG2(A-X<@N=8L
M(HM2U+PK>Z@+1-:TN:<P11QQWULUIJ6G:7?V(!][FY;)"6T\H'&Z,P$ C[RL
M'G1E=6RK*1QCKS17Y2?\$T_VS_\ A??[,]K+\>/$UIX8^-7P@\;^)_@9\3;>
M]O+>TN-3\2> HM*EBUJ82PYN+N_T/6M'_M*]C6.&[U6&^FBBB5A&I0!^L>U?
M3]3_ (TGEKG//TW''Z=?QI]%2HQ5K12MM96MZ!W7=6?FGI9_(3  P/YG^?6@
M #.._7K2T57?SW\_47*M-%IMY>FH5&8U+%^<GK\QQTQTZ#IZ=:DHHNUMH4FU
ML[7T?H-9 W4GIC@D?RI/+3&,'_OINV/0CTI]%';RV\O03U7*]8]GM]P@4#ID
M?B3GKUSGUI:**!))*R2271"$ XSVZ=:0J",<X]B?7.<_YZFG44!9)W2U?7J1
M^4F2?FR?]HT\*%Z9[=?:EHIW;W;*;;W;84444A!1110 4444 %%%% !1110
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MR^)]=AMT>^OVT[2([>UA59)/LT4DD0O;J*".[OGDNIY9'* /7:*** "BBB@
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K &(=W_Z'-7[W?\$?O^3$OA%_UXG_ -!AHHH _3Y?XO\ >/\ 2BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>chart_001.jpg
<TEXT>
begin 644 chart_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $X IX# 2(  A$! Q$!_\0
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M!9[W5/#-_9WNF64'B.2ZU*[O+;1K:&;79UTT@']#-O\ %3X:W=OXEO+7XA^
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MAZ#_ (4%@=>V,]#D9!^T:* /BX_MZ?L\D8,7[1&/;]B_]LT'ZY_X4%G/OGC
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M@KJWP<:^N='UOP?I?B;1_#6H:#=>(HO&FH:EJTQ==X_^!1_^2#YK[U_F>H^
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MACPOH&F6VC^%;WP5X%_9^\+Z5IEI:_:#X@O=9\3ZGXCO[N75%B@\$N?V=?\
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MG_X0X+_Y4>Q?\+73_H R?^#%/_D.C_A:Z?\ 0!D_\&*?_(=>.T4?ZLY-_P!
MM3_PLQ?_ ,N#_7OBC_H8T_\ PAP7_P J/8O^%KI_T 9/_!BG_P AT?\ "UT_
MZ ,G_@Q3_P"0Z\=HH_U9R;_H%J?^%F+_ /EP?Z]\4?\ 0QI_^$."_P#E1[%_
MPM=/^@#)_P"#%/\ Y#H_X6NG_0!D_P#!BG_R'7CM%'^K.3?] M3_ ,+,7_\
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M4\7.=/#1Q%6V'@U*JHTJDHQU2DKGZ+_\+7C_ .@%)_X,4_\ D.C_ (6O'_T
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M.FJ6&JSE3@J<YJ?(H5*:56C.M3E"I/\ 57_A:Z?] &3_ ,&*?_(='_"UT_Z
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MX7+ZM*K3E=QJ4ZE.$X3A))N,HR::3VU2]B_X6NG_ $ 9/_!BG_R'1_PM=/\
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M_P +6CY_XD,G.0?^)B@R#U'_ !Y]^_K1_P +5B_Z #_^#%/_ )#KX[_X7_\
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MWPD((_X2T<_]03Q&>_\ V"*MM^T%\(3I]G;CQ:3)#?:I-(/["\1@+'=6VC)
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MG1_PM=/^@#)_X,4_^0Z^.O\ A?WPD'_,VCJ3_P @3Q$.I)_Z!)H_X7_\)/\
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M,'_T7W"W_A?P_P#_ "P^Q?\ A:Z?] &3_P &*?\ R'1_PM=/^@#)_P"#%/\
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M/_D.C_A:Z?\ 0!D_\&*?_(=>.T4?ZLY-_P! M3_PLQ?_ ,N#_7OBC_H8T_\
MPAP7_P J/8O^%KI_T 9/_!BG_P AT?\ "UT_Z ,G_@Q3_P"0Z\=HH_U9R;_H
M%J?^%F+_ /EP?Z]\4?\ 0QI_^$."_P#E1[$?BQ&.N@R\G QJ,?7\;,CU[?\
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M_+@_U[XH_P"AC3_\(<%_\J+^M?\ (;U[_L,ZM_Z<+JJ%7]:_Y#>O?]AG5O\
MTX754*]?"_[M0_Z\4/\ U'H'S.-_WS&?]AN,_P#4K$A1116YS!1110 4444
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MJ?\ 0+T;_P *+3/_ (Y1_K=PK_T4.3_^%U/_ .0%_P 0]X^_Z(_B7_PUXO\
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M+<%3P&=4ZF+QN"Q&'P\)U\OC2HPG4J57"]2I[L8RC*[[;GN]7K?_ )!VM?\
M7'3?_3E%5#<,9R/SYJ_;<Z=K/O%IPXYY&I1?3@]O?T'-?SSBM*<5_P!/</\
M<L30\O)_<?V/A4_:3NFO]FQBU4M6\'B4K>X^KM\T4:*3(]1^8HR/4?F*Z3GM
M+^2?_@,O_D1:*3(]1^8HR/4?F* M+^2?_@,O_D1:*3(]1^8HR/4?F* M+^2?
M_@,O_D1&_A_WA_6M&3_D$Z?_ -?NJ?\ HC2*SC@D#(ZY]>G;]?T-7Y#_ ,2K
M3\_\_NJ<]/\ ECI0_'&!V[CD\XYZWQX?_L(AW_Y\XGR_4Z**?L\2K.ZPM33E
ME?7%81K['97W*5%)D>H_,49'J/S%=!SVE_)/_P !E_\ (BT4F1ZC\Q1D>H_,
M4!:7\D__  &7_P B+129'J/S%&1ZC\Q0%I?R3_\  9?_ "(M7=3_ ./BT_[!
M6D?^FNUJCD>H_,5>U/\ U]J>F-*T?KWSIEM[_P"1V)XK";MB,-Z8K_TU27F=
M%-2>$Q:Y9)REA$KQDKMSQL4O@?5I?.^Q17H/H/Y4'I^7OWZ?CTI 0 !D< =Q
M02",;AS[C\:W>[]7^ISVETA+R?+*V[:^S?MV?IT_.3]MC1_B#?\ B_PO<GPM
M\8_&GPHB^$'Q#M-"T3X/:M\9+".P_:*N/$WA.3PKKOQ$A^ FH67Q%FTL_#^+
MQ/IW@/5Y(=4\'^'/&<US<^(+6Q74(K]?%IOC+_P47TE?$VG0?"[7K!/#W[.,
MNK>'-%U7P+J_Q%UJ?QEIG[/GASQ!I.J7'CZR\'7&D^-?B==?'635?!.O^%M1
M\7-<:SI]MJ$T7PSL[R.#Q5JW[!8ZE7VY&.",?R.<C@\\<GF@ #'S+_AST!SG
M&.#G\N:]O"YZL/@\/@ZV2Y7CXX:-2-.>+C7?QU(U'.%*$Z=.G5G9K$5^:O4Q
M,W&<^14H4CXW'<'5\7F6,S+#<29WE,L96IU*M+ 4Z,>:,*3IJ%6O44\5B*-!
MN-3"4'/#PPC5>C2E6A5]I+\L/%7Q0_;_ /"_CC2/!^D>'Y?&.A:5\:?%WAI?
M'UW\&KZQL_B'X9MM:^#$GAFU\16GA'PQXEL_"'@V;PUXL^)ZV_C[3KGP18O<
M>$Q<WOQ!DU/PY?Z)XPYS7O%_[=.L67A^3Q!J'Q/TG0;OQA\,_&VMR^"/@9'8
M^)/">A>'OVP_$/@#7O"D5KH6F3ZIXLTW5?@GI_A;XJ^(=!O;'4;W6M&B<+9G
MP/KVKVE[^N6/]L=#P3ZD$<Y[8XXY/6EXXPP ]L9_ DDCCCKQBG#/:=-4''A_
M(XU*4.6I5CA7*=>5I)U7&JZE.G4<FZL53I<BDU#E=**I+.KP9C:SK*7&'%;I
M5JJJ1HRQDX0H152$Y4>:C*E7KTI4X0H3J3KQKUN5U:TY5U#$+X;_ &1?B=^T
MIX_\7_&:V^._A3Q7X=\-V(\*ZK\-O^$L^&4WP^O+&;4O$7Q+T[Q9X46X@\/:
M3HVLIX?L-#\$W$0LM?\ B/Y<>KC4H/B3XFM=4\K3ON>F>GS@X/.2/T_ECL.G
M2G9'J/S%>9C,13Q>)JXBE@L-E\*GLDL+@U-8>G[*C3H\T/:)3;J>S4YRDDY3
M<I/64F_I,HR_$99@*6#Q&88[.*U.=><LPQU.,<555>O4KPIU/9\T>7#1JO#T
MDI-1HPITXMPI0;6BDR/4?F*,CU'YBN8]*TOY)_\ @,O_ )$T-:_Y#>O?]AG5
MO_3A=50J_K7_ "&]>_[#.K?^G"ZKEKSQ#H6G7(LM1U[1-/OFCBE6RO\ 5]-L
M[MXKB1HK>1+:YN8)V2:16CB=8RLKJZ(2ZE1SX9I8?#QU;>'HM))R;4</AN9V
MBF[14DV[62=VTDVNC'RC#%XQSG"">.QB3G.$%?ZSB6U><H]-=+MI.RDTTMJB
MF$LI.0> >" "",]1Z#!W$="I]#56>_L[6XL[2XO;.VN]2DGATVTN;JW@NM1E
MM83<746G6TLB3WLMK;*UQ<1VT<SPVZF>4)&"U;\R>SOW2LVK)MW47*UDKOLF
MFW9Z<S:BKR:2O%<S:Y;SER07->UYU+TH*]YU8RA%-Q;+M%,W'('/)P..QR ?
MJ2"/P/'!H&]BJJ"S-PJJ/F8DXP 1R<X'&.3CD\TN=>?S5OS>G6]]N65_A923
M;22OS-179R=K1N^5)N[LFU?EEKHN=]%>>6?Q9^%>HPWESI_Q4^&-_;Z;;WUU
MJ5Q8_$/P=>0:?:Z6MH^IW5]+;:Q+'96VG+J&GM?W%PZ0V2W]D;EX_M=N7]!^
M8,588*G# @@J>>"#T(Q@CL:N49P:4Z=2FW:WM*56G>]K<OM*5-2T:=X\T6FF
MI--,QI5Z%>/-0KT*T;)WHXBA6TDVD_W%>O973CS.T6U)1E+DJ>S=1112-0HI
M-LC';&I8XR0 2>6"C@ _Q,H'J2!U(!<T<Z9W12*<X 9".<$XZ9/ /H<KTQFI
M<XIV;2>N[72UWHVUNMTGY6U9N[:7\W&/2Z^.4$[JUK-IW23;T244PEAD'"E2
M00W!&,YX(!&"K [@,;<9R#2J2>O4=>,?_6/.1^%--/9W^:O9[.UWI):Q?5:Z
M"332::UVU5WHF[+1NR:;:35FGS--#JV+I]/2VTD7-I>32'2U)>#4;>V3;]OU
M$*#$^F74@(Y^8S;6R-J@YSCUY)^T=\3/$?PE^&$'C#PAX0B\=^)C=^#/#FC>
M%I-1GLY]1G\4>,CHMQ<Z;IVGVU]XA\7:GI-A<WVKV?@;P?IVH^,/%CZ>^D^'
MK&:\E!7-X>6+Q."PU-M5*]>=.G:LJ"YY4>5<]64HPA!-WE*;4(I.4I1BG):3
MQM++<MS7'5X\U'#8>C4JVPTL7/D5>HG&EAX>_6K3<HPI4J2E5J2;C3A.2<7[
M/OTD_P#,.U(>W]L6O'YZ&*-^D_\ 0.U+_P '%I_\I*_-:]_X*(^";#X5:EXN
M?PAJ^I>+='\ :UJ>JRZ$E_-\*=)^+-KX'^*GC?PW\(=8\0>*;/P;\5=,U[Q)
M8?"#Q7]KFN/@\;/P;>I!X<\87^D^(VCL[CK+']MK3]3UOPGX3TGX?:WJ_B#5
MOC=X<^%WBS4[2:PMO!7@;1/%O[0/Q(^!OAK5=4U._P!6M_$E_P")->D^%?C+
M5=*TK0/"VM:*L^DI#KVM^'X=7T9KSUI\+9O!59SPF-A"E4K4ZE2>+C&FG1IU
MJU2:G*O&,J?LZ+E"?NRJ*KAN2C+ZWA?;?-+Q X8G.E&./R^I/$4J=:G&.62E
M.7MJ]&A"DTJ/\>5:NH.FG.,71Q;EB%'!XF5+[]WZ3_T#M2_\'%I_\I*-^D_]
M [4O_!Q:?_*2OC*3]H;QWX?^-OCKX?\ CCP=X'@\!^$]=_9^\/:;XA\(^(_$
MNL^--4O_ -J7XGWOPN^$GVWP_K>A:#H%C!I>L6:7OQ%FM?$-[_96G7(F\,Q>
M)[B V<O!ZA_P44^#-EIUSK-O\._CMK.BV.@ZCXBOM7TCPO\ #UK*TLM%\ ^(
M/BGK4,BZC\5=.O9;S2OASX1\5^++F*VLYHIK;0VTC3KB_P#$VK>']$U?*'#F
M9U7!8?"8_$^TI4*T98;$.K#DQ%.G4I)S=:A&-1QJT^:F[3A*<8/FD].BIQKD
M%"-26+Q.!P+I8K%824,;E4Z%1UL%5G1Q#A".'Q?/2C5IU(PK*485%"4X+V=J
MDOT*\S2?^@;J0]/^)S:_UT0_CT_"D#Z3_P! [4C]=8M?_E)7Q)>?MP?"^'Q#
M;>%]+\#_ !@\3:SK_C'5?!/P\AT+P]X*6#XI:AX<\>>)OA?XKU7P7<ZY\1M%
MBLM!\*>/O"6K>']9N/'S>"-3E62PUS1M)U7PW<2ZO;_9949P ",XW D@X/)4
MG&01R..G4 @JO'B<KQ&"=-8NAC\*ZZE*DJU6=-U(QG[.<E&-23]VI^[GSQA.
M-12IS4:E.K3I>E@.(,MS5U_[.Q&5XYX:4%7EAL+3J*G.I&<Z<74E3IQO*%.5
M2FHU)*5+EK4W.C5H5:^CYFD_] W4?_!Q:\?^42DWZ3_T#M2_\'%I_P#*2L_9
M_G=_]C1L_P [O_L:YOJT?Y\1_P"%-7_,]!XJ3WH85^N#P[_.;-#?I/\ T#M2
M_P#!Q:?_ "DHWZ3_ - [4O\ P<6G_P I*S]G^=W_ -C1L_SN_P#L:?U:/\^(
M_P#"FI_F+ZR_^@?"?^$6&_\ DC0WZ3_T#M2_\'%I_P#*2C?I/_0.U+_P<6G_
M ,I*S]G^=W_V-&S_ #N_^QH^K1_GQ'_A34_S#ZR_^@?"?^$6&_\ DC0WZ3_T
M#M2_\'%I_P#*2C?I/_0.U+_P<6G_ ,I*S]G^=W_V-&S_ #N_^QH^K1_GQ'_A
M34_S#ZR_^@?"?^$6&_\ DC0WZ3_T#M2_\'%I_P#*2KT<NEC2K[_0-0V_VCI.
M5_M:V+$_9M:VD,-'"JH'F!@R.7)CVLNQ@V#L_P [O_L:Y#XA>/K/X<>#9==O
MM+N]5AN?$_A_2%M[.X@@E26?2O%EXL[/.K*8PMDR;57<6D!'RJPIT\NK8ROA
M,)A(XFOBL3C,+1P]%8A\U6K*I*481]K.$.9JG-Q;E&S6Z(KYSA<IPF/S3'_4
M\)@LOR_&XK%XEX&FXT*%*G1]I5DJ*J5.6//&_+![I=CT#S-)/73=1]?^0S:_
MTT7 ].,\ <T>9I/_ $#=1_\ !Q;?_*6OD/\ X:KT \_\(7KGISJ=AVX[1>W?
M)]Z/^&JM _Z$O6__  9V/_QJOK/^(><6_P#0ES/Y8S"V_#'-;6ZL_/?^(S>'
M2T?$V376C_X3<9NKI_\ ,!W7SWZGUYYFD_\ 0-U'_P '%M_\I:/,TG_H&ZC_
M .#BV_\ E+7R'_PU5H'_ $)>M_\ @SL?_C5'_#56@?\ 0EZW_P"#.Q_^-4?\
M0\XM_P"A+FG_ (68;_YN#_B,WAS_ -%-DW_AMQG_ ,P'UYYFD_\ 0-U'_P '
M%M_\I:/,TG_H&ZC_ .#BV_\ E+7R'_PU5H'_ $)>M_\ @SL?_C5'_#56@?\
M0EZW_P"#.Q_^-4?\0\XM_P"A+FG_ (68;_YN#_B,WAS_ -%-DW_AMQG_ ,P'
MUYYFD_\ 0-U'_P '%M_\I:/,TG_H&ZC_ .#BV_\ E+7R'_PU5H'_ $)>M_\
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M_AE*7_HH$7_A+2?_ "^K^C%XC\&O59N[/5?[#FBT>JT^J::-'\7OP=\2;O\
MXQRLO)9GE%E?6VF:I:7MHDKIGR%Y?O\ I_\ 7H\OW_3_ .O7U[_PRE+_ -%
MB_\ "6D_^7U'_#*4O_10(O\ PEI/_E]1_P 1'X._Z&[_ /"'-/\ YD%_Q!WQ
M)_Z)RO\ ^'/*?_GL?(7E^_Z?_7H\OW_3_P"O7U[_ ,,I2_\ 10(O_"6D_P#E
M]1_PRE+_ -% B_\ "6D_^7U'_$1^#O\ H;O_ ,(<T_\ F0/^(.^)/_1.5_\
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MQCKSQCZ>G;_/6N$^*7CB]^'OP_U#Q#86%GJ5P?%/A?3S;7LL\<(BN[3Q,SR
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MG_0"TS_OYKO_ ,O*/MMI_P! +3/^_FN__+ROA/\ X:I\3?\ 0J>'/_ W5O\
MX]1_PU3XF_Z%3PY_X&ZM_P#'J/\ B%G%G_0MI?\ A]P__P TA_Q'W@#_ *'.
M-_\ $4Q7_P PGW9]MM/^@%IG_?S7?_EY1]MM/^@%IG_?S7?_ )>5\)_\-4^)
MO^A4\.?^!NK?_'J/^&J?$W_0J>'/_ W5O_CU'_$+.+/^A;2_\/N'_P#FD/\
MB/O '_0YQO\ XBF*_P#F$^[/MMI_T M,_P"_FN__ "\H^VVG_0"TS_OYKO\
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MTCJ%1,*C;RV$W;W8#^=:$@_XE6G_ /7[JA_\@:3_ (_RK"K0I\]#6KK7@O\
M>,4W_"Q+W>(;6VZL[:7U9TT,77Y,3=TO]UFXM87!IIK$X6-FE@[.+O>STO9V
MND)]MM/^@%IG_?S7?_EY1]MM/^@%IG_?S7?_ )>52HK?V%/O6_\ "K%__-!S
M?6\1_-1_\(\#_P#,9=^VVG_0"TS_ +^:[_\ +RC[;:?] +3/^_FN_P#R\JE1
M1["GWK?^%6+_ /F@/K>(_FH_^$>!_P#F,N_;;3_H!:9_W\UW_P"7E'VVT_Z
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MQL]K!=:59>"S<7\4NN>)=/\ B1J/Q#LO$.B^+++QKIKZ;#X<UNP6UUY/UO\
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M /E!1_PRYX _Z#7C3_P9:&?S'_"/G(]1CFC_ (BIPA_S]S%^7]FS_P#FD?\
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M&(>UK;U[;I=-TFK-*T+&Y5NN'\L[?[OA+KF6JNL!I=/5:76Z:/:_^$-\*?\
M0"L>3D_NY>OK]_K1_P (;X5_Z 5E_P!^Y?\ XOV'Y5XIM/K_ .A?_%4;3Z_^
MA?\ Q5'UG'?]!^,[?[QB-NW^\;>6P_KN5:?\8_EFFW^SX/3KI_L'Y,]J_P"$
M-\*?] *QXZ?NY>.O^W[G\S1_PAOA3_H!6/\ W[E^G]_TXKQ7'?=QZY;_ .*H
MP?7_ -"_^*H^LX[_ *#\9_X48C_YH!XS*MGP_EEKIV>&PEKK9ZX"UUT>ZZ-7
MU]J_X0SPI_T ;'_OW+_\71_PAGA3_H V/_?N7_XNO%=I]?\ T+_XJC:?7_T+
M_P"*H^M8_P#Z&&,_\*<1_P#- OKF5?\ 1/97_P"$V#_^8#VK_A#/"G_0!L?^
M_<O_ ,71_P (9X4_Z -C_P!^Y?\ XNO%=I]?_0O_ (JC:?7_ -"_^*H^M8__
M *&&,_\ "G$?_- ?7,J_Z)[*_P#PFP?_ ,P'M7_"&>%/^@#8_P#?N7_XNC_A
M#/"G_0!L?^_<O_Q=>*[3Z_\ H7_Q5&T^O_H7_P 51]:Q_P#T,,9_X4XC_P":
M ^N95_T3V5_^$V#_ /F ]J_X0SPI_P! &Q_[]R__ !='_"&>%/\ H V/_?N7
M_P"+KQ7:?7_T+_XJC:?7_P!"_P#BJ/K6/_Z&&,_\*<1_\T!]<RK_ *)[*_\
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MO#\S_P#%T?6L?_T,,9_X4XC_ .: ^OY3_P!"+*__  3@O_F(]K_X0SPI_P!
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MO_PFP?\ \P'M7_"&>%/^@#8_]^Y?_BZ/^$,\*?\ 0!L?^_<O_P 77BNT^O\
MZ%_\51M/K_Z%_P#%4?6L?_T,,9_X4XC_ .: ^N95_P!$]E?_ (38/_Y@/:O^
M$,\*?] &Q_[]R_\ Q=/3P?X90DQ:+91EHY(FVQR?-',ICD0YDY#H2C =58CO
M7B6T^O\ Z%_\55VP&)+D=?\ B6ZG_>[6,YQ]X]:'B<<U9X_&-/=/$XAI]=G7
M:Z+INEV+AB\J<XI9!ED6W:ZP^#NKI_\ 4!VNOF_GZ\?!?A4==!LCGGF.4_\
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M-@__ )@/:O\ A#/"G_0!L?\ OW+_ /%T?\(9X4_Z -C_ -^Y?_BZ\5VGU_\
M0O\ XJC:?7_T+_XJCZUC_P#H88S_ ,*<1_\ - ?7,J_Z)[*__";!_P#S >U?
M\(9X4_Z -C_WZE_^+J1?!WAM$DC31;,),$69-DF)%C8.BGYS@*X# #N <UXC
MM/K_ .A?_%5>MQ_H6I9YRMD._P#S\Y[D^G;'Z4?6<:_BQV,EU5\3B-&M4_X\
MM4TFGI9I?*X8S*G*RR#+8MPJ/FCA\&FE"#DU_P B_:2NGY/9['KG_"&>%/\
MH V/_?N7_P"+H_X0SPI_T ;'_OW+_P#%UXKM/K_Z%_\ %4;3Z_\ H7_Q5'UK
M'_\ 0PQG_A3B/_F@CZYE7_1/97_X38/_ .8#VK_A#/"G_0!L?^_<O_Q='_"&
M>%/^@#8_]^Y?_BZ\5VGU_P#0O_BJ-I]?_0O_ (JCZUC_ /H88S_PIQ'_ ,T!
M]<RK_HGLK_\ ";!__,![5_PAGA3_ * -C_W[E_\ BZ/^$,\*?] &Q_[]R_\
MQ=>*[3Z_^A?_ !5&T^O_ *%_\51]:Q__ $,,9_X4XC_YH#ZYE7_1/97_ .$V
M#_\ F ]K_P"$+\*GIH-CCN/+E&?3GS/7ZTX^#_#.Q8GT2S,:/)(D920JDDP0
M2N/GR6D$488GH$7&.2?$2I]>X_O>H_VO\^U7I!G3;([B";S4CQC_ )XZ9QR&
MZ9QQBCZSCMWC\8[.Z;Q.(=FDU=?O]'9M7O?5^A<<9E5IVR#+5^[;=L/@[22G
M3M%KZAJFY)]KQ6CZ>N_\(9X4_P"@#8_]^Y?_ (NC_A#/"G_0!L?^_<O_ ,77
MBNT^O_H7_P 51M/K_P"A?_%4?6L?_P!##&?^%.(_^:"/KF5?]$]E?_A-@_\
MY@/:O^$,\*?] &Q_[]R__%T?\(9X4_Z -C_W[E_^+KQ7:?7_ -"_^*HVGU_]
M"_\ BJ/K6/\ ^AAC/_"G$?\ S0'US*O^B>RO_P )L'_\P'M7_"&>%/\ H V/
M_?N7_P"+H_X0SPI_T ;'_OW+_P#%UXKM/K_Z%_\ %4;3Z_\ H7_Q5'UK'_\
M0PQG_A3B/_F@/KF5?]$]E?\ X38/_P"8#VK_ (0SPI_T ;'_ +]R_P#Q=/?P
M=X:E*M)HMF^V-(D)24%(XD$<2 !QD)&JH">2JKD\$GQ+:?[Q'T_^R+#],^]7
M+_F2W'II^E<GJ<V%MZ8[\]_;%'UG&MJ^/QC:O9_6<1=7T=G[>33:26EO.ZT-
M(XO*N2H_[ RU13I*45A\&E+FG-1YO]@UY7%M>;>JZ^O?\(9X4'_,!L?^_<O_
M ,71_P (9X4_Z -C_P!^Y?\ XNOG7Q)XI\*>#=-_MKQEXJ\+^#M&^TQ69UGQ
M=XATCPQI'VRX65X+3^U-<O["Q^USI!.\-KYYN)DAF:*-UBD*6]%UK0_$NE66
MN^&]:T7Q'H>I1-/IFM^']4L=;T74H$EE@>;3]7TJZN].OH5GAF@>6TN9D6>&
M:%B)(G ?UK'?]##&_P#A3B/_ )I,?[0R7F</["RGG23<'0P/.DU=-P^H\ZNM
M4W!)ZM-K4]__ .$-\*?] *Q_[]R]^O\ '2_\(;X4Z?V%8X]/+E^G]_TXKPM;
MNU>[GT]+NUDU"UMK6]NK".ZB>^MK*_DOH=/O+FR69KFWL[Z?2]3AL[N:)+>Z
METW4HH'DDT^Y5&W=]96"027]]9V$=U>6>G6LE]=0VD=UJ.HW,-GIVGVSW$\2
MW&H:A=SQ6EA8Q%[F\NI8X+:.69UC9?6<?_T'XS_PIQ'_ ,T%?7<I:_Y$&5M:
MK^!@FKK=?[BU=7U5[J^J1[K_ ,(9X4_Z -C_ -^Y?7/]_P!>?K1_PAOA3_H!
M6/\ W[E[]?X^]>*8SW_]"]<?WO7@CU.#UKG=:\6^$?#5]H&F>)/%GA7PYJ?B
MN_;2?"FF^(?$FC:%J/BK55,*MI?AFQU34+2[\0:DIN;=6L-(AO+L-/ IAS-&
M&/K6._Z&&-O_ -A.(_\ F@4L=E"UGD&5)MK66'P2N^EW+ K7:UW>UK+8^C?^
M$-\*?] &Q_[]R_\ Q='_  AGA3_H V/_ '[E_P#BZ\38A%#2.D8+Q1!I7\M3
M)/*D%O'EGQYEQ-+%#!&"7FFEBAB#R2(K5K"^L=5LK34]+O[+5-,O[>&\L-2T
MV[AO].O[.XC6:WN[&^M)YK6[M;B%EEAN+>:6&6-A)&[H0Q/K6/\ ^@_&_P#A
M3B?_ )H']<RE.SX?RM.U[/#X).V][?4$[6UO:UM;VU/=?^$,\*?] &Q_[]R_
M_%T?\(9X4_Z -C_W[E_^+KQ7!Z9]?[W8X/\ %V/!]._6C:?7_P!"_P#BJ/K6
M/_Z&&,_\*<3_ /- ?7,J_P"B>RO_ ,)L'_\ ,!>U3_D*ZG_V%+__ -*9JIU<
MU3_D*ZG_ -A2_P#_ $IFJG671?/\V>;6_CUO^OM;_P!/U0HHHH("BBB@ HHH
MH 1NAXSP?\^O^>U?G=XJT;]OGQ#\2?%NC^'M9OO GPXG^)>OKH7C/3]6^"&I
M3P?#CQ#\3_V<-%T*Y\.:)K.G:SK*7'@3X*>&?V@_&$\/B_1Y-0U3XD?$)=#^
MPZOI&C: A_1*G)&TLD<:#YY'5%.<<NRJ,GIR2.O&,Y(%5&7*[V3WW./%X/ZX
MJ<?K.*PRC.[>$K>P=124(<M22C)\J:4FX2@_B;ND[_BUX_\ @U_P4@^(GA[1
M/#OB75-8U672+237=-:;Q?\ L^6W@R/5D^$_Q,7PA%XUL].T;3/$_BGXG^$/
MC;XG\$R:KJE@(/A)J_P_\#V5P-%U;7];U%[;T^+P=_P4*TF#QIHNEW_B^/P3
M'\3=-TCP3IOAGQ=^S%X5\9:3\(M-\'_%VT\.6'@.?6O!WC3PAX;T+1?&'_"C
M+/Q1XJ\4Q:IXS\2_#_2_$3Z5\'])\5P:T_C#DKO]J7]N+Q?H7CWQO\&OA7J?
MC;P;JNN_$72/AS?V/P:N'72;/1?BYXETGX8:KX?U@>+]2N/BEIWCCX8^#]73
MQEXEMO!LNC>!/&/BKX:QWMA:Z<WBK5+/4B^-'[9WQGM_'/A#PCI.B74'P^^+
M'P5\"^+/%7PI>[T&76?$^HWGP5^*WQ4\%:7XN@\2:B? VB_"CP]H'Q8^$?Q2
MU:YGN-4F\1_%#PEX8N9;*Z\+>)(KW9232;LFU_6[N^^O<^+C_9GM75I5.*YU
MJE-JG.U=2Q$(<\80C4J4_P!\E3A6K<T5>%-K6A4JT)UMO1_AO^WSX4\>^(=8
M\/:A<C2_%WQ/\4?$V_MT\5?!:7PO?6Y\=_$#2-6T?XAV_B'P_JOB6Z\0^,/@
MAX3^!&E_".U^'8\/>!_!7BW5?$^K^//['M-)O]-O:7AGPO\ \%18K'X/QWWC
M9!=V.M>)+WQK>^*9/@9J#ZL;+Q1X5ET9/B9I7AMH?["\'^*/!&F>(K.S\+?"
MOQ+\3->\+^(O%-[>7/BP6.G^#['PDS1_CK_P49OG^&5I/\$II#XG^)7P^C\2
M^(]4^"FI^#K/2_"^I2_!K3_BMH.M>'4\;>*-4\'^'O!6L^+OB?-X3\<:Z^F7
M/BKPE\/Y]8L=:O9],LE\>^[?LC:Y^T]X]\7_ !"\??M$Z9XL\&VK_#OX1:#X
M;^'NJ>"M2^'?AC0O&M_<^./%GQ9L]!T2]\4>)H_&2>"[[4_"WP]LOBNSV4_C
M'3M#^TVML-.E2[OY<FK[6OI[UW]V_P#2.C#T\)B:U+"T*_%5/VDDESRQ6$P]
M*-2+QDVZLZ?L[4Y0G2I\G):=9.FE1J256_\ L=?#KX^^'KOXJ_$']HZ_\57O
MCOQO:_!OPQI*>,==^&.LZM;Z!X ^'[:EXFN(8?@_!;^"-(TC4_C'\0/BE)X?
MT^.)]:C\+6OAR/5KAUM[&WL_HO\ : ^,&D? ;X77GQ0UWP_XA\2Z3H<?ANRN
M]/\ #J:='/;#Q%XK3P]%K&KZIK%[IVB^'/">B2ZC'JGBOQ3K-[!IOA[1;>[U
M*Z+K$L,GJ0_Q_G_GZUR'Q0^''A7XI^%;'PIXOBUO^SDGT'Q#87_ACQ5XH\#>
M)M$\0^'=:FU30=>\/^+?!NKZ%XDT75M+OX4DAN-.U.W$\+3V-['=Z?<W%I-E
M>[OMK=6]6]_(^MIX6KA<LQ>'PE:?M_9N5&O7FJDE7JXOVO/+G7+)*4W[.#Y8
MQBTKKWDOEV\_;Q^ >G?#<>.M0U>]M];?X3ZM\6H?AY:?8/$.J3VFF^$?&WC:
MQ\(Q^/O"EYK_ ,&AXR\6^'OAWXOUCP/HLGQ%6\\6Z)HUWK^CV]QID,LT6LO[
M:?P>;5/!WAN,Z_=>,?&OQ9L_A39^%M-TRXU6?1IM0^,OBKX(V'BOQ3KNGPS^
M%/#FC:AXF\$^*KS2=+U?7+'Q-KMAX=U^+0]'U.]T348(*DG[ _[*TNG?V0_P
M]UQM'E\.:MX;U'1S\4OBP=)UZ76=$\>^';[QCXGTUO&SV?B7XF?V/\3_ !]:
M6GQ,UJ&^\;V#^);B]M-:AU'3M%N]+Z>W_8Z_9]M/%>A^-++PGXBL->T'Q;:>
M.H38_$SXFV>CZMXJTOXH^+OC+H.J^*O#EMXOB\/>+G\,?$/Q_P".M:\+V_B3
M2]3M- MO%FK:-IL,&C_8+&Q>GF^_3MY^OX,\I1XD_=\T\J4.2C"JH*K)W52A
M*M."=+E3E3IU[.+2C*HW"\G%S9#^TY96OQ@\9?"GQ?\ #7Q;X&L?!FI_"W1[
MCXC:QKW@/5/"NJZA\=_&]W\._@=::=I7ACQ+K7C!9_B;XKL9M,T]+[P];+X9
M9[>7QH_A^WD:9,S5?VY_V4-&1Y=1^+T4<$6DRZY-=6W@+XJ:C8V^E6VC7WB6
MZNY[_2_ MY8P"S\+Z1KGBR^@GN8[K3_"GA_Q%XEOX;71/#^LZA8>F^,_@!\+
M?']SXWO_ !+HFKOJ?Q!7X/MXBU?1_&/C#PSJ\=Y\ _&%YX]^$6J^'M3\.:WI
M=YX4UGP9XOO9=<M-6\.RZ9?7MPEM%J\M_:VL%NGFL'[#W[,]OX9O/"$7@76!
MX?O]#UWPW=6<GQ&^)5Q<3:/XD^%'BSX(ZS;OJ=UXMFU1Y[OX:^./$NA_VC)>
M/J,5W?1>(8KM?$5C8ZK;G];W_K^M36K'/H2J1H2RRLG6KS53%.JW&G*<I4*"
MCAX*'[NFH4Y2Y8KEG[KG.,E'=O\ ]L#]F[3-5U30KCXG13:SI7BE/!1TS2_!
MOQ%UR[UOQ0VO:UX4FTOP7%H?@[4?^%@KIWBWP[K?A+7M3\"GQ%H_A[Q5ITWA
MS6[^QUAX+:3T'X3_ !J^&'QST&^\5?"?Q9'XQ\.:=JKZ+/K5MHWB/2=/N+U;
M2TU"-]+N/$6C:0NMZ;<65]:W-IK6B_VAI%W',JVU[)*D\<7 :+^R-\ _#WC>
MT^(6E>$-7C\3:5XVN?B!X>DN_B#\1-4T7PCXBU+Q!XA\7:X/!?AC4_%5YX;\
M):)XF\8^*M<\7>*/#F@:78:%KWB&ZMK[4+&8:5I$-AU7P<_9]^%7P$C\91_"
M_0=3T>3X@:]:^)/&%]K/B_Q?XSU36]4L+$Z9ITEUJOC+7=>U%Q8V#-;H[7!N
MKLN]UJ=U?7Q^U%:=//[NWW^7_ VP[SEUX_6EEJPS]JJGU=UO;<J@Y46I5TE)
MRJRC3E'D=H4XS4HSE*,?::***1ZH4444 %%%% !1110 5XI^T/XAUWPQ\*;S
M4_#NK7^B:@?&/A.V^W:=<-;7/D3V?B?S81*F'V2%$++G:=BC![>UU\^_M1D#
MX-7F2!GQOX.QD]<6?BG/Y=Z:W7JOS/&XBJSH\/YY5I5*E*I#*<=*%6E4G1J4
MY*%"TH5:<H3A):VE&46M=5JSX@'QD^*X_P":A^+OPU:Y[<'H3R,?RQ2_\+D^
M*W_11/%W_@VNO\:\U!& ,@8 Z\=J7(]1^8K=J-]D_/OY['\T+.LX22_MC-%9
M)66:YHEHET_M/3T/2?\ A<GQ6_Z*)XN_\&UU_C1_PN3XK?\ 11/%W_@VNO\
M&O-LCU'YBC(]1^8HM'^5?U\@_MO.?^AQFG_AUS3_ .>9Z3_PN3XK?]%$\7?^
M#:Z_QH_X7+\5O^BB>+O_  ;W5>;9'J/S%(2"#R.A[BBT?Y5_7R'_ &WG'_0X
MS3_PZYI_\]#]7?@[JNI:W\,/!FKZO?76I:E?:;=37NH7LSSW5U*FL:E DDLC
M$LS"&**($Y_=HH['/IM>1? ?_DCW@'_L$W1_#^WM7KUVL'NUT5]>^I_3>23E
M4R;)YSE*<YY3ELY2E*4Y2E/!4'.<ISE.<YU).524YSDVY=DA&Z'Z'^57)/\
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MA*A7C.-2I2<)0=)J2FIT'"4=KJ:<=4WLCD/^%3>#C@_\*V\(<_WO!^@Y]/\
MGP]OZ=J/^%2^#O\ HFW@_P#\(_0?_D&NB$1/2,<<$>63W]>.U+Y)_P">8_[]
MFG>2TO:W3M^!QK!92U?^S<([ZW5'!-.^NC^J.ZNW9W>G5G.?\*E\'?\ 1-O!
M_P#X1^@__(-'_"I?!W_1-O!__A'Z#_\ (-='Y)_YYC_OV:/)/_/,?]^S1S2_
MF_K[A_4<I_Z%F%_\$8+_ .8SG/\ A4O@[_HFW@__ ,(_0?\ Y!H_X5+X._Z)
MMX/_ /"/T+_Y!KH_)/\ SS'_ '[-'DG_ )YC_OV:.:7\W]?<'U'*?^A9A?\
MP1@O_F,DL?#DFEVD&GZ;HB:=8VR>7;6-A9065G;1EWD,=O:VZQ00H9'=RL<:
M@N[,1DFK?]F:C_SY7'_? _QJ@8B.L8_[]FF;,<E$ XYV'C/3J!C/OCH?0TK=
M?\_\CI3P\$HQIR@E%)1C4HQ2C"-HJ%.-%*,80@DHPARQC'9:FD=+U$@@65QR
M#_ /3ZU:DTW4#8V:BSN"PO=3)79R ]OH^TGGHWEN!_NFL38HR=J=#_ /_KU<
ME5?[.LE &/MVJG!^[Q!HN.._4^W<\DDGW?U8T@Z3]I:%3^%)N]6"VG2T_@?=
MO=Z$O]F:C_SY7'_? _QH_LS4?^?*X_[X'^-9VP?W4_[X'^-&P?W4_P"^!_C1
M;S7]?(CFH_R5?_!D/_E!H_V9J/\ SY7'_? _QH_LS4?^?*X_[X'^-9VP?W4_
M[X'^-&P?W4_[X'^-%O-?U\@YJ/\ )5_\&0_^4&C_ &9J/_/E<?\ ? _QJW9Z
M=?K).6LYU#6&HQ@E."\EE.B+UZLQ  [D\5A[!_=3_O@?XU=L% DN.%'_ !+=
M3Z+C.+&<X/7(R 2,X/&011\U_7R-*4J+J0M"K\2WJ02V?_3@D_LS4?\ GRN/
M^^!_C1_9FH_\^5Q_WP/\:SMB_P!U?Q7/ZG_/M1L']U/^^!_C1\U_7R,E*C97
MA5V6U2#_ !]@:/\ 9FH_\^5Q_P!\#_&C^S-1_P"?*X_[X'^-9VP?W4_[X'^-
M&P?W4_[X'^-%O-?U\A\U'^2K_P"#(?\ R@T?[,U'_GRN/^^!_C1_9FH_\^5Q
M_P!\#_&L[8/[J?\ ? _QHV#^ZG_? _QHMYK^OD'-1_DJ_P#@R'_R@T?[,U'_
M )\KC_O@?XT?V9J/_/E<?]\#_&L[8/[J?]\#_&C8/[J?]\#_ !HMYK^OD'-1
M_DJ_^#(?_*#1_LS4?^?*X_[X'^-6X=.OQ:7ZFSN SK:%5V<MLN,M@9ZJ""?;
MWK#V#^ZG_? _QJ[;HHLM2 489+('T/\ I0."#U''3-'W?TBZ4J+J:0J?PJ^]
M6"_Y=.]OW':_X$G]F:C_ ,^5Q_WP/\:/[,U'_GRN/^^!_C6=L']U/^^!_C1L
M']U/^^!_C1;S7]?(CFH_R5?_  9#_P"4&C_9FH_\^5Q_WP/\:/[,U'_GRN/^
M^!_C6=L']U/^^!_C1L']U/\ O@?XT6\U_7R#FH_R5?\ P9#_ .4&C_9FH_\
M/E<?]\#_ !H_LS4?^?*X_P"^!_C6=L']U/\ O@?XT;!_=3_O@?XT6\U_7R#F
MH_R5?_!D/_E!H_V7J/\ SY7'_?'_ -?\:MOIU^=/M$%G<;EO-19EV8(5X]."
MD@D'!*, >GRGVK#V#^ZA_P" @?U_Q^AJ[(H_LRQ^5?\ C]U+J"?^66F]B!C'
M3)ZT6]"X.E^]:A4LZ4K_ +V-U:I0MI[#KIN2?V9J/_/E<?\ ? _QH_LS4?\
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M]S?^%/#?AZ_\4^#/%5WIMGK&OV?BK5M-\.Z^FD>&]1U7P_K>FV6*_P#P3_\
MV76TIM!'@[Q.FA3>'=3T#5-$3XD^/5TCQ#?:KH'C_P ,S^.O$FG'7FM=:^)4
M.C_%+QY;V7C>\235;.77_M4)%WHOAZXTCK+7]CKX$Z?XJT3QCIVC>+=.UC1/
M%]AX^\FP^(7C.ST/7/%>B_%3QI\:/#>H^+/#\.L+HWB9?"WQ!^(OCC5/#=MJ
M]I<0:5:>);W3(8_LMKI0L-+4_P";KWZ:>1X$%Q,W34_[)46L/"I[U64DO:82
M5:K%2@J7M7"-=7]RG!SM"#A&*;[?]IO3+?XN^,/A/XM^&?CSP)!X-U'X9Z3=
M?$CQ!JWPOOO!6K:A\;_'%S\._@A;:58>%?B#XB\<-/\ %;Q99W&EZ-!>^$;&
M7PXQMI/':>%$G@DEHZI^W%^R;HBEM3^-6C6T2:2^N27"^%?B/=6L.DPZ7>:[
M<7MQ>V7@JYL[=;/P]IFL^);^*:=+BP\+^'_$WB>]A@T#PSX@U+3?0O&G[/WP
MS\?7OC?5/$&GZ]'J_P 0/^%,R:YK&A^*M>T#5+.__9^\8WOC_P"$>M>';W3+
MVVE\/ZUX2\77TFLQ:AIX1]1EC@MM42ZM8$AKRZ']AK]G"W\,7G@^'PKXC&@W
M^A:]X<NX)?'OB^XNY-)\2_"/Q?\  [64.I7.J2W[7=S\.?'7B32A?S74MZM_
M=0:Z+@ZM9VURDQ47?F=OF_\ )FT_[?AS1H_V=53G6G&KBG-3C2<FZ%#V>'C#
ME]G%*$I3<M9.:;:<3KM1_:\_9JTK5-9T6[^+6COJ^A>*(O!=YIFG>'_'&MWU
M]XIEUS6/"[:1X7@T/PKJ3>.'LO%7A[7/"6L7O@D^(=-T#Q=I=UX4UV]TWQ$(
MM,E]#^%_QB^&7QJT.]\3?"OQ;;>,_#UAJ;:1/K-EI?B'3=/FNQ:6]_%-IDWB
M#1]'_MS2+VQN[:]TSQ#H:ZCX>U:UE$^EZK>1I*4\QT3]D/X%>'?&^G?$+2O#
M_B)/$6@>-KWQ_P"%([SQWXQU#0_!6O:OXE\1^-/$5OX+\/WFKSZ1X8T#Q5XS
M\5:QXL\3:#I5G#IVK:Y)92O#!:Z3I=K9=7\%OV>/A5^S]!XR@^&&C:IIA\?Z
M_;^)O%EUK/B/6O$E]JNK6>G_ -EV5Q/>ZQ=W,TLUO8@QS7TS3:SK$TCWWB'5
M-8U#%Y2DHKX7??K>W;HOZU-L/+.G7A]:IY8L,_:JI["IB)5H_NU[!PY])*57
MFC55O<ARS=W)QC[=1114GJA1110 4444 %%%% !7S[^U%D?!J]P/^9W\'<@X
M/-IXH[]<<#OQV%?05> _M/12S_!V\B@AFGD/C;P>WEP0RS/M2T\4;F*1([!1
MN&6("X/7H"UNO5'B\2W7#N?6O?\ LC'6M>_P47[O+[]]&UR>_H[=3\U,L>0S
M<\\ENGX-^/XT?-_>/YM_\75T:;J0 SIFI=,?\@^\[?\ ;&C^SM2_Z!FI?^"^
M\_\ C%=%UTLUT_JY_+O+6ZPJWTO>E-NZ23NW2;;NG=MMW6K92^;^\?S;_P"+
MH^;^\?S;_P"+J[_9VI?] S4O_!?>?_&*/[.U+_H&:E_X+[S_ .,47\E_7S%R
MUOY*O_@J?_RDI?-_>/YM_P#%T?-_>/YM_P#%U=_L[4O^@9J7_@OO/_C%']G:
ME_T#-2_\%]Y_\8HOY+^OF'+6_DJ_^"I__*2D=W]X_@6_J^*^ROV0"QO?B$"2
M0+7PKC<Q. UQKX;J3C('Z+Z#'R%_9VI?] S4O_!?>?\ QBOL/]D6VNK>]^(!
MN+6YM@]KX5"?:+>:#?MN-?+;#-&@;;N4,!G!=1U89BH_=MI>^GR/KN!(UEQ5
ME3Y*JBIXF\O9U8Q3>!Q<8\TE3A!7<K)3=FVEN?;#=#]#_*KDG_'A9?\ 7[JO
M_I/HM4VZ'Z'^57)/^/"R_P"OW5?_ $GT6LNGW_H?TC#:I_UZ?_I5(J4444B0
MHHHH *N6/^MN/^P;JG_I!/5.KEC_ *VX_P"P;JG_ *03T%TOXD/\7Z,IT444
M&:V7HOR04444#"BBB@ HHHH *NP?\>6H_2R_]*35*KL'_'EJ/TLO_2DTU_G^
M3*I_Q%_UZQ'_ *9D4J***1(4444 %%%% !5V3_D&V7_7[J?_ **TRJ579/\
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M_P"%6O[1U#MJ.H'Z7MQ_\=_,_P#U\']H:A_T$=0]/^/VX_\ COIS1IY_@/\
M<K>5=>L(+I?KY:^C3V:*N1[_ )'_  HR/?\ (_X5:_M#4.G]HZCG/_/[<?B?
M];QU'7_]9_:&H_\ 01U'U_X_9^/_ "+^>*-//\/\PM15KRKJZNKP@KII--7:
MNFFK-?GH5<CW_(_X49'O^1_PJU_:&H?]!'4.W_+[<=SC_GK_ )[9I#J.H#_F
M(ZA_X&S]^?\ GK_GM1IY_<@M1_FKZNWP0WO:V_?N5LCW_(_X49'O^1_PJS_:
M.H9Q_:.H?^!L_M_TU]3CZ],THU#43TU#4?\ P-N!_.6C3S_#_,+4?YJVR=^2
MG:TK\KO>VO*[:WTV[U<CW_(_X5>B=UTV]*,ZDW^EC*Y4X^SZON&5Y&>,@X!^
M7J=M1_VAJ/\ T$-1_P# V?\ ^.U<2_U#^SKQS?7VY;[3%5S=W&]5>#5BX#^;
MPK&-25Q\Q52<[00?UT-*?L4Y-3KK]U6M:,4]:;3MRMMO5:6:[K33,\^;'^ME
M^A,A^O\ %1Y\W_/63\Y/_BJF_M'4<#_B8:D>O2\N#W]I>GI_6C^T=1_Z"&I?
M^!EQ_P#'*=WW?]?]O$/V-W>I63N^962M*[YE:_27-_5B'SYO^>LGYR?_ !5'
MGS?\]9/SD_\ BJF_M'4?^@AJ7_@9<?\ QRC^T=1_Z"&I?^!EQ_\ '*=WWE_7
M_;PKT?\ GY5^Y?YD/GS?\]9/SD_^*H\^;_GK)^<G_P 54W]HZC_T$-2_\#+C
M_P".4?VCJ'_00U+_ ,#+G_XY1=]Y?U_V\%Z/_/RK]R_S(?/F[32#W!D_^*II
MD9L;WD?&2-Y=L$]2,YP2, D=0!5G^T-1/_,1U'_P-G_+_6]>U']H:C_T$-1_
M\#9__CM2W?=O^OFP<:+>LJS:[PIMK79MN36JNTG'9-W5KU"<@]>A['_"KDA!
MT^R/;[;JO8][?1L?R/;G!QG:V$_M#4>?^)AJ(X//VV?_ ..FKDE_?BPLR+Z^
MW&\U0%Q>7&]@L&C%59C+R%+,5!X7<Y'+MDZ=?P\O^ 7!4;5/>K?PI?8I_P U
M+^\9.1[_ )'_  HR/?\ (_X5:_M#4?\ H(:C_P"!L_\ \=H_M#4?^@AJ/_@;
M/_\ ':-//\/\R+4?YJW_ (#3_P RKD>_Y'_"C(]_R/\ A5K^T-1_Z"&H_P#@
M;/\ _':/[0U'_H(:C_X&S_\ QVC3S_#_ #"U'^:M_P" T_\ ,JY'O^1_PJ[8
M\R7)YXTW4QT(Y-C, .?<TS^T-1_Z"&H_^!L__P =JY97U^TDX:^OF T_47&^
M[N&P4LYG#*!+PP*@ANH(&"*-//\  TI*C[2'OUOB6\*?GYF3N'O^1_PHR/?\
MC_A5K[?J/_00U'_P-G_K+1_:&H_]!#4?_ V?_P".T:>?X?YF:5&R]ZMM_+3_
M ,RKD>_Y'_"C(]_R/^%6O[0U'_H(:C_X&S__ !VC^T-1_P"@AJ/_ (&S_P#Q
MVC3S_#_,+4?YJW_@-/\ S*N1[_D?\*,CW_(_X5:_M#4?^@AJ/_@;/_\ ':/[
M0U'_ *"&H_\ @;/_ /':-//\/\PM1_FK?^ T_P#,JY'O^1_PHR/?\C_A5K^T
M-1_Z"&H_^!L__P =H_M#4?\ H(:C_P"!L_\ \=HT\_P_S"U'^:M_X#3_ ,RK
MD>_Y'_"KMN?]"U+V6R/(()Q=8X&,GKGC\<=0S^T-1_Z"&H_^!L__ ,=J[!?7
MYL]0)O[TE5M-C-=W!9"UR,E3YHQE5*G'4'G(HT\_P+IJC[3XJW\.O]FG_P ^
MG?[7:YD9'O\ D?\ "C(]_P C_A5K^T-1_P"@AJ/_ (&S_P#QVC^T-1_Z"&H_
M^!L__P =HT\_P_S(M1_FK?\ @-/_ #*N1[_D?\*,CW_(_P"%6O[0U'_H(:C_
M .!L_P#\=H_M#4?^@AJ/_@;/_P#':-//\/\ ,+4?YJW_ (#3_P RKD>_Y'_"
MC(]_R/\ A5K^T-1_Z"&H_P#@;/\ _':/[0U'_H(:C_X&S_\ QVC3S_#_ #"U
M'^:M_P" T_\ ,JY]C^1_PJ[(?^);9?\ 7[J9Z$Y!BTSD8[>AYS@CMFF?VAJ/
M_00U'_P-G_\ CM79+_4/[/LW^W7H9KO45++>7&\A(M-PK,9<LJEF*C.%+,5
MW&C3^K%P5'][:5;^%+F]RG_S\H6^UZ&1D>_Y'_"C(]_R/^%6O[0U'_H(:C_X
M&S__ !VC^T-1_P"@AJ/_ (&S_P#QVC3S_#_,BU'^:M_X#3_S*N1[_D?\*,CW
M_(_X5:_M#4?^@AJ/_@;/_P#':/[0U'_H(:C_ .!L_P#\=HT\_P /\PM1_FK?
M^ T_\RKD>_Y'_"C(]_R/^%6O[0U'_H(:C_X&S_\ QVC^T-1_Z"&H_P#@;/\
M_':-//\ #_,+4?YJW_@-/_,JY'O^1_PJW?\ ^M@X/.G:41@<\6%MVX_^MWYX
MI/[0U'_H(:C_ .!L_P#\=JY?7]^LEN%OKY?^)?II8K=W"EFDL;=F9OWI!9F8
ML[<EF))ZFC3S-(JE[.I[U:W-0O[E/_GY4M]KN9&[V;Z8Y^M&[V;\J\-_:$^-
MOBWX/Z#X!OO#UJ-;U+QS\3M.^'JKJB?$?6H-+@O/!?CSQ=+JT>@_"_PYXS\<
M:W<1GP6FG)9Z+X?NS NI2:E>2VUG832CB[C]L7P[X2CT[1_B7%X[T[QC+\+-
M2^,NH6_AOP=X^CT&;X<Z.-=BU?Q/I-OXVLO#/B^W@T/7M.\/^ -7\.^(_#NB
M^-(/'_C[X>Z9#X:N-(\8:9KK%OZT_P SSZF/RVC5J4*M>M2E1C1=2=2--4X.
MO3E.A3E.,ZKE*K"E4<;4H_PYQ;<HRC'ZFW>S?E1N]FZXZ?Y_Q]J^;;#]JK;\
M3+KX=^*O"'Q-\"W;Z!X8O-,L?%%J+?Q0OB._TK]JKQ3XDTW6++3M;U?P\WAZ
MS\'_ ++NIZIX<\2^&/$?B/3_ !+>^([.PCFAACN)UY*/]N?P-K,U[8^$K/XB
M:KJVF77PLDN-'OK2T@UG6-)^)^I>$;;28= \-V7BF[\3IK6HV_C+38_"DWBK
M1O#7A3Q;J N+GPUXDUG0]/OM7@:BWK9_AZ]62\RRM14GBI1YJLZ,8RCRSG.E
M+DG!0G3BU*+UE%KG5G'ENTG]@9'H?R/^%)N]F'X5\B:O^W_\!])OM$M6\8>*
MM1M-?.E7-AKNGKIXT:;0=5T/X:ZZOB:P?5/$VF:GXCTS3X?BOX5LM3TSP?IG
MB/Q=%J%KXKCM?#%Y:^$==N[3J?BE\>?BQX9\2_%?1_AWX5\-^)K'X"_"[1/B
MI\2)/&/Q!U_PMJFO6VO0^/-5LO"/@)=+\/Z[I]EJ4'A[X=ZYJ5SXK\5WEOH*
M:I>Z+HBV30#6M;T5)7T5[]M _M++'"<Z6)J8A4Y1C-8:-.M*+G1J8A<T(\G*
MGAZ-6LIN33A3ERQFURR^DBV.Q_(_U]^/\C(&!['UZ?X9KY'OOVW?#LL>BGPS
MX,^,.MOXF\>Z1X)\*R:E;:/X8TKQ>(_C;\.O@C\0;[PUJ%_XLGE:7P%K/Q*T
M2Y>PUZT\/IK\SMI^D:@T6F>)M2\.9UA^WK\/X_!>C>,->M?B;+87UAX:L;S7
MO"VA7.J>%KCXD^(_A7HWQH@^%^@/J.MZ;XGO_$\GPXURS\3VL][X>LO#,J&7
MP\WB8>,;>?PZE<DDKM/3?9_J0\WR;WO]NDE"$:DIRARP4))M.3]C9-<KO>T4
MN25W&I3E/[*R/?\ (_X49'O^1_PKD_A]\3$^(WAV7Q!IB>+]#>R\1^+O"&LZ
M!XH:WL_$&@^)_ OB?5?"'B?1]3CTG6=<T>66QUO1KV.&]T;6M6TG4+3[/>V&
MH7$,V4[;^T-1_P"@AJ/_ (&S_P#QVIT\_P /\ST(/#U(1G"=:4)KFC+DBE*-
MY*Z4E!VO"<=8JTH3CO&27G?QD^)VA?":"UU_Q%9:S?V?B'XN_#SX764.A06-
MS=0Z_P#%KXCZ-\.O#M[=IJ&H:;$FC6.L^(K.[UN>&:>^M]+BN9K#3]1NUBLI
M?)-!_;)_90\4WUCIGAS]HGX3ZUJ&IQ7$VGV=AXJM)I[R*UT"]\4320(0FZ(Z
M!INIZC;R[O+O&TO5-/LFN-4TK4K*V]<^,GPPT'XLPV6@^(K[6=/L_#?Q@^'7
MQ4LIM"FL(+J;7_A'\2-'^(OA^PNVU+3M4@?1=1U?P[9V6N0PP0W\VE3746G:
MCIMXT5[#\EZ9_P $^?A#I7AOPWX9@\9?%1['POX6^!OA*RN)]4\&->SZ?\ O
M!?QF\#^$[F[:/P0ENU]J^F?'#Q3>^)6@MX+:YU/3= ETJVT>VAU6UU>H\G*N
M;?Y_IYWZ'DYE4SJ&/Q#P5# UL+?F_P!HJU:=55%6Q7MX0Y)0CRRO1<9579*,
MDFG*4EZOI'[9O[)^NM=?V+^T7\)M1;3]"\0^*+W['XKM&-IH'A/PX?&7B#6)
M6&"FGV'A%)_%*7(/^G>';.^UK3!>6&G:A/;<)\3_ !3_ ,$^M,TO0?"OQB'[
M*BZ)X"O?$/A+PMX9\?>#?AYJ.C>"I[30? 'BWQ3H/AK1]7\.WNG^&H;7P]X[
M^'/B;Q!;:3;V5C#HVNZ#K&K!;&&2:U\.UG]G']B%O[>^'FO?M+:5;ZA8VNI:
M'XG\,7?QK^#&F>(M*3PK^Q==_L7Z[;:MIHTB#5M'N-!^$4&H>,-:2YM;>31_
M'%M=:O<)9>%(9O"<?J+?\$_/A[?6'C6'Q)\4_C3XMUKX@>%_CSX;\5>*-6N?
MAC9:I=VW[0_PD^"?P:\6ZC;6?ASX8Z)H.GW.A>$O@/X1E\'K!I!LK6_U'7I-
M<A\16=UIUMIUJ4(Z*^ODVK_/8\]5L\Q'M(+ Y%BG"3A)K&0Q%&G)5)<M*O2E
M/$5-*L/95%9?O4DTG**7L/AN;]DGQ5\1O$/PK\):?^S[XA^*?A&&YG\2>"M$
M\->!+[Q1I$-AKO@?6=2>2TMM*:29]'\3^'OAIJFMQ64UQ-H7B+0O 5[JT=CJ
M6E^'2GG?P\^-'P2T#XG^)O!OPM_9Z\2>$_#>N?%7Q=\/O&7QU\$_#3X<>&/A
M5K7Q:\"VFJWGC2/Q5=Z'X@T_XAW]GX=U:'5O#6J_$[6? 4G@:T\827&ES^*D
M-S]MFDM?V#?@K)XDUG4O%5SXX^(/@R\G^*>IZ+\(O&-]X??X=^$-9^-_B?PI
MXQ^*^MZ/+X>\+^'O'>H3^*O$O@[2-3AM?%7C3Q!I/AQY-2@\.V.G07D*6G-:
MO_P3H^!FM>*M,U6^UCXA)X T+QKXH^(^@?!>&7P!_P (/X<\8^-](.C^,;KP
MQXKN? %S\9_#GAKQ.6&MZYX(T?XHV7A:^\2I;ZP]@&M[:VA?/%[N_P!^W_!"
M4,^<<-.EEN54JD<1.\:57#N3HOV,:*4L3A4Z<)TE7]LZ$XXR4I4ITZ-.]=3]
MBNOVQ_V4[#PS8^,[W]H;X4VWA74KW6-.L-<E\3VRV5W>:!I>CZ]K,,/R^<5T
M_P />(="\2R7#1K:2>%]6LO$UO<3Z%.NH#TWP_\ %_X6>+/&OB3X<>&/B)X/
M\0>//"%NUUXF\*:/K=I?:QI%O$^GQW,L\$+LLZZ?+JVE0:L+-[A]'N=5TNVU
M9;&;4;))_COPU_P3:^"_AGPE>>$8_&7Q0ODO_!'Q>^'MWK4L?PHT?6[CPW\7
M_@SX>^!%\+T^%_A;H&G:CJ_A7P/X:LIO#6M:IIUYJ%UX@NM4U#Q3)XBL+J#2
M;3U7X0_L:_"SX*_%SQ5\8/">J^++W6O%$7B[9HNOP^!;G2] OOB#JWAW7O'N
MHZ1K>G>"-,\?3?\ "2ZUX8L-0?2-9\9:IH&D2W%]!I&E6EI_9<.EP_9V=M^F
MYMAZW$4JF&^L8'+:=*<TL4Z6+JU*E&"AK*GSV]HYS:TM[L=5HTE]:@Y_7]#T
M_P Y'7VRM(!CL/?'_P"H?R'L!2UF>\OGOUM^GX?CJ?//[2WP!C_:-\":/X(E
M\7R>"AI'BG4/$Z:M%X<C\3/.]_\ "OXI?##[";"77- 6%84^)KZ[]I%Y*97T
M1-+-O&FIMJ%A\R?&+_@FO\./BIX,T/PEI?CKQ#X!N?"OP8\5?"_PMXFLK?7O
M%NMZ+XB\:WGA*W\6^-XKKQ1X\N+R31/%G@G1/%/PW\4?#%;^#0M2\)>/]:AL
M=8TB[LK2>3](:*I2DM$_P1YF+R;+,=*O/%X2G7EB:5.A6E-SO.E2514X*TE[
M/E]I-J5-TY\S4N?FC%KXV\=?LG:AXE\?6?CO1_C)XI$MMXO\+^-8]+^*-OXE
M^+,/A[4?"OQ#D^(JZ)\.+I/B+X$F\!^"?$][_9N@^+O!\,>L:5J_ASPUX:TA
M!!:65Y#=?9)*EF*@JI8[59@Y5?X06 7<0."Q )(.>1112;;U;N=='"T,/*M.
MC!PEB)^TJWJ59J4[R=TJM6HH7<Y-J%DW)W6RB5Y#^T/JGBO1_A[HUWX5O/$V
ME12^)OA]8^-M>\$:$WB;QKX=^&E]XS6V\=:UX7T5-(U^XN=1MM)<17EW8:%J
M^J:%H-SK'B'2+/\ M72;*YM_7J^=/VP_B;XM^$/P,N?&_@;7?!_AGQ%!JOP]
MT6+7?'>(/#FGZ=XB\?6>BZT9-8O;2Z\*>&-6NM(NKNT\.>*/B-)I_P --%U^
MXTZX\;ZI8:0[R,+?[M.^JT*Q<HT\!CZDY5(QIX>,I.E'GJ65:FW&%-RI\\IZ
M1252E+5M36I\WZ]\?OCKX-TV]M/AUX.\<_%#2=.\)>(]<\$7/Q=^"_Q"A^(/
MQ-)OOC=/'J7_  D/@W_A$_#_ (9\*_#>#P5\/HK73?&/@R#XH?%_PIXMT&^:
M?0O%OBWPWJ?B&+Q_\9_VL_#6M^&K6\L_"]GIMA\3OB#87_B;PM^SA\;O$.@W
MOA_P1X;_ &A_#.E1^+?">D?$OQ3XCU/0_B;XET3X5^(?"4WAGQ#X<?PQJUYH
MTUWJWC_1M4CM)?"-0_X*8>,[3X3E+'PCINK>/KCX">*_&%EXRU2>Q\*>(]5\
M8V/PV^._C72OB-X:_9_TJ3XC>'O&7P)\.WWP;BT?QY\3=#^.<WAE]8\2Z7=^
M%M.O?#6I62-Z%9?MW^/+OQ_\,OA9#H_A'3=5\4?M%:)X(UOQ)XG\2P:;KFO^
M!=5_:T^+GP-N-)^%_P .K3PA);^+6\-^&/A;')X\\6S^+=!NO =QXS\%7+:?
MXHN-2DDEIJ2LVEZ:/]+]?/;=O0^1>9X6<J:AG.9*=;V#IPI86480E6KTE'#3
MYIS]Z^)A"4XU.2G1P]*2E.3JU:OH+_'[]J;1K3Q/KUW\'G&CZ&GC&\N?!MW\
M.OB%XQ\>2:M=V7[3^O:+IV@Z]HWBOPYH6K:/X1O/A+\,O#SZ;9^'IY?%\'C^
MS33/%'AB75?#-Q<<9!^T9^UA<WS:XW@*\U"WM;/44TWPEIOP/^)V@:7J3>'X
M/VL8KOQ[,P\0^*=:O=*NK+PW\#]6O?A[8^(M7O\ Q/)JFA1_#OQ M[XAM9]6
M]#\6?'WXG_"'XU?&:3QSX]T'Q#\&?AUJG[)<2Z)=^%/#W@0>%=!_:O\ C3JO
MPQU'Q3XD^(Z7&K2'P]\"]'T]?%-W+?V.G0>++2"]@UW5O"]LZ:O9>.WW_!3G
MQ6WA:]\;>'_V=-!UGPW8>#?$'B^YGU#]H'4M'U&=?"WP0\=_M!ZO:V%G!\!=
M<MYX'\!?#CQ!8Z/J%QJ%H^I^+M1\.:=-8Z;HUQJGB#3%KIMY;;K7^N_=]'B,
M52@G&OGN:86=.>*I^S>&]I5J5:3J4WBDL.ZL'36E2$&HPY86C"3FT?2/PZ^-
M'[0?B?Q_X>T_7/!'AP_#:3Q1;>%-0\36/PI^*WA#4_%^GZC<_M&C3OBCX;/B
MGQKJ<?@'PLEG\)_AO+/X8\3:-XNO+I?B;:WD'C"UT_4_!]QJW)7_ ,=OVI=0
M^(&H^ D^"O\ 8>B:1\4-#\.CX@6OA;QM/INM^%O#/Q@T3PMXN\1Z>(];%LFE
M^*?"7Q(^#/B'PS%]OFAN-!TG]HU;J\2W\'6U[X=YFW_X* >(?$'Q+N/A=X.^
M".@ZUXAU'XNW7PJT&+5_C=>:/<^'9;#XB>/?A]+>?'73=-^#GB2[^$>O^)8O
M 5S\0_AMX0T\_$";QU\.;X:ZNL:+-9_9;KV_]D3]JN/]JGPUX^UMO!NG>!;_
M ,">+[7PU=:)I?CIOB/!):ZEHEKK>G7=SXJT_P (>&_"#ZF4GN;74-)\):UX
MTM]+:&!]2U6QN;^.P1N+CO;7T?KT\_ET\NRGBJ&.E#!X7/<:ZTZN)ES+#2:G
MR4)5'05:I2C%0HTYT)4W?VE6-'6;JU*J7#_LH?$/]I+Q)K&AP?&<C6?#?BBR
MLX[W4-0^$WBKX<^(_"WBCP[\ ?V9];\02RW5_JK:)%X;UWXB^+?BSI#:%+X3
MM9X_&^@>(K[1O$QT.,^"M!Y;1OB-\<KGPWG1W^/OB3X\>/=(U/PIXE\%ZC\,
MM$\/_"+X.?$#Q)XA2[-WX>U[QKHO@_1[>3X)^ /#WQ N?"R?\)7KO@;XO&U\
M)I\1_%K^+/'_ ,+[[7OT:.2<EB?8G///KD]^!GBER2 "20!M ). N<[<=, ]
M!4W]'==MM>G^>NYZG]GU?94Z;S#%/D56/.[NM%5HJ#=.K*K>-2$?:>SJS5?V
M<JBE&G+V<.7\OM$\6?M=>)9?AMJD]K\1O#NEZ$W[./PJ\<W]_-%IVLP_$&R-
M]KWQ<\;:M\,5^&.HZ#\2O#7Q)N[_ ,*?"74?%VG_ !"\)>#_ (?ZSJLGC6!K
M+PIX>\1:]8?2.LZIXMG^+OA3Q;XIUGXK_"GP%HOPSLO$/C/P2FK:/K/A*?X@
M^(_BMX7\%_#'PI/J'AC1_$EMK-[>6]CXM'BC1_#GB*>6\MO%?A9]3>P$5K,W
MU?D^IX&!R3QSQSVY/'O364, &56"NLBAU#!9(V5XY &#+OBD1)(V*DI(D;KA
MD4@N32RV5--2QF)K-U:59NJXQBYT5+E3A3DI*$O<4H*K*,G%2FVGRQ^+_C)X
MN^)=E\8(-*&L_$OP9\"+*'X=:'XY\4> /!>K>(M:34M3T3XX>+]7;0KG2/"'
MBO6;*TU;4M&^#'@C6_%FA:7J,^@Q:Q=Z#8SZ!XBUZVUW2^S^ GC+Q3J?B/Q?
MH7C?6/B'+<VFB>!$\#:)\4?"&G>%O%^H^'="\">"?$_C#QOXFM?#>EVGAN+Q
M)>>)_C+HWP\\70Z?=QV<WB;X=ZM'H^D6%SIGBF"T^GP6'(8@C.""<C/7N2<]
MR22><GFFA?F+G!8@ M@%RH+L%+XW%5:1BJDD EF #.Q)?_A_Z_KS-8X.I#$O
M$_6JM1>WJ5?8SC)1<)PE3=&\:_*H*\:M%JFYQJ<ZJ2<>3E_/BY?XH^'KL:UX
MH^)7[16G_#/Q'\?/BYX4U>ZT_0+_ ,7^+?"WPV^&UAK?AOP78Z58>&/A[JWB
M31].^+OQ%\':IXDLOB+;:+?:C/X3U[P[X5T#5;"T\6Z%J\=;P1JG[3VJ?%+P
M/=ZMJ7Q0TWX::E\3-#\)V^M>-(M)T_Q(WA[P/\$?#FO^*=)^)_P7\-_#'_A%
M-&O/BCXVTGXD:0WQ?TGXF6'A_P /^*O[%TS0-!@6\\*Z=J_Z) L#D,P.,9!P
M<8QC/ICC'IP<BCUY/(QP3T[#\.W;/(Q3OZ?=_7]>IA_9;O'_ &O$I1G&:BI2
MM-IQO&I.51OV5U*7LX4XS3DVJSNJ21>@XQ[?2O"/VD/$GB#PM\,8=1\-ZUJ6
MA7\OCOPS9RWFEW3VEP]I-HGC*5[9I8R',3300RE22-T:X Q7O &/U_7FOFW]
MJ_'_  J2V)('_%Q/"O4XY&@>.#^7'7\.M+KI_5VD9\3U9TN'<_JTJDZ52&5X
MV<*M.<Z4Z;<L-[\)TY0G3:4W9QDI)2MOM\7_ /"X/BO_ -%'\8_AKEV/K_'^
MO)H_X7!\5_\ HH_C+_P>7G_Q=>;;L]",?4'_ -F'T_7O1N/J/T_^+KH2LMTO
MG_P#^:/[7S5ZO-<SN]7;,,PZZ],4EJVWIIJ>D_\ "X/BO_T4?QE_X/+S_P"+
MH_X7!\5_^BC^,O\ P>7G_P 77FVX^H_3_P"+HW'U'Z?_ !=%O-??_P  /[7S
M7_H:YI_X<,Q_^:CTG_A<'Q7_ .BC^,O_  >7G_Q='_"X/BO_ -%'\9?^#R\_
M^+%>;;CZC]/_ (NC=[C]/_BZ+>:^_P#X ?VOFO\ T-<T_P##AF/_ ,U'ZT?"
M?4M0U?X:>"-4U6\N-1U*_P! M;B]OKN5YKJ[N'FG1IYY79FDE8* S$\@*,#'
M/H=>7?!4[OA+\/NG_(M6AZ^D]RW]1Z\$'O7J-<SW=MNG?_/:VY_4&3RE/*LL
MG.3G.>6Y=.<VVY3E+ 863G*3UE*3;<I/WI2YN;5,1NA^A_E5R3_CPLO^OW5?
M_2?1:IMT/T/\JN2?\>%E_P!?NJ_^D^BT^GW_ *'J0_Y>?]>G_P"ETBI1112)
M"BBB@ JY8_ZVX_[!NJ?^D$]4ZN6/^MN/^P;JG_I!/072_B0_Q?HRG11109K9
M>B_)!1110,**** "BBB@ J[!_P >6H_2R_\ 2DU2J[!_QY:C]++_ -*337^?
MY,JG_$7_ %ZQ'_IF12HHHI$A1110 4444 %79/\ D&V7_7[J?_HK3*I5=D_Y
M!ME_U^ZG_P"BM,H*I_\ +_\ Z]?^Y,.4J***"0HHHH **** "K5]_K8/^P?I
M/_I!;55JU??ZV#_L'Z3_ .D%M36Z-(_PJO\ BP__ *<JGGGCSX<>#_B9I^D:
M;XRL=5O(/#_B"W\5:%<Z%XO\:>!-;T;Q%::9J^BP:KIGB;P!XB\+^);&<:/K
M^M:9*EMJT=O<V6IW4%U#,KKL\]O/V8/@5JDCW.M^!)/$^H2Z2_AZ?6_&/C;X
MC^-?$UWX;ET+QEX;F\+WOBOQ=XQUOQ+>>%9](^(7C1)O#%UJLV@R:AKLNNOI
M[:_9V&J6WO=%(XYX7#5GSUL/1JR<8IRJ4H3?NJ7*]5RJ4?:349*"DE)I2L?*
M/C_X!_LP^"O GC'QIXZ\)ZI;>'O"NCWGCGQIXP'CCXRZMXYGT_PII7Q3N-5U
MC4O%FF^,KWXD^)M1G\/?%OXKZ)K2/J^I:GXP\.>,]1\':Q'K>@Q:3HME@>"/
M#_[)]WXSMAHO@OQ5X=\;>"KSPV+30_B)HOQ]\&R_#N'3+>#XJ:#KNF^%OB5-
MINA>!_"^O7?P.L_$6I>)](TK2_#GQ \4?#Y;'Q7J.O\ B.UGLI?H/XR?#U?B
MW\)/BC\*GUC_ (1]?B7\/?%W@,Z\=-_MA-&7Q7H5]HC:F^E#4-).I+9+>FX%
MB-5T]KME6V%Y:B7[1#\<?%;]AW3[G3_B/-\+;ZSM-%UK6[OXE:%\++K0;75-
M0N?')^$_C'X9WGAJ?XB>*_%MM'JWPZU^/6] U)/A[XQACT.R2W\;^#;7Q1X7
M\(?$@7G@6E)K9_A^7;<\C&X:O1JQJX/*\!B*=.ESRO1I*M*O#VLXN+<7)234
M??@W*=1QG.5:HJ4Z?JNG>!?V-Y-1\/?#S0D\!:;+X+T.]\=:!I/ASX@:]X>T
M34?"OQ*\;^*/'^MP3WWA[Q=I>B?$SPEJWC/X=:[XM\0> -:NO%GA;1H_#]E?
MW_AS3-"_LD&#XLZK^QOXX\#7GQ\^)WB#PQK7@V'X2Z+XJ\1Z[IWC'Q?IK>)?
M@IX@NEUCP_9_$?P1X*UO2[_Q[\.M0U/7FDLO"7Q.\->(/#-OJNN:Q:W>E0R:
MIK\$_E?PD_8\UNX_X27Q]\4HO!'ACQSXU^*?@;X@GP]HGPX\,6Z^#],\ _M,
M>.OCA<:39#1/B!XXTG0[OXH:)XI@\/\ B;2]!\:>,M/\/SK<:K?>)?B%+<7E
MI#UGP'_8TO/@WXS\*^)M1\?^$O%%AX?^&.@_#W5M%TOX5ZIX>'C&Z\.?#?X8
M?#33?$.JCQ%\5OB)X?T*[CT_X5Z%K-[-X/\ #&@:_KM__9^E^)O$>LZ-X8TB
MS!MK?5/\OPW,:<<=4@J:R3+Z6'Q$YQM.C^[IQA4K4Z-6KAFH*4:="%.JZ:49
M36(J4V^?GOZIX8_9I^"]ROB'Q7<6.K^+[WXC^+/$_P 3;?Q#?^*/'FERZ,GC
M_P"*FF?'2Q3P+I]EXATV'X<M8^)]$\"WLFJ>#K#PKXB\1R^!?"UWXQN-3OM/
MVKIK^RG^SY&;()\-;5;73K/1K6RTD>*O'H\/6MSX?\,:9X'T;Q%#X9_X2L^'
MAXWL? NC:5X&7XAOIDGCZ?P78P^$[KQ--X>\S39/H&.-(D2.-42.-51$C18X
MT1%"(B(H"HBJH"HH"J  H"@ /H<Y-6OIMLO\CV5@,$HI/"8:36KD\/2;<I.I
M.I).49-*=6O6FU)U7)R3G*3C%0Q-#\.:)X:BU2#0M/CTV'6O$GB7Q?JD44UU
M,MWXE\8ZW>>(_$VJL;N>=XY-6UO4+R_DMH&BL;62=X;"UM+01VT>W114G7&,
M8I1C&,4KV48QBE=RD](QBKN4YR;LKRG.3NY2;N:I_P A74_^PI?_ /I3-5/Z
M_P"?Y?X>M7-4_P"0KJ?_ &%+_P#]*9JIT=%\_P V:UFU7K-6NJM5J^JNJ]1J
MZ=TU=*Z:::NFFFT?GK^T7^RIXM^)_B/]K#7O"&B_#^*7XS_L3Z!\#?!-[J+V
MVFZC'\6[7QS\=-;U[5=7G@T"\ETK3M1T3X@^&()O$]O/>ZCJ<D5Y9W=D8=-@
M:Z\C\4_LH?MAVWCCP^GP^^,>O6_PO\.?&WQUK_A/2M2_:"^)2>)/"G@W7]9^
M >N>'O$&MZOKFD^+[GXBPZ9#X6^-6B2?#SQD_B;3=/MO&*VUA%)8>*;^_P##
M/ZR@8Q[?3_/L,=J6G=JZ3T?E\CY^OP_E]>JZO^U4I.I*I*5#%3P[ES8FGBIP
MG[!4N:G.K2@VI-R47*+DVW*7Y$ZQ^R9^V%:6?P:;PCX_O)?$>D_$+Q3\0OB9
MXAU;]I_XV"Y?5IOV@/"?B+P_H]AHNI7>J>"=0\$R_ '0+GP3%X<'ANW@L_$%
M_>65R^GZ3JOB+6=8\3TKP/\ ML^"/A#J7QKL)_C3:^/[#6/"UU\+_AAJ7C3X
M^_%CQ)\8?BSI7[1?C2:P/Q*^&-]H8M?@K\,[[X#7^H?#G6K:]U.U^'M[!<>%
MO''B#6=.?0O#VJ7'[PXZ8)!&.?I[=/Z=,@CB@ CN>F,Y.>W7U (! / .<<$B
MB_\ 6W]?UZ'-/AC"<TY4,3CL/*<&ERXFK*,*JI1I4*\;U%*,Z"3FE'G]M5=-
MUG[*FX3X#X4^"+WX:_#'X>?#W4_$^L>-]7\%>#/#OAO7/&GB#5;_ %O7/&&O
MZ9I=M!K_ (IU/5=3FN;Z\N?$&M"_U4M<3/Y,5U#:P[;:VMXX_0*0#']!T 'I
MC_/M@<4M(^BIPC2IPITTU"G",*<92<FHPC""4IMMR=H7<FVVWJVTVTR._'U(
M_P :,CU'YBK$=S)$@14M2 20TMC9S2')).Z26%Y& Z*"V%'"@"G_ &V?_GG8
M_P#@LT__ .1Z>G?\/^";*,++]Y)=TZ;=GU5^=77;0J9'J/S%&1ZC\Q5O[;/_
M ,\['_P6:?\ _(]'VV?_ )YV/_@LT_\ ^1Z-._X?\$.6'_/Q_P#@I_\ R94R
M/4?F*,CU'YBK?VV?_GG8_P#@LT__ .1Z/ML__/.Q_P#!9I__ ,CT:=_P_P""
M'+#_ )^/_P %/_Y,J9'J*MWA*PV([/IBHRX&&1[F]21'!!#QNKD.C!D=6(92
M#1]LF_YYV/\ X+-/_P#D>KEU>S+'IY$=ES8QG!TZP8#-U=# #6Y"J, A0 H.
M2!EB2?UM_P $TA&GR5/WC:3HMWHW3M6V<92DGZ-->1DF1^\I.(S$,MG$3&,F
M$9)(A8Q1$Q@["8TRI"J%3><8WC&'&,@_ZQD:3&<@>8T4328 WM%$6SY:;;?V
MV;_GG8_^"S3_ /Y&H^VS_P#/.Q_\%FG_ /R/3;ONV_D91A222C.R7*TE026G
M*X^ZFHI)J+2LDFD[7U=,'AEW+M8,K*<,"C*59"#PRE692KAAM)4 *2M*6SG+
M@DL6)."6+ ABQZLS9.YB=QR3D-@BW]MG_P">=C_X+-/_ /D>C[;/_P \['_P
M6:?_ /(]+3O^'_!#DIIW51I]U2:?_@2FI??)OS*I=CG+YR59OFP69$$:%CU9
MEB5(E9B2L:A%PI8%I8G.7R"[RMR!NEE):69L?>EE?YY9#\TC?,Q))S<^VS_\
M\['_ ,%FG_\ R/1]MG_YYV/_ (+-/_\ D>AN^[;^0<E+3]YM=+]T[I/=1?/>
M*=W=1<4^:5T^:7-4R/4?F*,CU'YBK?VV?_GG8_\ @LT__P"1Z/ML_P#SSL?_
M  6:?_\ (]&G?\/^"/EA_P _'_X*?_R94R/4?F*,CU'YBK?VV?\ YYV/_@LT
M_P#^1Z/ML_\ SSL?_!9I_P#\CT:=_P /^"'+#_GX_P#P4_\ Y,J9'J/S%&1Z
MC\Q5O[;/_P \['_P6:?_ /(]'VV?_GG8_P#@LT__ .1Z-._X?\$.6'_/Q_\
M@I__ "94R/4?F*,CU'YBK?VV?_GG8_\ @LT__P"1Z/ML_P#SSL?_  6:?_\
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M_P#";A&ETU<:,E%><N5=+WT.%_X5]\/_ /H1_!G_ (2V@?\ ROH_X5]\/_\
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M ,%/_P"3*F1ZC\Q1D>H_,5;^VS_\\['_ ,%FG_\ R/1]MG_YYV/_ (+-/_\
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M/_P4_P#Y,J9'J/S%&1ZC\Q5O[;/_ ,\['_P6:?\ _(]'VV?_ )YV/_@LT_\
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M=U>UKIV;*F1ZC\Q1D>H_,5;^VS_\\['_ ,%FG_\ R/1]MG_YYV/_ (+-/_\
MD>C3O^'_  0Y8?\ /Q_^"G_\F.U3_D*ZG_V%+_\ ]*9JIU<U3_D*ZG_V%+__
M -*9JITNB^?YL*W\>M_U]K?^GZH4444$!1110 4444 % RV2H)"_>P/N\;OF
M)X&0">>2,XZ&@]#CKVK\[_VS? _[0?B3XD_!/Q!\%])^*FN6/AF"?[9I/A+X
MC7?@SP!-KT_Q"\!Z@;KQI_87Q;^%.M^&M3M/"FE:VFE^.M3T?XY>#IM!N/$O
M@S5/A/)<:Q!>:L''C<5+"8>5:&'JXJ49TH>QHNU24:DXPE.+4*C:IJ;E90;D
MX\JY;\\?T/!)Z G/0  D\$]B>H!(Z9P<9P< )/W5+'Y> "3\V-O0'EL@*.K$
M@#)90?R>E7_@I?XF\47GA7QGI>E0?#K2/'7PWOK'Q5X5/@71=<\7:1X ^/\
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MI/9OV4/V5=*_92\/^./#6A^,;KQ5IGC#Q-I^OVMJ_AR#P]:Z!!I>@VN@6UG
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M\<>#_&6N3^ -)O\ X?3^"O%%OXW@TWP_K.E^(_0/VE(/$1\>?%7^T;?]I.\
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M$%M_:4UYKM[J-Q=ZQ<1?;-9GFEU*^>2ZNYG;7P>[,<DG.XYR1CKG.<8&<YP
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MLU&#]]RG"48K7EGS-)V5;]8P, #T 'Y<59O#A-/&0"VG1D$D?\_=XO(ZC."
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M]T[7E4>G6%'JK/[75.S\G9^>?DY)RG/7D]J,GU3\ZT/[2U+_ *"%[_X$R_\
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M7]/N"U+O4_\  */_ ,F4,GU3\S1D^J?F:O\ ]J:F3A;^^8XXQ<R\GT'/T_\
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MJ?\ (5U/_L*7_P#Z4S53I=%\_P V%;^/6_Z^UO\ T_5"BBB@@**** "BBB@
MIXDD^5%=^3\J;F(+;0@./[VP*@/7: O0 !E.1VC=)%P&C=74D @,A#*2#D$
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F%*G&G3ITZ<(4H)4XQI4HJ*]Z+Y;03C==M5T-^BBBD;!1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>chart_002.jpg
<TEXT>
begin 644 chart_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $X IX# 2(  A$! Q$!_\0
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M!9[W5/#-_9WNF64'B.2ZU*[O+;1K:&;79UTT@']#-O\ %3X:W=OXEO+7XA^
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MAZ#_ (4%@=>V,]#D9!^T:* /BX_MZ?L\D8,7[1&/;]B_]LT'ZY_X4%G/OGC
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M@KJWP<:^N='UOP?I?B;1_#6H:#=>(HO&FH:EJTQ==X_^!1_^2#YK[U_F>H^
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MACPOH&F6VC^%;WP5X%_9^\+Z5IEI:_:#X@O=9\3ZGXCO[N75%B@\$N?V=?\
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MG_X0X+_Y4>Q?\+73_H R?^#%/_D.C_A:Z?\ 0!D_\&*?_(=>.T4?ZLY-_P!
MM3_PLQ?_ ,N#_7OBC_H8T_\ PAP7_P J/8O^%KI_T 9/_!BG_P AT?\ "UT_
MZ ,G_@Q3_P"0Z\=HH_U9R;_H%J?^%F+_ /EP?Z]\4?\ 0QI_^$."_P#E1[%_
MPM=/^@#)_P"#%/\ Y#H_X6NG_0!D_P#!BG_R'7CM%'^K.3?] M3_ ,+,7_\
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M4\7.=/#1Q%6V'@U*JHTJDHQU2DKGZ+_\+7C_ .@%)_X,4_\ D.C_ (6O'_T
MI/\ P8I_\AU^<'@?]MOX">-)_B:K^(;WPSIOPT\9_$?PHVMZSI]U=:9XPTGX
M60?#V;Q?X]\*S>'8M:,OA.UE^*'A""QDOEM-5U,:FEUIUA<01SM;\2?^"A?P
M:BL/$-]<>&/B9;R>$I-77Q!9R>%Q(T0TGP3\?_'FS1KR&YFTSQ'=7.C?L]>)
M%^QZ;=.;*;7=+DO)HK31O&$WA[HCX><]2I1CD.9.K2E0C4A[7&*4)XE0E0B^
M;$Q3E452"48RE*,VZ=14JD9TX<\O&EQHT,0^+LH='$QQ$\/4A2P-55H85S]O
M.FJ6&JSE3@J<YJ?(H5*:56C.M3E"I/\ 57_A:Z?] &3_ ,&*?_(='_"UT_Z
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MX7+ZM*K3E=QJ4ZE.$X3A))N,HR::3VU2]B_X6NG_ $ 9/_!BG_R'1_PM=/\
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M_P +6CY_XD,G.0?^)B@R#U'_ !Y]^_K1_P +5B_Z #_^#%/_ )#KX[_X7_\
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MWPD((_X2T<_]03Q&>_\ V"*MM^T%\(3I]G;CQ:3)#?:I-(/["\1@+'=6VC)
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MG1_PM=/^@#)_X,4_^0Z^.O\ A?WPD'_,VCJ3_P @3Q$.I)_Z!)H_X7_\)/\
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M,'_T7W"W_A?P_P#_ "P^Q?\ A:Z?] &3_P &*?\ R'1_PM=/^@#)_P"#%/\
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M/_D.C_A:Z?\ 0!D_\&*?_(=>.T4?ZLY-_P! M3_PLQ?_ ,N#_7OBC_H8T_\
MPAP7_P J/8O^%KI_T 9/_!BG_P AT?\ "UT_Z ,G_@Q3_P"0Z\=HH_U9R;_H
M%J?^%F+_ /EP?Z]\4?\ 0QI_^$."_P#E1[$?BQ&.N@R\G QJ,?7\;,CU[?\
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M_+@_U[XH_P"AC3_\(<%_\J+^M?\ (;U[_L,ZM_Z<+JJ%7]:_Y#>O?]AG5O\
MTX754*]?"_[M0_Z\4/\ U'H'S.-_WS&?]AN,_P#4K$A1116YS!1110 4444
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MJ?\ 0+T;_P *+3/_ (Y1_K=PK_T4.3_^%U/_ .0%_P 0]X^_Z(_B7_PUXO\
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M+<%3P&=4ZF+QN"Q&'P\)U\OC2HPG4J57"]2I[L8RC*[[;GN]7K?_ )!VM?\
M7'3?_3E%5#<,9R/SYJ_;<Z=K/O%IPXYY&I1?3@]O?T'-?SSBM*<5_P!/</\
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M%M_\I:/,TG_H&ZC_ .#BV_\ E+7R'_PU5H'_ $)>M_\ @SL?_C5'_#56@?\
M0EZW_P"#.Q_^-4?\0\XM_P"A+FG_ (68;_YN#_B,WAS_ -%-DW_AMQG_ ,P'
MUYYFD_\ 0-U'_P '%M_\I:/,TG_H&ZC_ .#BV_\ E+7R'_PU5H'_ $)>M_\
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M_AE*7_HH$7_A+2?_ "^K^C%XC\&O59N[/5?[#FBT>JT^J::-'\7OP=\2;O\
MXQRLO)9GE%E?6VF:I:7MHDKIGR%Y?O\ I_\ 7H\OW_3_ .O7U[_PRE+_ -%
MB_\ "6D_^7U'_#*4O_10(O\ PEI/_E]1_P 1'X._Z&[_ /"'-/\ YD%_Q!WQ
M)_Z)RO\ ^'/*?_GL?(7E^_Z?_7H\OW_3_P"O7U[_ ,,I2_\ 10(O_"6D_P#E
M]1_PRE+_ -% B_\ "6D_^7U'_$1^#O\ H;O_ ,(<T_\ F0/^(.^)/_1.5_\
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MQCKSQCZ>G;_/6N$^*7CB]^'OP_U#Q#86%GJ5P?%/A?3S;7LL\<(BN[3Q,SR
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MG_0"TS_OYKO_ ,O*/MMI_P! +3/^_FN__+ROA/\ X:I\3?\ 0J>'/_ W5O\
MX]1_PU3XF_Z%3PY_X&ZM_P#'J/\ B%G%G_0MI?\ A]P__P TA_Q'W@#_ *'.
M-_\ $4Q7_P PGW9]MM/^@%IG_?S7?_EY1]MM/^@%IG_?S7?_ )>5\)_\-4^)
MO^A4\.?^!NK?_'J/^&J?$W_0J>'/_ W5O_CU'_$+.+/^A;2_\/N'_P#FD/\
MB/O '_0YQO\ XBF*_P#F$^[/MMI_T M,_P"_FN__ "\H^VVG_0"TS_OYKO\
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MTCJ%1,*C;RV$W;W8#^=:$@_XE6G_ /7[JA_\@:3_ (_RK"K0I\]#6KK7@O\
M>,4W_"Q+W>(;6VZL[:7U9TT,77Y,3=TO]UFXM87!IIK$X6-FE@[.+O>STO9V
MND)]MM/^@%IG_?S7?_EY1]MM/^@%IG_?S7?_ )>52HK?V%/O6_\ "K%__-!S
M?6\1_-1_\(\#_P#,9=^VVG_0"TS_ +^:[_\ +RC[;:?] +3/^_FN_P#R\JE1
M1["GWK?^%6+_ /F@/K>(_FH_^$>!_P#F,N_;;3_H!:9_W\UW_P"7E'VVT_Z
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MQL]K!=:59>"S<7\4NN>)=/\ B1J/Q#LO$.B^+++QKIKZ;#X<UNP6UUY/UO\
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M /E!1_PRYX _Z#7C3_P9:&?S'_"/G(]1CFC_ (BIPA_S]S%^7]FS_P#FD?\
MQ CQ"ZX?)4NK>>X9)+JVU@[I)7;?9,Z;]GG_ ))/X?\ ^O[Q-^GB#4L?R ]@
M!C&*]];_ )!&G_\ 83UO_P!)/#M<'X-\):;X&\.V?AG2I[ZZLK&6]FCFU*6"
M6[+WUW->SAWMK:TA*B:=Q&%A!"!0[2/F1^\;_D$:?_V$];_])/#M?SSQ!BZ6
M/SO&XZ@I^PQF=8G$T?:1Y*CI5HXFI3E.'--P;C+6+=TT]]S^Q>#LNQ64<*Y7
ME6-C3AC,MX;P. Q,:515:4<1A*>"H5XTZBC'G@JT*B4N2'-=R4?>;=*BDR/4
M?F*,CU'YBN0]86BDR/4?F*,CU'YB@!:NZ?\ ZV]_[ VL_P#IMNJHY'J/S%7M
M/YDOL<_\2;6>G/\ S#;JL,3_  *GI#_T_AC?"_[S0_Z^/_TSBRB.GXM_,TM-
M! ZD#ENI]S2Y'J/S%:P^&/H8=_5BT4F1ZC\Q1D>H_,50"T4F1ZC\Q1D>H_,4
M +129'J/S%&1ZC\Q0 M7K?\ Y!VM?]<=-_\ 3E%5#(]1^8J_;_\ (/UG_KCI
MO_IRBKFQ7\./_7[#_P#J30.C"_Q9_P#8+C?_ %"Q)1HI,CU'YBC(]1^8KI.<
M6BDR/4?F*,CU'YB@!:*3(]1^8HR/4?F* $;^'_>']:T9/^03I_\ U^ZI_P"B
M-(K.8@[<$'YAT_&M"0C^R=/Y'_'[JG?_ *8:3_@?RK"M\>'_ .PB'_IG$G11
M_AXC_L%J_P#J7@RC129'J/S%&1ZC\Q6YSBT4F1ZC\Q1D>H_,4 +129'J/S%&
M1ZC\Q0 M7=3_ ./BT_[!6D?^FNUJCD>H_,5>U/\ X^+3_L%:1_Z:[6L9_P"\
M8;_#BO\ TS2.B'^YXWUPO_I6.*BRRA @DD"8.$#$*-W)P 0!DDGZD^M*9IER
MPFE!R&.)&!)#[P>OWE;+J>JO\P.[FH@0 ,D=!W]J7([$9[<CK6KA&[]V*NW=
M\L=V]W[NO2^[=EO9'.]FNEV[=+W;O;:]VW>U[N][W9X#^TO\=;W]GGX6/\1[
M;0=*\2SMXV^'?@J/3O$/BS4O!N@VC>/_ !CI?A :UK/B'2/"'CW5;+2-!74_
M[4U%=,\(ZSJ%Q9V4D%E:O,ZQR_/7PY_;_P! \4Z5%K7C?P9+X5TFY\.^(-7T
M.?P=K/C;XG2?$FZM?C;X2^!7@ZX^#]C_ ,*G\&WGCKPQ\3?%?BW2[#PMK%]%
MX8\12:U#+ILOA*70X;CQ9;?:GC+P/X8\?V.C:;XKT^;4K+P_XR\$_$'2$AU#
M4=->T\6_#OQ/IOC'P?JGVC2[NTGE&D^(M(TZ_>RN))K"_%L;/4+6YLYYX)?F
MGQO^Q-\'=>\.^/M/\&6,WPZ\3^.#=3P^);6\\3:_I?A>]U'XJ>$_C-J<WACP
MA+XLTC3O"\=_X_\ !]AX@AD\#WW@W5?#^KW6H:SX4UC0-3N);B3UL ^'/JJP
MV9X+$QQ,J[D\PHRDX4L-.KAXJ+I1G=1HTE7J5)QH5*W+)TX4I5E2JP^.SS#\
M9+,IX_(\=@Y9?2PD/^$K$0HQG4Q='#5W4DJTZ$90=:O]7HT8RQE"C*I1ISJX
ME86,L,\?2?V\_ACJWQ+TOP>F@_$*W\+:UI&@)#XWF\&^,5N=$\=:K\>?%G[.
M;^#_ ![X5?PVE[X'M[3XA>'K70['6]=U))=2U?7H-.BT6"WL[W4(J_PS_;]^
M%/Q"3X<:+:^'/B3H'Q&^*7ASQ'XK\(_#B^\*ZS+?S:=H_B#QYX>T2>XU>#3T
MM GB2_\  6KV_P#:&FVFJ:7X:OYEL]?OK>&33K[5>D^%/[%_PH^'?@_3]"UT
MZEX\\1QW>F:CK/C"\U/Q-HLNK7V@?M :Q^TUX9\G2$\5:L]I:>'OBKK,FHVC
MZEK.OZ[J]A;1:?XL\0^(H[B[,V[I7[&O[/&CZUX&UVS\(:])<_#373XD\$:?
MJ/Q*^)>L>&O#^L1>(]:\7:;=V7A75?%EYX=!T#Q!XCUB_P##T+Z6T&DO=B.W
MC^S6MI;0=567!R]O3IX;-I<D'##8F-?W,15I4,1&E4G2J\KC2Q%>K1>)LE5E
M0HJ5'V%>=2,N&A2\2YPPU>KC,@IRJU>?&86MAXNI@Z%?$T'4H1K4HSIU:^"P
MJQBPL8R</KN);Q+Q-*$9Q[G]G^]GUKX>KXVU+X/ZI\!_%WQ*\0ZWXU^(?P]U
MNX2?7H?&Y:V\*:EK.L7$2Q)>SZOIOA72)K&]6"UCO]!BT>]CMP)S+<>W^9(,
M$22 C&"'(V[6W+C!XVGE<=/Q.81@8Z'!QN/?.?NY)QDDDX]6Y;K3LCU'YBO!
MJ.-6K5J^RC356K.HJ?-5JJE%NT*2J8B56O.%*FH4J;JS<U1A3@W96?V^$H?5
M<-0PSJNO+#THTYUW1P^'=>K>=2M7E0PE.GA:,\16JU:]:GAX^R5:K6<)24[C
MB6(VEF*\9&XX.W[N1G'RY./3/TIH !SW]:,CU'YBC(]1^8I));)+T27Y)'1^
MM[^=][][];WOUN?3LO@_PS-))--HMG)+-))++(4D#2R2LSN[!9 "SN26/<DU
M'_PAGA3_ * -C_W[E_\ BZ\BU0?\374P./\ B::AW/4W4Q/ (Q_GMQ5+:?7_
M -"_^*K\<6)QL4E''8R*2LDL3B+)+1)+V\;62MVT5K))'[S5QF5JK4C+(,MD
MU4J)RE0PDG)JI*+D[X!ZR<;[MZZM[GM7_"&>%/\ H V/_?N7_P"+H_X0SPI_
MT ;'_OW+_P#%UXKM/K_Z%_\ %4;3Z_\ H7_Q5'UK'_\ 0PQG_A3B/_F@S^N9
M5_T3V5_^$V#_ /F ]J_X0SPI_P! &Q_[]R__ !='_"&>%/\ H V/_?N7_P"+
MKQ7:?7_T+_XJC:?7_P!"_P#BJ/K6/_Z&&,_\*<1_\T!]<RK_ *)[*_\ PFP?
M_P P'M7_  AGA3_H V/_ '[E_P#BZ/\ A#/"G_0!L?\ OW+_ /%UXKM/K_Z%
M_P#%4;3Z_P#H7_Q5'UK'_P#0PQG_ (4XC_YH#ZYE7_1/97_X38/_ .8#VK_A
M#/"G_0!L?^_<O_Q='_"&>%/^@#8_]^Y?_BZ\5VGU_P#0O_BJ3'N??A^/<_-P
M/?O1]:Q__0PQG_A3B?\ YH#ZYE/_ $3^5_\ A/@__F ]K_X0SPI_T ;'_OW+
M_P#%T?\ "&>%/^@#8_\ ?N7_ .+KQ>..25BL2R2,%+%8TD<A1R6(4GY0.2W0
M#DG%(R,K%6RK E2K!P01G((+9!&#G/3!!YH^M8__ *#\;_X4XG_YH']<RIJZ
MX>RQJ]KK#8-J^FEUE[5]5I>^JTU5_:?^$,\*?] &Q_[]R_\ Q='_  AGA3_H
M V/_ '[E_P#BZ\69'0(SAE$BAXRRNH="2H9,D;E+*P##()! )(I,'&<\<\_-
MCCKSN[=Z/K./_P"@_&_^%.)_^:!?7,I_Z)_*^G_,-@WOMM@'OT[K571[5_PA
MGA3_ * -C_W[E_\ BZD?P=X:E$?F:)9R")!'#N20>7&'9PBX<':&=V&>06/.
M#7B7EOM#X<(Q95?:VUF4*6"LV4)4,NX<X#+G&Y35N\'[O3N>?L$9_.\O/3 [
M]NP^F!XG'.U\=C&ULWB<1>-U9M/V[:;6FEO/30N.+RIPJ/\ L#+.5*FI)8?!
MVES5+)2_V!II-<R33U71ZGKW_"&>% ,'0K$]B/+EQU)Z>9CJ2?J2:7_A#O"O
M/_$CLN>OR3<]>O[SGJ?S/K7BF#Z_^A?_ !5&#Z_^A?\ Q5'UG'6M]?QC6FCQ
M&(>UK;U[;I=-TFK-*T+&Y5NN'\L[?[OA+KF6JNL!I=/5:76Z:/:_^$-\*?\
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M_P"+KQ7:?7_T+_XJC:?7_P!"_P#BJ/K6/_Z&&,_\*<1_\T!]<RK_ *)[*_\
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MO#\S_P#%T?6L?_T,,9_X4XC_ .: ^OY3_P!"+*__  3@O_F(]K_X0SPI_P!
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MO_PFP?\ \P'M7_"&>%/^@#8_]^Y?_BZ/^$,\*?\ 0!L?^_<O_P 77BNT^O\
MZ%_\51M/K_Z%_P#%4?6L?_T,,9_X4XC_ .: ^N95_P!$]E?_ (38/_Y@/:O^
M$,\*?] &Q_[]R_\ Q=/3P?X90DQ:+91EHY(FVQR?-',ICD0YDY#H2C =58CO
M7B6T^O\ Z%_\55VP&)+D=?\ B6ZG_>[6,YQ]X]:'B<<U9X_&-/=/$XAI]=G7
M:Z+INEV+AB\J<XI9!ED6W:ZP^#NKI_\ 4!VNOF_GZ\?!?A4==!LCGGF.4_\
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M-@__ )@/:O\ A#/"G_0!L?\ OW+_ /%T?\(9X4_Z -C_ -^Y?_BZ\5VGU_\
M0O\ XJC:?7_T+_XJCZUC_P#H88S_ ,*<1_\ - ?7,J_Z)[*__";!_P#S >U?
M\(9X4_Z -C_WZE_^+J1?!WAM$DC31;,),$69-DF)%C8.BGYS@*X# #N <UXC
MM/K_ .A?_%5>MQ_H6I9YRMD._P#S\Y[D^G;'Z4?6<:_BQV,EU5\3B-&M4_X\
MM4TFGI9I?*X8S*G*RR#+8MPJ/FCA\&FE"#DU_P B_:2NGY/9['KG_"&>%/\
MH V/_?N7_P"+H_X0SPI_T ;'_OW+_P#%UXKM/K_Z%_\ %4;3Z_\ H7_Q5'UK
M'_\ 0PQG_A3B/_F@CZYE7_1/97_X38/_ .8#VK_A#/"G_0!L?^_<O_Q='_"&
M>%/^@#8_]^Y?_BZ\5VGU_P#0O_BJ-I]?_0O_ (JCZUC_ /H88S_PIQ'_ ,T!
M]<RK_HGLK_\ ";!__,![5_PAGA3_ * -C_W[E_\ BZ/^$,\*?] &Q_[]R_\
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MBNT^O_H7_P 51M/K_P"A?_%4?6L?_P!##&?^%.(_^:"/KF5?]$]E?_A-@_\
MY@/:O^$,\*?] &Q_[]R__%T?\(9X4_Z -C_W[E_^+KQ7:?7_ -"_^*HVGU_]
M"_\ BJ/K6/\ ^AAC/_"G$?\ S0'US*O^B>RO_P )L'_\P'M7_"&>%/\ H V/
M_?N7_P"+H_X0SPI_T ;'_OW+_P#%UXKM/K_Z%_\ %4;3Z_\ H7_Q5'UK'_\
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M)66:YHEHET_M/3T/2?\ A<GQ6_Z*)XN_\&UU_C1_PN3XK?\ 11/%W_@VNO\
M&O-LCU'YBC(]1^8HM'^5?U\@_MO.?^AQFG_AUS3_ .>9Z3_PN3XK?]%$\7?^
M#:Z_QH_X7+\5O^BB>+O_  ;W5>;9'J/S%(2"#R.A[BBT?Y5_7R'_ &WG'_0X
MS3_PZYI_\]#]7?@[JNI:W\,/!FKZO?76I:E?:;=37NH7LSSW5U*FL:E DDLC
M$LS"&**($Y_=HH['/IM>1? ?_DCW@'_L$W1_#^WM7KUVL'NUT5]>^I_3>23E
M4R;)YSE*<YY3ELY2E*4Y2E/!4'.<ISE.<YU).524YSDVY=DA&Z'Z'^57)/\
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MA*A7C.-2I2<)0=)J2FIT'"4=KJ:<=4WLCD/^%3>#C@_\*V\(<_WO!^@Y]/\
MGP]OZ=J/^%2^#O\ HFW@_P#\(_0?_D&NB$1/2,<<$>63W]>.U+Y)_P">8_[]
MFG>2TO:W3M^!QK!92U?^S<([ZW5'!-.^NC^J.ZNW9W>G5G.?\*E\'?\ 1-O!
M_P#X1^@__(-'_"I?!W_1-O!__A'Z#_\ (-='Y)_YYC_OV:/)/_/,?]^S1S2_
MF_K[A_4<I_Z%F%_\$8+_ .8SG/\ A4O@[_HFW@__ ,(_0?\ Y!H_X5+X._Z)
MMX/_ /"/T+_Y!KH_)/\ SS'_ '[-'DG_ )YC_OV:.:7\W]?<'U'*?^A9A?\
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M^!_C6=L']U/^^!_C1L']U/\ O@?XT6\U_7R#FH_R5?\ P9#_ .4&C_9FH_\
M/E<?]\#_ !H_LS4?^?*X_P"^!_C6=L']U/\ O@?XT;!_=3_O@?XT6\U_7R#F
MH_R5?_!D/_E!H_V7J/\ SY7'_?'_ -?\:MOIU^=/M$%G<;EO-19EV8(5X]."
MD@D'!*, >GRGVK#V#^ZA_P" @?U_Q^AJ[(H_LRQ^5?\ C]U+J"?^66F]B!C'
M3)ZT6]"X.E^]:A4LZ4K_ +V-U:I0MI[#KIN2?V9J/_/E<?\ ? _QH_LS4?\
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M]S?^%/#?AZ_\4^#/%5WIMGK&OV?BK5M-\.Z^FD>&]1U7P_K>FV6*_P#P3_\
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M3*I_Q%_UZQ'_ *9D4J***1(4444 %%%% !5V3_D&V7_7[J?_ **TRJ579/\
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M_P"%6O[1U#MJ.H'Z7MQ_\=_,_P#U\']H:A_T$=0]/^/VX_\ COIS1IY_@/\
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M_00U'_P-G_\ CM79+_4/[/LW^W7H9KO45++>7&\A(M-PK,9<LJEF*C.%+,5
MW&C3^K%P5'][:5;^%+F]RG_S\H6^UZ&1D>_Y'_"C(]_R/^%6O[0U'_H(:C_X
M&S__ !VC^T-1_P"@AJ/_ (&S_P#QVC3S_#_,BU'^:M_X#3_S*N1[_D?\*,CW
M_(_X5:_M#4?^@AJ/_@;/_P#':/[0U'_H(:C_ .!L_P#\=HT\_P /\PM1_FK?
M^ T_\RKD>_Y'_"C(]_R/^%6O[0U'_H(:C_X&S_\ QVC^T-1_Z"&H_P#@;/\
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MC\Q5O[;/_P \['_P6:?_ /(]'VV?_GG8_P#@LT__ .1Z-._X?\$.6'_/Q_\
M@I__ "94R/4?F*,CU'YBK?VV?_GG8_\ @LT__P"1Z/ML_P#SSL?_  6:?_\
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M_P#";A&ETU<:,E%><N5=+WT.%_X5]\/_ /H1_!G_ (2V@?\ ROH_X5]\/_\
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M ,%/_P"3*F1ZC\Q1D>H_,5;^VS_\\['_ ,%FG_\ R/1]MG_YYV/_ (+-/_\
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M/_P4_P#Y,J9'J/S%&1ZC\Q5O[;/_ ,\['_P6:?\ _(]'VV?_ )YV/_@LT_\
M^1Z-._X?\$.6'_/Q_P#@I_\ R94R/4?F*,CU'YBK?VV?_GG8_P#@LT__ .1Z
M/ML__/.Q_P#!9I__ ,CT:=_P_P""'+#_ )^/_P %/_Y,J%AZCJ._OS5Z3_D&
MV7.?],U(_G#IASU/&>G]>M-%[-_SSL3_ -PS3_\ Y'_SUJW)=RG3K,^79$F\
MU%<'3[%E 2+3L;5,!52=V"5 )4*K$A% -/Z7_!+A&G^]_>O^%*_[I_\ /RA;
M[?H9&X>H_.C(]1^8JW]MG_YYV/\ X+-/_P#D>C[;/_SSL?\ P6:?_P#(]&G?
M\/\ @D<L/^?C_P#!3_\ DRID>H_,49'J/S%6_ML__/.Q_P#!9I__ ,CT?;9_
M^>=C_P""S3__ )'HT[_A_P $.6'_ #\?_@I__)E3(]1^8HR/4?F*M_;9_P#G
MG8_^"S3_ /Y'H^VS_P#/.Q_\%FG_ /R/1IW_  _X(<L/^?C_ /!3_P#DRID'
MH0:MW_\ K(#TSI^E=?:PMOS'>C[9,>L=B?\ N&:?_P#(]6[Z]E$L&(K+_CPT
MPG.GV+??L;<G&ZW. "2$485%^5%50 #^MO\ @FD8P]G4_>NW-0O^Z?\ S\J6
M^WW,G(]1^8HR/4?F*M_;)R2%BLB>N%TRP) _"V_4_C0;V;/^JL_?_B6:?VP<
M?\>W!]B,^W3)IW_#_@F25/2U25K:7HR6BMT<T]-.G^94ROJ/S%(<'^+]5_#M
M5S[;-_SRLO7_ )!EACMV^S9YR.>G49R" ?;9O^>=EQC/_$LL.,Y()_T;@$#]
M">@.#Y_@#C335ZNMKJ]*_NO:6LW9.^FS[I,J97U'YC_/7GZT9'J/S%6OMTW_
M #SLO_!9I_J!D_Z,?4<<')&<"E%Y.QXBLFQR<:9I_3U)^S84=MS87(//RM@_
MK;_@A[.FWI.3>CTHR[V6O.HIWT2NF_,J9'J/S%&1ZC\Q5H7TIQA+$Y&?^098
M8QR>OV;T!_*E^VS?\\['_P %EA^O^C?SQGM1IW_#_@CM3Z56^O\ "DOPE*+T
M=U>UKIV;*F1ZC\Q1D>H_,5;^VS_\\['_ ,%FG_\ R/1]MG_YYV/_ (+-/_\
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M@#)90?R>E7_@I?XF\47GA7QGI>E0?#K2/'7PWOK'Q5X5/@71=<\7:1X ^/\
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MI/9OV4/V5=*_92\/^./#6A^,;KQ5IGC#Q-I^OVMJ_AR#P]:Z!!I>@VN@6UG
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M\<>#_&6N3^ -)O\ X?3^"O%%OXW@TWP_K.E^(_0/VE(/$1\>?%7^T;?]I.\
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M$%M_:4UYKM[J-Q=ZQ<1?;-9GFEU*^>2ZNYG;7P>[,<DG.XYR1CKG.<8&<YP
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MLU&#]]RG"48K7EGS-)V5;]8P, #T 'Y<59O#A-/&0"VG1D$D?\_=XO(ZC."
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M]T[7E4>G6%'JK/[75.S\G9^>?DY)RG/7D]J,GU3\ZT/[2U+_ *"%[_X$R_\
MQ5(=4U$==1O>_P#R\RGIC/1O<?G1?T^X+4KIWJ75K/DHW5M%;WNBT7;H4,GU
M3\SWHR?5/S-:']IZE_T$;W_P)D_^*H_M/4NVH7I_[>9?_BNW?THOZ?<%J7\U
M32R7N4=+*R7Q=%LNB,_)]4_,T9/JGYFK_P#:>I]]0O1W'^DR\C\QT[_A0VIZ
MFN#_ &A?8/\ T\2\\@<?-R<GMGGCN*+^GW!:EWJ?^ 4?_DRAD^J?F:,GU3\S
M5_\ M/5.2+Z^(&<G[1+QCUYX/]>#SD &IZIVO[YAU)$\^ ,X)YX..^"1WZ<T
M7]/N"U+O4_\  */_ ,F4,GU3\S1D^J?F:O\ ]J:F3A;^^8XXQ<R\GT'/T_\
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MJ?\ (5U/_L*7_P#Z4S53I=%\_P V%;^/6_Z^UO\ T_5"BBB@@**** "BBB@
MIXDD^5%=^3\J;F(+;0@./[VP*@/7: O0 !E.1VC=)%P&C=74D @,A#*2#D$
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F%*G&G3ITZ<(4H)4XQI4HJ*]Z+Y;03C==M5T-^BBBD;!1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>pg80-149_002.jpg
<TEXT>
begin 644 pg80-149_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %3 IX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^Y/0?#D6O
M/KU]?:OXF$B>*O$%I$MKXEU:QM[>TL[MK:VMK>TMKE+6"W@B&R&&-0-K98E@
M:Z'_ (0'2_\ H,^,/_"NUK_Y,KFO"WC7PAI+>)+#5?%?AC3;Z'QGXF\^UOO$
M.C6MQ"7U#SD66">]CFCD,;!C&T>\ @D 8SV/_"QOA_(<#QQX-..<'Q/H9P1V
M.+X$8ST/<GVKJJ/%^T:A2K2@HQ<7"E5DFIQC.+]VE+XH2YH]'%IJYYU%X&5.
M+J5</.;<HR_VBA=2ISE3FK>V5W&<7&6NDDUT*?\ P@6E_P#09\8?^%=K7_R9
M1_P@6E_]!GQA_P"%=K7_ ,F5</Q"^'O_ $/'@L^P\3Z)D9[G-^/TS[4?\+"^
M'O\ T/'@O_PJ-$_^3ZSYL:MZ-=?XJ-:/_I5"-S;ERW^:A_X.H?\ S04_^$"T
MO_H,^,/_  KM:_\ DRC_ (0+2_\ H,^,/_"NUK_Y,JY_PL/X>\?\5OX+.>@'
MBC0^?I_Q,.>.:3_A8GP]_P"AX\%CZ^*-#_IJ!Z<?G3OC7M0Q$EWC1K27WQH2
M5_*XFLL6\\.O6OAU^>)14_X0+2_^@SXP_P#"NUK_ .3*/^$"TO\ Z#/C#_PK
MM:_^3*M'XB_#T?\ ,[^"_P /$^A__+"D_P"%C?#S_H=_!G_A3Z'_ /+"G_MW
M_0/B?_!%?_YG%_PE_P#/S#?^%&&_^:2M_P (%I?_ $&?&'_A7:U_\F4?\(%I
M?_09\8?^%=K7_P F59_X6+\/AR?&_@H#_L:M#_\ D^C_ (6+\/>G_";^"\^_
MBG0QP>A_Y"%)O&K>C72[NC62^]T$OQ'_ ,)G\^&_\*,-_P#-)6_X0+2_^@SX
MP_\ "NUK_P"3*/\ A =,_AUGQ@6[#_A+=://;_E[;_T%O]T]*L_\+%^'W_0[
M>"O_  JM#_\ D^E'Q&^'HY'CCP6#U'_%3Z+P?_ ^A2QC_P"7=7_P"?\ \K0O
M^$O_ )^8;YXC#?\ S2?E]XW_ ."FG[#W@?7/BGH[>./V@O%%G\'OB%X8^$OC
M+QUX*^&WQP\1_".'XI^(?BW\./@Q>_#?1/C+'HEO\*?$'COP9XU^+?@N/QOX
M5TKQ=<:UX<L;R^O)K2]?2KNTA^RY/BG^S#;:-XR\2S?M*^ ;?PYX \4Q>"O'
MOB&3]H'P]%HG@SQK<3I90^$_%^IGQ3'I_AGQ/+<&*TAT#69['5I)R+:*R&R)
M&_*+4_\ @FQXV/PJ^,'[*_A[]OWX,V7[(GCG]IW3?VJ/ ?@C6/@SINJ?&?P+
MXLN/VQOAM^V-XE\$:I\7K7XZZ9X<\4^ X_&GA+QE:>%=GPIT7Q9:?\)^K:]X
MCUS3O"MCI=_\K:E_P0SU+5?^%]:[J/[>?[-^I_$?XO>//A!XN\*^/Y_V?KK2
M;SX5ZQ\'O&W[0'B/PU\5= T#PU^T_H_A._\ C-8Z1\=I]"M4N-!@^"MYH^AW
M7A_Q#\(=<L?$NJWAI/$V]Z.(3OM&E)JW_@O?_@ HY;+53PSZ75>@]O3$?@?T
M2/XL^!OV3XF75O\ &>TU,?!RSGOOBQ;:%\4IO$>J_#J"VTN?6VC\7Z-H.KZC
MJV@7<NDV]QJ%K8ZA8PW][:Q&2TMIQM!XK]F/XN_ O]L/X)>$OVB/@%X\\=>,
M/A/X^O?&=CX6\07MWX[\*W^I2?#_ ,?>)/AIXF27P]XD@TCQ#I/V#QAX2U[3
M-NIZ;%.]I:+=;1'>EA\:?L2_L;7'[&?BO]K_ ,6:'^U)\ -37]H;Q GBOX?^
M"M ^&H\.?#_P!X\\[Q5K.M_$WQC8W_QO\1^,/%OB#XD^*O$L&O\ Q"\%^"?&
MOPO^&$&H:=J>H?#WPIX%N?%6HK::7[(/['%K\$OV(M<_8J^.?[7/A'XBZ1J7
MQ$^*?CC3?B;^SKJ'B[]E'Q]I=K\7/C?XF_:(\1Z8GB#1_CU\1/$MK?VGQ%\9
M^)--L=8\->(O#277@"32_#6KZ;?WMOJ^N:Z<N+W5+$-;_P "L[]GI0U^3L+E
MRR_\3"WO_P!!%"_W?6=[GO/[27[5O[,O[*?BGP!X#^*'BWXUZS\0?B=::QKG
MA;X=_"#PA\:OCCX^_P"$%\*W&EP^+?B7KG@_X2:#XLUSPO\ #'PI=ZMI=EKO
MC;6;'3]%M[B[AL8KVXN9)[9=OXH_M'_LR_"BUL[G6?BUK'B.>3XX_#']G?6-
M'^'WCBZ\;>(O!?Q7^+6N)HOA+P[X\T#1M;DU7P9-+> 2ZG'KUK97UE8+.QL&
M19E?P7XX_LO:YJW[3_P>_:Y_9=_;"^%'P=^*W@']GC6OV2_&=M\:/!4?[0WA
M;QK\$-<\>>$OB(E_8P67QI^$GB;1OBIH7B3PG#>6?BK4_%'B32-:CO[BWU[P
M]<NINIOSP_9__P""(_PY^!5SXMMX/VN/@YK\-Y^T-\'/B[X;\?S^#_$R_&'7
M_!'PP_:?^(G[3MQX"^,NJ:I^TIK?PO\ %^O76M?$*Z\-Z1X]\#_"GX:WUJ;2
M]\1ZIINJMX@O] A=L4M94\0EW]A53^7-025_6_:X_9Y;UGA].OUBC_\ -!^H
M5U^VY^R9IW[.G[+'[5?B'XB?$'PK\$_VN_$/PM\,_"OQ5XIUC4O#\&EWOQ9\
M.ZWXP\+WWQ&DU378=-\$Z-::-X<U.77]7U34#::1+$MO/),ER$C^H;3QA\ [
M_P 3:3X+L?CQX>O?&6O>$(_B%H7A*U^-NFS^)M:\ S6QO8?'&DZ#%XB;5=1\
M'S60-Y#XFL[2;1);0&YCOFAPY_&77O\ @D1X"7]D/]E[X >%/VO_  !KGQ"_
M9RU+]D[6[W4/V@]*UCX]_LO^/[G]E+P?XJ\.:3I:_LF:K\=_#?A;P%I?Q O/
M$K77C&\\'^*[/6;Q+2&:\O=5O[>TG@^=?"7_  06\/>%M4_9UTS4/V[?@E\1
MOAC^SY\%+OX;6G@?XD? G2[I_&&J>)?@#\>/@E\1-$\0ZEX&_:!\ O>_!3QQ
M<_'*^UR;P'J,>I^./#/A/P_IGPS\(?%30=+WZW1_M,OAAB)6WO1JNU_\-&5O
M/;7OJ'+EJVGAW_W'H.WR>(_(_H5T/XA?LY^*?^$"_P"$9_:'\(>(Q\5)]?MO
MAB=#^.^BZP/B/<>%6,?BB'P#]@\2W/\ PF%QX:D4IKL7AW^T)=%D&-16V88K
MR;3OVGOV9M=^+'QK^"WA3XE^)O&_CC]GKX+Z5\<_BBG@?QA=^-=*T+PSJGBC
MXG>$G\,C4M!UV^B;XCZ;KGPB\56FK^!KY++6].232)Y[<IJ<:'\5OA3_ ,$+
M/"_@CXM?LC_%?QU^V5\#OBY)^SO8?##0[[PGXG\ ^+M&TOP?X>^"?[1/B_\
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M:S\HTJLG]T:,G\[6\Q\N6_S4/_!^'_\ F@I_\(%I?_09\8?^%=K7_P F4?\
M"!:7_P!!GQA_X5VM?_)E7#\0OAZ 2?'/@K@9/_%4:(/U-^!^N*;_ ,+%^'O_
M $._@O\ \*G0N_?_ )"/3_(HYL;UHUE_BI58_P#I5&-_7;YBMEBWEA__  =0
M_P#F@J_\(%I?_09\8?\ A7:U_P#)E'_"!:7_ -!GQA_X5VM?_)E6A\1?AX?^
M9W\%_P#A4Z%Z>VHGZ?\ UN:/^%B_#P<'QSX*!]#XIT//_IPHYL9_S[J_^ 3_
M /E86RS^;#_^#J'_ ,T%7_A M+_Z#/C#_P *[6O_ ),H_P"$"TO_ *#/C#_P
MKM:_^3*M?\+%^'G_ $/'@O\ \*?1?_D^E'Q$^'A.#XX\%@>I\3Z)C_TX=Z.;
M&?\ /JK_ . 3_P#E0O\ A+;LIX9M[)5\.V_DL0RI_P (%I?_ $&?&'_A7:U_
M\F5R?C3PE!I>@R7=CKGBU)CK'A:V9CXIUHD6VH>*-$TR]0%KQANFL;NZB!
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M7X?=_&_@K_PJ=#/Z?;^:=\;_ ,^JO_@%3\_96#_A+_Y^8;_PHPW_ ,TE;_A
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M?P>3;2PRQ3/^&VH_\$*]1G\)ZY+X<_;P_9+^''Q0\2^(OC5%>7?PT_9!\/\
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MUNZ%9+[WATOO:7F'+ER^UA__  =0_P#EY^_P\":2Q8#6_&!*':P_X2W6LJV
M=K W@VM@@[3A@"I( 925_P"$"TO_ *#/C#_PKM:_^3*L1_$3X?8.[QUX*)[
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M:EI]Y\4-.\4V'B3X9K!H?C?P+\(?#GQ+TK7O'VA>*+/P>_@#QQX+O/A/X?\
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MJ^'9/C_H.L^.?!U[?_$GQOX:^*/Q^\#>)_AQ\6/%.N^*/'/B'1/"'A#1!?\
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M^%EUXXG@U;6]1;5K:;X4ZW\7O!?G^!?$MKIWCK6/#FNZ;JUM:3+(9'Z#3?\
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MI9-UL0[V2:VCHFNMWVNVF+ZE@=X9;1CW_P!GPL=.W[M4V]>CNM=$GJ8WC_\
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M6E^#]9U'5?'VFZ+JE]KFN?!7QE>6&J^%[_7=#@T)+'4M3U"QDN_LD/Z+ZO\
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M!:3<Z3+:RZ3X8F.FZ?Y<*00$MCUJ\1S.W2<Z23TZ4XVD[7LW9K;;4KV&5?\
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MX1?#36-=O;+Q%IE]K&H^"?#]WJ-YIOC#4-5U7Q3IM_=RV;/J%EXFU/7-:O\
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M=2^-D\-:1J=QI?A6V\:3:Y;:#IQ@TFVC?1;*RTVW^C#%)\N$D97R8V$959%
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MN"Q&3@F_J^&=N6E2;M=_O;^2>D^^U[_F2J]2[O4FK_!>G+5=;_\  9\(6?\
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MUTJW%O:.;87UQ LYCN[VPLG1&)2]U+3;.0I/=E(=@I(K^64<2;F0QL%#;UW
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M=U&[?NKM*<6EWM:UEW[V^9%F]GS>D91_]*3O??2QJY'H?^^3_A1D>A_[Y/\
MA44,D=W%#<6KQ7=M<10S6UW:S17-I<PW4/VFTGAN;>22*6WO+?9-:W$+30W$
M<L+0O(')7-36]#EU5]!AUC1Y]>1KQ&T*'5+&;6O,L+/2M1O8CI4-U+?1/8Z?
MKV@ZA?\ VB&'[)9:[HUP^]=0A%._5*Z[J<4G\FF%I?R2?FFOU5_P-C@]OT]L
M?RXI#CKCKQTS_*JMU=V=@;07M[:V0U"_M]*TYKRY@M1?ZG>-*MEIMEYS@W%_
M>&"46EFA^T7#*4@CD9'"VC'+LWE'V\D[AP%#*H<&,ND@W"='2-WE26!HECD:
M6#S#F6UTWVYE>_:][+M?;0+3_P"?<[?+8,CT/'3Y3_A1D>A_[Y/^%4K2\LM0
M>]CT^[L]0?3=2FT?45L+F&]_L_5[6&WN+S2;\VDLXM-5LK>\M+J[TR3_ $^&
MTNK:Y-N8KRQ-W<V/G[CXSC(![",MA2ZD@*X<-]TQAYB5@42LTXOXGR+NY1DK
MWM:T;6?KM:UKL=GUA*/K9_DA<CW_ "/^%-W)[?E_]:JM_?66E6-QJFK7UGI6
MFV@!N]1U*Z2RL;57F2UC:XO;ATM(/-NY8+>(33H)9)DCB:28B$W6AF4X9)1R
M!R!SN9U7 5V;)*,"" P*2'!CB>0-M?9]_NU)1L^UG>^FMQ-6^UR^L)2O_P"
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M.54+&-PH.,@$Y&X@,"NX%9 !Y(5C)*^8_+22*X6!K12KOW+(-A96)5@ RAV
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MOF.38MM(EP6FGLN;TFE9]M;D>LN7UA*5_FDK=OQ%R#SU^@)Y'KQ].M&1[_\
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M,OAO\3_A]'\)_AQIWQ!\.>$[>V\ >._&NF^ ]-\'S^.O&5RFG>)X?&GAJ_\
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M\)_XYUOQ/JG@F[\/Z'X7_9FG\):*?L'A'2[KQ=J,5YX>O[!-5TO2_G_4;?\
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MJWKP>:>#_!/_  5A\%P>-_'/AC7?''CWXD-\#=%^&L7AKX_GX.W7A;QK\3_
M]E_P4#UC0_'UO>^&=9@31M,M/%6N?LLZ/H.I:?;>'F^(7AOQ)I5I\3[%H/#>
MHW'A :IRLXT\3R27+*/,TXIJS<;*Z2;;MK;EWU8+VMU&57#QE?FC*,5KKS13
MU:L]%LMW=-'1^$/^">G[:'P]TGX2>!?AU^UGK^C?#7P-J?PVUS7?"&D?&OXS
M:9?P>*-$T#0;#QMXC\&ZKK?@7XC6MIX+EUC0YFT;]G^^T>W^#>HZ;XA\0$^'
M_"]\;.[U+TKX1_LC_MQ^%?C5\%/%_P 1OVG+G5?A=\-/&OCK5O$'@/1OC?\
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MQV-OX/A?ZT^&_P *_P!I3XZ>+=3T']K[4?B=:^"_AJOP%^(_PU\1?#VXT?\
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M-X\T7PLU_:7WCCP9\<+7PA+KG@C1K'Q!X:\01> M0TSQ)*(9K^:Q@[OX6?\
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M;;)ZVWW#V]'_ )\KMLM?\OEV\V?FY^TU^US^TM\$?'7Q"MOA]^S5'\:_A_\
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MF&9WB(2-2ABBBC3D/',LLOA^]::669Y-3\*[WED>1I#_ ,)5X?C!FWLPFX5
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M[7?A%H'AG1;?4O'$/@F+6M>LO$]W;6WC)O&&D^,-'LS/I%U-=W>DR3?;M_\
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M%FO^./BC/\+=3U#P7\=_AMX7^+6B7?C3XJZ1X13X:ZC?>%(+?X>_#?X1Z/\
M#_P-K?C;4_B[<WWBGQ5IGQ9T9O"VJ20:9I&N^*[>F_\ !2/]K[X@^%/&7C+X
M:_L.W_@[3O#5IK?B/0['XV:3\7M%U[QAX2/P?^/'[1?P_P!/TK0_"?ATW-AX
MQ\2?"OX;?"?PAXATN?S;'P/\9_C'9>"1:ZW<>$4T'5/6?"O_  5Y^#_BS1_@
M=K<_PG^-GART_:$U^"U\!Z5XFU'P#:^)]3\&:QIOPSO/ WQ*T[0Y_$L<'B#P
MEXJU3XK^$/!]U<)J%A8^%/&2ZCHM]J=U#:)<:SZ-^SG_ ,%)? /[3GQ;\&_!
M[P5\+?B]9Z_K7AS1+[Q_K5Q)H6K>'O@AXLUNR\>ZI8?#?XDW&GZE'J=GXEM9
M_AWXGT3Q//#I[VN@>.XH?"JQWUU%J^IZ6E+_ *B))/O&>FB;=];6L[VVUM?J
MVEJ_JW?LEU].^_9+N<_^TE^U+^TW\+/&OQ5B^#/P/M?B/I/A_P"%G@/XE:'8
M>/+#Q]#I-U_9OP+_ &COC3XX\'Z!J/PZ\)7FIOX_\2Z_\,_ _P ,K>YOM1\0
M:;H'B+QAHVI?V&;^&U\-^)>%U_\ ; _;FMO$<_A30?V;?@])>>&X=:TGQ1XD
MUC3_ -H<>'M6\4V'B3]L"WM-7\"VVE^'WN#X,;PU^S+X+O);;6[^76I-=^.G
MA5+>[&CQZ>_B"Y!_P5Q^'#R>']/@_9^_:%O/$_BK7=";PAX.\/R?#KQ+KOB;
MX>:P/'<R_$_3%T+QA=VELJ-\,/&LMMX U6ZTWQ=J2:59WJ1VR71FL_2_@=_P
M4N^#W[0GQB\8_ /P-X2^)>F_$3P)I/C35/$0\16NAIH^D6GPWT^:R\>7L=Q8
M:W*=5M? GQ7LC\$_$0TZ/SHOB)9RVT .D1I?&U)1?O8IJ_6TE>U^D79;:Z):
M>J%RV=_JME:^\7IIW_K[CR9/V_/VCO%FH^'_  =\.OV8[?0OB'JFNZAIOB5/
MB1X=^.$?A+X9Z==>(]<G\$W^MZWH/A+3(_$LOB#X::;IWBTVNB:I:V\6LZO9
MVNIW^BPRAH>J^#G[<'[0OQ-?]I'4O$7[*LWP_L/A!\$=:^)/@7PSK=_XQ7Q[
MXK\8Z7X%\/\ BK2O#MW:_P!BA]<\/?$N^UG5[?0-1\,:-IFM>'ET?^P=3TWQ
M#X@O-5BT?GO#O_!6CPGJ-EX5DUCX*_%74/#=[;> K?Q'\3](\2?"VP\$Z=/X
MHTS]E'5/$^J6'@_6/B=?^.O[#\'W_P"V3\'8QIL?]K:EK+2>(WTR^U>;PZMY
MJ5S0O^"M7PZU*9V\3_ OXR>!M!_LWPEJ^G>)?$'B_P"#>HZ5=Q>//"?PX^(7
MA<FWT3QS=ZEHXG^&WQ'M?&&NW>IVEMI_ARST"_T2_N([Z[B:-NJN;_>I1:O%
MI0DTFKO6VCT?1-K?L-0;2:PVCU7P?UOW.'\4_M[_ +87@C5OC!X?\1_LP^!I
M+CX2_#[X2^(KKQ#HMM\5;B'QIJOCNU^ /B3Q'J?PR\&2S0ZO\1M!L].^+GQ'
M\">&?!USKO@C5;CXJ?!&;3?$?BW2(O&G]D^$N5N?^"G7[0>HP?$ZZ\+_ +/G
MA/5M!\*?&+XG_"ZR\;/X._:/U/0OAVWPI\>_M/>"]+\/?%K3]'\(W.N>(O'?
MQ6O?@)X*T7P\?AC<3^$_AMXH^,-GI/CJ:ZGT:VL/$7L>K?\ !7OX)>'[+5/$
M3_#OXK77P[TG3/'%Q;?$+0-;^&NL:)JWB[PG:?&[5['PCHFDZ5XP?5Y_^$LT
M+X!^,M<TSQ;:V4GA33(9-#.J7MI/>ZM-9>G>)/V^_!?PE^$/PB^)5_\  +XM
M^$]+^)'A;]J#XL>)/ -K'X \+^)/A3X:_9YN+_Q+\;_%_B;1Y?$&FV7B9_%.
MN:B=:\.R>$!?ZM\0[OQ9I_C'61IC7^K7MLN?2_UR5E=-\E2][+1*UM4[]-$]
MFU%JR32>&U>RO#IYW_/\M3Q+Q+^WC^U1X6OO%]_KW[+FD^&O"EIK=A'X>1='
M^+WBSQ_H.B:'\4?AC\/O'6GZYH&E6>AZ)\1/B-=:?\0KW7?AQX8\$>)_"NFZ
MUI7@'QG?+XBUZZ&EZ;?S_#K]OC]H_P 5^+_"ND>+_P!EVT^'OAKQ)^U1-\#[
M^RAL_'_BWXE>$_"[W?BW2;*XUKP=8OIFD/=6&HZ)X;U?Q=\3_P"V+/PW8>$?
M%T7B72OAWXBT73-2UG3NNE_X*H>#M*AT&/7?@1\:?!.N^*-!EU#PMH?CCQ3\
M,_!3^+O$*?&O0/@C+X9\)^(-=\5V&C:GIMI<^,-#^(6K>+M7N] M=%^'>N6.
MM1:/->37T6F<[IG_  6!^#WB#3/#FH:!\*OBWKL?BR\MO NB:?9>+O@^=:O_
M (NOI'AC7[SX;0:0_P 0S.WABRTSQ-826'QRA*_!WQ%?"&RL-=\KQ+X9NM8%
M43>F+J-]O9U+ZN]K:WM_P%IH/E_ZAK>K@OQ>Q2\??MV_M/0_%G]HOX5?"3]G
M'3/$4?PD\06%EX1\=?$#P/\ &SP[X-U6VLO"G[0>N>+=+OY= EUF7QA-=R?"
M3PC'X0\8>'AX7T35+;XH6YN- U"WN=+U/Q-I_"[]L?X]^//BY\?/$7BOX7Z[
MX(^%OPG_ &1OB9\3=!^$5O\ #7XK>(/&T7Q#\)^,M%O_  W8^*M4O?">BV/Q
M$\;>-OA_#-J?@WP+\'M1DN-0\.:RVFZS9)KB:=J#W_$7_!67X7>&[31H-3^$
M/Q7A\1>(=+L(_ GA(Z[X"FU3QQX_3XOR?!+QKX#\&3V&OZEI6H6_PM\?VEG;
M>-?&T$T5C8C5/!OV+2+L>)](FG]>T'_@H-\/M<\&_'CQ9J?@SQS\.I?@!X;^
M"WC+4/!?Q4UWPIX/\;:_IOQ['V;X=7+:-%JVM0>&#KOCBUU'X=Z?>W]_JTNM
M>/O#^N:3I4$^KZ6=,N&U=IO%3233NXSC9K72[6KMRVW]ZR\IDERM+#J3:M:+
M@WWZ;>MU^A\'0_MU_MFZS$?C+9? _P :RZ!HGPXT76)_@[I_PY\4:1X:\8:O
MHDG_  49T#Q%XB_M*30O&WC?1M"\16/PH_9Q^(/BK1?#VN>*_$.GZ!9Z%H/@
MVY\277C#19?$?H&L?\%'/VM-#U;PIH5A^Q-J/Q,3QU97Z>$OB7X(L/BSH?P^
MU:74/B9\3?V?_AQXEU/3O%/AV;Q+X)\)^-?B_IGP<\6ZWIVMW2:EX*_9Y^)?
MB+XB27NL0>#)-5U7IM(_X+._!GQ+#K%]X8^%?Q0O[7PWX%\(^+M;O=3\:?#K
MPR-.\6^-U^'3^$/AP\$^N7M[-K_B:Z\=6VF>#=9T^VN?^$FUOP7X]MM,TNWM
M?#]K?:MU7@W_ (*K>!/%>L>&X--^&OQ,\7:#XW\5:%::)XH\-R> ]''AC2_B
M)?>%/"GPFTGQ)H.O_$>XU7Q#XS\4^-?$NF>&[V\\*/9:%H\M[::G=1:5I]M>
M7^H3=<[<<2^39KWDKW=V]5\];^;LD.$5RV^JZ\K7,W%6T?NZOYW_ .#;]4)H
MO(GDB\U+CR7DB,\2/'%<&&0V[SP)))-)Y;NH(4RRLNX+N("UT_PS.?'6M$?]
M";H__IZU:OSP_9/_ &V+']J_QGXUT/P]\,I?!GA7PQ\)?@U\3-.UW4/B-X4\
M1^(KC5OB7XF^,'@SQ)X"U[P;HL$5_P"&=;^&GC#X.:WX9U34_M=W:2>)+/6=
M%U$Z=?Z=!#J/Z'_#0_\ %>:WQ@_\(;HY/!4Y;6M7)RK*K ]R"JG)Y Z4LTDI
MY+FKB^;EP2C)[:J6#Z;:WZ75[J^A&#IRAF.6)KE?UF>ET[>[CUT;_IG'I_R&
M?&1'!7QMXEP1U!-W&,^F<'N"/:N<O/ O@/4M9O?$NI^!/ VJ^)-2\,WW@K4O
M$FI^#/#&I>(]3\%:H@35/!NHZ]>Z5-K%]X1U-05U+PO=7LFA7R92ZT^5/EK2
MN]0TS3-8\2G5=5TO2UU#XA:QI5B=2U.PTP:AJ>H7:166D:>=0FB_M#6;]SLL
MM-M%N-0NF&+6VFD"BO$?$G[5'P.\)_M >"_V6=?\4^)+?X]?$?1#XE\%>"+#
MX2_%W6[+6O#\<D%M?>(5\?:'X(U/X<:?HNAW=UI5GXFU34O%5GIGAJ^UC1+'
M7[C2]0US2K2]]!2HJE3A5Y7:C@FD]DU@*3U=FK)7>MU?ILUS*,Y3DHIQO5S"
M<K7;:^N.KRI+6]JJBWK\+>S/35^&?PP33?!^C#X8?#?^QOAWJ5CK/P\T9OA]
MX.;1_A[K&EW(O--U;P%I9T4V'@K5-.NU%U8:CX7M])O;*Z!N;6XAGS)3)_A;
M\*[RRU/3;OX5?"N[TS6_&"_$36]-N_AOX(N-/UOXAH(%3XA:U8SZ#+::KX]1
M+:V1?&E_#<>)E2&)!JFU% \N^'_[7'[-'Q1\0^,O#?@/XR^%=7NO /BNV\"Z
M]K]_'K/A7X?:AXWN?$>H^$HO"7@+XJ^,=*T+X9_%#Q!9^,-#U3PAK6D_#;Q1
MXQN]+\4:?<:!?6MIJ$<D,W":%^W_ /LC>(O!/Q=^)6G?%AHO GP)TKPAJ_Q1
M\27G@OQQY6@6?Q#\<>+OAI\/K73;"'P_<:SXJUWQGXT\':MI'AGP]X8T?7=<
M\0P:AX5U/2=.N+7Q?X<EO8=7!]J$GI?G:=D]%LHVO9)>5M+E^SJI:0KM._V9
M=-^G3K_PY],:O\/?AWXATYM'\0_#KX=>(-'DN;*\?2=?\!^$-<TIKO3-9NO$
M>FW;:;JFBW5C]IT_Q'?:AK]C<" 2V>O:EJ6M6SQ:KJ-[>3MU?X>> =>U$:UJ
MG@KPC=^)(O#.K>#;'Q?_ ,(WH<'C;1O"FNZ;<:/K'A_P]XW@T]/%7AO2[[3;
MNYMI+31-6L8=D\Y5%:5RW!_#G]I/]GSXM>!]#^(_P]^-/PXUOP;XA\*>)/'>
MFZAJ'B;3O">I1^#?!7B;6O!7C3Q'KWA?QE+X<\8>&-$\$^,?#_B+PGXUU+Q1
MX?T&V\+>)- U?1=;:SO; Q-U5S\7O@]:6>JW]Y\8O@[9V&B66@:CK6H7GQ5^
M'UK8Z38^*[)=7\):CK%W<>)?LND67BK2"=5\*WE_+;V_B+11+J.C/?6[I.!3
MP<U?_9DKZI-6;C?5J75:[KILQ<M9-6IUUUTAY]'T^5B;3OA7\,]-\%^!/AU#
MX \'7?@3X8Z3X8T7X=>%==\.:1XETGP7I_@WPU_PAWAB/P_;^(+/45TR[TCP
MH9= M]2L_)U$Z3=7ME+=/!>W2S:LW@7P+<:]H_BNY\#>![CQ7X<N-;O/#OBR
M?P;X:E\5>'[SQ*2WB6]T+Q,^F-KVCWOB-V\SQ!>:;J-M<ZU+^\U.6Z=I&?D=
M)^._P+US6_$GAK1?C5\(]2\0^$/'^F_";Q/HEM\2/"!U32?BCK>@6GBS1_AY
M/:R:K ]QXXU3P]?6NM:=X5T@:IK%U&\MG'%++97J6V!\1?VEO@A\+_#/A[Q7
MKWCS3_$&E>+?BCI/P8\+VWPLM+SXS:]K_P 4M6TO7=>D\%:'X6^%D/BCQ#K/
MB#1_"OASQ)XP\0Z)I>G7>JZ!X3\.:OKFIVCVT+L[Y\)>_-1;5EO'ILMK?C;R
M9/+6UBH5K-[<DNNO1:67E:VNQZN?"OA-O-9O"?A)FEDDGF$GA;P\RRSR7&LW
MLD\ROII2:=[WQ'XCO7GE5Y7O?$?B&Z,AGUW5GO/,M)_9P^ .BZIX@U;3_@_\
M.4/B;3?AMI%]HMSX2T&_\%V&G?"#4_%.N?#>W\*^ +W3IO!?@L^%?$/C;Q=X
MBL;CPMH>EW4GB'7[_6KB>3462X3YK\,_\%2_V!/&.G>&M7\.?M!+J&E^+-+\
M3>)]&NI?A)\>;&*#P)X-O&TWQ+\3_$AU'X66+>$?@YI>LV]UX7F^,OBFWT'X
M:W/B_3=6\)Z5XIO_ !)I.O:;IGIWP@_;C_9<^/VN>"?#/PB^*+^+M;^(-C\7
MKOP[93>"?'OA;4(9O@;HGPC\4_$;2?$FC>-_#?A77O"^O:;X4^.OPJ\9Z+H^
MKZ)9WOBWPAXGMO$GAHZGI2W$H4IX._,I4^R3DNNK716ZZ]M^]JG646O9U;73
MT3T[=.I]1-I6CLJQMI.C&)-7F\0I =)TTP1>(;B]GU*?Q!#";8QQ:]-J-S/J
M$FMHHU5K^:6]-Y]JEEEDY>3X9?"^2Y%Y)\+?AE)>#0=6\)B]?X<^"GNQX4\0
M6<&FZ_X5%RVAF;_A&-?TZV@T[7/#V_\ L?6=/BCL=3LKJU2.)/EKX2_\%'?V
M,/CM\0/#'PP^&/QAO+_QMXUNOB-I?A;1O%WPO^+7PICUK7OA1JOAGP_\1?"N
MD7/Q>\"> H-:\8^$/$7BSPYX:U;P?HTU[XDMM?O+S0);"TUJSN+8?4 ^*OPH
M+*O_  MGX2AI;_Q)I2*OQ1\",3K'@RV2_P#&FE1G_A*'WZAX-TZ1-0\860WW
M?A>PD2]UQ+*V996?M<+*ZDZ6BV<H;?\ @+)5.JM7"MKM[K6O6VFY')\*/A)+
MI^O:1+\)/A3)I7BB7PU-XGTQ_ACX$?3O$D_@R&WM_!EQXALFT VVMW'@^WL[
M6#PG-JD5U)X;BMH4T9K)5(;3MO ?P^LVUEK+X>^ ;)O$>L:UXA\1-9>!O"=G
M_P )!X@\3:>FD>)-=UT6VD1#6M:\1Z/%'H_B'5=4%WJ&O:0BZ7J]Q>V -N<F
M#XO?!RY33Y+7XS?!VZ35](N?$.D/;?%CX=SC5?#]E-=V][KNE&+Q/(-1T.SN
M+"_@O-7LQ-I]K/8WD4]S'):7"QP^-OB]\-_ /@[QOX[U[Q1!J'ASX;6<]_X\
ME\"Z?JWQ3USPM965_<V&I3ZMX1^&5EXN\4P0:7/I^JG7)&T";^P[+1->U#41
M:VFA:M+;4OJLMO8O5Z*<+ZK?X.J>_;KV3C/FLX5K66MGYZ/3;377U*Y^"GP?
M;XBW'Q<E^&/@>Y^)%QX.?X?'Q;>>%]#OM1M/!MWJWC'6M4T/35O+":'28/$F
MK>/_ !E<>+Y-.2TG\8+KVH0^))=3MYVCK7L?A9\*M+AT:#3/A7\+=-@\.:9<
MZ-X=M].^&W@>Q@\/Z->737]YHV@P6N@0QZ-I%W?N^H76EZ<MK8W.H227]Q;R
M7DCS-4\+?%?X>>,?"O@+QMIGB>WTK0/BDBR?#I?'5EJ'PP\1>, \5Y=V\6B^
M"_B38^%/&%Q>W.GV-UK-M8-H,=W<^'!#XDM+>31;NVOIN-U']ICX%Z9XS\)^
M [CXC:!=:UXX71Y/#.HZ/=IK/@W4[?7- ^,WBBPOQX[TLW?@VSTX:5^SY\7)
M+[4[C6TL-(G\)R:;J4T%[KNE1U+>&4M503O_ #POI9O[KW>CM>]NC3=75<M6
MRNE[KVO;\3T+3_AQ\,]'T:P\-Z1\,OAMI'AS2H[N+2O#FE_#SP;IWA_3(;^]
MOM2OH=-T2ST6'3-/AO=2U/4M1O([.U@6\O\ 4;^\NO.N;VYEEHM\)_AD_CGP
MY\2D\#>';/QOX4;Q]/H>O:7IMIH\\6J?$W2/"GA[QWXAO[;38K6UUSQ7KGAG
MP7X?\-R>*M9BOM?MO#MO<Z+::C#8ZA>PS[G_  FW@@-X<!\<^!P?&5E+J7@S
M'C/PNH\::;;V(U6ZU3P8'U7/BK3[72-^IW-_H/\ :%E!IJF_FE2V'FA-&\<>
M!/$TJP^&O'O@+Q).VDW'B%(?#?CKPCKLA\-6VI7.C7?B;;IFK7Q'AVVUBSGT
M6[UV54T>TUF*72KB\COEDABJ7U6R3=&R:LO:0\MKP2V:W?7J*\]^2M]W_ *,
MGPR^&$^K3Z_/\,/AE/X@N?&&D?$2Y\07'PZ\%7&OW/Q"T'3I=)T#X@W.N2Z'
M)JESX\T72)IM,TCQI->2>)=-T^:>UL=4MX)G0Y/C?X,?"?XB^"O$'P[\8_#W
MPEJO@WQ5IT6D:[H<&A:9I,=]IT0GCAM5N=+M;2[MHX(+R_M(/LTT?DV&IZO8
M1[;36-4AN^9M?VE_V?=3\$:#\0_#GQD^'7C7P?XFT[P!K/AO4_A_XLT7QW<Z
MSH'Q/\9Z%\/O!7B33=%\,ZA>:Y=>&=9\8>(-#T.'Q!+IL%EI]Y<RC56MY[6_
MMT[^Y^)'PRM+35;ZZ^)WPRM[#1--TS5]:OYOB/X(AT[2-)UY;M]!U/6=0FUQ
M+32=*UU;&\/A_4[^:"SUN*TNY=-EN1:R[)7U5MRC[%)I.SG%[)O2R=K7OTZ;
M[)MU5M"LN]XM/7[O/=?=9E:Z^%7PGOM"M?"EY\)OA5=>$[$:$NG^$KOX:>!K
MKPMIR>%9KVY\+1V/ARXT"31;5?"T^J:G-X8$%BG_  C\FK:Q)I)LWU74#<M\
M2?"WX<>*M ?POK7@KP[_ &')K'P^\0)::-I=IX:EM]=^$_B;1?&7PTUBVO?#
MT6F7D%]X%\2>'='U'PQ-'.HT8VOV2R6&PN+FUFYCQ=^T!\'/ ?Q%\(_"CQ=\
M0/#N@>,O''@+Q7\4=&M]2U+3]/T6T^'?@K4M$T36/&?B3Q)>W]GHGAWPW?ZW
MXCT?2/#&H:EJ%H/%6J3ZA:Z)+/'I=_+:]E/\1OAO:BZ>X^)OPSM8]/\ $D'A
M#4);GXA^#+9-/\8W2PR6G@V_EDU^.*Q\67D=W:-;>&;DIK4L=S;&.UN%FCEF
M+89-Z4%HK^\MEL[VZ);IWTM?2PG*K*S:JNSTT>[U?XN_J:;^$/!LD4L#^"_!
M1MIX1;SVH\'^&1:RVBZ1=>'X[*: :6(YK*'P]?7N@06DJO;PZ#>WFB)&NE7=
MS9RTM=\ > O%!LW\2^!/!'B.;3?$MKXSTNXU[P?X9UB[TCQI865KIMAXTT>\
MU+2KJYTCQGINF6-CIVF>+-.EMO$.GV5CIUI::E#!8620<CXS^//P5\ Z)X>\
M1>+/BO\ #W2])\9Q>)I/ =TGB_0M1_X6#/X-\,ZWXT\2:5\/$TZ\N?\ A-]:
MTOPOX>US6&TCPW/>7TD=G+!&)+R6WMEW_"GQ2^&GCK0O!'B+PE\0O NNZ/\
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M &%/"G_J7:!775R/C;_D7KK_ +"GA3_U+M KHPW^\T/\?_MU,FI_!K?X(?\
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MDM;G4;CQ7I)USX6ZVGQ&\<GQ]:W+WOA=DOM'L/%4T4VEZ#)9^F_ 7X!?LK?
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M5JGC;XX>,_".I?'+XN_'/Q1:VWPO^'?PFM+32?A[\8OBIJ_Q&U'PCXNU76?
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M$U'P.GAV>T\0W6F>(O$VE>)XO$CWXN/#M!_X)E?M#Z->>";Z;]I6ZFO%U?\
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M*^B>"=(UO7?B+^R+XCU=M+\+#4]+L=0T&_\ "/P2^/GAW3_"OC.V\6Q^&?\
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MICG-%^E].U_TN/TV>_9^O<6BF[A^C$=.0@)<CGD*%8L1D #W&5# G R2 3@
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M/P?JVI+I,7C#P+X/MM<\0>*HK+Q+HU]H>E^K_M#_ +5W[4OPN^*?Q=T3X<?
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MNBUO;DUT>M[7LE=FEL.W?ZG7BW9\O9]5>^ST]+GR_P#M/_\ !8G6_A_^S/\
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ML^&KG]G_ .Q_#'P3H-WXCUSP;\#;>YT_3?AMX4UO1-8T:;1-:\.?#*6U\0^
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M!8>%K@?#R,M\2O[0^ /C^U^(.E6NCQ^+-%TCP=<3ZY)-I^@7J:)ZK\+/C?\
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MA?I?AO\ :!L-:U/0-6M+_P"%'Q6^$U]=#P_?>)]6FL/M?XE?M*_LB?LU^/\
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M//CGP7J]_IWBN?6&\0^&=,^.T<NG^-[+0K/P1J>DP6EFDT6LZ7+=2>?^!O\
M@KW\'?'D'AW5=#^&'Q3OO#&M^/D\$>-O&?A[Q7\*/$GA?P5!J?C_ . ?PU\)
M>+DDM_&5KJWQ-\.>+=>_::^$\MA;^ -&UK5['2KKQ-+)!,NBV \1^QZG^UG^
MRC\#OBW\4_@IKGA;0/@MI_[/.@^ GO?&UE\/-/TCP8FI?$SP#JWC&_T+P/HW
M@/PQ=:C!H/@+X/>![;Q)\3_B!;VFF>"O#7A.RL[/4KY-&T:.]M=ZU^/_ .QI
MX.\/>%M8\%Z!X1D\+>(_VD[?]FGPY=_"_P#9^?\ L1/CTFI'5Q;VLFC>"=-M
M_P"RM&\2>#+&YU/XF:/%=^&;/Q3X:TYH]=@U7PZ^I:5I"=1*2>)H2<5SMV>B
M=FK7@^;6,FGHU9Z>\DIG&%TXX6M%/1+F;N]5?22L]M-6N^AXY\)/^"D%Q\4/
MAE\4?BLOP<\37VF6?[4_[.7[-_P=^&/ASQ_\*M7\9^);K]I3X2?L_P#CGP1K
M7C+Q1!\0=8^&&C746M_&C^U]=MI]>_MSPQX8L_[(N]#U#Q;#MU3$T/\ X*Y?
M"#7M$TWQ>?A-\<-"\$:UXPU7PSHOCCQ5<^"-!\,ZO#:>'M9UO1DTN^NO$):;
MQIXNUG2]2\&:-\.;JWT^_M_%)M]+D\017&K:;8WW<_"#]N?_ ()^:Q\-/AKX
MD\/>(OA3\'M.^)WC;PG'IGPXU3P'IO@?5=$^+OB"S^'6L>'+CQ%HNB>%=/T*
MTUP2?$GX8#1/BI;SKX;U34?$?A<>'/&3F>RDK4\9?'+_ ()\:=XV^+_PG^(>
M@_#OP9XL\'^/O'G@?X@WFO\ P'G\*23>+;KX$^&_BA\5/&>B?$C0_!'-IIOP
M?^(6F7'CKXOV_B+2KG1[6Y:VU758D?1KS4$I5&E)8J@TUS6VY4M6V^75);NR
M=UVT#W;-?5:Z:O>\[)K3N^FMK7[6OJ>2Z=_P6!^#$\3OJ7PH^+&DW>@:UX0T
M_P"(EI9^,_@CXL?P9:_$J[^&$?PUU7PSJ/A;XD:OI_QJDUN[^-/@H>-+#X73
MZ]JWP?63Q:/&IBNO#UO_ &W/J/\ P5D\%1>'[N\U+X3_ !,^&GB23PMXOUV)
MOB1XG^&NIZ3IFIZ7^SEX,_:F^'FA"^\&^/\ 4D\8^+O'WP?\9Z5XFMO"6D:]
MI-UI5GHOCBSGUK4Y/#%Q-==I'^U1_P $UOAG\)_ 'BWPT/A7+\// ?@SXT>(
M?A%9>!?@6VNZGI=E\(X?&%G\=- ^&^GIX'@ETKXF:/9^$/'4WQ \&V=]I7C[
M6=/T37=:\2V=U81W=]-VC_M4_P#!/N]^(:>"M1\0_!N'XCZ?=P^#IH/$?P:N
MM/O/#K:W8>'?!,V@ZEXIUSX;Q:+X:TY;'6_ WPV\36]]KUGI^BW&M^$/AWKL
MD<M_HFGF5-W_ -]PWW[WM=7Y'I=/3KU>I-J2?^[5UO\ :=[^E_O=_D>4VO\
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M\<:+XOO]2TK7O@S8? ?P)XG\-^*/$D]I:?"71](T;0K,Q6/BJ72]5[#X2?\
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M;>'-%\6^)O#OPH\03: NKV=IX(\%ZGXUTZ\A\5>++>ST71_%&I^!/ -]XZU
M)X$\&?8_*6_X)??L^?$3QI\0?'5YX[O_ (AV.K_$KXN7UQX:'A/X5Z]HWAS6
M_%_C'XU>+?B5X-\7W\/AB^O_ (@:[X1^(7QM\177A^^\>MJ/B3X6Z5H&E^"]
M/CM+.ZUQ=4]M\1_L$?#OQ5XV^#/B_7M;U76[+X5_"S]G+X5:AX:\2>"_ _B6
MP^)FE_LL>.]1\:?#76O$^JZSH.H:OIMX^L^(/$$/C73]%DGTK6TO]&FQ;77A
MO1[U[C3KR3<<-A6^9S356+?VK1MO)-O;2R3>RT&Z:3YL16MI>RM=-J_IY/KY
M%=/V'/V0]2\'V?P/A7Q#<Q>'XO"'BJ]L-*^/WC!?BC+X5_X4E8_LT:)%XAUW
M1/$L/C>Y^''BOX%Z#'\,#97C6.A>)=!DU8VEZNLZE?7Y^L/%5E9:;X1CTS3+
M&QTO3-,F\#Z;I>EZ9:6]AIFE:9I_B3PU9Z=I>FV-F%M+33]-LH(+*RMK55MX
M+:"*.%5C50/C#]E[_@G+\+OV4/B#9_$GPCXI\7>+-2TSX8:!\--.E\<:7ILU
M_I%M8_#GX/\ POU'4].UW3KJSM[#3?$GAGX(^";G4?"W]C"RMM8MKBYTG4(=
M*BL+"'[6\:?\B[<X)(_M3PI@GJ1_PEV@8)^9N2.N&(STXKT<NI..(HU)4X4Y
M.:@^3712IM+T7X[Z')BJC=*M#VDZD%",TY]&ZD5UOK;<V?%&C:1XCT'Q)X<\
M0Q)/X?\ $6B:[X?U^WDNFL([C0M<TR\TK68)+Y&1K%)M-N[J)[T21_9%8W!E
MB$9D3XRTC]GG]AO_ (1MH-#UKP#>^%/!$.G>.-0N['X]V^I:5X<TW1OCA!\8
M+3Q3KVIV_C.[L]/T*#XU>$S>B_UFYL],;4M&N?#-S>2JFH6$'V#XY\+6OCGP
M?XV\#7\]S:V'CGPIXJ\%7]U9);R7MK8^+]#U'PY>75G'=I):O>6UMJ<LUJES
M%+;M<1QB:*6(M&WY=WG_  2<_9BU[3/'7@[P5XONO">LVWB7PE+XC'P\\-_#
M;3+GPUXLT:#]CWXC>!-%\9Z+X=TO1Y;_ $V*R_9:^'/C&V\%>(KF!=9T#XF^
M)=4L[K3TU+PW>V_+BE+F@U&DTXI7J2M+:GLKIM+RW;6J6^F'<.2TIUH62=J<
M.:/PJUWT=U]RTOT]CM?@!^PQXRU?Q7\.M/U--*\6>%/$?A[P7Y%A\:/%/@KQ
MGI_C#X??!3]D#QOX7UOX9ZROB?3=8U#5? _PF^ _[*_C>T\<>!UU*+1'\++X
MGO+U-0O?%"33Z7^QU^PE<>%/ OAG1+K0[G1[JYNM-^&&KZ;^T-JM[X@U#Q/X
M$\*>"O!-SJO@;QA'XTN];U[XA> ])^$OA*[O=6T>ZU/Q#X=\1>%9?$NL^5J-
MY>W6H>1:Y_P20^&>LW7ARQT[XN_%7POX0\*>(O"WBP_#CPWX>\)P^&/[6\(?
M![X5_!3P\;>.]T^XU[3;2TT/X7:89+:^O=:*2^(=:T*TCLF\N[N-/4O^"2GP
M6OM6O[O0_%OBSPKH'B"7P1;:QX2\->!OAA:V$=O\/=-^#C^%[?P#>0^%X-0^
M$^IW'B?X*Z)XK\7^(O!#V&H>-QJ^IZ7K"+;VVCW>CX^QJ;QHT'MK=)6=G=/F
MVU;4K*R=TM+O5--76(JI/5)Q?-UWU\E_P=CT;3OV;?V"=*TV]OK'Q?X1FT+P
MSI$^J^)[N;]II=3TJ*Y;2/CI\)O$OQ6\=75UX[N+<^._%J_M(?&?P_X]^).O
M:E'J/B_QGXM$FNZB/$FCZ,EEVGAK]D_]D7X8^*[ :+;Z1X:USQ3XNU'XP^&?
M"-S\6)+*WU#Q)9>%?&VD>+?&O@;P]-K-IK%_9:CHOQ,\8:SXOGTR:_T$7>NW
M'B>>;3+NULIC\OQ_\$Q?V:M.L;[2/AG\8I/A1XB>TLO@'J&O?#KPY\&M UFY
MUZR^&/[(WA>\^&NKPV&E6=Q>^)-5\)?LE>&/$VH?#_[39>(;8^.?&^OZ1'IJ
M'3[NU]1\;?\ !-3P=XU\,?LO^!KOXR?%W1O!G[*'P$\&? KP_P"';#2O"0A\
M66G@WX>7/PQ\.>/_ !+++I<$VE^,KGPSJ-WYT%K'=:#.+A(]!L=&W7\NK3[*
MIRM^QPKM9NU5.UW%6:5[WYM?Y5:3NFD.+2LY8BJUV46WUV5^_GW/*[;]B[_@
MGE\%=2^#WC6P^(U]8_#F[U*V^"_@7X<Z/\>M;\4^%?B]\3_$/Q4^$*^&UUL>
M'?$5Q>_%:7P'XG^'7PVT>'PE>IJWAWPA>:2?%_B-;+47UB]U+URX_8<_8*T?
M0O&'P76^T[PSX>\;W/PX^&WB_P"&MC\?CHEQK&KZ;H>B6GA+PC<:9)XB;Q5:
M^+O'FB^#=)OYM-AOQXC\73Z,WB?1K1-72;6(?&G_ .">7[(_@SXH?#K7-)_:
M \&_#W4? ][X%\4VGPW/_#.UC97.B_L]>(?A%JT<GA72M3L-.UOX7V.G>+/@
M-&_Q8\5_#R/1+W5X+S6?#7B>XT]?#^G3Z7Z%\4?^";/@SXO^.?B;KB?M!?$S
MPII7CK]H#P7\9?&'PO\  6C?#MO"EMXS\%>5JMQI6H6TL%WK2^*/$]_-X<UG
MQ-K!OM+>\_L[P_<WOAV2^U6;6M2F,):WIT&]-(RYM;*_6.W?773>)4IP:7+6
MKK>]X<NGK?77\#V+XO? S]C3XZZYXP\1_$7Q9X5NO$'C>76=2\<:GX;_ &AU
M\'W.O>'_ (=?#F;X6?$WPWJTGACQOI\G_"N(OAIK1\+_ !J\-#;HDVCW$%_X
MRNM+OK+2KZ/J=2^'W[*Z^"OAY\+5\:^#_#'AWPOX^\-?&_X8:9X?^.6D^%]>
ML/%.L>-K[Q)X=UKPQJ%EXMT[5;SPEXKU_P ?:CHMAH5H]_X6\4:%XV?P?IL,
M]CK5O&?FS4O^"6/PGAMDTWPYXYU;PE;OX)^&/AO5K4_"WX/^(#K/B7X,_'SQ
MS^TC\./'LK>(O"MY]G,_Q%^)6N6_Q<\,6\#^%_C?X8BM=*\;1+<-K#:EB-_P
M2(_9PNM(\7V&L:KJ&NZQXUT7QMIFH^+M1^'OPK.NZ->>/O@CXS^#&J:AX0(\
M+21>&+30V\=Z]X]\%>%M):UT3P;XAFMM+T:X;3;.9;O2-"NU>.%I6>GR3T2T
MLK)NUMKM+J1*<'RVQ571MZIWZ?WO0]\\._L9?L=7WB31/&O@?1;2[\2?"'6/
M#?AA-9\&?$^\U^Z\/W7PK\&?#WP79_#7Q/\ 9]2UF.&.Q\'_  [\ 6VM>#M9
ML+'6I+G2DU:^2WN-5O\ ^T/*-.UG_@GI^T%\8_B3:7>M:YK'C_X[#XN_";QI
MX4^(TOQ@^&W@GQ?X@_X0/X8_ #XT>$/#OA?X@V/ACPVOQ*U/P5H7PO\ !/B/
M3?"3Q^(M2E\.Z+-96G]JVL\]U[7^SY^R&O[//Q ^+GQ"TOXW?$;Q[J'QL\6:
M+XC\=V7C+0_!1BOM.\*:1X^TWPAX<M;[2]/M;NQCT&;Q[+>OJ>G1Z?\ VO%H
M&C:-/9VFFC4+?4.3^(/_  3Z^$_Q)'B7_A)?$GB.[E\0>./VB/B#9W5UH?A'
M5+KPAXD_:-^)'PF^)?B#4O"%WJFESW&BZIX1U+X1:/HWA+6K1+75X=(UW7)[
MN^EO(8'H=*JFE##4XN]I7NTWM\-M$[M/7K?=V0YTI/WJU5];J35GO9_]O)>N
MUCS/XJ_LM?\ !/#X<^#;WX[?%34+[4_#?P7\+^)_@+J?BX_&3Q'XFN](N?BE
M'\0?@_<^#M0M?"NK!YOBE=_\-*>+/!>AZ=#!9>*-*O?%FG-<0&_T?2-:T_TF
MW^"7["GB'1IKSQ#J_AZ_A\<1Q:GKMA\5/C)>Z9XH\5KJWQ9\"_$">X\7Z#XT
M\1Z7KMU+XG^*GP5\*ZA<-?Z8D7B8^'=0LH3=:5KVI17%+X7_ /!.GX0_"SX/
M?$?X,:;XBUW6]$^(_P 2/@UX_P!3\1ZQHNBW7BQK?X$_$;PK\0?A]X?URXO9
M]3TSQ9-IZ>%+3PK/XJFL-$U%M%N9YK;3+34+6UF'*:7_ ,$P?A!H$_AW4=!\
M;^(]*\4>'_BGX#^)</CZ#P=X F\?1V/@?3_&.BW/P_TCQ4VD6UUHOA/QIH/C
MWQ3X=\5Z?=6NN:1J7AK7=<TAM&,FH1ZA:OV%=6_V*@[..\'M>S=G9W35]]=-
M[W3]I#7]_4_'?^M#I?AM\#OV"]/\(?"_7O FOZ/XD^'6N_#.+6/AKX^E^*NH
MZWX N?A-\-/B9\&_BI8HGCYM6MO#:Z+X=\>^%/A3/9Q^*=2&M7]K8ZGHFHW]
MS-/XBCKHI?V;_P!B>_\ !GP*\-W?C+1;WP9\ [*3X3_#&>;]IR98+SP5K.I?
M#OQA!^S_ .-/$$7C'R_B7\-KIO!7PDU&Q^&'BZ_UJ)-$\*> 4LM/N],.[5<K
M_AWO\,[WX5_LZ?"3Q#XPUOQ#X:_9I^'E[\*O"R77@[P#9VWB[P.?BE\ /B7H
M]AXVT"WTJ?0M0U"PB_9O\$^%M:U6*UB;QC#J_B+Q3K=G%K]W$MIXW=_\$>OV
M8;OPJG@Q[R]/AZ/PCK_AF+2V\ ?"HZ0-2\0Z%XJ\.7OC4Z*?"<FG1>+$TOQ9
M?6\>I^6\LMI;V6F2S"U25KA3H8B]E@\.K*]]8^]=*[T=[66G3OM8]I27Q8JK
M'M9-W[]N_GN^]G]6:K\ /V5?&OPS^#G@W4=0T+7_ (1_"'6[3X@^ -(M_BY'
M<^#M6O;^;7?$^DZUXEU"W\1,GC329)CXFUG2Y+_4OLT^FGQ);V]ZOA]_%,$W
MC?A+]AW]A71)/A5-X>\2ZWJL^G+J_C3P!->_M:^-/$S?$G0/"DOP:OYI]5>[
M\?23?%CP#\,K_P#9X^".I:7#?-JOAKX?7'@'3]06;27?74U+@_B#_P $F_A#
MX^;XEZ7%\5_'WA7P%\6-5\?:]XJ^'.B^#OAE+X?&K>-I_P!J"+2_[(FNO#\E
MWI6@>#/#W[5_Q!\/V7A6V2/2M5BTKPS>ZG"^W5;*?2\6_P#!*;X)^)?%WQ#\
M26GCCQ;X7T;XFCQY/KG@[0?!_P .$LM NO%5S^T3=^'8_AYJTNBKJ7@'0_!T
MG[3/Q"^W^%M!E72/B+);^'!XI5PGB-]=GZO5>LL'2O\ XG+JK6]WU?;3?5#4
MJ5KQQ=7[K='?:279?/L='X>_8Y_X)Z:1I'CS6M#\0>$;K0]4^%GB[P5\9O$C
M?M&V>H:=XE^'?Q-O_B?I&I^(/BEK\/B5[?3]0N=5^)'Q.TWPIXYAN/"LUCJ.
MK:C9Z==OJ6A:?;Z?V]]\&_V0(/'?Q!^"WB#QAK7B/XO?M'^"?A[KWB]==^-O
MB#6_BC<:+\ ?$'AG5O@UXNLO&%KXAM]:\%>-/"_CKQEH'B_X7>,I9],\9>)/
M$EQI%SH>J7^F^';&STORF\_X)5? BSU+0->\!:S_ ,*W\0>%/%6N>,M!FT'X
M4?"&^\+S:YJVH?":[L8_%_@B\\-Q:#X\T+PNGPDM(O#.B:\B0:/=^(KSQ%I+
MZ/JVG:=+;<EX5_X)$_"CX?WF@WWP_P#C-\2?#%WX$U/PGXH^&6HW/@WX4>(M
M>\(^./"GBC]GCQE:^(==\1W?A6PUWXC:&==_9O\ "$6E?#WQ%=P^&?"VA:QX
MAT#PPFD6,/AY]"KZOB$ER86DNKOS-M;\O97:7>S=[7#VE!M)XNJY)I*RM9Z+
M^;7\+VZ=/4-4^#/[&'B#X2?M3_L]^$/BC9_#=?B'X7/P%^+_ (PO/B=+-XXN
M+WP?X.N/VFM3\4>'=:\;:Z)O%_BG3/"_[2.I_%/QG\2/#MWJ,\.H^.KO6M2U
M*+4_#J0Z=CZ5^QI_P3@\8^5\2M%\1:-XC.O_  1\;WDWC=_VH]<UF]U[X5_'
MB[^)$7BOXTZ]XBO_ !L^K7&H^.=6^*_CR8_&#4+FT^U>)=:M[FVOCK>E6267
M,Z1_P2:^&.DM\*[0?'3XQ7?AGX9_$?P;\3[KPE>:1\/3IOC;Q'X)^%?P+^$V
MFMK,MEH-@U@ESH?P-M9]02P@ELB_C;Q5::?IEI:M8SV5>R_X)'?!X6UW8>(/
MB?XJ\4:5?>&/"&@7FFW7PU^$>DQ7MYX3\%? /X937E_-IWASS[_PEKWP\_9P
M\ Z/>?"^\GF\%V?B'5/%OCNSL&U?4+&STM_5ZJ;?U6G'5*Z3ZKU5WHM;K:UM
M!2E"VF)J=-]5]UWW]/O/<KS]CS]B:]'B'XF7<^G267B;P3\0;KQ]XZG^-@?1
MO&_@;XGZS\2M8\5^*_&WBB;Q#+93Z=-XG^(OQ*O-(\7IJFG6&FZKJUY'::BR
M6%E9Z<WQK^RA^Q1XZD^(ECKOB>TL(/B-X>UKQK\5]"T3]I"?0=+\8^"?''Q'
MC^+EWXM\:Z#!XIDM+SP1<>-_$LNJ>'O%1CLK+0H?%B6/AW5++^V+&:TRO"7[
M!VF>&]'_ &U=!TCQYJ'P]M/VH?B@^M?#:]^']KI]W=? 'X1PZYIWQ*7X;^%+
M/Q%HL.EQ6GB+X]>)OCM\5-=T*UL8]+T>V^+]YX?\,:W9W>BZ?XAM_CJ[_P""
M,UM9:-XET;PY\9],F@T3PG\(_!WP7G\5?#/P/JFI6T7@OP!\*_AUXK\2?%[7
M&\+7&L>-8Y]!\%^)(_"OPA-Y<_"A[V[\)Z_K=DFIZ.1;Q[*OHXX.#>FFONVL
M[:75M-E9>[=:-!&4+N^*F]='JK[ZN[O=^=WKJWJS[W^)WP$_89^*7Q/\+?'[
MXHM\'M:^(GA#PU\&O$_AGQAJ?Q9T2SM++PIX'^(UKXN^$/B'8?%-OI&H^'=8
M\;>)+'3K3Q/>PKI?C_3]5T[PC<ZCK^G7%MI%[ES_ +&G[%N@:*WAJ^>WTKPS
MJ^@Q?#.VT'6?CSJ\&B2K??"KQ'^R==0Z3;:CXMLD/C7Q!\-]4UKX7:MJ%E*O
MB35M9L;5=K>)M&N)T\:E_P""3WP6C\$ZEX;TOQYK5EXGU7QW#\0;_P"(%W\)
M_@KK<UQJMWX1_:!\&^*-#'@34_"DW@R/P!JEM^TQ\3==\%^!4M6\/?"?7XO!
M]]X*TVV7PW'%=8.N_P#!'/\ 9QU;4%OH/%_Q ^R6'C?P[XBT'PUXGBT;QAX6
MT?PEI?PVU_P-XI^',FG3'2;O6="^(GB;Q=XW^-'B/5;_ %*37H_B_P".O$VO
M++=V&H7>B7UNG7;3>#A&WJ^E]E'2]WI>Z>K>P.I16CQE5/JK;7V2?,NFM]NG
M<]D^+?AK]@C4_BS\<?C/\1KK2KOXH? OPQ\$;C]H;Q%H'BWQ+,=!\%/XVN/^
M%2^!/B;IGA:]?2=9T*R^('PK_P"$@O?AUX@CN3X<\0Z&OBK6=(TDZW=WFIZ_
MP\_8<_8K\/:#8V/@E9_$NAWMB-#T34[O]H/Q5\0K<:$^@?!&XT/PUX7UZ^\8
MZQ+'X8T+P;^S?\&!X2TC2L6VC^"/!IGL;:*UUS6;V\XK0?\ @F=\,_#_ ,.O
MVK_AE!\2O%EUH/[5?AOPEX-U6\NO WPI_MCP7X?\#?%'XL_%C03=7*>%4M_C
M'KUSXB^,OB:S\2>*/B_:^(=4\4:+IFBV.L+-)'J%S>:GP _8!\/? ;]IZQ^/
M=AXJA\1:+9_#?Q0-1\.3Z%I7A^#Q9^T7\1OBQ\0O%GC/XW7G@SP[IMCX)\'?
MV'\*_&U[\%/!.F^&9)IE\%Z_K&DZFK1^'=)O=<'1Q$DI2P<&W=)+W;/HVW^7
M:S>VHY0:?^U5+7\]5Z+?H]^MNIP7PF^"_P#P3Q\<^,O@9IGP ^(_@W6K']FW
MQY8_ME?#KPMH'C;2/$GAFYL?'/@#XF?#WP=?>"]8O-2:&;X8^"_[*U_Q#-HO
MA^;Q!9>#]?\ "'AR?Q#/IL>CZ+*>B^.G[-_[!WB]_#]]\3)_B!XNT+]HSXIZ
MYXP\#>%/AO\ $KXP^.?A_P"+?B#XF\-:C<_$3Q'X"\%_"^X\3^&=&TWQSH5S
MJ>M_$SQ3I=KI6C&5;[Q--J&F7-[JTNH<7<?\$A/@+JOP]O/AYK_CWQG>0W?P
MTTCX/6?BW1?"WPX\'>,]$^&^A_#_ /:5^&FE>'=*UW0?#(FLT&@?M,:Y?>(5
M6W.F^*-;\&Z'?:UI=W;:WK]E-]$>'?V$O@[IWA/]G#PCXD0>+=+_ &;_ (D?
M$7XNZ-IZZ+'X>T7Q9\1?B:GB>35_$>KZ7:ZQJ-UHTNEZSXIO/$]A;V&JW$5Q
MK@=[R.6TFNTD%AZZC)2PU+?F3DF]M$M+;MOM:[\@=6"::K5-%RO5ZZ[[+33;
M4^<K[5?^"7FHZ#KOQ_D^)FJ>!K+X#)X5GU7XCZ?XU^-?PP\1^'/"GQ9^,GQ;
MLM O=*9H]"UOQ+\+OC#\6?CA\7/"%UJ_ARQU_P )^*!J-QH3ZY:1>#[6Y\-^
MZVW[,/[+/P/2U\(^%/&WBCX 7OA?1M)N]'\46WQ4N_"O_"-?"[7OB1\-]>U;
MX:>&?&?B6]M="T[PWXTN/@EH_@6?2UU34_%MEX+F\46>AWD;ZX+FO+V_X):?
M#;7['P;H_P 3?CA\;OB%HW@/PW:> _#VFV<WA?X:0Q_#O1K7XKKX=\)7=WX"
MT^PUBZ?3M;^+6M>+-5\1SWTVH^(M7T'P=IM[:6ND:;>1W7?^./\ @G?\+_B9
M)\%YOB)XU\5^.I_@M\(-#^$.GOXM\/\ @;Q!!XO@\/\ PF^._P )](\8>*;3
M5M&N[?\ X2RSM?C[K?BF/4K..!;?Q3X7\/:U';0.=1L[R(4*DG)O#4H-.R<8
MN,6M7=K9OK\TE=JX3JTM%]8J>>NVU]+_ '=TDW;HOQF^'W[!_AK]H.]\??%R
M\L?"GQRUWP1X]^/7B22;7?%MO:Z_\*?AQX9^%7@GQ[-KUG;66H^&G\&Z)I7@
MKX96\'AFTEL=3O-0CN-2T*S8ZMXE2Y^6+/X6_P#!']6\+:7KOB#4=0U74=.\
M7Z+I^L_%+QW\>CXG\&V&F>&[SX4^,OA_XR\6^+I+/6OA8;_X;?LM^*/@M>?#
M/QA=>'+_ ,3?#7X?^-_!JZ)KFCWFM-J7W/\ $']D>T^(%]\'$O?B=J2>#_A%
M\"_B5\!'^'_B#X;^!/'/AOXA^'?BGX'\)>"O$FL^.CKRK>75XD'@;POJ"Z38
M&WTZ\N=/O$EC6#5I39?'NJ_\$9?@1KA\+MJGQ7^++'1M!^+NG:W=6D'A-->U
MK5OCKJ/Q>UCXIZCHOB6]TJ[U7P9X>\;W'Q@U#2?%_@6UDU[2O%'AKP;X%T;4
M=3A.GZKJ6IU*A7<V_J\&KI)I:-62T5K+1+:^NE]V.$Z:BO\ ::C?_!?F>P6G
MP_\ V&/!7A/X&W>I1^/;*T^-OQ"\"?"CX.0^/)_BAX?\<^.O%OA'3?C'XN\%
M6A\->)-,\)^)(],T'PWXG^*WB"?Q#K.@6.E)X3GT^^U35;U+?27GJWG[$/[#
M5]_PCGBWX=>,[CP1XSLO /B"Y^%?C[X4_M W.K>)-(TGPIX.\2^#=0^(?PVM
M8O$^LPZ_KGP_\+WOBFRT[Q'H>G:BNE:V)=4UR*7Q!H^@7FE[]Y_P3>^$FM?L
M_P#AO]GGQ+XP\5:AX:T+XF?&KXI'5-&\/>!_"2V>K_'CX4?%CX2^*/#_ ($\
M*:7HL_A3X4>"?#VD_%K4=<\+^%_!NGOI]KXBT*VNKZ?4(]8U**YZ[X%?L*?#
M?X'^-/BE\3(M>D\8?$?XO?#V_P#A_P"*?$MS\//AOX+L]&MM8U[Q3KFLW?P[
M\/>#M%M+'X?V>LIXBLK'7_#FC70T?7Y?#>C:YJZW^M/?W4Z5"JTDZ%/;[2W2
M:MS-=U>ZU[6L+VD%K]8JNVMKO7T?3I]U[BZ]\%_V6?VH/%/PA^/6F>)-'U'7
M=.\:?L@_M*6)C\2P2ZUK^G?#?P5\3]>_9@M/$/A;5]336?"$6L:7\7O$/BA3
M<Z!I^N^,XM-:SU2VDALWCM/(?$7[*_["WQ*^"?Q#^#WA3QO:?#C1M)@T_P""
MP\;+\4;S3]6\'ZEX8\ >&/@WHFH^$-3\8>)((-:F/@7Q3I'A+P_XPL+R\M+[
M7M>L[_2]8N_&=I8/'A^"?^"3GPO^&VH-X@\!_&+XA:+XUT]?AM)X,^(.H^%_
M!GBGQ;X,OO =AX*T[4W!U^WN_#VOZ!XK;P/I>K#PAJ'AY++PMJ4MRVBZJT%K
M:6D_GP_X(F_L^VV@77A^Q^*/Q+DT[5M.^%FG>(M,\2:/X/\ $6C^(8/A)\%M
M<_9_\/6>IV4%KH5[#H&I?#+Q9XLTSQ%X1TO6;#PC>>)-6@\;PZ$-:L=1EUQN
MC-0O'"TN>]I<WNIK7;5ZIVNEJU=M]"G6I7L\3422NG>^O;=>;O?Y'TQXA_95
M_8(@T#XD^$?$[Z)XE^UV_BC5_BGH6K_'?7_&/Q-UW5_#'@SX^:GXLUCQ5:0^
M+KWQ[KOQ'M/"_P >?C%XDU74$2/QC]KU73M<B%O=^%] OK#4T?\ 9U_8S\-^
M'_%/C?3;B_\ %O\ PB7V:Y^)?BM_BMXL^(WC^;Q+<6_QCOC??%-K+7=7\4W?
MQ$U/3_VG?B*VLMXBL[37Y-)\1Z79C3Q9>!M!@L/+-=_X)0_L[:U>^)M5M[[5
MM"UWQ1X?\5>';GQ+I?A'X>)XBM[;Q?XQ_:5\7ZG,?$+^&8]9GGE7]ISQ!X=O
MKJZNKVYU;0O!OABTU:2\ N3+UOA7_@G-X+\.Z3^T]H^I?&CXI>+H_P!J#P!\
M//ACK-]K6E>"[6_\">#_ (7>-O'?CCPG:>&X]-L+;2]1N;.\^(FLZ0DVHV$%
MI!I-AII2R.I_VKJFOJ-*LEKAJ-UHE%WTLD[RT5TE?:[LEHVFI=2D]L34DGJW
MKOKT4GO?=OJ^F_>?![]B_P#9L^%7Q#D^(WP!U[Q-X?OM$\47FA^/M+\(?%W4
M?&'AGQ)-X;TCQC8P_"[QU;SZIKPMM(\,>(O']]\0+OP5<75I>P>,K+PC)K$D
M.B>&=!T:S_0#X9X_X3O6B!C/@[23C@]=;U8]1U/3)Y!)SN;J?EK]GOX!:5^S
MSX=\>>%M"\6:KXBTGQI\6/&GQ4TW2[[2=)T'0OA\/&5OI8N? W@71]'AD:P\
M(P:CI=WX@,%[J-PY\0^)O$$UC#IFB2Z5H6E_4_PT_P"1[UO&<?\ "':1C.,X
M_MO5L9P2,_0GZUGF=-4\ES;W.6<L$G+71/GPFRU=K+17*PD^;,<M5W)+$S46
MWK\&.U??J<7&,:SXS))&[QKXB5\%@54W<:R'*$.,(S$D%<#J0,FOS[^,/[-/
M[3/B7]H37OC;\'_C!X-\.Z5]B^$EY8?#SQYXO^+EUH?B'5?A[YMCJ.@75MX-
ML+:T^%'@W5=)U?Q#J7B6VT-/B9;?$'Q7#X7UVXT'P'<6WB&[US]!HR/[;\8G
MH#XX\1X. QW&]@"X!!#-NP%0!M[ *%8G!_,S]ICQA_P45L_C3XZT;]G3P+KI
M^$.G?"6VD\.^(I++X->+;37?'43>#=6CM_ ^EZU9V/C/PEXIU"6;QSX O_$7
MCFX^)GA?0OM6F^/8?A9JECH^G:7XN[:EO94U)SE%4,'_  W;3^SZ"=UK%WLG
MJNGJSDI2G[6IRJ$).OF$%[5*2M[2F[7;5MM]^C6J/);K_@FC\89M!TWQ+?\
M[0FE>,?C]X5;Q8/!_P 0O&WBGX[W?AG2+35_V._A]^SKI6DV.A6_C5)-#MY_
MB+I/Q&^)>N3V&G7=Y<K\0CJ.L6_C+68]:T75J5S_ ,$\OVP+GP''X5N/VI;3
M6-5A^'OP2\)IXH;XK_'W0-=L--^&?Q-O?%'CSX+Z9?V&B:MH=QX,^-?A:>SL
MM>^..I^#;KXGZ%KMD= N?A_XB\&G3=.TWZ8^+WC[]O+3_&/@'3OA%\)[R_\
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MVMOXITS5[[2K^QT1/'O@W\,?^"F6B_&[X,>/_B$UW/I?PV\):;\!_'>D:O\
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MA:9X?\+>*O /P<\<:IX7^"WC_P ->/==MQXY\#_#;Q_JGAOPQJEOJCI^LX7
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M*H ("X#@!@H 4$#&<;1UR<Y)))8G\*_%_P#P67OO#G[)'QS_ &S=&^!DVN>
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MG3]FCX;?';]H:PT"TT==&\.Z]\3O#%AXD\"^$?"<VIZ^L=S_ ,+-T'[7\1?
MM_K6H+IGA[X;'1]6\>ZQILVHO+2>-PZ:3KRUVO26^VGNMZMI:+UL/ZGB'=QI
MQA;>TO:7W>O,VHVMW5[]=#]+_P#@1_\ '?\ "C!]3^0],^GIS].>E?D)X6_X
M*O:<+SQ]X:\:?LZ_%35?&_PX'QE\4^/].^#D.D_$'P]X \ _#OQW\=]#T&XU
M;Q9IVN:KX8\3:K<^&?V??'>J^)]5\.ZU;Z,=;&@:#H>E7FL:]+I'AR[J_P#P
M5@\ ^)I/$FG?!;X8>/\ Q)::%XG^#6FP?%CQ!X>N[OX.ZEX6^*OQL^$OA73?
M$]OJGAR:&[.C>/O@]\2H_B+\'==?4F7Q!J][H^AW&D7B6]VEX?7,.U=5I/TI
M)]M?A\[^B;U$\)B$[.27K&"\_P"O^"?K86([9 XSGC.<=<8SGC'][@<T;_4$
M#K^&#[=._7M7Y0S?\%<O@\D0OA\(/B8+%+/3_&U](OC'X,W3:?\ !S6M!\%>
M+M \?V[6OC<_\)#XUNM!\;V5S>? 30IIOC!I.IV']GW.AL^N^%M1U7DO'7_!
M7/PV/A9XL\7_  N^!?Q$D\06YUF[\%WOQ870? ?P\\3^"M"U?P-HNJ^.K74/
M$.O^%M2\4'2[WQ[INFZA\,_"$M[X\DU(W"6:ZK:Q""]/KN&_Y_-ZVM[)*[NE
M:]E9WWUTLV5]5Q%K?5XK1_O.?96^.U[>=K6N[>G[&;O]ENN.G?T^OM1G/.2.
M.F!Q[G@XR.?ISZU\$?M%_P#!0#P!^SQXZ^+'@FZ^&/Q$\=W7PK\6_"3X:W%Q
MX3U+PK-J7B3XJ_'#1= \5^"?!FB^$#>S>/)--'@KQ/8:SJGQ$;1'\)-XACO/
M!]E_:WBEGM8O-?AM_P % ]9\9>-?VA=$UWP-)X9T/X>Z'XJOOAG8CX<_%'6?
M'2ZS8Z<-5\.:5\:M)\+1^)K?P+%:69DL_&>N:A'X6\,:/J8-C<:_874]O%,+
M&X=JZE=6O=:]M+*[OKM:^XG@L0K7N[[)I)^NS_IGZ@G_ 'CZ=!U[#IR3V'4X
M('0TG/\ ?_\ '1^?TZ<^X]1G\COA_P#\%;_AOK?A_P"$-IXS^&'B:P^*7CY_
MAIH_B+P1X(\7_#OQK<6>M_$WX<?"SQOX2UKP:OA_Q-JNFZYX0\0ZG\5?"OA>
M.74O%6E2^$_$&H'1M;OM7U:"W@N]=/\ @K?\$YK>VNK;X3_&;68+/X:S>.?'
M5UX8T^PU?2_AEK\]W\1=*LOAUX]UV]BT+3?">M6OB?X8:UX"\:WOB>XT:V^&
M_P 0[NQ\+>*X6FL=<O\ P^_K='N_P_S!86LOL_?%/_VU6/U:R1_M9]L8]O<\
M]/8^]&X_W3QUYZ=1SQQR"/J".H./S&7_ (*$ZEH'PB\!?%7Q[\+8Q?\ C?\
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M]?\ %6J6_B_XC_"CPUX>\6^&M-\=_$N:;0?OS]M/]K#X[?LFZ-K/QXUCPSX
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MCZ=\%?B7=?&?Q7\/[GPQJYE^'_@^V\6:M9W%MX>.F07FD=%X3_9"_8@TO4M
MNOAI??\ "+7UC\0=1^,/PZB^%O[2/C+PX_@O7_$6M>./"'B]_A9_PB_CB&]T
M3P+X\\1_$3QIX9\6>"["]O\ P7K?B+Q%>:#IEG8WFGZ);:4N;%.^M!;Z*-/N
M[7T35]$VNMM1J--;1Q/=WE/LMO>[W[?Y=1X,^.'["&E6/C+P;X#\0_!WPC8>
M'=*\4>"O''A71?ASK/PYFT?PUIFM^$]%\0:)K&B+X#\*7D/A\>(?COX*&ER_
M9?\ A']7F^)=MK^@W6K1W6H:@.2^&/Q<_P""<<&A_L__  +^''B3X*7NB>*]
M#\,>#/V>O!^K^#O$FK/XKT;P+X+U#X*>!GTK6_B!X3NK_6!-\//"FM?#KP#X
MS\3ZW)?_ !2\):%K&C>#]?\ &6FKJP;F++]@;_@GQX5M)DM?[0T.WTM+/XCZ
MW<C]KCXK:?<S^#M1U'X=C2[7Q=J+?%2UO]:^#,VJ_"WX6/I.G^)'N/"NK:MX
M)\/:A?7FH:U>:A-KGH7@W]D3]CCX1?%/3OB-X>NI= ^+EE%K_P 1+_5O$/QZ
M\1WNK>,-*OM8U#7I_%OC70?$OB:;3O$'AKPYK>NZQJ.DZO%IUEIF@W.L7]S<
M7-PU]<R"[U+*[P]U9-N-.ZO9^]II;1/EUM=ZLEPAJ^7$==.:I:_3[77ST^1\
MYS_MN?\ !/OX;?&'XO\ QIO? ^L_#_XK? ^3XV?LV_%;X@7WA>'0(O!GPS^!
MGQ4^#GAWQIXH2SL_$?\ 8S_#/Q7KWB'P!J6E_$G0M"N/$WC3PO\ !BZ\,Z_<
MSO\ "O2?#-E](VWB[]C#PWHOP=\2^/OA+\-/@7K/Q5'C;X_?#[PM\1/@AX1T
M/QYH,%CIFC7_ (U^,_C9?!WAKQ'IGP<D?PWJO@K5O'/COXB:]X5D\/OXA\.>
M&?&VL:=XJ#^'K;E/&?[/7_!/*]^(OPXU[Q/HO@K6_B+\>-6^(G@_X>3V'C[Q
M/XFN?B?;_&#XK:A^UUXSL;C2= U[4M/U_P "ZC\2OA=K7B^SU?7],D\'^&T_
MX2#X=:1J&F:'XKU'PI>]=?\ [-7[%^KZ1X!\&7FJ65QX?^$7AOQU^S)HGAFU
M_:.\61V=Q\._C7+8+XI_9;^(MO:?$9+OQ]X%UQ?#NC67A7X/^/9M3;0K#PSH
M^C^#[33;"UN+668^VCSM/!O5<J?([ZQOO'E324M[OMKJ-PI2C!.&)BVOWC3D
MVM&U;5-^]:]FEJ[+H_'YOV^OV#=*M[+PSX<M_ >J? G5O#EE\0/%?Q!TKP9H
MWA[X0^$+7PQ#\3&N)?'O@36M$T+Q/:ZMX!TS]G**>+39O!4^M16#^ #X;M[R
M.RTYXO6OB-\9OV.['XE?!WX1?$[P5X&NC^U;X.UOQ7X#USQK\'VG\.^,M1N_
MBQ\+]#L_"GBVT\2>"YM>\.^)?B!\3?B5X/U2PE^(MIX:TR^\8VEJ^IZG%XFO
M-+M[RAX=_9 _8P.C:+<:'K.I:NWASPS9>$-$\=P?M'^+=<\1Z9H7VCXI:1I(
MD\6MXOD;4;ZQN?''Q.TJPU'5(=9O-4-OJ=A=2Z[+H"Q+HZG\)OV&_!OP^^'?
M]M>)? VC_#WX$_!G3KOP7?W_ ,>M1DMM$^"/PJ^)7@#]H8^++K6)O'@U3Q1X
M;\._$+X+>"_%VK>,+VXOH3:>&=5T:2\CT6]U?2);3K=9X;WDD[JE9.]]$H[Z
M6:5H\NM^:UDX4]$J>(:N[OFJ)]/-MV>JZW\C&F_:7_X)O:S8WDVL^-/V>DL/
MAAXONM4NX/&7PPNO#-Q\._'$]_8Z;J'B&/1O&WP[TG5?#'B+;%I6I:KXJCTV
M-[+09=#\6ZCJMIX8?2M=E\)TWQ1_P2V^!G@/]C7XD?#_ ,)^#[+X*Z-\7OC
MGP4^)/@W1/B5?:#\./B_X(^%'Q#L/B%\1?BIX9ELI_B!XK^)'A_PQX=\<^"+
MOQ_\7/#7B7QQ\-9[W6_$=YK/A[36U/5XNM\"_L*?\$R+_1].\,Z'X6T3Q=8W
MVM_'O1M'L_&?QP^)6NZIXKO?B_\ !#PI\!?C-;>'9_&'C>RUGQWH-U\$/"'A
M70M$U#2!JV@^'DT2X\8^"M2B\7R:QK]QZOXB_9R_8T\8? _P#X1\0>/+B\^$
MWPU\5^+8O"_C?3_VIO$_AJ^?Q/\ $+2=?\'^//"WB#XM^%?'6A:GXK?QCX3\
M6ZYX3\0^$-;U.[-]HVL>0;.UU*UL]4L9<*TDW?#MI-+2EOK=.T;7U6EG%IN[
M?4_<P:UQ2;:<DW432W5G=W6^MT[["S?MN?\ !/+P79WNC+\>?@5H>D_"_P ;
MOI8TG1M(U)]*\,>-K^3Q]<WFM^#[#0/"=WIFHV-I<>'_ (JW/B[XG?#ZTUCP
MCX8FT/XB/XK\7Z)]CUMJV(_CM^P9XV\*?&+5_P#A)?@?XC\#? 70KF#XPW]_
M\.Y9?#W@_P +^&_$NO>%+G,NL> [>T\4>'-)\<>!O$_A@2>!D\6:8OB3PM?Z
M#:%-3L5L*\=U_P#9A_X)N> ]"\0ZO=:SX9\$Z'\+-=\=_'=+7PQ\?=7C;X-R
MZ)H'C75/BW-X$\-Z/XKU75/#_A2\\.^/O&-WXY\"P:;JVARV?B)8K#2]*OM.
M\(+I/IOP6\"?L7_$CX>^,[KX&ZYYGACQKX>;X1^.9M#^)?C/2/%OAQ_BCX^\
M6?M!)X UNS\1ZO\ \)#\./B!K7C+]H+Q3XEM]!O;#3?$B6?C*V\%VUK<:7I-
MCH-LO:8I35Y8;X6FK4K7Y6K)J-FT]KVO9+K(3IT.1J%/$-R=[\T]4VFWK+JK
MZ)7O\F9M[^V+^Q1XE\1_&OX6_$&^\*:1-X T'P,OB/0/B#\+M:N(OB+\.-4\
M*?!KQOX.G\/>%;_P#J&H>(TTK4_V@/AUX=T_X0'3KKXEZ#XO\0V\4/P_L5U>
MQCNFI^T%_P $V?%(24^,/V9-9G\7^']*UJ.VO/A]:3ZGKV@_"U/AEINAFXT^
M\\$C6;N3X<Q_&;X::3I&BWL9UCPA=>)H?"]MIVFZAH'B?3]&'_9&_81L?#>G
M:);R:7H.F_#^Q\*2:'K&E_M)>,M'\2> ;F?PW\#_  E\._%6C^,?^%BIKWAS
MQ8^E_LS_  2_X0OQ/+JD=]=:UX/FU.TGN-0\1>*8]4S-+_8)_P"">5UXD\'^
M.M(\!^#]3\3_  TG\"V7ASQ-;?&_QKJUU9:E\./^%IZ)HDFNZ@_CN=M>UO4]
M<^+'Q%O_ (A:CXF6\U?XB^.SI&N^.5U_Q3X#\%W.AUS8A/5X9K1;4]+M_P!W
M\$K*_6P>RH_RXG[YN_E\73N_+J].IF_:B_8;\3?"K2_C%I%_X1^)7PRUCXQ?
M"OX7V6L^$/@AXL\9W,WQ/^+'B.PU[X87#^%A\/D\8'3];U/XGP_$#1_B);Z%
M)I&H67C2Y\8Z)KNHR>)YKF^M^#OC;^PEIWAO]H[XB^"_&_PWE\(VNL>!(/VC
M]7M-%\;:IH%V=0T2R^"'PJACT.\\+WMOXH^'NO:!X0'PY^&Z?"_0_$?PS\3Q
M:/JUGH)U&X76)[ZMK'PV_8M^&GPS^'O@VY\0)X*^''Q:^(7P+T#X8>+M&^,'
MC&RMM1^(G[-OP]T>+X*S>'_BQ9>)F@\/W/AKP'^SQI=K]MN=<L])\5WOAFZT
MWQ,FKZ]XEGLK_1\(_LR?L=_"[2/B'X%\.R:7I>EZIXG^"FF>,]"USX\^)M:O
M/!<OPQ\:WWQ$_9Y^%&C-XN\<WNJ?"WP3X0\8ZSXAU7X7_"+3!HFD"'7O$-BF
MC7]G>)9VT\U=2BY/"^ZM6HTFUS75[<MKZ726EU:5D-TZ-I*,<4KO1.4^FVO-
MZ^=G=:V//-'_ &O/^"8>G:'X>\9:-\2?V>?#&D>$-2M?ASX:U9_A7K/@VZ\(
M3^/K?7KN72M,T_4OA?IFO>&?"6J+H?BY?%/B**PM/ FAZAH?BZQ\6ZY8:QHV
ML6EE'IO[6_[#^H_%WQ7X.T+PUX+U&7X0>#/"6E:E\2M)^%UN=*TG0="_X6KX
MDL/ _@73H?",?COQKI/P]O/@5>W.F-\)-%\6>%K74;K1;CP5+/?:-KG]C8GB
MSX+?\$W#\,4_:LU+Q-HT7PV^'MC?>+=/^-GA7XW>-]0MH-,^&UY\:/$OB#2-
M!U'3/$>J2^*/M-Y\1_B];Z]X&TFRU;Q#XMDGM-*@TVXUG0?#B6]M/V.?^">W
MB#2?&%U/-J]KIFM:7=3ZA'XC_:3^,?ARY\"^$O!?B_XA:196?@C2?%GQ L;G
MX7_#/PCXU\<?$*R\.:=HUCI'@/[;K=Y;"TU[2Y[6TF=ZZ;][#O2Z]VDGJFU:
MT?P=EHEU;*Y:.EZ6(>VO-/INM9?*_P#D<[<_M,_\$I)?$-MX\UC6?@[H#?!7
MQ'I7B;PQXZUCX0^+O#/P_@\5?'[P#H'Q9G^('A&YD\"Q>$_$FO?\(;X0TC7/
M'GQ&N=*;Q#\*8O#D\7BO6_"]I;W]VGL?Q5^-G_!/7X/>,?$?P[^+=]\"_#7C
M#PQ!!\;O%7A_4/@WJ/B8:9>:U=:'I=OXZO\ 4/"GPUU[08_&FOGQCX4@M8!?
MR^.M3M?$_AZ\@TV6SUO2);CD'_8?_8(TI+*R@O'\/GX:0?#>T1+?]IWQG;/X
M2FL/"^K^ O"&HZI#=>/+^UM?$'CKP+XBN_!6M:OJ\ O?B/X:@\+PRW5Q?:#H
MMWIW-_%3]E[]GC3OCQ\?OVYOB7\:=6NO D>B?#?P_P#&?X;^%YYKW2+/6?@K
M/\+1\-_"VI7?@?5M2\0B_P##WQ%\#>"/&NA>!]-\,:7\0]<^(&K_ /",Z[XA
M\3?#S4-+\"0J]9)>]AU[W,Y6IV3TMM&VK;O>UFE;<5J;NN7$KHHMS5UKHFI7
M>BLN^K>R*?[0W[=W[!7@[4_[0\<>%+'XR:UK$OB3P)\69XOV?/%NN>+O GP]
M^&OP]\4?'S6+SQYH_B_X6-XLUWPU;VG@N_N? 7AVTLKO1]?\9"X_LV_M9?#&
ML:KH_P!0:G^T3^R!\,;"[UC6?B+\)OAS;:KX.\*^(-7?4M&_X12];PAX]UBU
M\,^%X?%>GMX>L=5TY[S6YK72-;\+^([6#4?#;PO<^*M#T33(4OY/DKP]\'/^
M"8I^(/C7PGI%SXAU'Q?\5/BA\1_@]KU[J?C+]I/4?!^N_%#XG^'_ (R_"_Q[
M\*O!_P 5+]G^&;:]%!X_^,/A$:-X6\=3W7@?QQJDNE3ZAHWC+2-%MK'7\8:-
M_P $MOBSX;\$^/O'NJ>"O'6A_#.+XG?#?3?&^HZO\5+6\\07WQ0_9?\ %GBK
MXE2_$+5M'M]!U;XP>)O%'[-7@3Q=\3-.^(OC(>*;^T?1AX^\(^(K'QM=Z#J-
MQ,*E6+DG4PCYFK)N'=I:>SLM;I6^*W>Z'*G1ERVIXM)+7XMTDW]KM9]+7OHC
MK-)_:@_X)?OIGA=-!\1? "XTNUDO]1\+Z=H/P%U^[.B:KXK^)+_"74+ :+HG
MPADO_"'C;Q7\4M)N/!+^"=3L]"\>>(=5T6[N(=#O].TN?4E]*E^+G[!^G:MX
M'\-/>_ \ZYJUU=_!7P!H.G_"UM1U.Y;7]?\ C'X-USX>Z'IVC>!)[J#0;[Q#
M\&?CGI_B?3_+M?"-K%X,\9ZKXIN+73EBO]2\/^'GP[_X)[?&GPSJ/P'\!>+/
MB!XJM?BSX+OM#\3V$OCOX]^$O'7B#PS\!O%.D^-]3\'^*M4\1VOA'QCH&N:(
MO[0OASQ OA_5=/\ #WB7Q7\.?%-CX@TMK_0/"]EK6F<YXN^%'_!+_P #^+?B
M_IGB_P <:SH'B'P?\3OAEXV^,/@.?XZ_M"ZAI'A#Q3?)\;OVJOACX<@\##7-
M1TGP[X!URX\0_'CXR:;X.\$V]AX-U#4SX@TR\DCGT[1?#D51JU%&\I8=IM)-
M0IZ7Z64=WJG?3L]B'2I-I*.)6C;3E/\ -R\]/^">_P"J_M*_L7_#GQ9%\%/&
M5]\)/AM8>&?%W@7PK\+[>ZT3PW>>!O%?BCXE:'8ZV)?AW!X4T;5])T*UTJ]U
MG0=%\9^,-3MO#GARR\1>)=#M]7UN"^UBQCFS-=_:R_8HM_&/PJ\'&^^&7B"S
M^.]GK%GI/B6S\+:0VCQG5?#;>*/#&A:MIVH:%:ZYK+_%30OB;XUO=$M-'TK4
MH+?3[SXAZOXI.F:1<>(KU!?@?^PA\2M<T;]HO0SX2TBX\!?$R?P]H/Q)\&^.
M=;^%O@FW\9>%[C0_!&M> ]%M([SPYX"U[PMK6L>$= TG7]$\/Z3>>'?%/BGP
MK;7"71UO2;Z5/&O%/[,'_!,7X/\ B/X<:9XHL]6F\1:G\6+VQ^%B2?&'X[?$
MJ]\%_$?0G^'/PUF\"^'KW3O%7B*7X7:;X7TOXB>$/AQ9_#ZXN-)T;3?!'C#6
M] ETB7PQJ_BJ.>O:8E:1EA5'2UXT]^6[2]UMW=]]=-'8<:5!J[CB6];ZS[V3
MTFMM/^'/0[_]M;_@F!XD'AGQOJ'Q3^ WBR7Q/<>./#GA/7H_A%XF\5ZY?2ZI
M?>#[7QMI5BUG\*=2\0:?!X[U'XL^ [6W35+:WM/BC>?%#PE_PCJ^*F^(&FC6
MO0/#W[2W[&'CCQ3X U6VU;X8S:_XC^*D/P_^!?C*;P3;ZO\ \)5\1?B)\,_A
MI\0Q+X2\6V/A6^7X;>(/'.@?%+PA:1Z3X^U;P#XL\2ZF8;"32[E)M*:2EX!_
M91_8K^'&@_#)?"-Q90^'/"7B#PIX4^$^I:K\?]>UW2K35_!OQ/\ AG\1/ _@
M30-;O_&US;>(H_"WQ!^"7PUB\/>']1N]7O\ [)X6N/"MQ/?P:CK%IJ7E_@#]
MEG_@G!>)\,_B]X+:+2;3X,^++3XQ^$KW6/CW\2/"]EX?U[P7KG@3X<:/XL\<
M^$/%_CC36O-)L/$'[/G@K1M(/C'1%T:_U#PW<30/JL7B+4?MROB+:2PUY)-7
MC26M[W=HW2>C;Z)OE5TD/V='^3$V3W4I[>5Y;VVZ:)/=G7Z[^U;_ ,$_?A?/
MJGPK\=ZG\*/AK=)JOQ%\)K\.U^%=UXKM=:T[2M5\3?#37FBT7X:^ _&&@Q6O
MBU_AOXD\.P^$-5%CXBU^P\$7FDRZ!.=%>"VM3_M2_P#!-P^)M+^$=SXX^ EU
MK&F^(O!%KHOAB7X6:KJ?A6P\12VOA#3/ TECXC'PXG^'MM-:V7CWX>>&].UJ
M+Q&MCHH\?_#_ ,*W-]:7'C7PUI6K[]_\'/V--/\ C?;^&]5:VT_XT?$*UN_C
M[IVFS?$KQKIH\5VL'C#XK7-WXF\-QKXCM_#FIR0>)/C;\2M0?PQX?DGG?1M>
MBF_LM?#NA:$VFLT#]EC]B>X\,VL&@6GAK5_"2W6E7<$EE\<-<UG1)Y=,\<?"
M+XAZ<DE^OC.2VN8Y/&7[)OPZU,Q1SR+>1_#CQ3I5T)],U7QU:W0UB-4JN&?O
M+2U/1;6OR)]>]_-:H<8TU]G$[?S5'KWLYV1YQ8^.O^"8?@"'X6^ =-UWX2^'
MT@^+7P_^.WP^T?3]'^(A>_\ BWXIL-!\=_#/XH^-==M- F34&GD_:,\*^(O#
MOB#XRZS-X1T3Q!\0_ TBW&C:U:>&+71^I\%_MI?L->//$VH>*KS5_"?A3XD>
M ])TOQ'>^(?&WPXU.PU2T77/@W\-?B%>3> _BG'X8U#0_'USIWPS^(O@>TU:
MZ^'?B?6M3-E,;738]1TC2UOXV^%_V*_V&?!>CQ#2HI;G2OB];:/X8T/5O%/[
M2OQ"\5-XVTJPF^#]UX5\)>"-<\3_ !"O_MFE^'[#]G_X0Z+X7T/PE>2Q:5H'
M@^V\/:?!)'K>N7.L\_\ $C]B7]D.\L] \*VWC=/A8?A+X_\ @?\ 'G5=)N?B
M]+K%QX;N?V>O@SJGP0^%'B2\\.^//&$]IX'L[?P[KO@3_A,?$)T[^R/B1IW@
M?P=I'C4ZK/?R7=0_K$;.+PW,Y1O=0MRV=]>5M^]KJV^BTT0U2OOB5+E:BFI2
M;N]_CLK:JRMKJ[[/W7XM_$C]CSX4>);?1?C--\)?#7BWPG\./%WQ-M[77_AA
M/K=_X2^&VH>)+K3O%GBB6?1?!FNVOA?2?$/B[5]5TR:QN)+#4/&?B/5=42#2
MM>UF2^AKSE_VJ_\ @GIX,M5\2CQQ\)/"4-_H_CCXKPZL_P (/%.C7=RGA/QI
M9Z/\1M01H_A?!JL_Q1\+?$#P]I-EXS^'LC?\+CT;Q-X>BG\0^$+2\\/O<P<_
M\6OV>?V6/VI]&B\%ZS\=M:\2?$'X%>#-.^$K^--+^/>H7WB_P+>ZEX.\.Z_J
MWB[Q;I^B>(]/T[4/BIXO^'U[;>(K[QOJ47FVL'B*#QMIZVFN:-X2U+0^*\1?
MLG_\$T_AO-KWQ<\0:@LM_P#"_P ,_$[Q?XKO)OVF/BAX]\3&7P[?:M\4_C-\
M0O$7A>R\?Z[XD\:?%*;4;K5_$?Q%UQM,OO%=]>7E^\EFEW=7"O<JE;F?*\.E
M_@I;M*[U7=O?5_-MQ"E3Y5SQQ$I==9Q33;Z*6FEOZL+X&^)7_!,WX8_'?QK\
M5--U/P;\'OC=J6G_ !#T37[[6]0^*%CHVD^"M.E_L_Q1K!\,NVH_"7X*1>+[
M#]FAH[OPUJ6E^ _'^I2_""30+C0!XETG4='E^^OA1\7?AS\</!L'Q!^%7B<>
M+O!USK/B7PXFKG0?%/AB:+Q#X.UR]\->*]$O-"\;:#X9\2V&I>'M>T^[TG5+
M>^T:#[/?V\UN6+Q\_$/QF_9E_8G^)UO^T[\']5U37/!?Q"^,4_@>Y^)FM:=K
MOC[5-8M/''QQO?CKJ'PP\5^$_#VL7%_X9UFXGUGXW?&+6[OPSHM@V@Z%I>O1
M?\)M;Z%HN@:'-IO0_L3?$_\ 9I\'_ /P[X'\ _M$)X\\(^'--UGQGIWB_P"(
M&AZ[\,M$T+P?XK/@_P"(&EZ#I5[\0 @M/#V@Z3\8?!J:%I_BWQMXF\?W=MK'
M_$^US6=0T[5)-+,-4FI*,ITHT[[1E%Q5TKZJ*:M)66FSZ=)K*-5<\(UG.^J<
M&KZO7XGNFKKI;YO]!:Y'QM_R+UU_V%/"G_J7:!6A;>*?"][K][X5LO$_AJ]\
M4Z=8V^JZAX7L/$6CWWB33]+O5CEL-2U#1+6[EOK33[^"19+/4)8ET^=98Y(K
MR2.6T:XSO&I!\/717D'5/"N#DG/_ !5^@<Y('![<=.G%>QAFGB:#4HR7/O%W
M7Q4^QR5HN-&LFK/D@[?]Q(FEXQU;3=!\+^+]>UFWAN]&T+PSXGUO6;2X:P6"
M\TC2-%U#4=5M)GU5DTI(KK3[:XMY'U.6#3E20M?7-K:B6XB^"_"O[3?_  36
MUC7/"7P^TK5?@'I_BORM6\(>'O" ^#=W;Z;H-W\0;>ZT?QEX+L?%=K\-G^'=
MM9^)=8GE\$>*8M'\5_\ "-^+O%=_;^";[4+_ ,0>)].TG4OOWQ+HFE^)]#\1
M>&=<MVN]"\2Z+KGAS7;5)[FU:ZT37M-O-)UBW6ZLWCN[8S:;>748N+21+F'=
MYENZS*C#\^?!GPV_X)X>)+?Q#X.\'ZMI.H:1\)?&<6DZ]=)\3_B%%X/T7Q9X
M?^*OPP_:"CLK;Q]?:_!X1\0R0_%3QS\+M=AM['Q#J!U+4-2F\%$2:18Z_I-M
MP5^?FARRHKW4[5%!MZ4_YE=1O;5-.]['10C%T[R55[).G*:2]V/2+2<M]UL=
M/X%_:M_X)V?%)QX6\#^._@OXC,NGZ7X:&@S_  GU_P /02Z7\7_&'PC\/:3H
M$%MXM^&>@65Q9?$OQ9\4?@-?MHT*RP^)8/'GPU\=ZN)?"VL:3XFDSKS]I'_@
MF?<MJ/A[4?%?[.<\?A3X>>'/%]WIMY\)KI]+L/ >A'1-<\%0:)(_PX.EZG>Z
M6_Q0T76/"W@#PO/JWC2U7X@M=Z%X7MUUNX\JIXJ^!7[ 5M=:'X-UG5X-+U3Q
M/JK^&]%U/PQ\=/B%9:CX1\4_!'X1_ KQ1%?S>-_"WBUG^%GBSP%\-/V)_@EX
MATCQ!K6H>'=034?APU[;7%YK'BGQ ^N&I?L9?L VG@+PMX3O-$_M#P;>7WAS
MP=X0DL_C7\4?&&IMX@U#PM\+_ GA34K#Q+I_B_7]<GUO2M!\'?"358?'&JZA
M*FB:A#IOCO7M8BN]8O+W5,+U;)<^&;6K:C2[O35+6]FM-;:NS9MR4[OW<3;L
MYU-=M_>^7S/>]0_:B_98U7PO\+O$>I?%?P%KO@SXT^&[WXD_#/5Y-+U?Q/H'
MB#P1X0;3+K7/B3J+V_AW6-/\">"O!6HZEX>L];\<_$1/!^@^%/$^H:/X?UG6
M['Q-+'877RS+^W;^P3I=[H</AJS^'NL?"^YTS3'UOXJZ-X)T'1? /P]L(M&^
M."W%GXNT'Q'X<T7QEI;>$_#GPY\5++I[>&ENKKPY\0M)?0;34;'Q;<SW7M^N
M? S]D#QGI7PBL-8\4:9JUAX:\'>._P!GKP//9?M$ZUI3_%#P%XT&BCXD?!+Q
MU<>%_'6EI\9])\2:AH7A_5?$WA77(]4N!JUC%=;M/DU"33]7Y>R_9&_8D\-3
M:)X:&MRVGBCP=>>'/ >C7>K?M'^)5^(NAZO+H_CYO!?AJ>XF\71ZU-XM.A?$
M3QC+H6EZQ87^M:[:744NH)K+Z;8W41)XMR;;I./9*FM+6MM>\='97BW>+:20
M0A16OLZ\&M4ESRC?TYDFGWW5DSW&?XA_LY?!#X4Z)\5 _A7X5?"GQ+!X&T[P
M[JNC_#CQ)X;EU8>,M3N1X \-V?@'1?"-O\0;K5=1UKQ+>Q^'_#<W@R36+'4-
M4UJ2?3[*?4=0=Z&K_M1?LN:5K5A=:I\4?"+^(;*\/A+238>&O%_B3Q;!+XM^
M('CSX=:AHF@Z?X9\*ZIXEGL]3\?_ +/GQ!TKQ#!X=LS86;?"+6M<\4366A:%
MI^JR>3:?^S1^RQ-^S_XG_9EOOB?J_B/X">)_$?ASX9Z;X,'[1ES;'PG#8>'=
M%\.:5\"/"?C+1O%P\30W>N#2+SQ#K&B3^(9?&?B'Q-XDUK5X[B&1]+.E5])_
M8_\ V+I/&+^+O".N^(+#QYXZ\<?\)3X4UKP1^UI\5[?7].\2>"_$/Q<\0ZSH
MGP1CTCXGW$_A'P[!K7QT^-9^(/@?X?0VFFWX^)VLVWBW3&"^';C1G*I7C!QI
M^QBI)*\_9N-U?57B[-O5WT5M!<E)MSK0K2M:W*I)VNNO-?;3?_-5_@C^T#^Q
M+\;?A7XG^.?A?PIX$TJT^%WBY_'?Q-TR]^#B7GCKX;?$;4[JXTVT\8W>E>'_
M  %>^(?%'B;Q4/#SG2O'/PZM?$R>)DT2[L=-UC49="U)+#43QU_P3R^,_@#X
MJZM%=? ?QI\-/AK\+;/Q!\7O%-OX%N=*\*^$/A+XF\&:!\1&M->\96_A#0H%
MTC5/ D'A_P 0>)_A_I&KW5^?#5SIVA^+O"C:?JQT*^G@_9^_8BD\!_$/X6Z5
MKGA.P\)^*O"G@30_&EKX=_:&U)-;TGPU^S?XFU7QSX,NX-;M/B!-K7AQ/AEX
MJ\;ZCK>L79DBL;^UU/3]/\9KJVBRPV$O#VG[/?\ P3V^%UC=_#&74-/?2/VB
MO@?IW[,D?A?5?CKX\\9VEY\!]!\$^,?'=IINF:FOC*^O? /AE?#&A^*O%MM\
M8[K6-)N8=5LQ?:-XTTO5KNVLKB;UFO>J86W3E]FU>][R;BFI*W16?+&[UE9J
M,$ER1KQ32NG%R=NR?-MY/:[W21IZ1^WI^PIX\N=&\5^-?&G@/P?XLUC5OB]%
MX0'Q4\$7]CXZU#PY^S-XY^+FG:CXW1=2\%MKW@?3+36/AM\6O%/P^\/^,&\*
M^,9+C0O',?AGP]-XCL_$-I'A^+/VT/\ @GHNB?#NSCO/AE\1-%^-OB&P^%D>
MC6?PHNX;'3/"UGX@O?"7B#4?B3IGBWP%HL7@_P $^!)? ]]M\.^-TT:[UVR\
M)1#P#I/B"[T+38Y-<?L9_L(Z=*^I7^K.^I2Z?\4?@[XI\0>*/VH?&>MZ]XZ;
MXIZW\1_'OCSPI\2_$&O^/-1UCQ/XR7Q!\:/BCXRT-IKJ+Q=X+NO%U[/H,NGZ
M);:'966OKO[&7[$'BGQ/H?B;5(9O[8^(VMZEXTTJST?]I'XA:'HOQ<U8#5O$
MD6M7'AC0_B%9Z!\4;;PFVJ^)-9\*P7%CJ^G>#'U;6=6T>VMH_LUQ;3;$Z-2P
MSO:[:I+?ENTU'6VKLVNUGHRH0PZ<N:.(>_+_ !+/>R:4]+JRTO8YW2OV\OV+
MX=6OO#_@VR2ZNI_ ^K^+O#ESH_PLOO"_AOQ7\/KOPQ\&O'VN7.HZUK?A7PYI
MWPPL-?TKXR^ M5L]%^+1\"W/CVU:'7=%BU/2]4\$76O^L^'_ (Q?L6>#_AVG
MQ1\&7OPTT#X:^%O'NG^"- \1^#/@]KVF6UY\1M2N[G2]!LOA5HGAKX<P:Y\0
MM3U^2_UF'P_KOPCT/Q9I_B&RFU_6-&U"?3_[2NXO+?B+\&/V ]#TV;XJ^,?$
M5E:Z-XPU;3/A7J.J>%OCEXWU+3_B-J6M^'O@3^SCIWP]N?#W@[Q=>Q>,DT_3
M_A7\!K2_\/V6GS2>'/$GA"S^(^HI8ZG/KOB'4_1]9_9P_9:\,?#2[^"6L^,?
M$7A;P7\-/%_A'XKZ%9ZC^U/\0=%\4_L]ZCH4EU:_#V?X:>-]2^(</BOX,>!-
M&MK_ %/0/!WAS1]2T_PG=^'M6U#PQ8VVM:/JDL%4W6224L+*5G?2F^FNBBNM
MFE9QW4K*R9RT+Z4\0ET<7-.U^[EM:Z>M]N^GA?BW]K_]@;P7=:/I_P -_"7P
MO^,6O^&_B[XO\,7NB_"KP'X.M+[X<?$>X\$?$?Q!K_B"%O$'AOP]93GQ2/A1
MXL\!WGB7P3-J6FW_ (G\.7OA:^OGO=$O;>Q^A?#FL_L<:SX/TO\ :0\%MX#3
MX<?LNCXUCP_\1_"WA;Q/X6\$_#>'2?#B?#WXR^(M T.P\-:-H>N6ND>"_"'_
M  AS>.=(\/>([?3/#UIJ^F^!=9ETV]UNWD\,T#]F[_@G-<3_ !0\):9=:7';
M?"'XH:AX]\=^&M8^./C?3M"^&GC'XG>";WQ#?:WI#ZUXLLIK/P'XO\/_ +1.
MI:W!+::CJO@*77_'C66E36FN:79:1I_M_P //A!^SS\&_%/Q=UO0?BG(V@^+
M/#/B+Q!\7_AWXY^-EOXR\%-<_$[5].U#Q)\7O&FE^)M=OIK:\\6>&=/\+>!M
M&UO55L?#.G^#H;JWTR:[U3QQXGU;67S5$XW>&:]Y6<:=KNRB]$[<J>EM[>]J
MR)07*U'ZQ!NVK<Y[7[RTOUZ=CQOXC?MC_P#!.KX6ZU:RZMJ_P8U,Z]\8O$FG
M_$GQ1X2^']CXFC^'?C_X<Z-\:[_6OB+\3Y?#G@S5-1GF\,ZW\./B1X2D\2P#
M4-4TZ]N_$>OF_M? UOXKU]:?CS]HO]@7X8>$_&-KJWPV^%L\EEJ.A> /&WP[
M\)?"+0?&+GP3;?'^T^ VA:GXKN/ OA'Q#X.L_"MOXJ\.ZKX@\$^"/$NJV'BC
MQ18_#_4_^$#\*ZUXE\/"WT^7X6_L0_\ !.+PCHVL_#_X8>$]#T*#Q%;:CX(U
M?1Y/C-\0[?Q)XG@\!?!/XJ?LZ:[/9R^+/&B>(?$=E9_"GXO?%>VU;QKI9OM,
MU[4O$VH?$RXUG4?$UG!KUA0\>^ /^"=GP8M?#'Q@UW7_ !5HWASXB^.O!NAZ
M?JOPH\?_ +1OQ(\ _$WXD>#_ (RW7QI^%=AXQ\/? ^Z\<^'_ !%X@\*_%_Q3
MJ=W\.QXELHP;GQ!>>#[=M7@@T2PT^).M9RYL/9R6T8-I7][10^5UVOI?1I03
M47]9DU&UTI13T=M.:V^O?H[]?HBZ^,/['(\+>"+F[UKX43>#/VD_#VL:3X5A
M?X>7LND_$GP3X1NKZZ\5#QEHEIX*=] \"> ]1\5WA\;7GQ4TKPKX2\"^(?%&
MI6OB&XTG4M9D^U>>>$/VF_\ @G4+OPQ?^"O&7P,TK4/&_B;1O"&CW6G?"K7/
M#6K'7K-? FD^$8_%'VCX=Z3?^!=,NW^)'PXL/AWXF\?Q>'/#/BH?$7PC8^ ]
M8U\^*='LINP\5_L]_LE&U\&:+XHN[?PW;_"CPI\4-:MM$E^.?BOP5<3_  H^
M/'B2WU_XL>'_ (K:;#XUTK4O&OP8^(_BBUTJ]\0>&_B&EWX:N;[1M+T>"*W%
ME'IC_._@K]FC_@G+KGC_ %GP%X?/C;Q)X^^#NH77BKXB?\)9\:OVAM2'B*P^
M$]U\!KG3+3XQ>./%GBQO#WQ9^'OPJNO#7P N_ 6@:_KNN^$O#<'A?2[G2(KN
MRMO&37].I7<H1Y\-R)0>L::;:Y$[KDTN^O>5NB!4J-IMQQ/.^973DU9\UM>:
M_;I^(S6_VS_^"<VIWVBP^$/#OPT^+4OCSPA<^/K_ %#2?@[:^'-+LO#'PG\$
MR^*_!&H>+?$GQ-\">#=#AD3PLFG2?#:TO-337!X8UWPWXELH#X!\1Z1J]W[A
MJ'[5?[!'BOP=J.AZK\0_A3XC^'&F?$30?"&J:=K?PM\7:CX%TWQYXA\5:K+X
M;U74-+U#X;MHVGZ9J?CC3];?3/B5=VD?@1_'&D:Y$_BU?$%AJ<</GGC/]F[_
M ()V>'=*MO''CGQ=HGA_P9>_"_0_#-NVK?M5>--*^'.L^#H/!GA/]F+2O'J>
M&C\25\,:OXOG\ :=\/O@_<?%^SLW\1M8:)X7T_4-<34]/BO!%XR_97_X)\>/
M/#?A/QMXEL=6N?#_ (3U?P?\/="N=-^+'QFT2YDN/#7Q-\3:?X5\)ZKX6TKQ
M#::SK6D0>.O%?B.\2YU+0FMM3T"2/Q1-J0^&L-]K$1&5>*E:>&YFVMJ3O=I)
M_#967:UU?F5TKMTZ4G%.&)LEWG>Z_P"WNK\]&M.IVWPD_:7_ &"?C!XH\">'
MOA_?_#:V^)G[0$GBKQ1X5\!^*/@YJ7P_^(7C;4=!N_'>F^(=1U6P\5> ](B3
MQ%J,'PU\?:GI$>N:I'J7C7PWX,\2:QX077-.TS5+J.KX6_:!_P""<^B^*/%5
MQX1\;_ W0/$5CX,\8^$O$:Z;X2UK1--U#X>>$]?U_P 2>-=/T2";PE:^#O%_
MA$^(U\5:CJ6K^"UU_2?'NL:/XE2UU3Q/#X5U"RT/6^ ?P$_8TM?%O@C]H;]G
MSQ+!XHU>.WUS1_!OBC0/CYXA^(OAK6+"^U#XD^-K7P[%I.J^)]>LM0M/ D?Q
M)^)5S\/])6W27P'X0UB\L;$1^&_#GAZWT:W;?\$]/V0H?[&2Y^%>J:S:^&?B
M+X$^)O@VP\3_ !/^*/B72_ NK_"_4O'^M^!?!W@O3M:\67MKX>^#N@W_ ,5/
MB1(GP=M(6^'NI6/C/5-$U;0;_1;31=.TFH_69)<OL).+=_=IJU]TVEJK.ZNK
MMW3MHR''#QTE]8C_ "WE/9/_ !+R3Z=NID^!_P!LG_@GQ;6FCZ!\+?BA\*I;
M2ZT_Q=X>T3PU\*OA?XXU66X\.^"K'0O&OBZ/3_#?@SX9W][+X#AMOB=X<\4V
MFOC3_P#A"?%G_"?Z=?>'-5UJZ\1R74F)\,_CM^R#\2?BKX)^$7PI^%'@3Q'H
M_BKX7^(=?\"_$G0/ ?@2T\!ZEX!T3PGX:^)=YH]K9ZEH]AX@TJTEG\=WEM-H
M>JZ+IGV+Q1#XEM=5T[3]UQ+-VFA?\$_?V5?#OA"Y\#:-X-\:6?AA_ 'C;X6:
M79I\8/BD;SPK\.?'NN_";Q)J_@SPEJJ^)EU71]#TW5O@5\*6\(!KRZU#PQ8^
M$SHEA?C1-=\2:?K'6_"?]C/]G'X&ZOX.U_X9>!M7T+6/ /A?Q)X,\,7U_P"/
M_'OB6XM/#WC'3M.TGQ);7I\2:YJL6KWVIVNEVCSZGJ:75Y%=![NSFMYW,E5R
M8MWNZ2LKP3A324G9RORQT]Z^B;35G>^B.;")*RK<W5N4G^+EZ:O7HM+GCNA?
MME_\$^/B?-X.\&:IXO\ A+<^*OB_I'@:ZMO 'B/X<WGB6UU*Z^*=O\*?&.F:
M!J_BO3_ VH?#/6'.J_$'X,3^(]5M?&-QX=TSQ)XK^&<VOZK:7/BSPJVH3> O
MVM_^";7Q%UGPG-X!\?\ P-UC7-+_ ++B\":@/@_XBT"73)?&=UX!\-Z!9>$-
M>U_X8>'X;&Z\56WC+X<II6GZ)J,.H:MX6U7P_P"*;%#X/M)M:MO2_#7[#O[+
M_@_1_"7A[P[\/=9LM'\"Z98Z)X6LY/B/\2;P:?IFF:A^SMJ5I;2W%YXEGN-0
M47O[*/P(N)Y-1FNGNF\%RBX:1?$?B5=5HS_L&?LNS^%]$\'KX%\46>D^&HO#
M8\,W&E_%GXJ:9K_AF^\&_#OX<_"[P?KWA[Q%9>*8-7TOQ-X6\*_"3X<?V%KT
M5T;ZTUWPK9^()))]4O-5N+^O9XG=^Q=FW;V=/5=%=Q6N^M]7N^V=Z#OK6_\
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MM;_9.^!'BOX?Z9\+O&7A76/&_@S3? 7Q=^&C6'BKQQXMN]0UKP9\>M&;P_\
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M .">/B'7)O%6M?$OX6>-/$%A\"9_BK)XHM_A#X\\?ZI:?L_>+;3P7/JNJ_\
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MR,<$8/N,8P?;_"C 'YDX]R,$^N2./I4>YN"#N!8IE!O'F*<,F5!&]#G>F=R
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M#T'Y"D*DDG<1[#/^-.R/6BA2DOM2?K)O\[@U?=)^J4O_ $I,/K11D>O^>O\
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M3/BWX_>%/V?]2^%-KX9U#PQ\2/V4Y/BCX[^'?@+XL?\ "''2?B!XA\#-\4O
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MP]JH@\27OA>Q^"/Q0\/ZAIDFO^,_#VDW%;P+_P %%OCK\2=0\#W/@/\ 9?\
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MJ?6XWU>_=UTK7]+H^!?VP/VN+SXR_ K1+[P)X^\6?L_>'OB'XF\ _&3XPR_
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M/^%S:G!X?GT7Q/JGACQ/J-O\*_/\7?V;H^M7UR%M[ZUU%M.M-+U#4+:_X_\
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M=;@FU/P]:AM2_131?A_X \,W5]>^&O '@7PW>:EXDUGQG?W?AWP=X:T&\O\
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M_P 7W_B274OB7XCU>]M8M*^*'Q$\2_VO\0(?VC/AA<'7]7N-"O-0\-Z%X_\
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MFE2W=W>S:=XDU"+2?K7XR_L%?#7XY_&N]^+'BW5KB\CU/2OA%:>(_ 5_\//
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M;_'>M#39OB/XC\4>&/"_PG^%7@SP)K?B_P")?PI\9_!G6=5\!>$?#NE1:/X
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MQ"T:;3+ZW^'NIZ+XXE\&Q2_'/X8:SX2US0?&NM3^*K>;7O#%[J.HP1>E:?\
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M]E9\VK=HI:ZNSZHJ\-.;&55M=.DE9>G*GW+FN_LZ?L!?$S0M3^&_@/XF^*_
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M5%15HJR]+;[Z7?\ P=^I#E*3O)W84444Q!1110 4444 %%%% !1110 4444
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M4O$WA/P+I]Q\&X? '@OP#H-[K>J?#?2M,TKP[X/^+&E^*_"%MX:\.:9XJO\
MXC6=Y?>)I-*A\6:'XD\0\(?\$V/VH?"?A[XE+I7QE^&=OXN^)'@6X\(Z\]QX
ML_:!\6V_B#Q%??\ #(&G:[\1]2\6>*=6O/%UCXO\5:;^SI\2]:$4,FI^'_"F
MO_$:QM(])U_2;36)-7^D/V4?&7[5OPU\3_#_ .%/[1W@/XHZWX'U;X9?L]^
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MM]?:3:ZK#XK2]E=J5#$J"7*FI-2;3:MU=WY7;NDMXL5Y)W^L4'*[?P)QOO\
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MPJ\;?'CXD^'-<^)6O^$OAO\ $_\ :!^&_C3XA_$V?PK9_'W0_P!H'P7\=D\
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M\4?$/_!1G4_VI/&7P]^%7AN[\&?LXW&D_#W3-&^,=]X0^!WB_3-#U&[^(_P
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MGPU^QWJ>HR>(AJ/QF:T7]H_339:9:R^#]-CU! \/,)*_^RU;K97CKK9=.O\
MP!_596_CT//XM-O[W^1^Z)(7.X[< $[N,!ONDYQ@-_#_ 'NV:"0.O&,@Y!X(
MQD'T(R./7CK7XF^+-._X*T1?"KQEIW@RX\6^%;V"'QEH_ACP_P"$/#GP2\1?
M$C2+'2-+@^(&C^.?#?C_ .)_C;Q%=>(/&OBWQ39ZQ\+M*\*^+=9?PBUCK9L7
MAT2WCTG5]']6_:@^+O\ P4$C_:#^*'@']D7PGJ_B+1?"O[+_ (*\=>&H=?\
MA9\)#X+E^*'COP+^U:\4'C7QGXO\4^'/$D7CZV\?_#OX(1>$OAGX-L[GP(;G
M4_%&G^.=2TG0=2AU+3-7C&K?[/5U[N-K-V3O;3TU>ZN[,%A9/:M1V_O>O=Z>
M9^KA91G) QG//3 W'/T4%CZ+R<#FE.0"Q!"KG+8.!@9Y/0<>I]NN17X_>-9O
M^"IL/CI/#NEZO\0]4\ ^!?C5\-KSQ1X[\&_"_P#9@T2^^(7P=T7XX_"&VDN?
MA3"OB*:\\8WWQ#^#>H_%[Q'^T9X+\4>'?#J^#)O"NC>&/AG'#>7%I8>*,CPQ
M?_\ !6KQ.=)O?&6BZ5X1\7'XJ0>&;S4](\!^ %T7X4?#WQ/\3?V>M&\=ZUH.
MFS_$N3P+\>O"OA[X:2_&7QE\-?%GB;P_J?BNSN='O[6[^WZ]<V%MK*6-;=OJ
MU79OXHWNG:UN7OOU75:6#ZK+_G_0_P#)O+7<_93'SY[?-DY'&S*OGTVD$-GI
MCFNL^&A \=:UD@?\4;H__IZU:OSI_9;\4?MK:I\1/%VD?M-^%[VT\&VOPN^'
MUQH.O1>%/AQX.T"W^(]HEGIWBW384\.>(?$WB7QGJ?BYH+WQM)J=A=Z#X,\%
MQ7=OX%@\)6-SI%CJ_B3]%?AMC_A.M:&X8_X0[1L$#@@:SJX7C@]/\\USYM/V
MF3YJ[./^QI-2LVO>PFEU9775:%X./)F.6IM2MBY1O&]G>.,3:O\ XM->AQV%
M.L>,MVW'_":^* =P<J0;F,,K*BNS*0<%<!&Y61HXV9U_.GX^?MH?$KX4_%KQ
M_P##S1? '@NWT?PE?_!O1-/\3>.=,^+M^7T/XI6>E7_B3X_:DW@+P=J6AS?!
M#X;ZKJ%]\/-9TG2M2_X2N\^(FGWD^NWWA?PL;>Z/Z+ XUCQB1N)'C;Q0<*<-
M_P ?4(PI!!#'HNWY]V/+R^VO@7X_?\%&?!W[.OQ ^(7@#5_@E\>?'&G?"GP^
M/$GCOQS\/]2^"UMX6T>RL_@EXD_:/\4PV.D^-/B]X1\8:G<^%_@?X2\0^*;E
M=/\ #KVNJ:S8:7X-T/[9J>K6T]ITRE%8>AS5W1?LL&U91;3_ +/H[7BV]_QT
M[+*BYNI67L56BJ^/T=TO^1E6_E:;_P"!J> VO[?'[7U\NG>*XOV0/#NE>"8S
MX>;Q%X<UC5?C'_PM5K2S\ _LK>.?'::):CP)9^'Y)KY/VC]>\.^ 1KPB*WGP
MOURY\5);7 U:QTSS#2/^"B'[2?Q4E\/^)? OPX67P;8ZOH U*Y^#GA_Q9XBT
M#Q4_BWXH?#CP;>?#;4M7^)?P[7[+X_\ A=X:;7?$'BG7/!K3^";_ $3XBZ,-
M,US3+[P_?:GI'T^__!5WX$#QQXM\!VOA'XJZSK>B?%KPO\%/"E[X7N_AOXI\
M/_$_XE?$#6+O0_A/X3\'ZWI/CZXAMM=^(VK:/X[ATW3/$5OIT'AV#P+XLN_$
MNH:='AGN?%#_ (*'_#CX(_&#4/V7?AY\(-0\9>)_A_\ $3X)?#!M/\(>-_@_
MX)\ :3I_Q-^*7P?^&VN6NEK-XGMU\):UX'OOCMX#N]/\$^(])\.MXE?7L/-H
M&F2Q7=Y@ZD%MBY2W;3MHK6O;EU6F][>5]5U*,VE_L<8;*ZYM7V;YOG^%SYR\
M>?\ !2K]H6'PK\.[/X;_  6\*^)/B7\5_ _Q=UJ.QTGP!\=]4\-?"#7M ^&7
MQ \6^%_#WC&^\0:=X<N?$'BWP)XZ\)6/@3XF>$_#FBZI::IJFM6NIV7B/PG=
M:AI>FW/1-_P4'^/?A_6KG3A\$[;XCVMQXFT"?P[+9Z!\0=);XI>'=?\ "?P;
MN-9T[X#"U\$26=MIWPOE\:>*_BMXJ?XP:R=0F\$:?+X:TV_FO;=AI'3Z9_P6
M&^%5KX?\!S?$?X7^._#'C'QW\([OXHKX1\*_$KX*_$.'2]0?Q3-X=\+^!]9U
M.+XAZ,OAVZ\<0QV.M:=XD\90>'O#V@:>U]_PF%QH\>FZIJ%KU^A_\%&[_P 1
M:+_P4,TVR\#RZ3\1OV*/"_B'QN-%U?7?#6H:#>:(?A%X5^(7@CPUJNJ>&?&N
MJP^-M?D\0WGB32_%_B3P \OPWT40>'-(3Q1'X@OKFVMY]I%-?[3.ZM;1;+KU
M]-O7747))ZO"Q=M/M=5_B^?7[BQ+^V=\?-"_9[UGXA^-?@KX,\-?$#2_B_\
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M'CSP;X&\/>'==\4^'KO0]?U#5]/TV_M[EM<+S+H7_!6F/3-2M-?^+WP-\<^
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M]3^-7CB;2O$?PVL_@G\2_$%]::SIFA^ ?AAX2^'_ (O\>^/?BF/B)XAU76?
MVDG0;?P3IFH:;>>(-4@Z/XT_\%+?!_[.OQU^(?P\^*7@WQ1JG@?P[H_PJ;P)
MXV\ :M\/]0U&\\7_ !%^$WQ(^+-EX1U[0-=^)&B^);2TU[1_A9K"Z/\ $6+P
M_;_#?PYC3[;QGXFL[6XN=6\/N$XM-RQ4E?W=4K=G9))ZW7-=7CTUO<E"IS24
M<+%N+32U=[-N_P!VJZ-=^GSIX?\ VN?VOM6BTSPWX=M_&'B6T^*5E\2[WX7_
M !=UKX3>%M?TW0;+]DSQ-\1[W]H74M9O_ _@SP5X,\4Z!\8_ \GP./[.VI7_
M (0\,77BO4-8\71:-I=W>>'%EM^1U7]L/]N*/0?#EU\3;X?LW3W^B_#:_CU?
MP9\$_P#AHA-9UW7/V%=:^,EEX?N=$NOAGH6HWEWXW^/EK9Z#JO@;0[33]9T*
MY>7X;>%/&VF3:E:W=>T^,O\ @KUX2LM=\/Z/X3^"OQ6U6?PW\4=7\!_M"Z9=
MZQ\(=1UCP@W@GP?^TOKGB3PW\-;#0OB_<W?Q:\06<G[.GB+7=*\8>"M/UKX?
M7/A<G2[K5=-\72:AX=T/N?VA/^"CM]X+^"_P]^,_P(\+KXK\/_$GPK^U)\1_
M"FI^*Y8/L/Q"^&_[-PTK2M,\1>!7TCQ9IEN]C\9O$'C+PEXH^%6IZUJ^FV]U
MX NVU;6HO#]U=VTEIC^Y2<GC963M%:))SV^>FEU;5VM<UY:J7++!Q4IJ]VGJ
MH/5;JR]Y7L^U]-J?[0'[=G[2'[/M[\%]%U/]BKQ1\0/$/Q0^ _PV^(VO6'@6
MZUW7;+X?_$W7=/USP-\1/A1XAU+3-(U:U6Y\(?M">*_V;_"6E7RWAO;CX;?$
M3XE_$MDFA^%6L3:CY!<?MV?MI?";P9J^E>./V?/#GQ4\=)XJ:X\*^.;:_P#$
M7@OP)#X7\1?%/]L/PKH^@?$S5[_2?#^D^&M3@E_9N\%>'M"\5Z)+>Z;'X=^+
MG@SQ1K.C^(M3ATS3_%WT/JO_  5)^%&C^(=5\+'X-?M R^(_#LNM:1XU\+:3
M)\%]1\3>%?B'#XD_:'\'^&?A=IFF6/Q< ^(OBCQEX@_9D^)UC;>*/AW<:KX%
M\/F?P3-XC\26D.I:Y)X5I_"S_@HY_P +?\5:!=:-X%T?PA\)IOVA?#_P0U3Q
MAK'Q1\#^+I]6@\9_LCZK^T?8>*K>#PKK03PA'X*UO2Y/"OC(>++:VT6?11+J
M,.LZ9J?AWQ)I6A[1J4H^S_VZHW+[+4596NGHF]$[W3=[:Z&4XN.DL)!=.=<V
MKO;1-VWTM:^M_3(\-_MM?M-7_P >O@K\,-?_ &8/#6B^"/C!\1/'VF)XOD\6
M^(M*N/#/P^\(?%W7?A5<1FX\2V.DZ=KWQ1L8_#]Q\7M3\,^'=(U#1O$'PVU[
MPY%H6H^>NH>(H>#U/]KK]LKP_P#&7Q0C^ /!OCGP%\,?C%\?O ?C7X>^'?!W
MQ!T+7M0^'&G?M'_LR?#KX):]HVNW>AZY%J/Q.;X8_%WQ#\0K":VU"V^'OB3P
MI8ZC<7EK]JT_[5H?LO[3?_!0VR^ '[1?AO\ 9\L]'T368]=^!_B_QUXH\7ZK
MK.LPVOA#XH>)?!GQ5\2?LQ?#^]CL+6;1;F#XIW'P+\>66L6^M:OI.KVLFN?#
M&/P_;ZI'XYEEM/(O!W_!7GP'I/A*VU'XP^"/%C:E8'Q;>^*=8^%TO@NY\,>%
MM)3Q!\?].^&6EQ>'?%_Q'TKQUXFU7QC;?LY_$6+7M9\(:/K'A/P'>S^']1\8
MZCH6@W^L:IX:'-/W/K51.-5:I16O/*S4K=+<NBMHGJ]6^1J//]6@X\OGV2NW
M?2^^KW>W1=CX._;2^/OCK]F+Q+\;=1^ LW@;Q7X>_:&^"7@G2_ GAS4D\3>(
M]5\!^+=?\!-X_P!+\8:%-IGBB^\(>(?"']L^(?"?BSS3!J$MAIB>+=+/@;4-
M0;2-/YG1OVVOVS[BZG\/ZQ^S)\)K+Q!K>I_#O0?">I:7J7QXD\(Z?K?CGQ+^
MQ;;ZIJ_CC[5\/[:^M_"_A3P;^V1J\,UQHR/JM[XB^ 7Q);5Y=-LM3N8M!T=%
M_P""PGPCUG34U8_ +]IJ,V_P;\1_&C46M+3X5ZY9:1X6LE^+MSX#6;Q)8_$G
M_A'9]/\ C)IWP8\2ZY\./&,>JP>%I3XB^'NF>+-5\/W'BJ_7P]K^)/\ @JG\
M/=.EU3PMIGP=^.&G^/-$\#_%W7?&=MJNC> M>\-?!KQ-\*/%'[0_P^U/P_\
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M[76EV?PW\3V>E?%C3O&>NG6=8_8B^-2Z?XB\*:/<^$8[.;P2^H:UI4FMZF=
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M81?\%//A%>?%@_![0OAY\6=7\4:OXQUOPWX!D3Q5\"-"\/\ CS0?"?C;XM>
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M0\-:E>7]AIGBGQ7X<M_!'BKP_=ZE\*?"&O\ A/7K;_A(/"_B>2QGO.G\5?\
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M\(_#2T\5QMX:\&IX86YUG0?AY!82ZEI>H2:8-)?13QD525*BJE-T,-KS0O\
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M,,\5MJ_9[@%AY$Y*99OW<R8C#%2TA,;20<JWRW$,10AEN# \3*_Y7Z7^Q/\
MM)>&?A'^PW\*_ GQ?\"^"%_9W^*OBKQ]\8-0T?Q'\5))?$6F:_\ 'K2OBQ9>
M'?!^OWUKJ6I>-=$A\%WWCGX?^*[3XGZ;:ZYXTU;Q/H'B2?Q1I=E:^(="\9?)
M7@']AC_@HG/\.OV6_#GB/XI77A#Q+?:7J&O_ !;U$_M'_'/Q0/@GXYL/@S\
M_"MI\0KW43J;:Q\6_BKX@^(GAOXA^.4^$BW5S\ =+\2"\LAXBM]'UQKF]GZS
MB-/]GG=MJUH>=GLTDTKZ]='JTF?5J'2O'3SDNW=Z[G] ;0SJ2#%<#D ;X)4)
MW/%''E22\9D,@\M2KO/(4@M8[AVB:XH:GJ6GZ)9OJ.NZGI^A:<E[I6F/J>L7
MMIING1ZCKNJ6>AZ'8R7MW+%:)=ZYK6H:?HNCVOVEIM2UG4=-TFP^V:A?P6Y_
M)&Z_8,_:TTC5$U/P-^TO;+J-[X3\2W*:QXX^(W[0GB"P\.?$#5[C]HBZU_18
M/!-IJ]KI'C/X<_%F/XI_""R\0ZA=:QX2\3_";3O@E;1?#;3+Z:]T*W\/<_#_
M ,$[/VE/$G@[1/A]\7?C/H?Q)\,3:-\*=,O)]3^,?QTMM5^&MG\._P!L/7OV
MAO$>E>"+;0/#_AS0/B+?_$#X777@WX<Q_$'Q=IGA'Q5\,->^&'AJ]\'(VCW.
MG'P^_K&(ZX:2[7]F^NNVVFVMWY[#C0H+:O'7S;[][_Y'[/B&?S/+,-P'$IMV
M5K>3>MP@0R6[*@8_:4+!);=#(]J&$ER8R'B6%V14FD=XUCMXYI9GDDACCBC@
M5Y)I)Y7E*0+!''(TY;>56,M$)%9S%^-^I_\ !/O]KBXU#XAR7'[5_CS7=-UK
MX31^ ?AS:6?Q\^(7@"S\'1V&KVTFG^&_$-A=?"?XJW_C6PA&E0>*[[XA7?BN
M+7=9U#5_$'@+Q+X=UC0!%K,WTW\1/@!\;?CI\-/@7I/Q"L?ASI'CW]GC]I'P
MSXTTUK#Q;\1-)\)_$KP'X.^%'BWX5WGC"X&D2:WKOA/Q'X@U#Q]XA\?^'? &
MO7_C31[;P[H?AKPGXHU>VN?$VMW^D-5Z]M*$E-;-*-KV?:UEW:5]>X.G13_C
M+;I^FFY]VZ;>V>L:;8:QHM]9ZSH^JV%IJVEZQI=U;WVDZII&HVS7VFZMIVI6
M3W=I>:9?V0%[::A:R3V-S82Q7\%RUL2QN+',P4B*1P^0HB21W<[0P$0$69"H
M822B+S66#,H5HD:8_C?X#_X)R?M%?#?4_@7H?AK]J'QC;?"#X4ZO\*=3?X>:
M!\6OB'X>N;'5/"WP_P#V<M(\;Z[IFK^)/!GQ.EUSP[XG\:_"7XEW4OPANAX7
M\+R>"_B[K-A9Z]X6FO\ 41;^J_$/]BW]H+XB?'/XG^+[W]H+4-+^$OCOXD>%
M?$3Z+H7Q-^,_ASQ'KGPLMOB?^S?XRO?@S>Z!X=NM-\)?#*R\!>#/A)\7/"/A
M?Q;\.M7@\0?$B#XWZM%XY&C6\7BJ34H56LVFZ%6[:N[QLFWU2EJM4^UM/(GV
M5-M_OZ=F]FIWL_E:_P"J/TKLM2TO4;K5[+3M4L-0N_#U^ND^(;6POK6]N]!U
M233++6H=.URUM)YYM$OYM%U+3=92RU,072Z3J=A?M";6YLY[W0$4^WS/*F\M
MMI1V1EC.50@>>0\2EGD1/WC1"(NNXN<!_P A? ?[$_[4GP[^*/P)O;CXX:QX
MD\.^)O'/A2]_:WUW1_$.O6__  E?@CX'_L^?L]0>!+VXFU;4+#6+SXE>.OCW
M^SSIOA#6_$]M8ZM<>(/@/\1_B?I?BK4+74?LS1]Q=?L-_'J'XM^-_B[H/[1N
MNVGB#7OBCXP\?>&M,U[XA_'35? F@Z;K_P ?OB9XQL/#FK?#^U\6Z=X:FT*P
M^ ?BWPA\&[KPUHMKHMC&/#NJ76CWNE745GKPI5Z[<U["5H.S;4;2UMHN6_=_
M+NT4L/06JKQOVO+]6U^%S],]5U*PT*T_M#7-0L=$L#>Z;IJWVM7=OI%F^I:U
MJ-OI6CZ:+K4'M[9;_5M2N['2]+LFF^VZAJ6I65K!:+=O!9WFEY%P<XBFSN"!
M3"Y<OAB<QA1(&&THT2AFCE'ENRY#U^'T/_!,O]JGQ9\+_$'A/XB_M<ZAHWCJ
M;1O#\7PN\5^%_%GQ%\:Z;\#_ !6GQWT_XL:YXYT7PMXHT_P]X9\8Z]I?A_2X
M]'\ 7'BGPLDOAR\!T[3K_1[(2ZDW6Z5_P3T_:.U#Q7%XP^)?Q@L_'3Z/\6/V
M>/B=X8^'K_'3XVO\)=+M/A7XETC4[WP?H^A77@:Y\>Z+J/@O0XO%'A_P%\1-
M9\=^/M1\>Z3JHT[XC^%+?6'O?$5L>WKW_P!W?W0_^1_R_4?L:/\ S_C_ %\O
M^"?LB(Y66-PDA27S1$VT!9#"%:18V#!96021"3RFD\IW,6))0%)Y,_ ,4X9M
MP4&-U^=025.]E8E3@2HJ^9"?W;*QDBD;\@OVA?V2OVU_%OQV\>?$?P7\1O#O
MBOX8?$7X@_#+3(?@[#\7_C'\(M)F^'NB:_8ZEJ.K?$/6/!D4NJ>&)-(T2VUW
M0M;E^&NL^(9?%4WB"TB@\.Z)H-KJ-BO'?#/]@W]LN_US6K'XM_M%>)/^$7T[
MXC_#C1/$WB2+XP_&6/QC^T5\)_!GC/\ 93\1^)A/X=TS65T+X,:7?Z!\*/C?
MX>\*R^%==M?%WBA_C'J:_$+^PK%]6U'7T\367_,//9M)1CTUM\-K_-:]=VD\
M/0;O[>.MDW=V[7T>WHC]KFBF4J#'(N\*4:17C1E9]@9=Y!D4LK(GE%RY*N_D
M;)XHL[5]2TO0-/EU;7]5T[0=)@DTZ*XU77;ZTTG2[:75=4M=&TQ+C4=0N8+*
M.34]8O;/1]+@:42:IJ]U!I=CYNIRI8G\C-'_ &!OVPH9H?-_:_U+PM;:AXD\
M#>%/B*= \<?&/Q1=?$3X3P:OXRU;XV?%73AXPN;5?A;^T-\4]#N?A=X*T/PS
MX8^W?#?X;>'_ (;ZOK6GZ_>:OXWNH-&X6+_@FU^UGJ/@WP-X5\=_M'GXC_V9
M\4_"GC_QJ?B#\:?BWKV@IK?@WXE?LT>/Y/B-X&\-^'?AWX)M;R]\7V?P2\::
M1<?!'XE_\)?X(\,>(_B?<^.]&\?ZA<G4=(O#ZQB.E"::>[4?PLM7L]/TLQ8>
M@G?V\=-5K+I\^Y^UMUJ-A9:CI6C7M]I]EK6O#51H6C7EY:6VKZT^A017FNIH
MVE32+?:R="L)XK_6?[/C=M/LW^UWB6UF%NI-'R9N<03#Y?-^1))%$9V,&!$<
M;2((6,K2M%;+\A"AH&6[K\IOC%_P3S\;?$+]H;XV_&;PQX[TSP9'X[^*/CCX
MV?#[6M,^('Q=T3QMX?\ B+XF_8W^#W[-^A6^M66C7,6CVN@^#_&GPBNO&GV?
M2=0O-'\5>'_%-OH.N>&)W\*V5K<X_A+]@K]J+3]4U'5O&'[4WB?QIJL'C?XT
M>/;*YU[XK_%"X\$^+O%?B3P1\3]+^"VNZK\-?"'A[X=WO@_3/!GB;QAX4O\
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MJ:JR')VN,DX./,+9)8L7 &[>S-(K;4#)(NU0N!2[)/1_^_;?X5W<G]^'SO\
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MW^07C_,ONG_\@+12;)/1_P#OVW^%&R3T?_OVW^%'L_[\/_)O\@O'^9?=/_Y
M6BDV2>C_ /?MO\*-DGH__?MO\*/9_P!^'_DW^07C_,ONG_\ ("T4FR3T?_OV
MW^%&R3T?_OVW^%'L_P"_#_R;_(+Q_F7W3_\ D!:*39)Z/_W[;_"C9)Z/_P!^
MV_PH]G_?A_Y-_D%X_P R^Z?_ ,@+12;)/1_^_;?X4;)/1_\ OVW^%'L_[\/_
M ";_ ""\?YE]T_\ Y 6BDV2>C_\ ?MO\*-DGH_\ W[;_  H]G_?A_P"3?Y!>
M/\R^Z?\ \@+12;)/1_\ OVW^%&R3T?\ []M_A1[/^_#_ ,F_R"\?YE]T_P#Y
M 6BDV2>C_P#?MO\ "C9)Z/\ ]^V_PH]G_?A_Y-_D%X_S+[I__("T4FR3T?\
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MO!/_ $#+[_PHO$OU_P"@QZ\T454\17]W]_5W_P"?D_+^\%EV7W(/^%7>"?\
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M7>"?^@9??^%'XE_^7%'_  J[P3_T#+[_ ,*/Q+_\N***/K%?_G]5_P#!D_\
MY(++LON0?\*N\$_] R^_\*/Q+_\ +BC_ (5=X)_Z!E]_X4?B7_Y<444?6*__
M #^J_P#@R?\ \D%EV7W(/^%7>"?^@9??^%'XE_\ EQ1_PJ[P3_T#+[_PH_$O
M_P N***/K%?_ )_5?_!D_P#Y(++LON0?\*N\$_\ 0,OO_"C\2_\ RXH_X5=X
M)_Z!E]_X4?B7_P"7%%%'UBO_ ,_JO_@R?_R0679?<@_X5=X)_P"@9??^%'XE
M_P#EQ1_PJ[P3_P! R^_\*/Q+_P#+BBBCZQ7_ .?U7_P9/_Y(++LON0?\*N\$
M_P#0,OO_  H_$O\ \N*/^%7>"?\ H&7W_A1^)?\ Y<444?6*_P#S^J_^#)__
M "0679?<@_X5=X)_Z!E]_P"%'XE_^7%'_"KO!/\ T#+[_P */Q+_ /+BBBCZ
MQ7_Y_5?_  9/_P"2"R[+[D'_  J[P3_T#+[_ ,*/Q+_\N*/^%7>"?^@9??\
MA1^)?_EQ111]8K_\_JO_ (,G_P#)!9=E]R#_ (5=X)_Z!E]_X4?B7_Y<4?\
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B1E&56I*+5.ZE.33]^6Z;MT1T8=)5(-)74IM.RT?(MM#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>pg80-149_003.jpg
<TEXT>
begin 644 pg80-149_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #1 IX# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^X_PEX/\
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M .@O*?\ PLPW_P M.S_X5YX-_P"@''_X$:A_\FT?\*\\&_\ 0#C_ / C4/\
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MAOAKX:LOAO=^'K[X.R>(_''PIL+K1-5&A^)_BMH?P"^%'@SXO1:G)K&E^/\
MP7H.I^&]4LH[/Q'J$B^:^#?^"5?_  3U\!>"/^%:>&/V\?B/I'@#Q;\%OC%^
MSW\?/#EE\6OV:K2#]HOX4?&#XN_'#XWW/ASQ[<6OPKBG\*2>$/'?[0/Q!7PS
MJ'PE;X?W,OAB[M?#&OG6+".X:Z.3.O\ GUFW_@6.OZ6>%T?Y[>8_K7#^WUC*
MKW:LL5A6[WM;^(];_P# [GUK9_\ !3__ ()R7(N/%?\ PLWPA;_ NW^%NE_$
MFX^.E[K&LZ?X?BO=9^,,7P2TKPE-X(O[:R^)<-_JWBZ>S&D:Y+X47P[JEOJ&
MG-I]]*FIV3W'K>@?MY?\$T_%.H_!73?#_P"T;\)=4N?V@_"VF>-?A'<6^OZ\
MNE^(?#NN3>)K/0KW4M9EA31_!=UK^I>"?&FC:#I'CN^\,ZSK>O>#O%6@:7I]
MWK'AW6+&S^2;/]AO]D34?$GPU\>?%+_@HK\1?C1\1?AA9? 32M(\:>.?B9^S
M+I]_J&B_LW_M+:!^TU\-=(U*Q\#_  L\*:6MO%XC\-V'A/6[BRM+6^U7PU/J
M-VUU#XEO&UM/*OAQ_P $I_\ @FU\*?BG\,OBSX2_:^N9]>\ 0ZLFK6GBWQ5^
MRMX[LO&]W)\9_C=\<O"NMWDGC7X4Z]?>#_$/@OQ3\?/&6E:=J_P^N?#$NK>&
MK#PW9:[%?ZE8WVKZH.&=;>RS?;^;';]_]U_3LN[3>(R%:_6,KBMKO$X9?C[3
MJ?L1\ OB5^S+^U#\/K;XJ_ ;6['XA?#V^OKBQT[Q39:=XST?3]5,-O:7T>I:
M0OB:RT2[UCP_J6GZA8ZIH7B?3+:Z\.>(M*O;35-!U74M/N(;E_;/^%>>#?\
MH!Q_^!&H?_)M?GI^PQ\+OV3/V#_A!K7P>\"?M:Z;\1='U[XC^*OB7)=_$+XD
M?"/3]/\ #&H>+&LC>>&?AKX#^&^D>!?AS\,? 5FUFUY8>#?!?A/2M'@U;4=9
MU)8EDU.2./[8/[2/[/P&3\;_ (1C_NHOA7 ST_YB?X<_G0H9WM['-M=K2Q[V
M_P"Y47US(DO][RGS?UO"KT_Y>G9_\*\\&_\ 0#C_ / C4/\ Y-H_X5YX-_Z
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M #ZS?_P+'_\ S*#QN1)7>+RE+N\9A5_[E.S_ .%>>#?^@''_ .!.H#_V\/\
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MZKJ%C9?:[=96EB^"])_X**_"KP]XT^'?A#]H_P#9(^/7[(H\<?"KXY?%J?\
MX76WAS6=>T/PE\&]9_9N\/Z<]OX4^"OBSXJ:AXBNOB%KG[2.@>'- T'1[B7Q
M=IOBWPOK?AF_\+_;Y; /]=_M.O\ L8?M=?L_?%S]FGXS?%_X9ZE\,?C3X&UG
MP+XQM](^)_A73M:@L=4B#6NL:!J;7MW#I^O^']1ALM<T&]N+#4+:VU:PM);F
MQO+=)+:;\Z/'_P"P9^S7\6])T.7XN_\ !6']HCXB_$7PS\/_ (G_  Q\,_%_
M4OC+^S#X=\;Z9X*^*/B_]G+QAJ?AR4>!?@]X6T#5]&6;]FOP]I.MZ?J^D7L?
MCK1O'WQ/LO&YUR#Q#81:/')G:6M+-OOQ_P"?U;\EIYV+^LY#UQ&5=[_6L+IW
M=_:]?-,^T;;]O7_@FO?V^D7MG\?OA[>:=K7P1\1?M%KJUNWCB31]&^"'A%O&
MJ:_X[\9ZS'ICZ9X#L+"\^&_C[3$T_P <7?A[7+[6O!GB31=.TN[UC2+RQAH_
MM#?MN_LA_ ']C:;]MV;2?&?Q)^%NH1VT'PZ\*^ ?"_B>+XL?%GQ3-J>IZ?;^
M$/ 7P^\;OX2\2SZ_9IH?B+Q)K$&JV&D#0/!OA+Q3XRU>2W\,:!J=]!^?7@__
M ()5?\$_? T?PSL?#?[>'BNUTWX5? +X]?L_:;I]WXD_8_O8?&GAK]H?Q#\9
M/$WB\_%VWNO@>UA\6?"&F:M\;?$^I>'/@AX\L=;^!&FZWI/A_P 11_#D:RWB
M&YU[W+5?V!_^"<'C']BWX4_L4?%#]IO6OB=X9^"NC?%.Q^&WQ@US]I32?#_Q
MI\)ZI\7M&\?^&_$FJZ-KO@C4/#'ANWTW2?"OQ(\0>!O"/@>Y\+7G@'0_AY'8
M> YO#6I>&8IM/G%'.FVE3S>_:^/VO_V"KR_$7UKA_P#Z"<I^>+PO_P L1^JG
MPS@^''Q4^&OP]^*&B>&;FRT+XD>!?"7C[1K/5)+F+4;/2/&.A:;K^EV>HI;:
MK/;K?6UGJ5O%=BWGGMQ+#)'#+(B!S\A_MJ?MG?LQ?L*:_P#L]:!\6/!7CS7+
MC]H7XD1>"K&Y\ :1-KUG\-/"T6L^&O#WB+XR_%2XGURT3PY\)O#/B7QYX!\,
M:]XB2&]NHM8\;^'[>"TF>Y9K>S\/OA7_ ,$[OA[H_P"RK8KXP^#/C3Q+^Q?\
M/=/^''[/WQ*^('Q/\/\ B?XD^$-%M?"5KX,U"^_X2.?6(GDU;7=%M$CUF=X/
M(NB\T=O:V-L8HH/GC]M']B/_ ()R?M]^.O$WCS]HG]HV;5;O5/V=-:_9S\(:
M+X0_:$\.>"=!^%^E^)?%;^-?$?Q!\*VV@7-M=:]X[UKQ#8^$+F[M_B+=^-/
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M=Z;K;:/#K>E1WLZ]GG=_X.;_ #ECK?\ J+^(?6N'_P#H(RGT^M87_P"6_?\
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MTDT3P3K]C+JGA74/&ME8^)_"GV?PUXRT6#Q:MC=6T)O]'&CZF8+JW^._AO\
M\$@/^"9/PI\3>$?$?A/]K_4I_P"POA%#\(O$=IXJ\9?LK^+KGQC;Z+I/QDT3
MP7XX@UO7/A)<ZY\.O'GA'3OCCXKM8M5^%NH>#[#6HM&\(-J>F&YTS5;G77[/
M.O\ GQF[TU]['>7_ %"Z?C;S0GB^'UOB<I7_ '-835Z=ZI^AOP]_X*+_ /!,
M/XJZIX&T?P!^T!X'\17/Q*TKQ'K7@.]@TSXF6WA[Q/:>%=)\6Z_K=OI?BG5/
M#UAX:EUF'0? ?C'7;/P[)JT?B#6-%\-ZMJVBZ9J&GVK7%<CX2_X*7?\ !.OX
MK:O\-XO@=\5_AA\6O#'B_P"(_B?X<^-O&FF>/[3P?IOPC'A[]GOX@?M)#Q7X
MLT[QW?>'M8OO"FK?#SX=:]J.GZ[HEA=:5+IMCKNN1:D^G>$_$DFG_(GC#_@F
M=^Q+J'B7X#^/]%_;T\8ZEK?[*_[.OPV^"'P4^'WC7XU_!K5_A*NI?!OX!_$C
MX">"_%6N:;_PA,WB#PJWBO1?B1J.K_%>P^%^K^#-*\7>(K'1M=.G6MSHUC$G
MF'P$_P""27[#.B_"3X?Z-^TQ^W#K/QM^*D?P<\'_  F^)VJ_\+G^#FE^%+SP
M+HW[$_QJ_8D3X.>#T\/^ ?"^I6?PO\'^ _VA?BOJ7@W7IS'\1]2\1W&A:OXR
M\5:\-+DL)CV>=;JCF]O\6/7S_P!U=O+Y>;!8OAZUWBLIM>W^^81:VVTJ7>_W
MV1^I?@3]O_\ X)L_$F7X<Z?X&^._@CQ3K'Q8^(-[\+? WA[2=/\ B+<>)M5\
M8:=;>![ZZM=1\,OH$/B'PUHL6F_$SX<ZM_PF/BO2]%\'/HWCWP;J\?B&;3/$
MNCWM]]\'X?>#<X_L.+/3'VB_SG_P,K\#/AI_P2__ &"OAEIG[/6F:1^W7K'F
M_L[_ !\T/X]Z+XGT75/V-OA]\0_&.I>%/#WP[\*^'O"'B[XD?#CX(^%?&W_"
M.77A[X:Z7H/CZY\/:UH>O_$WPYKGB;PYXMU>ZT:?P_;>&OW _P"&E/V?22/^
M%X_"$XZX^(_A0G![;1JQ(X]1VZ<XJ>7.5]C,[W:M[7&)Z>7L$[]+.-[VZZ#^
MMY!TQ>4:;)XO"W79?Q3LO^%>>#?^@''_ .!&H?\ R;7'>,O!'A>TA\-_9M,%
MO]I\:>%[.;9?:G%YEO<:BL=Q$VR]!998B8P,XW,">!2?\-(?L^_]%O\ A+_X
M<+PK_P#+.N+\:?M"_ 6]B\-+;?&CX53M;^-?"EU*(O'_ (7D\N"#5$DFED*Z
MG^[1$ 8LW''&3Q6^#AG<\70C['-M95=XX^HM,+C;>[+#I/6UG?3=79SXK&Y(
MZ$TL7E-W*C;_ &O#;_6<,^M2U]';S5EN>QK\/?!Q;_D"1$GD;KO425PH  +7
M1.T#('.1V(R<._X5]X,_Z D7_@3J'_R;7#)^TE^S[\I/QP^$IQG./B'X4Y)
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M?%.GZ7X[\0_#*S\,7'CS7?V?=-\-W/CKX!WL?B>X\;?$KX9^ ?&_P1TOXGW
M\#/'\.=?B?XB>#?!/@G5?$^KWVG0W6J:-<Z;K-MI/F2Z?<:LE*+GBH.*;;BO
MK-WOWJ]'T6WW%<C>OU>-M/ZWZV>_Z&7\9/\ @HY<_L[_ !H_:9\"_$SX5:[K
M_@+X5ZWX)T3X7>+O $^ESZQXG\1:Y\&_V=?&VK>"O%?AZ2_U76[6\_X2/X[I
M/:^.=.T>S\-Z;X2LH[2[TK6-9T^[U/5.!C_X*J/H7C/Q'I?C_P""OBCP[I4E
MA\//%>A^%M7UOPQX$^)O@7PAK'@#]G:_\;Z=XLT'Q5XC\[XD_$"'QY^T!I4_
M@3P;\.]*TW5-;\#6T8OK6#7WCDO/5OB-^W7\$_#O@'P5XM\6_ 7QWXGUGXN?
M 7X*_'J]T32OA->>/=%E\'_'GXK?"7]G2[\)ZGXJT?POXA?Q/\0K"W^)ND1K
MX"_LBYUGQ]X?T"'P[H-E.^J:-;+SGB/]KO\ X)?:#K?@WXFZX- M[WX7>'?#
M6E?#WQ1_PS5\4H-+\(V7Q0\%Z9\6=-T3PS8K\.ET:Q\=Z#\,OA'!XY\5Z7!I
MMW\0?@IX'\#7B7Z^$K*:UTR_AU&G;ZVI6>]ZZT:TO^^LWY*RLW:^H^5Z_P"S
M12>VB?W._P!_RV:.Y^)'_!1?PM\./CC\8O@@WP7^*_B*X^#OB'X<> ]4^(C3
MZ%X2^&%_\3/B=JOP#LO#OA"]\;^+FM-"\)V=S8_M!^&KZT\6:Q>SZ=<2>%_&
MMK)86[:;ICZUX%\+O^"O/@O6O@Y\%M>\?>#;.X^,OQ&^'7@7Q)K7A/P9XP\'
M:/X677O&OPX_9\\;6>IV%YXC\3ZW?>'OA7+J_P"T;X3\*W'Q&UW4M5\/:-<:
M)K^J7.K7]G)I2WOT_J/[4/[(GB_XXZ;\'T\!:E\1OBO\1O',_P"SYXGNS^SE
MK>K"VL[/P3XY^*VCS_$'Q'K7A)%U+X,ZO9_"+Q*GAKQ"DFK>$;N_\-G5?L\>
MEZ8GB!'?%SXX_L^_"3XBZ[\+_%_P&T?4/%D_AOX&>%-!L]-^''@O6+WXD?"_
MXI:G\1-"O]*\-:1I^CW.M:KX)^">F?"GQQK'CWP;'IEU9P:3IFCP:#88U*RL
MKNE6JV<EB(.$7RRG?$63L]'%5KZ[WMT5GO:73A>*>#BW*[YN3#_G*A*3L[*_
M,W?K>S/#/$__  53\-:3\6K?X1:!\+K;Q%JVA^*/AE8_$C6[+XI^';[PYX;\
M.^+M/\0#QLOA[7=,T>XT;QKX^\#>)-+TOP_I?A+PQJ.LV'C=M>M&LO$&E:KY
M&B7?T/\  S]N7P9\9?V</%7[3&K> OB-\*O"_ACP3XY^*%KX1\66=G=^.O&_
MPQ\"?#?0/BKJ7C7X>:':36E[XOTT^&_%&C:/<-860L[3QC<)H\>HWME?Z-JN
MJ<EH7[6_[!.KV&H^(O"VDV.JV]I8>&KGQ/=^&_V4_'-_?>'M?\.?$"[^&GPQ
M^'WC*70_A5.NA_&!_B1X*O?"WP@^'-[+!XEU'7/#]E)X)TZUMIO#EW?4/!W[
M4?[#WAKXL06\6@:;\(OB790^+_!MIJP^!WQ$\'6'@KP7XI\46FLZX_Q2UB#X
M<Z/X2^!%Q\0_B!X"M[?Q!H7CZZ\/>(M<\2^!M-TVZNM3@\-P0Z*XXB;=GB:>
MJ=[2Q#MIV=;OK;==+[ Z=_\ F'25T]^E[Z-Z;)KLVM>MNC^ ?[=,7[0'Q0\(
M?"?P_P#"#7=,US5=(^)7B#QQKMO\5/ACXP\&>!=&^'^G? C4+.?3/$WA34[^
MP^)5QXI;]H;P/IL4/@YW@\.:O8^*].UJZWZ)!-JGSUIW_!7[X9Z]I&OZ[X3^
M$OC7Q;HOA77OB%INN^(-&\=^$;/PNFA>$]*_9UO/"_C32M=\3P>'8M4\+>-]
M2_:@^&NG3:VEO;^'_!FD6OBWQUK>O7'@G1(-6U#Z>_9N_:S_ &,?B]KWPV^'
MO[-^J:<NH^+=)\;7?@_1?#/P0\6?#ZU\/^'=#OO"FJ>*+O4H[KP1X=M/!>DZ
M[=^+/!FO:9932Z<_BL:OHNKI#.Y@N;7R+X;?MS_L2ZG\*+SQEK/@D?";3=0\
M4V7@7XA^#[O]G/Q<EAI-U\9/$6O^#M&USQ!=Z=\,+;1_%?PN^+%_X'U/29OB
M?8P:QX#\0WVA:AHM[=ZC'X>O9HAU'RJ/UJ'-=MO_ &EJS5DOXU]7?5[=/.G3
MA*3;P[Y;)))I-/J][/3Y[W*UC_P5(^&]]/K6@6WPR\;ZA\1]&L_$QMOAMHGC
M3X=ZUKOC'6/"7@O]JCQ3JUG\-[Q-:M-.\=:'/JO[*'BWPGHGC/2VC\/:OJ7B
MOPO)%<07":KIEIW?[/?_  42^'O[1WQ*U?P%X2\$>--/\,Z#X6\.ZAJOQJOY
M$C^$=MXU\2>$/A+XPT_X>)XCUK3?#D[ZIJL'QF\+:!X7N9[2SU#Q'XPT[Q'X
M7?P[H^H6=B-0K1?M>_\ !.G6_$WPP\!Q:S\+=4U_QTOAKX*?#^Q_X49J<]E:
MZ7\2M#^'U[HWPYN=3G\"3:;X(\*:RGQT^'_A/5M%U:ZTSP[I?CCQ_#X(\2P6
M.MCQ3I\47Q!_:,_X)^Z=XUU'PAXV\-VEUXY^&_Q'\!?#;3[;2_V7?B9JESK?
MQ+^%WQ/\!V7@WP%\,M>\/_#62V^*LOPB^*_B/X9ZA<^'_!NI^(O"_P ,M9U/
MPUX@UF.PCTFYOM%E5JD'KBZ%M]?K&WSK;>NUWKHKRZ4->3#NZ7NIN[OW;6FO
M3TVZGG_Q$_X*(^/_ (=_M#?$GX:W_P $-%U+X:_!OQW\2/#'CO6=%^)'AZ]^
M(-SX.\+?#+]D;XB:5\4!X=U*XT@>'K>R7]I:[M+WP7/8ZSJOBJQTO2KC1]8\
M/2:9XA:[]!\'_P#!073_ (G_  L^*GQ0\(?"SQ_X-\/_  ^^+7PF^'GA_P 1
M?$CPW(VA_$+2OB+^T-8_ :_U?0;2SU;PY?P:KH>HQZJ=7TN2^GB\-7-]H5Q<
MS^()X-8\.1Z'_#=7[ U]=^)/%&K>+=%TC4Y_!_AWQ1K6N>./@/\ $#PSKOC/
MX:ZWJW@;PKX"\6:=>^*/A]INL?$/P1XPN_'O@V+P#>:3)KEIK^E17FHZ/9Q:
M;X/\01Z>SP-^W+^P/XHU:QL? FOZ=)J'Q9\>:79ZY/IG[/7Q#TVSG\9ZEXN^
M'V@>#_$OQ<UR#X=P:)X8'BKQE\2_A$G@+QK\1-1T^WUW5_B!X2FTN[DDNIY;
M2O:-W?UR.K[XBWEI[9;K3YI+H'(U'WL.KI7EL]4FY;IWV>Z:MNFKH\;TG_@K
M!I&I6FFZA>?LQ_%/1;+Q3X8\+^(? 4K_ !+^$M_+XKU#XA?#3P?\7_AUX9GA
MLM7#>';SQ)\//%AUF\U/5RNF:)J.G+H5R\UU?QW-M9A_X*R_#K2]!UG6OB/\
M(_'/PPDTBW\?3K:Z]\0OAMJ-E?O\//"'[2VLZE96WB"SU2VTB#4=>\7?LI?%
M7P-X/T^[EBU'Q#(/#FOV]BEOJMWIND^A?&G]NC]ESX5^+]<^$'A7PDWQ@^.?
M@GXB?"SX;ZO\)_ ?PF\4:G-H%[XM\1^ O!%W>Q>(=(^'OB#2+C_A5FB>/?!,
M/B?1/#4&JZIHTGB#P=X1ET^PN=>$>G</\,_^"AG[#WQ?\"^!Y_B/X5T;PKXZ
M\:?#OP9\:K+X&:Y\$/%/Q!\3VT7C.X\*^(/A?X7TJUB^%YM/%GQVUG0?CAX)
M\6Z9X%\+6-WKES%\4+K7O!U_XC\,ZG=^(;B)57&R^MP>CLU]8UT3W==[=[-6
M>CUNDJ<?BC@TNG-RT5;=6?)1A)7>EN9:[I[%#QI_P5B\+^"D\203?LX_'+Q'
MKUMX^U+P;\/_  QX.U#POXGUCXH:;HGBW]JCP=J_B328='FO/^$;G.K_ +('
MQ1M]!\,>)%MM2UJ;5/!8NKO1(-3U:?1?:_VA/^"A'PP_9B^)&M^$/B[X<\4>
M'O!GACX=^'/BCK_Q-O[W3H-)B\$ZKK>C^'_%^O:?H&VXOKVU^#^J^*O 5G\4
M]/N;[3_$FAS?$3P;>:?X?U30K]];7%/[8O[(7C#Q$W@#QW\/IO"/AV_\>?$;
MP!J&H?'KX#ZOX)T+4/&'PF\3_"P?VG<:)XV\#7$5OX9F\5?M V%R_C'Q5-X8
M3P5XKU>_M=;LM/U[Q)YDN)XL_:O_ & _C]\/?VD;^'_A&/BN/AU^SS#\<?BS
MI6M_#_QCX"U'Q=\(OAVVB_$>RTG4/%6K>$=,US7-)\*Z_#X8C\<>!(Y=4D\/
M:OJNBZ-XG\)R_P!I75K>4JTK-PQ4&]+-^WLKZ;JM?1[)/5M7LK%*&J4L,K=5
MU?Y?TO4\L\6?\%:;7P-/=3^,OV</&/@FW\#Z=\9;KXS^!O$_C;P_'\9O %U\
M.OA%X0^*7@RSL/ ]AITVE^)V^(Y\2:GI=A-H_B6]L;*Q\)^)=4FOQ?\ A[Q1
MH/A_:\4_\%55\+6^HW%W^R=\9X/^$:\"7_C;QK:ZQXT^'7A*_P##BZ1X%_:)
M^*NI6$&D^([VPU;5X9?AC^S%\1/%VB:LUAI:ZO'JO@C3)[#2[G4];D\._2S_
M +1_[%MX_P"TMJ5S!X>MXOV:X/B/\9/CYJNO?L_>)-)CBM/#]_\ $;X<?%#X
MH>&KW4/A]:V_QB>UU?P)\2OAWXM\5?#?_A)=3O;K3;GPM/+>IK5HEWYM=_MS
M?L ^!--?09X[OPK;:1HL-MJ/A"']D[XIZ)=>$AJ/B[XB?";2OA_XB\,W'PDL
MSX5\<:KK7A7XJ:'HOPQ\06EKK^I^'+7Q;K":+/X1U">_NU[6K+_F)I7TNKXG
M=;_\O]K[.VUA>R@_BPD97>C<*#TOHKU*4Y72Z<S2V221)^T]_P %+?@]^RSX
MXLO!?BW1]>\2_:OV?=:_:$N+WP]JMI%J.BZ#:^$/B1XW\-Z;XDT6]L2FB1>,
MM$^%/C!='U-]6O+^2]T^Z2R\-ZI'I]\Z>06/_!6?PIKEPGAZW^&FL>%?&*>'
MOA1XLU'3]9U6#QC::'8^.OC?^SS\.=5\*^(+;3G\%KIWBV\\!?M&_#WXD>$D
M37+F\L- \5^'-<\6^%;?[38^&M?[;XT_M>?\$P?B-\/KQ_B]XJ\&>-_"?CKP
M9K?A=I[+X5_$*^\93> ]$U:^O=4TW3;_ ,+^$K;XD>%]*L!X?U[X@6%IIM_I
M$\OA'P[JOC308M0L)"YS? O[2O\ P3S^$<_@GX0_!#X:ZOK4NL>+/$'PUT6;
MPC^SE\2=;@O?[ N?C1\1/$/BV]^*7C+PE+J'Q#^'&A_$?X0_$.+Q3X\TG6_&
M=AX=\:V46L7DJVVFWVIV+]K4YVWB:2ARI:?6;I\JO)+VO1^>RO=/0'2IJGIA
MVII\V\;63NHZ->EDE%=$EH<UJ_\ P5FTFT\'WVKVO[/7C#1_$TOA_7=6\/Z9
MXQ^(?A&W\(ZAK-_^R[H'[5WP:\'WWC3PK;>)K>Q\5?%[P#XB^Q:7I-[8:?:6
M6J>%/%]I9ZWK6JQ:#HNM_2VI_MP^$O#OQ0_9#^$'B'P\Y\:?M8Z'X/O[:W\*
M^,-.\46GP\U'QOX+\:^*_#TFJS6.G+8:YX0U2\^'WB;P]:>++/5K&6XO[;=I
M.B:[;V.L3:;YN?V]/V H--OO&NO_ &+3];\#Z5H]I/)9?LX^/_$>HMJGB3P_
MX-\/:KX'^$GB6#X3A?BCJ.A:#XM\*:#XSM?AM+>0:!X;OK"'7[71M/M[G2+?
M[@\*Z!\,/$.C?#?QMX:\$^%(["Q\(Z+?_"[49O 6F:#K'A'PEKVDVU_IECX<
ML[W2;76? =M)IMU$K^';2+2)M+C=M,O+.*XAN4+I3G5DXPQ,9-7T_P!HOIZU
MNG57?:^I,^6"3J8=)26C[/I^NOZGH?FR$ B60C .-Y;/3C*LR$<CHS YZD8S
MSWB^63_A$_%6)9%)\-ZX0^<D'^RKO:R@JV&#8"D*S!\$ X(/1$#!X]3T[^OU
MKF_%Y_XI'Q7RJ_\ %->(!EL"-1_9-X&9V) 5-I^=L9 Y7!P5]&DI*I22;OSJ
M\N:K96=-)O\ ?W>M1-66G+T=CAJOW9\MH7IR]V*?O*ZWTMI?^NOP5^T)^W[8
M?L_?M+?"7X)WGA[3M7^']U\/+CQ#\=?&36GC";5?AWXB\=:)XSE_9R\.:)K>
ME:?+\.-)D\8ZS\*/&UAXKT[XBZYI&NW=MXH^&TG@FSU"XGUR.+R_3/\ @J)K
M/B3Q)\)]$M?@-)X"L_B!H\.J:[<^/?'_ (8\0Z[X<NM2^(/["^E^']"T?POX
M6U'3K7QI)K?P[_;:\+^(-3O-+\2)=>#/$.F2"31?%.G:7?V.I>^?M*?ME? O
M]GW58_ ?B?PQ>^.?%&KZ7IOB/XBZ;;>!?$$_A+PKX8TGX4_%WXH^$]<^*'Q!
M3P/KG@;3M8OM'^!_BF/P-X4UJYNO&4MG8RZOH^G7,%G$FKXVH_MS_P#!/^Q\
M9:1X:\6^)O#'AGQ-HGBGQQH^F:QXS^ _C30O#7A?6_AW=VO@OQMK^G>/M:^'
M]IH>F^#-)\1>&8OAK9_$S2]4_P"$7\1>(/ E]X:TK6]2F\',VE\%6<U5J?[7
M%?O)Z-XEM6G*^BK^5TENK/XN9OOI1O2I.5#G?)&\F[.2MI_E?RMZ?,7PL_X+
M$>']:^"O@7QC\1OA2_\ PL2?P5I/C+XAV7@#XB_#>;P2WAZW^%OP\^)WBG7?
MAYJ.I>+-5DUOQPNF_$33(="_9N.KZA\6Y[VWN=.>YN)?LT]ST>D?\%:=)E^(
MWCC3-6^$FKS> +^\^!7@?X!VWA;Q+X6\3>/_ !M\8OC5XB^,WASPC\/_ !O8
MZ7KU_;^!?$OQ,O?AA(O@WP1K6D:+XF\%#0/%4_CBYOK?5M!_LWT'Q#^VM^R/
MX,>QT+3_ -GGQWIOA;PX_P $OCQJ&I^)/V1O%OPRT#PKHOQI\0?%[2=&^+FB
M^&?$/PXM?$5W\1O#UE\"O%&OQV&B^$8/&/C#1TTU?!NH:IJNB:QING>H>./C
MA^PCHGA;PU\9=8'AV_\ #FC?&[Q;XS\,^*/AO\*/&OB.75OBU\(?!WBO4?'7
MQ@33OA;X;N[[Q[HWPN\):UXTUW7/BM?V6M>"_#<*:IJ5IK%SKL:DXJK-WY<;
M3]S5OFQ5ENVKJLW=;;*RYNBUU]E2O_N=GT:AA[^NE!26SUO>]KM^]?Q_QY_P
M4XT/X7?'KXO_  _\:^$GT_X:>%_ /@#Q7X%\2^)FN_A#\0-/UK7_ (-_%SXJ
M:SH_Q5^%GCU(?B?I7AW5Y_A7-HGA7QO9_#RUL=.U?7-$\)W5CXD\1:M:;N;N
MO^"O_P -HO#OA_6+?X(?%ZYUCQSX?^'FH_#;P=%=VESXA^(&M>-=<\3>'-?T
MO0HM-TK44ATGX:ZYX5N] \6ZOJBV&NGQ%K?@S3H_!=I8>,O#NM7_ -4WG[1G
M[(?B7POK/QHFT1O'.D:AXTU[]FG3O$UK^S;XW\9>,/C%K%G#JP\1_#[X36$7
MP^O?&?QG\!6]KX;\4RZMJG@VVUSX;?8O"GBZX?4X[/0]1EM?F^R_;J_83UC6
M_P#A&[;X02-\*?%6K^*?ACXB^)\G[,^HW/PWU'2_A1I/P'\8^$M=NH-,^'>N
M17_P-N(OCWX1N[/Q]XGM=*\)?#BZL+>]UA-%.LZ1?7!*O..DL;"7:\L4V[[7
MO423MTOIM9ZF:CS7:PR2CI_5OS=NGD=!X0_X*(:W\2/B=\8_#?@KX3/IWA?X
M2_LT_'_XJ+H7CSQ/H&E_%?Q#\5/@9XK\&>&=6\&^)?"^AZWJ]_\ "?0(-1UG
MQ%HWG>,-"GU7Q/\ 8-/\:^&I1X5<6NIX'AO_ (*I^&O$GB7PW\-M-^$&I>)/
MBKK_ (9_9QU >'O GQ3\)ZYX6M?%WQ_UCX,Z)=>#;SQ_?Z?I/AV"X^'W_"\?
M!_B/5[BTGU:ZO_#32.VG:5K,^G:7?>Z_"G]L#]B7XB_$VS\*?!B_L?$OQ3^(
MGB&;X>!_ OP"\9QZIXBLO"OA72=1MO$/B7Q;9>!+*R7X.67A:'1QI'Q"\2:]
M;?#^5+33-$TW4+B]CM=&DQH_VN?^"?\ X!U+0+B*;PIX,?Q1XRO/AEX/\4Z=
M^SEXLT31_%D_PQ\7Z/X$U36_"/BVS^&UOIOB+X3_  [^(VI>'O!7_"R]&GU'
MP/X?\5:AHT&GZG-;7&G:Q=4JM2,6_K--W=[-XEO5:6_?:K1W7E9.RTE)MV>&
MVWL]/^!_P>O7PCX;_P#!7;PI\5M7\#Z1X'_9I^.7B1_B/KFM0^#KS2+G2]0L
M=2\*>'KWX5^'_$/BJ>XBLECLO^$0\6?%_P ,Z)XXLI)&T?P^=*\426/BG7[J
MVT"Q\1UOAS_P5RT3Q5X:\%ZEXB_9X^(UIJVL_!?X._$7QAJ7@SQ;X>UWX4>#
M/&OQNT+P5KO@?P1J?Q1U:UT70-)T'4H?&VGV%_XTU9XQX7UZ#4M#\0Z';RZ3
M>WAI_L7_ !:_X)^:/8VGA[PS\#=,^!6KSZ;H'QUM-+\0Z7XF^,!\+>&? G[-
M_P ,?B?J'CV+Q_K]EXFTWX;Z9\)?"7Q#T_X=^&[.VUO2[B*XT98M#L$M;K3K
MF'TCPK^V;^Q9_P (OHE[\3OA1:?#'XGZM\-=(?Q!\,=-_9=\<^.]1MQ\7C\*
MO%T_P&\)^(/#'P@FTKXK?$.[@_:.^#FN_$KX0^ WUW4K#6/B'>W6J:?=PZ#X
MJU73%]9FTKXBG&][:XB^G=JM9/1[/7=6Z7[-_P#0.O\ +Y?=VW\SS3Q]_P %
M+/B]X._93^%GQMLOA;\+=3\9?%7X:?\ !13Q>L\GCNWF\#^"_$G[&T/CC4OA
M_P"'[*PTOQ#>)\6D\;:9X5,7B*X\*?$+1[745T[5O$_A.]L]%NH;32N\\6?\
M%6/"7@GQ'\1?"&L?LX?'&?7_ ()^"/BIXU^-=IX>F\+>(]+^'MO\-KGXX6L5
MC-XMLF@\+:];^)+CX"^)[6XUQ+_2;/PSJ7B#PO:W5C=O/J_]B]UK?[<O["<3
M^$_!<VF76N^&-(\5ZSHT-Q_PSAXNB^&OPTT'3O!'QTUG7/C(+GQ#X&T[PW!\
M&;?3_@=\:_!6J?$_X>V^J^'9M;\/>)](U"6XTV&[DFI3?MV?L)^*Y&\:7&F6
MOC+3]*\-QWFGZM;?LX_$#QS\4(M<^)'B'XH^'?%?@V/X::7\-=1^(-A<:QIO
MPC\3^(?%MW&DFG:]H<"WNLP1::D6H:HU5FM7C(/=_P#,3;XMKJM;W=8I[NP>
MRIO?"*W7W<+V_P"O-]='_GN<[JG_  5'\,Z'XZ\5_"?5/A!?VGQ1\*WGPOT.
M^T(_&'X?6O@[3_%OQ$\7R^!-3\+>(_BEKMOHG@K1M3\ >)!:V7B(Z=?>([.>
M2\;2K2\C\3:?<Z#)SGP^_P""L?ACQ_XC\,>'_#GP&^,GCRY\=?\ "1^*M&C\
M&>'+*QN/"'PZM?#'A._\,2>,K_6/$VH>%]4\0:AXHUZXT'6]7M/$?A?P_8Z=
M<:#KMK836FH0_;?5OB5\:OV%/'WPK^*?QKU#X;I\>/!7PH^*7P5_X3B_\$_
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M#\4^&;WPC\#OA+/\$3XBFNHC#XG^&>A^+O%7B[P%\9?&WQ$U"_G2WO\ P?\
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M>%M4^+4.F:WXZT[Q':>(/AWX)N-,L1=Z+X>TFS-J,/X>?#__ ()ZQ?$GX_\
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MZ7>Z')X=^@_A[_P3(^$WA/Q/X+\:>(_&?B'Q9K'@;Q@/B#X=\-6_A'X=^'_
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M3?B#IT.B_%_2+/X>:-\21X^O[?6(_#$?ASP;\3+3QD8=?M_$\.I111\AX/\
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M:'\0M4T2^\3RZE%XAU/P]\R_M,?&'_@H[^R_X.\3^+4U?XJ3W>L>,_BU\/\
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M&FL^%+KQ5?>&]5\2:;IL-IJ]]HE]XZN]1\97>FSWD4OV6Z\3ZA=:U=1JMUJ
MAN9I(Z])&>_^?U/^>U?G/^S[XS_;?TSXA:7:?M >%?&OQ!\ WGP:\&Q7&M:!
M\,?AU\+9= ^*6J?%F?07N-;\/ZGXQN=7\27,'PPUS2_&'Q#O-,UGPKIG@6V\
M!>*VT7X<ZY>>,/#.FI^C.,%UQRCNAX499"5)"@Y4$J3M<!UP0RKC ]6C.-2'
MN1JVC9.=22ES:;Z):OR5E\T>?4A.$]5'EDKKE:T\M&]'Y]D!Y!'K7.>+L_\
M"*^*>?\ F6=>/_E*O,?EG\>_6NC!!&1R,@9'(RP! R.,D,I'KN7^\,\UXQS_
M ,(EXJ/S?\BQX@QMX)*Z3>'&3Q@<9X8\C"MD5T4U^]H_XWT??"F<]*=5_P#3
MM_FC:L_^//3^IW6=KD+UQY$2[A@@N00B;,CB1I2ZK$0UPQ2K$DSQR+'(&9)G
M$B0,@5&5F<Q)E=KK)NA,D;QLWE2RM"XKQK3O#WQHC^.1\77/Q,\&7'[.!^"V
MF^'++X)GX>RP^-;?XSIXMM;^X^)MU\6UU=A-X/G\%%_#"> 4\-/,FJWD>O'5
M+<6*K<?C!^W#^R+_ ,%"?AAXYNOBW_P3S^*O[37Q-\;SZ7\>_CU\0_#_ ,2_
MCY+'X+^(_P 0_$.N>"OAM\&_V7?"OA6Y\0>&?"_A?PAX(\(_%;]H'XU:!I<N
MDIH5AKO@3X<07OB1]6T+PM_9_+BJ[HRG/V%2HO:5%>+>MJM79+56UUL[VWZG
M1AJ,:CA'V]*"Y(/EDE:-XWUDTEOJ_>T[V1_0&L;LS1JLQF02-)$8V\V-(U+,
M94B\UD=%#/)@"VC5?FN."U,"G*@%W+D*H0%F+,0%"H#ND8G "+\S9^7I7\R/
MQ0\*?\%V[W2M2^&W@C1?&FN^&?@7XR^$,WP]U?Q1JOPNMKKXIM^SGX^\7:QI
M?C#3OB1I?Q+_ .%I?&K3/BA\-/A7\.M<\:Z;\>M1\,0_%/XZ?&V]\(^,]"TG
MX9Z9K.IQ=S\3_$7_  7CU7X4_';2M!\-^+;CQ%XM\6_$SX8_#G2?"'PC_9NT
M;QUX(\-67P\^,NG?"3XCV?CW7/B]H_AK6?"'Q3UVX^#-Q\:_$NE:(WC'X5W$
M'C&?X/:3K&LZI8Z/X7YOK\4F_JU>Z5TN9N[2=_LK9Z6Z6U?5;K"-R2>)H*+=
MF^2&U]'?5KOYJ_70_H[DM;N((9()XQ(XBC+13+YDG)V1^9$N_<%*_*[2QN'
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MX;\)Z-K/]A7OC(>'O OQ&\!?L^Z=XN^(G@/5_#O[7/BGP!K_ ,:;KP9XPMM
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M0)?'O@+Q%XU\(>%]:M]1T)2QZU:PV(=O.5]VNL6^C>SNK66]CZI-M7Q.'_\
M 8OI??I:]M_TO_2.\4D9 E1XRT?F+YBNI*;V4%0596!QAG#M#'./LOG23%HT
M'C>-VCE1HI8RID1DD7&Y!*H7S8H7)$92:0-$H$+,8I)6BD6OYN=*U'_@MUX.
M\5?M%:M\+OA5\5M-\,^/?V@M7^-OA+X??$C3?V>_&\EC8_$/XH?#K6[7X5?!
MWXA:S\5/%NJ^#O#]UX+C^(VA^.=5\=^$M5\%_!*XT[P,_@/PK?Z-XDU_Q#H/
MU/\ #B?]N&X_9=U9/V<+KQ'HU[_PW5_P4QOO >H^./#_ (?\8^)8_P!G+P[K
M_P"U=X@_9W\,R6'Q8O(I(_"/C#]HK3O GP_\)ZHAGN[?X2:YHRZ'/I'A>ZL-
M6TMPS#F:B\-76Z=I3WM?^7:Z:;M:^U[M)/#37-;$T;1_NQ2:VT3?X;O7MK^S
MV&_O?H*/G )QN ')(8*I/W=[JCJBM@_,PZC ZG'XW_$;QE_P52\)W.C:/X>T
MQKW1/"&K_'+4?%?QL\0>#_@])X,\5?"SP]8?$GQ'\/M9\2>$?#Z'Q#X>\4Q1
MZ5X TFVN/#=U&NO:-K%S(O@O6M9L_$.J:5Z??ZK^W?\ $KX9_L>_$SPKI5QX
M'\<_%'PY\0_'7Q=TRTL-!N)/V>_"_P =/B9\ O$WPT^'>L^%?$.KZ7X>\;^,
M_@Q\ M:\?>%M5UO7/#7B&X?Q_P""M>\06:Z9-J-K9ZO?U^-TEA:TF^FKMI?7
M1VT^=VM-3-89M/\ VG#V7]R*]+-6?_#.[/U#*NH4E)"KHTBD+@F-"0[ .(]P
M!!PR%P DS.%$#Y&26-G62,HT;;95*R_NFY 4GRAR<9;S?)V@_+YF.?QD\"^%
M/^"F5KKT/BOQ>VM:RGQ$^)7PHL_B=X(N6\':1HNFZ%X!T#X41:G\8?#&H^&O
M%MGK/@Z?Q;J'A#Q/;^+/ 7A34(?!.IKK_B"Z/A.[%\]>$>#O!7_!5ZS_ &:/
M"_@Z1/C]X>\4_"K1;2PTGQ)=7WP>B^.EQ-I?@SPS>?$+1].:'XA^(O!'Q4\.
MZMJNER^'OA#XK^+,LWC'Q;=:GXNAUK_A&H8-/UFXKZ]>48RPM2/,VD[M6LD]
M6X_+OI>W0/J]HRE[>B^5)_"^NG=?A>Q_0CG^\0.#SAL X^7[N68E\(%4$L6'
M&,T!92 P1\&00KA-X,NU/E+[T0MO9D:.+S'1D 59&?Y?S'_:C\2?\%'+?XF_
M$;3OV8_#EXW@\?#*VF^%6HZGX,^$>H>"YKZZ^%/BV77M<\:ZIK_B;3_'%I\=
MM#^.47@^S\._#6ST:W^&-]\/!J%]<ZA--<WDVDY'[57@O]M:P_:%\ 'X"7_Q
M3\=^!]:_9LL?@[\0_$T%I\-+'X=Z[J[_ !0\63^/O$OCF.?Q#X2UGX9?$>3X
M4:B=8^&/BCX0>$)9;[QU)X8\(ZE>V/AF,1)+QWN^[A:WQ.+<FXM-)/6ZT;ND
MD]6]$F/ZMU>(PZT4K*-]VUHN;ROV\]3]3B2"5*LK+D,KJ5(()4AE8EAAACYB
M&_O*AW*KW5D8JZ.K#!VL"-J[5)+%UC8G>R1@+%M\QI$,F86-?BYX1U__ (*D
M^%].\&Z#JW@KXC_\(OX73P/X9^*EQH/A'X"^,_&VD>$-(DTG2?!^K?LTZCXM
M\<.?C)XJU_P_8V5Q^TMJ/QIFTRX\(:M?>+;SX?6.MWEIIUK>?6/["VC_ +47
MA;0_C!X3_:9TC6["WT[XK^.]>^!][>:CHOB*SU#X3>-?BI\3/%&FQ:_X@77-
M7\4_\+1TR^UBZAUSPO>NG@+PI\,V^$$7PXDGD?Q-H^@NGB_:3C3^KUHMJ[DY
M:)Z];)-73NM'9/Y3.AR4W+G4G?1IK5:.Z7-=*W2S[+NOO&N7\5#,7AO@D'QU
MX3# ,$.QKR3>=V0P'$<?&0IE+N%4;AU%<KXK)\KPX%&#_P )UX18L>PCU#/]
MUVR&9"%C1FE<1QR$0LY'IX?_ 'FAHW[]2Z3L[?5<=?7HN_J<->_LGRN*?/05
MY*\;/%85237G%R7HW?35?F-\0/V//VS/%GQ,O/$VB?M(W7AWPI/^U3XR^+E_
M/X=_:3_:%\*>(?%GPBUO4=3O_A!X1B\*O\//&?PS^%>H_LT:7=67@K1? '@;
M3-7^'/QUTL3^+_B1J&D^++&PCO\ .^"W[!?[1?P9\;_!CQ%HWQ/^'D?AGP=X
M\TS4?B9HFC^-?BUX?\.^*?"UII>IVMW8R^!-&\):1IWCSQ?I<%[-%X D\;>*
M/#_A?P;-JOB676/#7BVS\02V]GT/BB3_ (*CV?Q.^*.O^"K_ $#5?!=G\0O'
M4GPA^&/B3P7\*=.\(ZSX2M?CL/!7@#2O$GC^VU"3X@1Z'?\ P(O6^*FIZKN3
MQ(=0TZ!9+B)[._\ #.L?/>K'_@K-=3O\1/#^@^.K;78/A5<?#ZQO_&GA?X46
M_C;2K#Q%\0?@+XG\>:W/\"/ OC;7/A9XD\<>%]>TCXEZ;\-]08W.KZA\&M/U
M.Y:_&K7MG+K'SL52IPIS5+$.;6KDW>$4J4E;W=$N;2^R5T]F>RY59)0]KAU!
M>T?*HJS;Q&)O[JM9OEC=ZMV5[]?4/'7[$/[;WC_QA^TSJ5[^U-%X+\'_ !(\
M9^(_%GP;T#X<?M ?M6>%[OPCJMO\-_VK_#'PWU?Q%<6GDZEX6?3_ !G\3OV;
M?$WCCP1X*UO6_AOKDOP4U*\@\.M96GAOPWJ&T?V"?C]XH?\ X*"+\4OBQX9\
M0:G^UM^RI\1?V>? 'C1?BC\>-9UG3=2\6^.OCEXQ\%^)?$'AK6+'1=$^"/@W
MPEHOQ4\#^"7\ ? ?4;G0]8L_ \_B&^L=4FUJ2W6KXO\ B+_P5 \,^#_B=JND
M_"[QKX^^).GW6N:5X;\.>#_AU\"-*^&VHQ:Q^SW\5H/@]XN^%USXM^*5KXKO
M(X?V@T^&>J?'K0OB1KEPW@+3[B[T7PS<>)=(?5;O4>8@L_\ @J+X0\7_ !0\
M-^&7N?#?PWF'[07B[X<:S>_#;1OCWJ&L>(O&OQ.^/NO:.VJR7OQ$T#5?#,_A
MHW7P8N_AQX.-Z=#7P%>7FAV'AO5M634]+\.U:C.SE3K[N[NULW;?LUY;+;4$
MZL5I5H:[)132_5?UV+'B+_@GY^U1%9^--7^%'QY@^%.H_%'QWK'BWXI^!-%_
M:#_:3O?!'B;0WU+]F^X\+^ -(\8:AH%]K7AC7;/2_AI\8=,\0_&30O!MA\1O
M& \<Z,?&7_"3VVK>((_#_HW[1'[('[7'Q:LOV?\ P?X1^//ABQ\(>"_V=?''
MP@^.&J>//B7\:;CQI\5O%?CCX1>/?AKJM]XBTOPKX4MOAI\5] \1W'BOPIK.
ML^)/&7@SPCX^LM6\.7VM:"C33VFC09OQ'M?V_M:^*/['?C+X<^'/B1X!UGQ9
M^S[X=^'OQZL+V7X-_$#X:_#KQUXG^-WPQUCQYJ?QE:ZU/PI81ZMX+^$\/C_7
M_!?BSX2^!KJ^UKQEHVB>!]1L]-T#5;[1;M? WBW]N'XT?LT?LU?%O7W\:>"O
M&WB;]IS^T/BE\/OA!HO@FVOHOV;X/"GC#X3Q6&MVWC@Z+)JO@[Q1\1-'T[XU
M^(]2TQ[;QWX9\&>-K>71([BZ\%:+ITCM2DG!4<2N[NVN5W34FUJG%*R;;LXM
M;W!SJ+WW5P[^RO<7Q::I)JSU?17LUY+R;0_^"<?[747AWPGIWB/XY^ 4OO!F
M@_$O3/!OA^[^)OQY^*]K\,;OQ'\#/BS\*/!EGX6^(_Q1\*/X_P!>TS1O&/C]
M_B(^I^((+._\+0Z]XE\&>$;&[T+PIX0M]2]-^"/['O[27P3^._P:TVS^(FMQ
M? *+XI?M&?&GXVQ^&_BW\5O$NC^.5E\8:A\2_P!G/0]0T_XBZE:W_@?7]4\=
M_%+7K+XJ>#_!-MK?@/Q[X%^#GAN^UK6OMNMW_AR#BOA5IO\ P5:^'J?LY_##
M6+Q-<\ >&-=^%6E^//B+XE\#>"_''B_4_"T_PP_9;U'QWX*\:IHOB33KU/#6
M@^+-4_:C\$67Q;LKR3QA#KGA_P ->(_$MUXFMK&P7QC[#XZTW_@H1;_%OXQR
M?#*ZU#1?A=+\;KN[\(6 L/ _B2;QC\/_ !QJ_P #_!6J:SI^N^*O$.JZYX'C
M^'/@>[^*OQ(\-:7X9A\+V">*O"=M<WFA:BM]?V'BA<M)1Y84L0DE>44W%-=;
MV3LY:M+1M-]@YZK_ .7U#?2\%T7F^G>[V1R.@_L+?M2>!O&VA1^#_C3IO@WP
M'H?[1GQ0^+9:U^//[3#Z]I?A_P"(?[6\G[0NHZK=?#/4M#E\!^//$OCOX*:S
MJO[+OB7X9^/_ ! _PS\*:7)+\4O"&LWVK^)M;TJ3H_'W[&/[57B'XC_&/X@^
M!?VI]3^&]]XB^*6L>-/@U'HGQ!^+=EH?P\T7Q?XEU:7Q>GB[X8:8EI\/?&WB
M.7P%>Z=X=T--:T[Q1;Z)?:;NT/5-"G6TU0_//PPT/_@J=\%?!#_#:PTSQ)JG
M@+X<?"K]G?2= .G>"?AS\1OB_P")8M=MOV?=;_:*\>^'O''CGQGI_ASQ)^T9
MHGBKQ-^U);WO@'XAM=^$O$%KI?AK7M"F+6-C%XL[K3+K_@JYH'CNXT+P_+XD
MU_PE+\7/CMXEL->^-O@+X4ZW9ZGH>L^,M$U_X-?#:^N_AUXHTFY\#?"NU^&.
MN76BP^);"5;KP+\2-*UG2KIM>T'2](TKQ(1=-2YG3KOF36[Y4KV?NRCNW9VE
MKTU3=Q^U:_BT+7T]R-]O17[==?-%7P)^PK^W5\/?^$C7P/\ 'GX=_#F#XI^+
M=-\2>+S!\=?VG/BQJGP[OM#UOX$WL/CCP=XD^)G@IO$'QD\7^*-)^&/B_P (
M:[9_$BX\(:+I7A7Q#H_A6PU#5?"!U+1-/]5^"G[(/[8'A'XP?L\>.?&/QVNI
M? GPJ\':'IWC;X=^&?VF?VB?B/;^(/'&G1>.K?X@^+M4;XM_#R]_X6OI'QWU
M7Q+X8U_Q)X9\9W/A.;X8:QX*TJQ\"ZIJ-K;37&H\I\/3^WYX=^ _Q.\6ZGH?
MQXNOBAX\_:E^%6N:Q%KWA+X"W/QPT?X#'X(_#7P]\4;[X/\ PGC\<ZK\!M/N
M-*^*7A[6=-\->'[[6;);[P2VO^/IM#O?%,T4UYY9\5O!G_!3WXQ6/C[1_$VE
MZ[IUGH7[0/B>;X;Z#\.)-*^%T]C\*'^'?[57A3PGJMM\4="\<V0^(NAZWI.L
M_L]ZAK>E:I8MJW@SXLSZCJL-U/8PV]CX?%*DW>$,3S::2?+'9IV=DK/5W35G
M=JVHFZCC.$JF&2LK245S:J^N[5GTL^E[GI'@S_@G9\:_ OQF\5?%/PA\9[7X
M>7X\:>+[[X?Z[X=^,/[0?B?4'\'^/_VK/C#\=_$[?$GX?^*?^*)\67EGX%^)
M^E>"_#?PYUVZ\:?#S2_$FAZYXBT:\T/4/&&H:O-2_P"&1OVX?"G[(GPL^",G
MQ0\1?&3XNR?'W2]=^)OB:;]KC]HKPMX;?X>3_!S6_#?B&:^^.OA?P3X0_: \
M-^"]6^*,>F_$8^!]&T?QGY/B[7;?3[;5;[0WN)M(^O/@_P#$[]JG2/AO\8K_
M .+/P8\<^/\ XI>&M7_:$\6_"&/^Q?AEX&\._%;0_"]]IEU\'_ :^&[/Q6S_
M  [U+QO<Z]#X<TK3->U7Q?:7>F^"O&/C#6OB*MG<^%K*^_+O6?V;/^"J.F_#
M?P!X=\0_$_XQZ_\ %']FZW^/WB;1?BA\)_BWHGQ/D^-&O_$9OV6?%WA^XTG6
MOC!H_P /M5\1^*]!BU#]K7X5_#?PSXW\*Z'X;\):'!H7A/2]0_LO6-/U]54C
M"G3YX4\0^=/FDY-VE)W;22^SKKHGV]V5G&4YS495</%1244HI*244E?7>36O
M7?7:WT[J7[#7[9J2>$]6L?VQ-?UOQO)XU;6/&WQ"UKXW_M&>'+?3GT>/]GVW
M\!?$SP7\)_#(U'X;:_KGA/3OAY\>8]5_9Z\26'AGX*_$"Z^/UWXD\<ZYK>JZ
M7*MEYYX>_8)_;W\'0_%O5_"_[0?PZL_'/QECTGPYXG\3ZE\?_P!JGQ!>WUG8
M^ ],\'?\+G3Q!K7@C4=5TCXA6NJV>H:[X.^#NA)8?"SP%%XMURR\-^*])LYK
M^VUCWCP%>_\ !2OQ1\:-2L_'6J0> _@^_P"T+;R&73OA-\.I-0TWX"Z#'\;]
M>TYM%\67FJ:GI^LVOQ,L-.^!7A[QS8P^&+GQA\//%NI>+3H6IP6FIPVN@97C
MO1_^"C+?$;XDV/PZNM8\,_"O5_'7Q&M=&@M++P)X@U75-!^(OB[XH^'8/&.C
M>+O&7B76?%'@^\^&G@*/X<^,?!OA[08+;0X_$#01W7A^:UN=;T@)4X3@I^SQ
M-KI--VL]K)VO>-GTTUOL-SGS<O/AFTF_@]//KZW9Q?B[_@G]^U!XF\2WOBK4
M/BEX2'CU-$_:6\%#Q_KG[0O[5GB*^O[+XP^,/AWXT\$^/V^%/B#0)/AKX%U7
M2=*\%R>!=:^#WABSN?AYH&E26'BKPKXAU36-,TS3;5\_["G[;&LGQ#+K'[6V
MK:.3HOC2XT!?#/[2/[5%S%X@^.C>&_%EGX!_:%\5W%U;Z--X6CN?&&L^#-5\
M5_LX^%%UWX)^&K3X;Z;>:+IGBN35=1L'X+X1Z9_P5&^$/@W3/AYJFE^*KGX=
M_#Z;X0^$$B\'?#_X9?$+XQ2?#./2-$N/$7C_ .'_ (Q^('CFV\*?$'XIZIXB
MO+ZR^,'ASQ__ &A>:7:W?BKQ#X.ADNM T6W\0]-+!_P4N\*1:G/9P?''QA<6
MGQ'^/&C>(_%L^C_ [Q3\1+?X6^(OC_XO\4_!>;X&> ]2\;:+\)O&%K9_#N^^
M%/A_4]0\9VQ\6>!_!C_%+1_#5Q?7?@KPOI]X*%.&U.NW:3;YF^CO:Z=DM;IV
MVL]+V&ZCU53#KRY%KY]]-K^K]?3?VN/V(_VB_P!I?XB?%UK7XTZ7I'P4^(_P
MUN?!T?@R[^+/QW\-"TTV^^"NJ>![KX5ZG\+/!%I:_"^/PEJ?QRO/#G[1=Y\9
M[+5W^+T=YX>M?A5;:1)X*U2^@FZK]J/]CGX]?&7QUJFL?"/X_:W\'?!(^&^D
M>'?#&E>%_BU\;?AKXEL/&'@_X5?&OPC\/==UC7?ANT6HZUHOAGQ[X^^'OC9K
M#5M;UFTU)O!LM_K6G:IJ\5A87CO@CX\_;J\)_$73]0_:L\.7NM^"OB)>67@#
M1/!_PM\#^!+[3_ 'Q(U6_P#@AIOAO7K#7]&UD:_=?#K5;;6?C_XJ\<^)?&6H
M2V7AKPOX!TQK*V36)=(TSQ5RWB_4?^"F&O?&+XF>&?!ZWO@CX:7GQ2.E^'O&
M_P#P@?P5UO0?#?PA?XH>%AX&\6_""[UG7+_Q'X\U[6O@D?%^K_'&#XJ>&]/3
MP)\11HFB^![*ZLYDDN;7L+)2IXOFE6M)IR=XVBG%OE=[Z;ZN-^B9+G5T;JX>
M\79>Y'2^NUUI\K)O<XSQ+_P3W_:7\17/B*RC_:U^)VF>&;3Q;XQM?A3IVD_M
M2?M:Z+JGAGX0:SJ'[7FL^&_!/BK4M'\0V^I^+/$NC7WQ2_9CMY?$OB/4O$VN
MQ:7\"-2T6U\7?V!;65EXIZZ']C_]L[Q1XMU6S^+?[2EO??"6^U'0[N6+X>_&
M_P#:)\%?$'Q;I&K?%NW^)WCNSU*[\.:1X*7P5%;^'_/^%_A*3P5XQ>76?!T'
MDWESX:TK43HVE^;Z_P"/_P#@K W@N[ND^&_C^Q^($S^ CJ.E> _A_P#LWZSX
M5TVVU#]FO4]1L9? =UXO\;QW^L:U?_M6-8>&OVE+#Q-?2:?\/?AT]Y+\*[B1
M;2P\3CA_B&/^"G>GW7QW^ _PWU77O#?B;XC>%_VH_P!J/PGXU\'R>&?$/BSP
M+-X8^(WBCPYH_P )/A9XE\>W-[H%G9_'/Q;\0/A;K_P.B\2ZGHMYX,\!_"?X
MF:(VGZ!%JEO]BE^Q@U)4\5+E>B<ZC3?PVM9Z7U=NU]'<OFK/2^%5^JA%-+>^
M^CZ?-VV/J']F3]E/]M3X9?$;4/&7QP_;'U_QNUW\./ACX:N[G0_$NM>/=*\0
MZMX7T#X2Z?XFM[_X0?$_X;6_A'09Y-<\)?$@Z/\ %CP9XBTWQEK^F_%#6[G7
M/#D&N7<4FE_,?P<_X)V_MU_##X9?!WX>67[3?AWPSHGPT'@S1[/0_"?[2'[6
MFM^'O >H^$?#WP T9OC9X1O]<\.VFI?$/5-6_P"%8_%>2+]E'XBQ:;^S;HEC
M\6)6TV[!&L6Y^Q?@3<_M=1?M#:UH_P 5M!^*&A? +6M3\;ZYX"UFTT'X8:[;
M7@U[Q1X]DOY/CKJ6L^,-1\8_#75]$\+P_"J[^%G@GX4:*W@V\UG6/%^C7VGQ
MZ78R6_A[PWP5;?\ !5#Q/XD^$MY\15T[X<WMSJ>J?#7XH>)O!^F> =>TS0?
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MXWC\$^'O!-S\-_%.K_$OQYH7PQ3P!XHG\1>*-%\,:[?:Q VLP7ND>$?5+_\
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MN.CT6#[7_8MIO*&[33;9G49:..>."*24?>),:N652B(SA2UU;L(Q+^%VC?\
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M)_A%^T=%X\\$>!?BU\1?B;X'L++X<Z_KGPQ\'_!KX?77Q(\0ZIJU[I7Q,O\
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M>_90^.WA[X6>&M8T#XP_"/\ :*\6_$#X=:GX,^+^E>)KWXC?#/08+[P;X2\
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MV;Z72V4H>[KA>O5TU9]]6ONO\KG6?#;Q?\=_VK/@;\,?B1X7\<Z1^SOJ=O\
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M>PN;)M!EO)=66TL-4@N-/B@S-0_X*??"+1+/X?:]J7AOXL6/A?XH^,/%^E^
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MF_/9-ORO<^$A_P %/OVI+KPM9?&.+]FNWT[0I/!NJZ1-\/H]1UR]\,^'M?\
M%/Q)_9ITJV\:_&?6(]&A\7>!KWX.:;\3?B%X'\:^&7U2RC\37MK:^/+NU\*:
M+>7]CX5]-U'_ (*@?$VR\:^-/"DW[/&G6%KX/N/V=&\1ZC=6_P 3]6E\,W'Q
M3.A1?$7P_HJV>C00?'OQ-X9FU^QO?A]=> 9/"NG^,/#KZGKVGP>)I-+&G:U[
M!HO_  5E^'&M)<7/_"D_VH-+N1I'A+4/"5MJ=A\+C>>,+[QYI'P$\3^!?#7A
MZ6R^+-]!IVMZUX#_ &E?ASXQ$NO3:-H>BV%[K^D:CJ<6L:2FFW&UX?\ ^"J_
MP>U7PJ/$>M>"_COX%@D\)>,/'%EI/BNT\%PW]_X0\(?#+XC_ !1U35;)=&^(
MFL:='%JMG\)_B!X?TVQN+]+R]U?2(;V\L[3P]J2:I(E.W_,9KUTK=Y;6CJM?
MZLFIY'_T"O\ \D_S_K0Y3X>?M\_%[QG\!/VA/C%XC_9PL/A_JOPL^(_A/P1H
MWA'7/$7BK4=0\+:;XE^(+> /$FH_'?0]'\/:GXVT*?X&63+XT^(Z>&='>+Q!
MHMO<P>&+?2;*SDUZ\\YT/]J[]LOQ/\$/VZ/VC[?PSX3\-S_#/X!?#?Q)^S]\
M(-2\&?$K7_!MUXELK#Q3JOCSXFFVF\,^%_B/XY\+_$;0])L/&/@*P*:=XETO
MX?ZQX7TWQ#X3T_75NWU'UOQ)_P %8OA)X:DN8;CX1?M0:YK]I\2/$_PW\ >%
MO"'@G1O&7B[XDP>"-=_:<\/>,?$_PYT+PKXSU:_70-&O/V1OC$+?2]4MM#\4
MZS!I6A#2?#E_%K*7%GZA\?O^"@G@C]G_ ,;>(_!>N_"O]H#X@:QX:B^$L-E=
M?#;PSHWB&7Q5XZ^-NE>-_%'@?X>^$="NO%ECXOO/&M_X3^'/CGQ/J).A66CV
M,>EVVA'61KFL:?I8IMVUQB=EHDJCU4NEU?;=ZR5VEI<5E_T#?^D'@.L_\%#?
MB]JWC[5?A5\*_@=X2\1^.=)UKQ#IM_XB\43?&S3/AOIFG-XVT>P^'?C"YUK2
M_ -]=7?A_P"*'P_N-1^(OARUTV]NKF'3FTFUN[JTLKFZO!QWA_\ X*4?M!W-
M]\%]&\4_LEZ)H>K?$;7O!PU#2]+UOXOZJFJZ+\0;']F'Q%I_@CX8:AJ/PLTJ
M"\^*WPR\)?M#:SXI^*W_  L2#PSX.N+'X+>*[71)$2YURX\#>\^,?^"I?PH\
M'WFN:?K'PU_:&2[\+:IX@D\0:+J.A^$O#?BSPSX#T+P'X>^)>L_%_7O WC'Q
MUX<\2Z9X'O/#?B 7WAT1Z9<>)/&EYX?\5V'AS1[G4- OK.+&U_\ X*Q_!SP_
M;>(;M?AS^T#JUCIGA>]^)ZOI%EX D_MG]GO2].^/>OW_ ,=+=+OXE63P>$+6
MU_9Q^,D]QX4U_P#L_P"*$MUH>DL/!T \36YFA.;<?]MV:;TJ*ZNN\5TOTZK6
MP-+7_9&][+W-'9ZJ[].OR/L3]F_QY\1/BK\!OA/\4OBKX6\)>!_'/Q(\$>'_
M !YJW@OP7?>*M1T;PG;^+=/77=(\-W-]XTT?0?$EUXAT?3;^VM/$LU[HNCQR
MZPMZMOIT=I%:NWM^!Z#\A7YZS_\ !2+X4CXJZ5\'!\*OVB=8^)6H?%7QO\.=
M:\,:!\.HO$GB?P1IWA+Q3\,_![?$SX@^'=+UNXUOPMX(\5ZA\6/ _B#P[=ZK
M;17FI^ -2B^(AM%\*>1J,GU)\ ?CAX9_:'^%7ASXK>&-,UGP[::]+K=E?>$/
M%3:3;^-O!NM>'-<OO#NO>&/'.B:7J>I/X8\5Z#K&G76F>(?#FI/%J>@ZK#<:
M1J,$6HVEY;V_HTZM-J,?:*4M%=W6OFVOQ;\V<DZ4U>7)R1[<T=/E>_W)GLK=
M/S_]!:MOP+_R/S_]B=>_^GO3*Q&((X.0,\^ORD\>HP1@_7@8K;\"_P#(_/\
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MPF_@;QYIFL_"L_%]=8N_&'Q*\!^.OCF/C+\9/BSXIT*WELM1^)G@K6/VM)-
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M:^GAJ_\ $7A_P_\ $O0_BAXYTGQ5X<U?6?$_A"0>.]4B\.:3X9O+K2Y],/\
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M:U@\_P# G[+?[ GQ*^#/AWX@_"OQUX_C^'/PSUC_ (6%X+^)^B^//%?AG7O
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MZ?XM_8]T[Q%\4=)\3?$>3QXFB^ -,U[QGI7PCTGQ[X7\5>(M;\1RZ%!J!O/
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M/ K:%+?:EX4^(6F:S\'_  K::.FB2>(M2:P\!Z%JGA^TM;+P^L_L'PT_8-^
M'PET7X@^&_"8^)#^'OB7\!M(_9N\2:-K'CR>ZL5^%NC>&+[PC!%IT>E:9H\W
M_"8S:-J5Q;7'C_Q#<^(_%EO"8M-T2[TOP_:6NA0<EXB_X)N?LT^+O#-EX:\3
MR?%W7I].\477CRQ\6ZM\1(]1\7VOCV_U[X3>(+GQD;J[\/MX>N]<DOO@OX+B
MEBU'PSJ?A^73Y?%&G7^C7MIXAEF1.&,;A:EAXQBZC>D&US<R5ES6;2=XZZV6
MJV$YX7]Y>KB'*48JVMN:-GO;X6U;M9N]['V9X$A\#P>"/!\?PQB\*P_#3_A&
M-$F^'Z^!HM.B\$/X1NK&*\\/R^$DT<+HP\/3:7<VUQI<VDF33[NQEMKJT*Q3
M(\LWB<[5\,L&"G_A//"(#X(4,+V5D_>*R%7W1@*%<,H+%5G8K&9?"7AC2/!/
MA?PSX+\/6XM= \(>'M'\+:);B'3[?R='\/Z=;:3I<#0:98Z9I\3065G!$PTW
M2]*TT,A%CIMO9_9E$7BG[GAKG&?'/A)<<C<&OV# 8P20-I90>5 R, $>EA5)
MU<-&33:=3IRK_=,=?=^>MV];Z]3S\1+W)6ORRG2C9)RDN:O1UTTLF];6\S\U
M?B+^T+^P/\._BGXUA^.?[-7AOX67]I^T;X1\*>._CI\5?@Q\(;#P;J?QGU+X
M7?$OXO\ @3Q_K'BVUU;7O$VO-JWP\T/Q7XDTGQ1?Z/+?Z6OB@+K9L+G4==B7
MZ/\ "DW[ 6GZYXI?P78_LDZ=K_[)6B^*-2\6WVC^'OAEIUS^S]X>\4KJH\;Z
MI<Z\=+MK3PEHNIS:3X@TGQEK&G:C/I\>H:9K/AWQ!/::Q;7VCOM_%7]G#X!Z
M[%\0?B'\1I_$FE6>O:\/B'XUUBR\5:I8VEMJ5G^SG\1?V4[BXM[?3K2]GM+
M?"#XD>+]/ETVTM+LR^)S::Z\<TVG-82>,?#K]DW]AZQF_:.^#7@'5X/$DGQW
M\&:[_P +>\$Z7X]T?7+[1O#VI_$;QEX>\:W'AGQ3H.B0:]H&K'XS:!XV/B31
MKGQ9JS^%/B1H>IQV7A?PPEK/8V_CIUXJFN7#R2IP4>9QEI:GW>E]=NJC>RO;
MT5[&4(2_VFFVI2?(FK^UJ5:J6JVA9*_6[:V)/#'BW_@E7>R?#OP-X5D_8>@;
MS9O'WPU\)P^$OAQX?AT&[\$7/C>*Z\3QZ;J?AW38O .J>&I_"WC^!7U]_#6M
M:;)X6\50Q%YM(N!IW,^+?CM_P2]\.>&-?^(VFZ=^S/X^UB+X3_$;QW#X8\&_
M#GP/=_$?Q]\/O'\_B?5_B)INF:/KV@Z(MU)\4VNO'_B6\\*^)3:W/Q TJ?QS
MXJM=-U30I];U:3M_$7["_P"R7H'@CXRZO\3[SQOXF\,>)-.3QA^T-XL^(GQ*
MU/5KKQA;>!]+^-^LZIX@^(5WH=GI)$TWAKXY?$9=5M=!T[2O.T(^&K70+&SF
M\.6HEHZM_P $]OV;OB9HK7_C/X@?'WXI:1\1O"_AN34]1\7_ !NEOC\1]1B^
M'VL> _ OQ0U(6GAK2DOOB3IOPO\ %EYX.T+7+6TL;-](FTPZGX:U?Q'817[2
M_K5U:CA'=)VYJ2>RZ<R[-+?>_:S4:&_M<9>^FC[OR^?7TOJ\_P"(/QH_X)I>
M"-)\$_!^^T[]G#Q7H_A;POXU^-GPN^&7@_X<^#/$7@KPWIW@?2Y_%FK^+/#^
M[0XOA[\/M8O+,7>N:)?Z[K7AN_UJ\MY[B2>[O6MKB7W!=;_8E\=SR7.W]FSQ
M<GAGXNZ?\'!J%_X9\)WUA8_&%I/'%UIG@73M7U31(["_U^]N?'7Q333VTJZE
MT^]UGQA\1=(2X-]J_B2QN_(K#_@G7\#'TOXH67B/Q!XTN)/BG\:OVI?B1XO;
MP3XHD\#Z;>1?M:Z;I/A;Q;\+=0L99?%(G\.Z+X4T#P79>%[&UN],O+37-(@U
MS1X-.MM1NM#/2?$G]F']FGPW^R[\6?@S\5_&OQ!L?V<O&GBS2)[M]>^)NJ+=
M?"+5=6^(_AR^\(>'_@KXJTFPAUWP!;:1\4;_ $J;PM;(-=UO2=7U61-3U:72
M-L&F4GB^5\U'!VY6G>I3UO&R2:>]]%YMINUF-J@G'EGB]U>R=KWO>UKV776[
M7G<^>_@SX:_X)0:?XQU>W\(S_!+7/%/QJ\8VU]X=\-^.M9TOXBV?B6;1/B[K
M^C^$_%GPWT>_;7M!\/:-K/QE^*NMZ#X+U&^?1?$=_KGBBW\"6\D&GQZ;I4/V
M+X-'[&OQMUHV/@32?V?OBCJ_PPE\&>)C-H?@GP[XA@\!76II=?$#P+?VNHC0
MCI>AZQ*WCJ;Q[I&GVVI-K.E#QO!XDGTBT7Q=;SZESFH?L*_ ",>/K#3;?QUX
M*U+QWK/@[4[BX\'>/YM!U?P;KOP]^.;?M#^ ]3^',*6%W#X6O_"_Q85[G0H)
M[/6K=] M+;PY<V-[IRSL_$?#K]E'X&?L[?%[X8CX=?&+XG>#O$D_@^.QF^'F
MM^-;+7;#XM_#+]GKP-)\/H=#\3WD^AV$#1>%->^(G@?QGXR\4ZY?:KXXU37]
M/\*>'M/U30? W]J>'8TO;124J-&,6U[U.I1E+79/E=[;OF[6Z#DZ<E93Q#=U
MI*,FM.NSU5^MK>HEU\;?V<)IOVL?BUXY_9F\0^&-3^ NL:!\//VA_B'XT^$/
MPVN]>\2+?>$?AMJ<-NVJ:7K_ (AU_P ;>'_#7PM\=_#3QGK6I:I+;V&B_#R"
MU=XW7PV=%MU\,?%S_@G)X6\8^(=,TL_LU_"?QE\,?BI\9/$=K/J?@[P-\/[]
MO'?PKL?$WA3XK_%?P-J<6F6;W-U966D_$7P=)XBM;BV\3>(=*\"_$33]$T_6
M/#WA.^N[?W^Y_9K^!UYKOQ9\3:[X*TG7O$/Q9UGQ/XF\9:SXC>TU+4M(E\9?
M!#P9\ /%<?A:XN+=+KP9H?B7X6?#GPWHFKV5I+Y>HW?]JZG+=*U_BV^9[7_@
MEU^Q[I]EX>TNTT/QM:Q>'O@]X?\ @U;NWCVTNM:U'2]&3Q4OACXA:EXEUC0-
M0\6_\+@BU?XA>+]:C^)&C:II$GB/Q%XCN[SQ1I>NFYAL:UE]83@TL/.-GHU"
M36MK6<DK/5].FVJ<)4TM95XN_P!F,DGZZ6NOGU/5KCPK^P?;^'_#WQ]U'P%^
MRYIGAWX@^*[KQKX>^+&M?#CP%H9\2^/O'&GWNK:KXC.N:MX:LM7B\8>)K3PG
MJVHZW<ZND&NWFL^'KF?59?[:LMCTM5^-_P"P WAW_A%M;\?_ +,C>!_$NE^&
M_&DNFW5OX8;X=ZSIW@KX>>&/BGX)UBYU!M(F\#M>^&?A)H?A3QQX"LKV]_MV
MU\$Z!IE_X4M[NS\,?Z)-X_\ V<?ASXM^!WQ!^$/[1WQ:^)WQD^&7COQW\.GD
MU/QSXGA3Q7X<O/#FK_#ZP\%^%K/Q-X4TF.[FU+7?'N@6VN>*]6N]+L_[5UKQ
MEK>C'3O"_AEXM,C^>?&G[ /[!'P&\(>'?B)XQ\4>-?A-\,?@G)XRNM/N-5^+
M$EW\./#>H>.M6^(@N;S4?#FN^&?&.EZC<:-9?%;7O!?A71(]/FTU? 6C>"_"
M'B+1M8TWP)X?AT^93KMV5##J]/G=E!M<ME).+EU:;TU2V3=DS]S=WJXI6G&%
MK66NSV\UH[:]4MOJ#Q'_ ,,7KIWP;D\8>&?@5;Z;\2/$?A*^^"#^(_AKIEE%
MJ_B_PRQLO!%QX=35_"*3^%?$.@W'B_\ L3PNNOKX?O4U7Q:OAK3Q)J^JOHLO
MFVG_ +17_!,_QWX6T+PSIOQ1_9&\4>"_CMK6E_#70?#T"^%;SPW\5=5\*WW@
M_5_#OAPZ;)I,5CJ^G^'M2^,O@?5O#>H:K!'H,%[\6/"FHZ)J$\_BVSNM2\3\
M6^"/^":E_P"%O@GX7\3_ +5VB1>&_P!@'P'HWQ7\.RZE^U3I5SI&G> +O5OA
M;X^\,_$3XPZCJ%U>:+\1-#L-2M/A9JVCZII%Y9WFA>'_ !YH/AC29-#\*?$W
M2]'\0<-\'_\ @GU^RE:^+OAG\'K+]IWXD_%GQU^S1\+[/PI^T'X,_P"$WO9-
M:^+!31_V0I/A[I/Q4?3[.2V\.?"CP?HG[-GP_N=#^!^EZA-JUUI?C>";5_$<
MSN]SXDS=6K)Q4*.&YG;W>6&KLOGJXR5[)*3LG919KR4XINI6Q+BKJZ3O97\N
MUG:^VY]/:)^T1_P3%AUG2O$GAWXE?L>V.M>+KG3?$FD^)--TWP9I%QK5YX;U
MW1_"'A[6[?6TT2SM_/M-<^%6DZ1X0O[F]AEU)OA+/-X;CU*P^&>I7N@:'B3Q
M_P#\$U/MLF@^,=:_8YFOOA2B_$-M-U[1?AWJ"_#^7X;7D?PXMM<L!<Z!=6^E
M^+/!D^CP>$-%T72S<>+K*TC\/VNAZ'=:9>:6U^W6/^"<W[,.OP6&FZUIWQ'U
M7PW:_"K0_A%JG@ZY^)%]+X7\6Z-X2^'_ ,2OAIX+\4^+]-CL-NJ_$3P9X'^+
M_CG1_#/BVQOM.MDN;W1=6O=*U*^\,>'KZPQ;7_@F1^RIID[7FA:;\2/#NI'P
MK\*O#]OK>C^.;<^)--\3?!4>!U^&GQJTCQ5K7AW6/$^E?&W1+CX=>#-1U/Q=
M9ZW::-XFO_#EOJ'C#PKK\VIZIY^CAC)1L\/AXN_Q>X[Z;:26E[._RVN97PS>
ME?%-;V=X]5UU^6SZZ6.)A^.O_!-G4M%^#GQ \4_#OX'^$?"W[8_A;QYX?\+>
M//'7PK^'^F:1XR\.?!GQQX7\-0>%O&6N?V;),VEW7B.Q\+:WX/CUG;I-A::'
MH^H:O<Z-?:)I*0^UZE\4OV#_ (9^ O$OB&VN/@/9?#WQQ\3_ ("KXZ_X0/P/
MI/B'1]>^)?[07BSPY=? CQ#XST#P?X<U%;_6/%NMZCX>\8>'/$>K:>\^D^3I
MWC2[$<L82==<_82^"'B/P)\+OAQJFN?&Y/"WPOTSXB^'E6Q^*^I6NL_$?PE\
M7/%>G^,_BIX,^,&LKHT\_CKPWX\UG1[%]=MU@T*_>S+V>E:EIIEG$COAW^Q-
M\-O OP<^('P=76_$UO:_$?\ :;U?]J;5/%7@:]N/ ^O^'O'-K\;_  ]\8/A)
MI/@R>[G\4?V1X9^#5KX$^&_@'P[HE])J&DW7A/PA/9G3+'2]9_L^SI1Q<;IT
M</[RZ1B]T^TG[R=E9Z75TV#6&M9UZ[UO\26VG;U?X::G"_#W]J;_ ()T^._A
MEX1^*MKXH_9T\(Z!J6M>&/#5OIOC#2/!6BZ]X/\ &MKX?T*XT'POK%B+.YBT
MBX\)^&?!7A@-K5I<2>&/"FA>!-&EG\1V&F>$XA9YGQ@^+'[&6D^)?BG\'/''
M[,NA_$B7X$ZC\!K[7O#D/P@^#'B6PD\;_$[7O#&A?!+2_"'A;Q1KUCK-UKUK
M??M!H+?Q5-H&C>$?"X\6>+;&X\6V%_JEU!J74Z[_ ,$W?V6_$+?#Z:_TCQT;
M[X8Z%X,\*^$M3D\86VL3P>$?!?A/5O!EGX3U.S\4^'?$>@:KH>L:!K5Q;^*!
M=:(^HW^JV>DZWHFH>&KJP/F^J?$#]D3X+?$>Z^,&M:KIWB+P_P"+_C?X@^#_
M (H\7_$'P7K&GZ#\0]+U7X$WGP^U+X:P^"_%EUH>L7OAO2=)U3X9^$=8O]#?
M^T=$UG5K"YO[NPB?4)VAGDQ*3_<T&[M_!;1W>GO.[5[:VUM;35OGH[1Q%9+H
MN9-I]GHMW=^5]CQKP[\7_P!AOX]^,OAU\#KCX3>%=<\1?%>P^)'BFT\&?$#X
M%Z)!I_A/XA_ OXG_ !%@\9?#'XBQ:MILUCX2^.&E_$;3_P!H3Q3X<\*27$M[
MXG/@GXV^,_#NJ:II@UG5=2J6G[5/[ /QVA^)G@_XEW?P5@M;GXE_$;X6>(O#
MWQTT'P@(?BC=_LQ:]XA\+ZKXMO\ 2]:BO)#X0\->(] \=:?\.-5\<QZ#J6M#
M0?$S^"[2\^RZAI\?7^$/^">7[+7@CQCH7Q(T7POXRE^)WASXD>'_ (MZ9\3]
M<^(/B37?'G_"?:--XXO];U:^UF]G<:G;?$C5?B?\5=5^*5A=V;1>+[[XE>+T
MBDTZQUFWT[3&^-O^">_[.?CV_P#&5UK_ /PM86'Q'U#QGJ?Q'\,Z5\3]3L/"
MWC_4O%/Q-^+/QBTN]\4Z8^FW,]PWPY^(_P ;_B1XE^%ZZ=J&D6WAN77(+34H
M=?LM$TNUMWR8Q_%2PUKJZ2BWNKV5W>VMGH[:[[#>'Z5L1Y-S376UU9+73377
M8Y'7;7_@E_XA\3_LU_$?Q%%^RT^K_%'Q3K_Q/_9KO]1\.^&=-TOXK^--6E\$
M>!;KXHZ!I=]H:Z9XC\2:/J>H> ?#OA/XA:[8A] U?Q3HA\+ZI;W'B>U34XI?
MV@O^"<6C:IJ/AWPQ9? K7/$7Q:NOB5X\\2Z/X2^%VA6,7C?7HO$'P]^$7Q<U
M#QYJ.L>'/#VB0^+M2B^,OA/3=>M?'^IZ=K?C;P5XOEN-/BU;1O$5HNL>K?%W
M]CGP1\;/B?\  7QMXM\7^.;3PG\"OAGXB^&\'PV\/:[)HFG?$6VU'XB_LY_$
MCPQ_PL770;BZU7P]X7UC]G/PW+/X=MDTVXUS4+Z.\N?$&GV]E=66J^:>"/\
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MKJ#_ /"07Z<3X7_X)K_LK^#O"=WX*\/Z+XXLO#=W:^)M-M[%?&%K82:9X?\
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MUXX2(:U\-KZS@\7>$XXM?T:RG;P7PE^R_P#M^W6L>+KCXF_M4?$2YTZ[\?\
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MIXQUGP/XNTOX.WEO=:):+!I?S[\,?V%_VYK'Q)_PD_COXQ7&C:[XQA\):?\
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M_P##!;_X<&Y\9Q>!O$W@S7= \)ZAXR\.Z-X5L-6\)?\ "8_L^M?V/@GQM?\
MANPN[.^:ZM=2U/QCYIX^_8'_ &E/%?[%G[-OP!M_$]S??$CX6_LY?MC?L]_$
M2\UG]IGXGWGA[Q=JGQT^ >O_  O^'OQ(UO4]2TR]G^(>D6OB^+0]<D\#>/\
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MPIX=\*77BZ71_B7^TO\ $3P%:RZWJQ\5:);VG@FV_:#T;P5:+<>#]1>?PO\
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M+%7?>[LKV/QP^-'_  2=U/XS>+?VH/%FL?M!>%[F/]HO7H+Z#P=XM^ #>*?
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M-/1+1]%IIY=EIL,^8DEE#$EB<$XY/)^<O)EC\Y!D*J6*J@8237"C..@'MG_
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M%\?Z19:OH?\ 8?BWX;7EY8"/7]0\1V'BGPX_X*:?M0?%#Q]XGTSP%\)O#7Q
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MNL];^'>EZG]T_M2_&_\ ;6^'?[2'QU?POI/[2UYH?P/^"OPE\9?LU_"#X-_
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M673-7.H:I_PC-KID=]?ZY#'.2G"Z4\;5MO'25G97YF[N]K-+1-7>S2:&DO\
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M#/Q4^ '@/Q=X]LOV1?C#X^;3I];^.6D^"/'=YX5U7Q'XENO"'Q6^&_C3X?\
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MS%I<K6[ZWNMFDDC>ER1A_#K/F;2<9N2WOK9Z??Y.YRFJ_MT_LX6NK>$[[3_
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M(/"^C^';/^T=3CL[.WX(_P""C'[%OC?5$\/?#C4/%WB76?%?C^T\$P:/X5^
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M1\6ZQX:^(?PY\-^$=9@MK1]<U?3H(]>&O6?BA?#WB*'7H9;^\C0WDD>SJO\
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MVN)A;64FW?7K9QL[-M+5Z6=MHEMU(I/V.$GK91M"Z[WL[JZU>F[[FM\,[/\
MX+!_$!KK2OC=K'A[X):;<:G\.(EUWX0R_!+Q+XJ&A^)]>L]'^)+V+^)-*\9:
M-:7WPXT+X6:EXXTC4KW1+Y-97]J&RTVRT^ZOOA1+'I/KOCS5O^"@X\-?"/5[
M'PGXJUCQ,_[&>@WOCCPO\&_$_P"SKX1TC4/VTKJ".'XF:7\2_$'Q7T'QVUAX
M)M].^SWGP3;X1:7J^F7?C/\ X3.T\227&ES^$Y4?^T3^TM^T=H/[0'A_X/\
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M4IM;^"GPQ^-VN^"?!'P,\=:/H]WHOB?5_B7XU^%G_"->$?%[:=XB\&_%6'4
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M_'^256'_ (-+_L'_ /;H">\O^WO_ $ICJ***U)"BBB@ HHHH **** "BBB@
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MK5_IG@?4-4^(6F7'Q \*27OJ/P[^//[('Q%\2?LK>!O#WP5^Q>*?VNO!>O\
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M_83P^*?C]_P2[^$VD6/@?5/^%):=#J>E>#/%.G?"GP]\#M=UKQ%<Z-\5&M/
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MKOMT5[K1>GS=GM?&+_@H9\)_@C\6=9^#WB#0_B%XC^(UEX"\,^-K/1/ U_\
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MC6O"GC'Q/X9EC^'=M\/-4'Q4NO#&HZMIGAM/&OPQ&F/=7WCRQM;2#X6^-?\
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M_P"2J+/^67W?\$.:/\T/_ E_D:]%9'_"0^'_ /H/Z%_X.=-_^2J/^$A\/_\
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MKHLNI30>(FM-5NM8>YN]<U*>X^@O^$A\/_\ 0?T+_P '.F__ "52'Q!X?/\
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MJC_A(?#_ /T']"_\'.F__)5:6?\ ++[O^"3S1_FA_P"!+_(UZ*R/^$A\/_\
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M!_0O_!SIO_R519_RR^[_ ((<T?YH?^!+_(UZ*R/^$A\/_P#0?T+_ ,'.F_\
MR51_PD/A_P#Z#^A?^#G3?_DJBS_EE]W_  0YH_S0_P# E_D:]%9'_"0^'_\
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M1KT5D?\ "0^'_P#H/Z%_X.=-_P#DJC_A(?#_ /T']"_\'.F__)5%G_++[O\
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M7A_X%'_KS#_TB)YU7^)+_K_/\JA'1116H@HHHH **** "BBB@ HHHH ****
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D "$;[_KQ'_I4***X<Q_W*OZP_P#2XF^"_P!YI?XI_P#I#/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>pg80-147_004.jpg
<TEXT>
begin 644 pg80-147_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %8 IX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /Y!/^"NW_!4C]JGP=^U;\0?V<_@-\2]
M2^#_ ( ^$J^&='U>_P#!UKI$7BSQEXKU?POHWBS5K^_\37MAJ.IZ5IFEKXAM
MM$T_2M!GTL22:?=WVK37TMU%:Z=]9?\ !#S_ (*-?M ?M*^//B-^SI^T+XH_
MX67J'AKP ?B9X$^(6I6.EZ;XJAT[2O$>B>&_$7A;Q%)HVGZ?9^(H&E\4:+JF
MA:M=6T>M6?V76;74[_6(;K35TG^>[_@I'\,?B5\)OVY/VD/#OQ4U;4?$/B#6
M?B5XB\<Z%XCU75_[;U#7?AWXQU.[U7X;W=U?9W136'@U])T&;2O+@M]$FT>3
M2+"WATZRM ?M_P#X(#_#/XJ^*?VXD^(W@N^U#2?AS\+/ GB./XRW5OJ#6=EK
MNE^.]&U?2O!'@F]M$).K_P!H^,-*L_&,5K)$UK:-X#.H330WMOI:3:67)NN]
M]-][?C8#^WNBBBLP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $) &3T%<=XW^(G@'
MX9^'[KQ7\1_&WA/P#X8LD9[OQ#XT\0Z3X7T6W5$+L9=3UN[LK-#L&0IEW-D!
M03Q7Q7_P5%_:;\2_LF?L5?%OXK> [Z'3?B1,/#G@7X=ZA/:V]Z-,\4>.M?T_
M0/[>@M+M)[*XOO"^A7.M^*=-M]1MKO3KC4=$M8+ZSO+22:WD_P _#QGXS\9_
M$G7[KQ9\1_&/BSX@^*;^5Y[WQ)XX\1ZSXLUVZF<DO)+JVO7M_?-D_=7S@B+A
M8U1?EJHQYM>E_F!^CW_!7O\ :E^#_P"UQ^V'=_$3X(3W>K^"/"WPX\,?#0^+
MKG3I=*M_&^L>'=<\6:M>^(M&M+Q(-3;01#XCM-'TR]U2ULKG4%TJ:]M[7^RY
MM.N;KZ]_X(.?MF_L_?LS^-/C9\-?CCXJLOAO=?&VZ^&4_@WQ]XA:2V\%/J'@
M]O%]C-X7\4:VS?8/"4D__"6IJ&BZYK(L_#UQY>KVNJ:UIUW'HEOJ7X  8_S_
M )Q]!Q2%0P(/(/!!P0>HY!R#UZ=.O8G.G*K<NM@/]2/1_$&A>(;*+4O#^LZ5
MKNG31QRPW^C:A9ZI9RQ31^;%)'=6,T\#QRQX>-U<I(I#(2"#6L"&&1G'/4$=
M#CH>:_S#?@]\7OBA^SYXYT?XE?!+QQK_ ,-O&^AW45Q8ZQX;O'M(KI4F2633
M==THDZ3XET&^9%CU3P]K]GJ&CZM#FVOK.:,@#_1)_8C_ &DK7]KC]ECX-?M
MQ:?:Z1J/C[PS,?%.C6#2MI^C>./#6KZEX2\=:7IWVF:>[&E6GB[0M931S>2R
M7<FD&QFG9GD9CG*+CZ7 ^JJ***D HHHH **** "BBB@ HHHH **** "BBB@
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MJ3=OZ_/R\P G&?8 _7.>/THR<9 _F/Z9/Y?X5^(O[;O_  4&\5Z?XLU[X/?
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MX.\G"53V<)4)TI1DZ5XN<(QY'+K?[R$5&WV79NS26]]_Z>I\EX..,=3S_7
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MME>)3]O5H_7JTY1PD,5*C&4J/+4_H),A!(. >, ALY/'?&<G)&.WKR0@D/\
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M[6O[*VI_!?5_$/BSX+6/P(^+/PL^.^H^,_"OAK6-%\*^*M<\:> ?'?A?QQX
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MV,Q%.:I^SA3IU/:8_%\SI1I4_9SA1IT*5.E!!1117(>P%%%% !1110 4444
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M:7=OX<\0?%/Q#J&J:M866FW^M_$J]O/^$;AU?1K37+C]"**^!+&[> ,\@Y!
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M)[RW-U:M#XBNKN">%)#$Y62"[;;)'(N)(Y C .C#*D$\O_PD_BG_ *&;7_\
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M_< 4445(!3'.%)QGIP?<@4^FO]QN >"<'VY_/TZ<XY'6D]$VM[!MKV/YE?\
M@K#\=]6\??'M/@_9WDD7@KX,V%BLVGQ2-]GU/Q]XCTNTU;6=8N1&46>72-#O
MM,\/:=%<+(VESKXA>VE4:S<PK^V7["'@?2_ 7[)'P%TW3+>*)]:^'>A^.-7F
MC1 ]WKGQ MH_&>JSS2( T[I<ZTUG#+(2Z65G:6J[8;:&-/YJ/VY-*O\ 1_VO
M?VA+/5(Y(KF?XAWVJQ+* #)INN6&GZQI4BXP"DNE7]H8F.3MQN+,&%?T?_\
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MVP=/L?$7@_3TDBMT\*>+]7N-2F\&ZCX<N#%<)H>LZ)XST_Q-X)T/RD\UXI?
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M_P $]]'BTY-NH6OQD^*T'B1MI#2:TVIZ==6<A<*H<+X8N?#T(8%P$1(RY,;
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MT:?8_.)PG3G.G4BX5*<YTZD))J4*E.4H3A)/52A.,HR71Q:Z!1112)"BBB@
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M!CA6WNHT9A=2E_*/@Z1_PEOQ/Y_YD;QO_P"L\>*/\17S_P#L\_\ )8_V@O\
MLVSX9_\ J(_M1UXMEV7W+_(^:Y5V7W(_2ZR_;<_:%G^&7[0OB>3Q!X=.L?#W
MX$V'CSPK*OA/31!;>([G0H]0>XO+?(2\MOM,G%I*?*6+Y.HW-K?LW_MH_'[X
ME>!?@#K_ (KUWP_<ZA\0?@IXK\<>)I+/POIMC'<:]I7AWPOJ5G-:PQ96SMX[
MG5KMFM8CY<J,D;G]VI/QMII!^"?[7.#_ ,VLZ1_ZBMK6_P#L9?\ )*OV2_\
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M"?#RSOIC<7MIX&\(Z!X2M;V<L[F:[M] T_3XKF4O+(Y>=)&+NSD[F)KO***
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ML/\ [7'PV_X*!_L[_M6?"C5?V>M8\":9^R)\*?V2_C]H_CS7OB#9^(](\/\
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M7X2^%]*T;7/$UW\0+/Q%X'T7X9Z=KMQKNCW_ ()TSP]9Z#<7/@O4I-,NM/\
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M!@+71]+5RS-<ZUK$H6UM8U0.RH7EO[DKY5G9W=P\<+?4WC?X4>./V.[GP/\
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MKZ>)'CL%MT:T\]H7NKJ"W+S)^VUI$D%K;P1H8XX(8X8T8Y9(XE$:(QYW%54
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MF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <MXW\(Z/X]\'^)O!6OQ&71_%.B:CH6H!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1THICL "O.XJ< *3GMZ8SGH"1FC^ODMW\D'_#_
M '??^3]'L.W #.1TS^'TZUXO\4/VA/@A\&)+>'XH_%/P5X(O+V..>STO6=;M
MH]<N[=R46ZMM"MVGUF>SWJ4>\CLFMD9=C2*37YL?MH?\%#]?T3Q9+^SC^RG;
M2>*_B]?:Q'X5UGQ=I.GPZ^-!U^9A;OX4\$Z:RW%EKGC&VG+0ZOJ=[%<:)X7D
MAN[&:"[U:WU"3P_YQ\)O^"1^I^,#+X]_:L^+/BJ_\9^)95U/6-"\&ZK::IK*
M7UR4FE_X2KXB>);/Q$^OZF2QMKZ+1M+CMX9XF6Q\1:E"8;@?18?)<-1P]/&9
MYC)Y?0KP4\+A:-'V^8XJ#LO:PP\G!4J':I5<7+1J/(^8^QP7#6#PV"I9GQ3F
M4LGPV*IJK@,!AZ,<3G&.I2LXUXX:<HT\-AI1:E3KXB4?:)Q:C%.Q^QWPU^+G
MPO\ B]H\FO\ PO\ 'OA;QUI-NZPWEUX;UFSU)M.GD#-';:I:PR?;-*NI$1G2
MUU&VM9V0;EBV8)^$?^"M/BK5/#_[(U[IFF2RQ1>-_B)X+\):Q)"2K'2%.J>+
M)H7=<.L%W>>%;*UG4$"XAF>VD#13R(WP1^S7^S5X/^*\GQP\6?L??$_XH?LY
M_M/?LK_M$?%WX >//AI\1?$FE^*&AN?AYXOU&/X=ZMXG^P>#_#=_;^"_CS\,
MQX.^+7AFXO--\=^"KWPWXMCT>"+Q1_8^H:D?KF'QQ=?M\? 3XS_LL?%+0;?X
M9?M7_#:TM[G5_"MXJV]A)XM\+WUO=^'_ !AX;D-S<Y\,:SJ"6FCZZUK<ZC%I
M6E>)H+^RO-3T?6M!OK[3"8; 4,?@LRP6*GC<NP>-PM3&TZ]!4<=@Z*K04:U>
MAS3IU<.I2@WB:$YPC).%6-&2A*?3EN!RK!YKEV?97CJF:Y-EF98&OF='%X7Z
MKF>74'B%"GBL3A5*I1Q& 56=-/'86I*%&K#DQ%*@IT:M3\0?V7/V<_%'[4/Q
M;TCX9^'KO^QM.2UGU_QIXID@%Q'X7\(Z?<6L.H:A%;%E6\U:\NKRSTG0M.)V
MW.IWT$UT8=*M=3O+7]R='_:V_8$_8C\?ZE^R=X,A\40:IX 7X?']H/Q[X.^'
MGB3QKX"^".L?$[4;'0_A=<_M7_&[3K!O#7@GQ5\1+[4X9O#VAZYJDFI:5H5S
M#K5SH?ACP3<:1?3?G/\ \$^_#GQ UG6OVFOV=O!7QCUS]E/X_P#C#PSX4M/#
MGQ1LO O@GQQXS\$3?#'X@2GXH>&M+\&?$JQU/PA?>([_ $/4KO28QK&E:DV@
M2)=>)H-/O7T![:3]QOV?_P!BOX%_LW_L^WW[./@'0]9U;PEXFN?%/B'XF^+O
M'FL-XR^*/QI^)/CZ3[9\0/C)\8?'>IQ+J'COXK>-=4*:KJ_BB^B2.R-KI&C>
M'-/T+PQX>\/Z%I71Q]F69SQ=;!89TYPP^$IU\#0J5)T,)C<34H3Q%.I7JTHU
M9JA6K1IT55]G6>'HS]O"E5J04*GTG'.>4H\587 9WA<=F7"^$HX6M7RS+,R6
M3ULUIXO!XA_7,/F7U/,J5.M2KU,-5P?UC!8W"+ZG*AB*+H8[$5Z/U<9H889I
M+F6.".+S))GD9(HXXH49Y)'=V")&D0,CR,P544N2 "1^/?\ P44_96\ ?';X
M;:[^TK\%+GPWJ_CWP'9WMYXPO/!VH:7J>G_$7PGH$1;7(=1GTB>:TN_&7@RQ
MC>_L;XR-J=YI-M=^&[V.[<^'_P"R_M-_A'\5?B)HNA?#7XOWVF?\*U\+I:6W
MB.?PYK=ZVM_'&/1G6'1;;Q/%]CLW\,^&;ZUM[:_\::)#?ZA<^(-4$VGI=0Z+
M/*K?%L'A"?\ 8=_X*.:EJ'AGX:>+)/V/O^"D?ASPOI'C:V^&_@/Q+XN\"?!/
M]NSX<?V=X&T3Q9XQ\,>$-.O-+^&W@;]J;X(7WA_PEXF\>S:1#X8M/'WP*T&Z
M\=:KIJ>+VU9/C.$^)9UL+A,YIY=G^29C#$NG7RW.,%2P+C1IT<*\72:^O8NK
MC*<L36Q>$HXF$*.$K_4*F-PRK87$Y?B*WY%D&>9[E.?PQ^&H4,+EV%PU!N=7
M$UY8S,<14J+ZY@YX.%..%I9=2PRE0E5Q&(JXK$XN5+$8.%#"4?:U?RQ_X)T_
M%74_A?\ M:?"[[)=2#0_B1J3?#'Q-91G,.I67BU3#H#NI5XS)IOB^/P]J45P
M(_-6U@O+1)8H;VX:OZWAT&?05_(_^SA\*YHO^"@?@CX7:$OGV_P\_:,\1(LV
M[S$CT'X->*->UJZN)9T(B"/IOA#R$G+".>ZN(((F>:XBAD_KA'09Z]Z^[XY]
MA/,<#6I149U\MHU:B5DW&51O#N=G=R]A-14I*\HQ6K44?IWBI]6GG&5XJ@DJ
MF,R:C7K:)5)0>(G]3E6LE>I]6J*#ERJ_+)6M!)%%%%?$GY@%%%% !1110 44
M44 %%%% !TZUB^(?$.A^%=!UKQ/XDU6QT3P]X>TN_P!:US6-1G2VL-+TG2[:
M2\U#4+R=\+%;6EK#+--(>%1"1DX%;7ZU^2'_  6"^)&J>%OV?_"G@#2[F:V7
MXI^/(+'7VBR@N?#/A*PF\0W.G,ZC<JW>O_\ "-32H&"W%M:W%M*)()IHG[LL
MP,LRS#"8&$N3ZS6A3E.U^2'O3J32ZN-.$W%=9)+J>IDN63SG-\ORN$O9_7<3
M"E.KO[*DE.K7J):W<*-&HXJUN;E<O<4C\\_VJ_\ @I5\7OC?XAOO!?P0U+Q'
M\./A?-?#2-''AG[9I_Q+\?F>9;.UN]0U.P;^V=&AU65A%I?A3P])::@\=U'#
MK5YJ%S.=/L?JS]G7_@D'X9N- T_Q7^TIXB\2W/BW6X(M8O\ X?\ @_4K;2K#
M0I[\?:)+#Q1XK%OJ&L>)/$*;U;5KK0KS1["SU(WEE;:AXBMHX=8NODC_ ()1
M_!S3OB5^TK-XQURTCOM(^#/AG_A+[.WFCCF@/C+5+P:-X2DFC?(+:=$FO:Y8
M2 ,]OJVC:?<AQ)&C+_4$B[3P".,?D%]R1SG ]CP*^PXAS)9'*EDV116 4*-*
MKB\33C!8NI4J1C.%.>(Y?:W=.]6HU)+GJ1I6C&%G^D<89TN%9T.&>%XQRJ-#
M#T:V88NA&#Q]>M6A&=.G4QDJ<JCFZ5ZU>K&TI2K0H45AJ5.4*GYG^)O^"3?[
M(>M:8]EH^A>//!M]Y3QP:UH/CW7-0O(9"K;97LO%K>)=(N/F(:02Z<-X7:'C
M+$M\_P#[-^B_$G_@GQ^T9H/[./Q&\0OXK^ 7[0=_=1_"7QFD4UE9:1\2XW@6
MWL+K29)[Q?#VK>(Y)[;0M;TNSGN[#5M7U/PKX@TVX1?^$EBL?VTK\W_^"JFB
M+<?LCZ]XWMF-OXA^$_CKX9^//"NHQ%H[K3M<;QKI'A"*XM9E(:.1+?Q7<2C.
M4$D,4I DABDC\7+\TQN8UHY3F.*JXS"YE-8;_:9>UGA\144HX3$T*LTZE.5'
M$^RYXQDE4I5*T&OA/F,HS_,\WQ-/(<YQM;,LOSB<<#;'2CB*F#Q=;GA@<=A:
MTZ:K49T,8Z#J04Y4ZM"IB(2@N9-?GM_P5L_99\(_#V30OV@?A]H::/9^.-=O
M?#?Q+T?2[=(='E\4WVGWNL:-XKL[)%2&PO?$$.GZS9>(EA\NRU#4X])U%(+?
M5-0UF[U/^@7P?J6D:MX3\+ZKH4D#Z'JGA[1=1T5[8!;9M(O=,MKG36@  40M
M92P&(  !"H'2OGSXN_#K2?VN/V7+_P +73P6#?%'X>>'_%'AO4)T+1:'XIN-
M-T_Q7X3U1BJR3"UL=9%C_:$<&)KG2VO;-'5;AF7YY_X)E_&#5/%7P4OO@CXW
M2XTSXJ?LUZS<_#/Q-H.I2(=5M/#UA=7EMX4,L8.##HT=A?>"=\#21G_A&([@
M2/'?6\DAC,16S#(L/"K.I5Q.18RMA\3&3E*?U7$J-/#U7*5Y-4:V'J823=U'
MFI0<E-J*>88K%9OPGA*>(K5*V-X5S&O@\6JDIU*CR[,%&A@L3*4G*I.&&QF$
MJY?4G-RE",J#G-73?Z6_Y_*BF*0  <YY['KGZ=?7WH\Q.F3G.,;6SG)'3'L?
MP!/09KYO?;4^(OWT=KM=N_EI_76W\MO_  5>\"Z?X/\ VN+_ %;342)/B3\.
M?!OCO4D15C3^W([G7_!%\RQIC;]IL_!6F7T\FU?M%Y>7<[;IVE=OU:_X))WV
MHW7[(FFP7S2FTTWXD^/K'1!*.!IDE[9ZC,L!P 81K>H:NV02!*95&""J_E7_
M ,%-O%3_ !E_;1/@GP';2^*-7\)^&_!'P=T_3=&:&]FUGQQ<ZQKNN7FDV#Q2
M-&]Y;:IXSM?#=Y#*\:Z?JVEW]M>/"UO<>5_09^R_\&(OV??@1\-_A-YL%U?^
M%]%W^(=0M26M=0\5ZU>76O>*KRT=XH97L'U[4K^/36GB6X&F1V:2A71E7[_/
M<1R<)9%@Z\N;%5X86M&+2YXT:-*NU.5_?2=.KAJ46U9N,HIN46H_KO%.,C2\
M/N%,OQ;OF&*IX'$0C-\U6&%PM#&.-65WS<LJ=?"45HKRBTG[C2^@Z*:6 ZY_
M(^N/3_/7I1N7W'U!'\Q^M? -I;NU]O/6WYM+^KGY'_PWS'9Q_G\?Z4A8# )
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M.4IN$8Q<YN\I<J2YI/N[:A1117L%A1110 4444 %%%% !1110 4444 %%%%
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M\[[+-#8^+-"CN(-1\/:Q_9VM:9+'$_AO6;C]H?@U_P %6_V9?'VGV,/Q!O\
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M@+]G?]KK5/%M]X4T+X$ZQ\0/B'\5?A-\ /!UYJVL?#KX'^&_'^A:/:7OP?\
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MGCC4=4B72/A_=7^DH;+3KG3=(N=)TS48]'\/S7;C2]?OM/UJX_M.6\@^>_\
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MI*^;WO?6_?5:W;5GIN^W^1^HQ32MY):-ZV25^EG9=!I4$ >GY],<_P">P]*
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M2N6P_L6?M13LP3X1WZE<9-QXJ\ 6JX.?NO<^+(E.,'=ALC(ZYQ7SRR'AO?\
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MZ=NG3CUYI::H(R"3]XXR<X'&.P[<X[9QD]:=7D;?U_PWY'V7]=OZ_KN%%%%
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MM5N;B\UBW.FWOT$_[-KSA*I+#QA&.'I5%"I6HU:<84<MA2C0I^SM4IRD\?\
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M^;?VIDCKRKRGB5/#X=Y94SJ5/F5:DI0A&,YU84E4^B_A-_P49\2?&KQ[:1^
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MXO5BZ!I-GH&C:3H5A'%%8Z+I>G:39106EG8P16FFV=M96T<-EIUO::?9Q)%
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M'NVX<Y8'!(S[>O\ ];/7 S@2445B=O\ 7]?U^-PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>pg80-147_005.jpg
<TEXT>
begin 644 pg80-147_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #X IX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BD8X&<<?7'.0 /QS^GO41FQN^0D*&/7DE?
MO*  <GV&<X;^[R 344PR $#U.!R#D9 R,9)^\IQ@<'.< TK-M&<9'^?TSC).
M HRS$*": '45!YX'56!R .&(R> -P4@G<&4[-X &XD)\U*)E) Q]X<9(&3U(
M'8@#[S D D#&6 (!-149DQCY6YY(/N< !AE"3V&[ZD"A) YP.N,GD'!SC!P2
M"1WP2 >,F@"2BBB@ HHIC.%(&"<@GCV(!QG /7.,[L#@&@!]%("&&1G&2.01
MT.#U .,C@]".02.:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BH3-M)^0G' PRY8\G@DA<;1N.7
MRH(W*,C+A(3T1N<[20P!  YR5^49. 'VL2"54KAB 245"9@&"[6.<Y."-N!G
M+Y VKRHR><N#MV*[*OFCG"DX&6_V1CJ?49!'R;CP" 58-0!+14#3A025)VC)
M"D,>_P H ^\Q((0*3N8%1A@14B,6SD;2, C(."0"1QZ9XR 2.<#H !]%1M)M
M;;M).0!R!NSUVYQG:,EL=@=NYLJ&B8'(56)QG!&,C:K$@]."ZJ0<,"22 HW$
M FHJ'SAN5=K<C)/IU_[Z!(PNS<6+ J"F6#HY!("1V..H)Z \X)'?'4@XR"1S
M0!)141F0%E.0RC.",;AN*<#[WWAM!VX=B%C+DU+0 4444 %%(QVJS<G:"< $
MDX&>  23[ $GL":8LJN0!U.[C(.-I /*DJ<-E>&(W C.00 "2BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P/
MX]?"KXE_%33/#=A\-OVC/B#^SK=:1JEU>ZMJ_P /_"WPT\3WGB:TN+06L.E:
MC'\2O"/BZSLK>UE9KJ"73+:VN7G8&=Y4BC$?Y9_L::S^TUXZ_9@U[]K'XM_M
MP?&[Q'8^'M!_:/35/ 6F?"G]GO\ LZ-?AV_CKPWI'B#2##\-_#FIWWB'1O[$
ML_%.EZ7J&MV.C:EX@LX--U%I-%DNVN?W"E9E,9 .-V&*C) )7((X)4KN)*MD
M,J'8XR!^97[,G[-WQ@^&W_!/'Q_\ ?%_A^PTSXJ:_H'[3%EI.BPZ]H^I64UU
M\2=5\=WOA%9M:LKN?28EOX]>TY[EIKM([%I62Y:/R7V@%KPU^WGX7T/PC\"?
M!GA?P9^T9^U=\6_&/[/'@?XXZ_9> ? /P^M?'-E\/=:L8;>Q^(/Q.@D\8>$_
MAOX;U_Q=?6NJ)I7@OPGKNJ7E_JEI/::58)IDVG74_P!H_!'XT^!OVB/A;X3^
M+_PVO;V_\&^+[2_DLQJ>FW6D:YI>IZ-JM]X>\1^'M?T>YQ=Z/XB\.>(=,U?P
M]KNER^8UCJFG7<(EF1 S?A[JG_!//XJ^$O$'PC^).O\ [,2_M,1W?[(7P*^#
M/CCX<^&OVH]>^ GC;X8?%CX/>'CHXU"Q\2Z#XF\->%/&/P^\0V7]FZ?J@&LZ
MCJ>E:U8W6O:7IUS:3S07_P!F?"?_ ()M?#?5/V>_A#X%^-GA74_AWXH\(CQ_
MKVI>"_V=?CI\>_#/@7P[K/Q1\5S>+-9TJ/6+GX@3^(_&=Y9&/3[2]\1ZSJ$O
MVS6$U74-+L].T_6IX& .>_:WE_;,\$:7^U)^T/JW[7>C_LN?!_X0:-'?_ #P
M=X=\#_"OQ]I'CA=,\,V5W=W_ ,9+SQ[X%U;Q-_:WCOQO)=^$=%\*>#]2LIM,
ML;S3+K3))-<5IYONOP1X]\>>*OV4_"?Q4\7Z))X#^*'B/]GGP_\ $/Q1X96W
MEC;P9X_UGX;V_B37-#6SU-)IHW\.^([FZLUM[^.29'LQ%=JY5TK\N?C%\-?V
MVO&?[4]WXO\ &G[&$7[17[/'P3UC2+7]EOX8ZE^U/\,O O@:/4?#]C'II^-O
MQ+\):WHGB.\\??$*]N4EU'P8?%+6L/P\TR=8+71[OQ)+=ZR?UU<>./'/P4E_
MX27P?%X(^(GC+X6S+KO@-?$MCXGMO"?C/Q!X2E&H^$?^$PL;73]+UV+0]9NV
MT@>([6RMM.U(6QOK:&&"95H _GUT;]HCX^Z%^P1H'[7UY_P5?,GQC'PCL/B0
MWP'\9>"OV4]6T?Q=XRBMVO+;X4?V%HW@#3?B%;7?C&YA7P[I\NEZCI>JVEYJ
M5O>W%WI\$$UQ;_J-H7_!1/PY+\4O"OP(U'X$?M :K\6F\%_!+QA\6)/"'@C0
M[WX??"+2?C%X<L-7D\1>,O$VK>,]+NM#\+>"M2NWTSQ3/J>GQZIIMO:ZAJ-I
M8ZO9:5J$\-/]AG]@[X2?!3]G;X 6_P 2?V9/@'HW[1O@OP'X?M/&GC*W^&?P
MRUKQE#XRL 6N+^3XA:9HL^H:SJ44L=N[:U#K%Q/<3QI*;G?F0=9X<_9S\;WO
M[47[=?C7Q3IT6D_#K]H?X1_!/X=>#O$UIJ6G7.J7#^'_  1XT\-^-&.F6ET=
M5TN32KG7[9[5KQ+6#4G$;V<^V%I0 8?@W_@IG\'_ !=JOPZOY?AC\>?"GP5^
M,/C=?AY\)OVE_%G@;1M.^"GCOQ/>7=]IWAV.UOK7Q;?^-M T3QKJ-F;+P3XE
M\6>"M#T77IG64W5E9LMTW'^(_P#@K/\  _PG<^.=2USX0_M,VWPP^%7QG\2?
M /XI_&RW^&&EZE\-? _Q&\.>+Y/!7V.[ETGQ?J'BO6],U;6%MULKSPQX7UJY
MMO[6T.RU2PL=9U-=*@\"TG]G']M7QO\ L_?L\?L)>/\ X2> O!GP[^"?C/X(
MIXS_ &G='^)FBZWH_CKX<?LY^*M%\7^#)?AW\,K>RM/'?A[QKXTG\'^&+'6D
MU\Z/IF@?\3R..?4-,U&*&#JO$'['OQYU#]D']I7X46_@W2#X^^)O_!03Q5\?
M/#>D+XG\.)9:C\-=7_:N\*_%"TUVXU9[Q;*TN9/ NDW6H-I-Z\6LQ301Z6;(
M7A@@8 ^F/#'_  4=^$%Q#\;W^+/@/XS?LUW7P&^&ND?&3Q5I'QV\':7H6L:K
M\,-=N=0L--\3>&K'PIXD\8?;YY-6L$T.X\-W4MAXFM]<U+2=)73)[ZZN(+*W
MX'_;Z\.^+?%6G> O$W[/O[2GP@\>>,?A]XN^)'P;\*?%/P7X0T?4?C9I?@W2
M1K.L>'? <^C?$#6]*L_B!:V3VMQ/X*\<:GX/OXK:]M[F2X%F;F>V\ _;%_8@
M^+/[37Q<_:4F\/2Z%X6\+_%3]B7P3\)/!/C77;^";3(OBUX-^.=U\4['1?$>
MB:=)>>(8?#5Y%9:5;ZMK$&C:A!!97=X]E;ZE?0+I\_9Z1X&_:R_:2_:)_9A^
M*?QR^!_AG]F_PC^R[+\1O%]U:P_%7P]\5->^)_Q+^('PYU3X7V]GX87PI9I!
MX=^'6AZ1X@UK6YK[Q'>P:_JVH-I%I)X<M%TV2^G .#_9K_X*5ZMK/[-GPA\6
M_&'X5_&#Q7\=?C'\3/BCX%^&OPY\!^"_!2:]\6Y_"WBGQAJ=Y?>!-,@\;0:-
MHG@KX7^#-,CTCQUXF^(6L>%)K+4O"VNS*-?9[34=6]UUS_@I7\$O"OP3\?\
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M"RQ1.Y53^=3_ /!9K_@FM'&TS?M-:$(U5F9AX/\ B*^ J/(P 3PBS,1&CO\
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M_$GB6SU'XB:I\.M?T#Q3XQ\6^ 9] L?"SBVT7PU'I;:G%X@C?Q%X:OKF.>]
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M3K"[ALV$=W;N;G4I;.TV3(1.0:]C:5%)#''(7MC<Q"J"<X4L2H4-C<64+DL
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M[=&E60U8J/B3X9MU1M1$0U (D""!%CNXRMNJ6X/D!HI.M_X*&^.['X1_!?\
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MNM:)X2LY=&N;RTM?&DDMMJ_B :K>75V;ZQM&TV>SA247/W#\3];_ &IOC/\
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M[PZ^KIJ<?B:]AUS3[M0#^N,R#'(=<\<@#YC@!<DXW$G YY.-I(*D^$_M#_M
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MYO;NV\$S7:0:7ITVHZ&NF&V^U6M[;-9ZC;6-U#[K\(-1T+]GK_@HA\ /@O\
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M-%AAT0S^%V\(:7J&LZ3?K?:WYRPQZF]UH.H;--DM9EDB\II.)%%>2?M5?\%
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M+KOB[5)K^[N(;'2;;0(Y[B$:5HMQ%& ?V8&15QN!4%E7)  W,5"C)(!+,X4
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M2VN+KP_XD\%W?A_Q]JO@SQ'IM_;VMQ&#-XGTIX+ZROK,6\KV\-RX!Z/\,?\
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M-=K\,?VS_A%\7/B#\(O /A6S\9PR?'C]G&V_:<^$_B[6=+TC3?"/BGP1+?\
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M&U5(DFO]4O;S4;V8@S75]=7%W.\D\TDC?EKX6_X*A_$#7/!O@SXX:O\ L?\
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M &Y/B!:Q:+X@^ O[.;?$_P"&U_\ "CPI\7I?C!\4?B[X7_9T^'&LZ1XWT_\
MMW0O"7@36_%^E:PWB?QJ='7[3XBMKJ+1-'\(W,UA9:SJ;74[16U&P_X*%3?$
MKP3^R[=_L]? [7?B;\4_VJ?ASXD^*GAOX<>*?&>D_#S1?AYX&\#R:98>-M>^
M(7CE]-\36]LFD^*-;T;PQH]CHNA:I?Z]J-UOA6PMTGFC /J\_LE_LR-\+[3X
M)M\!OA6?A#8>)_\ A-;+X:GP9HG_  A=IXM_M.?6O^$C@\/_ &3^SHM8_M>Y
MN-3^WI )_M\TMUO\YV<\_P",?V(?V/\ XA>.M9^)OCK]FKX,>+_B!XBTV72=
M=\6>(_ /A_5]9U:RFL%TN5;^ZO;*8W%S)IJK8O?R*;]K4" W/E_+7SC_ ,$V
M?B9\1OBGIW[8>M_$RV\8:!K^F_MH_%'08O 'C'Q7_P );>_#*RL?#'@(GP+I
M>J6MU=Z2N@Z1J4U]+I?]@2)HMQ:7(OK&&)+HH.5^+/\ P4PN/"7CKX\:/\-/
M@MI?Q/\  O[+=_-I'QH\4ZK\<_A_\,O%.H:_I&AQ>)/&7ASX,?#_ ,303W'Q
M#U?P9HEQ&U_)K&N^"[#5-=M]2\*Z5?3ZA )G /O?0?V=?@1X7\4^!O&_AWX1
M^ -%\8?#/P&GPO\ A[XFT[PSIEMK?@OX=1&Y,7@GPWJ,< N=)\,Q_:[H1Z19
MR16:+<2JL05V!]#\8>$/"WQ \*^(_ WCCP_I/BSP;XOT34_#?BGPQK]C!J>A
M^(- UJSFT_5M&U?3KI)+:_TW4;&XGM+RTN(WAG@E>.1&5B*_-3XH?\%0/A]\
M)+S3[[Q=\-_%UUX(^+_P-\-_&+]DCQ7X7N)M=G_:7UK7X](C;X,:;X>_L6UN
M/!7Q3MKWQ9X--CHE_=:_8ZEI&M7VJW,^FS:?_9]]T/B#]L[]H6#XT:+^SGX,
M_9 MO%7QD'[.O@7]H;QO877Q_P!#\/>"/ MOXJ\4^,/#6H> [OQC<^ [BXUG
MQ):ZAX8BTS2+[3M$FT?6-3U">6X;3=$T2;6;\ ^S=5_9^^"&N?"&'X ZO\*O
M NH_!.VT73?#EK\++OPYILW@>UT/1IK>XT?3;3P^T!L+6VTJXM+:?35MX8S8
MS6\,MLT4D2,OGW@K]BC]D3X;-)+X"_9N^#?A"67P/X@^&MU<>'_ .@:;=7O@
M#Q7*UQXF\(ZA<VMDESJ.A:_.QGU>POI+B+4)L2W*R2*K#Y#U[_@I5J6J>#?V
M6]2^"G[.'B_XJ?$;]JC7OC3X!T#X6ZMX_P##/P^U;P+\3/@*NM)\2?"OB[6]
M4M=1T%+'PY>>$O&0N==BN5CNK+1;.\TNVO(-:L88LCQE_P %-?$VBZ[\4=+\
M*_L[Z-XEA_9PT;11^T1'K'[1OPY\%ZSH_CE_!^G^,_'/PX^#>DZWIXB^+VJ_
M#NRNS8:CKUU?>"-'UC6]/NM!T64WDX>, ^H/V@/V5+KQ=^ROJ'[-O[-/B+P?
M^SE9V5K96?A*TM/AKX/\7_#BST:#49+_ %'PAJ_PZ\1:5J/AV[\*Z^UQ=?:X
M([!I[.Y>.\MAYT 4_'O[&_\ P3?^)/P;_:1TK]I;XT^)/V?+'5?!'P>O_@[\
M-/AM^S!\)KGX4_#W3+'5];O=8USQ+XAL[J>X&H:_JLM]?7,\EK# ANM2F2V>
MVTC3M.TJ+J_&/_!3F75?'&D>#/V</@KI_P :IK_X#?#']HB"'QE\8O"WP2\2
M>//"'Q>TG4M>\'>'/@YX2\2:-K&J?$7QH^DZ<\FLZ9&^EVNAZE/:^';Z<W]]
M:%^A^+G_  4-\5^$OBIH7P8^&'[.TGBKXA77P,\+_'?6_!?Q>^,?@KX">,FL
M/&$FI6VF?#+P5H&IV/BY_&WQ6M;K2;VPUW2M/O(/#^E:Q!!IBZ_<)>"[M@#Z
MU\%?L=_LJ_#WXFW?QJ\"?L\_"+P?\5[U]1DG\>>'/ V@Z3XC6;58KJWU6XM[
M^QM(S9W>I6]Y=6VHW=D()[VVF>WN9)(<1BKJO[%/[)&N:_\ %#Q3K/[.?PAU
M3Q#\:]/DTKXM:K?^"-%NKKXAZ=-K6D^([BS\5--:NNK077B#0M$UN[6Y5OM>
MK:3IVH7)ENK.WEC^7==_:N\%>#/V@/$'Q"^(^A_'#X=:9X3_ ."=B?M'>-/#
M'B;Q:8-#\*^&M,^(OB>35M!U/X)6EO/:#XQV,NGW-A)XNM_$[-?V LO#EM:;
M+3[:-GP'^W'\4#XS^!&D?'_]EO6O@7X+_:@N6T?X*^-8/BIX=^(5Q!XON?#]
M_P"+_#G@CXM>'=*T?13X#U[QAX?TJ]NM#?1=4\96\>I36^A:FE@;/6KO3 #[
M/TGX#?!?0O&^@?$O1?A=X'TKX@^%? EM\,/#?C*P\.Z;:^(]#^'=GY'V3P3I
MFJPP+=VGAFW^RVXATB&1;-!#&%B 4"OC#]JC]A$^-O@=!\)?V4+KX._ ""X^
M)TWQ+\7^"_$/P3\$>/?@_P#%FZU.&1-?L/B!X0U;0=17[9J=Z-/U-_$FF)!K
M*/9SJ)\3-=67COPZ_P""GOQ"\8^%_@A\8_$/[(?B/P7^SA\:OBGH7P2T[XGR
M?%SP?KVOZ7XY\3>*]4\":7JT7P_T[2+/4KGP"WC32Y?# UV^U/1]:F>:/4$T
M2&R6WDU/]A8P?F#<D,>>>3P3@DY(!Z9 P>!D ,0#\E/V-O\ @G/K7P=\>?'_
M .*G[0FH? [Q;KOQW^'6B?!J\^%/P4^&,G@+X#^&?A-I>E)I]]X4B\)ZQ=ZE
M/J4.M6EM!8:@+R5Q/9_:&U!M3N;ZXN3^J/A;PKX;\$>'-"\(>$-#TOPUX6\,
M:58Z%X=\/:-9PV&D:)HVFV\=KI^EZ986ZI;V=C96T4<%M;0(D4,2+&BA5 K?
MP/0?Y.?YDGZT4 %%%% !1110 4444 %%0/*RLP5<@ <X9L$^PQN(ROR AFW#
M82<BF&:0!R%!Q]W",0"03\V"6PH!!W+'\RE3M)  !89MN.^6 Z@>I)Y(X4 L
M>^ <9Z5\ ?LQ_ CXE?#+X=?MB>&_%^EZ99ZI\8_VF/VD_B5X%AM-:L-034/"
M/Q)MK1/"=W>S6[F/2[R\>V<7.GW96YLL'[0J@$U][NS/\I#+]ULKD'(;GH&;
M 4H20N%)PQ!. W8"5D*D$Y4\ ;4'(?<VT@C:,,,9^3<N$7 !^-'B;]EO]K31
M?^"?W[%GP+\#6U^_B/X/V_PLT_\ :/\ A'X#^-,WP?USXE^#- \/W&G^(_ W
MAOXT>'G1]'M4U::SU'4HK;4+"T\2:-:W.G"Z;S8XI/G*Q_X)Z_M$?\(5_P %
M#=*\-? 'P)\(]*_:E_9K\ ^$/A)\.[#XY3_$S4=-\9^&-3\36>MZ7\2_'OBR
M..>^\4:^MY#XJFUVR;5/"UEIVJ6'AY-:OM3TF]N;C^B(AL D$#/4MM"'(;Y@
M25W.QRJD $[ 0PX+3'N.6!4*<KR3@';M;/S!1G<^X;4=N7V^630!^?WQZ^ '
MQ<\=_'K]E/Q[X(L/"+:=\)_@O^U%X-\2:CXNDM]2T'2_%WQ/^&OA/PQX"CU7
MPEYHO/%?AJZUS2KT:_!IT9*:7!/ \XAO2&_/CX-?L+_'#2?&D$FH?!;3/V*/
MA#<?!WXQ>%?VJ]/^$/[1OB/XC_"[X^7'B_X?ZGX2L]9^&7P$MK:XL? !T?4-
M0U+QSH+W3PZCX<BO$\,V']J7EJUW??T%'  R!C("(<$E< *51CAB%QDIC=_J
MXVR,2>/>'OC?X,\2?''XE? +34U<>.OA5X+^'7CKQ5)<V2P:&^A_$RZ\4V_A
MQM-U#[3(UQ?)+X0UDZE ]M$T"M:/]HD# 4 ?SV6_Q@^+7CKP'_P2Q^ ,=S^S
M5XU\ >$OVKOV69?"'Q5^#_QD_P"$U\1?'3PE\'=4CU"'Q?X?^#0\':9XB^%^
ME>&_"&DWFL?$B3Q?K=U<:)J-NFFH)?MLDD/I7C+_ ()G?$C0]>^._@71_P!D
MSX3?'RW^+WQ8\9>-? W[1'C?]HOXA^#/#?@OPA\3]42_UK1?BW\#M UO2+WQ
MQJ7@>5]333U\,W(T_P 7Z=/I-K>RZ>VF727?[D>%O@+\!?AIXH\0?$OP7\&O
MA5X'\9ZO!J$WB;QKX7\ >&-!\3W\-P1=ZDU[K>D:3!JLJ7QB2ZOX//S>RJ+F
MZ6\N/+>N<\%_M*^ _B1I_P  ?$/P^T+XC>-_!7[1-CXAU?P;\0="\ >(+GP=
MX;TGP]X=OO$D>L?$S7)K6./X>VGB2WT\Z1X2?Q&ME-KGB.ZL]%MX4O;@)$ ?
M.7PK_9B\?_#_ .)'[=]]'H^AQ>$_C)\/_@AX/^$,UIJ<:-JR_#K]G.R^%^HI
M?:?<W^HZCH%E;>(;1;*S_M:\NIY;/%V][=QC[0WP;K?_  3G^*NE>&/V)?&W
MB#X$>&?VC-7^$/['?AW]F?XO? :7XZ:Q\']8T/6]#N-(\2Z1X[\!_$;P]?6N
M@:ZVG:M!K'AW7]&O[NTL[FTO[&_T\ZK<2O>:3_0'@C(=.2 V!E@<,54G'&]N
M!$2 S*P0 ^2RT$+PFS(884LV0Z[<C&X$2' .2OF[5)9VP0X /BK]@K]G[6/V
M>_@SK.C^)?AM\._A#XE\?_$CQ3\2M8^'/PW\1>+?&FC>%5UF#2=*T32=7\=>
M,]9U?4?&GBZP\/Z#I$'B3Q5I\6C:)J.H(\FF:%9Q1F:Y_,OX?:?^UA\2M!_X
M*>_L]?!?X3_#W7O OQQ_;!_:2^&=_P#&GQ/\2+/P\OP??QOX ^'OA/QQ?:]\
M-FT"_P!6\:Q:7X8U*TUGPG%H.HLU[K$USI>M6ECIME9_;OWE^('BJ'X?^!?&
M/CJ7P_XL\5Q>#O#.N>)Y/"_@+P[?>+?&WB)-#TZYU)M&\(^%=)C?4_$GB;4E
MMS9:)HE@CWFJZC+;65NC33(#1\":5X5L]&.O^%?!5KX&3Q_=KX_\1:<OABU\
M(ZW?>)_$NF::^H:IXSTN*UMKAO&DT$%AINNSZH)M8^U6 L+R8M9C !^)/QE_
M8>_:1U_XD?$7P9J7PNC_ &FO@[<_#+X5?#O]F;5/&'[5/C#X4?"?X&1>$OA1
MH7@7Q)?>/_@CX?\ MD_BW7+WQQINI>.K[5=+@\0ZAK]E=6F@/>:?;Q^1I/!_
MM)_#3XE? G]@G]@/PGHWB?P?X!_;S^ ]SX)^#?PR\,1^*=.UC7/%Z?%W0]5_
M9Z\<Z3X=_L:Y^V7'AV^TS6-*^)EQKEG:,-#B\!V_VV2TFL[V*OZ$M9U-=%T?
M6-;^P:GJO]CZ9?ZFVEZ+9RZEKNI#3;*6Y.GZ3IT9\V]U*\^S?9;&Q!1[R]>)
M$_>2QD?E%JO_  4"_9\UKXS^$CK_ .PS^V!JG[0_AWP)KOBGP/%K/[(MY>_%
MC0?AS+J^F:%XEUWPNU]._B72O#1US5M(T;6=0TMK:U%_J=MI]Y*LMV87 '?%
M#_@GEJ6IWO[-/P=^'[6>B_!+X8?L/_M5?LJ^(O&TSZ>FKZ5JWQ@\&?##PIX7
M\2CPI#<V%QKUWJ][X;UWQ'XC2QNX()[Z22WO+J$:@SOB:/\  S]L[XT6/['7
MP5^.'PJ^&GPB\ _LF?$_X.?%#QG\6?#?Q4MO'TGQ<U?]G>*U_P"$$TOX<>"K
M;PYH&M>$M-\8ZS96&H^)K[Q7=V,NE:,USID.DZE<3?9X?H+Q1_P46\"^'_'L
MWPVTO]GK]KOQWXWTSX>?#+XE>+O#OP[^!6L^*]5\!:7\6=(O-6\)Z/X^L=.O
M6N?"WB8_V5K=AJ.D:G%#-::EHFKVD#W1LKLPN\>?\%&_A/\ "C]G[6/VC/BU
M\)OVDOA-X+TCXDZ3\,'\/_$OX1ZAX-\=W^I:UHUKJMIKVE^&=9U*UEO?"C0S
MS64NO1W0BBU*PU2T\IYM.F6@#\KOC+_P3_\ VS?BUX.^)_AGQM\&M,^*WQQG
M^*VI^.M!_:B^('[6WB+4_"\_@?2?BS;^-O"?@WX2_ :\BE\/_#[7)? D%E\.
MXK?7;#2?#^BQ)JGB./6$O-6BL8OLGQW\#_VS?AQ;?MJ_#CX(?"#X=?%'P9^V
M3JWB[XCZ!XX\2_%JT\$7?P:\8?$WP!8>$OB#X?\ &?AO4-"UB\\9Z;8:IID^
ML>#=3\*7]O;W,&H6>CZ@NDP0RZQ%^@7QX_:G^$7[//[/.K?M/^/=5U"[^%FE
MZ/X1UN"\\-V(U35-<M?'>JZ)H_A5-"TXW%L;RXU*X\1Z?(L:W"&.RDN+R4BW
MMY7'L/@/QCI/Q(\#^"_B#X=^UIX?\=^%O#WC'1$OXA;7ITGQ)H]KK.FB]@$T
MR178L[RV^TPH\X@G62$2S*/.4 X3]F7P5KWPT_9T^ 'PW\5VUO9>*OA]\$/A
M3X'\26-M=Q7\%IK_ (2\"Z!H.M6MO?0%H+^WMM2L+F**]MSY%Q%Y<\1>.:-J
M]SJO#P[!<[<$D$D@'>1ZD$E@X;HP=7)SO %B@ HHHH *H7'^M_X!_1JOU0N/
M];_P#^C54=U_721,NG^*/_I=(_/_ ."?_)^G[<7_ &+'['W_ *B/Q'K]#Z_/
M#X)_\GZ?MQ?]BQ^Q]_ZB/Q'K]#Z\[+?]VK?]C7//_5M7/O\ Q&_Y'F3?]FX\
M(O\ UUW# 4445WGP04444 %%%% !1110 4444 %12=_HO_H8J6HI._T7_P!#
M%)[?-?FA=5_B7ZGSMXY_Y.(^"/\ V*/Q5_\ 0?"M?1U?./CG_DXCX(_]BC\5
M?_0?"M?1U>ECO]WRG_L7O_U-QI\OP[_R,.+O^RAI?^J#)@HHHKSCZD**** "
MOD'0/V??&&E?MR_$+]IVXU;PU)X&\6_LY^"OA!IVBPW&J'Q9!XC\-^.-8\37
MNH7MJ^E)HZ:)-8ZC#!:S0:S/?-=I(LMA#"%F;ZJUJ^N=,TO4;^SL)-5NK+3[
MZ\MM+@FMK:?4KBUMI)X+"&ZO9[>SM9+R1%MDN;N6.T@>5);F6*%'<>>^!OB<
MGB#X<>#_ !UXYT>W^$^J>(/!6F>,=?\ !WBKQ3X5O;[P8E[;6TE]9:IKNAZM
M?>&[^'2+J[@LKK6M)U*\T:6:6+[/>2+-&Q /E/2_V3?B7:3?\%%6M/B/IO@F
M\_; U&:Y^%_C+P?-K,OBGX9RR_ O2?A?;^(-4#6NAR0:WI'B&P?7;"+P]K;S
M):)#+9:WI>JLLEK\,_!S_@F5\=O _CW]C_Q?)X*_8:^%\/[,OCW1]=\97_P<
MT?Q_<_$OXZ64_A+7_!WB+Q5XM^*'B+P9IVM1:G;VNK/K>E?#^]MM>T;6M<OK
MVZU#QKHB6FEQ6_ZK_%?]I#PU\+?&_P"SIX-N]+DUVV_:+\=>(?!>B>)]-U?2
MXM$\-KX;^'?B;XD3:_JD\TC+?:5<:=X7N+*.2P=EBN+B&>5_LX<CKOB-\4KK
MPK\-[SXA?#OPH_QJEBO_  [9Z?X>\'>+?!VF2ZS!K?B;2=!U'4+'Q#XEUO3?
M#'E:!::E-K=W;RZJMW>6NG36&E0WFK75E8S@'P'!^P?\5XO^"?7@_P#9,/BK
MX?'X@^'?CSH_Q3N_$"W_ (D_X0Z70M-_;.E_:-EL;6Z;PV=;_M:3P8ZZ-%!+
MHJ6:^)<VAOAI2C5V\H_:[_X)W_M"?M)>,?B=:W-[^R;KVA^-O$MAJOPS_:-\
M6^!O$OA;]K+]F3P_$=.DD\.^!?$'PZTJPB^(47A>^2[U#P)+XE\:>&H[=F2'
MQ%_:ACBFB_1SX0_M/^#_ (L>*OC7X0^R+X/U7X.?&_7/@<D7B'7-&2?QQK>@
M^&/#GBJZU7PW91W"W+6CV/B*,+9R+)>1):374RI >,OXV_M06/[/]K\9O%OQ
M$\ >);?X4?!GX-0?%O4OB1INK>$[F#Q)?/J.JV=S\/=#\+3Z[:^)(?$ENMA;
M7D-[J5E9Z+J)U2VLK349+V&XA !^+7[3_P 84_9D\<?\% ?A?\,_VE?A#X 3
MXMZ<?%OCGX=_'GP)\0H?C;)\0?%OP8TCPD_B+]F*'P[<6^B_&VT^+HT_2M,B
MFNGLH/!OQ#M]6+P7]O!)9S^S:#_P3B^))T']GWXMZ'\(_P!D?XI>,;G]C[X)
M_!OXJ?!7]M3X?WFN:9X-\5_#WPRJ^'?&'A'Q'I_A/QSJ6CZ_I5OJ#^$O&_A$
MZ#8V6KV6A6S6^O6UY;6PM/UXT'XDS>*OB3H7A^R^'ES>>$KCX3V_Q*T3XOGQ
M!X+O])M]9U?7DT"?X?6FCV^KW7B^+5_[,<:K=:_;Z>/"]S!#-I0U4WZBVKTW
M1O$_AWQ!]MCT#7M$UMM+N#9:F-'UNQU5M.O BNMI?FQGN'M;G 5O*NE6X\@>
M8R8#"@#\Z/AC^PSXZ\ ZW^P1K3ZQ\&(G_9K\4_M!>-?B[;_#CX=Z-\'O"^MZ
MS\;?A?XN\(VMI\+_  !X#\+6'AJ#3_#^L>(=.L6O]>;2]=U'P[I']K:EJ&IZ
MY>7%H_FWQW_X)M^./C%KO[3?BQ]>^#\^J>-OVJO@=^T]\%?#WC_PY?\ CSX>
MZK/\)_@3X>^#VO?#_P".OA6\T>TAG\,^.((O%%O./#LVOMIT5WH7B*:+4[W3
M9M G_6&U\6>';K4;;1;3Q%X>O-9N[#^U[?2K;6-/FU.ZTLLZ?VE:Z?%>27=Q
M8&2)T^V11&V# HKLT;BN6^*OCSQ!\/\ PI#X@\._#[5OB3J$OBCP9H$OAK1-
M<\,^';^WT[Q1XJTK0-4\1MJ'BW5=(TI[3PII>HS>)-0TU+K^U]4L].FT_0[2
M^U>XM+*4 ^-OV.?V3_&/P;^)7Q(^+'CWX:_L;_".Z\1^&])\%>#OAY^R/\(?
M#OAO3M'T:&^&M>)]:\6_%6]^'?@CX@^*]3\3ZK::,J^&&BM/".C0:!:7R6=_
MJ]W]IL/!_B])^T7%_P %5]6E_9ME^#UWXEA_8)\)-XD\/?&NZ\9:3X8U719O
MCOXT@L+^RUOP1IFMZOI^KZ#JS0W:0RZ/>6.K:;/JNG-/IMT]OJ5I^L]UXJ\,
MV5W9V%[XET&VU#4+N;2]/L9]:TV*^OM5MP#/IUC;2W"7%W?6_P!Y[*V@:Y7
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MZ%H]L++09+JQM==UC2Y+ZT$OM_[/_P"U7\._V@?A+??%>TCU3X;P>%O$VO>
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MX8E%2MIS<MI-*W*I)22E=)U%%%=Q\&%%%% !1110 4444 %%%% !44G]%_\
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M?".N'1;_ .*FHZ['%IVC:A>VFF6%[8ZU+&;J?3[26T@BMT<12SAA!&[;5!.
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M:)J-CJVCZKI\[VM_I>J:9=17FGZA9W$9WP75C=V\-Q;RKDQ21(P! P?[TO\
M@D__ ,% ;#]MSX&+:>,;RQM/CY\+(;30/B9I496W?Q#:)#&FC_$33;,RR,MA
MXBB!CU9(BT5CXAM[ZWVV\$EG#7\#H8$ KPK<H20P(R!\QX!969%=&VNQ<,$,
M99E^IOV,_P!JGQO^QK^T#X'^-G@R2ZNK32+P:;XW\+)*J6OC7P+J#>3KWAV[
M5DDC$[6F+_1[XQF33M:M;.X0E(W22I)-.RUW5@/])6BO./A1\4?!7QF^''@O
MXK_#S5TU[P5\0/#^G^)/#>IQJ4,^GW\9D\NXC?!M[ZRF\ZTU"SD(FM+RVN+5
MU,D+9]&!! (Z'V(/X@X((Z$$ @\$9K$!:*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1@2
MI )!QP1USV[C^8SZBEK\6?\ @LS^W\?V2_@@?A5\.M;%O\?/C;8W6F:)+9W"
MQZAX"\!2B>R\0>/3L>.6WO)FBET'PR5DC<:G/=:E'<Q2:2$=I7=D!^&G_!;G
M]O)/VDOC6/@#\-]9>Z^#/P'UW4]/U.[L+E9-)\;_ !3LVGTK6]5$EK*]OJ.E
M^$VCN]!T-F>6WGD;5-0ME^SWD,A_#<#J?7U)8\<#)/)P,*#V4*.U-_BRQ+ME
M]TCY=W<^6KEI7R\CNR>;,4+)YDJ@LQ$=>G?!?X0>./C_ /%CP%\&OAOIK:KX
MQ^(7B/3?#NDQ8<VMD+Z=5O=:U21 WV71M!L([K5M6NW&R&PMK@D@X8:Q5E9^
M8'Z>_P#!'']@)?VP?CHGQ$^(>DB[^ ?P2U33]1\56UR)1:^.?&$1&J>'/ OF
M1KLET^&Y-IK?B:U:1?,T6,:9/Y2ZPN_^ZB"VAMDCBMTC@@B1(HH(8TBABBB3
MRH8HHD 2*.*)8XT1 JA8T   Q7S5^R5^S+X%_9#^!/@7X&> HDFL?#%G]IU[
M7#:QVM]XN\9:@(9?$?BW4%0M(UUJ]YMCA0R3+8:7!8Z:)I(+.-1].UG)\S *
M***D!K\HPYY5NG7H>GO7PA_P4#_8J\'_ +<O[._B3X0ZW)9:1XPMF;Q#\+/&
MUQ"TT_@_QO9P-]@N9#"!<3:/JZ^9I6OV<3 3Z?=F=8S=65HT?W@0""#T((/.
M.",'D8(X[BHI$0*,J",@8)X.00%&3QN.%&.YQCFLZD8U%.E.3Y*E.47'2Z^)
MJ<;[R4N1J[T=*+6K9[_"O%&?\$\29'Q?PKFN+R7B/AS,L-FV49G@JCI8C"XS
M"R<Z<D]85*4U*K0Q%"K"='$X3%8S#5H3I8B<3^.[X%?L)_#[]F&^G3Q!I<7B
MOXP:/-)I^N>+-;LT4Z3?0LL=S:^&M)E#1:/ I39'?2P_VK<PE;I;I(;A ?K>
M&:6VFCG@EE@N()$FAGAD:&>&6'+020S0A)$:!R9%<EG,F&=F8%C^FW[;OP-6
MXL_^%R>&K0BZLQ9V7C6U@@D8W-BJ"VL->=4!99K/_1;+49""/L2PRE@83G\Q
M<8Z@\#!+ 9! QV^5@"  X.'!WX&["_X\>.F1<8</>)6=8/B[-<PS?$UL1'-<
MFS7&8BO.EC\KKXFM6R^6%ISE36$AAI3E@<5@\NJT5#&8=Q<_;8JG[3YWQ1\0
M^/\ Q/XQS#B_Q*XHSGBWB''U*LX9EFN,G5="C.3E3R_*<$_^$W*,LP\)1HX7
M"Y9@\"L.J<_XM6O4Q2_<S]FCXT1?&3P';7%Y,C>+_#GD:7XJ@8QJ\MWY3?9-
M82%.5M=7BAEEC)4(MY;W=OM1H4W?2B @X[8R/Q(.?UZ_AVK^?SX(_%?4_@[\
M0-,\5VAGFTYV&G^(],BD)75-#N)(Q<(5)'^E6KA]0T[?%(S3DQJ0'+#]ZM U
MS3/$FDZ=X@T6\CO]*U>QM]0L+F%PT4]M<J'BD#9."5;8Z$YCD1E.2"1_?OT<
M?%F'B/PC#!YK7C+B[ANC0PN<)RI^VS; -2H99GRI)N?[^G2]GC4DI0S#VN(<
M5#,Z;?#EF/\ K=#EJ-+$4U^\@[<ROHG_ $M.[N;M%-YY))''3KCIR.H_2E'0
M?05_1BES;)M6OS;:W^%IVDGUU5K'HBTUFVE1ZG'\NGT&6/L#WP"CY"G!QZGT
M'K_G^5>?_$/QSH_PZ\(ZYXP\0W&RPT2PEN# '5);RZ9'2UTZV9A@W%_/M@A7
M)(+,W&SGDS#,<%E6"QF8YAB:6$P.7X7$8W'8JO-4Z.&PF%H3Q%>O5G*R5.E1
MISG*2;U4*:3J5:49S4G&G3G5F^6G3C*=23:2A",)3E-W:T7*HZ:\TX]'<^'_
M /@H-^T.?ASX*_X5AX8U"2U\:>/[(C4KRTE\NYT'P=(X@OY8B&$L%[K;0RZ5
M;L@>2*UEO+@;&,;I^$P. .IP&&-Q'&-JHN>"JAV6,'. Y)RQ%>N?&GQ%XR\>
M>//$7Q \7.UW=^(-0>=+B!WEM+"TB5+>QTJW!/\ HT-E:11VJ&/:LQ1IV4M,
MQKR+( _N@8/7&,8X#<@$8&TY*Y*DC'W?Z7\(,RX.SO@K*\ZX,SS*^)<OS.DL
MPJYQE==8JF\5*G!8BABN7]]@:^7NLL*LNQ]/"XF-/FQ$L/R\M:7^57CEQ7G_
M !/XA9EB,[P.,RW#Y74J8#(\LQ<9TOJ>38>O7^K8M4X.<*N(S2O4GCJE:E[;
MFJUZ"@^7#TT_1OA1\,?$7QB\>^'_ (?^%P!J.LW0$]W<1EK72=.AVR:AJEZ
M&=K;3X6#NFQ1<3>7"A^<8_IP^&7P[\-_"WP1H/@3PI;"UT?P]8Q6L$A :YOY
MFC!N]4OI=N9[_4+EY;JYF<DM+)P0H"CXV_8&_9W;X6^ 1\1/$UB(O'/Q$TZS
MNXH9H!%<Z%X6<BYTZP8R S0W6J9CU2^@8B2$"TMI2)(9 /T)BB15/.X]"2 .
M@ Z#CG[Q^N.U?G?B+Q2\ZS3^S<'7E+*LIG.E3<>6V)Q?,XXF4[2?-&E*,H46
M]4N9I*Y_87T</"V'!?#<>(\WP*I<3<2TJ>+4*T?WN5Y)6<:N&P<8RC>A6QLG
M#,L51B_W'/A<'*2C0BF,"5^7N05QTQSG@<<< \<?2IZ;M7CCITZ\4ZOSEMM[
M));6W\[].BV\S^E$K*UV]9--ZNS=[/TV"J5[IUEJ5K>6.HVUO?V&H6L]E?6%
MY#%<V=Y9W4+V]W:75M,KPW%M=0.T5Q;S(\4T9*2HZ$K5VB@9_GZ_\%4?V%[O
M]B#]HV\TOPWIDD/P1^*)U#Q;\'[^,SS6NF6,=UY>N^ )[F8974/!TUU;QVUN
MSR23^'-6T:9)9!;7BP_F>R[L=,9Y! ((ZX(((*G R.,],XR#_HJ_\%!OV0?#
MW[:W[-GC+X37BVMMXULH)_%/PK\13PK(VA>/M*L[AM(#2N4D32]8+/HNMQ13
M#%A??:"DDEO"%_SQ?$_AGQ!X+\2:_P"#_%6EW>A^)?"^M7^@:_I%]$T-WIVK
M:7<26E_93HP&);:ZAGC=CC> N%!S6T975NJM_2 _HM_X()_MW-X)\8W'[%GQ
M+U:=?"?CR\U#7?@KJ=Y-']BT#QQ.7O=>\#R/+*C6MAXU!N]8T:...:%/$EM=
M6<*1S:O#C^N^/[BX!&1G!ZC))P<\Y&<'/.1S7^6SHVM:MX<UK2?$6@:C=:3K
MFA:E8ZQHFJ6$SP7NG:QIMPMWIU[:31NDL<]K/"9HC&P9I%5%(WMN_P!!;_@F
MC^VWHO[;O[..A^,Y[BWMOBGX*M]/\(?&'P]%(KO9>++:U(B\16JA4/\ 8WC&
MWMYM8TZ4KLCE-[8#YM.D>2)K6_?\P/T3HHHJ "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD)P"?0$T +2%
M@O4@<$^YP,G ZG YX!J$W"J&=QY<: LTCD!%0?\ +1GY0*1\P(8@)EG* $#Y
M._:?_;:_9P_9+\#7OC?XO?$;1+&2*TN7T+P9HU[!K7C?QCJ"HWV;2/#GAVPF
MEN[F:]G06IOKU+/1K#<]YJ>I65I;37$;2N[ ;/[77[4WPT_8_P#@IXJ^,_Q*
MU*VBMM&M3;>&O#OVF&'6/&_BFY61-)\+:%;RMYMS=7DY2:\E@BE&G:5%>ZG<
M!+6VDD'^>9^T3\>_B#^T]\9/''QO^)VHF^\6>.-5%[);QO*^GZ#I%M&MIHGA
MC18Y&9[71] TY8+2QMV9P[0SWDC&64*?H#]O;]O'XI?MX_%<>-/%Z'PQX"\-
M"?3?AK\-;.YDFT_PKI4CYGU#49/-,.K>+M5<"75]7(5 FS3+$IIMO&)/A<9
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MK3Y8SQE6=-5*^3SJV3C#'O#4YX7FGR8?,Z.'Q$DXRJQGYV98#Z]1:C95J?\
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M$G+*_;QS'$YG0I4L91KSP5.EC::QE2BOFZ_!61<78C"8CB'*,'F=/+,33QF
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'J"<$N1G ;:  ^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "O!O!?\ R7'XV?\ 7A\,O_33JE>\UX-X+_Y+C\;/^O#X9?\ IIU2
MOC>*O^1CP+_V6"_]9;BPSE_$H_XI_P#IN1[FGWA^/\C4U0I]X?C_ "-35]A'
MK_BE_P"E2-7\4O7]$%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH ****
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MLM&T?3H6+$Q6.E:;%:V%K%N>1_*@MXUW.PQM>42%% '04444 %%%% !1110
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$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>pg80-149_006.jpg
<TEXT>
begin 644 pg80-149_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %" IX# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1E1^_P!NZ+_#]3R7Q+P_=Q6>934FMX4,=1Q4ONP7]H6Z]6U;7='V)O3^\O\
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MX$:7L6B^,]"LM=M;'5(8Y)5M-9TM;PZ;K5@7,FGZK:W=E*%EMW50#V:BBB@
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M9?%GQA^#WP(TN25C_P ([\%OAYJ/Q5\6V]JV"%7XH_%ZXTCPN]XB[D+CX%B
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M#7X/Z5>:=9>+];TK6M*T4:9I5_?Z_=RWFF7*7-EI-S8IY$MU'<0@'W'\"_\
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MDTHZ-]MB\8?\(B?%">(DM3]HC\4_VL?$:ZF%UD:H=6_TP_(W_! K]F/]L_\
M86_9Q^,O[$'[5?@F]M_A]^SQ^T+\0[7]D#XR/XP^'6OZ9\8OV=O&FOZUKNF7
M-KX?\(^+/$/BGPAJ&F^)X==\77FF>/M,\,7UOIGQ*T/0=/T]Y/#6K1VO[P$
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M3+35[+Q7XU'CB]\-?$"?3K)]0CT^_NM*L+.VN(%O[9+O47L[J+[G\E<YPN>
M< <C))'(]3_.G+$%&,+C&,  =.!@8QP!QTQVZ5Z53BK,Y5,'6Y<(JF!K4:^&
M<<,WR3HQHQTYIV7M8T%&M**C4G2JXBA[2-"O.G'YJAX3<+T*6<T7/-:U//\
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MK)1C&*C%)*R248Q2LDK)6TL>RK)))62226UDDDE962LDE:RVV"BBBF,****
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MU3#8:C1J8APE7J4X)5*\J<%"$JTVY.I)122<M%TBM&@< #THHHKZ,Z@HHHH
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M?-#XXVUAJC5HIJ]!R3[G\NU.H_K]/S3+3NK]PHHHH **** "BBB@ HHHH "
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MF7?BV72Y_$$D?BSP-X>\431ZDVC65AIBO#=:Q-'%%;6[1P0)#$T]XT;7$O\
M0%_P3T^*WB'XK_LT^&[SQ7=WFJ:_X-US7/ %[K=]))-=:U;:%]EO=$O+B>7=
M+<W,'A_5M*TR]O)I9YKZ_P!.NKV>4SW$B)KGF0X? X/"9I@*M=X3$NDI4<4X
MNK3]M3E.G)24*=TY0G#EE'F4HW4G%V.J<%&,91;M+H[7_!+_ #/N*BBBOF#(
M^2_VT?AUXU^,'P;L_A+X,TL7L7Q$^)OPKT/QQJ<BZ-<6OA?X;6'CC1_%'C;Q
M#?:7K=_86NO64>E>'FTJX\/PM<W.L)JWV(6KP2W$L/Y>>)_V0/VB]/\ AYX]
M\'>&/A=!=Z[KVK_M,7^NIX9LO@OX%^'&OZYXNT'P-^S;\*M;^%G@^QU'3K/X
M=Z3J7P(\6_$'QUKL5Y-!K\?B/1_$EAK^N:E+JFD1W_[[%5;&Y0<'(R <'U&>
MAIOEI_<3CI\HXXQZ>G'TKW<NX@QF64(X:A1PE2E&N\2XUZ4Y>TK<T'%U90J1
ME.$(P4(TUR147)\W/:_PW$/ .5<28^KF.,QF94,54P4<OC/"5J,%0PL:52')
M1C4I249SJU:F(J5'-RG*3HN#HVE2_%?5/ ?[>%AX6;0O!,/QZTGPC+_PMK_A
M3>B)\0_@W#\2? ?B1;/X;Z)\$C^T#XBN-9N-*O?A/I$EK\2_&-SX4\%WGBJ[
MCLKW1?"^L6EXD.F:?:]?KNE?M^R^,?V@M1TL?%?^Q]5T_3+3PG/;^(_A-HWV
M#3I/BM\.]-\5:1\(?"U[XQ\3>'=6UX?!JP\?>)_AUX[UQOAAJFGZUJ\/A_QS
MH?B+Q$^FZGI7Z\^6F<[$STSM&<<\9Q[G\SZUYYX\^(W@[X>C3H]>GGFUC76G
M3P]X7T+2KOQ!XM\2367DB[_L7P[I5O<ZE=6FFB[M7UC69(H-#\/6US#>Z_JF
MEV#_ &H;QX@Q%6I997E=2<[1LL)*<I?OZ5>3DU#GE*?L4ZU24E[6JY5IJDIN
MB>;6X P.%HNI5XJXFPN'HVDY+-8T*=.*PN,PL80_>*-*G36-F\+1C&JL/"G1
MPN&C-*&)I_EO<?#W]OSQ#;:7IUEXI^,G@K2-(;?X*N;SQW\.M1\:6UE\0/VF
M_#MG9+\7;^UO]7TOQ;K'P;_9^\/:WXNU6T@.L6.IMXPL/"B:GXLU"RU:"[N1
M^"/^"@ U_P"%&G0>+/BEI7A6W\3^*]4:_O+_ .'?C+5-"AN?VC_$5[I=I\8K
MR7XC^"IO$6AVG[/-GX8@TVUTVS\:Q7%[K7B:S30[3Q'8>&7M?O7_ (67\5-0
M/FZ+\)_"^AV;EE2+XD?%2+1]=7 ($DVE?#?P3\5M$ 9U8&-?%HE1-ID2.;S(
MHVQ^/OC):?O+WX=_"S4X%^:2+PY\7O$D>ILJX!6QL_$7P;T/2KB=P2 +_P 1
M:9!OV![F-',B:O-\<TD\NR713482P]"3O.G5IRFVX7=2]651N=5^_%-J+E-+
MSUPSDK?,N(N-6W[/VE>&,QU&,H4*^&K0AR1J4Y0HN6'C"G['"I*DZ,7*JJ<8
MUU^/W[+?PE_:4T>QLOB)I-U'J^D"X70/&/A^ZCTWQ5H45S)OGMK2_FM+VUO=
M.F95>;2=9L-1TQY@MTMI%=QQSK\4>'/^"2/PDL-96\\3_$SXA>)]&BD#KH=M
M!H7AV2Z175A;ZCK%I:WEXT4FW$TFE1Z/=$,6M[FWD"L/T!\'_%[PUXEU=/">
MH:?KW@3QJ\$]U:^#?&MM8V.IZO:6VZ2\OO#&K:1J6M>$O&=M81!9]5/A#Q+K
MLVA1S6X\00:7)=VR2^PH0Z(Q ^90>QY(]:\JCF6;9?1>%HXW$T*3NO9*2M'F
MU;I\T:B@F[R3I24;N\6W>3_5<-C:6*IJKA:T:E.[C>#OR3C;GIS@TI4JD+QY
MH5(TJBYDW3M:4N<\'^#O#/@'PWH_@_P;H6F^&O"^@62:?H^B:5 +>SL;57>5
M@JC+2SW$\LUU>W<[RW5[>SW%Y=S3W4\\\ORS^V5\1/ OA?X=#P?XIT$>+M7\
M:.YT+1/MTVG-82:1)#,?%$^HVR2W5E'I=P\$5O!:*MSJTL\FFB6&S?4;FV^S
M*_+#_@H#X/UHZ[X,^($5O/<>'4T63PI?W,:-)!I6J)JEUJ5D;LA2L$>KQ:C+
M%;S,5BDN=.6V9EFDMED_ ?I$9YG61>$G%V8Y-@J68XNMAZ& QKQ>"CF='#97
MFV*A@LWS'$8.M2Q%#$1P^$G=RQ=*KAZ-3$PQ==<N%A*//F=2I3P&)G3CSOEA
M&=US)4ZDU3J2:=T[1DVKW]YJ70^&AXGTB3;%=?#_ ,'_ &'(W1:=<>+].U&.
M(DY-KK,WB?4I!<8_U<^J6>KVR-EI=/FC7R)/T'^ 7Q/_ &:?@;\/M,UU=9\3
M)X@\>373:X=2T.^UG6;2?0+DVYT!KG0M.72(+/1AJ$5Q"Z/%=ZK%J<.KW%I;
MK>VMA8_F4Q 4DX  R3G 4#DG..BCGIVZ5V6LP/I/A'PQH]X&AU*\U/7?%LMF
MXV36&D:U8>&]-T5KE,!X)]8CT6[U:*WDQ(VCS:)J(5K74;>1O\SO#KQ%SK@C
M,\RXFP&5<.9EFF RFK3RS'9SDN'K?V5BL7C,!AHO!++Y91_M.-PE7'X&E"K&
MLZ5"->IA:E!0Q,:WR.$QE3#3E7C&C.4(>[*=.+<)-I>ZX\EG)-QUYK)MQL]_
MWG^'7Q8\ ?%:QEU'P'XGL]=BM"@U"S"7-EJNG&9"8A?Z3J$-MJ-JDI5A#-+;
MB"=DD$$TFQ@/2" >",]Z_!/]F77]<\/?';X<RZ$\OF:QX@M_#NJVT3-LO= U
M@FWU:.ZC4CS8;&WSK"!MRP7.F6]RH4P[C^]$?N>0.W3W'.>,G@=J_P!*/ 3Q
M9Q?BUPCC,VS/+*.79OD^:_V1F7U)UWEN+J3P=''8?%X)8B=2K2<\/4Y<7AG5
MK1PV)@XTZM2E5IM?69;C98Z@ZDX*$X5/9R<+\DGR\ZE'JM&DTVVGK>S2"15(
M4;01N P?3D\#!R<^OU)K\)_VH/AGKWPZ^+/BN[U"SN6\/^,-?U7Q+X:UPQDV
M-]%K-W)J=WIQN<-&FIZ1=W-S9W-G(RW+016]_P"5]GO;9V_=VL'Q%H>E>(M+
MNM&UC3[74=.OX98+FVNK6WNHRLJ[#(D=S%-")XMY>&1HG*2 ,N& KN\:O"+"
M>+W#N$RN>:SR7,LHQSS'*,Q6%>,HTZM7"SP>+PV,PL:M*K5PV+H2I7GAZD<5
MAZV&HUJ"J-5:-5YC@HXZ@H<W)4I2=2E)VY>?E<;2ZVDGRWB^973M))Q?\Z?A
MKPYKWC+7=/\ #/A73+K6]?U6=+>RTZS7S)69^&GG?(BM+*!3YMW?7+QVMG;H
M]Q<2QQ(S#^A7X<>&'\$^ _!W@^2X6[E\+^%]!T&:Z3?Y=S-I6F6UG-<1^8JR
M"*6:*1XE<!EC*J5!7%?-7[%,Z0?#SQ/X&\1Z?H4/Q:^"OC_Q-\&_BEK&F>'-
M&\.WGBR]\-SP:MX(\=WUMI%E812/\1_A9KW@3Q[,\=K;VBZAX@O[6UMXDM"B
M_96 .@ KP/!#Z/\ #P7KY[B\?GM'/\_S>E0P%7$X+!U<%EF&RW#5Y8ZC#!T\
M4YXS$2QU:O1QE;%8KV$O9+#4*>&BXUZ]7@X?I498*ECZ<Y2>,HQ;A.*A+#N%
M2K"MAJD>:5J^'Q5'$X?$+F=JU"I%/EY7(HHHK^A#W@HHHH **** "BBB@!KG
M:I;TQWQW'>OB']HL'XS_ !;^$7[*<2F[\+WSQ?'S]H%%8- /A9\.]>LU\ >!
MM320!/L_Q:^+,%A#<6^Z4:IX,^'GQ"TV6W:"X>:+[7O'CBM9I9I8H(8D\R::
M=E2&&)"'DEE=RJ)'&@9W=V"*JEG(4$U\9_L;P7'CG3?B7^T]K,)&I?M+^-I?
M$/@QIDF2XL?V?O \-SX0^ VF)'-_J;'7/#4&J_%H0* %UCXK:W(WSS-'#VX/
M]S&OCOM8>,:5#?\ WO$*I&E*-MY4*2Q&+=M8NGAY/W3P,Z;QE7 Y&M89C.IB
M,?I>/]DY<Z%;%T:MU90S#%5,ORNVOM*5?'12;YXO[.C(+9)^<@9P>XW GH,C
M(/. >!Q4Q4-P0#]:  .@ ^@'^>YJG<7=M#+:P37$$$UW-)!:1S311O=2Q6T]
MU+%;QNRO/+%;6\UR\<(=U@AEF91%'(1PZ):)V2VO>R2Z7:T25VV[Z2;9[S=D
MV[:R\DKN245=V5U>,5U;Y4KMJ]AT0$?*.C#CCKSQZ<US-UXK\+VOB+3?"%UX
MAT&U\6:Q87VK:3X8N=8TV#Q%JFEZ885U+4M.T1[M=3O;#3WGMUOKRWM9K6T:
M>-9Y(S(H/C_@OQ+\>_%WQ*\03Z_X$\,?#'X+^&[KQ)H.C6_B+59/$_Q<^)6I
MZ=J4=CIGC:SMO#>I'P;\// -REI?76BV&JWOC+QAXJT^]L;_ %+3OA])&=.O
MNC^'WP"^$'PU\2>*?&?@WP%H&F^-_&>IZCJ_BKQW=Q7NO>.]=N=7O)M0NK;4
M/&GB2\U;Q1+HL5Q*8]+\/KJJ:#HEBD.F:)ING6%O;V\._L:=/G]M/FE[.+IP
MH.E5BJDDWRU:KERQ4(N//&G&I).:@G&49->93QF(Q;HRP6&=.@L55I8BIF-/
M&8&LJ%%J+JX+"^S=6O[::E&C6Q7U2@Z=.57V52G.BY\QH'Q?^(7BGXG3>#]/
M_9W^)>A_#W2=6\2:-K_QC\>:MX(\):'/=:#'J$-E<>!?!4?B'6OB!XNTC7-4
MM+>UL]9O]"\*Z9+IUTNN6=WJ%F(DN9IO"'[1=_\ $R#6Y/C=X T;X3Z=KD-W
M;_#K0?@K=S^+=<T!( LVE^)OB9XB^)NKV:7=U=-(S7OACP!X>\B"."*(,[22
M5]#B- <A$!XY"@'C)';L22/J?6C:O]U?R'^%-UE%WI4*%.]+V4E."Q.K^*K!
MXE3=.I):*5.,/9I)4E!ISDX9?4E%+%YAC<5*.+EBX2ISAEL8IV5/"RIY=&"K
M82BHQ2IXFK5E7ESSQ,I\RI4_GCQE\#=1\:>.H/&3?'CX_P#A6QM9=&FB^'W@
MGQ=X9\.^ R^CR0R2+<VZ>"+CQ-=QZR\).M17?BBXAN5FGAMH[2%Q&LGQ5^ U
ME\5]8L=;N?BQ\>OA_-8Z0=(&G_"?XM^(O .B3Q_:KR]74K[2=*5[&]UA6N6@
M_M&6$SM:6]K:N&BMT0_03;$4MM&!C. .YQ_6OQ-^+O\ P7!^ WPU\2?'3P1'
M\#OV@)=7^#4?QPTV/QUK=C\(;#X1^(O%WP8TC]KN1K :CHOQ@\0?%/3M#\5^
M+/V)_C=X0TG5I_A-]OMKO2]+U;5-(T_0=4@U118K$*5.2JR3I1<*;4:*<(R5
MI12>'E&2ENW5562?PS0YY3@*D,33J8=5(8RO#$8F,J^-?M*T)<T9I_VC%TN6
M\N6&&EA:-^5RHR4>4_4?XD_##Q7XXL?#EOX2^.OQ8^#U[X:2[0ZCX%A^&VMG
MQ)Y\%C# /%UG\3OA[X\@U,6;6+3P2:6NBW+S7U^;BYF6:$6U?Q1I?Q^T;X=^
M%],^&OB_X>^,/B-HQTF#Q-X@^,.A:KI6F>.K&STRZ@U:X5/AE+IMOX*U_6=5
M.GWT>H6'AS7M#TVWCO[.+PK<-<VT]E^+NB?\%L_B/K-Y^V!:V'[)'A[5$_9C
MM_%'B#32OQSU;P==:_X#\(_MF?%/]DS5_&6H6GQ%^#GA-?$FB1V7PB\6^/?[
M;_9_N?CGX?TCQ9!9?!'QOK'@OQCJ5AJ<][XB_P#!;Z7X:_M$:[\#]4^#/P@U
MCPUI/[9D'[++?&/PK^TGXB\1^#]/MK+6+32?&-IXDTG2_P!GRX\56WQZ\'KX
MC\!/JOPL\.Z'XI^'G_"4:]X]^&]O\<+GQA\"/BW;Z"HUYQ5.+5*I"E*4XPJT
M*4TY2YF_:2C&E4J1;E?EG5<5M%1T2JIEM&<L14A5Q>'K8JC3H5:V&QN+IRC"
MERJ$\/3G5Q.%PU91BHNM0P4*E6-XUI5%*1^Q][\5/%7P^^%5CXY^,GP^U6T\
M1P7JV/BKPM\"H/&OQ^CTB"76+JQMM>THZ5X#\+^,]>T1=(CM->UDV_@./4=%
M2[ETX6>J26?VR[[?X9_%'P'\8/"MIXU^&_B:T\6>&;NZO+!=2LXKRUDMM3TR
MY:SU72=3TW4;:QU31]9TF\CELM6T?5K&RU/3+R*6SO[2WN8WB7T+8G4JN?7
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M':GKXG=1A9Y%&,85F ]@< 9'J",'C.<5X)_PD?O_ ./_ /UZ/^$C]_\ Q_\
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M<@U?Q$A&[PKX6BOO&GC#&2"Z^#O!UKKWBEXE*LLDRZ088]LA>1?+<KZ]X+^
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MI*<_9PIN<W/V*5*C1CRT:5.DG:ZA%1O;J[?-KIKL%%%%?1F@4444 (3@$GH
M3^5?.O[7/B<^$?V5_P!I+Q/#(\5SHGP)^*]_:.I*E+Z+P1KBV!4JRD-]M:
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MYMK*TO;:Y$T:^#-+U*WU6>XM+G1[W5-'\277AW1/$/G'C?X$^)K'PW_PRO\
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MJ?37SM.,9]^G'/H?3I6?_ _/^K^5]'L^%ZII[6U].OX7_I:^%>"/ GA;X?\
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M>S^*%GX+G-^TEEHL_B*VA75;BWIP;6+*'4='NK?5].N$62WU#2;VVU.QN(W
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MA3Q8WBB?1=!\%WOQFT_P983:J=(\"6T6NZ/X6T75='N/"VI:G82>?XU\217
M!^M>[C[K9]".F<=2,COSC.,'@GBDW'GY#QZ_ITSGWQDCL#D9_'?X.?\ !)9O
M@K\!_!OP*T+]ICQ=K>A_#+XU>%OC1\.[36O!%GI?@VQU?0M7M=9U*#Q7X,\"
M>+?!D_B.3789]?\ !4MCI'B?PC\/XO!4^@^(KSX<ZK^T3:>-?VA/B)\T?";_
M ((F>%/#'B>+P=\5/CGX8^-%S8V7[)_CN?0;W]DF^TWX;>'[K]GO]H;P_P#$
M_P 1Z1X#?Q)\4?B'X.^%?@OXO:%I_P 1_ ]E^S_X'UC1_#?P\TWXW?%_4='\
M*ZS\([OP'\*O @!_1"#D9'3_ #Z4USM .,\XQTSD$'\AD_A2J-HQG)R22>Y)
M)/TY/ Z <#BF3$A.#C.1G!)^ZQX [\=,C/(SS36Z\W;3ST_"]_D#];7LK[[M
M1VZ[[=;V6MCYT^)7PP\3^+OCQ^S9\1])N=*A\,_"*Z^,-UXKM[J^N[;4[N7Q
MSX"3PMX?CTNR@L9[344BO);F?4!>WED;2".&:W6[E81+]%Q<*!Q]T$XP><L#
M^&1QR?2OGYO#OQ-O_P!J&T\423ZG8?!SPY\ ]1T*TMX->C.C>)?B?XU^(NF:
MAJ5Q>^&8=165M2\$>%? .EQ:7KFHZ2T8MO'^LV&C7ZN=;MY?H15V]\\ =^V?
M<^O^)-;5V^7#1YZ<XPP\''V?V%4J5ZCIU']J<6_>;]Y*4(O1(\S+X1]KF=>-
M#$T)5\RJ.K]8E)JM/#X/ 855\-!Z4\-4C!1II+WYTJU527-)-U%%%8'IA111
M0!XU\?/@7X#_ &DOA+XU^"?Q/L[^_P# ?CZSL;'Q#:Z3J]]H6IRP:;K&G:]9
M?9-7TYX[VRDBU/2K*8O!("\:/$V4D=6^2[G_ ()@?LYW6FSB?7OC_+XUO?B7
MX8^+6H_&27]HWXP3_'&]\9>"_ ?BGX9^$99/BU<^)Y_&<&D>&_!7C;Q3H>D:
M)9:E:6%K;:U?*(F$[J?T9HKS<7D^58^M'$8W+\+BJ\:7L8UJU)SJ1I*;J1A&
M2JP<>2;E*G.*C5I.4W2KTN>?/]IP]XC\?<)Y<\HX9XPX@R+*Y9C/-I9=EN.C
M0P<\QJ4*6&K8FI0G@,5&J\30H4*6+HU95<'C88?#K&Y=C?JV&>&_.OQ;_P $
MQOV8O&MS97_C)OB_XBGN/"_A/P?\3#JGQ[^+;0_'_P .> -0NM4\%V7[1D2>
M*XH/C*WAB>\NH=/U+QK'?ZF=(6UT*]O[O1;&SL8>'?\ 9Z_X)UK\>[KXDK\3
M_"EOXYN?&WB/XCK\,H?VCK^+X5V/QG\5^%;[P+XB^+&G_!?_ (3,^ K#XK:C
MX6U'4-+F\20Z(E\EY<S:S#:Q>(BFK)X?_P %3/V@O%%GX@T']GWPQJMUH_A^
M;PW;^+/B ^GW$MK<^(7U>[O[71?#5[)#Y4AT2TM=.GU/4;(2O;ZM<7^GI=)L
MTO9/^=VG?L^6^K? #Q)\;+#QS:L?",>BSZWX0OO 7C#2M+%OKOBE_"MGIVC?
M$C5+6T\'^(_%45TJ7U[X9T--0^S64T:-J7VLR6R?3Y7X<\/XG"4,?C\+@\-]
M=Q-">$4,!3KR==N5'#U:]2M.;4JDY2;A.HZ-25ZM>G6Q$GB%Z_\ Q%GQ2GAE
M1J>(O&,,-++L5E$</3SJO##K+<;4]KB,&L/0PM"A"C*2<*,J=&GB,'AKX'+L
M9E66-93'^A3X3?L9? _X->*?AIXZ^&NGZ]H.N?#3X!^'_P!FO1KF+Q3JUU8^
M(?A+X6FM;[PAIGC#3Y9Y;#Q1JWAJ[BFN]!\472#6K-=0O[5;U["\FMF\AA_X
M):?LCPCQI;CPSXV?2O%X6UL- N/BI\0K[PY\.=$N/C'X<^/VN^&?A-X?O]?N
M=)^'/A[Q7\6O">A>*_$NF^&[6UCU![)-+C:UT8_8!\E_\$M?VA/%3^+M1_9Z
M\3:I>:OX7N?#NH>*/A^;^XFNI_#6HZ)<6(U?PY82S&25-"U73;Z75;6P,BVF
MDW>D78LXE&LS+'^Y=>+FW"65Y;B?J%?+,OJTZ#>(PK6%@J;AB:-*C*K"FV_9
M2JT<)1I5H)N+="#<7.$*YQT_%'Q+P>,QN-P_'W%M#'9AA\#A<?C:6=XJ&)QF
M%RW,<SS?+J->NJ<JM2&!S'.LXQ6%O.%2A+-,?AX5O[/Q57*I>3?$'X->#OB?
MKWPG\1^+;:[N-3^"WQ&/Q5\"O9ZE=V,-IXP'@[QAX%2YU"" JFIV2^'_ !UX
M@A^P7)\AKF6WN6RT"*/BOQ=_P2>_9$\:>#?ACX%U70?'MIH7PD\-^-?"/A1-
M%^*7CC2+N;PYX[\>V/Q.UG2-?N[/58Y=;M$\=:7IOB&S%YDQSV4%E<"[TH/8
M/^EM%<>+RC*L<ZCQN78/%.M&,:LJ]"%252,?9*,9N33:2H44M8NU*GK[B./A
M_P 1N/N$XX.'#'&?$N04\NJU*V IY1FV(P4,)5K/'RJU*$*<)PC*<LTS*;<H
MU/?QV)FDIS4J7PEK?_!.[]G77]&&AW=AXZL((],^.>FVNH>'?B?XV\-:W8C]
MH;XT>'_C[\1KBUUG0]2L+\27OQ)\+Z/J-G!--+IT6D1W7AJ]L-0T*_O;*?S*
M3_@D?^QT?#'A3PQ:>&_'.F1>"=,\-67AO5=*^)_C;3=;L-0\,?%CQQ\;+3Q&
M-2M-3CE;7KKXA_$?QCJ]W=86&*VU:+2],M]-L](T1=._3JBN>?#V0U)*=3)\
MNJ2C'DBZF%A-J'-"?*N:4K+FITV[--\D.:4N2'+ZV$\8_%C+Z<:6!\2.-,)2
MCB?KBIX?/\72A]:6'Q6$5>450:J36%QN,PZ555J<:.+Q-.-&,<175;\Z?#/_
M  2Y_90\)S^#CH^@>,X].\$VWP5@TW0+SXB>+-2\/ZE)^SUXJUOQ7\)KWQ+H
M][?R67B&\\-2^(]9T)Y=3BF&H>&=0O=(O$DAOKXW-OP%_P $QOV6?AU?>%-2
MT/1_B!J-_P" O&WPJ\7^ KSQ?\7/B1XWN_ ^F_!"3Q?/\*OAKX3NO%WB'6;G
M1/A3X.N?'?BBZL? EG,FE7EWJ2W&K?;WT_3/L?Z%T4H<.9!2Y'3R?+J;IV<'
M#"TTXN,:48-7<DO9^QI.FN5QISIQG",*EZDZQ'C-XMXJGB:6)\2N-<13QD:L
M<5"KG^)FL1'$/'2Q"K-X=3F\3_:>81Q,G54\52QE;#XJIBL)[+!X;QWX%?!#
MP%^SC\*?!WP5^&%C?Z=X#\$6VHV?A^RU/5;_ %R^MX=5UG4]?O%N-4U.:>^N
MR^IZK>R(;B:1XXG2(,4C4#Q'_@G8[O\ L0_LTEQC;\,=(BC]X()[N&V(]FMX
MXF'L1CBOL.^N$M+>XNI6"0VMM-=22,P542WBEE<L3T4*I);H .1BODW_ ()_
M6K6G[$G[+"LK(US\$/A_J6UAA@-7T&UU1=P.,,5O 3[DU]'A:-+#9-/#T*4*
M%"CB\#0H4:45"E2I4,'BXPI4X*ZA"G2Y(QBM(Q48K1'Y'G.9YAG7'$<VS;'8
MK,\VS/+>(LTS3,L=6GB<;C\?F.=Y3B<7C<9B*G[ROBL7BZE>O7KU/>K5ZM6I
M+WI2*O[1RQ:3\8/V(/%UPP6+3_VC_$_A&YE)P8XOB)^SE\<=$T\,21E)O$5O
MH-N$P=\TD!R-IKTK0_AW8^!OCG\0?B=!XJL-/TSXU:)\-]!N?!EY;PVLNH?$
MCX?VOBZW_P"$FTK5)=2B6_U+6_AV^CZ-J&BP:5+?#3O -EJ*W;6MK-!!Y=^W
M*5TGX+^'OB$P=Q\(/CO^SE\5)WC&&BT7PW\;/!-IXPE9R,QP1^"-6\2O<R J
M!;+,KR+&SL/5?V@O@\/C5X"7P[INNGP;XV\+^*?#7Q&^%_CQ=,76)/ WQ(\$
M:K'J_AO7SI;W-B=4TNY5+WPYXKT9-1L&\1^#=>\1^'VOK./57GCZE.+PN YZ
MOLZ=58W UIJ,9J,%BZ.+A)PDM5!U*-1RC:<8\_+S-<E3PITIPS7/I4<+'%8G
M"3R7/,!1G6=#VU:IE.,RNO&%5+E7MJ."Q-)*M>C.J\,JL80?M:/NX<$CE<'&
M,'/)Z#\1GGW'7-25S^C:]H^MMJ"Z1K&DZP='U2ZT+6!I6H6=^-)UW3Q";_1M
M1%G<W!T_5+$3VYN]-NV2]M5N(3<1CS%W7M8.K#2-4.@#3CKO]G7O]BC5S<C2
M3JWV:7^SO[4-D#>#3OMGD_;C: W0M?--N#+L%>9I=K6Z=FFFK:1:T<8M7C*+
MLU]I/9H^LA.,XIQDI+6THM--)M;IM74HSC+7XH/9J48WY'*+N R<XQS_ $Y)
M]!W. .2*^&/VP_\ @HI^S-^PI<_#RT_:)\1^(O#LWQ1M_%=SX1&@>"_$?BV.
MZB\%R^'(==%W)H-G=_8)('\4Z1Y"7*)]K2:5X6(MW!\M3_A\TT2">+_@F)YF
MU#+Y<_[583S !O,>Z .$W9V;CG;C=G)K^:__ (."3^V$-2_9-'[6H_9F2Y-C
M\<V\!?\ #.+?%22(VYN/@^/$O_"8CXFQ ^8'70/^$?.AC!3^VAJ8&S3B?C>/
M\_QW"_"F9YYEL<-4Q>"E@53ABZ<ZU#EQ&.H8:HY4Z=6A-M0KWBU5BDXINZ33
M_IGZ'W@]POX]_2(X!\*>-,3G.$X:XHAQ1+,<3P_C</E^;4GDO"6=9YA/JN+Q
M6"S&A3Y\9E]"%55,)452C*K"+A)J<?W27_@X0_X)I$X/Q)^(0)SC'P:^(IZ<
MG/\ Q)L\>P/?.._RI^V=_P %C_\ @GK^U!\!YOA-X4^,WB7PWK#_ !F_9<^)
M2ZIXD^#7Q6?2_P"RO@/^U#\'?CMXDT_;H_AG4+TZEK/ASX;:KHNAC[,+7^W=
M1TT:E<V.G?:KV#^(?7K;6[F+3_["U2YTV>'4HGO#;KHP^TZ>;>Y\V&4ZSI6H
M*%^T+:\6?V:Y*O)B9<*\?'Z3-\6)=6TK^W;&QM-,MKGQ&;XZ/=Z#<V6HZ:FF
M1Q>'1?6UU)-KJZI>:CNN9+K0[BPMK189K"]T2:.]M;O3_P $PWC/QIBL/*O"
MOP31<8U)2P^*H8RABER2E&*C2ECY^V]LXKD]C+]W"<:E5./,H_[ Y]^S ^B]
MD&=T\EK9;]*',X8BOEU'#YWD.8<.9ODDECEAY8BMB<=AN&N;*X97"O-XK^T\
M'?%2PN*HY:Y5J,?K/^BF?^#A#_@FD Y_X63\0B%^ZO\ PISX@[V)951"#I 5
M78DGYB%548\XQ7ZJ> OCY\*_BG\&]+^/WPY\8Z5XR^%&M>$[[QII?BC0A<7:
M7.B:9;W,^IQR:<8XM4LM;TB6ROM,UKPY?V=KKFC:Y8WNAZI8V>J6=S:Q_P"4
M'X-O/%-[X?L;SQAI]GI6MW#22M86,;Q1PVLD4$B)=6HU'5A;W2N9HKB&/5+T
M".*-Y6MYY+BPMOZ./^")T?\ P4 /A?X_S?!!_":_LB_V#K4?QGB^,/\ PDP\
M%MK!TF!O$$GP570$-VOQSC\"?:%G95A\&R:7_P (['\32TX^'AC]3(_&7B;$
M9GF65YIE^68R=++,YJ8:OD-"I6AA<;EV69CCZ>+Q#6*G0Q>4PE@X4\96IU*/
ML8<U>-2I&].?X3]*C]G'X-^&_P!'K,/&SPQXYXNX7Q>18#"<08C)/&;,,#@%
MG^6YA24,/PW@\,LFR[-<FXXQ.(J4*F1Y/B*&8_VO4G/*L53RRI4I9IEO]=__
M  W!^S[U_P"$AUW''/\ PA_B/^+D?\N)]?SSD @@+_PV_P#L_?\ 0P:]QUSX
M/\2=?_ #T(K^<7X_6_[11N_!FH_L]ZFT4VC:5\1M3\0^&M43X9_\(;XRUZ#0
M]-MOA7X9\9WGB[PUJ/CG3_#UUXQU$:QXLOOA?XF\&ZV? GASQAH]KK5AXMUS
MP7JVF^#O\1?^"DO_ !5KP_L^? WR]'U'QA8^$UN==BAOO&>GGPMXH;P%K\MI
M:_'.^M?#"VGC/2?#4?C#0[G4]3O=6\.>+7.@7.EZCX<N3J/\^Y;])SQ?S7!4
M,=A\S\(</[:+E4PF9UO[*Q6$?UFIAHQJTL;FD^=SE3]KSX>K.C"A.FZJA5=0
M_P ,X9SCJD(2B\![RBW=..\8O23JSBTVWM.5K;MJ5OZL?^&X/V?O^AAUW_PC
M_$?_ ,@5Q?BW]JK]F_Q4-#N'\:^/=%U/PSXBTWQ1I&H>']-\>:&)K[2DOHH]
M+\3VFC/IEOXQ\(:A:ZGJ-GK'@_Q$+W1;Q;Q=3MX+'Q%I>AZ[I/\ *KI?QU_X
M*0>*=4\46_AW]EKX8V5AX:U?Q/X9GE\?2^)? 9N/$6@:/JS:=<>';[4_B7/#
MX]\#>);Z3P[J-IX\\-6::7:7XUKP#!!K&G?8_BW']0_!/Q%^U-K/BOQS9?'S
MX<_#/P?X,TO1?"G_  @>O>"-9N;S6?%FN7=J\WBNXU31I/%_BR+P]96<Q%M%
MHLMS.VE7$"+:^*O&=K?O>Z9KFGTD_&G*,+B<5B<;X/57A:-.M4PF!Q^%Q^/E
M&J\+R0I8/#9Q.=:M;&4ISH0K>TITXUYS451G%.>;X^"DY/ ^ZKM1?,[/:RC)
MWOZH_8OQW_P5\_9L^ GB70/A/\;Y_'>H?%QO#EG>:_/\)_@_X^USX?ZIJMK\
M'M!^..OR^&K[5%6]LK:V^&GB31O&,^D:K=7MUHT.I+X736/$.N:;<R2_?_@K
MPGK'B]]$^(_Q/CMQKMQH^DW&D?#?3];M?%OPT\ ZC9ZSK^JV'B[PQ>7_ ()\
M):WJOC_6-$U30+#7O$^O6]RFB/H'V'X?V?AFSU?Q?=^,?XC_ -M$?$,_M<6!
M^)O_  @ZZ^-2^.?]C?\ ""MX@_L9? H_X)8_!P> 3JG_  D0^V#Q8?"CZ6?&
M M!_9*Z\+XZ-G3Q"Q_J,\-O_ ,%D?^$>T$6T?_!,@P#1-)\K=-^U4&$9L+<Q
M@YM\_<VG)PQSRH-?Z<XW),/@^#/#OB*->O5QG%_#> SG,*<_9QPV'Q.)R+AW
M,ZM/"4XPYZ=%8C-\3&$:M?$S5&%"+GS1E*7F<*<4X_/<^XPRK%T,)2H<.XS"
M8;!U,/"O&M7A7KYA3G/$^UJ2BVUA(.FJ=*DH^^I<]X\OZI4UR54D $CIG@=>
M]?G)X:;_ (*Z?\))X=_X3*/_ ()Q#P?_ &_HW_"6GPS+^TVWB7_A%O[2M?\
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ML/$/_P F?7\S7US17R+\&O"9[^&_!CLK*^0X)I622LG)I-**LTE)6TDG=O\
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M&:VMI=0N889)+>PBNKMH[.UEO952VCGNYHX(6F$TS)$C&O&?V?\ P]\7-/\
M!EUKGQUU\:C\2/'7B#4?&^L^%M/N[*]\*_"J#5;:QM=(^%?@R\M+6W?4=(\&
MZ-965CJFOW+SS>*/%DGB3Q-&UM9ZS;V%K%X>^$_B.Y^,VN_%_P"('C1_$_\
M9UOJ/AOX->$M(L)/#WAWX<>"];L]#?Q/-J<<5U/>>,_'7B[5]'MI-7U[6;J3
M2=(TC2M'T[PEH6@S3>(;W7??515)*@Y/7+,?YD^@YJ925.#I0E3J<ZI2J5/9
MM2BU&4G1A*:348RDO:2BH\U2+7-*G'EGE2I5,5B(8S$4\5AGA98S#X?#2Q,/
M9U8U'2I2QN)H4$H^UG&A.GA:-:K7^KX6I[5QCB,5-T550O3/XDGT_P ./J?6
MOD7]NKQ!\=_"_P"S/XWUG]FAM=3XTIKWPKTWPI/X:\&6'Q!UJRT_7_C#\/\
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M[1'BCPHW@3XTV&K?$74[CP9XR\9OX8;3-)4:/!JW]6AMXB22IR<$_.X&1T.
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MG4?M**J0:@W&4W:+]XI"<8X)SQVZ_B1U_P#K=2 ?!OA9\7_$/Q2&N7$WP/\
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MG0]"T2PM=*T;1M*T^%+:PTW2M,L8H++3["RMXXX+6SM((;>"%$CBC5% &O@
MY YQC\*6BL&VVVVVVVVV[MM[MMW;;ZMMM]6STXQC&*C&,8QC%1C&,5&,8Q22
MC&,5&,8I))1C&,4DDHI))%%%% PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *C<MQC.,\D''<=^V034E9>LZKIVAZ7J&M:Q>V^F:1I%C>:IJNIWDR6]E
MIVF:?;27FH7]Y/(RQP6MI:0RSSS.P6*)&8D $TU=M))RDVE&*3;E)NT8Q2UE
M*4G&,8J[E)I)-M$RDHQ<I-1C%.4I2:45&*E*3DW91C&*E*3;248MMJS:^/\
MQ4TGQ/\ VT?AKX45S/X:_9E^&NL_&?Q*BND]N/BE\9?[<^%OPFM9ER8X[W1O
M &C_ !NU:>!S]IM8_$'AV^\J..]M9W^T(\<@= <#^7]*^//V+=*O->^'_BK]
MH+Q'I\UCXL_:D\<:A\9Y+2^1/MVC?#NYLK'PM\#O#<A*K)"=+^#GA[P=?:A9
M.L8MO$VM^))!%&]S+G[&  Z #/)P ,GUXKKQJ5.JL,I*4<'3CADU9Q]K%NIB
MG%IOF3Q52K%2O>4:*;;2@H^'P_&=3!U<SJ7]IG6+JYK'F34XX*M"G0RJE).,
M7%PRK#8.JX-)0J8ZM&R=VUHHHKC/>"BBB@ HHHH *:W*D>HQ^!Z_I3J* _#S
M/BC]L^27P1X:^%G[1=@-D_[-GQ:\->.?$TD:RM)+\(O%T5W\+_C)'*J!EEM-
M(\$^,KGQQ*DBG9=^#+"Y!5X$S]GQ.) I#AT8;D=7RKJ22K*1U7&"""1@@@D8
MK!\9^$] \<^$/%7@GQ/IZ:EX:\9>'=:\*^(M.;*"_P!"\0Z;<:/J]DSJ591<
MZ?=W$!92&4/N7D"OG#]C/Q=KNL_!ZW\ ^-9Y;KXD_L_>)==_9\^(=U.CI<:G
MJ_PU%I:>&O%TH?.?^%C_  WOO WQ(CV%HT3Q:(8W=82[=K7ML!&3UE@:LJ4D
MVVWA\;*52FTGO"EBJ=6&E^1UX1>E1)^!'_8N(:E.T8T,\P<<1!:I?VEE$50Q
M,=K<U?)Z^"KI/WI2R^HU>%-V^LV1&&&4,,D\\\D8)]N*\S\6^";VWTKQ]J_P
MDC\"^ _BSXSM-/>7QYJW@J+7(-5UC0K1-/\ #]QXYL](U3POK7BVSTW3E;1[
M..X\0PW.F:?-MT^58X%M9?3J0@'J ?J ?YUR1DX-2C9V<7RR5X2Y9*2C4CM.
M#:7-"5TU=65[KVJU&G6A*,TU)QJ1C5@U"O1=2G.E*I0K*,JE"LH5)*-6DXSC
M?[4;PEX7X!^)'C"U\!W^O?M$^'/"OP7UWP]KJ^&]8OE^(.B:S\._$'G7&EZ?
MHOC#PAXFOI='U"Q\/>+]3U6VTW1M#\::7X>\666LLVBW&GWH;3M6U?W")]XS
MST4@\8(.<$$%@0?4$@^M8'BCPKX9\8:%J'ACQ9X<T'Q1X;UFW>SUCP]XCT?3
M];T+5K-V5GM=3TG4[6[T^^MV958PW-O(A90<#FO']'^#(^$WPNUWP!^S??:5
M\.[MKM]5\'1^-U\:?%#P/X4NI;C3S=:-I_A.\\=Z-J.D>#Y+"QFM-.\+>%_$
MGA_0_#]U?SZCI.G(!+8W.C]A4O*_L*DJWNP4/]EC2J63?-[2I7I^RDFVI0K1
MY)1C!R<=>&/U[!\E.2>886C@Y<V(E/\ X5JV)I<THP>&A0P^!Q+KTU&$:E*M
MA*L:]->VC;$77T)17A'A?Q?\7-"^'OB[Q%\:O _A_P#X2;PC#J-W;Z7\"-7\
M3_$=O'FD:9H\&I)>^'/#NN^%_"NO:5XEU>\:]TJS\#R2>(V2YM;=X?%6J0WR
MM!+\,OC[\-_BO9^)KKPS=>,-)_X0I+1O%]G\2/AM\2/A'J?AU;RVO;J*34]/
M^*/A3P?</;QP:=>R7%]8+>6$"6[2O<K$\4DBE0JI3G&*JTZ<XPG5HR56E%SY
M>5^TC;27,E%^S=Y>X[3O!:4\SPDY8>G.H\-B,52G6HX3&1EA<5*%)R5:]*K>
M"G0<)^VA]9<H1C[3WJ,HUCW*O)?C3K/C;0/AKXNUGX>36T?C'3+.WN]"CO=$
MN?$=M=7,6H67F:;)I%G>6%S,-3MVEL/M,=R#I_VC^T1'-]F\F37\'?$_X<_$
M2)[CX??$'P/XZBABCN)9O!OB_0/%,:6TI58KAFT/4;U(X9"R*DK,J,S*JEMP
M)Z'4+/2/$5D^FWIBNK>:YL;J2""\>)Y)=+U"VU&W61K:2*5X1<VD/VFW<^1<
MP"2TNDDMI98G\[-LOK8[+\PR]8C&Y;6Q6#Q.$CB\+*OA<?@9XFA5HPQ>&J*$
M*E'$T'46(PTVDXU*<)I634O1R_,,-2Q6"QU-8+,:-'$T:ZH5)T,5@<:J%:$Z
MF%K.E7G3K4:O(Z->G3JSFX3G%^S=FOC-/C+^TYX>\1-H.K^$?A!XZ23QOK?@
M;3[G2]7\:?#:YU.YT#P#_P +"U/68UUJP\::;!HMO8K=:&+PWIWZY9B((EG/
M]MC^F/A'X[UKXE?#SPWXZUKPI/X(F\3Z=;ZQ8:'-KMGXAD&C:A#'=Z1J1U&P
MAMHU.IV$T-XMI/;P7ED'\B\@BF#(.7U-?AO!J,W@^W^)VBZ/XPUJ[^(-OINC
M2^+M#FU^;Q/XZ6[N[N:W\/37EMJ&H7V@Q_:1HNE1KFTT])8I@YA6[BP-0_:/
M^!OP^\:Z+\"I?$VK:G\0[ >%?#A\'^#O /Q$^(&JZ,-8L-._L&?Q7)X&\)>(
M=.\'Z=<Z;>6.HSZQXHO-)TJRTN4:A>WL-DAE7Y?AK@[B7)LTK5:_&?$_$F5S
MP>)E0RC.J6"Q<\/*6(I3HXJ.91RO!8ZK1PM!5:*G7Q4X2E4@ZJGR2E+V>(.+
M^&L;@*48Y%PWD6-6/PU"IF>6XJO0IUJSIU8/ O!QS3%X*GB,77E&HJ$,/#$Q
ME3Y*5.$&YKZ</0]N.O\ ]>JTCF-6<L<*N6^8[5 !)RV0!@ DL<X /TKY\^(G
MBO\ :-M_&%EX1^$7PF\"ZGX?ETO3-2U7XL_$[XG2:#X=TV:?4;FWU+P_I'@3
MPGX>\3^-O$6OV>GV\5VLNH3>$/#CC4[/R?$-S-;WUI%-\5OV;_ 7QNU[2K_X
MGZEXV\4^$M)TZ.R/PB?Q?JVD_"/7KR._>]37?&?@_0Y-,'CC4$#I:IIGB_4-
M:\*+;6\$B^'!?(UZ_P!Y&E"*ISJUH1IU8.:]C*GB*J25X0J4XSBJ,ZLO=2K3
MC.%G*I1BDHS^2GCJU3ZS3P6!KUJ^'K4:,GBN?+L+-U)256='%U:5;ZS##1CS
MU5AL/[\I4X4:TW*4H)\5?BE\2]"\3^'OA_\ "7X/ZW\0O%6OVT&K:CXM\0WT
MG@SX+>!?#W]I26%Y>^*?'366JZAJWB,_9Y6TKP!X*\/>(O$=[OM[W6!X;T&Y
M76SVB_"/X=S?%4_&2[\-6VH?$J+PM#X-T[Q1JEYJ&J7/A_PPEQ>W5QIGA6RU
M"ZN=-\)?VU->L_B>Z\-6FE7?B@6FF1:_/J4.E:<L'IJQ+@95#M*XR%/3TXP#
MTQC&.,8J8*H.0H!QC( S@=!GT%1[5Q4537LFJ<X5*D)S4ZSJ-<W.[VA3Y8J/
ML::Y7KS2DI-%+ ^UJU*F-J1QL?K.'Q.$H5Z&&=#+YT*52,'A>6G*<ZZG6K2G
MC,1.K6?-&-*&&5.,IM5$7&U0,9Q[9ZXI]%%9?U][N_O;OZGH!1110 4444 %
M%%% !1110 4=:** &,BD$@88*0",Y'<=",\\XSR:^>/VCO 'Q8\<_"+XA>'/
MV??'OA[X.?%_Q;IVGZ-H_P 4M2\,_P!N7&@V3ZG;_P!MW$"6MQ;W?]M+H3ZK
M#X;U&07B:+K-S:ZE'92M$'B^BNO6HIES&P &>,<'J"/09_('Z'I54Y0I5:%=
MT:%6>%K1Q%'ZQ0HXB$*L-5+V=:$HNZO&24J?/"4H2FX3E&7?E698G)LTR[-\
M'#!U<3EF.PF84:&8X+#9GEN(K8+$4<51I9CE>-53 9G@I5J%)XG+\?0Q&#Q=
M."I8BC5IWIS^2_V3OV/_ (0_L??#G_A ?AOIC:EK&MS?VK\2?B3KZ17_ (\^
M*?BJ<SSWWB'QMK4@DN[\R7%Y>R:;I33RV&D6]Y-%;1M<7%_?7_)_MP?&OXI?
M ;X,:7IW[./PPUWQ]\;/B;XJT+X._!_2M$\,7>H>#O!?B7Q2MQ!:>-?'EW;6
MK:%X:\(>$[*WGOHY=?DM-%N]0AT^QO9;72#J>H:?\W_M(_ WXDZK\=M)LM8_
MX*A?%[X$6?QZ\5W6F_!;X(>#/"_AG1[R2Z\/>'-.N=<T'PYXAANY=5U>*S6-
M]9O-0OK&TCLEU2TL+F=I);5KK=^*'@[XX?L6_L3?'>S\ ?%S]H7]K7XY^.+^
M[L_A=JOQ"U=?%'CS0/%7CG1] \#Z=;^#UL19M9Z'X)BL]2^(L6GPR2EM574V
MCDS=%J]^I]1AB,)G>;9QEN*K8K$4)XAYO#$8+"<E?%TJ$ZF.SC'O X*G@L/B
MIX>->%/$T\-4]E##4W1=2G _H3 Y)A,]XRX&XWXE\0,B\5.+N/.+.'<QK\(\
M69)XE<.Y3GN(S/-)9=CJW$/'&<8'(>%Y\-\*9I"E1XCIY%B89/4RKAO,N&,F
MQ>6Y=%1P'U/^SE\-KO\ 94_9L\+>%/C!\;-7^(6I^!=#U3Q!\3/C-\5/%<LE
MM+JNIW]YXD\3:A)K_B>]BCT7P1HES?7ECX=@U2\2/2?#UI9QW4XE,TCTOV4O
MVPOAY^UZ_P 4M7^$OAOQ^_PZ^'OBR'PEH'Q8\0Z"FC>!?BO.MM(VKWOPYGNK
ML:UJ5GX>U&VFTW59=0T?3X56;2KJVFG?4+BUL,?3_P!DCPO\1?V3?AG^S?\
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M(4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%!('4X^M
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MJIVI%$PU/3([AU(2[UBVMU99+I%?]8BP!P3C/3K_ #Z5R'CKP7X1^)7A/7O
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MTL-/L(4M;*RM8E)6*VM;:**""-3MCBC1!P!6AY:'^$?E[$'\P2#Z@D'J:<
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M;B0SK!=6ER%\7F&[M-1O%NH+CQQL;7[V&2XDN56\>2-382LKQ:7$!::?!!9
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M)!XSTZ]/Y=?:OEOP_P#MN_LE^,=4U71/ GQ_^&7Q$U;1+"WU/4[+X=>)]/\
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M^B="%:$J^#3<81<Z^$<G.MAE&UW3;2GB<)%-<E97JTH*,<5'F3Q$O-P^8XC
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MBL/53=.OAJU'$4:B3L_9U:%6M"=G>+Y).TDXRY9)Q5BB@'(!]1FBH-PHHHH
M**** "BBB@ HHHH **C9RIQCTQW//L#GU[?3->;?$WXQ_"_X,Z$OB3XJ^/\
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M;[_Z[=EY+0]C^OU_4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\3KSX/>'U,7VF%?$UNOV.X]"^&7[+?@CP5XJC^)_C#6?%'QJ^-_V66U;XO\
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M74BP)@CG..G'MCUZ^_6GT45SGJ_U_P -V_SUW;84444 %%%% !1110 4444
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MG:9K23 DE9DOUE5CN5PW-<LO["OP TY&_P"$:'QL\%OP(W\$_M1?M+>%X[=
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M\R,Y29M>\86NNZS).G\,\E\TJC(#@$T_9Y>E>6+QM1[VIX*C2^3EB,9/1_\
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M2=8W0_*P5@17HQD8$ @]>3C&!CN"!QG R">O/'3P/XB_LH?LU?%:]DUCX@?
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8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>pg80-147_007.jpg
<TEXT>
begin 644 pg80-147_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #% IX# 2(  A$! Q$!_\0
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M/_:?[3O_ $)7P'_\.A\0?_G0T?VG^T[_ -"5\!__  Z'Q!_^=#0![Q17@_\
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M0=)NE\0:OX>&E+H&JZX)[.0:MJ>AKH>B+H]_J'VB[TQ='TL64L L+7RNIHH
M/\^O\Z*** "BBB@ HHHH **** "BBB@ HHHH *J:A%)/8WD$0!EGM;B&,$X!
M>6%T0%B<*-S#+'.!GC.*MT4 >7_!#PMK'@?X+_"'P5XAB@@U_P '_"_P#X6U
MR"VN$N[:'6/#_A32=)U.*WNXU5+J".]M)TAN$54GC"RJH5@*]0HHH **** "
MBBB@ HHHH **** "BBB@#EO%_@CP;\0=%NO#7CSPGX:\;>&[UH7O/#OB[0=)
M\2Z%=O;OYD#W.DZU9WUA.\3X>)I8&,; ,FUN:P]5^$'PFUWPMHO@;6_AA\/-
M8\$^&I["Z\.>#M5\%>&M1\*^'[G2PXTRXT/P]>:9-I&DSZ<))!8S6%G!):"1
MQ T>XY]%HH \O\8_!#X,_$74[76OB#\)?AEX[UBQLX].LM6\9^ O"?BC4[/3
MX9Y;J&QM;_7-(OKNWLH;BXN)H;6&5+>*6>:1(U>1F,OB+X+_  >\7VMO8^+?
MA3\-O%%E9ZQJGB*TL_$7@3PMK=K:^(-<N!=ZWKMM;ZGI-U#!K&L70%SJNIQ(
MM[J$X$UW/-* X]+HH I'3;!K$Z8UG:MIK6AT]M.-O ;!K P_9C8FS\O[,;,V
M_P"X-J8O(,/[LQ[/EKC_ !'\*_AEXQT/1O#'B_X=^!O%7AKPY/I]UX>\.^)?
M"/A_7="T"YTFW^R:5/HFD:IIUUI^E3:9:_Z-I\MA;V[V=O\ N;9HX_EKO:*
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M<7>O-XINIY_"VAS2W/B9O @^%K>(;AY+%FFUMOAFJ_#QM4D+7I\$ >%3.=#
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M7OQULS\,_$VIZ39^,?AS#X[_ &H6^)^G7/@FS\)_&Z?X+_ Z7X)^%]<UO4?
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M_5=QK_[8/_!,J[TK_A,=5F_:._94NK^VTL7Y>^76/!@NI5AM;6SDU:\U&_\
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M6\;W.EI/J_C7QWK&+;3;<WT,.I:-X.TFULK'ZH\0_P#!(7P;^S=\,++XG?\
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M6T4%K]P,@;.<\_3^H-5'7:&1&V[> 2,@ YPIY7@#)'S=!C&>1^;YAP+FN/\
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M)M!%OX,MO&GQ*\#S^!M<\*^*)WT/Q4-.TG6;_3]:\(V]MKUK[E\1?VB/A_\
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M&HZ=2G3;@XML_9N%*&&XEX4PF4TL1A*.><-YG+,,LCC:.'QF'<_K%/&898O
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MC@LQI_6'5QE/#PJ8?$1;JO!SK4:CC#^@3XU?\% /V8O@WX?N-1/Q+\-_$;Q
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M8GR\?]M^(+K4]6:-R61KUE8E@2?Y+/\ @XY'_&8'P7[_ /&-6EYSGD?\+/\
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MH/C*QTF_^V^&?%GA'QGIYA@T[Q3;16]CJ.IZ+'J%GXF\)ZQ&3<6\$*V-]/\
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M_P (QI8O&F,GSF4W D\POERV2WS$@>C@ =!BHK>.**)8855(H@(HXT&$CCC
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MD_H(*JW4 _4 _P Z6J4I)-)V3=WW^37X^0#%C1 JHBJJJ%15  15  50.%4
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M:&-VBBDN'6&$.\<?GRE6;RH@S*TDI1&?RT#/A6(!&:XGQ/\ #G2=7\"0^!=
MCL_!EAHL'AL>#O[!TJR@T_PA<>#+[3=2\(_V9H=L+2P32M#N]&TV*+1;<6=F
MVFVYTZ(P0N-OR!^U7^QC<_M!_L^?'GPYJ'BB?7?V@?&7PP\2Z;\(/B5(;KPW
M9_"/XF:7;_\ "1?";7/ASIEIJ-R/!,'AOXC:3X7U[5=1AU*[U[Q"NG-:^(-=
MOM,*:?#[.#KU,/FDLLGE=7"Y'3R^%3 9E@/[/^KT<13C4ISRW$X.IB,/7I<U
M;ZM4PM?"82O06&=:55PKTX*K_-O$N=YGGF*HYC6IXG-,^QV+Q&)XCS_/N(,S
MS/%YWB,5C\1BJV;XVICH8_&2S.&#JK ^QI8NK0S&M"EC<1BLOY<3AZG\Y?\
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MXCCUGP]%X>UB W)MM1\8ZCX'UZYU*ZMYX_$_@;6Y;:TO+'5=+U)OES_@B^?
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M%MJVH^$DL]8MQJ>B2>/M'O+#48Q$--.J^(/#=YXUM-5M[>P:XUK0M5\11O\
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M?^N4G\L_R!/X5/5>OZ2\D6]GZ/\ *9^DJ?<7_=7^0IU-3[B_[H_0<TZOE_\
M@_FS\X>[]7^;"BBB@04444 %-?&.1D YQC.< G'Z>AIU%#U_KS7^0;[ZKJ?E
MC^W7^R%XY\6>(]$_:F_9GO+KP]^T+\/D@FO[+17@LK_Q]I.EV[Q6DEBTP-C=
M^+-,T]I=(;3M5CEL/&/A>5_"VHB86>CVK_$NA?\ !8KXV>&HI] ^(GP0\$ZS
MXIT:5M.U22'5O$WP]O[:_M L%Q#K/AR_T[Q1+8:F)(W:\M4DTY(I2R165LB^
M4G]$S#./K_0^Q/Y<YKP#XJ_LN_L_?&^[&H_%+X3>$?%FL+''#_;\UA+I?B4Q
M1(L<4#^)=#GTS7I+>)$"16\FHO#&H*H@!(KZ/+\XP2HTL'G>7+,\/03CA,1&
M:IXS#4VY2=#VG/2=>A=MPIRE^Z5U%J+LOM,GXDRE86AEO%&31SK"X1.& Q<)
MRI9C@:$I.3PRG&OA_K6$C)N5*E.JO82E-1O"5H_SL?''_@I]^TC\8=&U#POI
M5SX?^$GA75()+2^MO 2ZB/$VHV=QB.6QNO&.IW<M_;QSY$4A\.V?AZXGC8V\
MLKPR2QR_<7_!+3]C#Q7X(U5OVD/BMH-QX;U"XT2[T?X6>$]8MI+;7K2SUA1!
MK'CC5;"X1+C1I-0TT/HWAZTNECU&XTS4-8O[NV@M+W29;S]&/AO^Q+^RQ\)M
M;MO$G@;X+^%K#Q#92+-I^M:P^L^+]2TVXCD$L=UI5SXOU376TN[B?!CNM.^R
MW$>!LE4 8^JT'4Y)SC&?88__ %_S-=F9<1X)X&KEF19='+<-B%RXNK*SKUH6
M7[N\:E25IJ*YYUJE23@_94U3BKOOSKC++7E=7).%<I_L? 8M<N/Q$X4H8G%4
MW9RH<M*M7=I.,?:5J]>K/D3I48T85*SJ.7'..,G)'H<#_/Z4M%%?(?U_E]RL
MOD?GBT_K[_QN%%%% !1110 4444 4M1L;/4["\T^_MHKNRO;>6UNK:90T<\$
MZE)8W'7#*Q&1A@<,I# $?'VHGQ[\ [Z[72%77/ NHW#3VK:C%-<6EK,[@>1<
M2V\D,NEZIM\N)YU8V.JA5N4@>=)HK/[.J"Y@ANH);>XABN()D,<T$\230S1M
MP\<L4BLDB,N0RNI4@X((KX?C'@Q<2QPF/R[-<7PYQ-E,:RR?B#+K>WH0Q'+]
M8P.-HM.&/RS%.$'6PE6,N2I"->@XU4^;.I3]IRN,G3J1;<9KI=6::>CB^J9\
M<7'[3.NO"4M/"FCV]P0<33ZA>W<:M@<_9HX+-B <D(;L8..2<BO+)]0\??%[
M7[>T>2;5[T$B"T@C^RZ-H\$K$27$B1(\-C H!,UW/YMW.%\A9+F400G[0N_@
M[\-+N<SS>$["-W8LZVDM[909;).+>UN8H ,G.U(T4'!QD#'::%X>T/PY;&ST
M'2[+2K5CN>*S@2(S2# $MQ)@RW$NW"^9-)(X0!=P  K\?K^$_B7Q5B:>!X\\
M088SANG7A.M@LIC7HSQT*513C">'_L_+L'"<U'6OC9YE*DY3^KT)2C&I3YWA
M\14=JU>]-:^X[.23ZJRM?SONVC/\#^%+3P7X;TWP_:.)A9PEKFYV[&O+^X=I
M[V\926*B:=V\I"28H%BA#%8UKK:**_HW 8'"Y9@<)EV!HPP^#P&&H8/"T(7Y
M:.'P].-*E33DW*7+&.LIRE.<I3G.4ISG)]:2222LDDDET25D%%%%=8PHHHH
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M.?\ !.WP7K]MXFT7]E;P!<:I:7,=U#'XHO\ QAXZT.&:-\HZ>%_&_B7Q%X9
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MI2G%6C4G%7;M&3BFWN[1=KLN-6K!<L*M6$6V^6-2<5=[NR:7X'"?\*X\#?\
M0J:1_P" I_\ BJ/^%<>!O^A4TC_P%/\ \57=T4_:5?\ G[5_\&3_ ,ROK&(_
MZ"*__@VI_P#)'"?\*X\#?]"II'_@*?\ XJC_ (5QX&_Z%32/_ 4__%5W=%'M
M*O\ S]J_^#)_YA]8Q'_017_\&U/_ )(X3_A7'@;_ *%32/\ P%/_ ,52?\*W
M\"_]"GH__@*?_BJ[RBCVE7_G[5_\&3_S#ZQB/^@BO_X-J?\ R1P?_"M_ O\
MT*>C_P#@+_\ 94?\*W\"_P#0IZ/_ . O_P!E7>44>TJ_\_:O_@R?^8_K&(_Z
M"*__ (.J?_)'!_\ "M_ O_0IZ/\ ^ O_ -E2GX:> W4J?"NC@'((^RX!!XP?
MFYS['C^7=T4O:5;?Q:O_ (')_F[:[>C%]8Q'_017ZZ>UJ6::::?O[68BC"@#
M.  !GK@=.E+129'3G/T/O[=#@X/0]LU)D+13=PR!SDYQD$=.O.,#VSU[9HWK
MZ\<<X..>G.,?X=Z '4$@<FDSCU_(G^0II8'('7@XP1@9ZGC..#S[<4 .W+ZC
MUZ^M&Y?4<\=:^(_VO/VT_#?[(<WPZC\1>!/$?C2'XB#Q:;5_#^HZ38R:6?"9
M\."X%Q%JQC2Y-Y_PDD)B\N>/R1;R9#%QM^9-+_X+&_L\7)0:K\.OC3IA/^L,
M.D^"-1BC..,-'XVMIY <'.+=>!_$*]3#Y)F^+P\,5AL!7KT*O-[*I3=)J:C)
MPE[KK0FG&<91:<;W5TVFCW\)PMQ#C\)2Q^"RG%8K!UN=T:U'ZNU45.I*E+EA
M+%0JZ3A*+;IQO;16U/UWW+ZC\Z"P'?KT[_RK\Q-/_P""LW[)=]C[3+\3M)&2
M/^)AX$>;'3YO^)1JVJ<8.<8)_P!GH#WNF?\ !33]C.^V^;\4]0TLLH.-2^'_
M ,0HMO<AVM?"]TBXP1P[#.,$TI9'G5.[GE6-27;#U)7].1U$]?7Y$5>&>(Z*
M;J9'F<;;VPE2?_IIU=OF??\ UHKXYT__ (* ?L=:DR^1\=_"D1D(5!J%EXET
M@@X)^;^UM#LM@/)RX4#N>17I&E?M6?LS:T5&F_'[X/S,X!6.3XA>%[24Y&0#
M%>:G;R!O]EE#9XQGBL)Y=F%/^)@,;"_\V%Q"^ZU%W];'#4RO,Z7\7+L?3OMS
MX+%1OI=V7L&]%Y'OU%>?Z;\6?A7K*AM'^)?P_P!55N VF^,O#E\I).  ;74I
M0<GC@]>.M=I;:CI]ZJO9WUI=HP#*]K<17",IZ,K1.ZD'U!(KFE3J0OSTZD+:
M/GIU(V?9\T(V^=CDE2JPNITZD&MU.G4@UZJ5.+7S2+E%)N'^U_WRW^%(74<D
MD?56'\Q6=UW6F_\ 6AG==_/Y=^@ZBDW#KGMG\/7_  ]>U-\Q.N>GL?\ #I[]
M*?\ 7];C6NVMA]%-W+Z_SHW*>_Z'_"E==T%QU%'^?SHSCK3NON%==PHI-RCN
M/Y_RH# ]#_.BZ[K[_P"G^ [K86BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "OG7]I#XF^/?A9X>^'FJ?#WP_X8\0ZEXK^._P %/AIK,'BO
M5=1TFQL?"GQ$\=Z7X7\0ZG8SZ79WUP^M6MI?JFEI);R6T%Q-]NN(;Z*T;3;S
MZ*KPWX_>)_A#X5\%6-Y\;=#B\3>$=0\;^ ]-T;0#X U?XFW6I?$$^)]/U#X=
M)I/A'0-#\1:M>Z]:^,-/TJ_T"\M-+>73-8M;+4$N;-K9;F, ^5=>_;G\9Z'\
M+M:^*/\ PI#0I;&X^)'Q"\"_#+PN/BAXKUGQM\2++X2:]\6-(^)&N1>&/ ?P
M-\<ZMH<^E6OPO_MK2;$6VLZ/)INNK<>,/%'@6WTFYN+C?LOVX-2U3QY;Z1I7
MP0US5OA]JNO+X)\.^*],\9:+<^-=<\?7G[(-A^V7HWAV+X;R:?;VMO9ZKX!&
MN>%1K3>.I1!XVM-$MH].O-&UJ]U?0+VO>.?V+?&GA/X2>&]=^'6E^*_A[\2)
MM4\>?#&&\_9]\9:GX!?Q7XO_ .$TU/5K!]0N/ Q\.^$_BCXQNY?'=CK'@K7K
MG2?&NMZUJ^I>&M;TI]5\5VFGZOD:A\8_V2KC7/ >@:+X%^&'B+P'XF@UKQQX
MH\8W?A>RTWPSX)L++]DG^U=(\2W5MJGA5K+6[G5_V9=5L?!6HI'>6M[H/PMU
MZQ\/:HG]BZA%HUP <!=?\%$O%EM\/[C71^S]:'XCZ+:_%OQ/XR^&6H_$GQ3X
M.NO!W@3X-_"CPC\5?$=UK5S\1/@CX,\66?CO4[+QYX4TKPWX,U#X>Z=HNLB]
MN_$5MX[/ABT@U:^Z?Q!_P4"N=&U/X[/:? CQEK7@WX*?#SXH>*&\9VD_B*WT
MO6?%_P )? 7ACQYX@\%ZKJEYX!B\%>%[+6H?$K:%X/\ $">./$&JZKK&@ZJ=
M8\&^'--O?#-_K_COQ2\-?L#_ !6_9RU.PT30O%'PL^$7A'Q_J<GQ"T+X>_LA
M!_%V@W_B?X2O<ZCXD\4^"_B!^SKXW\:?#C2KWX-ZK8ZOI/Q=T70_"5Y:>'ET
M/3-)\7LB6WA]O2?'7QA_8I\-_&CQ)H5_\*/ VM?VY\-/BIH/[0?QFU'X::K/
MH5M\./AK\(/!WCO7O"NI^,KCP)J&D?&*"[\ 3^$;+Q)X;T3Q3JNJV.FZ9X?T
MW5=.U*32;?3=/ )/&?\ P4)\3>!KBZ\(ZE^S=XGUKXNZ#XO^*>E^*?AWX'\2
M:SX_C7PA\)_!GP<^(>KZYX-UOP9\-]<U'Q/XKUWPK\?OA?;^'/"6L^%?!N@M
MXLO/$>AZ]\0-!TS1+/Q%K?VK\7?BE;?"CX<:W\0;G2[C5DTV+38[32@SZ=+=
MW^LWUI8:=;W4LL4SZ="MQ>1O?2-;S36\4<P2WDF"Q-PNB^!?V<?VC/#9\6:K
M\$-%UJQO/'$WBZ>V^+?P-U+PAK\OCO3]!TCPE)XJN-"^)/A/1M;NM0G\*:-H
M?AI/$BVMQ::MX;TRRT2._N]-L#:0^[>(_#&A^+M$U+PYXETNWUK1-8M7M=2T
MV]0O!<PLT; %E:.6&:*2..>VN+=XKBUN(HKFWECN(HY5\7B*AF^*R/-L-D&,
MP^7YW7RW'4<IS#%X=XK"X',:F%KPP.*KX9)NM2P^)E3J3AR5;I)NA6Y/959F
MIN%14I*%1P:ISDKQC-WLVNMGK_5G\\_LT_M'?\+XMO$EK?\ AM/#6O>%7TN2
M\AM+R;4M,O=.U@WPL;BWGFM[6>VNHI=.N8+NTN$E&WR+FVN91)/!:?5%><_#
MKX4^ ?A3IEUI/@+PW!H%I?7:WU^RW-]J%Y?7*H8HI+S4M4NKW4+A+>)C%:P2
MW+06D;2+;Q1"1]WHU>5P%@>+<MX2R? \<YO@\]XJP]"I'-LTP.'6'PV)JRKU
M9T5&*H86-6=+#RI4JV)CA,)'$58RJ+#4]75BA&M"C3CB*D:M9)^TG%6C)W=K
M?*RV6VP4445]>:A1110 4444 %%%% !5"_L+74K2[L+^V@O;&]@GM;RSNH4N
M+:ZM;F)X+BWN()5:*:">&62*6)PR21NZ,""15^BHJ4X582IU(QG"<)TYPG&,
MX3A.,H3A.$XRA.$X2G"I"4)1G3G.$DXSDF=]G=6::333W5GW/D[Q7^QY\'=:
M\(ZKX8\-Z))X'N-2U6PUM=<TJ:\U2\@O]+@U"VLX6AUJ]O!)I"VVK:C"VDV\
MUE; W F@\FXAAFCR+#]CKP99?!W6/A2VOZ[/=:UK]IXLF\7M:VL=Y;Z_86T=
MGI[6VE(S6PTBVLDEMWTN6ZEFE-_J-Q_:,5Y/%/;_ &117YO5\'/#"MBZ^.?!
M.04L1B,AQG#5;ZI@E@*$LEQ_MOK.$CA,!5P>#I2FJU1+%4<-3QU-2?LL93;;
M.:6"P<I.7U:BI.G*D[1LO9S5I1Y4U'WHZ7M=+9H_*SXA_L+>-+7P_P"#M-\
M>(+#Q9)ID^N'7(M<5?"RF[UF[LY$U;38HWU6)8UL[&UT_4H[B_EO7@T[39+7
M[2J_9H/T(^$7@O4/AY\-_!7@K5-3;6-0\-Z';:;=Z@OF&!Y4+R?9;,S(LW]F
MZ<L@T[2_.CBF&GVEL)8XI"R+Z717/P;X-\#< Y_F?$7"V#QV7XO-<KP&35<+
M/,\9B\NPV!R^5&I3A@\-B9SJ4ZE6IAZ-2O5KXK&3<U4]DZ$:]>$UA\'AL+5J
M5:,'"52G&FUSRE%1@M%&+;2N]7OKM8****_4SJ"BBB@ HHHH **** "BBB@
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M9X@L I!;)7[)J,(4Y!)( )))SDG/?:7\?OCWI8VZ=\<?C%9(74%(/B=XV5.
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M?V\/V6+W'_%SOL;,0!'?^#_'-LRDG'S.WAMH57/5FD 7/)]/YTT'$?\ N_\
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M?$'E18TRS\2^']2\/7<V;?5H#:229N6/[5'[..H?\>_QJ^'2?]?GB73]._\
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MZ#HMA!916WVC2$9&*/ZT _!W_@M4V)OV9P< X^,S'L/F/PM/&>?7M^-?AHC
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MK/[S^9ACRG3CS,\CN.W-(23(F<=NX/=NV??_ #TK^FC_ (9?_9Y_Z(O\-?\
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M$5^&?_A)Z;_\:H_X9:_9X_Z(K\,__"3TW_XW3EXEY7)>_EF/FFK.,I8&2_\
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M*MV^$\TIM_\ /G,X4_P>(J+[T_0ZZ?#'CC1LX>(O#]1+>.)R2=?F]7'+\/\
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MYXM\-_$#X2:7<Z?IC^'_  K\)/!.L>%-9U3X":Q\6?!WCZP^#WA'1]1L(?\
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MEJ>D^+_#7@:\\*2ZC=>*?!C^)O"WAB37 #]:NO2BD P /0 ?E].*6@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>pg80-149_008.jpg
<TEXT>
begin 644 pg80-149_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %> IX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MJ=S=I ""<8!)/IU].G0@]P?PR 6RRKU('_UZ89$['/T&?Q^G]:\ ^)7Q\^'7
MPM2/_A+_ !/::9>7$)GL](A2YU+7;V,LR+-;Z+IT%UJ)MI&1HUOIK>'3Q*K)
M)=QLK;?F.\_;Z^'JSE;7PO\ $2\@#$&X&EZ!;!@"?WB0S>)?.8$ ?*P1P#\P
M!Q7=A\LS'%1]IA\%B*E-[5%3Y8/7[,JDJ?-WO'F36J=B7."WE%>LE_GI\[=M
M]#]'/-3C+ 9['@Y]/K3@P;D$'O7P7X:_;;^$6N3QVU[J^J^$YY&547Q9I$ME
M:[B<9DU73YM5TBV0?Q2W]]9H#E06(R?JO0_&VFZQ:VMY8WUM>V=W&DUI>6,R
M75G<V\B@K/;7<!D@GB<999(9&5AG!/?&O@\7A6HXG#5Z+;LG4I349/I&,[.$
MI6Z1FWV3&I1>S3/2J*H6MZDZJ0P8=R.HR,C(XY)( &/;K@&_UZ5S_P##_+OZ
M>8PHHHH *,CUHK^?/_@L?_P4@\=? C4[#]F#]G_Q!/X5^(FM^'K3Q-\3/B-I
M;0_V[X+\.ZRUU#H?A3PG<.)6TGQ7X@M;:YU34_$ CCU#P[X?N-)D\/2P:OK4
M.K:$ ?O+K?C7P?X;N[33_$'BSPSH6H:AM^P6.M:]I6E7=[O9D3[);7UW!/<[
MW1T7R4?<R,!DJ172JRLJL&4A@&4@@A@0""I'# @@@C@@Y%?Y^/PI_8I^-/[4
M6F+XW\)^)?@KXI\:>-9_$UWX?\"^//CSX'MOC[\4KSPY)?+XCN=#\&>(M2N_
M$FK722Z;?R27GBR^T)KVTA;5?M$NE30:A<^J_L+?\%#/C-^Q+X_TC2K_ %OQ
M-XE^ S:PFG?$;X-ZU<W=[;:+IPNQ:ZMK?@&PU.7=X/\ &6@(+B[.FZ;)INC^
M)9;9]'\1VK74EAK&C@']W=%9.@ZYI/B;1-(\1Z#J%KJVA:_I>GZWHFJ64GFV
M>I:1JUI#?Z;J%K+TDMKVSN(;F"0 !XI4-:U !112%E'5@/J0/YT +17+ZMXP
M\+Z',8M5\0:597 R3:R7D370 &<M:1NUR!M.<^5C!XS5&T^(/@K4'6*W\4Z-
MYC9"I/>+9O)[(+SR-YR/X-QX(&2.,G6I*7*ZM)2ZQ=2'-?M;G]-[6NKKOTQP
M6-G!588'&SI-<WM88/%2IN*3?,I1H-.-DWS)N+C>7-RIM=M14:R1E582(RE5
M8,K*5*D<,"#@J1R".".E29&<9&?3O6O^5_EW]//;S.;K:SNMTU9KU6ZV:U2U
M36Z84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M(2!U('U('\Z %HIH93R&4C&<@@\<G/7I@$_@:=0'Z;^7J%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !17/\ BGQ9X7\#>'=9\7^-
M/$6B>$_"GAVPN-5U_P 2>(]4LM%T+1=,M5WW%_JFJZC-;V-A:0K@O<7,\48R
M!NR0#^0GC+_@NU^PSX6UV?2-%?XR?$BS@F>%O$?@GX=6MKH#,C;7>W;Q[XE\
M#ZS>0 Y:.ZM=(EM[B/$EM),C(Y /V;HKXZ_9=_;S_9@_:_BOK;X,?$6&_P#%
M6DV@O]9^'WB73;[PIX\TRQ,BQ/?KX?U>*)]<TFVDD@@O-=\+W.O:%9W-S;6E
MWJ4%W/' WV+0 4444 %%%% !1110 4444 %%%% !02!R3@>IIKN$4LW0>X'Z
MGBN6UKQ%9:39W5Y>W5M:6MI&]S=7=Y<16UI:VT2-))<3W,TD<5O!$@WO-*Z(
MB L[A<X:U:6NK459-MMZ)))-MM]$@.F:9%QSG/T'\R/7BF?:H>N_I[?TZG\*
M^'O%_P"UUX9L9)[;P?H?B'QU-$[I]MTR"/2?#K;01F+6M4"SWD9((BN=,T?4
MK*X!\R&Y: J[>/R?MJ^)[.XW:C\)Y5M 3N-IXT$ETJKW5+GPU!#(P&"%,L2D
MC;O ^8>G2R3-:\>:&$DE:\54G2I3DNC4*E2$[=;.*;6J[D.I!;RMI?:3T\K+
M7Y7MV/U!:XCVG!/(//3CU&.<XSCIR,>E?)?[37QKN/A=X30:&(9_&7B:XGT?
MPK!,AG@MY8HUEU'7;N YCN+71;::%A:R 17.H76FVLH>UFNS#D?#C]J#P/\
M$ASI^E7EYI?B!(O/E\->(((K'5_)C7=/-8^5=W5AJ\$05FF.F7MS+:(5DNX;
M>,[C\V_&**\^(OQUM;'YI[/PYX8T>QL(<D)]NUJ\O=4U"Z W,HEGBDTNUD.%
MW+IL"LC; PVRW+I/,X4,?1J4U0A/$5J-2+BYQIJ/+%.S3C.I.%I1<DTFD]63
M4G:FY1=]K-*ZMZ+7;3?1M-Z)H^"OB=XS\)_##39O'?Q9U_4-0UOQ'>W$EM;A
MCJ_C'QCJJI"UU]@MKFYA\Z&T26#[7J-[<V.D:7'+;VLUQ:/-I]M<_%>L?MJZ
MPT\S>'OA/H]OIJ;O+.O^(;^]U"2-<[))$TS3]/M;=W"[G@26[",?+%PRCS6P
M_BR=9^.?QL\=^*BTESH6DZWJ'@_P7 GS6UCX1\+W]UI^GFW4%E4ZQ/'>>(KX
MAB)-1U>Z<$1"&./H_ OP$T[6+SQ!=^+9M2L/"?@WPGJ'C'Q*FD) VMZC8V,]
MC8PZ3H_VE6MH+S4=0U&TA-[<H]K96QGGF0LBD_J"^KX>CSUG&\81;A3C:$$W
M%0IPA3:3G+FA%6O9W?PIV_H[A;PTX8PN7X6IQ#06:9KB:5&MB:5;$U883"NK
M"G-8:E1HU<.I5*=.O2I3KSG.4ZSE[-1BXM=G+^TWI?A_Q-=^#OB]X"G\'ZI9
M)8-=ZMX4U8>,-(LUU/3;/5X9+VT6TL=6@AAL;^WEN38+K%[!(98OL68M[?8/
MPP^*_B/X>#3O%GPV\1V^L^$=9$>HMIT%Z;SPIXCM6=LS*D;,ME>G]Y"VHV0@
MU&RN(FM[U)?)GLZ^._BGK\6H>"/#WC;P;X4TOPOJ_P 1!XE^&?B37]1-SK?C
M671_".GZ)HT$&F>))A:Z>;?5_#MS;:=KVHV>BVNHR3V[V4UU(O[Q/0?V8? T
MGA2%](FNE?PUXMDV?89) R:?XE:WS9:C9QEV6!]32)--U!(\)<N]C/+NDL5)
MPKRPU;#.&*HQ]G4G*C.A5M5IMP?+5M]J+4VN2490E%/>YY/B)X;\.8#!5<VX
M6K5L/6H*I5J9<ZL\7@JU&C*:JTZ&(K5JM?#XJA"C7E.DY5*;GAYT?84JR3?]
M!OP9^,FB_$KPUI_B'1Y9Q'/*UK>Z?<X-WI&JP)"UYI5]Y1*-/;F2)XIX_P!U
M>VDMO?08@N8T3Z;L[@3(A4@A@>.25P!U)].AQWYZDU^''[.?BFX\"?%]_"_G
M;=(\8)-;/&S,%CUC2HKK4M,N%X50TEJNI6)!^:1KFW4LICC#?LUX6OC<6<#$
M@$X[G ) 9\DX!P<G.>G'7BOS'.,OCEV-E2IMRH58*OAY23O[&3<.5W_DJ0FN
MZ3C?5GX3"7-&[LGU2Z/\_O.[HHHKRBPK^%C_ (*\Z7KNF?\ !13]HN37?./]
MKW/PXU?0YI@P2?P[+\)?!&GV#VH.5-M;7.FZAIS,C%6N[&[&U)%F4_W3U^1G
M_!43_@FK'^VMX?TCXB?#6_TKPS^T)\/M)DT;1+C7)Y;;PU\1/"#7D^HMX*\2
M7MO!=SZ-?:7?7=_JG@[Q#%:W4%K?:AJNC:S9G3M:36?#X!^(_P#P2V^$7QA\
M.^+?AU\9T_96\'^*OA7XK\0^*U/[7>J^.?#6B^)_V>M"M-)UGP'XR\7:$NL>
M+=0\,^']2\%B+5-<TNW\=?#*_P!7\0&Y5=#O3I6HVUS#^2'Q,T[PWH/Q&^).
MD^$O&$OC_P 'Z-XZ\9:;X8\?W2>7<>-_#>F^(]4M=%\8W0 P9O$NFQ6VLW$B
M@QS2WKS1JL<BQK[UXP_X)_?MG^#/$-YX;\1?LE?&^YU6&X%O-/X8^&VM>/\
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MW6KQ>=\Y_'OP3K>N:K9>.%O;H:%_9MM>:EH@>:X'A;1[&]MK?4-2T>^MHI-
MO[.[^WQW,+Z;/.TD]WYL,>H11O'!PNJ?LY^+=9TM+W3X[F/3?$&F2A[;Q)X@
MBE?5]-N@;5HV\FP\V/$B"WDB;6+J".2-;5[>.>#"_F<ZV95XXJ.&IRK5Z:J2
MI3K5)W52I3O3J3A&#:AS1BFO:.492E%QBTC^A_['X>HY?EF9YAQ?EF6+,*56
MBL/6PM;V%'&T%6:P-6I2Q'M']7<H>UQ&%RZM2G0E"HE*D^8^J_@+^U=X=U_5
MKO1O!6O:IXCM=+A@GU'0;[PSXLTYY+);8R7VIQS7&@C0] ECFCNX[2W?5X)=
M2:POGM].N[.!+BOTPT36K#Q#I=IJVFS>=9WL7FQ.05=""1)#,AW&*>"13%/$
M3E)%898;6;\>?V;KCP-\-/'^I>$IOAI8> ?'TND1:?=:OX8OM4GTS5["VCM;
MP3Z]9W^K:LD4\I,=_%<:<FGV\$,95O)D=["Y_3+1[F2.2\@AE>,!A.HB=EV-
M(QC='5& 5U*!F0C*LS< %37V7 V+S2MEO)G&*P^(QE.M5IU(8:E5IQP_*^:C
M!*M)U9.5-VJ\\4E.FW#W96/Q#Q&RBKEV.HO$X##8>OB,/1S##YC@*U"I@LVR
M^O#FI8JDL/:E5Y[2E'$QC1G*#Y<1AX.FIR]MR!U./_K_ .?PI:\UCU34HP-M
M[-T'^L*R\?616/TY]:N1^(M34X;R)!ZO%VQU^1T.?P/4\5]R?FAWU%<A%XEF
M/,MFA&?^6<Q4GM]UD;H>"2_OTJ]'XCM6QYL%Q$>^ DB]^ZN#QW^7V (YIV?9
M_<P.AHK)CUO3I&"_:"A/:2*51G( ^8Q[/S8'GIZ7H[RUEXCN8')["5-WN-N=
MP([C%+;<"Q12;@1D$$>HY''N,BEH **** "BBB@ HKEY/&_@N&]?39?%_A>+
M48[T::]A)K^DI>IJ+2>2NGO:M=B=;TR_NA:F,3F3Y!'NXKJ* "D) !)Z $GO
MP/8<UG:MK.D:#9G4=<U33M&T];FPLVO]5O;;3K);S5+^VTK3+1KN[EA@6YU+
M4[VSTVP@,@EO+^[MK.V22XGBC9-.U?2=<MKFYT;4].U>UM[_ %;1[FYTV]MK
M^W@U;0]1N]%US2YI[626*/4-'UBQOM)U:R=A<Z=J5G=V%Y%#=6TT2 /9VWMI
MZ]-M=^VI9GNHH$+O(J *6+/P@502Q<L5 50"6Y!PI]#CF?!'COPQ\1/#>E>+
M?".J)K'A[6XIYM,U)+6^L/M$=M=3V4X>RU2VLM1M98;NVG@EAO+2WF5X\^4%
M9"WQ5^USX(\>^&/#GQ6^./P4\1:GI'Q*LOA7K3:GX7"O<Z9X_MO!NDWFJ:9I
MBS6UQ;ZCH^LI;1W=KIE]I?FW4=Y+ FE-I%[J&HW][E?LH?'OX07/P&^$6L:3
MXO\ "N@:3X@\ :!XD32M7\4:):W^GZGXBM?[8\16=^MS<VBBZL_$MYK%M<-%
M!#:"2W=;"**P2V1-G"BXJ%*I4K8EPA5E2IT*O+2I)RA5E.?+)2DJCI*$8M-1
MDY235F>?0_MNKB:M6MEE/"Y/0J8C"K'/'86O4Q>*?L,1@?8X:E)8C#TZF ^N
M5,5];I+V=>C3H4:E1RE,_1JBN)TWQ98:A%#/;7-M/!.BR6\\$\4T$T;84213
M1%XYD!. R%@6X)!%=;!<"90000<88'J2!CC QGG&0.1@9)P,FFFTTTUHTTTT
M^S3LT_5(] LUY[\0_B1X3^&=GH&I>,;Y],TW7_$EAX5M;\VL\]E9ZEJ=O>W4
M%UJ]U&OD:1I$%KIM[+?:Q?2PV5DB!IY%5\CT(D $GH!D_05Q7C72M'\1:)>Z
M'KVF6&M:3J42Q76E:G:V][9W/E317$ FM;@/&\D%U%!=6TB@36US##<0O'/%
M%(K@X*4743=-.]3E=I<B^)QT=VD[I6]YI1TO<Y\5'%3PU:."J4*6+=-_5ZF)
MI3K8>%56<77I4ZE*I.E)1E3G[.:G&-5U(*<J2IS\N\*?'33/%OQ3\:> M&CT
MG4=#\+:%X?U*W\6Z-K"ZM;:AJ6K&5;W2IH[>V%E;26S+)'#)!J-[OET[4XYQ
M;RVTL%M[Y!<I(H(]<<%3P3P<;LX.<]/SQ7X7^ OB++^S#\3_ -J*;4+N'Q#\
M!/$/Q+T#QO\ "CQ0_C#2+72-"NM5\+VEEX]\"/KGB74+>&S\.^%M4L;6W\(V
MEA)J%I:Q6VIPPQPK/->)]L?"C]MOX6?$$Z?;QZDNC-J=Q'9:5J-QJ&CZQX5U
M>^945;'3_%OA_4=3TA;J0[$AM]7;1YIIW6TM8[FYE@23OEEN85*/UFEEN,IX
M:G'DDZT:?M?W3<95Y1A5G*U5155>Y90G&_*R<-AL9@Z:I9AF&"S#$SD\5*ME
MT:\<#0IXQ1Q-' 498FE1Q%3^SX5)8*I4Q,(8B=:E.52*YH)_H$"#T(/TYHKF
M-(UA;M3C&0!D C .0&4@D$'CIP!SSSBNF5MP!]<_H<'\..*\[;^OZ_X>YU"T
M444 %%%1^:FW=DXZ?=;/?MMSVZXP3@#J,NS?05TMVEM^+27WMI>K1)13/,4X
MP3R<#Y6ZY(YXX&1U.!T.<$9?2_K] 33V:?HPHHHH&%%%% !1110 4444 %%%
M% !1110!_)1_P7B_:@\4>+OC?HW[*>CZA<6'P\^%>BZ!XQ\::;;32PIXK^(O
MBRR76M$.LQ),8KW3?!WA6?2+KP_;R1Q"+6?$6KW]RES/9:'/IWYT_LG?#/\
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MSG\(6&C>/99[1-*^*>C6OP^T^Z\;>8>'/^"8GQ/\#_ SXX?!S0O&'PQU^_\
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M4ZN$EAZ,Z'MG*E7P[C"EAL*J%!SC@ >E!X!/I0.@SU[TJJ&8@@$ =/<GCCV
M/YU^BI7:7=]/Q_"Y_/9*HPH'<#GZ]_UIU%'/;J2 ,],DXY_.MTE%6Z+O_7F
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M1/>:-INH:6D]NWVBW>_2XBVO%N3ZO&?LP&>2@4G/&20I.?3UKY9_:5^']_\
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M';W&H:_/;WD5DD,-K?ZGIOVC\)[7X7^,M3O/B5X$L--L/ QTC18K"6WL(].
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MY] 1Q^-6*9&N!D\EN>F,9 X_#%/K( '+*/4C\E^8_P L?C5BHHUZL>_08P0
M2/KSU[5+0  ;F XXPQSZ CC\:CO)EAC+L2 JDYR1U^F3QM]#C(/%68UP,GDM
MSTQC(''X8K"UDL+=R#P/,S]\8!W#)*'<,>JC=C[N",TF[)OM&4K=^6+ER_\
M;UK?,#Y!^.WQYO/")U32/#MQ:6DFD#3X=>UZXLGUJYAUK6X_/\/^#O"6@12Q
MG7_&FLVJF]>*[VZ1H^EF*]O3+;MJ4^D?BG\0OVH_&?[/7Q4\5?$?7?A;X^\.
M:M\35\+0>./B-;ZOX.UKQ-XE@\&6$NC^$V\0^ 9- MM!2+0-'FDMK2WT?Q)/
M,+6:\BA%U-,1+Z5^V#\9-:^#_P 0?"7C%[2YN?#FB?';XJ6WB=)]S"WUW7;>
M-? ]_.LAV1JNC67BC3]/N)  D>H0V\4B_;(XY?B']IK]HR[_ &F+W3=(TG33
M>:A=;(H((U3SKB1%8!$5?X0"6+$ Y4*H8'</U+)\AP].EAG5PF&Q%"I2<Z^(
MK1C.<9N$91=W"RBXR?L[S24%9.QO0A*5.HU.I&-6,J53V=2I3]Q33Y9<LDIK
MFC&:C)2BI14DKQ37[?\ P^_X*,?!W3OA7!\2?BAXQT?0=$6VL[C2M6T>UU34
M;?QY!>^>EG!X2T2WAN];;Q&]Q:7=EJOAJYC%SH][;S2WEQ!;07PTWTG]E?\
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M2C).]TU=.*335U).-T?$O[87PH^&^J_"'4/#WBOP%X5\2>'YM2T/2M'T;5=
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MUAI^M>(UMF((PKZKHNFR..C"WV,-K$'Y#\"R16WD9PN!][C&04..2%SQTR,
M8)!.1]M?'SP9??$GX/:EIVBP/=Z[X:U.P\9:190JSSWK:3%?VFIVD"+EY;F;
M0]3U4VD*(6GNXK>!5+2"OC_PE\/=?DT*'5T#M!Y2RK(J,8RK(&W*W (V;?KG
M@E2*^JC.-.G-3DHR526^[N]+:W\TVW;1:V/Z#\),;EZX.J8=5:=/%4LWQT<9
M&\54<\3&A/!3GJIM3PM&<*<O>2C1G3;CRJ,OUY^$'BB[\2V_P[\<^"=2F9O
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M1^'M:M);'5='U?3;R.6VO;"_LYI8+B":-E9'.,, PZNB@#Y_N_V5_P!GB_\
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M?!^WF8EH8= \1^*M'^*?@'3KB8SW/ACQYXT\.>&-.L_!_P &FCL_:/C,AD\
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M1(@/')4L1[X / KN[J,[C_#GKC!)!!).>Q.W'M@ 9'3DM1B&5;H"#D#H.,C
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M@,,Z.*KXNM3]GB*-3#QE&>'JX5S5%3Q=5?4Z;4J=;VU1QPE7U']EWQGX5_9
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MJT:.<87*YM16+RVKB*;:5_K%+$R<8)W37-AH56E9\THVLV]/-;F19 <9(.X
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M?3HSI\+97FF,IX#ZI]<C[/%4<!1IN&-QV$^N+!RQT,3BXRPE6MC:M3RRXO\
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MFV*J %*^B]$\.ZOK$$3:9K\Y#A<12LK$ECP$D8X&TC)#*1C.3A:\X;X/F_\
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MF517@'H;:/IVU7WGU%1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0<>EAL?B\)1J4,-5]E&M5I59.,8^TYZ3O!1JM.4(MNTHKXHR:;5[G3A,ZS+
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M<07-O(!AXI4;O@;- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"%'A?Q6N]:T;3Y!/]FE!)@BEFC<3EB3'$9)5=%?:Y4NS1,TN"LA8,37T_P"
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M3Q,!#J.OV6AZWXBCMY [Q7.IV6G3WEM $5ED>VA:".%5C82S)&^PI+)Q\O\
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M<TIX[$UY8K.O9XO!9K.&'CE<WA\)AK5,JGA:TXUI_N\5"K-U)*G&2_%'PO\
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M$14_P:8" .<-K6G G/T/IQR3GM\4HA8MSC&,C (.0?<>F3TSZ"ON3XH0M/\
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M=;GY001P,[N2<\@\YP>.":YBWE8*"K;@!@DX!Z#&=Q^GZCKFII)\ G( P>I
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M1L>[6V@^VF @;X?M+)YIB<# A>3R1A1LP*M_'KQ_J/@GQM+X:TF'2-,EOO"
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MJ1G4G+"8&2Q4JE*C/#4:E:#A+L_"D44*QV\$:0Q6PA@MX4&U8888Q'''&JX
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MV:?FC]%Q56G@,+BL;.'/'"X:M7G%:.2IP<E&ZUCSRY(\WV7K9['U+X#\.?\
M",>&-)TJ0(+M83<ZB00V_4KM_/NCOSEA$6^RQD@DPPQ*2 @SV>T8&0,\$\=^
M,_GC!-"@8''..O?FG5]C",8PC"*M&,8QBM-$HI+HNF_>[O=MW_ ,17J8K$5\
M36ESU<35G7JR?6=2<INV[23E:*;;2C%7]U6^%/&.A-X7\5ZOI6P):&XDO--*
MJ2ATV^D>XM53VMCYEBV""9+.0G(:/%!)?E' X!'''4DC./YCN& &:]T^/.GV
M_P#9^A:T$"W,.HR:8SJ -]I=6T]R$D/4B*>T+(!]TRS<YD;/S[%)P/F(![@8
M.>ISUQDG*CT;\_D\91^KXFK!?"Y*I"VEH5(\Z7R;:Z=+(_;,BQO]JY+@\34N
MZL(2PU=M?%7PKC0E-/\ OP5*;7=N[;=PNI.&QD_*0"#G!*ENIR"00<'G(*]:
M^P_A9;_9? ?AM-H5IK:XNWP,$M>W]S=>W&V10.VP =,5\;3D8?CH",>NT.OZ
M@=3TSC-?:'PUG2X\#>%Y$.0NFQV['C_66DLMI+T_Z:PN/\>I[LF7^TUKZ_[/
M=?.:T/"X\<EE6"BE[DLP]YK2S6#KRBK+L[VTZ'?4445] ?E84444 %%%% !1
M110!GZC917]M-;2E@LB?*5;:RM@X*E?F&> 3D>U?(7Q#^%EJTMS.+>)W(?,F
MS<S DGYF.">3DY.<]LU]F8!Z@'\*PM;T>'4X)%*CS-A X'/L?7';G^+D$8KD
MQ>&CB*<E:\K??Y?U<]K),UJY7BZ<XU'&FZD7)7=D[I72373?[V?BYJGAB;1_
M%_B>Q"&,2317$("X\P/96MRFT8;):3"Y'&5./N_+]0>$CI<WAM&\U$G$(500
M26'EK_"/3C).WVR171_%KX9W:WRZ_IMONO+:(QW$"D!KF*-W>,Q%L!IX-[J$
M+ 2QL I#1A'^?GN/L9FCAOI-+<EEGMI83)"LFWYBJ%[>6#!7+1,VQ69MJ*,J
M?D)4'A*E2]-3>L>7K;5KE6K?H?N]'&TL\P=!+$N#O1G*<.>24H1491J1IJ51
MN6C3C&;6J:>AQOQ4M[&S6]NH+J3[0Z21@+LD$P;YEC,3*Z."PRJX#%NF237P
M3/I]CJ&HSVTXG@N;*>.ZN;2SO;BVMIQ>)(D<5];1RB.Y0-#*/+F4>1*VU"JE
ME/U7\3_%&G:-8W=Y-??;KR."7;,X58X RG/DP[W97*@KYSRR. /W;1DDU\F>
M#[K3[[4[AE2_.K7BV]SJDMRBF-!&9$CMHIH6:*.-&FE,49_>2!GDDQY>!T<,
M4L/7X@ITL2L$Z4Z5:,\-BH^T=>\4XQPU*5*I&K7A4ITJLGS0=*C"<VY1G*+^
M>\<<PS3*?";'8O):W$M#,L+C<KJ8?.\AG6PCRWV5>>'Q&(S?%T,?@IT<GQ&!
MS+&8%R=+'O$8W$8"-+#T:M*GBJ7K.G:?:6.GW6KZI=6FGZ;I]I<7^I7][-':
M6%A96D3W-U=W=Q,4AM[:V@1Y9I'=$1%)#'C/7? KXC_#[Q[XE72=.M]>C,UA
M<ZOI-_K&BG3=/\2:387=M:W=]H[23R7RP1275O*(M8L=*NY;>=9DM1)'/##X
M-^U=I^I2_ -[+3;B6RM-8\:^$]+\07*,0/[&DDU&[CMKAA@+;7>N6>B6[Y;9
M)))#;2+^_"/S7[+WCF\'C^:'QSIA\-6EEX(7PMX/UZYC9=)@QJEEJ-W;7MQ$
MC0Z?_:\%K;M'J=X8;5'T[[+-<127<*/^\4\'"KEV*Q4IU.>'-"C3ANO92IQ;
MG%7<FU)-12NN5-:VDOY8X&\*\NS;PNXGX_J1S',\\PN(QF&R+*,OKQE*%3+Y
MY7+$XG'X;V-;%9E4K+,,1*6'C*A'#82C[:BJV)E"G']0/BMH_A5=.B&CA"1
MOF[@H.\+\XX)R">!GL#D<X/P]J-FT$A>,%6C971L [61OD<;@< , 1Q@CC@5
MYE\<_CQXDT?Q)XVU6VUV]LO"7@[PN$\'VULJPV'BWQ6D@GO]0U19K<SW^CR
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MP,7B(8>E0]GZ[/\ $VUMM,.JRZG;'3E81B_M[A;N!W:<P".&2Q-P9F\_,8$
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MZ=1^TYVTTKW2C9OFWC:U]W;2QO6-I%:0)#$,(HX!.<=.,'D=\<X':KM)@#H
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ME^/^1^?XBO4Q-65:K)RG)MZN]DVWRKLDV]/GNPHHHJS$**** "BBB@ HHHH
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MN_36R5K''7S3&4\Q=?ZQ3KX>IS.M&I**<ZE22=1RC&<8QC91Y+).R5KGQ_\
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MC88!>1GI@ZSX4BN][*OS.&&550023U;&<'.T@C!X'(%>C(NT8P  ?E"] H
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M2_\ @I?\5/#S_M0^(_A5X^TWQYX)L?V,?^"@/[1WPBU+QKX#^%^@?\(SXO\
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M/0O'/BS3[/PO, ?T2^&?A5\+O!5IH&G^#/AYX!\(Z?X5FU6X\*Z?X7\(>'-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF,?-C=N^^W7).>OJ3].",$#"[!_>?MCYV/3'<DD]!G).<G/4Y?10 P(HQC(
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H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>pg80-149_009.jpg
<TEXT>
begin 644 pg80-149_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %0 IX# 2(  A$! Q$!_\0
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M#Z^O6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BN1\6^/?!O@2VAN_%WB72/#\5R7%JNHW:17%X8P#(+*
MS4O>7K1[E\Q;:"4IN7=C<N?"->_;!^"VE)=II>L:EXIU"S51-INC:+?V\T,\
MR&2VAO)=<CTF*T\^/$Z,^\O;$SP).%VEI-[)_<[??:WX@?4A90"2P 4$L20
MH R22>  .23T')I-RX#;EVL 0<C!!&00<X((Y!':OY._V_O^"AW[27QGU[XA
M_"O]E+PEXM\3M\)='NO$GQFUWP%X;OO&?AOX-:+9BYE:SU!HM/O-(U+QG'!8
M:G)KFMZ]:R6N@1Z=J&F^%](?6K'Q'-X<^=/^"8__  5Q^*OPS^*7AWX6_M >
M+)_&OPO\<ZK9Z19:_J$>GV=[X9UG491!9-<FPM[#3I[74KB2.VCU5K>*^AOW
MM+75[N[T:X2XT'149-75O2ZTN[:NZLO-M;KN)NR;6MNBU?R2NV]4[*S:O;6U
M_P"N;XU_M"_ []G?0[3Q3\<OBKX%^%N@W\LMKI5]XS\16.CR:S>VX66YL="T
M^:7^T-=O;:&2.>XM-(M+VY@AD266)8V5CP_P2_;&_9<_:.O[G2O@=\>/AK\1
M]8LX9;RY\.:%XEM5\4PVD)837T_A74OL/B(Z<A #:@NF_84)0-<?.F[\./AU
M^QS9?\%0_P!N[]JW]HC]I/6]4U_]GSX ?%[4_P!G7X3_  \TC6-2TNR\4)X"
MBM+VYT]]2L+RUUSP]X3AM=5T[QEK\.ASZ=JGBKQ9XWNT_M73+#0KFPU+Z:_;
M>_X)!?L[>(/@KKOC+]E/X=:;\ _VA/A'IUUX\^&'B7X:7NK>$YM?U3PS9OJ[
M^&=4DLM01EU36(;0V_ASQA;S67B+P[XB73KY=9.DKJVFZC\%'/.*,5''YKE^
M3Y96R;"5L9#"X3$XS%T<]S6AE]:O0Q6)PLH1>7X7VE3"8M8##XJ[K^R7MIT5
M6C(_L&OX0_1OX=Q7"/AUQQXL>(. \5N(\MX6Q?$?$/#_  MPKFOA+X:YOQIE
M62YWDW#_ !!]=S3 <9\0_P!EY?Q-PV^+,WX<=&EDU;,L1+"4<PAEF)IQ_<N-
MUV?>0?,^,$8QO;!ZGJ,'/?.>.E2Y!Z&OY-?V;_\ @N'\5?!_[(<GB7XVZ=%\
M0O&?@/XA:1\-=,\8C2HI/$OQ(L==\,S>(M 77+8:EH&BVOB/0;#1=>'BCQ'N
M675=/CT"X?2)O$%WJ=]J/V)^S]_P7^_9T\?ZSI7AGXKZ%K_PTOM3NH+"'6]0
MTN.'14N[EEAB6:;3]8\1Z?;1-<,JRWNJ:MH=K&A+('^5#]3D^98;/,JP6;X%
M5/JF/H^VHQJ0]G5I\LYT:M*K!74:E*M2JTI<CE!N#<9.,HM_SYXH^'/$7A%X
MB<7^&?%?U*6?\&YO4RG'ULMKO$Y?B[T,)C<'CL!6G3HU9X3'9=F&7XVDJ]"A
MB**Q$\-B:4,3AJ\9?T#45E:)K6E^(M*L-<T2^M]3TG5+6.\L;ZU8M#<02YVL
MNX*Z,I!26*14F@F22&:..5'1=6N\^""BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *:5!())XZ8/?U^O_P!?U-.HH ;L&0<MP<CDXS].WI@8
M&.,8)SF:QJ=AH.DZGK>IW"VFEZ/I][JNI7,A/EVNGZ=:S7EY<,!R5AMX7D8#
M.53&.M:M?*O[;/B6X\+_ +,?Q0N;1VCGUC3])\)EE8K_ *'XMU_2O#VJJS*R
M-MDT?4=0CV@_.6$9!#$5T83#O%8K#8:+L\1B*%!.ZBE[6K3@VV]%:,I:O1;]
M!I)M)RC!-I.<K\L$VDYRY5*7+!-RERQE+EC*R;LG:^"'[6GPB^/NJS>'_!UQ
MX@TWQ/;Z;<:T?#OB?1&TZ^ET:SN+*TNK^WO-/N=5T29(I]1L5>V751?JET&:
MT"+.R>I_"*]O=2^'^BWNJ7MW?7LMWXCCENKRYEN;AQ;^)]9MX@\\KO*WDP1Q
M0(&<A(HHXU 1 !^4?[ 6BZ]I'AK]HGXM^%-"7Q!XS\.>"&\-^ ]%ECE:#6?$
M/]G:GXJET241S6AD.I:EIW@^V,,5[:3'S_+,UJ9;><GQ\^-GQ0\#?"CP;X,T
M#Q#XS\+M/\2?%>H>'?&B^#_&GP1\6^+?!6E:#X>U6]GU;P1XK%EXM\.64?Q!
M\=^(-!M;?4K:SB\067@RSU:&"YT^ZCO;_P!G%Y/2EGO]D9=.4(OV,5+%RE+V
M4YT%6J*I.,.9QI*45)<KFFW%]#>M0Y,57P^'J1QT:56M"G6PD:M2GB*=)SE[
M:BI4XU94W2IRJN4J4&H0G.48PC<_:4*ISAF..,;B,$9'L3GGJ3QC& %Q)7@'
M[,7C#Q+XT^ ?PT\6^.=174/$FL:%-<:GJKQ06QOH[?5M0LM/O;I8(;>VCN[C
M38+*2\*11*]V\K! 6Q7N_P!KM<H/M,&9&9(QYJ9D=6V,D8W9D97RA5-Q#@H1
MN!%>'6I2H5JU";BYT*U6C)P;<7*E4E3;C=)V;@VKI-)I/4YDTTFMFKKT98HI
MGF)Q\PYP1UY!QR..1R.?]I?[RYJ7FIZ=IT*W.HWUI86S7%E:+<7UQ%:0-=ZC
M>V^G:=:B:X:.,W-_J%W:6%E &\VZO+JWM8$DGGB1LAEZBH$N;>0XCGBD/S9$
M;K(1MV[L["<8W+G/=T'5UR_S8]S+O4NBJ[H.71':14=D&75':*558@*QC< G
M8V "2BFEU !)(#=.&[],\<=1P<<\=:3S4&?FZ9SP>,8//''!!&>H(QF@!]%,
M\Q/[W3@\'@^AXX['G'!!Z$&EWKZ_F"/Y@>H_,>HR .HJ/S8\D!@2."!DL#C(
M!7&02.0"!D<CCFE\U/[W\17@$_," 1P.Q(SZ=3P#@ ?13/,3^]UYZ'IZ].W?
MT )/ -'F(>A_0X[=\8[CO_(T /HIF],D9Z=>#ZX]/7C/K1YB$9W<=<X.T Y(
M);& .#R3CWH ?15*/4=/EO;C3([VUDU*TMK.\NM/2>-KZUL]0DO8=/N[FT#&
M>WMK^;3-1BLKB:-(KJ2PO4@>1K6<1W: "BBB@ HH) ZT@8$D \CJ.AX]CV]^
MGO0W;5Z+N M%%&>_\N:5TNH!11GO_/C^=%%T^J *\3_: ^-7AWX!_##Q-\1O
M$EU;PV^C:=?W5K'<B8P-+8:?=ZI=7-TMLKW+:?I.FV-YJVI>0OGO9V4D%IYE
M]<6L,GM3$@9'7('')Y('2OYO?^"B_P#P41^ T/QPU?X":O9>-OBI%H.D:OX3
M\1^$?AIX<B\51Z=8:EI;3>.+S7#+JVF1W,TFDF07-EH9U*[T_P /Z7#JE^NE
MK.OG:0CS22>RU?DOT$W9-]D?B-^U=_P5+^-GQYU[Q#<^!=7UCX>>%=1N9[6Z
M\6QW'E_$+7;<F3R(9-;MF-O\/K". 2-I^@>$9;6_TV 3+-X@NHWFB3E/^";.
MJ75U\5?C1X>T3Q(VA?$3XE_ 7QQI_@3Q!=7<C+<^.;?4-+U:SU2[E=I7U'5]
M.1;KQ';W<PFN8['3=>NDD#O,LO[1_L _\% ?@M\'OA)I?[,OQR^*GA;P/X1\
M%65]-^SK\6M5^U:/\,OCO\"]1U*_N]+N+C5([)=#TOXD>#KF:Y\,>/\ 1/$
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MPV;;6?'N@>)Y_%OP5TS7=9\5WW]HWTC:CJFG:<D_Z7?!=K)_A%\,$T_5]/\
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MBF31(Y[8:AX3\+6^IPQ26&E--\1?##X[?\%"?V]?C%XAT7]F2^M/!>BZ:/\
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M6)T-QI.IZ5/%;3WB131V&M6$4VCZU;:AHMY=V,W\;_[-_CC]HWX=_"/]F?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ?Z3XH?1Z\2_"/A+PRXCXDJ\,XW(_%_!UL?D:X:XBRS/OJ>9Y54H*KD>>8S
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MB@ HHHH ***BBGAF,@BEBD,,ABE$<B2&*5<%HI I/ER*""R-AAD>M $M%%%
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M !C>Z#;VD0NGN]3U?19[TZ2Z6X62VBGNH;F1%C%G"RQJM?0/[2GPLN_!6F_
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M%I?ACPMH-M=3JL$\,&D+?W3Q6%I%9^'_  ]I6E:-IJ:=?7FM=-^S!^QCXD^
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MJ.MZA:>+K2.\;2[>RLDN]/N)H4\J\BAM6Y0<6K:N$5MNT[O[K+4#];J***S
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MC<PW%J+DS03PQ_9LW_!.+_@H3^RG\%O$?[3-E\0/#7@R_P#ACI<GC+Q-\)=
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M"BBBL2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS5HH',L,6IV-K?QPR%2IDB2[BF6-RI*ET"L5."<5IT4 ?SA?\%"/B-9_#O\
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MGP:'XKGU#79TM/#]M=:=](DU>[O]^F_<_%(IJ]W?[_U/HC_@L5\/?V=?V=_
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M;3=5T+47U*PTV+1+G2=3DO\ 5KC39;2VAFMAJ>G_ *X> _\ @H_^VCJ#ZO\
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M([2M.L-'TZQTG2[6&QTW2K.TTW3[&WC2*WLK*PMX[6TM+>) $BAM[>*.**-
M$5%54&T"OY)_^"5GA3XV^#/VS_BI^Q#\6]:U+6K?X$ZW'XF:TOKK4+[2M)M/
M _B/2V?4?#;:INO;/P;\0]%UCPGKNB:;.L5NMGJ^GW4-E97.H7WVC^NC&/YU
MRY%GD>(LKH9C]4K8&JJV,P>*P6(<9U<)C<!BI83%X=U(V52-.M!J-3EBY).]
M]UW>-OA3B?!?Q#S#@:IQ%E7%^!CE'#/$_#_%>2TJ^'R[B/A?C+(<)Q)P[G%#
M"XJK6Q.$>,RS%PJ5\-5KUX4JZFL/6GAY1AABBBBO7/R<**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#)US0]'\2:9=:-K^DZ9KFD7T?E7NE:
MQ86NIZ=>1;E<1W-E>1RVTRAU5P)(VVLH9<,H-<[X"^&W@?X8:5>:'X!\,Z5X
M5T>^U6ZUNYT_287AMYM5O4ABN;ME>24AC!;6EK#$C+!:VMK;VMK%#;Q1Q)W%
M%/GJ\CIJI-4G)2=+GJ>S<DMW3YO9WVUY.9-)WNE8/RQ_;H_9X^/'Q<\<^'/%
M'@+1;#Q9X8T/PK#HEEHMIKNGZ=K.FZM=ZG?7.LW\]GKMSI]A-;WR-I,1N;'4
M)KCRM/CCN+"*.V-U+^A'PB\"V_PR^&7@?P#;NLO_  BOAS2])N;A&9TN]1BM
MDDU:\1GPQ2\U22\ND& $68(JJJ@#T7 ]!^5+@#H,5W5\RQ.(P.#R^HJ4:&!<
MW2]G!PE)S5E[1N34N7FFXM1B^:;<G)E^UJ^R5#VM1T%4=94>>7LE5E!0E54/
MA]HX)0<K-\JLFDVF445X#^U3XJ\>>!?V</C9XT^&.HVFD>/?"7PY\3^(_#.J
M7WAR7Q=:Z??Z+ITNHM=R^'(;FT;5?)MK>X=('E:W20)/=6UY;12V<_ 0>_5E
M:MHNCZW;+9ZUI.EZO:><LGV75;"UU"W\P9Q((+N*:(2#L^W<HS@U^<FN?MB?
M%"Y\;7/PL\)^&_!\'C:T\7^+_"^N2ZSX5\=ZK9^$-,N?VMOV=?@M\)/%NJZ7
M::WH*:OIGC+X)_&?6?C#;VECXEL(=>CT6PN;'6M%T/\ M*5?-];_ &WOVA_#
MOPVM?$>L^#/ACINM:SX=^&/CRQUA_"GQ1N_"GA_2_'?P[_:)UR+X=:YID&MI
MK.I>-/$WQ*_9[TKX;^%/$MIJNE6L.K_'KP)IL?@?Q1XH\/Z?X?\ B< ?HI\
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M%6:^-UIC6&B?T2:9_P $.O\ @G/9>"YO"E]\)?%&OZG-9BUN/'>K?%3XA?\
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MQ,557N[ZZD+W5_>RA%$EW>33SNJHA<HB*.IKDE)RMY$QCRWUN%%%%24%%%%
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M\"__ )RM'_"N?&7_ $7OXL?^"CX%_P#SE:]:HH \E_X5SXR_Z+W\6/\ P4?
MO_YRM'_"N?&7_1>_BQ_X*/@7_P#.5KUJB@#R7_A7/C+_ *+W\6/_  4? O\
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M\&?&2\\>S:/837MTND>%H+O38=8TS6KC6=#0'VM_PKGQE_T7OXL?^"CX%_\
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M^)OC3\1_@+IVG>.X?&_PM\)^ O&?B;4-5^'GC/1_ 5UH_P 1Y/$,7AZ+PO\
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M/"JW7H1Q&%Q^#JU,+B'+$8+$/%8.O.=7"U)S****],^ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HI"R@$EE 7[Q) "_4G@?C0"#R#D'H>QXSQZ\>E "T444 %%%%
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M)8G(,/ER\/H4LUR?/N,\HSO,EF_%694\/PIP[0RZGA:=3P_ITJ&(P^#IY?'
MX&&7Y%%0P4J53%4:RK4ZM2%#Y[!5^+/";BG/LJQ&2_4<WHT\^X)XVX1XPRZI
M4HRRG,J,,JXDX9SG)\3*A4A"I'"X7E5#$X;%X.MA\!FN49E1Q>&RW'5?D/Q)
M8?&C]H7XT^&M.^'?[/'[+7[/GQX_9W\,V=GI_P 3/C'\3_ OQR^*/[/7A?Q[
MHNK:#I^L?#W]F[X-ZK>:='K$_AV^\06WP_\ $OQ,\;^#=(L]'U;Q'I>DZ7J&
MC^)/%6FW_P @_'S]L']@W_@AK#JOP/M-!^*'[7W[>7[4%G:>/_$7@YK.UU#X
ME?'C7OB)XD\3Z+H6K_%?XAW^CKX'^'O@+Q)XV'BK2],\+Z/IOB7Q!#'/JNM0
M^!?%VH7FJZ[J?ZO:1^QU^Q]^S3^TO^T%_P %#-(\+V7A#]H#]HKP]X.\ _$_
MQWKWQ$U/3M"\3?97\)>&?"_AO1-%\3^(K;P)X=UWQQK/AGX?:&TEC:V<VMZ[
MIVCA&2^U'5FU3\1_VX_V3K[_ (*M^+OV8_V@/#O@CQ'^S!^W!\+O :0_"GQ7
MX7\?>%OB9X4\"_%KPSXNA^(GA/PY\:=3LO 'B'1_''PT^'7C"S36+/5?#UCH
M5W%H?C[Q3K2V/B=;FW\*CV^(>)>$>#\=DV(XES6MB,XSC,J&4Y)0>'EF.9.O
MF^+I9?4Q6%R7*Z/M:&"]O5H4<USM8*LJ%+$TJ>+QGL*RI'I9KXI9O+ARIP5E
M&&RK@[A+,HY70S'(N&*680J9_#)Z]?%9+A>(,XS7-,XXAS;*LEQF*KXS*<BJ
M9C@N&<IQ=3Z]A\AK9A&CC\+^)?[/WA/]MSX/W?[9GC*+X@? KX/:O^W'\.=:
M^''Q"^%?@/X,>&O$WPI^&'A!+_5_AIX1^&?PMU&?Q7X?T7P?I/PO77C\!_"G
M@30U\06MG=1Z'X+F/B;QG9:2X_KE_P""9>E>,?V6O^")'[*6H^$O!/BKXZ>/
M/!/[#7A[XQ^&/A7IFJK9^)_'WBOQ9\/KKXRZ+\(O#NJ:O9E-'\S4_$=M\/O#
M"7&G7@T.P@TZTAL=1^Q16]S^6?[/W_!#G]IWX;>!-2^$5IH'[&GPJ\-^'FUC
MQDLFC:E\;?C1\)/BU\:/'G@?P]XIF\76WPV^)=[)\0_AUHOPB^-7@#X1:5I4
M>I?%77[_ ,6>'_AAH7Q$\"67P7\;@FY_9+]F7]G3PE^RE\9/@GX"T?X$?%;Q
M)X\?]B+X<? WQQ^UEI7BO7K[X%67AC]F632[+P3\+YO"/CSXQ^+O$VA:KJ6H
M^._%&H^"K^ZT#Q'XRO="TV>S\5^/_%#Z?J.LU^A:65M];_?H? MW;N[ZZ.T4
MK=$E%MK_ +>;?XGTK^Q1\</BW^TC^R[\)?C9\=?V=_%/[*/Q7\=Z3K5YXP^
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MUOQA\5?"/PPUCXA:A#KOB*?2=+UK0OB#K?@+P!J/BG[3_P (EINC_%37=/\
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MG*<#C,JXLPO]DY5QME&)SS+X9Y@<IXG_ ()-0_#3X%_MU_\ !1_]GOX?>-=
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MFT'Q/K.A++9Q7]U>WD,=Q;Z;%<F&>[N'225MLSQE*^//VB_VS_B=\$_VA(O
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MA_%/P-JK>/-:\,_9SXDTCP8MCKLY\3ZGX?%W:G6[#11>W6E"ZMC?10">+?\
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M2]Z4 A2,GY1@DG)&.">G)')X')I#&C#!4$<<<XX(8' XR" 0>V.,4J_=7C'
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MB"/#]EJ=_P"%UM;C1(M?\*Z_JMI!X7U'3M<N],75X=5TR:QK9^$7_!+7P/\
MLQ#XN_'[X<ZMX._9;^(W[1EK\,M#^*7@G2M>@^&OP?OS\/-7^(VHZ5KQTOPC
M#'X?T+X@^*$\7Z4^OVWA_3ET6X;PBFJM8IXE\1^.-6UC]7?$'QH\&_L_>$/A
MGI'Q-\5:IXEUK5-"L+*7Q#IEC)JLVL+H]C80:OXLO-EP9/[.EFN;>?ST>_U*
M_P#/\R&WO)OM$@_%> O'Q\'9MFF99YPWB>%.&?\ 4[AC,,SQ_&&;9+EB_P",
MFS!.GD6(P>7X['YMDV:Y5F.$PD?K&+P?U/,)5IX>GSPYY87ZGQ X-ROQ#R*>
M29G5QF40I5<'F>%S"FL*YX;%7G!0JX6=1TZT'3G.%2%65.#;IRI5%*G*,_S0
M_8S^"OB_XA_M%^!_CU=^&?$WA;X;_!?PM\0[/0_$7BCP_K'A6[^(7C/XD:=I
MOAQM.\+:1KMEIVL:CX/\.Z#:ZKJ6M>)Y;&WT74O$%[X=LO#=QK8LM<FTG]QZ
M^!?@;\3/'_B#]HSXJ^%?%/Q&\/>)/#</_"6-X=T&RN;"X6/^Q_$-K::9_8BV
M-E%)8II&B3RV6MV]_<M->W6ZZ"ZI);W&I1?>SL O?.TD8/(&"=QYZ#N3G\:]
MK!>+M/QGIU^*Z.68G*,/@<QS7A;#99B:F#KUJ$>'\SQV'J577P6-Q\*\,;7K
MUL=3JU:M*K[*M3@\-2ITJ4L1U>'O"66<$<,T<BRNOBL31H8O&U\1B\:Z7M\3
MBZM5>WK2C1;HT:=H4X4:%/W:=&$;RG-RD_SL_;R_;[\ ?LG:G\'O@%IOCCP+
MX;_:]_;)N/%WPW_8MT/XL^&OB;J_P<\0_&NTAT31_",'Q=UOX8:/JFO>&? =
M[X]\:> _#.I75@T.KW$OB2!K(VUE::MK&D_4WP0^.7@?XQ6'C#1="\??#[QG
M\1O@OXJB^$WQ_P!*^'&K7FK:+\/_ (V:7X:T#7/%_@KS-3MK35$33FUVVELO
M[0MH[L64\,-\L.IVVH6EK\N?$S]C#7/C)^WI^S%^VY9?M3_$S2/A_P#L\> O
M'/@VZ_9<T<VFL?!OXC^)?%-IXHL+7Q]JS2:R^GZ9XDTG_A);.:^N/^$;UC6;
MRY\$> 7TG7?"W]BZB-9\K_X*&_ML> ?V,]=T'Q;>_%_Q9\*]%^"_A+Q)^V)^
MTK\./ _[+]Y\5K[]HWX":;>Z/\ E\':7\3M0D\-^"/AUXW3XM?$/X5WXUB7Q
MC:^)K;1-"M[SQ =-^'5MK-\W=U::LUHUU6B>J:BT]=G%/;34^X4HRC&46FG&
M]U9K5NUFM'HMT?K117R!^RA\2_B+\?-%U+]I >.O"GB+]F#]H#P5\$OBK^R7
MX3@^&7B7P!\5? O@?Q5\.+#6_%=O\8=4UGQ9K5CXJU;Q!X@U&UU305T30_#U
MKH&E)/9O<:_%=VMU;VOV7M6\ >']1^-/P"T;]J7Q)^TO\4O@[\3=:\0_%V#X
M@^*_"WB3XD_"5OCIJ&J_%7X??#O7[;PMH7AV#0_#&D>$M6BT_P"'=C>:<98_
M#&EQVD4X@L8K&Q /K6BBB@ K\^?^"@7_  3L^%W_  4)\*?#SP[\0?&/C/P#
MJ'PTU_6M9\/^)?!$>@3:DUIXDTN'3M=T6Z@\1:3JUF]E?R6&BZB)(HHKB*\T
M:TQ(\#SPR?H-10!^3_[6?_!(3]GS]K32OV<-!\1>+/B!X%T;]FWP+!\+O#UK
MX/D\-O-XG^'=G;>%[.P\/^(;O6]!U&6.;3[7PTT-EJ&F"T,0UK5W:WD>6W-M
M])?'']BKP/\ '/\ : _92_:!U?Q7XG\-:S^R9J_BO5?!_A;P[!H2>&O$:^*;
M;0[=[+74O=+N;ZUMM.&@V8LUT:ZL3Y3S1-@&)HOLZBG=]]K_ ([_ '@?''C7
M]C/P?XW_ &T/@U^VO?>,?%=EXU^"_P -O$WPUT;P99QZ(?".M:=XFMO&-K/J
M6KRSZ;)KBWUI'XUU%H8[+4K:V>6TL&:-4%W'=.T[]C7P=IO[;VO?MRQ>,/%<
MGCC7_@3#\![CP/(FC?\ "&P:+#X@T;7QKT,JZ<NO'5VET2WMC%)J;V0BFG80
M[_+V?8M%*[6SM?1];QZI=M; ?'?P&_8U\&_ /]H7]JK]HG0?&'BS7O$/[5VN
M>"M<\4>'M:CT1-!\*3>";7Q!;VD'AM]/TVUU.6.^;Q%=273:M>WK(+>V2'81
M*\K?VU?V,O!O[;?@+X>> /&WC'Q;X*T_X=_&+PC\9-/O_!\>B27VHZMX2TWQ
M%I4&C7W]NZ9JD":9>VOB2\-Q);117<<T-NT<NP21O]C44)V=UN@/A']MS]A#
MPO\ ML#X,7FK_%CXG_![Q+\"?&UYX^\"^+/A9<Z!::Y9^(+F#3A:WZ76MZ-J
MLEE?:/?:3IVIZ1?Z:]G<VEY;EF:5741^"^+O^"58^)O[/?C_ /9[^,/[9?[4
M_P 8M)\;^//A]X[L_%GQ*\0>%?%'B3P9/X!EO)5T?PN;_P .R6-KI?B)[POK
M23V\\K2VUI+:O 8Y1-^M%%.[M;M_7]:@?GA\1O\ @FS\$?B7^VU\*_VX]9U7
MQ-;>._A?H^BV?_"&6:Z)_P (;XOU[PK:^(K7PAXQ\2--I4FNMKWAQ-<L7M7L
M=4M;:5_"?A97A6*QO(]0XCQ!_P $L/A=X@\&_MW>#9_BC\1[>T_;T^(.A?$/
MQQ>PV_A,W7@/4M \52^+[6P\&K)H317%C-J,SVUPVO+J-W]A")!<072F[?\
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M[/\ B#^T[\'O&.J>,]1\#:Y>_ ^'X3>)?@]\3K7P'\,] T_XPSZ6_P 0M/\
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MGDGD\TZBBO=+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ;Q/\0/%7@WQ7\4;?XM?$2QUOXG?&WQ;HNGVFN:MJWA_P?\ $#Q#)I%O\/\
MQ//X9T74M*AN;/X62>/;W54M_"NM^*?#%XEU!HWGR_L>?\%)_AQX(UI?V@?A
MOK'Q]^!_CRWAM_B)\*+WXW>$O&?Q/TZYE:*^LM<^'<.K^)K_ %G3_BMX<NX5
MU31](\(7'B!=<N[&?2M4T*]C*7NG?IG#G$?#7%&08[!XC/<AXE621I\,\:U)
M8?#X/*IYS/*\LJ9MA<;@<PJ+"X;#X]XQR^INOB<+2IXF67T\55J86I&7QU6A
M6PF(QF6YA2JT,?EN(Q&6YI@L9AZF$Q&&QV$JSP^,PV+P>)4*N%Q%&O1K4J^&
MJQ]KAZD)T*UZM*HY?KU\._A!\2_$6@^(;80Z[XEN=0\*Z+=1:K\0-%\+VOA/
M7]!\2Z99V^J:7X3LK_PK::-X>L/$FDWJZEIWAKP[/9^'IO#MYXTE\91^*/''
MBW6?%FK_ )W?MV_\$P/#7[.GPE\>?MH?!SXCZEX$^(OPVUKP3XXOO GA[2]&
MT/X>Z"=8UWPGX/U&#X;3Z;:6.J:#<6?BC7F\16MI-*_AN_L+K4?"^B^'= T]
M=(LQZO\ LR_\%1?#/[./@CPO\'?VGKGQAXO\ Z'IUUH'P2_:)\,>%;J^U/7_
M  OX0*Z5)\-/C+X!GGM?$G@_XQ?"X16OACQ1IR17VI)%'I<^N:<MM/8^+O%'
MDO[6G[;VD?MZ:!?^%O"^D>+/AQ^PE\)-<TKQQ^T!\3_%-G;:;XL^+NJZ!<P7
M/A3X4>#="M+V[6U?6=:N--?3]*.HW&LRZM=:)XDUU/#JZ1HNC^(/!\/_  KP
MG 68YMFE/B'.\XQF;PEA*]"M#*\JR.AA:&95\5ET:'#F19=EN40S'+<#4PV2
M+-9T)XVMEN P="56-*C2HTN+#87V$YU/:5*DJJM)-1A34>:\;4Z:4+Q@HTXM
M_9@GU:/NWP/KUWXL\#^"O%=_:16=_P"*O!WA;Q)?V$2;(;.]U_0=/U6]LXXG
M:0I%;W%W);K$SOM1 A+8);RS6H]9^&_C'2?$GA&ZN-#N;&]M=;\.:C:R2F2R
MU2QF@G: Y;#PI.JE[&0M;3Z?.+69)HWF0_DMXS_X*4_M-:1KV@^(M/\ A5X5
M^'WPV\0V2:QX"\+^*_!7B8P^*_!D5R]E#J.G^+Y[W0AKEKLB^P)K'@V&T\/V
M5W$UO'%<F']Y^YG[)>E:=^W?X)\%:[HD%UX;T#Q)H]QK_B&=VAO;SP1>Z)J=
MYH&L65O,T=O#J5VFO6U[I.E,\%N-3L';5GLH+>.YCM?VK*,Q65XIRJISP6(@
MZ.,IN"J1E3EHI>R;BI3AS22:?-R3G3^%MGI8:=*C7IO$TJF)PG,GB,/#$U,+
M[>$>9J#JP4XQ<9\E6,IT:W+*%H*G[24G^V7P ^,VD?';X9:'XZTY8+347#:7
MXJT:%VD.@^*M/2(:GIHW,TJVKB6#4]*DE99;C1]0T^>3;)*\:?E7^U%^QO\
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M4&IRW,6A:<\UKIJ6T<\_F?&7QI\6?MD?#SQEJ'QH\7S^)Y_@3\)OV@O#.G^
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M*M_AK+X7^"?C7P=XVM-5\(>$- D\::G^T#XWN=2\&>/F\5?'#6-:\//X1MO
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M2TY/#)DMO#EI=!BMW_;,,$?A@FTGT.WQIW]F75YYMVQ>Z47ES -T/EW[.O\
MP3R_9*_8GTS]JK5_@?\ #37[=/VI?'/BGXQ?'#2+GQ)XJ\=7?B[7-4@UR\O-
M"\-Z1K6JW:Z?I[S:_P"(SH^BZ4(+N:]UZ2WEU">*'2X]/\6U+]M;XL?LP_LG
M_$3Q%^TOX$\8>._C+\$]=\$_!?2OB&?!OACX7^ /VR/BAXJ\(^'-8L?B%\&?
M#_AOQIX_O-#^&UQJ>MW]GK%Q>Q6NH1GPMXADTGPZFI(?#.F_'6F_MH?\%';
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M'\LP6;8V&*KTJL,TRG%</8/._P#6'AK#*<<[S3AS$5*F.PF3X[$Y/@<3FM3
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MWJ$^KPZC9Z-;-XGOM:MM1OOBA>6T%QX@N-0UG3-3O-<MFFN)Y_MK]HS]D?\
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MX#?#K4OA7XF\8_"GQ=\?;GPE:?$/PWXI\(?%+P#K6I>#=8\6?";Q7+X@\?\
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M_:4\(?"SXI^'=1,MW>Z+\&K6_P#"GQ0\$M<R^?\ 9-'LO$6H-X'\?6NG(WV
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M\"ZY\0TM]&T[_A.O&OVKX:^%W[6?BO5_^$.M_P!E;XA^#/'\;QVE_JOCB_\
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M*** "BBB@ I"H88(R/3_ #_*EHH 0* <@<D 9.2<#H,G)P,DXZ9)/4FO@O\
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M_@]7W>BNWU;U>[;9]Y^H4U@2.#C].Q]*=10TFFGLU9^G];]]M@_K^KG&^+?
M'@GQ[9VNG^./!?A+QI8V5RUW:67B[PYH_B.TM+IDV-<VMMK%G>P07#H3&TT2
M)*4)4N0<5\]?MFP1:3^RM\4X+*"VL;2VT3P]9006T,<%K9Z>GBOP];M!##$J
M0VMI!:DH@14BMXU&W8JBOK>H9X([A#%-''+$ZLDD<J+)'(C8#(Z.&5T8<,K
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M7J.G//Z'\C0 M%)D>H_,49'J/S_SZ'\J %HI,CU'(R.1R/7Z4;E]1^8]_P#
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M7&L_$G6=9\?Z%<:1;ZYX%TKQ/80?KL1D$'N,?G3=HQC+<#'WCT_SWZCL0.*
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M\-_!U_'^O7OB:Z\':FO_  DEO\/?%&A:5/9:K8S7H_2WRQQ\S9'<$ XX]O4
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M]$U'Q?:>&_AEX*\8:=\';#P_)\0KB/2/B#J_C'4_%G@635M/\1^-9;.\TO\
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MQ+#)X(M%T^]\8ZA;?%[XL:9X>4M)H&GW?PICU+PSXUM+WE;C]IG]KW6/$O@
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M"&L7/A#7-)\$>+K?P[#XN\5F>R&MZ9X4N[FU.MWT5K87?V8:K;O/]!%!C&6
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MC&X^'-MJOQSU#Q1<>!H/"U]X?U#3-6,%AX6LO[9\0XEE^U+^V/I,'PE?Q?\
M#71[Q_%<_P '=?\ %_\ PBO[/'QJ.JV>C?$OPIX4U/6_A]H.D:CXVGT*U\6>
M =:O/$]IX@\0^+O'?A^YCL5LFM?A_>ZAX=\1:?=_K$$ S@L"<9.>>!@4AC!_
MB89ZX/!Z\GCG.>1T.!D' H _*WQ%\0OVE?!/PR_8;^)L.G?&/QE?>#_A+J'C
M;]HKX?Z7X3UO4?$WQ,FF\*_#?PC?:#XETF'0SJ-MXTT6_P#&^M_$70='>VL-
M7O\ 5O!.H6$=C.G]H01>9>!OC_\ MW_"_3-!\!:U\.[[XT>)-*/QQO=2UCQ5
MX&^)5AJ_Q<\2V'[1/[5FC6N@>$O%ND:/_P (MX'\/>$_!/P]^$VK>#3XET>Y
MTWQ1X*^(7A:"VUC3[.\TC7[G]H=O(.3QCN.<=,G&?;&<<GC).4\L8(W-@G/7
MN!CT^G'3@<<4 ?%'[*'Q5\7^+=;^,NE_$SQ1?Z[K&L_$^]UCX7S7?PE^(_P;
MT35/AEX1^!7[,%IXLN_"'@SXD3ZMKFC^']%^*'CO6=-U(ZAX@U$ZCXPO?%$^
MGB%;34M*T3X"U'XD?'Z^\%^,M>\"^.OVMKGP_-I'CZ7X;VOB?X:?$*'XO:C\
M>_#W@+4D^$6N>-=)NOA9X;M_#'@KXZ^.6U+6X_@Q8::?A3X/B\)^!=+\7W/@
MN[^(VM_";1_W1,$9=92H,JHT:RE5,BQLR.T8<J6",\<;L@(5FC1F!*BGE,D'
M<V0" <@8!Z]!SVZYZ ]10!^6/[0FM_MA>%O#O[95G\,V^*GC75M3T+P[??#_
M %GPGH/@RUG^#>A7GPT^)NN:O_PJ'2-?;PW:?$36K+6_#WA/PM,\.H>+?&T/
MBKQE_P )G%H.K6>B:/\ #F3Z+^(_Q*^(]U\"OBMK'@&XUF+X@Z!K7@+PSJVE
MZ#X!DUSXD?!C2O$^E_"C4_B-<-X<@U#QQHOQ2^*'PS\!>-_$GQ,T2U\*67B#
MP[XCU&'0?!]AX;\77%G>1>(?L/8, 9( Z 8 'IP!CCC'&!C/7),:V\49=HT6
M-I7,DC(JHTDA"AI'95!9V6.-&<DLR1HI)"B@#\J]4^-_Q0^&^H^%?#O[/^C_
M !\^)WAOQK\3-'M[76/V@?AC\3_%]E/HEUX@^"W@#6K7P3XQDFT7X@>&O"K:
MGXR\5^.=4\6?%?2-6TG0[3PQXVUWPI;)\*M-\.BY\\T+]JW]L_2-(\,Z;IOP
M\U;XB>(=<\&>,_%%W%XR_9U^+/A*XLO'/C_P/\4/BO\ #/PY<ZQI>OW.G:-X
M+\ >,+WX4_L_ZW;:GI%MK4EWI'C\)J=]=Z*VK6G[-^6.>6YZY.>Q Z]0 >AR
M.Y!)))L'/S/SU^;GICKUSC SG/'KS0!^7%I\<_VP="\1>-MOP^M_&=CHGQ!T
MVS.FQ?![XIZ+>?$NSC\<>./AEK-A\.+K6?B+J7AKX9:59^#_ (%^)?B79:GJ
M%UXJT+5]2^(WPV>1((?'2:WJWE:?M"_MA^.H/A[JNN>"_&NEV5CJ<FN:\?@W
M\)_BSX>'BK1?#VM? 7XA>(_"RZ#XYL)=6?4+KPAX3_:>^&7ABYN-5TD^)=2O
MO!P2ST?Q/J-MIEW^S90'/+8((QD8P>O!'Z=.,8QD$V?[3_\ ?6?3'7/0C/KG
M.>"10!^;'A?]I;]IR[_9K^*/Q+UCX8Z9??$'PS\5? /@KP>ME\+?BCX<T.[\
M$^+H_@X/%_Q+NO E_J>N>,?$7AKX92>/O'=Y-=^&]7&G^([#X?W"MJ>D6$6J
M^)X&_#GXX?M*OX2_:&^+/Q%\/:B+[P1\'_ 3>!?A+I'P;^(&G"^\83Z-XN\7
M+XXT_3==U'3_ !+K5MXIL?$?@[3_ !OX(ANDU7P!JGA#7?"L^J)J&AS:QK?Z
M4[!G.6S]1D$ @$'&1C)XSCDY!R:-@XY;@YY.3UR1DC(!]B.@QT% 'YO_  ,_
M:(^*.I:MXO\ 'W[1EIK_ ("\%?#_ .'WBR*&\LOA3\3O"G@[Q/)I/Q"^--[K
M'CBX\/ZOI^OZQI<NE?"_X*:#K6FRWFJ7%O?V7Q!TM-$$M]XTT32;J3]I;Q)X
MUTO]I+P=97%[\2[3X9CX9:%?%/"VL_M&>&_#[^*#\1-3BUR4WGP'^'OC6PUO
M78O#=OIJ3:)XXU#1[&.QFLY+0R6U[JMS:?HS);Q3(T<RB:-L;DE"R(V&##*.
M&4[2 1D<$!OO*I#]G! 9ADDD@\Y.?;W_ *_>YH _#K7_ !W^W%'IFN^$K>3X
MY!O"GQ+_ &H?B?:>,;'P+K#ZGXD\"^-/#?[0GAOX$?">*Y@T.9-2M_!'CG0?
M%/B&VL+6V.H:9H?AK]FRYN[Z[L_B)I1UGI/A[XU^-%QIMEIOQ"UO]HFP^ S_
M !4\/2^,O&GA.R^/^J>*[/1+OX%W+6OAFW\7>,OAQX/_ &A+'PM=?&+2/[<\
M>Z_X/TBYTOPSJ>L^"/!VF^-(/#>I?$O0]"_:'8.,%ACT/XX^G X'H*78,YRW
MY_7USQST^[T.,B@#\M?&/B_]IC2/V?OV:_&NE2_&/4/$'A7]HOQWXH\760\"
MWS_$KXG_ +,?PU\,_M(>*O"WAOXE>#[/PY;WFG>,OBQ\,_"?P^TZ*SO-%\.:
MHWQC\0>$+:]TS2/$5X?#8X;P/\</VR/#&H:[HWB;PSXFU:]\4?%*'Q-HNE^(
MOA+\1_$&HZGH/Q1\5^#GU;X3^!O&&@_V+X<^%^G?LV>!/$5QJS>*?'>G^(['
MQE-'>):BUB\%>-KP?L(5##!S^9[=#[D=03T/(YYINP>K=,=>V<_IV],G'6@#
M\I_&_P 2OVHO MI^PSXZ\/Z+\6/&Z1_LN^-I_CIX MO!NNZG<^-/B;XOMOV7
M_ WP\/C""/1UG\.^,?#OQ,\:WWB;5)-2?2KG1_AYIWQFUF[L_P"S_#^M3:;Y
MYX&_:%_;D^'.C>&?AY=_#O5OBIJ7A+X;>(3>>*?'?PX^*-SXY^+.N:-X9^,.
MLW'CZ+5?#&G6OAO2K>R\4>$/!?AF/X<WUAI^M^(K?5Q!I6N66J^._A9I^L_L
MWL&<Y;KD_,?Y]<#G'/&308QCJPY!R&YR,<\Y!)P,Y!_(F@#XO_9O^*OB'Q#X
M1^(EC\1_&.LZEXS?Q1\5_%?AS4A\*/'O@.:Z^%NCZU%HNB>)/!WP\\:VVNZ]
M_8]G-Y<6E:8]UXBDURY9+W3%O]*U:Q,GP9HGQ"_: O?"EIK7A;Q7^U'<:9K$
MOQ,U;X/^'_&W@CXA'XA1?%C2M)_9HTSX.^$?CK>7_P .]%MK;1_B;<S_ !U^
M('B;P?=0K\(_ UGXHU?P]-K^E3^ -#L/"7[@?9XQ(TP4"5T2-I0%$C1Q,[QH
MTFW>R1O)(R(S%%:21@H+MEYC!R"6.00<MV)Y'T[?3B@#\A?CSKW[5?AW_A=E
MAI'B/XLZEX;C_:M\31Z-XCT+PSXKL-4T[X?R_L4?#KQM\.O!7@7_ (5KX \2
MZX? S_'F_P!2\+VWBBWTK7K&Y^)%FFC^.KWQ<FH>)/A_XG^@?CG\4O'5W^S%
MJ.J>$]7\0R>-]7^*W@SX<ZI>>"_"WCFTUWP'9Q?%;0]/^)6B:_=_#S2?'6O6
M^I>%?"%AXK\->(?B5X*T1=%NM8"^(_"^F:-9W.GVT'WR(P#G+=".H[_0#GKC
MTR?;$<=M%""L*B)6>60K$J1J9)Y7GGD(10#)//))/-(<O+,[R2,S,20#\FS^
MT!\>/AH-(TSX=^!/$GQ!T"[^&_Q \>ZC9Z]X7_:D^*FNR^+-.T_XC2:)$OQ!
M^)NF^"M<T+P-$/!GA.)])TOPCXN\63^*M4U'PK;>$=+7QS\/?&6LWO%'[4_[
M4>CZ=J<F@>"Y/B%-IG@3Q'XBT>'P[^R]\=_"&O?%BTBMOC+/!XJ\+Q:WX@\3
MZ?\ #@>&_P#A#_ >FZ;X3\1#QCXE^)>M^(K.XTW3?"ND_$/X?-)^K13(QN<?
M1CGMWZ]L^G7L2";!ZMZ\L3SZ\T ?D1HO[4O[5'A$?#;P=/X+U+XDZ7IOC;P5
MX=U3XH2?LY?'/2V^+?PGDU7X/>#_ !7XVL+'4?$U_K_@3Q9X,U74OC?<>(K_
M ,8Z5J&G^*-/\)> /'FE6-EX=^(&F6>I>Q?$OXW_ +6OPZ_9V^$'BZ?P-X4U
M_P",7Q$FM;GQM8>'OA'\3M?\-?# 7OPQUGQ=9>#)O!'AOQ=K_C37M=N?&^GZ
M3\.X/$%QJ^A:7=7VJO,^E6&I/H^@ZC^BNSD'<QY)^]U[ '&.!G@>O)R>: @&
M<%N23G///7GK_7\ , 'YVP?&C]H'PW\'_B=X^UW2=2OO'OB3]ISQ'\/O!?AE
M?@_XX\1Z'\'O!OAS7;+X?M/JFDZ9?Z!XH\:^#-5L_ NO>.O#'Q!L#:6OBS5O
MB/X8N]/TI=+U6TT.VW?V7OCEX]\1:%?^.?VB-.\3?#OQ)\0IO@7:>%/ VI^"
M?'6B>']"OO$GP>^"<'B/2].M-5T>XFT/4[GX]?$;QOX4O-+UC5KN_MXO#+RS
M7UYIGAS5M8@^]=F/XFR!@'@GOZ@COZ=O<YC>VBE:-Y5$C0R>;"7"LT,NQXO,
MA8KNCD\J22+>A#F.21"2))-P!^77Q6\8?M4^%/C;\1[KP_;_ !.\5?!_Q1^U
M!^R1\/=+TWP_X4U"\O/A?X?L;O\ 9Q\6_$#QGH,MGIK7.N_!_P")'A_6/BYX
M"^*U_')J5MX-\4:5HLD1L;#5?&^H:+6_9Q_:)_:?^+OQ?^&"?$CP_K'@CP!=
MVWC>/4[=?V??B/X$L?%%YK7PN^'7C#PGHGB"Y\2^(?%=MX-U_P $^(K?XIZ9
M)J$/BC6-#OKG2+GP;J*6WC2*/;^J7EC& 2/H1ZY.!C R>O&.2!@$BC8.<ECG
MKEB>^?\ .>P &!Q0!^4>E_$SXK^%Y?&'B-KS]I'7OCQ9^*_BEIOC_P &ZW\-
M?'WB+]G;P5X$_P"%RV/A_P *>-M/\.6WA_2;3Q%H?P^^%]U8>,_AUHWP/\3Q
M_$CXUZ-!K\'C"XU76(]5U?P?:T_]H/\ ;<\4:I8V.A>#_!>@Z)-=:GH-MXL\
M1?LZ_&2^B\2VUO!^UAJVA_$^UT1OBAX9G\-:#XCT;X'_  D2U\%:Q>76H6.H
M?&?3C<^)';4/"%AJ_P"J6P8QEN#D'/0GN!T'?@#')XH,8/4L>O5O4Y(],<#C
MIQTH _+G0OVBOVT-5U3X?:[>?#3PUIG@[Q=XO\+6VL>#I/@=\7AXO\+^$]1_
M:0^$7P8UJWU'Q7<>.(+&+5(O OQ*\1_%E-?O/!=AI^EZ)\-M0O+K1+WP_-K>
MMZ!S=_\ M<?M<Z_X/?6/ 7P@BT_7/#'P(N?B'XQT_P 6_L]_'0KJ?Q:\&_"6
MX\9^,?@WX9M;G7/"EP;[5/'\,7@71-3L'\4FSF^V6.GVWBO7;7RHOUJ\L8(W
M-R<YSSTQU([CKWZ#.!B@QA@06?G&#NY!!!!';((!R0>1GJ3D ^*OVJ/B98#X
M-VNN^"M7^,=_)/\ %'5?A_96?P6T_P 86-_K'B_PU<^.O!NJZ1X^\6>&/ ?C
M/QA\._A;X.\9>'[[7_&OCOPWHKZA<MX.L?#GA^+QP_BVQ\!>-OFOPGJ_[3FM
M:SX[T!?B;\99?%K_  6^,'_"2^-&^%U[H_A*VO-$LO@D/@#X\^&7A;Q+X6F\
M'Z)X[^(7AVZ^)>NR>&M(37WL_%VL^*].\<>'M0N?AWHOAG2/UFC@BA7;$JQ+
MODD*QJD:F261II7*HJJ6DE=Y')!+R2.[9=V8O\M3C.3@EADGACSD<\'.?;DC
M&#B@#\I/A)XR_:3O?VGOA':>*+WXJ'P3J7P_\$:7XG\.:MX6\7P:6EK<_LSQ
M>--;\8ZW/>>%(/ %KH[?&3_BE[_7;CQ1_P +IM_B85\&SZ+!\.9WD/ZNKP /
;0#KUZ4@4+T)[\9XR3DGZD]3W)).22:=0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>pg80-149_010.jpg
<TEXT>
begin 644 pg80-149_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %4 3(# 2(  A$! Q$!_\0
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MI;2[L]899/$;6T6IX>!A;O):C]P/B-/XD\)-HLG@']GO2OBF+J:X.K)I^O\
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MU6RU'Q7X]?2_#&FZE\-TO;NU\-Z_KFK7^EV86YN0#Z0_X;6\+?\ 1 _VSO\
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M7XM:-J.LZ=X*^*G@RVL=0?3_ +%\5_AKXJ^&6N7,L-M#<K>Z=H7BJPL=1O\
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M/X5;X8^/++QCM_LB+6H[^.*6SEDGTF.6_L%T+QIIQT^)?"WB\_;_ .P$U#6
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M&M+I.G:SXLU'6=5@N+C5+N>XOM9BO8M<O[?R-,O=2GTNWBLU^DZ* /$/A?\
ML\?"KX,W<U]\./#\N@75QX+\,?#^:235];U5'\*^$/$WCWQ?H.GF'4]2NHA)
M:Z_\3O'-^UZJ"^F?7&A>X^R6EG;0>VHNQ%7.XJ "< 9(ZG   R><"G44 %%%
M% !1110!#.)&B81*K.2F%9MJD;UWDD*2<)N(3Y-Y 3S(MWFI^96E?LT?M5_
M/X]_M/?$#]FK5O@EXQ\ ?MJ?$[P?\6O&ME\:O$GC+P=K_P"S'\2- ^$GP\^"
MGB'QWX+T/P=\._B%;_M2:+XM\.>!?"_BC_A47B+Q]^RR_A[6_A^^@6?QEO[+
MXL77B'X4?IW10!G:1;7MGI>GVNI7IU+4+>T@BOM1:%+8ZA=H@%S?&UB+06?V
MN;?<?8K9FM;+S/LMJQMX8R<[4_%_A71)X;;6_$F@Z-<W,+W-O;ZMK&G:;<3V
MT;K&]S##>W,$LUNDK+$TT:M&LK!"P8XKHJ_SO?\ @\T6:3]KC]BJ..66-?\
MAFWXD2NRSO"FZ/XD6B^;((MLA\J$R9*N\K1ETBC>0A9&DVTEN]$)M)-O9:L_
MT#A\2/AV6VCQ[X++=,#Q3H9.<9QC[?GI[5\3?M<^"9?CY'X#?X8_M(^#OA=-
MX;U#Q+I_BG4;?XE-I9UCPUJ.EV/BS0X+(^'=4^36])^-GPY^#VIW4MX(OM7P
M]M_B)X76Y6W\57MAJ'^?C_P3#_X(E6OQ8\*^$OVHOV[-7E^"O[,6NS_VAX$\
M/Z]K6N:?\1/CAI\$;3)+X.\*Z8K:WK.D7KO:;C%-IVFK!/&][JBF2%!_3CX:
M_;8_8Z_9$TJW^'O[,_[#_@.;P3X>MDL;'Q'XVOM'T3Q/XFDM@&6X-A%X9\1W
M6G*\TD^QM1U2:>6(1S,T@D4U?U>[;:=WO9JWWZ=/Z1'M:?=_<S[XLOA?^VEH
MMU8VMI^W[\$X]%B\5^$-6N=./B72%4:0OAJZN/&&GV$FK>%-;U8P67Q&O+K6
M9M*UG6M8MOB9X7@L--UZ_P#!L]NT)]W^''PS\<Z?\'/V=/!WQ#_:E\!^,/B!
M\#_BYX'\6:QXXT3XH:OI%EXW^'_AO2[K1Y_!^OZ?IUWIJ>)98=&U&XTB"/QC
M'KUEK-[I-EXXU-K?Q3>L=*_#_P")G_!57X0>/- U2T\3?\$Z_P!FG7A?7_\
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M+6]6L4EE5TN([;5+V>W#0R()5#&E*AH^5W?9Z?B91KMM<RLNK5WTTT]?N/\
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MI6E7'BN/0?$=E,_A'Q=JWASXAVGA;Q)I\/ACQ5J/A+3;'5]4T^.UA,_\=O\
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MZC#Q8#3K*\2,'(J)QY;:[M>74N$N:^EK)_D?M5^Q1^V+\4-0A\*?$']H[0]
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M/Q-XC\)>/8I4TJXUCPE+_:D:VGZ*P2>8I.3D$C!!_A9D# \?*^S>H(R W/4
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MQ^#M(DT[PCJM]I\>@:980>.?%&CZI\2S:6AL+_Q5J-I>7(/ZT>8L1)<-AA_
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M%ZE;6VF_$SP\EA>ZA!-X'\9QWC3^')W>VN)DM+I\30+;3R@'T]1110 4444
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M,?C^X75[?Q+K'B+7=?O[:\MM<TS49BMAIFG-IFII>6Z:=HZH8=-2:&,HUW=
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M/QQXL\.:78@Z9H_Q!U3Q1JO@S0KJYD"Z'X]^'LWB73_&%M_;>E>%KZ  ^F/
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MQBCVD_YW^'^0_9T_Y5^/^9^,MQ_P;]_\$M+C0]&\.-\!=>BTG1M5L=:$-O\
M%WXJ6UQJ^HZ:,64WB'4(?%J:CKB0-EQ!J%W-;NY)DB=<*/<?%W_!(O\ 8;\?
M?!7QG^SUXT^'/B7Q'\)/'GB/P)XI\0>%;WXD>.88FU3X:VU_:^#QIE[I^MV5
M]H]GID>I7;/9Z;<6\%Y)(7O%F);/Z8 Y]1]>M(3@9H=2>[F[+6[:LO.[26GF
MP]G3_E7X_P"9^ -Q_P &PW_!&:ZGFN9?V9_%'FS?>\KX]_'2WC4;F;:D5O\
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MCN31--NFD\.V=]?2ZM;=[^R'^RKX.\3Z1X,_:;UV7QL/"GA63XF?$3X=P2_
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M\N+*.?XB?&XI)!&["6\3P3X3-E;%D&P23S-M2.Z9;*1!+Y[?(@/]@5?R5_\
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MB@ HHHH *_DE_P"#JG6[70- _8&N]2L)M5T6]^(WQXT;6]-L]5.A:G=:1?\
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M5>.BL-SJ_P (?'J017<D/A^-9@D6IS?:F1+C&P>2LW+']5_BJ-WPO^) /0^
MO& /X^'M1'?(K\&_#^G6-_X6^'=Y?6RW-SH_AKPMJ.F2O+.AM+VX\#I8-<1K
M#+%&7BMM3O$AWHRH9 7$@!#;4H1FI<W1JV_9B<DMS]?/V9?CGXD^-%CX\'BG
MP]X=T"_\'>(-+TJ)?#.I:IJ5A?V&JZ!::O!<R-J]AIUS;7*23S1-;I%)$(%A
MD$QDDDBB^I%(*J0, J"!Z C@?E7Y[?L'_=^-S?W_ !9X.DV\83?X*L6*+WV
MD[0Q8@<;B,5^@\?^KC_W%_\ 01432C.26R>GW(:=U==1]%%%0 4444 %%%%
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M&M&O!\0?"7@Y=4O/'^E:I!-9P:5*3X0TK0XM6\1P:?X;DLM23T?X9>+O"K^
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M>IC54E2K5\5_9ZHUJJ53#*%6A%27U:=:I7CB(1=M(X3#XB32;FXM14OZ7/\
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MYE_X)7_L(27B0+=O^S_X/:X2UB6&V27?=-)';1J\BBVCY$)5V4Q*C*<,*_4
M@'@@$9!P1GD'(//<'D>AKX*J[U\3W^LUWZIU'9^CUL]G;=GN4OX5&ZY9*C24
MUT4E'5?)W7D?+_PK_9)^!_P[\%Z)X6G\&>&?'UUH]G<6)\7^-/"7@[4/$.I6
M<^O:[XAMK2:>QT*SL8-,TJZ\07]IHVF6-M;V6FZ>L5O#"'$LLO$?'G0O@/\
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?+9>B_(****8!1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>pg80-149_011.jpg
<TEXT>
begin 644 pg80-149_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #F 8P# 2(  A$! Q$!_\0
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MFLZ1?Z,]M)-9S2:#IVEV.H:9?VURVTW=DU]:7%N MY/#<".W/>_F_P#)*/\
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MKU3_ +#NK?\ I2::V?R_,A_%#_M__P!)0[0?^/&3_L,^(O\ T_ZK6W6)H/\
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M6@)IQ_L[PY<V&JW-E='4-$\B^N;ZU236WGTT"1OQD_X9@_:;XS^S;\=QZ?\
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MUBG]H7X J2K?''X/JRLRLK?$SP6&5E.&4@ZWD$'@@\@\$ T >P45X]_PT/\
M #_HN7P>_P##F>"O_EW1_P -#_ #_HN7P>_\.9X*_P#EW0![#17CW_#0_P
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M5%RHXK,\NPU:*FKQ<J.(QM&K%26L>:"4E9JZ:9[!AO;\V_QHPWM^;?XUX_\
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M6^H6;[;JQG!#'9<1KN*L8F= 37<QON*YXPG.2.N!VQW'.1QCZ8K^;KP?XO\
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M* "BBB@ HHHH **** "BB@]#CD]ATS0!_+G_ ,'.Q'_"KOV1N>!\2_B3G'.
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M&]#U>];08-=TS4IO!0AMO#5W;ROK%M!?P:AJ-]:"\F22W@LM7T5O.N9?6/\
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M@AFU'4;_ ,.:A;6\322M$UU>W]W=!!<7<Y,D\S--,N6(]S1%7<%7&,\8/(#
M=^_RYZ>AQU)> ,L-N,+Z<YX'8>W_ -89K_*[@[P6X#X%R;,,MX?RI4<9FN7X
M_ 9EQ%BU3QW$.+CF&%Q6&KU'F&)I2^K0C'&XB5#"8.&#P4.7#PG+$1A-O_0N
MA@\/AU-4J:C*JZO/5;<JLO:RQC=YM;1^N.RBHI62]ZR;_,/X-?L(JL5EK?QH
MO_.E"0W,'@/0KF5;5,JKM%XBUR-$FNY5D*B6PTI[>TW)-#+<ZC"X8?H]X?\
M#NB^&-,M=$\/:3I^BZ19QK!::=IEM#:6EO%@A D,$:JW.=S.68Y+%L]=W:,$
M 9P5X(/.,YSCIW/UJ5>_&.O;!'3 X]CWY_*O5\/_  KX*\-<OC@>%,GHX6M*
M%..,S;$I8O.LQE&"4IX[,ZU-XEQDX\RPV&^HX*%U&%&I&*;>&PN'PD/9T*:A
MI[TG[U2>N\JC5WK]E<L5?1=1P_\ UX]>]%%%?I*5DKN[[G2%%%%, HHHH **
M*,CUH *PM!_U>J?]AW5O_2DUNUA:#_J]4_[#NK?^E)H7V_2'YR(?Q0_[?_\
M245+(ZO8Q2VZ:9!<(VH:K=13#4HX_,BOM3O;V$E/LSE6\JY3<I8_-D*3@U=^
MVZU_T!8?_!K'_P#(GX?7CK6=8V]Y?13W4FLZC"1J.K6WDPC3DBBCL=4O;*%8
MTETV9RHB@0%F=F9CO))Z7AIEP>?[=U;\]*_^4U.7LXMMRA=[VC/5V2T]ZRT7
M;:W0E.5OM?\ ;TJ:?WVUU)/MFM?] 2'_ ,&T?_R+1]LUK_H"0_\ @VC_ /D6
MH_[+N?\ H.:M^>E?_*:C^R[G_H.:M^>E?_*:H]I#^:'_ (#/_P"3%>?\S_\
M J7^1)]LUK_H"0_^#:/_ .1:/MFM?] 2'_P;1_\ R+4?]EW/_0<U;\]*_P#E
M-1_9=S_T'-6_/2O_ )34>TA_-#_P&?\ \F%Y_P S_P# J7^1)]LUK_H"0_\
M@VC_ /D6C[9K7_0$A_\ !M'_ /(M1_V7<_\ 0<U;\]*_^4U']EW/_0<U;\]*
M_P#E-1[2'\T/_ 9__)A>?\S_ / J7^1)]LUK_H"0_P#@VC_^1:/MFM?] 2'_
M ,&T?_R+4?\ 9=S_ -!S5OSTK_Y34?V7<_\ 0<U;\]*_^4U'M(?S0_\  9__
M "87G_,__ J7^1)]LUK_ * D/_@VC_\ D6C[9K7_ $!(?_!M'_\ (M1_V7<_
M]!S5OSTK_P"4U']F7/\ T'=6_/2O_E-1[2'\T/\ P&?_ ,F.\_YG_P"!4O\
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M:S_T!H/_  ;1?_(M'V[6?^@-!_X-HO\ Y%J+^SI_^@[JW_E+_P#E+1_9T_\
MT'=6_P#*7_\ *6B\._\ Y3J_Y"M/N_OA_P#*R7[=K/\ T!H/_!M%_P#(M'V[
M6?\ H#0?^#:+_P"1:B_LZ?\ Z#VK?^4O_P"4M']G3_\ 0=U;_P I?_REHO#O
M_P"4ZO\ D%I]W]\/_E9+]NUG_H#0?^#:+_Y%H^W:S_T!H/\ P;1?_(M1?V=/
M_P!!W5O_ "E__*6C^SI_^@[JW_E+_P#E+1>'?_RG5_R"T^[^^'_RLE^W:S_T
M!H/_  ;1?_(M'V[6?^@-!_X-HO\ Y%J+^SI_^@[JW_E+_P#E+1_9T_\ T'M6
M_P#*7_\ *6B\._\ Y3J_Y!:?=_?#_P"5DOV[6?\ H#0?^#:+_P"1:/MVL_\
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M/R%+11[.'\D/_ 8_Y )@>@_(4$  G X&>@I:0X[]\C'KP3@?@#1R0_DA_P"
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MD;Z+&]U+\//%L4*/XE4-X<0ROH_EJ==5T.D@Y-ZLD9@#;T)@7X,_&&7Q?/\
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MM*2C4G)*UTF[/]!3_P %B?VI^#_PA7[/WMCPC\2,-T[GXJ\9R .3STYXI?\
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M ,!C_D F!Z#\A1@>@_(4M%'LX?R0_P# 8_Y )@>@_(48'H/R%+11[.'\D/\
MP&/^0"8'H/R%&!Z#\A2T4>SA_)#_ ,!C_D F!Z#\A1@>@_(4M%'LX?R0_P#
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M;IX;#9CAZN(J<LI*G23K1E4:BG-J'M8SERIR4(S:C)QY9?QZDLQ!)R!V526
M!X&<$#Y@,\;6;!S75>&/&FN^$=/\<:9HQT]+?XA>%H?!_B&2]L9KJ=-'MO$F
MA>+(7TF5+FW2TOUU;PYIK&XNH;^%K3[1;_90\RSP??+?\$GOVP@SJNC_  \E
M56*B9/'%DR2A&.)(_-MTD"2  J)420*P#HI'R@_X)/\ [8G_ $!/A_C/?QOI
MW'N,0]@!C@8R<"OVBIGW#]1.-3,\OJ0;4N655-7C.%2#L\-;W9QC)7TO%)WL
MT_Z2J\4<)5H.E5SS)ZE-N#E"6(YDW"I3JQ>N#3]VI3ISB[W4H1>NJ?C/B?\
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M:\T:&[UCX@ZEJ&BZ+J6CSW4>K?\ "+WF@ZSJEQ<2RW>LR,6->G?\.H/VQ?\
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M#_J]4_[#NK?^E)IK9_+\R'\4/^W_ /TE#M!_X\9/^PSXB_\ 3_JM;=8F@_\
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MB/?^[60K#M+["N[;\C-RORD8:/\ @JK\6\_\DD^' Z\?\)'XKSP!P,0X[#U
M''K7V2^CUXN.UN&<%JKK_C(LC3L]NEGKI:^C4EK:\OB']([PB5_^,CQEDW&_
M^K^=VNKZ/5;]--G%Z7LOW:HK\)/^'K'Q<S@?"/X<GL!_PDGBO..<9S!U'!/?
MGVIW_#U;XN=OA'\.2?\ L9/%6/O8'/D8Y&3^ /0T_P#B7KQ<T7^K6!N]E_K'
MD-W^ ?\ $QWA&K_\9'C--_\ C'\\T_'0_=FBOPE/_!5?XMX/_%H_AR#QC/B3
MQ5SSS_RP'3]>E(?^"J_Q<X_XM'\.>3QCQ'XJYQUZ0]N_I3_XEX\76KKAG!/_
M +N/(?/_ "?W,/\ B8_PB_Z*3&?^(_GG^9^[:E0>" 3GH?7/I^AYQ4Q/ &1D
M8SZGCJ.IR<\8K\--"_X*M>.8M4LY/%/PA\*OX?#G^U!X:\0:V^MK; CS9-/C
MU.%;*2:)-SK#,5\UE$:D,P(_86R\?Z#JOP\B^)>DR2ZCX<N/"#^-+&6$!)[S
M2DTI]85(U<A%GD@C,6&(43 @_+R?CN*O#GC/@=X!<39-]0CFM6I0P%:CC,#C
M\/B,13]ES895\%/DAB$J]*:HUHP<J4U5C.44U'[3@_Q.X*X[69_ZM9RL=/**
M,,1CZ%;!X[ XBAAJGME#%*AC(.=3#.>'K4W5HRFHU:;A*G&3BY][GD\<G[V3
M@#KG/7T)Z=Z=@<' ]C[>U?A7/_P58^*+SS267PB\ )9O+,ULMWXC\3&Z%L9'
M\E;DP0^0;CR]GG>3F,-OV?*!48_X*J_%SM\(_ASD\_\ (Q>*\=AT\CKR,].H
M&*^O_P")>_%QI-<,8-)I2][B'(HRU47:47=IKFY6M;--:M,^+_XF/\(KV7$F
M+>K5UD&>-.S>J;:]UI7BVHWBT[13L?NS17X3?\/5?B]_T2+X<GU_XJ/Q5P?3
MF'KSVS0/^"JWQ=/_ #2/X<_^%'XJ_I":/^)>O%RU_P#5G!6_[*/(O\@_XF.\
M([V_UDQ=^W]@9W_\D?NS17X3?\/5?B[_ -$C^'/_ (4?BK\/^6/?(_,9YH_X
M>K?%[_HD7PY_\*/Q5_\ &:%]'KQ<?_-,X+_Q(\A_R#_B8_PB6_$F+_\ #!G?
M_P D?NS17X2_\/5OB[_T2+X<_P#A1^*O_C-+_P /5OB[W^$?PX''\7B/Q5C\
M?W!_E0_H]>+BO_QC."T3;_XR/(=DFWT[)OY OI'^$3:7^LF,=VDO^$#/-6VH
MKKW:1^[L9R#CD XZ].O\^/YT,RD9!'\7.?;^OZ8-? '[&O[8&N?M*WGC;1/$
M_@W2O"VL>%+73M3MYM!U&^U#3+[3;Z9K4I+_ &BJ7,5[#.@;Y0T+PMGY6'/1
M?MG_ +7MC^RGX5\*MIOA<^.OB1\1]5U+1? 7A674/['THC1+&+4O$/B+Q%JQ
M21K/0?#]K<VDEU':QOJ&HRW,%I8KYI=T_+N)\ES+@K,<QRGB>A3RS'913HU<
M=2]O0Q5*E3KT88BE.-?"\U*K&K1JPE!TES.3=/D4T^;]I\/L93\4J>13X$A7
MS^7$F)JX/**5*A4PM;$XBC6KT*].5'&NG.@J$\/6E6G7G&E2H0E7E4]DK/[7
M!Q_$I^O7_P!"HS_M+_G_ (%_G\J_G+?_ (*G_MK[B4^&'[)(0EBH?6OC>7"A
ML .RV94,!C<1QG)' J>U_P""HG[<5]=6=C9?"S]DN[O=0O+/3K&S@UGXX//>
M7^H7,-E8V=NOV/\ >7%W=W$-M!&.9)I$3@GCXN/&/#TFE''2DW;E2PN*;=[)
M)+5MMM)*UVW:S>A_14_HL^.-.,IU.$L!"$(RE.<^*.'(0C"$93G*4Y3C&,(Q
MA*<IRDHQA%SE*,4Y1_HMS_M+^7_V5&?]M?7M_CT'^37\\6E_\%+?V^=;U>?0
M-(^#/[*^I:[:P:G=7>DVNI?')KRVMM%B>;5[B=6M%2*#38XV>]F>18X!M#-O
M=$;$7_@JE^VLY^3X:_LBMG9M(UGXY'(D;RX\D66$WR812Y4%V6/.\XJY<6Y%
M&U\76C>4HKFP6,5Y1:4HJ\%>46TI15W%M)I-I/GI_1C\9ZCG&GPWE%25*A0Q
M56-/B_A:;IX7$PE4PV)J*&(FZ>&Q%.$ZF'KSY:->G"<Z-2K"$I1_HXS_ +2_
ME_\ 9>U&<?Q+^(_^OBOYT+__ (*B_MQ:9>7FFZA\*OV3+._T^\NM.O;*?6/C
MB)[2_L96M[RRE5;)E-Q:SJ8[B)&8QGEB!AC6;_@JE^VLH9F^&G[(JJBN[DZU
M\<?E2-@LCM_H(\M(G.)'DVJA*AB":A\8\/IN,L=)--Q:>$Q2:E&_-%IVLXM.
MZM=:W6[-H?1;\;JD8SI\*9=.%11E"<.*N&IQG&:BX2C*%2491FIP<91DXR4X
M.,I1DF?T<9_VA^&/ZD_RI-W'WE[=1SS[ ]?ZU_._K'_!3/\ ;T\/74%AKWP=
M_94T>^N=,TW68++4-5^.$%T^EZQ;B[TJ^\@VA=(-0M&2YM?-"2O"ZNT2 C.7
M_P /3?VVST^&/[(_7'.M?'$>O_3GDY.,<>N>H(J?%^00DX3QM2$D^5QEA,5&
M2E:+LXM)IVE%V:3M*+V:;FC]%[QKQ-&&(PW"^68BA5A[6E7P_%?#5>C5IN56
M*J4JU&I5IU8.5&M%2IU)Q<J56*;=.:C_ $<JP ))'RC@CWZ<>^??KUY%!(#$
M;API/KR2>_3O^ ]LU^:/[$?[>&H?M'>(=?\ A9\4/!FB> _BOHWAH>,M-/A;
M5K[5O!/CCPQ!J-GI&MWGAR35TBUNPO\ PSJ6H:1!JNF:M'YT]OJMK?6326\-
MX(/4_P!JW]LKPS^S5+H&@IX>N_&7C7Q):7&HVNBP7D>GV6FZ3;.(&U'5;MPS
MQB>=_)L[6%!+,RO*"$A85]?PSEF/XTQN"R[A?"U,YQF8^U>%HX;DBY1H1=3$
M5*LZ\Z-/#T\/!.=>=><(4XVOS.483_!_$>E4\(JN;4/$6*X9JY(\*LPCBFL0
MDL8HO RP<L"L2L?#&J5\'/!*<:ZC4E'V2I573^V]V!@9.1SD\#@\#^7?^M(3
MTYY Z\YZG^E?BJ?^"L&MJ./@M8[0._BJ;C(&1S;\C/&>GKCFM[4/^"G'C_2M
M*TW7=4_9Y>PT76!&VD:E=>(GCMM228.T+69\LRS+*J.R.(_+8(Q4_*:_2:G@
M7XH49T85N&Z-&IB)RI8>%;/.'Z4\15C#VDJ5"-3'QG7J*DO:.G2C4FJ:]HX<
MGOGXK#Z0'A16C5G1XEJU84(*>(G2R/B"<:%-S5-5*\J>"E&C"51JFIU94XRJ
M?NU*4_</V-SQU.<^IZ>I]3VZ^GI2;CC&3^?\O2OQGG_X*C^-K;2[/6Y_@";?
M1=0:(6.JR^(+A+&[:=7,*P3_ &<K*9%BE**N2PC8@?*<Y0_X*R:T0 /@Q8DG
M&W_BJ)2!W!&+?D$9.><#GIC-4_ CQ2K*3H\,4JRA.5.;I9UD%50J4Y.$Z4G3
MQTXPJ0DG&=*4E.$TXRA"6A%3Z0?A-1LJW$\Z4I0C4C&KDN?TI2IRBI0J1C4P
M5.4J<HOFA447"<6G&<T[G[7%CS[].>GKCZ_RHSGUP,#&>#C^70?G7XJ'_@K'
MK73_ (4O8EB%^4>)YR3OX0@"W.X$XQC.[^')I%_X*QZXZAA\%]/*X!5AXIE(
M;<"00?(Z  \YZ@X][_X@)XK[?ZJ/W=_^%;([I7WM]<=E;2^BO=;ZD_\ $PWA
M'92_UJT;T:R?/;/KI_LB_+?3?W3]JP>>.ISC)YZ' SZDXY] :R=!YCU3K_R'
M=6ZC'2Z8?EZ'N.:_,/X*?\%+=$^(OQ$\-^!/&OP_E\%Q^,-5M- T;Q%9ZRNI
M6%IKFIM]ETFSU>"1$FBBU?4Y++2;2Y@W+%?WMN)P(Y"Z_IWH) CU3G'_ !/-
M5/)];@D?H1GKSGFOB.)^$.)."\;3RWB;*:V5XK$X6&+PT)U,/7IU\.J]6A*I
M0K86M6HU%3K4Y4:T8RC.C4252FN:,I??<)<;\+\<X*MF/"^:TLUPN%Q,L)B9
M1I8G#5<-7]C3K0A6H8NE1KPC6HU(U,/4:G2KPYG2J/DE"$>B_P#(-F.#D:OX
MAQG&"%\0:FV<?7M[&OR.^._Q<^(/PI_:@^)>H^"O$-S8QS/X*?4-&N";O0M4
M">!?#IVW^FS$PEBC.J7$ BN$)R&9E7'ZXZ*?^);-D\'5O$.>I//B#5 3QGU_
MSS7XT?M)>$/%7CK]J?XA^'O!F@ZAXDUB;_A"B;/3H0RVL;^!O#@%S?7DI2TL
M+7Y3_I%Y-$I"MY0ED41U_&GTK<5GN#X+X8K\,8C-</GR\0\ACE<\DEC(9K+$
MSRCB%0I8.. 53$U:E2TDZ,:5:G4BI1K4I4G)Q]K.95882DZ+JJL\914?9.2F
M[QK\L8N*=]=TTXNWO)JY]N_!O]LGP%\0S:Z'XN$/@/Q=)M017]T#X=U6?>JA
M=-U9_EMI)&)D2TU$QL"C*L[Y5:^"?"_[1WQ+^$'CGQE!HFJ'6_"S>._&3S>%
MM:G>\TMHF\5:J[R:7/N:?39)0RA);:1H60+MBV9W?6GP<_88T;16L_$'Q>NH
M?$VIQM'/#X1T\N/#=E*&!C&I7)"W&N30D<Q,(; N4)MV92Y^%M$^$GCSXI_$
M'QEI'P^\.2WMI:>.?%EK<:G*IL_#FBVT/B?4X8TN]2D&P"WC2.-;2S%U=JH4
M&%5RP_ ?$/.?I#PR'PHQ&>4<1EW'%3.\[AP^N&/K,>*<PP\LERMU%Q'E&7>V
MR7VDY>S>(HN52A.E[6IFGU*SE3\[%5,WC1P+J+EQ+K5%3]BW[:<73CI7IQO3
M6MG)*ZMK5Y7=K]8OA#^U%\-?BU%%90WW_"+>*F16F\,>()X+::5V.PG2KYC'
M::G#NX41M'<Y< P$J6K\8_\ @HN=O[6?BH,,$^ ?AP""""?]%UWOCH/PQ@YX
MZ?K!\'/V,/ WP^EL==\9.OCGQ?:M%<VTES$8- T6ZC(=9-*TX,7FGB;;LOKY
MY;A6!,>Q6"#\G/\ @HUD_M8^*LGEO /PZ'/O::Z..#CU)SP,\'/'^K'T%<1X
MCXGB;#S\3\'DF X@?"^?N,,IJU/:SP[HY8XU<XP]-3R_"9E*;_VC#Y76KX5.
M3E[15(RB?A7TG'B9>%F'>,C2C6?%6075)IZ<F9I.2=X*5K-QIMK26KU3^&S>
M6@E\H7%N90VPH;B/S=P 8J4W%A@#H1G&3@UT_@W7_P#A&_$WA'QNME+J6G^&
M/&7AS52L#>7;WNH:-JEIJJZ-'?A'MX;^]2V"Q0%FF*N'$3ID5]#:;^T%X3L_
M"^C>%+_X9Z9JNG:?I&CZ=J%O<6&BB35CI]A9F^6;4EL1?QQZEK$$M])(LYG$
M<_E%RNY3V\G[57PO72_$>D?\*ZU"2RU.6VO9(KC_ (0NVB\07MMHTVF64'B6
MVM=&B@M8M#>:WDTN^T-++59(]*LA?W$LCRL?] <PXGXOJQQ6#I^%V=8C#UJN
M+P56I_;>31C6RVI*O@:N(7)7IU:-7%86LJU*E-WIJHU.4G%P7\<8+A[ABE4H
M8O\ XB-E5"M2I83%T4\FSCGI9C&E1QL,.G.A6I5J>'Q=%TJE=<D:C@N2FF^<
MHZ7^U+KGA=TU7QM\.]:DA72-4T&ZB\\^"_#NKOJ'C#Q?XHTVPUJQ&G6UG<6T
M-OXDEL9_L\L&L27%A=7EG.!<S(.1T[]IOQ%JMQ'X7;0[G4/AY>> K+X=ZUX,
M\*WAM/$5S/?^'?#7@G_A(+'Q%9QW%W%KYNM)TVR\/"XC6/[-?R:%,MP^H?O/
M3+7]J;X>VVNZ=<>(OAUXICM]%@NVM]-EGT"<^9?6^H_V:NH:9X@TF>&ZTZ"7
M5(M5AMY;<?;+FRM1YDEG+(DE+1_VI_A=H6B>#-$TOX?:]!<Z/;^&+;Q-K'G^
M$O[6UX>&/'/PX\;BU\R'28DBM;I_"OB2VF 026@\3/):M&8(PGYK0X=GA:=2
M=/P/QV(QE2G&-&M3XFISR_"J=&<(8G"^VS6K4P^*PD,+2]EB\'*6)I8BI_L]
M3V<,2??SS^6(FE7\9,#2PT*U6I6A6X>K_7<9*G7A5='$1I993A6PV,J8RM*>
M#QG)AJF&I<]>'M7AZ4OC?QAX@TO6_$VO:O:6LNB65Q>@P:9JNN3ZUJ6FP1PQ
M00VFIZMJ4GVNZOQ%;YGEN-F9=ZQJL*HJU+33M2OX-0O-/TO4[^STF"*ZU:^L
M;"[O+32[65GCBN=2NK:&2WT^WEV.L<]W)%&?+F(;;#(R_65C^T3X'TG0=*O-
M,^%I34;+3I]'LM?O['PW=Z-X?UEU^'#:C8Z'=MHX_M1O$">&/$OBS64U^[U'
M5[#7/%[?V?);:8WER1?##X__  T\%:9\??#VL?#KQ#=>&_C5XDU.;^S_  _K
M&F:>UCX(GAU2'0?"DTMS93-:GPP==U:Z2?2S;+K<=]<:3J*2:>ENH_2Z'$O%
M>'RBLL+X;YQ1K9=+*L%A\'5SK*L94Q5!YG1R_-91J8?'4JRQ&7995KYG'ZS5
MC+%590HUX4XU)J7P$^'N&*^;4EB_$'*IT,:LTQ6)Q=')\SPU'"5J>5ULQRRD
MZ57"5:<J6.S&GA<KJ/"T)1PD)*K0G6Y%.GYC^S*<_M(? $#"X^+7@HY !!4:
MK$"N.GW@0.Z@Y' Y_6W_ (*E213_ +/G@.2)XY8F^,^@"*6)TEA<CP3\0%)2
M2,LCA64IE"VQE*G!#"OQJ^"GAVY\6_%OX6>#X?$?B#PG=^*/%^C>&XO&/A&\
M73/%7AFYU@O8IXA\-WSPW$>GZ[I4DIO]*O'@F2VO8HY#$XC96]\^*?[!'B?]
MBGX :I<>(OVH/C+\=6^)'[2NI^)8?"WC35@? /A.3Q-!\1O$0U?2-%E^T7=Q
MXTU&Q6T7Q3XAN[]H;_5+G5WTZQTZPN(;6/\ +_$NW_$P'@Q*S5Z:DX-IM?\
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&=_LQ/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>drsaa_004.jpg
<TEXT>
begin 644 drsaa_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &  IX# 2(  A$! Q$!_\0
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M&!Z#\A1_9N7?] .#_P#":C_\K#^VLX_Z&N9_^''&?_+#H/\ A*O$O_0=U/\
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M\]J+_3Y;BT^TV]Q;B82PRJNKXL_:$\'^ 8=#N?'/QK\&^"H/$\:3>&I_%OQ
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MXE_Z#NI_^!3US^!Z#\A1@>@_(4?V;EW_ $ X/_PFH_\ RL/[:SC_ *&N9_\
MAQQG_P L.@_X2KQ+_P!!W4__  *>C_A*O$O_ $'=3_\  IZY_ ]!^0HP/0?D
M*/[-R[_H!P?_ (34?_E8?VUG'_0US/\ \..,_P#EAT'_  E7B7_H.ZG_ .!3
MT?\ "5>)?^@[J?\ X%/7/X'H/R%&!Z#\A1_9N7?] .#_ /":C_\ *P_MK./^
MAKF?_AQQG_RPZ#_A*O$O_0=U/_P*>DC\4>)&DC5M;U+:TB!A]I<Y5G&0<]L%
MMP!&>XQ7/D#!X'0]A4D/^OA_Z^(O_0EK.KE^ C3J<N"PD7[*K)-8:BFFH3M9
MJ"L:4<YS=UZ">:YFXNO03B\PQ<E).O1BTTZJWBYQ_P"W[]$?8J]!]!_*EI%Z
M#Z#^5+7Y ?TR%%%% !1110 4444 %%%% !1110 4444 %%%% 'COQ;_U&B?]
M=M0_]$VE>,=S]!_-J]G^+?\ J-$_Z[:A_P"B;2O&.Y^@_FU?IW"__(IH?]?<
M1_Z5 _ O$#_DI:__ &#8/_TS(6BBBOHCXP**** "BBB@ HHHH **** "BBB@
M!#V[]>/_ -?Y?C7A'Q>^ ^B_&#Q!\,-?U3Q9X^\.R?#3Q</$\-IX0\=>-_"U
MKK$0\,^+?#QM&A\,>)]#MK#5S)XI6X_X2I;>[UA-*M+WPXKC2-9U",^\45%2
MG"K%PG%2B[.SVNFI)[K9Q3WZ+YZ4:M2A4]M1FX5%&<%)6;2G&<)64E))N,Y*
MZCJGKK9KXP_:W^"/QE^.I\ >&O .I?"[2?!VF^*_!GBS7=?\57GC>R\9^#_$
M_@;XA>'/%VE>(O#^B:+#JG@CXL:)+H>FZMI<OPR^(]AIGA^'Q1)X?\8)K4EW
MI-K'I7EWQD_99^.?QC^+WAKXA7VJ_"30-%\1P?!W0?BO86.M>-[[5/#_ (?_
M &=/VI==^/GP]U#X;M<>%[:'7=;\=^'KO3?#WC:R\0S>&K7PSKYNKW1]1\0:
M=:VYNOT@HKEJ8"C5E.4I5;SE3G*U2VM*W);W79))WCK>[U5SOH9OBL,J*HQP
MR="GB*4)NA&4^7$S]I5<I.=W)U%":DE&TJ5)I)P?/^?OQA_97\>^/_VPOA?^
MT;HL'PH7P;\/'\!V_B+P3KNJ>-8-1^*UQI$_C5H_&_B:+2]*F\+6_C#X$_\
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M&*=E!W3DG&4YR?POX]^#G[0WBK]J_P *?%%;/X(:O\#?AO;?VMX \*ZGXO\
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MWBHL?/,_V-K4KHB*&,'D"X5N/.,O\"A-/7QT-?U'^UF\''PH4N1I*Z9'K_\
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MCTSFN&TZW^)HT?5QK&H_#^7Q"Z0_V!-I>C>)H-$MWY^T_P!M6EWKL^H7:/\
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M;7HS9HUS-X@NX)/*GVV:B:,0II+>=-).SES:6M?F^#X?L[7OM%[F?UR7(IO
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MS-A:3XL_:<E\16WQ.N%\3Z;?P^!O@KIVKZ'+\,9TLOB1H6H_M'^.O"KZA?\
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MQIQ9G=?*L?C74RK.ZV(> ='&8#/LOQF$Q. PF<PPE>6(6>87$8FK.CBJ4JF
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MO=U[-7C/P#_Y)II7_80US_T[W=>S5^=YA_R,,=_V%U__ $L_I#A3_DF.'O\
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MQHT\93IO!Y;7S+#99B:3PU6,.?$PK5J56LJ;Y3^%AZ9'Y<8XP.O3CIBI(?\
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MK!$/BOPL--36CXH\.#1Y)_LD>KG7=+&D278W9M4U+[3]B:YPCG[.LYG 1LH
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MR?Q/_P E+G7_ &.,;_ZDQ/O+X!@'X::4#_T$-<_35[LC]:XG]I#XW^'?V8_
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MGX7^+K'4/"&O#2]6T>_L#'K5U9:7-'JTOZ*_M'?#[2/'%W\(]0U>:Y6'X?\
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MN=2AU:;1-)N=9B,:V^JS:993:I$4\P1+#J$D#7<7EB:81!)E""655 61PVH
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MB58<1Z?'/:NME$!;0+Y5LL28@AX_=1[?S?\ &^J?"SQ=^U+_ ,$O?B'\)/\
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M5/RZWM;K?>WK;H%GV>]MI;V3M\.]I1=NTD]FKNHINX>A'I[_ $QG/UZ>]+N
M]>F?P_E^1]SQ2NNZ^]=&T_N::]4PUT=G9JZ=G9I-)M::J[2OM=I=4+12$X_R
M/\?7OT]\<T@8'IG\O\^H_P#U4[KNNBW77;KUZ=QV?9].DOM)./3[2::[III-
M,=130P/^>O./KU]OK1N&,\_Y^AQ^>.AH_K\_\G]S[,7R?7H^F_3IU[=1U3V?
M_']9?]?,/_HQ*K;AZ'IGU_EGV_,58LR#?6?;%U"#G@<R)CGH/QY]:BHU[.IJ
MM*<V]>CA-7)E\,GTY)ZO1:TJEM6DM;JSND[JS=T?(7[!/_)EW[,__9*-!_\
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MK>+-+UZWUFYBQH/QRU/0=&EL;>*TN+"PTC3O$B::ZN?.$U]:O&+J.[DC+&X
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M?ZQC_P#F'M;,,6K+#)\L5RRIVA7E*4\;!\T,=.<I8E-O3D;.S\:Q^);V[O\
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MM[2RCA^:;P25OJ,IREAFF].";2/B$?#<=@OCG0%\4B_$TWB(^!F;3)--&_\
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M**904444 %%%% !1110 4444 (W0_0_RI\/^OA_Z^(O_ $):8W0_0_RI\/\
MKX?^OB+_ -"6L:WP5/\ KS6_](F:T/\ >,/_ -A&'_\ 4BB?8J]!]!_*EI%Z
M#Z#^5+7XJ?U6%%%% !1110 4444 %%%% 'Q?\6TW_$>^&0A>'15#D A";.U&
MYAR"$ZD'*D @]Z_EX_9NO_@8G[87PH^(NG_ S]DO2=0^+'[2OQH\">&/"?@'
MX^?'KQ'^V5\)/&GAY?BE]N^)GQI^&/B/QSJ/@%],U5O"6J2^,+1?#=G;^&]/
M\8^']4M9YC D,O\ 1S^V;8W=[H?Q0%CXS^(_P^N--\,:7XBD\7?"#0K#Q/\
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M:-INI:?I=PNK6UII]BN@:J#K%C=16L%UKEE)']KA_M))X8#??<>".0>"0?8
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M .130_Z^XC_TJ!^!>('_ "4M?_L&P?\ Z9D+1117T1\8%%%% !1110 4444
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M,YXQD\#KUR!ZD#FEJCJFIV>B:9J6M:C(L.GZ-IU]J]]*Y"I%9:7:37]W(Q/
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MUY9VEW"S0SP/)"L5W;W5K)/;R>H$Y9^<\D_3))_+&/\ ZW2F$<^O) '<L1P
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M>"CPE7H4GE]:.2J4,?1K<^)PU:M4?M*M&A5A5KTI4:U+V')E'C]D>8>/.:\
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M@'U';FODK4/VJ[:Q^*M[\,/^$%N))+#]H7P!\ SK0\1Q+'+<>._A;<_$U/%
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MKZ(^,%HHR/6C(]10 449'K1D>HH **3(ZY&/7-+0 449&<9&?3O29'J..O-
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M5%^R>/->U2)GRAA\.7)9HQ:^<GZ%?M:.Y_:S_84D+,9!XS\18<D[Q_Q.?!F
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M^(]6?QMHVEMX7EGN(HKVW6PN;.9]>^P6[371DT]X$N_)$$6V1PX^(M8_;/\
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M'P _^<]7VA17#_9.6_\ 0'A__!&'_P#F4]+^V\T_Z#L;_P"'+-O_ )Z'Q?\
MV!_P4._Z/ O/_#4? #_YSU']@?\ !0[_ */ O/\ PU'P _\ G/5]H44?V3EO
M_0'A_P#P3A__ )E#^V\T_P"@[&_^'+-O_GH?%_\ 8'_!0[_H\"\_\-1\ /\
MYSU']@?\%#O^CP+S_P -1\ /_G/5]H44?V3EO_0'A_\ P3A__F4/[;S3_H.Q
MO_ARS;_YZ'Q?_8'_  4._P"CP+S_ ,-1\ /_ )SU']@?\%#O^CP+S_PU'P _
M^<]7VA11_9.6_P#0'A__  3A_P#YE#^V\T_Z#L;_ .'+-O\ YZ'Q?_8'_!0[
M_H\"\_\ #4? #_YSU']@?\%#O^CP+S_PU'P _P#G/5]H44?V3EO_ $!X?_P3
MA_\ YE#^V\T_Z#L;_P"'+-O_ )Z'Q?\ V!_P4._Z/ O/_#4? #_YSU']@?\
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M#)86#W=T]I;Q-<3%U\$ #P]; ?\ />[_ /2B2NMKP,1IB<2NU>K^:/T++E;
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MS6_](F:T/]XP_P#V$8?_ -2*)]BKT'T'\J6D7H/H/Y4M?BI_584444 %%%%
M!1110 4444 >+^+U']O77'6*T&><\P1G/7IG\CCZUSNU1V_4_P"-=5XLC$FN
M7)R1F*VVC) &($ZX^GO7._9SZ_\ C[?_ !-?38::>'HZ-/V4$_6S_)O7S/SS
M,(WQ^,?+_P Q-3HNZ/6/!H T*  8'GW7'_;=ZZJN8\( )HENO<S77?/_ "V<
M]?I73U\]B/\ >,0ULZU1I]U=*_WI_<?<8!6P.$_[!Z7_ *2PHHHK(ZSQWXM_
MZC1/^NVH?^B;2O&.Y^@_FU>S_%O_ %&B?]=M0_\ 1-I7C'<_0?S:OT[A?_D4
MT/\ K[B/_2H'X%X@?\E+7_[!L'_Z9D+1117T1\8%%%% !1110 4444 %%%%
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M,-7QGLJV8<9\4\.Y'6Q$E4@JBAEF&P^+KX:G%OVE3'8F%;V=*5.2XOI+^#&
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M^/D'Q$^.L?C2V_:$T;4]/\67H^%6EZ;XLTZZBN[+4/ L6C^*[KQ5K5Y9^$_
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M$S6A_O&'_P"PC#_^I%$^Q5Z#Z#^5+2+T'T'\J6OQ4_JL**** "BBB@ HHHH
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M#X-8%Y<J2R^NI+&QQSJ?7.3_ &%QEA&J2PBG=XQ-?6I0Y5A'&3DU]+77Q)\
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MZ63T]G=6;6Z6ZM=--_TDY_VE_P _\"HS_M+_ )_X%7\VQ_X+I?% ';_PSO\
M#D,.H/C'Q2O.>V;+)&WD%@O.1C(Y/^'Z7Q1P/^,=_AMSDC_BM/%(! Z\FQSS
M_#D#<>..,G_$*N//^A5AKK=/-<L36VZEB(R6\5K%6<H)J\HIS_Q'_P *5OG^
M+6B>N29HM&DT]:?5--=T[K34_I)S_M+_ )_X%1G_ &E_S_P*OYM?^'ZGQ/()
M_P"&>/AN ,?>\9^*1DG& ,6)SG/7@>^:!_P73^*/?]G?X;#V/C3Q5GGU_P!
MP/S)SQCT?_$*>/;V_LG#WUNO[4RVZM:]TJSVNKZZ75[7'_Q'[PJ_Z'V,Z[Y'
MFW2UW?V+5E=7=[*ZNU=7_I*S_M+_ )_X%1G_ &E_S_P*OYMC_P %T_BCC/\
MPSM\.,8)_P"1S\4D\8)X%D< *2<GTQBC_A^E\4>?^,>/AL<$Y(\:>*<8&#D$
MV()X(/0#L">,G_$*>/=?^$G#JUKWS3+4DFF[W==*R2U=[*\5=N5DO^(_^%/_
M $/\7_X9,U_^5?+IKHKG]).?]I?\_P# J,_[2_Y_X%7\VQ_X+I?%+@C]G?X;
M8(<C=XT\5)G8 1_RX$99CMQDL.I&"*/^'Z7Q2XQ^SO\ #4G'S ^-?%8P>P4_
MV>0_1NF.%SWX/^(4\>Z?\).'UT7_  J9;UM_T_MU[[)[\LDG_P 1_P#"K?\
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MH6\9T?\ 9F\96'ASXE6U_P#'35KSQE\9-4UGQ)\2/&=K\.? L"7_ (I3P5X
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C=#]#_*ODW]NO\
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MVE;XD>,M,3P/XDG\6'P%]JU%O _@;^T-%TVXU6VAUC4=8)N9+$^*_#_]F_\
M:B^%MK/>^%K'X67?BCX5?!3QQ\$O@QJ.I>*+R\L/&<_Q'^-NG_$:Z^(OBG3K
MO0+>'P\OA'P[910VWA.\;6DUGQ2GG/=?V7BOU(V#U[GL/\/\]@*78#U)/^>V
M<\?F??UJ.+K1IQI*%#V<8PBXN%3EJ<KC)RFE7UG4Y>6K*\7.+LVK1<<J_"6
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MB0R:7IOPE\*>#?!GAS5M(;Q[HVGZ;K/B34-!L)?!7[;WP \-^%OV?(K[QO\
M%35O$_@'Q=X2\6:OKNO^"[_QIXE\ 7T_[,7QH^&GQ-?P[)XI^(D_@/4=,U/X
MN^,_"NN:%X1\(>$_ 6CZ]X9TC3M6^)VM^+O&DVJ7>D?BOEL %B<;L \J W+
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M;XEKHB:I?> OAWX^^$+?%_XSV?PJTN;6OB!'\>OVHKOP;\7_ (M>%/A+\4O
M_C3PW;>"]3\"6OA[X=^ M#TW78?%?PWN;'2_&'@'Q]HRVMQ/&GX6_-G(;!Z
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MX$:A_P#)='_"!^$?^@1%_P"!&H?_ "71_KE@?^@/&?\ @6&_^3#_ (AGF?\
MT-,N_P#!6._^0/FJBOI7_A _"/\ T"(O_ C4/_DNC_A _"/_ $"(O_ C4/\
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M[27B#P_X<U[7]2\)/<V/PW3PCJGBW2[[P]<>')-!BT[3GT:ZTV6[TN;]N?\
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M:-#XF^,<MQX,U_P]XHL[7X;WFDW_ .W0\!^$  !H\("@!0+C4 % & % N\
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MD>.HH'C@O+J*Y_SGHQC.;4E)J%.I4<8NTJBIPE+V<7HTVU=M--1C.2]Y1/\
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M#G@'XE_%?2_%^@ZAJWQQ\?Z-J%F;GQ/!8>%)[R[\7:)J5U;^)/&-UX_^,O\
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J#,)8C&YAP[G6"P=",LBSFG"5;$XK+*&'I*52<*<95*L$YSC%/FE%2__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>drsa_011.jpg
<TEXT>
begin 644 drsa_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !J IX# 2(  A$! Q$!_\0
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MQ%K_ ,8O'WC/Q!X3M_&-IJFIVMG'HVD>$_#VEWFFV%A'!)<WLEYYLIB\:_\
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MKB*:WNXF"SVUU'+;7"I-$\:?D_HO_!.;XFV_C[POXRUB]^$%XNF_\%._B?\
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M&]_^>O7T+Y/^V?S?_P".4R2,JA8-D\ 9+@9) &?W@P 3DXR<9P"< G]H5O\
MGWA/_"#"_P"8?ZOX3_H.S_\ \/&+_P SY]_X0O\ :._Z++\._P#PR-[_ //7
MH_X0O]H[_HLOP[_\,C>__/7KGO'W[8/P,^&?Q4MO@YXJ\0>(?^$S,7@J;7F\
M/^!/'?BKPU\/XOB5J6H:'\.F^)OBSPYHFJ:%\/T\=:WI&JZ=X8G\4W>F0:A)
M932%X8(I)A[I<>./!UK%K<ESXO\ "MM_PCET+'7S<^)-*A30KZ2WDN8;/6G?
M40FF7<UM&;N.VO6MY7M5>0#:CLI_:%;_ )]X3_P@PW^8?ZOX3_H.S_\ \/&+
M_P SRS_A"_VCO^BR_#O_ ,,C>_\ SUZ/^$+_ &CO^BR_#O\ \,C>_P#SUZ]5
MD\:>%(H-:NI/%'AM+;PVD,GB.8^(=+\KP\EQ;I>0/KDS:@D&DQW-I(EU:RZC
M+:QS0/%*"!,@IS^,/#,=S86+^(M!_M#5HHYM*TQ-;L)-2U2.2T&H1OI=BEZ;
MG4Q/8G[3 -/CN3)$-\7G0L)0?VA6_P"?>$_\(,-_F'^K^$_Z#L__ /#QB_\
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M@[1M0U/6-3AU!K'2WMOL=W-%>7%K!*?VA6_Y]X3_ ,(,-_F'^K^$_P"@[/\
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M:ZO\.=-\1^)[^72X[/PA8MXP\/Z[IUV?$L^F26$.DW]Y?1V]M9W$R']H5O\
MGWA/_"##?YA_J_A/^@[/_P#P\8O_ #/1O^$+_:._Z++\._\ PR-[_P#/7H_X
M0O\ :._Z++\._P#PR-[_ //7J/X=?M3? 3XLZQI.B?#WXF>'_$MUK_@?PK\1
M= N+66YMM.\1>%?&VH^(=)\-W>@W]_\ 9+;4KZ^OO"VMJ^BV[OK%I#:I/>65
MM'<VQEZ*3X\?"I/B)J'PK/C714\::1X+D\?:O:27@33-(\/1^)(/");5==:9
M=(TS5#X@N8+%-$U"[M=5<3"=;7RXI0I_:%;_ )]X3_P@PW^8?ZOX3_H.S_\
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MH5O^?>$_\(,+_F'^K^$_Z#L__P##QB_\SPS_ (0O]H[_ *++\.__  R-[_\
M/7H_X0O]H[_HLOP[_P##(WO_ ,]>N2^$'[97P5^-EYXMLO"<WQ T'_A!]2F\
M/>)K_P"*7PN^(?PAT;3?%UG+:Q:GX(DUCXCZ)X<T]_'&D+?V-QJWA!)SKNG6
MES!=75I';W$4I^@+OQSX,T^SU;4M0\8^%+'3- NSIVO:C=^)=+@L=$U0&,'3
M-8O)KZ.UTN^7SH2;2]FAN7#_ "0G R?VA6_Y]X3_ ,(,-_F'^K^$_P"@[/\
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MJ*\U/4;J>ZG!,-E:S/#;1W%Y*J6UK/(A_:%;_GWA/_"##?YA_J_A/^@[/_\
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M^T*W_/O"?^$&&_S#_5_"?]!V?_\ AXQ?^8[_ (0O]H[_ *++\.__  R-[_\
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M:#Q3=1JQ>U\.RKJ!CUBX0@F2+3FNY$6*8O&I"!S^T*W_ #[PG_A!AO\ ,/\
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M_H.S_P#\/&+_ ,S-_P"$+_:._P"BR_#O_P ,C>__ #UZ/^$+_:._Z++\._\
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M1#D$$?\ +;G&T8SV '08H]E6_P"?-3_P%_Y!]:PO_03A_P#P=3_^2/P_N/\
M@D#JEOX!NO EGX_^$.IF[\"? G15UK6/A9JMCK%KXG^"/BSQUJFGWFG:AHOC
M*%]/\-ZEHGC.ULDTFX77(UU;PWH\EQ97&G0_9K/]=/@'\.=:^$'P7^&7PPUW
MQ+;>,]6\!^#=%\-7_BBS\.6'A*TUFXTFW2U^U6?AK3?]!TB 11GR[.V_=;55
M@%+,H]-_M;2LEOMNGY8 $^?#DA=V 3YV2!N; / W'CFE_MC2QP+^P X_Y>(N
MPP/^6W''%'LJW_/FI_X"_P#(/K6%_P"@G#_^#J?_ ,D;507./(?=]T;2V6"@
M*KJ26)Z* "6X?*@@1R$^6U%-9TYC@7]D3D  3Q$L2<!5_>GDG@<$Y(X--?6-
M.!"M?V8(+;@9XEV\<;@9LG/0>A(/&.5R5MO8U?\ P"7_ ,B'UK#?]!-"W?VL
M+??S'YO_ +1/[#OCGXU?M#^%?C7X=^*'@[P/#H;?#(V6O6_@36K/XT>"[3P!
MXEGU_7]"\(_$;PSXP\-6>N^'/B/:W2Z=JWA[XH^'?%UIX>=KN^\.PVPNKF >
M.>'/^"6JVL.F^%_%_B+X(>+? NA_&KPA\1;Y[KX%0GQ_\6_#7AKXM^.OBM>:
M)\<_&&I^*KJV^(.KZG-XR7P_'++I$/A](],N+R]TN[:ZNK*']?O[6TGK]ML,
MXV_\?$73YCC_ %W<NQ/<DY/(&$_M72 <B\TX<L?]=!R6)+9_?<[B2S9^\Q+'
M)))?LJW_ #YJ?^ O_(/K6%_Z"</_ .#J?_R1^(4__!'F\BTOXRZ99_&;0VC\
M<>-?#/C+PW=77@G5YY?$=IH'QZ/QU3PA\;+&+Q/#I/CG0OW@\':4;.UT^]LM
M/@M-0A\^*V.@2>@^!?\ @E38^$=3TCQ%+XZ\%7/BC0-2_9)U'PYK8^'U[<ZI
MX/M?V=]?^(FO>+/#WA?6]8\2W>O:9HGCN+Q^-,LK*"^MXM%T[3(X-2AU*QGM
M-/L_U_&L:6.!?6&../M$)Y!!!YFZ@@$'KD"D.KZ4QR;[3R<$9\^'H3DC_7="
M0,^N!G.!1[*M_P ^:G_@+_R#ZUA?^@G#_P#@ZG_\D?D9\-_^"65MX%U'X:^)
MM0\=^#=9\6?#4?LGP:)XLA^'3Z=XETS3?V=;SXKS>+-.T#6I=7O-3\.0_$J#
MXCV=L\=F\D>F'2'EU2U\0*\1@Y;_ ()G_LI_%_X(^+_B)??$;X5Q?"_0K/X#
M?#_X$:#J>HZ+\,M+\6>.M4\'^+_'VI:AXR\4R?#7XA?$&'QIJVHV'B/2;[6/
MB!JUWX:F\27]Q-)_8-A%;NT/[._VQI><_;K#/'_+>'''3CSL<<8X[#T%)_:V
MDX ^VZ?@$$?OH!@C&#Q-VP,>F%QT&#V5;_GS4_\  7_D'UK"_P#03A__  =3
M_P#DC\EKG_@EWIND_LG>%_V>O!/BWP;:^+?^$C\$:W\6O&GBWP?K_C3PQ\2(
M?"4?C6-[>U\):]XLU2#P+J#7'B_[?9ZCX4NK6XMY=/:SG?[-JJ&'#T+_ ()9
MZS%9:=H^N?&C2+NSC^&WP]^&FMR:9X'N4U*^L/!W['OC#]EF[U.WFO?%DR_:
M+V?Q:GC*PM;][F*"PLDTB0W$]T;BW_84:OI0 'VZPP.0#<1''YS>Y_,^II!J
MVD@Y%YIPY!XF@&,8QC]]Q]U>!QD ]11[*M_SYJ?^ O\ R#ZUA?\ H)P__@ZG
M_P#)'Y,_#S_@FMK0^(OPZ^(WQQ\>_"SXE3>#/%O@[Q-<>'=*^%%Y9Z#=WG@+
M]F-OV>?!]]IS^*_%7B=(==T2_AL/'\&LW,=X;?4K)(+&R@FM[2>'Y[B_X(P:
MU:?"S4_ <'Q;^'6H^((_&WA77=(\6:Q\//$SK/#X5\&_$#P?'XN\4:4?',NB
MZS\3]5@\>WEUJ^K76BZAH.M6UA<:7J-B9+ZVU#3_ -ZCJVDD8-[IY& ,&>$@
MA<8!_?<@8'!R#C!I?[7THG)OK#I@_P"D0\C()X\[!.0#D\\=:/95O^?-3_P%
M_P"0?6L+_P!!.'_\'4__ )(YOX>^&[SP;X)\%^#]4UE?$6I>%_"_AW0+[7UT
MRUT--:NM*TJ'3I-2&CZ>S6VF+?R6TMQ%IL#R6]C#Y<"2%5&[O7575D895@58
M>JD8(/L1D'V-8IU32V(/VNRW9'(GA#9YP0?./(R<<$\X'!J7^U;%0'-_:>6,
M_,UQ%RW3!)E (!]N#QZ&DZ=9-+V-1W:6D7U^0EB\+)M+$T-$V_WM/9?]O'R5
M^W'^RC<_M=_!O2_AOH_CV3X9^(] ^)/@OX@:!XTCTJ?6IM-;0Y+_ $CQ/IL5
ME;ZEI,V?%7@#Q!XN\'O="] LX=>>Y>&Z2(V\OR;X<_X)?:7X:\3_ !5U/3OB
M#I$WA/QS^T)\%?B3X/\ !MWX(>ZT_P"'WP@^$>K>*?%-W\%-+,FLR6DUOX@\
M>>._'/B=[Y$M+"&35XDO-'NDC$B_K*VLZ8PPU_8$>AN(>W3_ );=J;_:^E8*
M_;K#!()!GA.2 %!.9N2  !GI@8Z"G[*M_P ^:G_@+_R']:PO_03A_P#P=3_^
M2/QU^'W_  2HN?"FG_"!M8\;_"J^\2_!>U_99TCPGXE\/_"%M*U"VT[]G']H
M+Q!\6M8U*QGG\27,^D>+_BQX;UB+PUXJU;3[JWBN=;CO+^^BU#3+IM*KF=(_
MX)#E9[[3?$WC_P"%&O>#[B^^&5I=Z=#\&)8=>^(WAOX=_M8Q?M+7-W\7]4N?
M&%Q!XX\:^)=*6\\ ZAK?V"RLD@C2_DM7WRVB?M@-6TH=+ZP'3_EXASP,#GSL
M_P")Y/-']KZ5P?MNG\ #_7P] "H'^NY !( / SD<T>RK?\^:G_@+_P @^M87
M_H)P_P#X.I__ "1^+OBO_@E)XI\0_$GXP_$/2?C!\.O!^J^+= ^(^F?"Z]\*
M_!VTT#4?AOK6N_$CX>_$7X4>)[N/2O$.GZ7JU[\+YO \WA]%CT^TNM9T_59;
MJ#4;&5[NWDWOA+_P23\(_#>\\/6>L^-]"^)7@OPE\<_"?CKPWX2\;^ 8]8AL
M?@UX1\#?$6UT[X0W!U/6;RVN2WQ7^+'C3XAG4[^TDL)(;C3M/NM)^U6_VQ?V
M$.KZ401]NL.22?W\/)."3GSL\D MZD9.3S0=7TD];W3S[&: CN>GFXZDGIR3
MGK1[*M_SYJ?^ O\ R#ZUA?\ H)P__@ZG_P#)'YM/_P $]XM9_9^_87^ /B;X
MCO=Z-^R3XE\,Z[XFU?P_!XD\*:OX_P!(\-?"?XB_#NRT?PQK&B>)['Q'X$=+
M[QCIMXMU;ZK?,='TN\T-B$U%]GG/Q3_X)<:1XP^+/PSUCP/XA^'/@7X-_##0
M_ .A>&/A_<_#)M<\2:7I_A*3XEKXCTH>,GU^"XU[3O':_$R76[P>)FOKJSU'
M1Y!%:W@UK4KFW_6H:KI(QB]T_@* ?/AR N-O/G9XVC]?4Y0ZKI!ZWFG\ @?O
MX> Q!('[[@$@<#TP.,T>RK?\^:G_ ("_\@^M87_H)P__ (.I_P#R1^)&I_\
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M&*YTDZ;%!#'\+/\ @D[;>$+7X6IXG\7_  J\02_#/4_C=KEMI8^%,^K>$/\
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MPXT/Q?\ 9-,^&_@2WTVX:?P9H4,U_=RZS*QM'_9-M2TS)!O-./SEA_I$(R0
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MG_/_ 'W4E%=/L:7_ #ZI?^"X?Y'-[6O_ -!&(_\ "BJ1[?\ 9_S_ -]T;?\
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MI6YZ+6(Q*_<QO:O47-TN_>\K]=?O&[?]G_/_ 'W1M_V?\_\ ?=245U>QI?\
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M?5/S-)GMQQCH5[8]^QR0"/3I73?\(5XI_P"@/)_W^A_^.TG_  A?BC_H$/\
M]_X/_CU)YMEDM'BZ?DU.-UZ.[!9%G*:D\IS6ZO;_ &:"W5GZZ/Y;GAWB_P"#
M_P //'<OB"X\4Z!'J5SXG\/:)X7U:Z6_U&SN?[)\-ZT?%'AT6,]G?02Z?J7A
M[Q2(M=T76]/>RUBTO[6VNOMK31(5WO!/@?PY\/=!'AWPO:SVVGMJ-_K-U)>Z
MC=ZKJ6IZUJT\UUJVM:OJNHRW-_J6J:A<3%I;FYN'8(JIEB"S>I_\(7XH_P"@
M0_\ W_@_^/4?\(7XH_Z!#_\ ?^#_ ./4_P"U\NY5#ZXG%24N5U4X\R32;BW:
MZ3=M%:^ASPX7QU.K*O#(LQC6DI1=986DJC4Y1G)<Z5[.4(-^<(_RHYH'W&<=
M20?3/?/J1VY[4N3ZI^9KI/\ A"_%!Z:._P#W^A_^/4O_  A7BG_H#R?]_H?_
M ([2_M?+-?\ :Z>NNLX_YK0Z'D6<O;*<T2M;3"T]]6V[;N3DY2>[DVWJSFLG
MU3\S022",IS[FNE_X0KQ3_T!Y/\ O]#_ /':/^$*\4_] >3_ +_0_P#QVC^V
M,M_Z"Z7_ (''_P"2#^P<Z_Z%.:_^$L##L>;^Q(Z&^LOP_?H.?\]QZTR8XFN!
MW^TS'V_UMT>?3K^E=-9>$/$<=Y9R/I4RQI=VTCMYL!"HD\;,2/-(.U=Q)Z<?
M7+9_!GB=I9672)"'N)6'[V#_ %9:5E;_ %G4F3&!C&!R<USK,\O6)E/ZU2Y'
M"R?/'?FOW[6?Y^6\LCSCZFX_V5FO.L32=OJL/L4W15]>E-M-=9-2=FK/E<GU
M3\S1D^J?F:Z7_A"O%/\ T!Y/^_T/_P =H_X0KQ3_ - >3_O]#_\ ':Z/[8RW
M_H+I?^!P_P#DC#^P<Z_Z%.:_^$L#FLGU3\S1D]RGYUTO_"%>*?\ H#R?]_H?
M_CM'_"%>*?\ H#R?]_H?_CM']L9;_P!!=+_P.'_R0?V#G7_0IS7_ ,)8'*SQ
M)<VUQ:RLXCN[2YLYS!<36DRQ74<D4C6UU;LEQ;3A)&\JX@>.>"3;+$ZR(I'E
M_P )O@QX ^"/AY/"?PXL=5T?PY;P6EI8Z1J'B?Q!X@LM-L[(2_9[72;?7-1U
M#^R(/,GN+BZCMI)#?W4QNKF3SD)D]Z_X0KQ3_P! >3_O]#_\=H_X0KQ3_P!
M>3_O]#_\=I/-\M>^,ANG95$DW&]KI2L[7=KJZON92X;S65>AB)9-F;K8:4I4
M9O"T[QYTXR7G%WO:Z5[/I8YK.,X*\Y[]\_X?7GIQ1D^J?F:Z7_A"O%/_ $!Y
M/^_T/_QVC_A"O%/_ $!Y/^_T/_QVG_;&6?\ 0717I*"_]N-?[!SE))91FB25
MM,+#S?WZNYS63ZI^9HR?5/S-=+_PA7BG_H#R?]_H?_CM'_"%>*?^@/)_W^A_
M^.T?VQEO_072_P# X_\ R0?V#G7_ $*<U_\ "6!S)YSR/FQT/3'KWQ^>!R:O
MR9&EPC@_\3&Z_#%O"3]?NXX[]:V?^$)\3C_F$RC _P">L([<Y_>_R(]_2K;^
M$/$C:?#%_94GG"[N)G3SH1A7M[8(=WF="SNO3_EF.@; YZV:9?*5'EQ5)J%2
M$G[\=ES.]^;S6F^NQT8?(\XBJT993FJ4Z-:/^ZPO:K[&4OM::X:E;LE)?:=N
M,W-_L_F/_BJ7<WJ@^I_P)KI/^$+\4?\ 0(?_ +_P?_'J7_A"_%!Z:/(?^VT/
M_P >KH_M?+?^@JE_X''_ #1D\@S>VF5YJW_V"P_S9S63ZI^9HR?5/S-=+_PA
M7BG_ * \G_?Z'_X[1_PA7BG_ * \G_?Z'_X[1_;&6_\ 072_\#A_\D1_8.=?
M]"G-?_"6!S63ZIQR.IY'(XRN1G&1N7([CK7-W'A/P_=>*-+\;3Z>K>*=%T+4
M_#6EZF;B8M:Z'K5U8WVJZ?Y,<L%M+'/=Z98.DLEL;A%MT4S$$BO2?^$*\4_]
M >3_ +_0_P#QVD_X0OQ1_P! A_\ O_!_\>I/-LKEOBJ=ULU.*?IOL]+HF?#V
M:U$HU<FS.HE*,U&6&BES0ORRLIQ3<7*3BW>W,[-79S7. -PP.Q(P<'(. 3C&
M>,,?<4N3ZI^9KI/^$+\4'IH[_P#?Z'_X]2_\(5XI_P"@/)_W^A_^.T_[7RQ;
M8JDO^WH;]6]=_,:R'.%I'*,U459)?5XR44DHJ*YI2:C&,8QC&]HQ22T.:R?5
M/S-&3ZI^9KI?^$*\4_\ 0'D_[_0__':/^$*\4_\ 0'D_[_0__':/[8RW_H+I
M?^!P_P#DA_V#G7_0IS7_ ,)8',[F_P!G\Q_C6AI+'^U--SCC4+(\$$G%S$<=
M>^,#WQ6K_P (7XH_Z!#_ /?^#_X]5S3O"'B2'4+":72G2.*\MI)'\Z [529&
M+8\WG&,D>@[]#GB,URZ="O&.*IN4J-6*7-'5RIS26_5NWS-L/D>;JO0;RK-%
M:M2;;P].RM4AJUIHK7>NW4X]F^=@.\A;\&"$#KUR,'/'?H<TA)'3&1NSDCN<
M^H/Z"NG/@OQ1N)&DR')R!YL&."5R/WF.0@8#!X.,87);_P (7XHY_P")1)_W
M^MQCK@<2#GKG^E5#-<M2@GBZ3<:4+VG%=(JUK[KJ14R'.>>JY97FDDZ\W%QP
MM./66K]Z6EGUZG-;F_V?S'_Q5+N;U3\__KUTG_"%^*/^@0__ '_@_P#CU+_P
MA7BG_H#R?]_H?_CM7_:^6?\ 073^<H_YD?V%G'3*<U_\)J;.:R3U*=1W]#FL
M'Q-X;T;QCX>USPGXCM!?Z!XDTN[T36;'SI8/M6F7Z&*[A\VVF@N(V>,D!HIX
MI 0"LJ'YJ]#_ .$*\4_] >3_ +_0_P#QVD_X0OQ1_P! A_\ O_!_\>I?VOEE
MU)8NFI1:<91G%2BTU)---M.,DI1:LU))K8F?#^;5(3IU<GS2=.I%PG"6&I\L
MX-24H23TE&7-JGI>,'O%'@__  I;X;/\0H/BC+H4[^,;>YM-1MYWUO59M%MM
M:M?#Z>%4\1P>''NET0>)8O#0.@Q:TMC%>O89:27S9G"^J# QR/ID':-Q*KDX
M+",84.0&8#)4'&.D_P"$+\4'IH[_ /?Z'_X]2_\ "%>*?^@/)_W^A_\ CM)Y
MOEKMS8R#Y5&*YJL6U&"4815WI&$4HPBM(Q26MB(<-YI2]K[')<SI^VG*=5PP
MM-2G.<N:<I26K<GO?<YK/7!3DD]>W;I_7/UHR?5/S-=+_P (5XI_Z \G_?Z'
M_P".T?\ "%>*?^@/)_W^A_\ CM/^V,M_Z"Z7_@<?_DC7^PLY_P"A3FB\EA8)
M;)?I^9S63ZI^9HW'U3\#S^&:Z7_A"O%/_0'D_P"_T/\ \=H_X0KQ1WT>0#(R
M?.AX!."?]:>GTH6;Y:VE];I?^!Q_^2#^P<Y_Z%.:_P#A+ S7R-%M/^PI?<]L
M"ULL_P C@G ]ZR\G.<KGGKG';IZXQS]17;OX0\2?V7;6_P#9DQ=;Z\F8>9",
M1/'!%$W,G\?DY*_PY(YQDYY\%>)\#&DR-S_SV@&.,]I>2?PX&:YL-F>70A4;
MQ5)7Q-5KWX_"V[/?L=6*R3.)SI\N59H^6C#F_P!EAY/^;N^QS.3ZI^9HR?5/
MS-=+_P (5XI_Z \G_?Z'_P".T?\ "%>*?^@/)_W^A_\ CM=/]L9;_P!!=+_P
M.'_R1R_V#G7_ $*<U_\ "6!S63ZI^9HR?5/S-=+_ ,(5XI_Z \G_ '^A_P#C
MM'_"%>*?^@/)_P!_H?\ X[1_;&6_]!=+_P #A_\ )!_8.=?]"G-?_"6!S63Z
MI^9HR?5/S-=+_P (5XI_Z \G_?Z'_P".T?\ "%>*?^@/)_W^A_\ CM']L9;_
M -!=+_P.'_R0?V#G7_0IS7_PE@<UG(.2I)Z<]./?W Z=^?HGN2">>XQC&!WY
MZGKUSR173?\ "%>*?^@/)_W^A_\ CM'_  A7BG_H#R?]_H?_ ([2_M;*[M_6
MZ5WUYX-KTUT^75)]$/\ L+.DDHY3FD?>C)N.%IJ4G&565I/7FBY5I.46K2:I
MW^!7YC:.F2 V0>A!Z].1^> 3TXXKY>_:X\3+X>^&7AC2[CQ%K'@_3O'?Q=^%
MG@C7_%>AR:G:WN@>#Y?$2>+/&=ZEWHT4NHZ8MYX3\*ZIHWV^+RG@.O01>=;W
M$P"_9)\%>)\#&DS<<Y\VWQR.@S-R.,\@=O>E'@SQ2FUDTR4>6'R3+"V[<Y<*
MX$RXB!VL881$ADBA;:(T:%XAFN C.E5>,I5(-5(U*,JL-)N-2-*2?*W3Y7*G
M[R4U:"NGJWR8SAO.<7@L;@Z>59EAYUX*@Z\LOQ\83PM18>.+A4=.4>93HT94
MZDJ<H/V3J>S:YHRC^,VL?M#_ !=^$VG3Z3\-;?QAJG@_Q7X_\9^)_@U-\3O#
M^H^(M7U_X96L_P -?"6E^'++6?$%];>(+>QU?QSJOCWQ'I%A=:?J7BRU^']M
M9:PM]I>BI;_:>V\8?M4?';3O#'Q UBQB\/Z*/A;\2O'OPLU[6$\&76HGQOXC
M\+>*?%NJ/!\-4N[U?#RZEH_PRL_",-I9>*]4T70_%OQ"UG5_"EMJVDZI9V\J
M_K#)X)\3R1R*^F3.LJ2+*@GB.Y9$,<I#-/),LDT9=;AE<(00T,5LP=I,#PI\
M(9/ _A_3?"O@[P;9^&O#>E1S+I^BZ:J1:?;&\O)M1O)$ADN7>::_U&XFOK^>
M^DO)[Z[N+B>YDDDD4Q^RN),BE&E)83)958N3E6G7E*==R=-WKWY54O0ITW;D
MA'VDJM9)3E&*^2AX>\8TG6HT,SSVA1J4W2CAH99BE&FI4_9RE1HU88GDH2K.
M:C75:55P]G3<.6\E\8?%GXL?&7PQHW@B^\,+IEC)IGP*\3?&GXJWA^%NMZ[=
MWA\.VG@^UT3P=X6\&7GB'3)="U?7O$.N:C+?Z5JNN2ZEHNAZ?JL:SF]2'4(?
MF_PU^U+^T]XJTO6X-'B\,B?PG_PE>KW6O3?#>XU>U\864?B/X2^$/ GA_2_L
M&L6VA6D>K^*O$WQ$>\\1V5S?7$WA'PWI]W#!/+'<ZO-^P'_"&^*B 1IERQ5@
M^_SXC*74L0'E6990F<NWE-#*\D<3&<JDL<RGPAXJ4H1IERIC(,8$MM^ZPCIF
M/YQY>%<G"!4(C@4)Y"/%-S4<^R>A0E2K8?):T^:,H5E6G'EIJK.I*#C&:4F_
M:N'-*5XP45&+E%2EVXK@?BS$8J%?"YGG^&PR@H5:$,MQ,>><(*&'J:X:37+0
MA#F46E.I*4I)-VC^-^I?ME_'I]:GBTN/P;;6:R7#?$/0+OP;?6DGP TFX^)E
M]X,\-W6H^*-4O5T[Q?=:OX6\.:CJDVH:E90:%#XEU/3KV&ZG\//:07'UPWC/
M]HG7/V?OAKXM\.^&@?BIXB^RWOBG2],\-^%]11=#N$U5K+5)="^(?C[X5V6C
MS:G:KH.H:IIEOJU]?:9J]]<:99VE]8027X^GO!OP!TGX>/K#^!?A]I'A.37[
M@7FLR:/:VT#ZA*)9KB(3L\\NV"WNKN^NK:SB\JRM)KZX%M:PVWE6T?;OX-\3
MO\S:7-@L7WF>!CEE,8.TRE=NQF4AD? DEVE2P*;XGB#(Y.@L-0R:A3HU%6JW
MQ524JU-QFG3K6JI3I*4X\L4X2M"#G-SYW+++. ^,X0S%8_,>(,1+%X+$86E-
M8*=*. YZV&G3Q].-:@N:M3C1E3]UM_[55;44XI?G'^U)XJ^+VF_!;X1P7.L/
MX U;Q/XI>'XN^)9])OP^GV>C^#?$WB&Q\("S^%?B/5[K2KGQ_P"+-.T+PW!<
M^'?&DD$<[)86NKRO<1Q3>:?#7QE\7Y_B%HMS#HWQ9\7_ !(\+7NK6'BSX2ZA
MXHAT?2_#7P@T+X8^%-*\)Z=JVK>+'TCP9=^+?'_C*_N/&8\3ZA<1:EJEY'J-
MH6BATBYMH_UH7P;XI1B6TR7#!%&9;96*IED4-#)$JA"6** %5F4E'"L&/^$-
M\5@ /I<K#CY?-@4@*[L"LAF>0$!]J!WD$9,ODJD,@@CPCQ%E\,%+"2_LAN$J
MM5557;J\V(56/*ZEW4E"-*=.,(<R4'0H.,DXU'5Z,1X?<0ULZ680IYQ0I.IA
M).A]7]S#SP>'PD*-:C&,H0A6J5:$\3*HHRYOK=6$X27*H_G'XIB^)][\4?B!
M\6?AKX,^(&I^(?AIX5\.V</PJN/B+/:^&_%_Q>^(>BZ?_:7]J6NHZU:>!]3\
M(?!;PA?P:O<V7AZ:WA\4>*6GMK*_%Y:6<UO\H:/XQ_:&U2P^!-H^K_%/5?'?
MCAVUS0]*\2ZQ<^#]=T_4_$OQON[G5_B5XC\.Z#:ZWX8\2>";/X6Z5_94/@V;
MQ-#;?#VT6>VU;3#'XDTK5C^Y;>#O%+ AM*E#,4(Q+; *%=I2RJC)%N,CRR([
M1EDE=7.]8T0//@WQ2<DZ;<=,G][;8.5*3#".@831[8YMX;:(XS:&T)E,MT.)
M,!AZ3I/^R:C]EA*-"4JE&3IT\'2KPI1DY8:;FI3Q-2=?GGS5G"C&;4:,#GQG
MAMG^*Q-.LEG-*,)UI8B-'"TZ:JSK5Z=:=2%XS<*G+2A%33ERJ==1BE6ER\M)
ML,DA0G87;;DJ?E#G:001D8SCH " .,TWN2,'GC=@@<Y.1N&?3&1G)Y%=-_PA
MGB@]=)D/N9H <=L@2@9QUX%'_"%^*/\ H$/_ -_X/_CU>:LSRRT8SQD9\L>5
MWJPG%_#=WY8W3Y=):-Q?GI]C'),WCJLGS)/]VVXX6G%/V?LK6BI-1BW1BW!6
M3O):*5ES&#G)8L2#DLZLS$MNR[84O)DR-)*P+32.K,%,29<#C. ,]OF'ZG(/
MX=.!WR:Z7_A"_%'_ $"'_P"_\'_QZC_A"_%'_0(?_O\ P?\ QZKCFN5PBHQQ
M-.,5TC**7W79+R'-FXMY/FC<$E%O#PO&T'337O6NH-I-IVNV<UN;_9_,?_%4
MNYO5/S_^O72?\(7XH_Z!#_\ ?^#_ ./4O_"%>*?^@/)_W^A_^.T_[7RS_H+I
M_.4?\P_L+..F4YK_ .$U-G-9/JGYFC)]4_,UTO\ PA7BG_H#R?\ ?Z'_ ..T
M?\(5XI_Z \G_ '^A_P#CM+^V,M_Z"Z7_ ('#_P"2#^P<Z_Z%.:_^$L#FLGU3
M\S1D^J?F:Z7_ (0KQ3_T!Y/^_P!#_P#':/\ A"O%/_0'D_[_ $/_ ,=H_MC+
M?^@NE_X'#_Y(/[!SK_H4YK_X2P.6E.4<9!)0#CIG>I_E7UQ8Y:QL\#K;0>G:
M,?XU\W/X+\3X(;295!PI(E@. 74DD>8=V .!W]?3Z4M4>&UMD92K)!$A4CH5
M4 YVDC((['OCJ#GX_BS$X?%QPLL/5A545*_+).VV]F][JQ^E^'>7XK"SS)8S
M"XC"\\:=-K$1]G.<8OGC:-N6+3D[N+=U:Z6IH-$K$L2V3CN.,8QC()!XSD'.
M>>M B4=V)]2S']"<?I4E%?(M7W_-K\FC]0Z6TMZ+\[7_ !&;!ZG]/\*3RU/=
MOSQ_*I**GE7;\9?_ "0$?E+ZM_WT:7RQZG\__K4^BCE7;\9?_) ,V#U/Z?X4
M;!ZG]/\ "GT4<J[?C+_Y(5EV&>6I[G\\?RI/*7U;_OHU)11RKM^,O_DAD?E+
MZM_WT:/*7U;_ +Z-244<J[?C+_Y("+RE[EB,8P6)&/\ /]>Y-'E)QC<,=@S8
MZ8S@D\^_7@5+13LK6UMZR_\ D@[^;N]7J^^_D1^4OJW_ 'T:/*7U;_OHU)12
MY5V_&7_R0$?E+ZM_WT:/*7U;_OHU)11RKM^,O_D@(_*7U;_OHT>4OJW_ 'T:
MDHHY5V_&7_R0$?E+ZM_WT:/*7U;_ +Z-244<J[?C+_Y("/RE]6_[Z-'E+ZM_
MWT:DHHY5V_&7_P D SRU]6_,G^>:3RE]6R,\ECGG/'7ISC'I@= ,244[+\^K
MZ[]0ZWZ[$?E+ZM_WT:/*7U;_ +Z-244N5=OQE_\ ) 1^4OJW_?1H\I?5O^^C
M4E%'*NWXR_\ D@(_+7U;_OHTNP>I_3_"GT4<J[?C+_Y(!GEJ>Y_/'\J3RE]6
M_P"^C4E%'*NWXR_^2 C\I?5O^^C1Y2^K?]]&I**.5=OQE_\ ) ,\L>I_/_ZU
M(8U((RPR.H."/0@C!!'4'UJ2BCECV_&7_P D%B/RER3EN>Q8X]./3\/KUI?+
M7WZ8Z_XYYI]%.RU\TD]7LMEOT_KS222LE97O;7?ONQFP>I_3_"D\M?5OS-24
M4N5=OQE_\D,C\I?5O^^C2[!ZG]/\*?11RKM^,O\ Y(!GEJ>Y_/'\J3RE]6_[
MZ-244<J[?C+_ .2 C\I?5O\ OHT>4OJW_?1J2BCE7;\9?_) 1^4OJW_?1H\I
M?5O^^C4E%/E7;\7_ /) 1>2F<YDSR/\ 6.>"<XY/0=O3 QT%+Y2_[70#[S'I
M]2:DHH22325DW=J[U???];>0=;];6^78C\I?5O\ OHT>4OJW_?1J2BERKM^,
MO_D@(_*7U;_OHT>4OJW_ 'T:DHHY5V_&7_R0$?E+ZM_WT:/*7U;_ +Z-244<
MJ[?C+_Y("/RE]6_[Z-'E+ZM_WT:DHHY5V_&7_P D! ;>,DEBQR=QRQP#G/'0
M"O._B5K/C?P_\/O%VM?#;PC!\0?'NF:)/=>$O!EYKMKX;L?$>N\)::9=:_>*
M\&E6DC,LMQ?2HR00%B>1SZ748BC4@A ".A[C( .">1D*!QC@8II6DY+2323=
MWJDK+=M:+LD)I22B[M1NTN:5E??[2^YW72UM#\][K]O?P5H6K7/P[\1>%O$,
M?QIT/3)=/\3^#=$MTUS0],\?VLVB0ZEX<L=<2>(ZC;Z99>(=%\4:A>1)NM/"
MNO:!>70ANM=TFWNJ>B_MXV-R^C:KXD^%GB/0_">M>%M3UFVU*QU?PWK$KZI)
MXU\:^&? -G*\&JV\*)\2['P7-J>@H=QT;^T[-/$D^F0$W%?>C>#?"#7\^J-X
M5\./J=S<7-W<:B^B::U]<7=['HL5Y=37;6QGEN;R+PWX<BN[AY&FN8_#^B),
M[KI-@+?._P"%:_#H:;<Z-_P@/@K^R+R&[M[S2O\ A%M#_LVZM[][^2^@N+'[
M#]EFAO9-5U22[BDB:.X?4M0>97:]N3*UHTU9-62=EI:/*K:?RZ>GW@DEJKWY
MN:_-*_-S<][\U_B]ZWPW^S;0^$])_P""@.APZ%J&L>+/AKXBM&&K>*H--;1O
M$/@6]TB[T_PV?$VK3V@\27WBJUT/4M3L_!?A34_%%W=:5>2Z'J!O_#6D:#?:
MCJNN1V]OUC?M]?".XU?Q+X9T'0?'7B3Q=X5O+'3=4\,:78Z3#>C4+J[U+2+N
MVBNK[5[33/*T#Q%::=X8\0W\UY#8:3K^OZ9I4MVVH6^JVMA]@3_#7X<W.G6&
MD7/@#P5<:3I5[9ZCI>ES^%="ET[3=0TZT>PT^_L+*2P:VL[VQL99;.SNK>*.
M>UM)'MX)$A=D.BG@WPA'<W-['X5\.1WEYQ>7<>AZ8EU=?\36^UW_ $FX6U$L
M_P#Q.]3U+6/WCMC5=0OM0_X^[N>:1WT:Z/=65GZZ!RJUM;*UES2Z)17V^D4E
M\NKU/C+XC_MN>$/AI??"W6-=\.:RGPZ\=_"N/XG^(M8A^Q77B7P38ZNEC+X7
M@O/#,&I'4-:&H*VL1:@/#4.M2:?_ &1/?S>7IL<]TO+7'[=LMEXFMXM9^#WC
M;PSX;?P1=:^;#Q,VA:1XSO-7M8]>\2ZDL>G7OB"VMM-T#0?ASX5U/Q4EUJ!&
MH>*9=6T+3-%LENYI$;[ONO ?@>^O++4+WP9X4O+_ $W2+OP_IU]=>'=(N+RP
MT#4+=[2_T.RN9;-Y[71[VTD>UN],@>.RN;=W@F@>)BAXS2/@Y\+]&6YBM? G
MAR2WN/$.E>*;>QO=%LK_ $W1]<T2TATS0KOP]IU[!+8^&?[)LT>'1DT:VM!I
MK7=U-&T<EQ,\DR2E?F2=XN#NMXMIN+\KI.WDAW?=[):MO1;;M_UO<\;\"_M;
M^&_B%\1](^'/A[X<?%&XGU6&\U>3Q.='TZ3PUI/A$WWB;1_#_C36[RWU>8Z9
MHOBO6O!GB?3M(@N-NL!K"UN9M/%O?*T7G-O^WKHJ:'H>I7OP;^)M[JWB:RM+
M_0_#WA";PQXQO-2'BCQ3\0=)^&FFV4NFZXOVC7_'GACX>:QXR@TTPQKH>FM:
MP:U/:2WEL\OTQ'X@^#%G82?%":\\ Z19>%I-8\(MX^OK'0M$31%AU?RM5T6U
M\27\-A+#IQUDW,=Q!IETUAJ%_)-<*DDK_-IMX8^$UM;:-H\_ACX;P66NWUCJ
MFC:<_A_PU'8ZKJ6E07.OV-_IUJEB]I=WND1G4-:@NX#+/IRS/J,-S&MTY)97
M;LKRMS.RULDE?3HDDO0'JFGLU9^:_KS3\SY;U3]OGP/:ZZVG:7X!\7ZCI%AJ
M_B./6M??6?"%JEAX3\(^"_'WBWQ%XHM])7Q%<ZM/<6$G@"^TV'PS<VUCKEY_
M:>EWD=JL=];1/<A_;M\+O-%I-Y\(/C3:>*[[7M!\-Z%X,LM+\.:_K^OZIJMQ
MX\35$MO^$?\ $VJ6%G%X:M_ASXFN-4?5KNQ-P([-=/6Y2=)3]/7?@SX3:/+:
M07_@OX=Z;)XD\63W-FMUX6\/6DNL^-=4T[4FN+J*'^SB=0\2W^DV^J?;+T,;
M^ZTQ;YWN#;&05L7WA+P+JLJ6FH^$_!^JW%G?66N"VO\ 0M#O'M-3CEOY=+UD
M1O:W'V:]CN;S4GL-0<177FW6H&TFDFGG!??;7?1:].W8/T/FSP!^V/HWQ+^)
M/A;X=>&?AGXU@E\27FIW$FLZ_>>&M*MM/\'V_A*/Q5H_C!;&'5K^]O+;7DN;
M""WT9%CUJQL=7T36=2M+>SU:T#<3X=_;Z\$:SXBU\7.@7=IX+%KX#;P%JL.J
M>'K_ %SQU-X[U_P]I.D26FCV6MSRV4FIV'C+PQX@T_PW<(/&,&AR:E?ZKH=D
M(K>&7[&L=*\"#Q')#8Z-X03Q9X?M+#57CLM+TE/$&AV>MV;^&=.O@(;:/4=/
M@U33/"UQHMK<^9']MT[P\=.0&TL([>"DGP[^%FA/IU[;^ ?A[I$NF:]=:UI5
MU'X2\.Z;)I_B76IHEN=7TZY.FVZV>O:S="%;K4+>6&_U"41CS;F81@SRQ[?B
M_P#Y(+(^;[C]M/01\-/!OQ6M?AIX^@\*^./BA;^!M'D\31:+X3N[CP<GA;Q)
MX\U/XK6%MJ^J)+J/AVW\$^%]5UFRTM$AUG4YHH[&SMI#(;@'B+]M?PGIGP?U
M;XE:9X0UVZUJ'Q%XJ\&Z)X.OM4\*64FJ^)O#?AU_%'E+XB?7U\,2V4VCO92M
M'8:Q=ZJVJS7/A>VTZ?Q'8SV%>X:7/\")]'TG1M)'PF/AG3O&$&EZ#I-C!X23
M1+7QQJ-G=75G8:-IPABL+?Q=>V=W>SPPV,(U*XL[W4&1F$TA/1V?@KX9ZMX<
MT'2+3P?X!U+P=I,EMK7AG3(/#6@7?AO3I1-/=6FK:!81V+Z?ITR237-S;WEE
M#$[7-Q=S02!O,+G*NWXO_P"2%9=CY'A_;R\,Z=I]C8Z[X)\3ZKXXU9=*A\,>
M%_!5DVJW7CK4=3UCQ=I:P>#K2:0WVH:?;)X(UN[O=;GBMM*M&ETFQN;B"YU2
MS,VE+^WQ\*;:\N%OM'\1Z?H-MXDM= G\5W5WX8?2[6.XT/QIJZW6IVNGZ[?Z
MEHFHS7'@36=%T?PQK-I8:[XAU:33K/2K2>YU/3XKKZL?X:_#:X%T)_A[X!E^
MU7VCW>H+-X2\/O\ :M2T1 -"NKHM8,);_28)E&CSSYFL/.5+-X0Y6L^R\%_"
M2YUK5#IOA#X</KNCZE<ZMK$UGX;\,C5M/U?Q3I327FJ7TBV'VJ#4_$6CW$BW
MMY,ZRZOI=U,MQ</$Y1GRKM^+_P QG@]W^V1X3TWX=_#[XB:MX"^(&BV_Q*UW
M6+'P_P"'=?MM$\.^(%\-Z'!<7M_XWNK;7=9T^,Z&VF0PWVG6D+R:[JG]I:5;
M6.E3W%_"'YBZ_;V^'FGP:#=7_@CQW9VWBMM,7PP9Y?!Z7VM?\)H^K?\ "IQ#
MH_\ PE/]J6D?Q-MM(EO=*O+^WMK#P[I^HZ%>>,KS01J\*Q_16N_#?X)Z-_PC
M7B;Q'X2^'VCZ;\*K'6(?",VJZ7H6F>'/ R^);G2GU2]TO3KB*WT31;R]GTJP
MC@U.UB@U#RGN[.UD7[;>)<<1\0KC]F.:T\4>'?&NK?"K2;NS\,6'@?Q+ MUH
M&E^*-'\*RPV>LV'A1Y+6-]:TW1%LQ:7Z>'TA73_L;K>?9(K=G>CE7;\7_P#)
M >46G[>G@O4GT&WT;X9?$_Q'>^)-5M/#>DV7A>+PIXDEO_%)76-1U;1M/ET3
MQ)?0:A;Z1X8T2X\4/XFMI#X5O[#4M!M['5Y+G5[4 U_]O;X;Z+:6TT^A:_ID
ME]'XVDMEUE;;[1$_@/QKIO@W7]'ET;3;FYUBY\6Z<U^==U;PC8PSZ[H_A]['
M6;BWFTZ\6XB^AI_"GP'^&_@WPCI&I:#\,O"O@70=0\.:?X.77K;PW!H^G:U;
MVD>C>$6TF]U9)D;7'L%%IH]\MPVI-"SQ)<Y;RSEV-Y^SAI&H2&Q;X'Z=>:=K
MEI\.6>RB\#V-UI_B>XFN]2M?! DMX \.J22RSW\/A\B*[665[H02M</*ARKM
M^+_S \L\/?MI>"_$OBW0/!UKX)\;0:UJOB>/PSJ?F/X/OM.\*G4;;0KWP_J&
MM7VF>)KZ&\36(O$5C;W6F:&^H:KX?U+3O$VF:S:6U[X>NE?[2C164DMN(9U)
M5AC*L05.TD!D8%&!.=ZL2 217GG@K0_A;):(O@C0O 'V#PKJ=YH=O_PBND>'
M([3P[K.C:AJ2ZGHT*Z3"(]+U+2-3O]2-W:1QVSVUWJ%Y+M$MY<Y])550848'
M)QSU/)//J>3ZDDGDDTU[NVGS?ZMB:3W5_P"O*WXW'4444#"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>drsa_012.jpg
<TEXT>
begin 644 drsa_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #Z IX# 2(  A$! Q$!_\0
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M+69I['?';"V@MXK:*)?OE(0C;@S$[=OS'.!G.!]6)8EMSDGEC4U 'YC^.O\
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M&3DA0Q"C)^8DJ Q+$DLQ*X38JRT %%%% !1110 4444 %%%% !1110 4444
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M:AX]\>:KK/BC6+72H'DCA74M1G=58J2"69OU]4;5"Y)P,9))/XD\T +1110
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M6".14W:S:T;4%;=2EMIU5M_,6E]55M&+FW"$'"R=O>E)KE=]5:]U?9V/S_\
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M#^UTOP_5'6/^"L/[0UUX]\-IX7^&7P-U31_A_P#!KXM_&;XQ^'/#WQTD\1>
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MJ%A!KOAK4=*UVPAOK4O:WCZ7J%K/+92W%MO>.9T;T9_N-U^ZW3)/0]  23]
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M%SG'0D@J>C+EE)4$C\B/^"77_)=O^"Q__:4SQ1_ZR#^R30!^OL?^KC_W%_\
M0161K>J/HVD7VJ+:_:Q8VTUW)$+FUL ZP*9'WW5_+!:6R!%)DFNIHH44,SNH
M&3KQ_P"KC_W%_P#011(<(QR1QU!(/4="&7'_ 'TH]3C-)M)-MV23;;V26K;]
M$!\Z^"OVB/"7C[Q//X4T!=/OM2LK^TL[M;#QSX U:2-;K2-.UIKZWM-,U^[O
M+RWAL]3M/M$ME!*\<LLB8#HV/H:+<&;)!Z@#C*A3M(7!)*D@L6;YMQ(;H /-
M_!4LK>*OBXDKRA5\:Z$\2LZLJ(WPN^'Q8*5#;2THD+;%$98%E)8D5Z3#C&%!
M P#ZX/0@L>6)()SC'H<Y%/\ R3^3U3]&MGL^X=+]+VOTOV]='H34444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-;A6/\ LG^5.I&^
MZV>F#_*D]G:][.UM7>SM9=7?9=79=0>J:6[32]7HBHT@Z-@  $D]%7@DGTZG
MYB0 >3P#7,Z]X3\+>*1:?\)-X9\/^)!9-*+1M?T32M8%L)0!,T']HVMT(0X4
M++Y7E,^T;V.,5TTPW*P1<L=I)ZE3D$$'GD$YW=5]L<_A)_P5T\5_\%7_  SX
M8\-3?L2^&T?PT?',J:IJ_P (+(^,?C(VBQ^'E?35USPKXATJ;1K31Y=7;5EN
MK_0)-2NB8-!CNOLT<\ZU]5P)PA+CWBG*N%*&?\+<,2S2JZ?]O<89M1R;),%*
M%'$UJM7'8VM"K&C3<<-*@GR2O7Q%"G;W[KU<ERJ>=9C1P-+'X/+)2BX2Q68X
MBEA,*FJ=2;<JU:4(+F]FX+WE[TX*]Y'[EZ7IVF:-;0Z5I-AINDZ=;*8[33-.
ML[73[2V1F9G6&RMH88(D>0RO^[3:Y+N.^.:N?AU\/[GQHGQ(N/ O@R?X@6>F
MS:+;^/9_#&AOXPL])N8EBN-*A\4-8_VS#I\D _>VWVTVYC=H#&%?8?E[]AK4
M?VOM1^ _P\N_VQ?#_@70_B9-\/O"%SJUOX7O]0G\2IXBFTI7UU?'%B]G!X=T
M;Q,S-;RZQ8>'K^YTRUUR75K&UN7L[:&=_P X/$GQD\0^%?CC\9K_ ,9>+OVN
M-=_;0\)_M&^*3^SO^S+\)H_'5S\+_B#^S_I_A9[WX=6VJ>$VTD_!JX^"7BG0
MAJ>K_%'XNZK>0>-/#7C&&?2=(\16WCF'P[X0UKQ<WRR62YQF>32QF59C_9>8
M8S QS#(\7''95C:6&JU*-/%X/%QI4(XC#8ATI5,/6ITO9U(2C)2O>_)CL*\%
MBZ^%]IAZ_LIN#Q&&JPK4JKBVN>G4@W&<&E=2BVK-:M--_MKI'PM^&'A_39]'
M\/?#;P'H.E32Z\]QI.B^#_#ND:;/)XI9%\32265CIEO#))XF-C;_ /"0220L
MNM111+?&\$:;)K3X<?#RPUK5_$-AX!\$6'B'Q%JFG:[X@U>Q\*>'[37M;UK1
M4:#1=8UC58;**_U/5M'24PZ9J=S<RWFEJYBMI5#[J_G3;]L;]O7X@^*-!\;?
M#GXA:?XD\/\ PD^$_P >?B!JWB[2?V>_B'HOP\^*_B2P^$_P2\?:]^SQJ_P\
MU+5K'47\:?!_QA<ZUX3TSQU;WEY>O'XQU3P[;Z')X^\*>.-/MO4K/]NK]O#Q
MO\0]!^&W@BP\)>'_ !'\0?C;#\-OB1INH?L^^.-3E_8=TZ/XU:_X(\-:)XTO
MY]9TC2/BKJOC_P"%VGQ>,M%UYKS1-!-V&\3Z4DO@'5-)>\X#E/W2U+X5_#'6
MO#=QX+UGX=^!=5\*7^M2>)+KPQJ/A'P]?^'[KQ$VI?VU+XAGT*]TV[TU];;6
M7&L?VE)9+>Q:G+'<^>;HJY] LHHX56&%((XH(D@CBA 5((XLHL*(H6...,JT
M:1Q(D:*BHJX4 ?S]^+_C1^W=?_\ !*_1+OP/9_&SXN?'O5[_ /:)\+?';XQ?
M#'1?AEX*^,OPATCX<>(_BG>V:^&_ /Q.\9>!([[Q;XAO]%\(_##0;[P[!XBO
M_#OA_P 177CW3-!UZZTS2+?5?W.^$VJZMKWPS^'6N:_I>LZ'KNK^ _"6HZQH
MWB)[-_$&F:G>:'8SW]EK;Z=J&JV#ZI;W3R)>M;:G?H+CS0+F0?,P!Z)1110
M5\N?MM?M*:;^QU^R3^T+^U'JWAJX\9V?P*^%GBOXB_\ "(VNHKI$WB:\T'3Y
M)M,T(:PUK?KI,>J:DUI9SZI]AO386\TMT+2Y,0A?Z:6<MD!&)P,85L9Z-\Q
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M^%WP:TR+4?&?[+'@KQ9'X7T_P=XX\0VUS?6&H6WBC2K'Q1X[TS1[C7(O<O\
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M?8_4=1[T44 -5%7IGODDDDDXR23D\X'M[4ZBB@ HHHH **** "BBB@ HHHH
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M"'Q7:>#KK4;#19_B)<?#'P#:0R>,-!\.7^L^)_$UY;ZE%^J7_!(_]O/XW/\
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MC+-'T'4,8F96XR&Z<X !/1110 4444 %-90V,Y&#D$$C!P1GWQGC.>>:=10
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MUNNG:MHGBC2&\8>)_!NEJK%H]6AN6DO?&?AG3U5C8:Y:M/XX\-3BWN!_;,,
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MV*Q6(R;,,SH9=6J1J8&&:X&6(Q<HM*,U66%J4)THJ5[5I0FFFDZ?,^9_:9=
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MXY;PGX@FU:/X<^&8O$YU_P -Z%<>&[58]0\*Z]JD>K:-J.HZ[IS7-O91-/\
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M]N_XY^'/AA\ O$-Y\;/@'=^*O$&N^(O OA/PQH.B#1?$UKXV>P\>:!XXO_\
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MIRM&K1J\N+PU6FK6I3PV-6*H)::3A3IU%>\:D6DSP:Q^/?[0O@:ST[5/BO\
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M?M$?!/X=?%C2[O6_#R?$KXT_"33]4\??"KQ-9^-M3^),T'CKQ+X>N?AWXO\
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M?QYX(N[W7_#L\WAOQ?;^%]=\3>'8=>TXCRKU-#\0ZYIHD(^SZG<J2X_9X?,
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MS'-;+<7%HUQ!-&ES;K;&XMGD C6>V^V07-K]HA5RR">WN(\?>A9=P/S#X=^
M_@G1/B!=^-M)^,7CN[\5:C9^']*N[0ZS\-+Q+FU\)7OBJ\T^V&F6W@03H8;C
MQ7XC6[-IY<T_GR>9LFM_/;3#SJX>G4IT*E7#0KQJ1Q%&C6J1HUU4ES25>FJC
MIUTYQA5C[:-10J0A.FJ;BU+5\LHI<L;<RD_=C>36GO-Q<GZ76R/"/&/_  3X
M73?%&I?%']F;X\>/?V9_BYJFJ-K>MZ[H&C:#XK\"_$*_;,TB?%KX6WD.AZ!X
MYCO[ERVIZJT^F>,I%)DMO%-K=F.XAP=6_:]^._[-\]AI7[9_[/\ =7O@X"W1
M?VI_V8I+KQC\%7FMIP3-\3/AMXGFL?BE\!9[F%U!.I7OQ&\ VSH88_B2LA%F
M/TZ0'8AP,*JY*@ #*@X49;"KP  6ZX!/!->6VBN8I;>:..:">)H9XI$5XIX)
M4\N6&>&3?'+')&S12(RGS(F*.6)##W:/$_/##8//L)@LXPU&DJ-!5IK 9WA<
M/3@Z4%A<[PZ5>O[&$:<J%#-H9KA8*C0PZ6'PZE[.'2?,Y4)K#2;3DZ<813U5
M[P<)4_>5[\L(2;>DT]5XGX0_:/\ @MXST;2-?T?QKIT.E:_!%<:)J&IA[#3=
M6AF7=&VEZQ,&T34D89^>PU*ZC4JV6&UJ7X^2Z+J7P(^+&NSZ\++2-'^%_P 1
M-9_M[3?$C:386D%IX+UMKFZNM:LIXK:"QM;<2SW-Q/.;:"-#/(%1&8>!>./V
M'/#NE:QJ7Q _9;\;:A^R_P#$+49I+[Q%HWA[0;+QE^SS\4;R643%/BW^SOK5
MQ#X4U2>XFW?:O&OPYO?AI\6&C9(&^($UA"NGM^(/_!63]JG6?V=/@KH7PG_:
M&^ 6G_"/7_B?J'B6U\;^//@C\6#8? ;XT^ M!\)>)M1D\)W5FFEW?CW2=%^*
MGBNP\+^$/%7A?Q5\/]2ET#2/$K:0/%_B""\?4G]K(. \?QYG>#RGP]G5S_-L
MVK.CE_#Z>$H<0^UC3G6G&%.NX8?-J=.E3J585\BQF*JNE2_X4,JP<J]-2J=1
MX>/MJDG)TG&2J<TKQDI1Y9).3AS1DXN+E&332:5TK?U">$=/L+'P_ID%C=75
M_:7%A:7D=Q=:C/K3R&[M;>=)([VYEN/-MWC*-!LDDB2,@PMY97/0FW<.98VE
M10%!A4/&K8 !+!<+C /&P$GJ#7XF_P#!)CXC^#/VCOV;=.MM5^+OC36+[PCK
M=UX<\'Z#:?M+IK>I7?PL2*!OAY>3Z!X,N_#&KZ#8QZ6[:-I5EXKT+3_$D^DZ
M18ZGJ,4<E\(4_5R+X%?#7RR]UI7B2]#'<XUCQ]\0=5)('_+0:CXEN 1G@KMV
MG@#Y2!7S&?Y!F_"N;8[(.(LNQ&69KE6)J8+%X3%4).-.MAY2C4FZMZ,9<LN=
M*I!>QE4]M1513P\D-5(UX^T<G-SDZDG-\_-.5^:;32BJDGO))/S5W>WXT^#W
MP;\<^9)X\^&?PR\5._#/XN\(>%]49W)R7,FKZ9>ON?)))YR23GO\^W?[('[%
M=FTL^G^ OAYX/N)$)6?P9XLU'P#+&!@^9#%X5\1Z- BIP=B1J"0.0<&O>T^!
MWP>7>S_#OPY=G)W-?VTVIB1FRV2;Z6Y.23F61PH#$_,QP:U;;X4_"NP02VOP
MZ\%PR1C=$8O#.CAU( *A3]ED^<MP "23QC-8X?/<WP<+X?.\SPV&E.E=83.,
M51PE2<'-4EB,.\=4P]10<VJ<.6JE>4>6*]V7?1S+'X=<M''8NDKQ?)3Q6(C'
MW?A]Q5W!6N[)12[IJQ_+U/\ \$Z/@;H__!9_P?XRT;]K+Q);VUG9V7[0%EH]
MW%J?B&6RUKP_%9V%C\')_C]?^,Y8AJFN:;%<>*K#PI<Z#=WUO\-M&OK.6[*Z
MAI<MQ_5-I_B#P]<EOLGB#09U8$(EIJVF3!<,O:*Z?YFSG:NT# 1P[*)7_*W4
MOV//@9=_M*R?$UM9_:<@O[G7I/C5/H-IH_AT>$XO%6E^+_#UK965I:GX5OK$
M7A\6EK'HITJ?Q!*TWAK_ (E5O)'IAE,_Z4_\*B^%FI%I[KX;^#9FE8R!IO#>
MEK([LS$O*BVX N')=IW4)APL?)CW5]/QUXE\7^(\>&*7%^>+.:G!7#.#X3R*
M,<+@<+6P'#F$FZBITYX+ 8..,QLI-.MB*\J^):474G%35^K-\]S'/7@99E65
M>678:&%PTE%1E[*G*<HJK)3FZLKU9-N3C>ZM"-G?U.!U*[D(=6(PZ$.A&/O*
MP)!7IT)//0#I-N/9'/\ WR/3LS ]_3L:\?\ ^%#_  D?/D^"[+371\YT:^U?
M1&5L<%'TG4;-E('0HRXQ@<#%1R? KP:@SIFL_$S0G!R'T?XM?$F$+D8(2WN_
M$]Y:*#W"VX!SSFOC4[ZWFU)N474A&$^63;CS0BW&+47%-)O;5WN>/W\VW][O
M^O\ D>P>>A;: Y(8K]W@D*')4Y^<;6!PFXY.W&\%17MM2L[V"TN[.>*\M+^*
MWGL[NTEAN;6YMKJ$7%O<V]Q!))#/;S1.DD<L+R*\<B3(6A/F#XG_ &C/@U\:
M7^$/C'1?@+\3?BS?^.O$$-IX;@M=;\?^%XK?3O#FM7T%GXJU>PU;Q5X4OI4U
MNS\-3:HF@N=8L[B#5I;.]%V7LTCD7]A;X=?%GX/?":X^$OQ-\)Z;X5\.>!/$
M]Q8?!S3K#Q79>)Y=)^'%ZD>IVOA"9[ SQVFD^!M;FU+P_P"$(+FZEDA\(6_A
M_3$B@;1XGD8'W+1110 4444 %%%% !1110 4444 8RJX+1L<GRBH^4 86,+R
M>@+L&VG&0I(YW U_/-\<?V=/C9J?_!0G7_$NE? OQAXBN=?_ &C/V9_C?X(^
M/5CH5G=>&/!_PB^$'PQ\0:!\1_!TOC4R1W.C:U>WTU[H]EX "Y\5)XKCN[6*
M[6*]DM/Z'G!:-!QGA0A; +9P1D8^;!(7GCJ,$X+/*C#+A=I(*.!DD*<_>&X%
M1DMSM8-EL\LV?.S7*:.9T</2J5JE"%"K"K"K2G*$Y3IRA))-233ER)*2=U*5
MXN[/MN /$#,?#[$Y_B,NP.%QSXEX:GP[BZ6+EF&#IX; 5<PRW,(SI5,%.G/&
M35?+Z5#'8#&RC@,=AZ[H8RE*E""?\WGQW^#_ ,>?C)^V?X=^*6D_L\?%>T7X
MO>(?V(?'WP\\>^*/"\>E3_ #P1\&-:\<ZC\</ ?CS5?MT]SX#U/5+#5?)NO"
M<,DEMXQA\0?983J0\\0_4/P8_90^.MK-^U9\6?V=O#/PA_8R^-OC7X[CX=?#
M"]\?? .W\2^%=,_9F^$,QT&T%AX!\*>*?A_+='XIZJ=9\<Z7XADUHYM]0M8Y
M+=[>W@MHOVB(12"(LA6))V]&5MY*H."7<^86 RS@NV6&:M1HJ'@ 9<.>,9:2
M6,NQ[,QW$9QE0=HP,"N2AD&$HXROCIQ]I7KYE6S/FJ0HRE3Q%?!K!RI1J*G[
M6*C22J)*LK\S4E.-D_HL]\7\_P YX9APGA\'+)LLAD6!X7QD<'G?$-:CC\OR
M_,*>:0ISP>*S.. IX>H\/E].6&IX.MAX5*>+Q5&-+%9OFE6K^%W_  1Y\._'
MVW^&G[8]IXD^*/P[U?QGIO\ P4?_ &K[+QWXCTCX7ZAI.A^)_$UOK6S6]7\-
MZ'+XNFG\/:3J%[=>&VL=)N+W49;$:+JL+WMTVK)-:_KA)H?QX\EHX?B)X CE
M-O.L,C_#O4G19FTW24MI9(E\8KB./5(=:N)8PX\RUO+2W#HUC)+<_G]_P23Y
M\/?M^CM_P]$_;%  X '_  DOAQ< #@?+Z8YYZG-?K88HVZJ#[]^F.O7I_,^I
MKW-E;HNG]7/R=ZR<FH\S;;:A"-V^6_P0@M>6-]%>R;N]7X[+HGQO>0;/'_@-
M8/M&XQR?#[4I':V%QO,8(\7*/,-J?(\S'$YWF/GRZ\A^#_AWXS)HGBDVGCKX
M?P-_PL3X@1R2I\.+Z/?,OB.;:V8O%<;LFYY_O,9-[EA(<%5^L+\WJV5\VEI:
MMJ(MI_L*:BTL=D+WR7^R"\DMTEN$LVN!']I>".2=(0[1(S[0?,/A/X;\<^%X
M-?L/&$OA">'4?$6N>(;"3PP^M^8DNO:E=:G/:WD.L0H ELLL212P.6=@=Z(,
MT 5?[ ^-YD+-\1/ PMS(K(B_#R_64*)9#(#(WBMP6$+PHI="1+%))('1C$OP
MW>?\$_/%W@/QA=_$S]E?XTZ/^R5XUU37)_$_CCPU\*OAO(?V>/C#K-QIZW6N
MW7Q3_9TU'Q4WP^/B?Q1X@7^T]=^*?PWL_ /Q?U&Q:YLM2\::M<K'<Q_J:8T/
M51UW>G([\8_P/>D\F,;2$&5QM/.1MZ<YSW.>?FR=V<G(U>WEKNU^35_G?T#[
MO5))_P#@22D_G)GY&:G^UG^U#^SQ+'9?MSZ#X/\ A!X5.H+9P?M3?"CP%XG^
M)W[*BV3:MHJ6NH_%35AXA'Q _9KBGTV/4K*7Q!\5= ?X2VFJ:O8BZ^*EO-:0
M66I^N>+O%<FN^-?@OJ:>+_AY\0XO%5[?ZOX0\8>%?@J?&FB>*-)D\+>+[];[
MPGXCT_Q'J%MXGM%T74/#<;77ARZU"/39+2\OIW:#4$AM/T6>&&12LD4;J0RE
M7164JZE'!4@@AT)1@1AD)4Y4D'^/[_@IC_P;B^+/VF?^"D7[-G[3/[+_ .T%
MX&_93^%%EK.@W/BSP'X7\/>(M%\3_#KQUX+U;4?'GB/XC? ?1/"]G/\ #^WU
M_P"(%G8V4VN1:DW@J&U\7V,7B34#XQN-:O;&P=WH^J=UMH_*R7_!ZW$HI7TW
MOJ[MZ]I2<I1_[=E&W2Q_3UK/P\^*GB329-,\0^+OA?JZ20PR(MY\,+N:"&]3
M188H[X0S^+&=)8=?CFU>&17BN+:S,5E#/'<Q"];+L?!OQX\*:?K">'?B;X;\
M1S/-9G0M)\4^'-6N[?2+:/5?.O[5M7;Q%>:_>2W&CA["Q_M.XN(["Z NU:6V
M#6E>)WG[.G[<>BL#X&_X*(2ZC:PM'Y-C\9/V5_A/XZ)56W[;G4?A_JOP<U.Y
M,C B23[1$ZJS%'C;:ZMO;'_@J)X=6S72/$'[!'QD$#%)IM=\,_M!?L_WEPF"
MID\[1?$'[15C;7+;LNT6EK$5#0K$HE,B;4<35HW@[5:+::IUESTDUI=J;;BM
MU)QE%M;WLCS\3E>%Q555U&KA<4E98_ OZO4FWHO;SBG"LD[-O$4,0TE922;1
MZY;>-OBRE[;Z5XF\;^$O!&JW+-#:P^(/AY>?V7J=RPMU2+1O$MOXS?0=18.M
MT5M&O+75W5XM^FQ,A5^LU:P^/#Z;(+'X@^#Y;OS8@C:9\,VU&X>+^UO-F$%G
MJ?CW3=/EE71VAM\SW\)@N-]ZR,C+:M\T:K\9?V_=&AET[QW_ ,$^OA3\4-.F
M0P:@OP!_;.\,>+#>1&/+ Z!^T3\%?V<+)7=5V"TN->FB#O&#=F,R31?%7[67
M[6GQ"^%GP>N=7U#]GW]MS]A_PMI/BWP'<>/?B9XVNOV=M=^#G@3P7;:_;_\
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M#$[$M+P$L;E#![+Y,9ZHIXQR,\8*]_\ 98CUQQT KR_XN_&#X3? GPE)X_\
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M_*L65BBN&9DB\L@':V82!M$C.GS%,D%2%YRV3MSC:;[K?[I_E644$BE3M#,
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MC0>(WAT6/6HKN^4_TH8C!?>%VN&)DR <').YS\V#EB%!V@%LD$D4-'& 6(#
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MH+:[BFFN+6W^'G@>WFN[=$)W6L-Q'+;2,&<QWD%PC%&&T>R>3%UV '&,@D$
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M_3^+F_\ CU_P5R@_;2M-#UCQ-\.;CP=%J7B/PQ=_%?0];^+\'@K3/"DGQO\
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MI8KA]RI$CV[TP,5='^/JH_F?$3X<EO+4!A\/-:"I+YMKEF'_  EQW1M%'>J
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M-\RV=WV[WT!R:3O=I[I-^:OH][-Z[V>Y_*]\0?\ @AE^S_J7_!1_PCX[\/\
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MZ_8-HZQ61^']E\4/!7B-O"?Q*&H_#C7=2^'5MX=GC&FOIT=L ?T>DA068@*
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ML:'#-M)Z;@1G! XR.?F*KQG+,BCEE!!63W2>EM4GHM4M5LFVTMDVVD(0/,'
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M YC@^('['7[.^MVS]0@G_P"$"3X6W3MN*&0Q75J&(RGE*25_G_\ VU?V%?\
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M7K_2= M/C/+XG32_B!K.D:CKKOXLM([/7)/[*A"P()E=L  [@A+#.6R0!@N
MH8+MC&"51<C;&+4\EG5V88<&,[&!*%UP7,FS<KNB-*VQY79C)TH _EC^ _\
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ME^TE$KZJ\T$T5]Y"_M6F)(H#;Q+_ &:@&GW#9EF@+YS_ $=CH/H/Y?A_(4M
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MK2GFU#64N[, _+C]B[]F#_@J+^V9^RA\"/VH=$_:7_8\^'>B_'7X=:)XXB\
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M;1/V-_)$9MF*?\%"?VNUN?L0-BX=;E_V56\O5P^FVI.J[2NQKQ19JU]<._\
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M@W;)G! /Y7/"?_!*+3[WQ_\ L?\ PT^ ?P._:&MOV0_CS\,OV9OB/^V1X?\
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MA;4/B3+\-/"WA'0_%_BKPQ!?:=I]AHMKINFVWZG(BIG;D9QP6) VJ%& 20.
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MG6L;.S)!8V-M#;0*[,ZQIAF+,Y;?H BE?8H.57+!<MP,G.!DD*"Q 12S 98
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M>K9;'<98G:PR<,OW67)"L"H) H D P /0 =AT&.@  _  >@ I')521UX&<9
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MG]EKX3^,O!=KX7U6*VTOP#\1?"'PYU-+WP]K>C7T6H:G_6I^U#^S'\)_VO\
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M"T__ (*F_ 2/X#_M4ZS^U!??$*[U'X6^'?"?PP\7?";QS\*=+\/:'\$OB?\
M CXS> _%OCR_\?7OA;P8EMH?A_XT:MKBZOJ6GWOB/X<ZGI,OA?0H(M0_;_0M
M(LM*LXK*W1)52,//>310?;-2NI(XUN-5U.6..+[3JFI,IN-1O'A62\G8S2$
MHH *?@3PIHG@+P;X5\!^&H;NV\.^"/#7A_PAX?MM0U*]UC4+?0_#>D6>C:3#
M?ZIJ5Q=ZCJ-Y'8V4*7.H:A=75]>S![F[N)IY'D/64@ !) Y/7\/;I^77O2T
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M.*=10 4444 (0",$ CT(R/7^=&U?[J]".@Z$@D?0D GU(&>@I:* "BBB@!"
M>" 1D'!&>0<@\]P>1Z&C:O\ =7MV';./RR<?4^M+10 FU?[J\# X' ]/I2@
M<  #G@<=3D_F>3[T44 %(0#G(!SUR.OU]:6B@!-J@DA1DG).!DGKD^ISS0 !
MG  R<G QD^I]3[TM% !1110 4444 %%%% !1110 4444 %%%% !1110 FU<Y
MP,@D@X&02,$_4C@GJ1Q2;5X.U<J25X'RD@@D<<$@D$CJ"1TIU% !1110 =>M
M)M7.=HSZX&>,8_+ _(>E+10 4444 %(0#C(!P<C(S@^H]#R>?>EHH **** "
MF[$Z[%SR<[1U)#$].[ ,?4@'J*=10 W8F-NQ=O!QM&,@  XQC@  >@ ]*7 R
M3@9/4XY/;G\ /RI:* "BBB@!NU<D[5RV"QP,L5^Z2<<X[9Z=J7:N<[1G).<#
M.3C)SZG S]!Z4M% !1110 A (P0",@X(R,@@@\]P0"/0@&C &, #' X' XX'
MY#\AZ4M% !@=<<^M%%% "$ C! (/4$9!_ T8 Q@ 8QC@<8Z8^G:EHH ;M7CY
M5X&!P.!P,#C@8 &!Z#TI0JJ,* H]  !P !P/0 #Z "EHH **** "BBB@ HHH
$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>pg80-149_014.jpg
<TEXT>
begin 644 pg80-149_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (0 IX# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M378]&6%!8Q66F:.5E$EQ,\]S+--)^I:P[<_.2#DD8 SG.?S%.,7HS >@Z?\
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M[@4DBY **2-^TL 2I ._&0=I'?&*>98QC,B#.[&749VYW8YYVX.[TP<]*_G
MM/\ @LK\6=/\&>./B=J7PR^#-K\*-*T_XE^&OAK_ ,)%\2-9L_BSK?Q ^&-I
M;Z% _B;P]%I<VCZE:>*?&+K$D>E7NAW-G:7%I<R3&:X=8OD?3O\ @L=^UM^T
M1X_^%^GZ'X3\*?!W2_#=[^V5\/?C-H,=UJ<EUXMU7X4?!WPYX]T/5M :=[FX
MT:XTZ#Q%:7.DP7CWDLNI_;I9)#;% H!_7MYJ;MN?FS@C(R.%/(SD<.A.>@93
M_$,KYB $ET  R3N& ,$Y)STP"<^@)[5_+]\#/^"SWQCN]$T)(OA3X6\2?#'X
M6:O^S5\&_BCXF\8>-[QOC%XO\>_'?18;S3/%'AZUTVPM_#ZZ%HOGVJ:BNH6M
MW=7X6Y:SN T;/']0?\$Q?^"KWQ7_ &Y/%7@"S^)'P3\&?#;PS\8_@KXB^,GP
MWN_"?B>_UO5[6T\(>,Y_">L:?XIM[Y6MQ/=O&NHZ.+)-L6Z:&YV%DH _>+>A
M) =25^\-PROU&>/QJ(3@YPK8&/F*MM.[I@[<$'C'KD8ZBOYBOC[_ ,%@_P!H
MJ7X9>/\ 5/!'PW\ >$_"_P 5[S]K;X+? 'Q':>(]4O?B7X*^)'[.7P^^*OC'
M4O&7CG3V0:'-HMYI7PB\42:3#I,%G>6.MZEX9-U'=6IN)H^4^,G[3/[8WP(_
M8,_X(Z^,],\:^(?B?\9OC9\<_A/!\2;.#Q'#I%Y\7M'\:Z;)K0\)WWB&^TW4
MX-.BNH+N NYT^ZCMWA?:H4\@']4'G*V% ;Y@=KJ"02,Y .,$C:=WIWZT"3'R
MC:_!.3(H)&>N.H ) ]L@5_$;;_M7_P#!0;]HKXC?M"_#V7XA?%/P+=:7^V]X
M[\.O\"OAW\3?#VD_&G1O _A_X.>$=8T_PEX$\:ZAX)U30?$.D^'M9NYM;UBS
M;0],DO!(D,4L>Z5TQO#?[2W[?_[3GCCP]X1_9X^.O[6_C;Q?X*_9N\'ZAHZ^
M#_#_ (+\.:7+\5[3XL^*?"NM7/Q\L-:BU.)=.CL-'73+W4M">WN+WR+FX^QP
MAT4 ']Q8D4R$",Y Y< E0<[2"P&W((*GG(P0>AQ)YB$?*ZMD!@%(8E6Z, "2
M0>Q'!K^1WX._M#?M,?&'XM?'KXY?'#]O&]_9K\7?LS?M7?#C]G:V_9VM_#L&
ML_"+5K2XT:"36]+\06EM!!?:QK/Q-U6>X'A[7(M0M!H\>DS)<6P62)7]K\??
M\%LOCG<P?MN?#[P_\(_!_@KXG?"_X7?%OQS^S,)M1O=2OO'UO\+?&=OX1DU0
MZ?=.EAXBL]3M9FUF.XLKC1(])ADBM)H;R?#. ?TXS3PI$SR.J1@ EW9451G@
MEF( &1C)P/KTK)U98KO3[RT9BD=U87-L;A74)']IMI+=7),BJPQ([+NS$2A#
M,I9"W^9-\8?^#@__ (+7^//A'\2/!OC#P'X'T#PQXM\$^)=%\0>(M"\+_P!G
MZQH6D:CH]W'>ZMI=[;^(#<Z?J5A:2M=:?<013RP7L,2F$?,R?T[?\$-_VP?V
MNOVK?^"37B_Q5^T3X2U*QO/ 7@GQKX>^&?QVN/$<,NJ_%_2=&T?588M7GT@0
M27FGZEX;GB72KG4I=0G^W75N[Q0VQMF-SG5JJE3JU'"I)4J<JCY4G=13=EU;
MTM^2.O 82>.QF%PT91I4Z^.P>"JXA5*526'>,KX>C&K4PJ:K^SC[=SY_ADH>
M[97:^U?V8?\ @E?HOP M_P!FRUO/B=8>.4^ 'QT_:/\ C-8PZAX;T^*/Q'=?
M'^[N+@6-I'>/-:VD_A87L4]M=0(S"YB\R,Q22!C\+_#C_@W>U?PW\5=6^*OB
MK]IV'Q;J6MVG@BTU -X'9)]13P3\1;WQ]8W^I&]U:ZMKF^U"6\6WN6CBL;6V
MGMUN(K4RL&; ^$'Q,^,.A>,/V9/!;>,_%>NM\(?%T&L:G#?:S>.WC;1?BMX,
MM?%OARTU6YDOE.HB#4] \7:2OVI%^SQO:26Z,FYJ];\/?\%$?V@I--\46?\
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MDN/B/J$_CF^3PQ*/#LD$5MX:LM @TR>%7:2\D:*:&W5.&Q\5?\/5_P!JR?\
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MU+6?%OCF?1TTS3];\0ZIKVIO<WU^]G;#2;$+=21K$GE) #'C'V,;F%6*EB&
M!*E6#*#MQN!&1G< ,]3D#)!P 3T5"D\4C%$;+#=D8(^[L#=1V+A?]X,!DJV)
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"US0++Q%H^IZ'JL?
MG:?J^GW>F7T*2-&9K2^M6M;F,2!2R&2-W42 %DW;@"17RMK/[!_[-OB#]D&#
M]AC6/!<M[^SI;> ](^&]MX3?4YXK^W\,Z UHVCI#K5M'!>1ZA826-O/!?C,L
M<P;AD8@_8U% 'YG?![_@DK^QI\#K[P)JW@CP?XH?6/AUXW\3_$7PYJWB'QEJ
M&O:F/%OC#P)K'PUUS4M0O[VW:YU W'@[7=2TN-9GQ")(Y$^:-"K;G_@DC^Q5
M<^!K;X<R?#S4SX4LO EK\-[:Q'B2X$@\*6GQ+NOB[%9M<&Q:7S!XXOKJ_9R6
M5H!%#L!RR?IG10!^3&K_ /!%']@C7-<^*&NZE\/O%4TGQ9T74M$\0:3%X\UV
MW\/Z,-:@TN+6-6\':0C-!X<UG4+G2+/5)[VW>9WU)7FX1R@K>'/^")/[!/A/
M3]!T_0? WC+3AX?\;>-?B#:7L7CW5)-2N/$7Q$\'Z9X&\9C4;Z6W::_T[7/#
M^CV$-W9S'8]Q"+@;6"A?UPHH _+"U_X(V?L*6'Q0\)?%BQ^'OB&SU_PAIW@R
MRMM(M_&6IQ>$=;N_A[97-CX-U_Q/X;6+[#K?B+0(+J1;#4[C#PM'"ZQ@H!7N
M'[.G_!/3]F+]E6Z^'EU\%_!EWX=E^%W@'6OAGX.:ZUFXU(:=X1\0:\?$NK6+
M1RPH)YKO5V>Z%R[AH&*K&IC'EU]OT4 ?F&G_  2$_8E'Q*^('Q1E\">([K6/
MB)9?$>UO] N_&&I7/@OP]=?%O3+W1?B%KO@WPU)";/PYX@\2Z3J>JV-]JEKO
MF>#5M13C[2QKWGQ?^PM^SQXZ\'?LW^ _$?A:]O/#7[*'B7PIXL^"=FNKRQ2>
M&]:\$Z='I/AVXN+@6[2ZBMG8QK&R3%1*0"Y)&ZOL.B@#\M?B#_P1Y_8J^(U_
MX]UO4_"OC7P_XG^(WQ:U+XU>(/%_@OQ[JOAGQ1'XYUCP]I_A35[K2]3L( UA
MIVJZ#IEI97VEJDENP$DB,LC[Q[Q^S?\ L!_LU?LGZTGB#X)>#+CPUJW_  KG
M0OA;/=W.J3:I)=^%_#VNZGXFL9+R6XA6>YUB?6M6O[O4-3>8379N9/,YQGV'
MXX?'_P"&?[/.@Z;XQ^+GB!O!W@B^UJPT&\\97=I/+X;\/76I2&"RN_%.I0@Q
M^'])GNGAM?[8O5.G6\LL9OKBR@)N%]8TO6].U?3+'5M+OK/4]+U&SAO;+4K*
MZAN;*ZM;E$DMKF&YC=ED@N%?,+*,O]W /% 'Y\>*?^"4O[&'C#]I!?VI]8^'
M-^GQ,F\0:3XOUK3].\3:G8^ ?%?C#08[J+1?%GBGP5&&TO5]?TM+RX2SOIP6
MC$K%E<@5>^%'_!+7]CGX.?''X@_M">%OAS-J/Q#^(L?B6TU-O%FL7'B/0-&T
MOQGJO]M>*](\,:)>0K;Z3I>M:F$NKFREDOX4,<<=NL$<:J/T2'(!Z9%% 'RE
M\6?V*OV;?C#\+O'WPH\1?"/P!IN@_$;P=K_@C7-0\/>#_#&EZ]::3XCTZXTN
M]GT;5CHUS+8ZC#;W4DEI=^7(T,J1LJJP$B=7\&?V;?A=^S[\&O"/[/\ \)_"
M^F>&_A3X)\,1^$]$\-QP"6.32UMY(+EM3:);:*^NM1\^:2^GE@:2XGFN+AY&
M>X9$^@J*+ON[6:M]EI[IK9_,%=-.$I4Y*=.HY4I.G.4J,H3I<TX6E)0E"+BG
M*RLTK79XQ:_!#X:Z;?VVJ67@CPG::I;'2!9Z@FC68GMGT2UGL=&,3-%P=.@O
M+NWLR0Q2.YE"#<V*_+S1OVL/V)[S7OBA\)K/]GGQUITEBPF^)EE=?"![/38H
MYIXX["ZUB\"Q"."XFF:XTRY>2..X17GMRTF2W[/W"!F!.<A=JD?>4L3RO! ;
M@?-@D=0/7\Q/BE^QI\1?&?B/]N#5]+U?P_;0?M'^$?A?H'@E+B>YB?3KSP;'
M:1WUQK31)OC+O 4L)H)"Z*S%U(=J]')\)P[46.IYM0A-?4Y3P<;^RC#$?7*-
M)OW8M3C&G4JR]FU:37FFNG$YYQ+347A,VS:U:K3]NHYMF*YU0J5*V'O&.-BH
MK#5ZDZ]#EY?8XB7MHWE=2]U\0:3^RWX4\(Z\/$.A?#>T\-^#? O]IZYX?DL-
M,DO-,\(VLEKJJ>=I*KYODQZE#933))%(SW8L22))LG+^%?QK^ 'QK^$=Q\0/
M#&D7">#/@O?:C--H.N>'+G1=9\%R^%--EN;-K?0;H)<6UX=$BEN]+GA&)+*X
M22WPLHK\_/"O_!.C]HCX;?&SXH_%/PKJ_@/Q'J.IP?$#7? 7BKQ'K6OSZG/K
MGC:PTVQTWPKXGT%HY-,NO#7ATVTDUHUR+FS0VEF([=9$!KWGX'_L5?&2R^$7
MB_3?BOXTO?#WQ6UV\\7ZAKFK_#SXB>)'\._%K6_$N@76EIK'Q0MY!!'J<.G2
MW:VMEI$\$UEINFV-K#:PCR8P/7Q.0\+8/#2E@\UPU:$JV'=3$QP\*57E<X<Z
MJ8>"]_V2<HQJS;_AQDU:[//AG_$F)JQEB<3F-2?-7Q"J5\?BJU3ZQ)XARJ1G
M6JU'"5:%>IAZO+%.IA9/#R:IZOE=8_;"_8L^)^K^$+*+X*>+_B9-\1+/PQ\3
M(+G2OA?_ &Y#:KXHOIM&T?5_$5U;'S;*>6Y\/BQO/,D=+FTLHHI?,W87U#X1
M?'+]B'QSXD\.^-_AGX:T*#QMK?Q=N/@V;FW\,1Z?XHT?QS) 9)?[76,QSZ=%
M-8^4([^56$L#QHH,DC;_ ";]E#_@F;>_#*Z\(:G\:KFUU[4?!GP=^%_@G19/
M"GB76].BLO$O@?6O%.NWM[?VMG/;0ZG9-<:KIQMTNA(':.5'0J[8\_U3_@E7
MXR6Z^$.O>$O$^@>"?%>G>-/'NI?&.\T&-K>/Q7I&H2:W-X"UV%8(1]L\5^''
MU-;2.YG;[3]C1(X79;, =4LLX JUZU&GC*F'JTZE)1QKHN47)T)54VM.:/MH
MQO%<K<7R)N,FT4^(^,:>$E0AFF<PPM2-7#8C"4\XS*E3Q6#G",)8.M3ACE3J
M86<80YL.Z<:3<5)P;1^J>M_"[X%?%[6['7?$/AOP%X\U[PNYAM-0N[:RU>XT
MJ1+AI$MG:+,D<>Y5D^SM-AY;>,.@D,N?EWP?^UO^R;HGP-\/_M,>%M'N=&^'
MOQ'^*NB_ F;6K/PO'97O]NCQ!=^"].;78X#"+?P[87ED]L]^96@AMVA:,E&4
MGS/_ ()V?L2_%G]EWQOXL\2?$:#X865C<?"SP!\-;1_A[YJ7'B/4?!6O^.]7
MU#QUXI,T,).O^)+7Q7IXUF5WEGEN-*CWLT83;\5_"G_@GS_P43L?V=OB]^Q#
M\2U_9N3]G/Q9;_&34_!?CK0-=UZ;XF:!XK\0:^?%/PZU1K:6PALK-M+UA(EO
MKBTN/,AA64Y8L2?E<SR_+<-F%58.5'&*=JGUV%*$)247&T'RIVU47:^O+L=M
M'.<YQF6_4\3CLTIX.RHK 5,RQU2A"FG&:A2HU,1*%*DITZ<U"$%'GC&;O)7/
MUY\ ?M)?LW:9K'Q:^'>B>(O#_P /=/\ @?\ $9/ASXI.NW%AX:\.S>.=8LXO
M$]]IV@74LD/]I7/E:AYNHA6::.[E,;;I"[#TF/\ 9K_9]UCXB7WQG;X4_#V\
M^)>O^'7T+4?'T?AVSEU?5-!UC3S9W-K<7RNXN8-1TV1K2XG*1S36Y(,S!R:_
MFX_:!_X(J?M@?$[]FO\ 90TN[U[X-?$_]I;P3XH^*OC[]H7QGXL\1:_H$'B+
MXB_%BQ:R?QEH&IZ?:SKKT.G6T-EI<^@Z]:2VVK64,5K \,-I&!_3?^S_ .!_
M$/PV^#'PH\ >+;W3=2\3^"OA[X4\+:]J.CVD=AI=UK&B:/;V5_)I]E"D<%K:
M231-+"D:'Y9&0-M4"N=:))))*R222V371+N9U)SK5JN)K5*M:O7J2JUJM:I.
MK4J59*"G4G*<I-SG[.#G)N\I+F>IV^E^!/"NB^&-,\%Z9X=T2R\)Z-8VVF:7
MX=@L(_[&L=/L@5M+6WL'#0QP0+M\N)<!&&48$DGQ+X^?L?\ P _:8^%VO_!G
MXN_#S0M<^'?BB337U[1+.RL=+;48-+NXKV"PDNK:Q%U%8RW$,;3K!<1SNJF-
M9U1F%?3M%!)XQXV\*VWA7X+^)_"?@;1H--L=%^'6L:-X6\/Z+:^7;V4-CH\M
MOI^G:=:0@,5PL4$2_-(I<HBRF1Z_FL^&NF?\%!M/_9_OKG3/$WQL^'UQ\(/^
M";7P=OOAW\./#F@6UAH>I_'S7UT[3O%+74-Q8W-W>:WH*-<2PZ-#*B!VFFE6
M-"(1_5A.%,B!CR%+ !"[;<@OC;RC95"C#+%@50%N*\J^*?QE^%'P6\.R>*_B
MY\0O!_P]\.P[2NK>+M6LM+AEF PL=G#=A;B\O'=%06MG%=7GF%$CM@<$@'\F
M7QB^+?\ P5@^%/[77P_^&WP@U7]J+QU!X/\ #_PT>[UWQCX>35/AIXT7XA?#
M37-1\97WB--,\-PZ3$FE_$W7-&TN&.77H-5T,6MM9PVLT-N7/RQ%I_[<WQ9N
M?'_Q$\6>"_VJ?'OQ;@^#'P3\(>/S\7/ 446C6'Q(TO\ :VGUOQAX:^$<5G:P
M07/@S2M"=;R(R&6[M;4PW*3_ #25_4QXB_:S^.GQQTZXT;]B/X$^(-5&KXAL
M/V@?C=8S> _A+IMB':.?Q#H.F20W/BKQS+%L22TTL66A?:7:"]BDDAX/TW^S
M?\+_ (T> -*U34OCY\<]4^,_Q!\3&TFU%X-)L?"G@?PPT,*QG2_!WA>P\N.T
MMI JO<75S$UW=2KYLCF0OD _CE^./C3_ (*7_'+_ (:A\'ZU8_M?I\+K[3O&
M^HZKX<CTJ\0Z?K7PJ^,_AZ7PS:?#J:+POI\%H\_PUL_[5M=/TR\U>WOVEB+W
MOVHS1#Z[@^-'_!7"?]JWXO:'\,_^%L#0--^'OBZZ^'WAWQMX1U:?P'>_"^#P
M):_\(!>&Y?1=+L=.^)C:G]OG<C5+ZYO-46VM;C0[1K<S7/\ 7P8 23G.1\RD
M95CG<"5SMW;L$L "P"HQ95 I!;@!AG.XDMQC.X .>#PS@<MDD-EQ@DY /Y8?
M^"*NB_'^Y^//_!2/XQ^+])_:1G/Q$^%'[+W_  AWC#]H+PL-)\9^)?&OACPS
M\7$\9KI.G*FDZ=<Q:5XHU.W6"U@:W62*XM4\];>)6F\"^#W[2_\ P4I\)_LV
M?ME_&3XF>)OCDOB+]FKQ)X1^(NC7/Q-TJ/PQI/Q"OK35_P"R?&GPLTK2;_3+
M:/3]-O+?4].GCAT/5=?TR$VP6WU4*_DK_8TUK$=ORJ"G^K)16\OY64F/<"4)
M#G.#CT R<\/\1/A5\.OBWX=/A+XG>"_"_C[PPVI:9K$F@>+="TW7M)?5-%O!
MJ&CZB+/4+>>*._TN] NM/NT"RVMQNGC(D9F(!_,E\;+O_@IIHO@GPAXZ\(?%
M/X[ZAXO\'_LZ_LU_&R#1/#NAVEUX>\7?%?XL_M#>$)OB3X*\26D>E[M2TOP3
M\*_&?B'0(=+LS9S1P>'K/4+B>2='<_#?B;]NC_@H]<_M?6_PH^&GQ+^+&J?'
M'7;7]K.36_A_?Z;H=W\$[B_\'>#!<?"^Q^&AT^&;43=:9:/"VKK=/.1K2.EW
M#')"%/\ <,EJD<21HD:>4?W8CB2-0%R/D1!L0\[EP"JOM<*" !X;X4_9;_9W
M\#?%#Q#\;/!WP/\ A3X8^+WBWS5\3?$W0_ GAK3O'&M)< BY34/$EMIZ:K,M
MR6+W2BY03R%V<9E>@#^5O]E;Q!_P5*^/\'A3P-\0_BO^U-X+^$WBGXB>,;:X
M\6KX8DT3XF:&NE_"XZIJ6DKXGU[P[!/-X>/C".Q_L9YM B+75SJEA;SS6DMO
M,WF/ASX]?\%F-:^)O[-^B>/IOCEIUQKWP:^$L&BP6_@G4'\&^)[RXTK5K#XL
MK\5K"U\/W%M%K]_/%I9N;F^UW18[!6D2PM;E;@*W]M#VT;G+ '"[5# , "^]
MACCAV5-P&,A #D<4& 8 5MJCJ" P8$;2K@\%&'#+@9VH<Y7) /XT/V2_&/[=
MW@/3/V3OAQXXTW]K/X;P#P[X=?X7^%O@[\.M)G\(:GK]_P#%#QI!\94^/-IX
MAETRTL-*M/"Q\*SZ#''<Z;);PW-W<VLEQ</&'^X_^"B^H?\ !0+4/VP_%NE?
M GQ]\<_ _P *?"O[/'PB\2^'5^'.F6TVA:[\2-5^*6F:)XJM;][^PU,74ECX
M6N;J]>P\[=:^6T_F2,2M?TF&#D[6"@@Y4*?F8%/+9B'4ML <$$D.7!;[BTX0
MC#+DA6+%@NY<[OO$E6'S,226ZDG/7F@#^.<ZE_P5A\,7WQAD\$6'Q*^(?Q$^
M"O\ PVEX+^"_C_XG>%5O_$=S\-8?$OPMUCP_=0:I:VFF6GB#Q(_ABZ\<7/@2
M.6WCCU;4[6PM5\RWMXG.?\>OCM_P4ML/V?O@7KGP$U[]KQOA#K7BCQW;ZSXQ
M\>>!$M/VAK;XAVVF6R>$-#U#2-"TW7C??"T>+/.GMYKS1/#LM[)!]ENK^QLY
M//7^R8VX+*S%6VD$ H,@AE(*G.0<+C)RV23G!VT@MD4@J0"!MR$1?DW*P4!5
M  5E4KP0#N."6- '@'[+-[\5=2^ 7P>OOC>R-\6;GP#H<OC]ETL:.9?$GV*!
MKZ5],5Y1I]SNG"SP+<31HRLB $G;]$57CMTC<R?*6.>?+12,@#Y2%W#( #<_
M,0#QCFQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!R/C'P9X5\=>&]<\'>-/#NC^+/"7B72[K1O$/AG7[&VU
M32=<TR_C>"ZTW4+"^CEM+JTNHV,4L,R%&0LI&'K\Q]<T#XP_\$[TLM<^&>EZ
MI\9/V,;;6+&+Q/\ #&/[=JGQ3_9YT.^F:WOO$/PV\P3OXP\ Z)'()]4\,W%_
M_;&B6B22Z7%?VD<GD_K*0#@D XZ9[=#_ # J.:&.:*2*2-)$E1XY(Y$5XY(Y
M!MDCD1@4='7*NC@JP.&!&10!PW@#XC>#?B?X7TWQG\/O%&B^+?"NKQ1S:9K.
MAWD5[:2PR;3^^*E)+>:($)):S(D\4A*2 LN3WO.001CO[C'&/QQ^%?F)\1OV
M;O'W[/7Q,?\ :(_8RTV$VVHI?)\;/V6XKY-&\#_%F.YD6[B\7^#HIQ):>#OB
M7H?V=TANK(_V;XCMK^X@U/2_-CL93]5?LY?M'>"?VBO#5YJWA7^UM"\1^&=1
MDT+XD?#?Q?;OIWCOX;^*8 R7/AOQ1I<GS6MS %4VUS"+C3]5A'VNUU&=C+-<
M 'TE1110 UD5B&.<KTYX[]NG<TPPH<_>YYX8CZ]#CGH?45+12<4VFTFTK)^7
M,I6].9*7JDPVV[W^?<K?9(.@4@9)QGCD,#@'(&=Q)Q@DA3U4$/\ L\1QE<XZ
M9]/3Z=3^)]:FHI.,6Y-I-S5I?WE:VNMGIIL'52ZJ]GU5][/S(1!&!CYSSG)<
MDY(4$]>IV@Y]<D8)-)]FCQCYC@ #+9(P!R"?XB1DMUR6((W',]%4];WUNTW>
MVK2LF]-TM%Y!^CNO7N1"%!G&[D8.6)R..,$D8X P,#\SEJVT2!0 Q"MN!+,S
M%O[S,269O0L25Z*0.*GHHZ6Z ]7S/5VM?K;L0M;QL K;F4=BQ((!# $'((#
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M4!0 <+]WYFX_7D>QR*=TZ44 %%%% !1110 F.0><@$>W/7^GY"EHHH ****
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M/6M.U6^\-:EJ%G'J-G9Z_9V-Q-)I-]=64J7D-I?Q6UQ+ WGK&R@O7\GNF_\
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MO0;2X\.OIINH9KX?.Z0S-%])^"_^"FW[%7Q$\(W/COPE\</#VI>&-.^'-_\
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MKJYAMM*TG6M/:W:WMO"M[:VD4DFLI/J'V>=G26RW8%?TA_LF)^U&OP.\*_\
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MD)(N][E]T;(P! !^X!<9(8$>@*D]"1G(!X/;@?CFF[A_?8>P3@#MU0G]>O3
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MT7P'X&\,0O;Z)X=T"T6STZS1I9;B=D0#S+B>:XGEGN+NX9I[B61G=G.<>H4
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MOX9>?KD$UM(NKW4%O&]G9*+^>.\M_)SN^7]YCT/T/^>_\C7Y1?\ !1SXJ_\
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MPAX,\(>%M9\/20Z'IUSXPF2Z\9ZIK*Z-;:5IDXFDN8T+.OQ'X._;Z^.>I?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC)R0L8<+@XSDAV#$DDC Z"IP,# ]_P"><?0= .PXI:* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI
MK.J#+' SC@$\X)Z $] >U,$T9YW'\58?H5!H6M[:\MN;RNKJ_:ZU7D+F7,HW
M7,U=1ZM=[6V):*16##(.1TZ$?SQ2T;CWV"BBB@ HHHR,@>O3\* "BDR.?;KP
M?\G\*0NH /.#TX;_  J>:-N;FCRIVO=6OVOW =12!@W0_F"/Y@4M---7333V
M:U0!1113 **** "BBB@ HHII8+UST)X!/ P#T!]1_2@/\TOF]$OFQU%,$B,,
M@\>X(/7'0@'K[4UIHUZD_@CD]<= I/7BG9WM;7:W7N.S;Y;>]VZZ;Z>1+13!
M(AZ'MGHP_/(X/L>:?2_K[MQ75VKZIV:[/L_,**** "BBB@ HIN]0<9YY['MU
M[4T2HQV@G.<<JX[XZE0/QZ476O\ =LGY-VM?M>ZMWNAI-WLF[;^7KV)****!
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4'H>,^WK[44$9_^L2/Y4 5+J81A%W,&9Q@*N2^0PV#W/;I
MG& <D50>>-65@TA79Y@98]P\L?Q,Q;*#)Y4@. 02.F/F3]NSQ9XJ\!?L>_M)
M^-?!&L:AH'B_PI\&?'FN^&M9TII4U/3-:T[0KR?3[ZREA82K<VTZI+"1NQ(H
M)4U_()_P3O\ VW_VK_&?[9?[-WA+6/VHOC-\3=!\7ZIK%OXJ\)^(_%^L>*-!
MU&RC\%ZG?![S1[^2:P@EM[^"W9Y(K:W>%@(P[H7C?Y_-.(L+E6:Y-E>(PN*Q
M$LXG6A1GAZ-:5.C.FTN;$58Q=*$==%4FK]$?HG"WAKF_&/"G&?%.79GD&$PW
M!&'PV,QV6YIFW]FYEFU'$7O_ &/1@G5QM3#VM4HI.[DELV?W10W41^4;B=Q4
MX7.UP=OE$ EF9=K990R *<OTS+]KBYSD /Y>3M"EMRJ<$MR,MQW;:0H)P#_*
MG\,/^"C/_!4_1/&LZ_$7X27WB#PQX'NO&6@>(]5U?X5MI&@ZW%XM^,,6C>%/
MB/JEQX4M++6AX=^%'@+44U/Q+I?A465_KEIHD[PPR7]VL+>Q?$+_ (*D?MZ:
MW\-OBC+X!_9EB\,^.?#7@^#6_!>B6/@_QMJ7B?XC36R:%?#Q5X6;6O-\-:=X
M,UJYOKKPW'I&O11^*[:^AN)Y5CMX7G7Z"S6DM6M[)Q[_ &7JM+;]K]4?GCWV
M:VT<7%JZ3LXM)IJ]M4GU:NS^D<WT(?RP'9\,<  #Y=H*EB0 ^70;20?F+#*H
MY4-[$ "%<[MH7*A-QD.V)5WLH+2N0B ?Q$%MJ?-7X%W'QN_;X_:#3X5_%7P1
MXT\:?LY^$-?^+G@7X*^)OAMX?^#G@[6[BTGBL]<UKXH>.[BY^)'A?Q!JMEIU
MC<WWA7PMI-^MVMF^H:-XED@*6TD+/X:__!3S]NZRTGQSX"\2_!S7O!C>'?A7
M=:]#\;H?ACJWB/X@76NM::3>6.MZ#X$M]-G\"ZE'J$NHOI$FD-IGF6M[;7=Z
M^GH!':D$?TTK=Q,JNNXHX4AMI ^9=PR#@CY<DD@ ;2#R5S&M_"RLXW!$**2R
M[?G?.U>3P" IWG]V=Z@.2'"?S[_%#]K?]N.S_9S_ &?M8U;3O&7P]F\0ZGJX
M^*7QQ^'?P^\,^);_ ,1?9OAQ\1/$G@O1=,\(:QX3U.P\*S:OXHT7PAX7\3:U
M-X42SM-3,T.E6\.G7IEE\@7]HG_@JYX[^'G[0'QC\*3^./!^D^$/AC\%[;P%
MX/U#X??"2/6]7\>>,_ /PZU7Q%.?#NK>![G5]0U%M:\0ZW+=2VE_%X>TB[2Z
MLI=)#61CB+<S2O:[5O-[I?\ ;S]WYC6KL?TT)=HX=D#$KD8P<G;(T?W#\^"P
M(5PNQAA@=O):9=H=BSKMW,V5XPI!)!R,J 225! "DG'2OS$MM;_:[\ ?\$UO
MVA_%_P ?O$<#?M(>$O@#^T)XN\,^(-!M-"M]7TO^Q?AYXDUCP#-J*^%='TSP
MZWBO39K:T>[?0],MX3*MM"OF3Q2M7\IO_!,?]O;]LSXG?MV_LL> _&'[5?QL
M\>^%?&_CU-*\7^$_$GBG4]7T74M+N--O9Y9;[2=02>R"V+()+5YH'2&4+'*D
MB*!7MY3P[6S?+\WS2AB\+@Z>3T54Q%+%5:5.5;FERJE0ISDI5:C>RIQDVO+?
MCQ6,AA,30HM.:KS5-.,922D^K:BTEYNR\S^^W[5&R;L."-CL0I&%9G0,<$?=
M96#@%MOREL!Q4AO(0P7)Y) ..,@X/&=P&"K!L896# D<U_/%XX_:5_X*%?LX
MQ_$OQO+??$3]I>UT3]JKXD_#3PWX U3X2>"_#]A'\*O"WPLB\3>'?$TFH^!/
M#.C^(KNPOO$VMM;76H+?7$M\NBQQP?OI2JZ7P#_;W_;3^*G[0GPYAUCP#<6_
MA_5/A?=>(/'OP-TOP!-H/A^34#;:9'H6I^ /B7XFT%O$-[JVK74]YKL^@ZOX
MA^P:+H;KIMW:SWMO,X\*,>7>/+)I-I.\6G>SC9M6:ULGI>S2.QJS?FE^1_0<
M;A ,X;KP,8/1CDY(  "LV21Q@C)(%1&^M\D98L,G;L;>0'$>Y5(!*[R 2.@(
M;&QE8_SF_"WXH_\ !6+XW?%37/L&L^(_!7@'P397=]JUF_A'X0>&WNDF^+/Q
M0L+1=GC/P'J]YXA>W\(:!H44B:#=6)EC"2\/?V[OYGX&_P""CW_!3;X;Z==1
M_&CX#/XQU*P^%7@W5K+Q+<> M6T_P1X@U;Q7\0O&ES;:K<V?@FWM]9L_$FF>
M"++0/".K:-:10Q66NPMJ5W";:Y0I0C^HA&W#.".2,'&< \-P3PRX<9Y"L-P#
M9 =7FGP=\7:SX]^%OPY\;>(=";PUKOC'P+X6\4ZUX?=;A'T/5M;T6QO]0T@I
M=EKL'3[J>6UQ=,;A?*VRG(R?2Z "BBB@ JO/N!5@>@<$8SDG;MSR..#S5BH9
M3ADY R&XQUQMYSVQWX[]0.J;26J;6B=M[-I7TUTW^0G?EGRZ/DFD[7M>+5_E
M>Z?1V>EC/DO(H8Y!*Q"QG$DAPJ*P ;&688&W<3QP%W,5!&<:T\6^&KNX2UMM
M<TN:XE<116\5_;O<2RD@!(X8YFDE8DYQ'&VT9SR#7F_[0%AJ=]\%?C##HD=_
M)J\_PU\:QZ5;Z6)#J%UJ,WA_4DM4LVA*3?:FF\OR$C9F,APHRQS_  @?\$]_
MAE\7K#]M7]C69OA9\:=(OK'X[^#+[QKJNI^$/&NGV5KI=O\ VG_PD]WKFHZA
M'%8'3I;I(C/]J>6-V+2HQC94'S^<9Y+)L;E>$IY9BL?3Q^*A2G7HRYOJT9TY
MOVLTK^Y"22>GVEH?H?!GA_A^+\BXZSBMQCPYPRN#\OPN+P65Y]5FL3Q$YJU>
MAEE2D[O&RE)1I49R7-#GGM%M?Z$*7$/\#.=S9Y(WX#*"VTMN" R L2-RJ59@
M%(JX+N%@""<')Z'@*&)+$9"D;&&TG=N 4@%AG^5D?"+_ (+/>$?C;<^+_#'B
M/XBZKX,\&_&3X^^*_#&F:OXNMM<L-<\(?%2'XB-I-AJ'AW5[RYTO6+'X=6/A
MCPHO@/1=8M);"WU?Q7I-F(8[9B$]XFU[_@LIXP\-:[X>U>S\3Z;+K_@+7W^'
MM]8^$/A7X5N;R:#Q"AT:^^+VL:%9VFN>#O',>F1Q@^'/ -_:Z9<VL4\ER1-+
MY8^@2<6XMW7QQN[R2GK:7FC\[BN5<JLH)6C&*=DTVI23DN:4:C7-%OI8_HK-
M_;JY0MA@<#<54,2P1=I9AD.[*BL,C<RABI--_M&WY^_PKO\ =R2B L[  Y.T
M??7&Y2&5@&1PO\[^K? C_@H7^T5\*/!.L_''5?C/X#^*7P[^)WP#\ :CHGPN
M^)M]\*+#Q;X-O/VA- D_: \<JGPZU/0K77?#S? F\.E:/?:LKZO92Z3JE\8S
MJ;//-SVM6W_!7'P-XV\8?#S2-'^(&M_LY1W?Q7GT6'0[G1];^*?B#P@-8O)-
M)LHOB]KM]+XQ\+>*Y-/CM[?PG>0ZP8Y;:>XFN95OFM7MF4?TC&[A!(+$8+#)
M''R.J.21D!59T!8G;\XYX;#?ML(P3G!4/D;6 3D;\JQ##<-HVY+9#*"AW5_/
ME'X _P""A%[^Q9\,_#WBS2/B7KUC8>*K#5?B#X,TOQ]XYT7]J35/#EU<^+))
MO!/_  GJ>,&U?4M,T"]G\(A=6LO$T/B#Q!IUGK-O/J#6;&";R'P-^RC_ ,%+
M?''A_P 2>,O&'C7XK_#/4_ WP,L_#'P[\!GXW_&74KO5/%]E'+;V=\E]+XZG
M&L:@8_WFHZGXR_M;49!*K02)/$)@ ?TS-=1*#(V0H)5CP0IWD%@P.QO+VNSE
M68A4/7C.)'XP\-2W$5O'KNDRSSW'V>""+4;)I9I51'9(XA<;Y657!;RT(5LH
MQ#\5^?7[)/P ^/?P _91\9^$/C-\6-?^+?Q \0^&M7US3H;_ ,0^,_%E]X0N
M[CP!96+^$]-U[Q_K>O>*]3E_M^#4;R>2?498TN;QXM-6SMHH8C_#5^R;\(OV
MCK#]L/\ 9QFG^$W[0UAJ&G_M*^&KW7]5U'PYXU@LDTJ'QI<W&KWNI:K<I%82
M:?);N!,UW-+:26\83RD !3WLCR"CFV%S?$RS6A@)Y/0J5J>'Q+][,K4*E;E@
MWM*\>2FFTVW%*]T>=BL;+#U<)3E@ZV(5:7)6J4_W<:#E-1IS:E;G2YHRERWT
MC(_TNQ=Q'C/S8'R93S,D%E79NSO9=I"]?F"G#9 /MD/SGY\(-Q.W@I@-O'.2
M@4[BV, =<'BOP(^+7[-?[;7@3XU?M _$S]G'6/C%KNH77Q'T/5?@SI/CGXV>
M/O$WPUCTJ;X4:A?ZO#<^#?$/B:_\/0Z.?B>;(?9%T<VMM%BT6!X0X/F_PZ;_
M (*K>,/C%^S?K_Q,T'XN6WB/2+[Q!<^(?%MS#;^"O@P-%AU24Z-X,^*7PK\
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M-!URRT;PCJ^H:3X@,_A)(-,@BM_&_AN/3M7NYXM*U\:A%)X<O=8MUE>.D?\
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M^&FF_LJW7B3PO\*/B%J7@=?%S?$.TL6\0V.E1VCWGB"WTV2Q>:QC(GN#';W
M\QHT564,&KUS]B+_ (+[Z3^UM^T7X$^"OB7X!1_"_P ,>/M*\7:GIOCB7QS_
M ,)(]G=>&M&_M:RL[G2K#2EGFDU.*,Q^9$D<%J?GDE4#GWX<+YYB,KEFU/+G
M5RUX!XZ==U:2A]7E4E0M.FYJK:<FXZ1=XMM=#GK8VGE^-PV'KN>&Q<YT)X>%
M:A4BG6YY3IQ]Z*BVI8;FUDHSARN,FJB9^/VB?\$,O^"E$ME\-O#&I_#GX;:?
M8>&O%?PYU'5=6?XI>%[J%-.\,Z_IVH:C<65G%J,DS3RV>G.OD1(CMYD41+$
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MX2Z6QN[::YD1)+:UAN(FGN(VEC5@#ZM(1\C*DJ<, 02#Z-W''8X/2F,@)!'
M&> I'4Y/('<Y)^O6O _A!^U%\ /CQ=>-+3X/_%+PSX_E^'TMC%XM;0[F>2#2
MEU2;4X-/NQ<SQ107VG7EQHNJPVVJ6,EW82O93+'=L-I?WJ"Z@N55X9$EC=0\
M<D3"2*16!(:.5,QN",-\K'Y65_NNA8U[Z=/+^OD+5.ZLGU=D[KL2JH YP3R,
MD<X(&1R!P>_K3L#T'Y4M-9E098X'T)_   DGV H]=1_UV$W1D[0R$X/RY4G
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MW&]9.,7&3M?E][FLG[TK1A/W8K=M)<UHWU-<;#TVGKTP>X)_4#/N![4[ '0
M5CP7D!^[,K,.2%8%U#'@,HRP *G<K@%6 5P#UU(V+9!YP 0?4'/7\OQIZ/9W
M7R_1M=A)WNUJKOE>J?+I;F4E%J5[W5M-.Y)1110,***:7506)PH."3Z[MO\
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M%'-+^:7WO_,.2/;\65?L]M_<7_OD?_$T?9[;^XO_ 'R/_B:M44<TOYI?>_\
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M?3['3[;QKJUO:V%G:0>(;:ULK:"**..);>VB2VC0JFY%Y_T_ICB&0^D,I_\
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M/[3UA\6?'WP8L/$'CKQC,?&?B75Y=>\36UOJ_B?P</"&G^&]7N]/MM5M]/\
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M._98_9ZN8HIXTN_A!X$GCBN8FCN(4DT"TF2.Z0EO*N5601SQ*6$4R.H9@,
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MO@UX6C_M(RE506?F03QR7&3"CP2JSJT;@?A+^P[^US8_#JT_9T\+>%_VJ(?
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M:'HUKXWT.3Q%9^#_ !;HGQ'T72XKR6R\_P 4^#H[VYT42^4RI=P.9[B&2RN
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M8_\ JNJK^O\ @'^B_P"S6T\8\_;M:/"M:J_*%/,LJYI6\N5Z*[=M%M?]GO\
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M1-/T+P/-::7I&C>)M3T^PM;=KWPM<7!2*W@C4F6>61@H&_J#H_"O]O#]K?\
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M1&31_#MA'!>WFC)9S>((;ZWBN7L_[+OOTW^#>H>+-5^$WPRO_'UO?Z?XXO/
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MUR1^F*_#[7/^"1'C#Q3IWB_0M>_:4U2#1;>R^/K_  7MM \(:7ITWP^\1?M
MAXO%&O:Q?"/[5K[V>F[],L[=V6/:8KC:LKR8 /T[TK]J?]G?7["VUC2/C?\
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MM[^SOXATO0M1^&/AGQ;XY#_$#P)X \5C4KJP\!KI$_CK73X<FU'P?)K5I?\
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MS2J6M)JR>ET_NTUN10K4J])5:4N>+LOP5_Q[/\=#]GZ*_$GQ5_P6H^%GAGX
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M"RJQ]Q:]PZJL60V[!+D-E3C;MV$EB,L!GI[YP\W1PQ\EN.1DE05QD$DK\N>
M002.>N,%NRW<5MO)+=75DVF[KHAQDI.:5[TY^SDFFK2O"-E=>\DYQ3E&\;O?
M1V^?]1_9._9NUBT%EJW[/OP,U*V.H6&J2V][\)O =S;RZCIMG)IME?&&;077
M[39V,TMO9RL7DMXVE2-U6=P/==&TBRT*PMM+TRSLM-TVRMK>UL=.TVU@L=/L
M;>WC$4=O9V5M'%;VMO'&J*D$"+"@&$1><W%N2SE!$0 #DLP!SP5PH!RK DAM
MW!&"*L@Y /J ?S&:;36_9/Y/8$TTFFFG?5.^S::?9IQ::=FK:K86BBBD,*1F
M"@LW ')/H/7_ #R>P)XH.<'&,X.,],]OU]C7R]^US\?=<_9O^!WB?XP:)\/F
M^(K^%KSPQ'J/A\>(;+0!;Z3KWBC2?#E_K4UU>07$=U%HO]JP7TNFVH-]>0!U
MC$+* X!]-&YC#!2'4G PR[3DA2%520TA!=5;RA($8X<KUJ195;H#D=B5Z<\A
M@Q1NF#M8X) .*_%W]J3_ (*<^*/@5\3/'_@?X>_#+PE\7M-\&^#O"GB3^T_#
MOC*/4]8TE_$'Q(\/^ =0NO%F@V%_:S6EE:6>H:U>:=I5J[:S/<>&+H75Q!&6
MDCZ7]D?_ (*;2?M)ZK\7)K_X6:C9>%OAY\.-5^(NFGPC9:KJGC/5M-\/>.M<
M^'VKZ=J'@V]D74-/US4K_0;KQ-X=T]9%%QX:N[9WN+O>+R@#]5/&?@_0?B#X
M6\2>#?$MDNI^&_%FA:GX:U_3FEFMEO\ 1M9LY[#4[1KBU>&Y1;JQNIX%>*5&
MB\TNISG.MI>BV.D:;8:58VT%O8Z;9V]A96ZH76WM+6)8;>!6D=I&6*%$C5G9
MG*J-S$Y-87P^\;:/\1O!_ASQOX?COXM%\5:-IVO::FJ6OV#48[34K2"YABO;
M!GDDLKN-)!'=6TK>9#<)+&05"N_:4 5?( Z1QX[?(O\ C6+X@O!HVAZOJ\-C
M-J$VG:7J6HPV-G9O<W=[+I]E<7:6<%K &GN9KIH/(BMX099Y)%B3YG!KI#P#
M5.28,&79RN&!5\').1@[?ES_ !$]!GAL8(M6EW^[YO9?-H.C?1*[?1+NWLC\
M"/A%X\_X*\_#G1)/B9XH^%8_:,TSXOZ_>7FE?"CQ1XK\"^#=7^#7AJ\\;^+-
M0TZ]E@/AGP;<6J0^ K[P?IMSX;U*X\4Z^-3T:^O;ZZEFORK^?:#^U=_P44F_
M9X\7R^+? GQ;T[XIS?%;X:6YUK3?@5K=YK.@^!K[1[U_C!I^@6%OH=[9Z_8^
M&?%D-KI>@ZA%#JD>JZ1<27]B^KPB;48_TQ_:4U[X.^)?VC_V?O@I\1?B1XG\
M.ZYXQTGQWJ/AWP+H&MZEH,/BR^L-*^TI<ZUJVE3QRQ):PVETVD6TV8KN:"95
MBD:W$4GIT?[&_P &Y/G6Y^)V=S$$_%/QD7VX>)9@6U(DJS&23:2%;<)'7)YS
MA5I5)5(0JTY2I.U2*G!N#M>S5^W:_3NC>KAL11CAYUJ%6C#%4_:X:I5IRITZ
M].[2G2G-*%2+::3C)IV=KV/S!\<?'7_@I?I'AWP[<7'A;6;GQ%=_%SX&QZGI
M'@CX5>($O+CPIXC^'UW>>-/"%I?:9H'C&RLQ:^+27N_%>J-HWA72X[2/3[W5
MM/D(5OWFTE//L+9I8(X9I+>*26(I;N8I'B4RQE[<FW9XY2ROY)\O>"%"J H\
M-^$?[/NE_!SQGX\USPWXI\5ZAX9\9Z%X(TZU\(^)=?U/Q);>']4\+77C&75=
M7TNYU2XGN WBF#Q)I4.I0-*L2GP[:OLD:0-#]#QGRU(8M(V]R6 W$*SLRJ H
M!*QJ1&"5+80%V8Y<Z'.G=7UZ[IIZ-K9V>Z?Y[-'*>&_ _A_PD=<?0=-BL'\2
M:Y/XCUHQ3W3K>ZQ<)");\QW,T\4,SFVMLB"-(U\H[$&0!V=0B4]UP ,DY( !
MZ<LB+G.006&,=S@4>=C.4;C)R 2, X)&0'/'.50K[]Z!DU%1+*&QP!G)/S#I
MCAER 64G@'"GU%2T %%%% !113'D5!ELC/08)/X@ G [X!QZ4 *PW*1^7U'(
MZY'4=QBO.O&/PL\#>/Y["X\9>$O#WB>?3-/U_2M/GUS3;749++3_ !98IIWB
M6T@6ZBE1;;6;&-+/48,8NK941BNP$^@I,'X"E6ST9DY&/O H7X)( #!6.?NB
ML3Q1XIT'P7H&K^*O%&J6.A^'/#VG7>L:]K.I7,=KI^DZ58PO/=W]W<2[42"W
MC3<Y/SE3E%8C;0!\]>%/V+?V7O ^J^ -<\*? KX::'K/PNAU)/ &IV'AFQ2^
M\,MJIQ>R6=TZM-/<2QR7,<=S=-++:K<3?9C&9G-<C&I'_!02YB!^[^QW:A3\
MN<?\+I7<A;&YHV "X<L^"XW_ ##%WP7_ ,% ?V.OB'JOPUT+P7\?OA]XAUOX
MO2ZG#\.M+L-5D-WXGFT9)GU.WLEFMH8X;FW2":1+>^DM);R*"X>P6Z:"1!4@
M9G_X*#7,FQ@#^QU;$*0VX$_&IU96RJH&3R_G 9B"2HSMR4^:SY9<K[_UYV?R
M ^Q%50 &^9@,,Q$>68?>8YYRQR3GUIGEK_>3_ORO^%7QM8!@ 0P!!QUR,]P#
M^8'TI<#T'Y"A2DMW5;Z^\K7ZV7-HKWLNUET)Y(/>*^[_ ()0"*"#E#[")%/Y
MD<?Y%2J!\VT8.T\@)QT Z>Y'7CO@XJU@>@_(57N)?*"A51FD+  OL)*C.%/E
MN"3Z,5'O1S-[NI%=6YI)+SO)K^D')3TNH13:5VU%7;22NW:[;25]VTNJ/G+Q
M$7_X:<^&B9&!\(/BRIR!]P^)?AD6' P=Y"#)&Z-0VTG>P'T(JAU#':,L_6-3
MGYN3TX)ZGZU\]>(6)_:=^&H !/\ PJ'XK;LL,*I\2?#$9)7>2V>-@&?>OHRW
M($0X#'<W8CJ2>,C/!)'/IG'.!S8>I%SQ/+4J-K$2IJ,I<KYJ<8.I92:=HJ<&
MY+W7S*S?3LQBI^SP$N1J*RW#0?-&2]ZGB,5&2::3T;3B[6DKN+:U(?+4_P 2
M?]^4_P *41KD?,G7_GB@_I5GS!DC8./<'N!Z>]-\P;2WE]%)QO)Y S@8!)X]
M!GT![]+J-*[=5*Z6DKZO1:*3=K];675HXU"GU@GM:W]Y-K^NG7<^>?VBLKX4
M\'$* ?\ A:/@;E!L(8ZA)@97!*Y5B3D<X./3Z(0,6;+$=0 "V,*W'!. 2K(3
MQU)'.,G\SOV[/VWOV4_@!=>!OAU\9OC;X'^'GC6Z\3>#/&T'AS7M3:+5I?"T
M.JWL*ZW%:) \C6,LMM>1I*0K[[5T$;%CM^\OA=\4? GQF\">&/BC\+?$FE^.
M/AYXVTF#7?"/B[0;I;K1O$.C7O-IJ6G3LL;O;S)&2#+%%('#H8\)O;HK4,1"
MC0JU*&)ITIU)\E:K2JJC4;47:G7E'V,Y6WC"HY+JE?5*=+GG2A*"G!*4X*4>
M:*=[-I/K:WR/0]I_OG]?\:-I_OG]?\:C,S@D&)E 7.YB=N>P)57(& 2QP0O&
M>M.$H(R%88."#PWY>XP1SSD=*XXS2@I2NDY-:QDG=RE:Z:NKZ6NMFGLT6]/^
M!K^0[:?[Y_7_ !HVG^^?U_QIX.1D=#R**U YSQ5X6T?QGX9\0>$?$5K_ &EH
M'B;1]1T'6M/>::%;W2]5M9;*^M6FA=9H1/;S21F6%DE0-NC=7"L/BWX9_P#!
M.+]F7X4>//!WQ%\*^'/%)\2_#Y[V3P;+KGQ%\>^(].T)]1T^71[F2STC6O$=
M[I_F)ILDD5N9X)HHOM$@2%2H-?>M% $,*.@;?U)[,2#RV"1@+N(P7*JNYR21
MW,U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%5Y'8,RA@O
M''<C@>OUSQS4?F..6D/&X]%QC: ,_*> ?F&>?7/2HYU=JS=K:JUGH^:VOV&N
M67]YI*X/[WKIUV]W>WQR]R/][=I:ERBJ'FLPW+*0K8"\#@NF1G*G RP(/H.F
M,X0R2C \TY)'4#(^5LC[N.Q(YSTZ4O:*]K/57IO1*I9I5%"[^*EKSQERR]V7
M*I6$G?E:3<9)-27PN]K:_P"&2E_A=S0HJAYDV.7.>W"]L^PZG SR>.O)JQ"S
MG?O))!&,C&!SC& .V.>3ZG.:M-/9W_72^GIU!-Z:-7OO;2ROKZ]/-D]?,?QC
M_:Q^%WP.U$Z9XPM?B!J%Q'<6L-Z?!GPT\:>-;;2HKN"&XBN-6O?#FE7]KIT,
MJ7,*0-<R1M/*7CMTGDCECB^G*_$S]N7X<?$3XE_'W3-#\=Z3\5;W]F^QU;P]
MXMBMOAKX.UKQ5=Z]XV\):=X>U+PQI\MO9ZI;6[0PZW_:L:XBA,4UU<'S?WCY
M8S]+_BW\.O!7[5/[/GQ"^%^K7%V/!7QL^&?B#P=?7\=F%U6STGQCH5SI@U&S
MLM5@F2'5[**\EFMTNX&N+:Z1&+)MVC\V?%__  1G^$WBWXBZ_P#$5OB[\2M/
MU'6]18Q65M#X:DL[#P]KGC%/'OC;18#+I%Q+)+XC\0PVL^G:G-)+#H&G6XTZ
MUT]KM_[2'Z\^$KQ;[0-*OTT^]T87&GV<Z:5JUD=/U#3HS"(H[6\T]Y)#87:!
M5\R#S'.% )SDU\[^(OVUOV3/"/B[Q#X&\3?M ?#;1/%WA37M%\,>(_#6H:VD
M&J:+KGB"Z%EHFG:A:"-VCGOKJ"6U67+VL$ZI%//:RRA9&K*49/I*Z];7\A2N
MXR4;<]H\C>RDY63=KNVCV3?XGX1_\%E_C3\7/@/\8= LOA'\2?&?@*T\4P^$
M[O6[31-=OC;7,UIH?BZ* PQ7\UY%9XCMXOM*6<4,<\B0R3;Y(T(_&&^_;F_;
M BL+NYA_:,^)ZRP6%S<HQUFW=1+%!/)%E9+)@522-9 .&W(N6QE:_5/_ (+Y
M@?\ "[O !VEC_9OAH!RORJHT?Q>"BNJF(NQD9I51PH41,%8L77\ -2.=*U'M
MG2[\''?%C<,,_0\U_'/B]GN=83Q%PF&P>:YAA:4\+@'3HX?%U:5#VU;%QHJ<
MH0:233;FTI-Z:-Z'^U'T-O#O@3B7Z-F99QGW!W#.<9G.?%ZAF.:9%E>/S"A&
MEE[C!T,;B</5Q%.5.HDZ7+.T%=QM>S_T<_V?M6U'Q!\#O@IK>L7DFHZQK/PD
M^&NL:MJ,Y!N=0U34_!>B7VH7EPZ[4:>[O+B:XG*HN9)&. "!5[XV:E?Z-\(O
MB=JFDW;V&J:=\/?&6H6%[#CS;2]M/#NI7=I=19R!+;W%O$Z%@1P002PQA_LU
M_)^SS\!-O!'P1^$Y]>G@/P\H.#WQQFM7X]HA^!WQA)4$CX7^.B#SU'A76"#^
M?]?4U_6_--9?[2]Y_4Z%Y-N4I2]C0YG*3U;<E-WW;E=[V7^-:I0_U@=.,;4I
M9\X\CMI1AF<Z$*:44H^[&M2222BHP:7PJ_\ !AI7[<G[8$]AIUS-^T7\3FG>
MQM9W<:U$NZ5T)8@?9" I9<J".,_>P>/Z)/\ @A?\<OB[\9-#_:";XJ?$3Q'X
M^?PYXG\(VVA2>([N.[?3;>YT+S)X;9DAA*I+(=[[BS%R3N XK^2S1&/]CZ2V
M3DZ;:<]^$;&/PS[_ )#']/W_  ;Q 'P[^U#G^'Q;X((^IT$9_G_(=!7\E^$^
M?YUF/BA7PN,S7,:^$DN(:GU>IC*LZ//2Q4>7]W)\K6B5OY596T/]B_IE>'?
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MC!UZ%/+:%98>-.E+#5:DJ;E-N=.G6Y)VNZBC*T376)2",OPS8^8C!(Q_#@'
MZ9SCU-?#7[??QF^-WP8^#VAW/[.'AZU\3_&?QS\2O!'PX\(:??>%Y/&5K /$
M<]])J>L7'AR/Q=X"CU"'2[2Q#NDWBW0;:-ITDGNW4^2WW$@8AR&.&<D=,YP!
MQGG'&3GZ^IK,U%["(-<:@+=H;:)I);BY2$K;1!=TTHEFPEO$D:,\\@9,)\[/
M\H*^LY)1<INW+92<M[VC?;2]_P"M&?,6;DHJ\YRERQBK<TGULO+5;W]WNS^?
MGXG?\%,OVX?A+X"/@#QG^S/J.B_'+PU:13>.?CW>?"KQ]J'[.5HLNF2ZY8PZ
M?H^G:NB7VI^);B70O B:=IOQ0U&WT#Q?K<M^-0UK1]*>TNO2/$?_  44_::U
M#XSZ1X(^&7PO\.:OH\OP+\0>*[WP_P"(/#?C.QU6_P#B#X=^&Q\6:]J=OXMM
M[B33M-\*>&O%\-QX*OM C\/:OJ>JW2))!KFFA\CZ9^$2>%_VI=6^*^N>%_VP
MO&?BVVT;XAZKI<OA_P"%?CVYBT'PE:Z:P%KI<VF(Q1A'<6;RKJ4<<MK>7((M
M;F60LS^T:S^REXBETO4&T/\ :0_:"L];;2=2@T:]F\>WK10:E-;3?89+H!@T
MMJE^8+BZB+ W,:R(QW2%@J=6G5A&<9Q<)N2C.#]K%RC=<K='VBB[Q:?-91=^
M:UG;;$X:O@Z\\-BJ-;#UJ4U"K3KT*U"I3<J4:L'*G5IPJ<E2$X.G-0<91G&:
M;IR4G\T?LE?MD_M"?&3]J#6_A5\3_"OA[P_X*3X*^ _'>D6N@^ O$5OJ=CXA
MUOX=_#CQ/XDD\3^,]5\5RV5C;S>)?%^O:!X9T2W\)":YC\,7ZW.K/?6%]'7Z
MWJ"!@G..!ZXQQGU/J>,^@KSCX7^']?\ #W@GPAI/C74;/Q#XXTOPMHVF^+/$
MUM;16QUS6K.TCAO;]U"B;R;N=7N(%F=V D9I5$VYJ]'  SCN<GDGG\?ITZ"K
M,!:*** "O%/CKK/BG0OAGXHU'P=XEM_!VMVFCWLEIXEN/ ^K?$E-%F$#;-2;
MP5H^N>']2UU;,@S?8[;58GG";0< AO:Z^6_VQOA=I_QG_9P^*WPNU7Q!H7AC
M2O&_@S6_#U[K/B;6;KP_H=I!J5A) \VHZMI]U8W]A91!@9Y;.Z@DC0%T8,H-
M 'PC_P $]?C!\?/BO\7?C;I^L_&+QW\3?A#\.]0TW2H?$?Q)^%6F:-:>,O$&
MKF\DD;X8^,?#NH:-IEAIOAI=/VZYX7NM(\::A;)K.C?;?%5M=B^TZ'])OV@?
MAA)\;O@M\4/A)'XBN/"+_$?P7K_A-/$\%A:ZC+H1UBSDM5O_ +#>LEO=I;R%
M//@:XM99K=I%MKJUN1!=0?%?[#'@#Q9X&FAT+2E_9BM?!7A'PAH/@W5[_P"$
M/BS4?'OCOQ/+H\FH2>']1\3ZS'?75GI^FE;C5VLH=4!U.:;[07GF<93]-GRB
MLS>80&894 N1G"GC&Y0#CD$X^]D@&@#^??\ 9Y_X(E^(_@5XB^&&I)^T/X=U
M7P]HWBCPMXK^*GAC3/A'K6F#Q#>?#D^*Y_AYIOPSUS7OBSXNUGP#I,%[XRUN
MX\4?\)%>^/[KQ"C6L4-YID47E-^BOASPI9Z#_P %%_%VJVEYK-S<>+/V2M/U
MF_AU/4IKZTL[F+XQ&V6#2+61473K-HXP[VT9=3,SN&12$'WD)(F.W<"1@@L%
M(/H5R<#!X&,!2#C!S7QQ$JC_ (*$70 X/['5OD$DYS\:2><DG)+L2<\DG- '
MVB!@ >@ _*EH_P ^O\Z* "JMUM(0,"0Q(XST.%(R 2,[A@<9QCKBK503*#L)
M )4D@;06SCJF"'!'7Y#G'7CI,U)Q:@U&3VE**FEJM>5Z.RNTGI>W8:=M;-VU
M5FD[]&FU*S3LT[-IJZU2/Y'_ (W?\%B_VC?!'[:7B&RTKX>?"J?PI\+/B3XG
M^!-K#):^)[W7-2\,:Q\1_#6AZKJC7-MJB0RZ]'_8-K<V$-KIZ6P,MPDEG<&2
M(P_TCZ;^TY\/Y+?P\+^T\;:9+X@FTBRMY=0^'7C/3+ ZGK6P10F_O-*@LT1K
MB5$#/(H&22WS#'@?BG_@E5^PAXS^)6I?%WQ#^SQX2U'Q_JWBM/&U]KKPRPRW
MGBB+4HM835YX5BBB%R-4ABOBRG$LZ ,'1F1O?_C]I\5IX)\.QQI&GE_$#X?0
MQ",@(L<.MVZQ0LL952L:PQIC !"$8 RI^<PN#SC!5<SKX_,Z>84<1F5;%8)+
M#QHU</AJM*C!4).*4;Q=-MJ+E&W*^9NZ7Z?Q!FG ?$?^IF7\,\+9GD.,P61X
M;+>(<=C,X>/AG&<0EB*M;&T\,H<M&BVU[-WC45Y1='7F/H>&X\Z,,%\DMG_6
MC)P2>"05SUQU^\,]*M2#<,9(WQ]1M!!^;!^8,O\ WT&'/(/%4[0,;=2\<:E5
M50%Z # P!C'4$#IQVY.=,PQG&5S@8ZGIW!YY!R<YSG)SU-?0VYJ<&G:<J;BY
M;.,:B5VM[R5E;9)]>_Y;[\744;-JLY03V5.3;C%Z/WHI6TT\S^:[_@K3_P $
MCOVE?VW_ -IW0/C9\%_$WPCTWP[IWP?\)?#N^T[QYKFOZ5J<>I>'/$OC76Y;
MJ :3X?UJ'[)<6WB>T0J'MFWVR." KA_TC_8=_8:U']GC]DSX"_ _X@_$#Q1<
M^./AK\/M*\-^)[CP+XOG@\*2ZQ:EVNSHD5UHUO/]A43Q1JTT*,'1L*@8@_I:
M;>(G)3)R2"6;(R #M.[*@@ ;5P,#I3A%&.B@<YP"<9[G&<9/\1ZM@9)P,>UB
M<\S/%Y1@<BQ6(5?+<ODYX>E*G",U-I?O)3BKRDW;1RLE%6ZHYH8'#T<3B,93
MC*=?$Q49>TD^1).]HI7MN^GW;GSU-^S]H"QRL/''Q3?9$Y ?QBAS]S<H+:2S
M ,HVLN<$94+EB1;_ &;=3U;6/@E\.=2UK4KS6-3NM&N5N]1U"19[V\>VUG4;
M:*6YD1(UDE,%O%&[A%#$9VC->VW<B+#+@/AH9,X& 1\O<D8[D^W4<UX'^R]*
M%^ WPT7=AO['U$CIT/B#6!ZG& N>O/KU!\BI*HZ+E.<9/VJ?--Q@Y66D4G:\
ME%**Y4[M);LZDM5",+7C=137PK1M:W:3OT1]%IG8N<9VCITZ=J=34.Y%(& 5
M''X>U*3@$^@)_+Z\4N9O7D:OKNNNNV_RWZ;C_/\ 7_AQ:*K23A5))=1Q\P /
M4@#C;R,D9]JC%P.,LPW?=X4L3U&Y5(( QR#W.#2]I!NRG%NU[<T5):-_ VIM
MZ/:+_!CY9+XERKNY1M^#O^!=HJ-2Q/.>.N0%!R.HY.><CV(IXSCGKS[=Z:FG
MR6UYXN2:V5K:/SUZ=F(6BBBJ **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /BO]O[QQ^T%\,_V6/B[\1/V8=4\(VGQE\#^'O^$E\*:7XW\)W'C#0/%$UA
M-$TOA2XL+37M N-/DUR/=:6^MK<7?V&>6/-E-D"OR=^*O_!83XF2_P#!(#X:
M?MP_!S1/!LWQW\:ZAX4\!>*="U_2[^Z\+_#WX@0^.-.^'GQ2EU'PX]SIM_>V
MWA+6GO9;#1'U73I=2A,*C4>?,/[4_M.^$_C#XX^%^K>&/@=<_"NQ\:ZEJ.@.
MUU\8;+QE?>#AI%GK-A>:K#);>!;[3M<EU":PMKB.P/VI;..Z>![I)8E9*_"?
MXE?\$3/CR?@1^U+\$/@S\=/@_IVD?M,?M#Z)\<K71_B+X>^(-_X9^#EG%>^&
M?&7BOPY\/K;PY?6=^5\2?$O3M?OW;4Y9(AH.K6T3!]2M/.K'#)>TQD:KY:'M
MLK="2UG%8?,\/B,VA5@[)4,3@:\U&LI.:E345!J151P4<-*+?ME'-H5:2LXR
M>(RO%4<HJRE>\7ALTI4Z\H<K4XRLVE%L^S/!W[6'[1/Q[_:1\1_L>_!/QM\,
MO#/BC]G'X8_"?QG^TU\=O%7PZO/$.FZMXO\ B;97.KZ7X"^'7PDMO%VG&R4Z
M5IMU-J^NZUX[MY-$GDMK>'2]2<_-O?\ !0#]KS]H3]D7]F'3?C!=R_#;PK\0
M+3XH:'X<?29?#'CCX@^"/&.BWWBF+11::IXJTW1M-M_A)8WVCWT>JW'C;Q-;
MWNG:-<Q/;-9ZC#F9ZEC^PY^TA\*?CQ>_M7?L\>/?@/HGQC^+?PK^&'PV_:>\
M">/_  [\0=2^#/B^[^%]K?67A_QSX$;P_J=KX[T?Q'!IM[-IDD&L:C/I]W;H
MK7UO<2J&'N'QU^ 7[4'Q?L],^'%S\6O@YXI^ /Q ^'.K^ /V@/"?CWX=W@\3
MZA/J\LIF\5_"S6?##65G9ZM!9NMDECXFBO=%D@M4OUT^WOY6O(NK%NC&IA71
M49*&*P]?%4TFG]9^M9E6K4Z;^SAL3AZM*-HQ^&E%I2?/R\^&2@I0J3<:4\+!
M4.:TG%+(\NPLZ[;U]K''0K8ATOAYZG(I\O+,^*/BE_P4G^-WAG]N_P /_LX:
M-/\ "O0]'O[7X%WG@#X<:WI&HW^K?M0^%?BD=9_X61\0?A;\7_[9T_PUX?TW
MX+6FG:9?'P]?Z5>:MXMCUZ(;-*)MXI/WALVW*QY/* DY^\$"N,'</E92I*NR
MD@CJ"3^)?CS_ ()2:YXI^)/P[T_2/B'X6/P"\#^./@G\2=.N_$=EXGU/]H+P
M/J_P*T*?P_X8\%_#3Q5;7</AG1_ 7BFQNISXQ@O;>34+TE<><"C1?MK:C <?
M+@$ X)+9RWWR<DL$V!BQW%@Q( (JJKPRHT(TOXGUK,HOW6F\/1G&.&JM[7K1
MG)NG_P N^1+F=[**:KNO.<U:F\+AFXWOR5FW[:"ZOEM%<SLVIO317MU^)7_!
M7GQA\0/#&H?LK/X!^+GQ)^%[V_Q8US5-?M?ASX:_X22'QK9Z>O@C[#X-\0-#
MXL\,2V-[JS7E_)X;M[BWU&RU&XBU,W/D1Z>'N_VUK^?'_@LYX9TJV^)_[&%]
MIO@;P'J=[XS^,.N2>,-:\4^%[S4T<>#['P$WA>:77-.TZ_GT?4K";4+A-)B?
M[-'J)8132O';'&)TG[XZ4&DTZU<M/F:V@9WE55N2[0%3)(J9C$C'E\;L-Q\W
M?\AOB-_P1U^#7Q*^.7Q*^/=_\2OB7I?BKXEZT;K5;"RNK"32;+1-1\5_\)AX
ME\.6-O>VK8L-;U>.UCCO0L=U:V=NGE,DKL3^OND.HTRUR<?N8&Y^4$85LJ6"
MC&T@C.,+C.*Y?4/B-\/M+OKC3-3\>>#--U*SNK&QO=.O_%&AV=_9WNJLXTRR
MN[.YOHKBVN]196%C;3QQSW;(RP1NRD!VO;_$OQ30+1Q_O3I1_P#)I._F?RD?
M\%X/#NDZ-\=_"E_8I>1W&MVGA"XU!)M1O[V!/LGA_P :VT(M;:[N9K738Q&N
M#!IT<$,S(99%WHAK\&M0"_V7J@'0:5?;<]>;"Y]>AS_@.U?T!?\ !?C_ )+?
MX .#_P @OPSR5(X72?&I8 D#.."0,D<$@9&?Y_K\8TS4L_\ 0-NB/_ 6>OXF
M\9E;Q0RU;WH91^.9)'^Z_P!!M\OT6<>[)VJ\90MZX-Z^OD?Z,/[-7_)NGP#/
MK\$/A-@^O_%!>'CU_6M?X\G'P1^+XSC_ (MCXXR"?^I6UC/'Y9^HSUK$_9G_
M .3</V?.,?\ %D/A+QZ?\6^\/\5K_'X$_!'XP<9_XMAX]_7PMJ7'X[3^7/:O
M[*E_R*W_ -@=#_TU2/\ $".O$=N^>R7WYS1=_D?YP^D!?[(T_ &!I=K]=VQ\
M]..F,8K^GG_@W@_Y%S]I_/7_ (2OP/\ 7_D7QGZU_,)HX_XDNF<?\PVQ&?I:
MH"/P/_UJ_IZ_X-X_^0#^T]_V-G@O_P!,"U_&O@TO^-J5W_)'B.-N]\4M?+TU
M/]M_IPR_XY6P,;;0X(Z_].<'T_[=_$_I>DZ$\G 3@=_W<@_+G^O:OX-_^#D&
M-7_X* ^&UPF5^ OA) =^QQ_Q.;YMR,J,Y&<AE!&[&0)7"Q/_ 'DOCN<?<]?[
MDF>F.V:_@W_X./XR_P#P4 \-;A)M'[/_ (50X97;<=9U-@L:@*H<J.69LA<[
M0%,AK^IN-U_QC5;_ *^4OPQ%/_/^K'^6/T7_ /D[N3/M@,X:\[4D[?-K<_+C
M]@V0?\-P?L=RKNPW[3GP$7)+\@?%/P@H7YO-" Y8*P<VL3,Y:<PO'=W'^H7%
MS$."/N9!SD89\@Y]/49!'()&"?\ +S_8,*M^W%^QZJ\ _M/? @EV5AY<J?%#
MP\EPL*@A96 *)%%)AIII9I)PLD,:G_4/3:B* ,;<A1\Q(P77!)))8# ))RS
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M4\XV@BK59TYJ:DTIKEE*FU/^:#LVM.^X$*01H0R@Y P#QT V@8   "X48 )
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MOV*SC]DK]FA3D.OP+^&>Y2"",^%-*/0\]<C\*^H:_BO,_P#D9YC_ -A^-_\
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MHYQJ2]HZK]SVDDW&32<4TG?]"XVSKA3,LFX(P_#M7B=YADW#LL'Q(\ZJ8:>
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MP&0+=ZCX9L;0*X/RL;E=RD,@89Q]"1'J"3D_,<C&#G#  X?&0"-R@<\$\X_
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M^(OQ ^*GBSXUV_BK3(M6AG!T$6MQX0T:XLIH)_Z%0G3CCCG$?Y_<%?-G@_\
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M%M1\(:IJVK>&)+J[OKV>6XCT.XUN_ATZ.0E8+-XK5?W<$>W[G$:#H.@ ZG.
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IR> &)R6&0Q()! '!2""78^QQBGT44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>drsa_003.jpg
<TEXT>
begin 644 drsa_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %# IX# 2(  A$! Q$!_\0
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M / *7_R8<V8_\^\O_P#!N._^4';>;%_?7\Z/-B_OK^=<3_PK3X>?]$_\$_\
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M_@G_ ,)70/\ Y H_X5I\//\ HG_@G_PE= _^0*/W'\U?_P  I?\ R8<V8_\
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M_OK^='FQ?WU_.N)_X5I\//\ HG_@G_PE= _^0*/^%:?#S_HG_@G_ ,)70/\
MY H_<?S5_P#P"E_\F'-F/_/O+_\ P;CO_E!VWFQ?WU_.CS8O[Z_G7$_\*T^'
MG_1/_!/_ (2N@?\ R!7!_$J3]GWX/>#=:^(/Q-TGX:>#/!OAZ&*;5M>UCPSH
MB6UO]HF2VM+>&&#2Y[R_O[VZDCM;#3=/MKK4+ZZDCMK2VFGD2-JITZ=6<*=)
M8FI4G*,(4Z=*G.<YR:C&,(1E*4I2DTHQC%MMI)&5?$XK"T:N)Q,\JPV'H4YU
M:^(Q&*Q5"A1I07-.I5K5J=.E3IPBFY3G.,8K5OO[EYL7]]?SH\V+^^OYU\I_
M!7XF_LF?M#V_B";X01> /%4_A2YLK3Q-I,_P\?PWXAT*34HYY=,DU/PWXJ\,
MZ)KUK9ZDEK='3M0?3_L%\;6Y2UN99+:=(_<O^%<?#K./^%?^"\^G_"(Z'P,
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M'H>ES9C_ "9?T7\;';O;>@M_EZH[SS8O[Z_G1YL7]]?SKYITKQ=^S3KGQ?\
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M&MZRGQ[\/_#OQ[XVUZ$7WQ)\5V\=A_PE&B:#X@36=85Y="-I)]KT[29OW_\
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MQE_V.UU_Z9- KLYONCZG_P! :N,\*_\ '[XR_P"QVNO_ $R:!6B_A5O\%/\
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M<DP :O;?&%W/I_A/Q/?6K&.YL_#VLW5O(IPT<\&G7$D3J?59%5@>Q -?E^I
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M7_8.7_T;+7;UQ'PW_P"1&\-?]@Y?_1LM=O58C^/7_P"OU7_TY,>7?\B_ ?\
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MS8R =W!( .#@DXQ@XY'(YZ<]:DH33V:?HT]TFMGU337=.ZNM1!1113 ****
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MZ/:>'M5U'1]&\*^+8]-U;QA&TNEVMN?@'PMI#QCX:^#/C]\._P!I3Q7>:/\
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M,J6:2RO#97BURJC6A252$:E"I>G%U(5%BI8BM3Q">'A#ZFI^UC5?SOI'AO\
MX+*>*]$3QG;:Q\2[&&> 75GH^K^(/A-X/UZZ@;J3X-U)M)N-,G3RR18:]I^D
M7[9'EV3"93+E?!K_ (*A?M%?!SQS/X(_:AT74/&NC:?J4>F>*H-4\+6'@_XL
M>#)4 ,DUO:6=IH.EZTL4$L=X='US3+:]U2%X9M,\1VUL8TN?Z/Q'C.-O/MCZ
M\8./SK\F/^"KO[-VA>.O@Y=?'C1M-M[?XA_"5-/?5[ZU@1+GQ)\.;W4(;#5-
M+U)XU4W)\+76H)XGTNZN7D.FZ?;^([.U0'6I*,NSC 9KBX9;FF4973H8ZI'#
MT*V#PZPU7"UJCY*%ZL5&4J?M)4XSJ-N4;J?LYKF48R?B3*<_Q]+)L]X;R+#X
M3,:D,+A,7EN#C@L3@<36?LL+>O!QJRINK4ITYUU*%2#E"<J=2BZM)_J+X-\8
M^&?'_A;P_P"-/!^L6FO^%_%&D6.N:#K5DS&UU'3=0@2>VN(UE6.>%RK;)[:Z
MA@N[2X26UNX(+F*2).GK\HO^"/WB75M:_9>U[0K^6:73_!7Q;\4Z-X?W_-%;
M:5J^C^&?%MU96_RC;&GB'Q#KE^WS-^\U)E 4  _J[7RV8X-Y?C\9@N=U%AL1
M4I1FTDYP7+*G)I;2<*D%-;<ZG;2Q\-G67?V1F^8Y9SNI'!8NMAX5))*4Z<91
ME2E)))*;I5:7/:*C[2-3E2BXI%%%%<1Y84444 %%%% !1110 4444 %%%% !
M03@$^E%-?IV_$D9]N/6E)VBWV3>EF]%T3T;[)V3=DVD[H$+@'&&.,YQCC'X_
MY[XK.U6>Z@T[4+BPMOME]!87DUE:$X%W>16\DEM;$@@@3S!(LA@?G/*X!K\F
M/VUOB#\2M.^+[>'8O$7B/PUX8L=!TB]\-6VD:K?Z-::HEW;EM5U>1]/FM6OK
MN+53<:6?/EG%C%8Q^0+8WDAE^P?V>/C);S_L\Z5XZ^*7B_34_L2[U?1M5\0Z
MGJ,,MY,FG7LL>EIJB1!KN;Q!<:>UJD=F8KC6-9B^R:CLNKC4O,E_"<D\<\AX
M@\1.-?#:K@<?D&(X2P>:XBMQ!F.)R_#8&K2RB>&H9EBO95Y8>KE]##K'T<7@
M\5CJM7#8K#T?;R]E3K8;VW!2S"E4Q>(P?+.G*A&7-4DX*,N72;2=K*-U)2YF
MG%<S5M#\T_#'QY^.\GQ*TC7(?&'BW5O$NH>)+.VF\)S7^I2:)J%Q=ZE'!-X8
M/A3S?L%K;-([:?%:P6<-S8/F2&:WO(VN!^W'C34M8TCP=XLU3P[9_P!HZ]IG
MAG7=0T'3_+DG^W:O9:7=W.F6GDQ'S)_M5Y%!$(HV#S%S&A#,,?DE\7OVC/!>
MH_%_P=\3OA'X032M5\'WFKRZGK>K:=9:6GCMM0ABM!)J6GZ>%U%TCM&U&"*_
MU.\753!?@_9;&6W&+D'[?WQ@6^$DFD?#6XM=Y_T!-*UN)\ Y5!<CQ1(RNA_C
M,!8LN2F:_FCPQ\7^"_"V?B)P_P 3>)W$O&,LUSM+)>(<LP&;9U@5AIY/B:-?
M/\)5S3,U5P^-EF68N.,P]&%++JV,R>CB,!">"KT*AY.#QV&P?UNG5QE7$<]2
M3I5H0E4C"#C;VB=_=;G)Q:LXWIW2LTWP/P>^-_QHG^,/@R=?&OBWQ/=^)?%N
MC:=K&@ZGJE_J&DZII^J:C!;ZI$NB22G3-,2RL9;B]MKFRM;6/1EMUN$6.S@F
MB;]R%?@Y#$@GISD X&/7_P#6>!T_(?\ 9>_:"^&'@#4M?F^(^A26_BWQ9XFU
M/6IOB9%I=E?_ &.'6!!)<:5<"VM_[<TK3#?)>7,O]F1ZA;22W;-<6]O%%O3Z
M#_;5^*NJ:/\ #;P:O@/Q?;V5GXYU662YU7PWKL*:AJ>@V-DUS$-)O;"<71T>
M[O)[;[?J.FSQ*WEVNFW$QM]1EMI_L/ SCG*> O!WC/C+-..L3QYB,+7>?XSA
MEYA6GG61SJ5997AL%6AG>.KUZ.(SO%U,'F.-Q>&5;):52K)8*6,KTL3&MOEV
M(A0P%?$2Q+Q/*_:RI.I>I2;]U1E[6<I1=234IM)TU/2":5G][AP2%P02I;!P
M#@$#IG/?T^N#3Z_-/]@?QK\0?$&I>.]%UG5]:\0>$-,TW3;NWN]9O[S4_P"Q
M]?N+ID73K&[O3+*D>HV GNKFQ2Y,%L]C!<16T+7TLEQ^EE?U#X9\>87Q+X-R
MOC#"9;C<IHYC4QU%X''.G4J4JN7XRI@JTJ.)HTZ5'&86I4IN6'Q=&$854JT+
M*IAZL8^MA<1'%T(5XPG34T_<G:Z:=GJDDUV:W]4[%%%%?>G0%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>.?'+
MQ3J'A?P/*VERR6][K-]!HR7<3^7-:17$-Q/<S0M@LLK06TD*.N'C,OF(R.JL
M!:M+N#TU.TU#Q_X*TJY>SO\ Q3H5K=1$K+;R:C;^;$P)!21$=S&ZD$,CA64]
M0,C-+_A9_P /_P#H;]!_\#X_\*_-D*.IY)ZDG/H.?4@ #)YP,9P !-;"T%W:
M_;EN&L/M$'VY;,Q)>-9B9/M*VCS*\*7+0EUA:5&C60HS*P4J=>1=6_P,^=]E
M^)^D'_"S_A]_T-^@_P#@?']/3UXH_P"%G_#_ /Z&_0?_  /C_P *^7['4OV<
METW5?-\/>((Y=L7DV]\^I7&H718XVZ9/!J,MM:-$?FG:ZGME*X,;3<I7D/BZ
M7P=<:I%)X)L-6L-)-G&)X-8F$\QOA+,9)(6,]S((7A:#(DF;$JR%552,)1B]
M5S?@-R:W2^]_Y'Z +\3?A^[J@\7Z!N=@JYU")1DD 99MJ@<\EB% Y) YKM(+
MBWNHH[BUGBN8)E#Q3V\B30RH<X>.6,M&ZG!PRL0<<&ORC*J>P_+^?_UL'T(K
MZ9_9N\3:BFMZEX4EGEFTN;3IM4L[9F!AL+NVN84N&@4KF-+M+K]ZB,(S)$CA
M-Y=V'"R;3>G<2G=V:W/LFBBN1U?Q]X'T#5[/P_KWC#POH6NZC;B[T[1M8\0:
M3I>JZA:F66W^TV%A?7D%U>0B>"6(R6\4BK)&R,0W%0E*3M&,IRLWRPC*4K+5
MM1C&3=EJ[+3K;<T.NHJK;W,-S$D]K-%=6\@W1SV\B3Q.#T*2Q.\;CW5C_+-D
M'(S@CZC!_*I3NVK237=6_P"&?D]0.0^(!(\$>+QCKX6\09/_ '"KD>W)SGZ
M\'I7\_?Q%_X*YO\  /QUXD^#/_#/2>+5^'5_%H9\2'XLMH+ZPLME::J;G^R/
M^%;:PFGLO]HM;B'^T[\'R1*9<2>6G] GQ _Y$?QA_P!BOK__ *:[FOY$M.^#
MG@W]H+_@JM?_  ;^(2ZNW@SQQX\\3VVN+H6I'2-6*:)\$=6\4V!L]2$%P;9E
MU;0[!ISY3>;;++;_ "B7?'^=>)&;Y_E>!X?H\.8RG@LPS?B3#Y1&I6IX6I2G
M]:P525*$WBZ%>-**Q"A*4X4YRY>;W6U9_P!9?1'X'\+^,N(O%'&^+F08GB+A
M3@/PGS;CFIA,%C,TP>,HSR?.\ L77PBRG-,HKXO$_P!F/%T:&%JXR-"I4JJ4
MHQG"-6'U[_P_1M_^C5I?Q^.L8/Z?!TC_ #T%68/^"Z&E,K?:?V7-2C?<0JVW
MQJLKA"@ ^8O-\++5@Q.1M$9  Y;/!=IW[)'_  2GU/3OB#J=M+^TM]F^&D>I
M3>)@^M7L<JII7B'7/#%W]@B^P$WI&J>']05-OE^9$L,RA1)Y:9WP_P#V7/\
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M@C2-3>)M?]F^.7_0[R'_ ,"R?_YS$?ZS_LU_^C:^*R\^;C96^_CVR^9F3?\
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M.E1HT:U6K.480I5)24'ZWX. _P"$-_;$X 'V+QOV &/^%S?%?\,<?I7#_L>
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MZ9^EX.<\@_3^M?RD:#K]]X=UK1?%&A3H-6\-ZQIGB#2I4*R*FI:+>V^I6+.
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M<L,5G4J0IJ*G.$95)*G3C*<8NI4DI-4Z:E.#G4E&,W&%/GJ-1G*,)*G-P/\
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MI+8^&_"^G7EPJ;Y;N\D5/M6I:E>SS2'==:A?7,ES=SMMC22XE9(4BA$<4?\
M)E?PQXI\2N.>+L5XE\19?Q-X04YY[/A++\GXAA&EEV8Q<,NH5Z.&RC#QG@LT
MX9PF%S;"9A/,\?F"69?6)4L'*4J\*/CO!5L9B,1+%U:=; +VCH0A6TIS5DI>
MXERSI1YHRO*=I:N/-M^&&OO\;OA-<)X8UW5OB=X"^S>:EGID?B?Q-I.DRQP%
M5=]'DTK5$T34+2)3&GVG29KBT4;4$H.$&#_PM7XG8)_X6K\2<#N/B)XN"CZ9
MUKIP<'\\#D^Z>(OVGKSXC?%SX?\ C?QOX8TV[\$^"M=N9]+\'V_F2,FE:P\,
M%Q>:E-<27$&KZW:I;V%\8Q;VFGW<]@+%88X)FF/ZN^)?!_PM\'^'_$/B^Y^&
M_@IX_#6AZOX@NS:^$O#RWLUOHFGW&H2QPR_V<&,TD=H4B);ARO3''\X\%>$]
M+Q'K<9XC@/Q@SC \+<(8^EA\/4S^CQ-2QU3)'E5;'K,I4,HSO#8.AA8O 9G0
MPT%1I8BMAL!#%XC 9?+&4\'3\O#X-XIXB6%S&M"C0J."]I*OS."AS\S4*R44
MN6<8Z>\H\S47[K_%WPOX4^.?QTN8M(TN;QWX[LX;J,37OB+Q%KM_X8TB<%)3
M->ZMKM[-I=E-%&5N%MX7DU.5%5K*TN91&A^B/%/P_P#%O[%$O@;XB^&O%6A^
M(O$7B.RUCPOXGT/5M#GDT29Y(DU-CI4L$]GJ0TJR:*Q4RO?Z7JL^H6L-R%.F
M:E>:1IW*?LW_ +2&L?#WQC#X431+ _#[QYX_6[FT6)KB34/"UUXIOK/2[=]%
MOS*B7=GIJ&PCN;.YLF:\M;622V>VNIOG_4[XJ_"3PG\9?#!\+>+HKH6L5Y'J
M&F:CITRVVJZ1J=O%/ E]83RPW$!9K>XN+>>"ZM[BUN()G26$R+%)']9X0^&7
M#_'/A_Q%Q5P;Q-G69^,F45L-2R_.LYQ^8Y=0X<SS"8BKC\NJ9/B)5<?5Q6$S
M;*J>)I+,LU^NQI1Q]7 8W)\'&CB:537 X.EB,+5KT*U6>/@[1J57.,:-9-2C
M[-WDIQJ4U)<\U)\NDJ<+6/!/V5_VFM9^-FH>(_#/BW1=(TSQ%HFGPZU9W?A]
M+Z#3-0TI[J.QN4FLM0N]0GL[VRN9K-O-74)H;^&]S';VC6;_ &C[/KPKX*_L
M^>!_@9;:HOAA]3U/5-;$":IKVNSV\^I3VUJ\CVMC"EG:65E9V4+S2RM';VRR
M7,[B2ZEE$-LD'NM?VQX6Y?QSE?!&48+Q&S*AFO%E*6->-Q="K2Q/^S3QE2>7
MT,1C*&%P-#&XO#X-QIXG%4<'AZ=6;A%1G*C.O7]_"1Q$,/3CBIQJ5TFI3CLU
M?W;NRNTM&TE?33N4445^@G0%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5\;_\ !0?XQP? /]BO]I/XH/-##?Z/\*?$VB^&S.VU)/&?C:V7P1X+
MA91\TJR>*?$6D^9$A1I(@Z^;"I:5/LBOYD?^#AS]L#1]'\">$_V*?#\!OO%/
MC.X\,?%_XEZEOC-GX?\ !'A_5]4;P9X<BB7]Z^O^*/%VC+KDLKRPC2-"\+QQ
MW%G=+XLLKJQ:5VE_7G^ '\E\$:00Q0)G;#&D2]?NH B\GZ8]<\XQ4U?JY^W#
M^Q7X:_9O_8H_X)T?%?1XX+CQ?\9?!OC'7?BOK=L$:'5]:^(&G>%/BG\/[7S
MJLS>%/"6I:AX.C=,VEW:Z+;WT4=O<S7<M]^4=;IW :Q[=SG'X#DCZ#_$X&2/
M[EO^"!WQ B\8?\$\?"GAK?(US\*/BC\5? 5T)2AVG4_$1^*%H(=K-)Y*Z?\
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M I2?+&3[1;^Y-_H:45S5J,59N=:E%)Z:RJ1BM7HM9+5[=C\A/^"9;#_A@GQ
M<$[?VK_B," -Q&[]F'2^H7)'WA@8R<K@?,*^:]3<FW_:" 1LC_@F5^R85&U\
MNS? ;7E**-N0RMP590P)"D U\A?LX_M[?M)?LL>!+SX>_!OQ#X8T?PUJWB>^
M\9W]OK'@[2/$%Y+K^IZ-H.B7<RWVH!I8K<Z?X>TQ$MH\*LB2N2?,*K[_ /\
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MG[?#\TK14JM-TW-J'M5)P=3ZWHHHKQCYD****'LP/GSX^?'&\^"FF^&-0M_
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M/!_@WXRWPNPRK8O_ &WX;\4Z+H4O[I&\4Z]HMF#]HOEED_J _;Z_X*%?"/\
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MRHO,,;4A&=*A4JPM5IT$ZE!35)QE552<7->R2E^A&EC_ (*Y_%G28?$<>N_
M3]GFVOU^V6'AC4-):Z\206;Q*]G'J=GJFA?%I;*6>)D>ZAO]0L-5MKKS8[S2
MM)=3IL'/VGBSXZR^(=/_ &4O^"D?@SPAXV^&WQUNX_"GPZ^-GA&*RM-*E^(@
M!N]!T&\U'0K/1(-'UO4+E8H?!UXWACPGK]KX@C18+7Q%HU[J%]H7['H.QP2
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MRL1"M]CT_P >Z)J&IN22H,<>EVMX\JYR8E<!7+!3_>C^W+\!+K]IW]ECXM?
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M** "BBB@ HHHH **** (IONCZG_T!JXSPK_Q^^,O^QVNO_3)H%=G-]T?4_\
MH#5QGA7_ (_?&7_8[77_ *9- K1?PJW^"G_Z?D<6(_WC!^N-_P#4.F+\-_\
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M-.-67M*M2?.H14*;A'FO.:YH1EVW_!-S]@^V^+5SI7[07Q>L([CX9:/JLS>
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M;>7=&2)GEMXM*:@VU-ORL^OGOTV%)M)M=#ZZ_P"'D/P+_P"A:^*7_@A\,?\
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M1]1\0:KXG\5-=IH]K##KVN^'-,CAEELY(Y;BXU2%82T98&,R.G/?#?\ :/\
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MNQ#8!Y.><<5+117DK^OGJ?7[679)?U_74**** "BBB@ HHHH **** "BBB@
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M1=%GMM'N=&O[>""_O+_4O[1M9;S48$\XII?D&TOIED:*X$D<0CA,GW!17?\
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M@_\ X*V?M=:':6T6LR?"[QRXCCDDOO$?@>XT_4)0T2[HY&\&Z_X7TT(S$O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>>_$WX4?#OXR>$;W
MP)\3_"NG>,?">H7%G=W.CZH;E8OM=A<)=6=W;W-G/:WME=V\J?N[FRN;><1/
M-;F0V]Q/%)Z%150G.G*,X2E"<)*4)PDXRC*+NI1E%IQDGJFFFNC+IU*E*I"K
M2G.E5I34Z=6G.5.I3G'6,X3A*,X2B]5*,DUT9XW_ ,,]?!0>./ WQ)7X;^&4
M\;_#3PS!X-\!Z_':/%<>%_"]I;WUI8:-I=M%*EA'::9;:IJ4&D^9:R2Z5%J%
MZFG2VRW4X?2^&/P3^%'P8B\2P_"SP+H7@B+Q?KL_B3Q''HD$D*ZGJ]QD><XE
MEF\BUME:1-/TNT^SZ5ID<T\>G65JD\JOZE16DL17E%PE7K2@XQBX2JU'!QA.
M52$7%S<7&%2<ZD8M-1G.4DN:3;VGC,74@Z=3%8FI3E"%)PJ8BM.#ITZM3$4Z
M;C.K-.%.O6K5H0:<8U:M2I%*<Y2D4445B<P4444 %%%% !1110!^(G_!9[_D
M3?A%_P!C;+_Z8?$U?@".GXM_,U_2U_P56^#OBKXH_#/PQ>>%+&;4M2\+:O\
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MR:!7S<$U1K)Z^Y3VO_S_ 'W;>]]V<N(_WC!^N,_]0J8OPW_Y$;PU_P!@Y?\
MT;+7;UQ'PW_Y$;PU_P!@Y?\ T;+7;U>(_CU_^OU7_P!.3#+O^1?@/^P+!_\
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M-EKMZK$?QZ__ %^J_P#IR8\N_P"1?@/^P+!_^HN'&[EYY''!Y]*=7QG^T?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>pg80-149_016.jpg
<TEXT>
begin 644 pg80-149_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &D IX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S[XJ_%;X<?
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MOV"?BE^T-\#?%6I>-+3XQ?#/X8:/\*?C[>75Y!-\$)M8\'^*=&\>Z!)X7O\
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M],\]O\1^8H 6BBD) QD@9Z9.,_3UH 6BDR.3D8'7GIQGGTXY^E&1ZC\_7I0
MM%)D 9) 'KGBEH **** "BD) P"0">F2!GD#CUY('U(]:7(]1_\ JSG^1_(T
M %%(648R0,],D#/TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** ,G7=%TSQ'I.H:!KFEZ9K>
MA:U97>DZYHNM6-KJFDZQH^HVLUGJ.EZGIM[%/97]A?VTTEM>V5W!-;75M)+;
MS1-'(V(?#GA[1/"FC:9X<\,Z)I'AOP[H>G6&D:'H&@:;8Z/HNCZ5IEM'8Z?I
MFE:5IL-O8:=IUA96]O:V5E:016UK;11V\$4<,4<:[E% !1110!D:]X@T+PMH
MFL>)?$NLZ9X>\.^'M*U+7=?U[6[ZVTO1]$T31[2?4-6UC5M3O9(+/3M,TRQM
M;F\O[^[FAM;.U@EN+B6.)&<&BZ_H7B31M'\1^'=8TS7_  ]XATW3=9T'7M$O
MK;5=&UK1]9M(K_2-7TK5+"6XL=0TO5+*>"[T[4;2>6SO;>:&6VFE25"TU[IM
MOJ-K>6%];6E[87\-S:7EE>P)=65Y97<)@N;2[LY5,%Q;7,;RQ7-M,)8;A))!
M*"LIC3\K/V3I9OV(_CW??\$]?$MS-'\$/&-EXD^*?_!/S7KYYIK;2OA_87'V
M_P")7[))O[J1YI-0^!5S?KK_ ,*;(^;+)\%-7L-#@GD'@"Z5P#]9**BCF24!
MD)()(!/0E?O 'D-@Y&Y"R$JP#'%2,VW'!.3@ 8SGD]R/2@!:*;O&<<CW.!^A
M(/IV[C.*3>,C@X.<-QC [Y![\[1C)P>,4 <CJW@/P;KGBGPUXVUCP=X4UCQA
MX+36(_!7BS5?#^D:AXE\'KXELHM-\3#PQKEW92ZKH \0Z=:V=AKO]DWMK_;%
MC;6MG?++!:QJ>O4851@C"@8/48&,'EN1WY/U/6C>,%N< X/&.^,\]N_T]^*<
M#D9'0\B@ HH_7_/O3=W^RWZ'Z<@D<GCKP>N!@T .I"P7J<?Y'^/^<&HS-&HR
M[!%Y^9V55&U6=\DMP$526)XQR,KDCYT^)_[3'P\^'R&VL[M?&'B&.;R3H.B7
M< 2%C@LU_J[13V-J8\$+;Q//>2ON5+9@C%0#Z-,B*<$D$@$?*Q!SG ! P6."
M0H.[ )Q@$CG=7\9^$/#[!-=\4:!H[L,K'J>KV%E(_)&(X[B>-Y&RI!1%9@1R
M.17PUJ_[8/A/Q';PZ9K_ ,-?$\-EYZ3W@T_Q9#;W$8A57'_'JFG7,P"2L[6T
MTUHKJ5*AV8JN;JGPN^"?C>R35_ GQ9T[P['K%Q:W$^F>(9=.O=0L[C4BEK';
MI->2)KD%V+CRMEE/>S63S2B2*39)')0!]\7OBK1+/14\0_:I;O2Y4CDMYM*L
M=0U>6\65BD7V:UTNTO;RX5FX9HK=UC'S2%$!:LKPIXIO_%"SW+>$O$/A[2QM
M^Q7GB!;&RFU)/EQ)#I"W;ZE9AP1L:]MK8L2"@-?(FCZ+IMS#>?":S^/GQ$\;
MW<VH"UU:S\&:+$\^C+:[5D6XU^\FO38:.LI,<CKJDD$CH\2[GBE5>D\8_$3X
M+?#SP5;^ ]:\6^,?&4 NKBW+Z)K7VC7K&ZT"\BAN+6XU.*_THZ0+:["JL$D^
MVX0>;&\D670 ]J\<>,OB3X>O]OA;X7GQKH\-M#-=75OXHT33M2N)G8F==+TF
MZG\^98@!S+LEFF($<<B@N/0=+UFUU2V49@L]3$,3ZEH\E]8W5]I5S(F6MKY+
M&>>%Y[=R%D\N3#E& <LNT_GI?CP[I.J6&L>&=8^.^M?%":XLM5ATO4=-TOQ1
M>>&K&[ED*3:QIT.I)H<;WT$EM-I\4^IWLUM 8YUMRY8@\<^'_!-]I_AVSU?Q
M/K_@7QY/-<75]HUMX.T?4OB/XIUG59?M,^I:K'X6\1PPZ%%*O,>CZAJEL\$,
M9N)8T!S0 GQFF_:,TN[UG4=>\>:?IGAG3]0<6,^C^+=&\.+/9R3E+21M+MKE
MM64[)E+^<T[9ARUN%;+?,7BCQIK/B)[I_$MS::MK"0Z?;)KD5TK-);Z<61KB
MX:Q>*QOKB[MYH(_M)ME?9&B7&)8F ]XT_P 3>#);>PT1?B6C7MQ<?V9&L_P
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M3>L3-)&V!*JE #,3@, <8\,<CEWB5V;:V^15>7>#NR9&4R91PK@^8R87C+8
M<8D[(&(8$.ZJ70G.YES&VX,6D+*KQG$F &.=DU% #0#@!CG: J \A(UR$102
MP557 VJ=N<D=<EU%%  >A^GT_7M7>_"_PV_C+Q59>'AXR@\(K?/#IWVBXGU.
MW-[;W-TAN-'LI[.&XMK:X>+>MI9:C-:K/</&JO*'"GCK33KV_B$EG;/<B2]M
M]-CBA9)+B6_O(S+;6L=LC-,[S0K)(L@0VZ^4\,DR7+0P2_H1^SI\"/'/@Z6\
MUSQ6=*TB/5)=.=O#]S;P:Q>QC3KG[0ES*C,VGVES)*5^Q7D<UU?:?%N@4%ML
MR@'K_A/]FSX=>&%ADO(-8\77T2J$O?$NL7MX$V\A8;%)X+.*-2,J'23:V",L
M%->^VUO%:PQ6\$2PPP1K'#&I^6-%7 11SA5  '+9 '-3@$8'8#&<]^.V/;KG
MVQWI: /S;_X*E>%?$T/[-^F_M'?#O3+C5/BI^PU\3O!7[8W@JRL)7AU+6O#G
MPHEO[/X^^";40(UY>#XC?LR^)?C-X#72[0/<ZCJ'B#38;6VNKX6D5??O@SQ3
MX?\ &_A7PUXS\*:E:ZSX6\8>']%\5>&-7LF62TU7P]XATVUU?1M3M94^26VO
MM-O+6Y@=3AHY%*DK@G2UK3;'6--O=)U2VCO-+U2SO-.U*SF1)(;JPOK66UO+
M>>)\I-#<6\TMM)$5?<)LXPIS^</_  3!U&]\$?"+XD_LD^(KF:?Q+^Q'\8_%
MWP"L?M#S3WE[\)'-MXZ^ 6L-+,WFSVT_PF\4>'='CNGCMT:YT"]B$4?V=\ '
MW;\2;OXC6.BQW7PRTO2-9UQ+Z!;JPUBX6UCETWRIVN#:2RW-K#]L$BP!%FD6
M,JQ.258#XI_X:&_: \1>*+'P+HOA;3M*\2RGR+^Q@TFZ>\M9HKAUNKIYM6\N
MTCL;4*#>WHCGL6SNM;F89)_1@CS!GH",8)_7*D@,#D94D$=STJNUE;M<?:S;
MVYNPC0K=&*,W*P-C=&LYC,BH<?-%N*.>3ST /D_0-5^,][KT?A;Q#XRU/PSK
M]NL7VA7^%ZZOX;U*%2&%WI_C'2KF;2_,GC;:\&J)IUQ$R<Q< 'ZPM8;B.*!+
MB8SRQPQI+<;5B,TBKB1S A,<?F,-XVEBH8KD5,K< Y!7!Q@DE@H.2N" 1R ,
MJ",$<C!IWFIG .3D#M@9Z<D@=>,?>]L<T 25#/%YL;H&D0NCIOBD,;IO &Y'
M&<.!RIVG!_60,"2,$$9ZC\C[9[ X) SC%.H \_@\#7-MJ-CJ">,O&$XL;F>Y
MCL+G4K:33Y1/"83;74"V:&X@AW&:!)&;;,"2^,"N.\2_ _0_%FJV6L:MXD\<
MM?6%Q#=VJIXFNHK!+NWW2V\J:=$$LX7AD/F-Y4<B2*NURS<5[C6)KVN:?X<T
MO4];U:X%KINE64E]>3'9\D-NKRLJ*SINDF ,<(!PSJ59DX) ,KPGX8/A73!I
MIUO7]?F:=[B:_P#$=\=1O7F=F+&-RD:01L6(2.)?+4 "NHN+NUM%5[JYAMD8
MA5>XE2%68\!0\A52QZ[<YQDXQS7Y\>$_$7Q@_:2\5:M<:9XLOO 7PYT2^*_:
M-)B6TNY(;AW>WTR*:#S3J.K&S"W%Y+-=I8V<<B,@E=Q$/J&Q^ _P]B-O-K4&
MK>-+JW^9+GQAKNI:YFX&#YJVMS<+812,2"NRV4*.^ * /:Q(C %6!#8*D<A@
M>A!'!!SP1P>QI]<3XF\6>%_AUH UGQ#>1:+H5BUK8)(L$DB#SW$%I!%;VRO)
MC S&4654AC=YF1E:KNG>-O"FL6MC>Z3KEAJ=GJ3F&RNK&9;BUFN 546K729M
M[>ZD=ECCMKF6&:1SM5"0< '1S#(4C[P)*DD@!N &(Y!VYWC<K+E0."0:^79_
M@M\6;'59M?\ #WQ\\0R7YNWN4TSQ!8)?Z%+$\SNME+:17,""".)@F^&,2+M(
M"G@5ZIX[^+O@[P#:1W^KOJ5]:M<36+S^'].?7%L[U 0+6_\ L,CO82RLI2/[
M2(DD;*B0;6Q\)>/OVMO'>JWTL/@;4+#1]&=8Y(9_[!:/68B"=T%RVI3WD(D4
M#;(UO$4!.%8GF@#[V\$0?%.W?4H_B'>>#M1@^1])N_#$6J6,ZN-H>*\M;^(1
MA'/*O'._HP%7-7^*?PX\.ZROAS7?&OAO1]<Q;EM-U#5+:UGC%TK/;F7SG5(5
MF"-Y;2NBL1@') /Y$7'Q<^*EU<RW<WC_ ,5&>;?N,6KS6\8$ARZK'$@BC4<X
M5(<-V,?%<#?7-]J=Q+=ZC>7.HWDPC\ZZOYI;F>5HB1$7EEDEF=8U9O+C,BK$
MW*,P)P ?O)8ZMI>IVR7FG:A97]I(TB1W5G<PW-O(T3;)!'-"[QOM;@E6([@D
M<U>#J>ASGN.1[ GH">P)!)XK\$HM2U:VA6WM]4U*"VB9I(K>&^O(8$DDDWRL
ML,5RJQ%L*05,FYA\X KZ)^%7QFO_ (67EG=:QXQUGQA;WMJ3/X1TZYGU33-)
MC=@?-U#4M0B-S_;#("\-GI,5S8H %N]2M7'DL ?K+D9(SR.H]/KZ9SQZ\XZ&
MEKY47]L/X,A(VDN?%*,8UE=&\.7;F#S<#RYGCD>,LN>65V0 $[^F>ZG_ &C_
M (-QZ3=:K#XTTV\-K9->MI=N^S6)@%#"V@LKLVN^[<G8L32HN[.Z15!:@#W&
MBOG'2/VKO@EJT]M;GQ/<:5+<L$!UC2=0LH(G9@JK/=B&6SC#%AB3SVB499Y%
M49KZ#M[ZUO((KJSGCN[6>-)H+BV=9X9X7&5E@DC++,A7Y@T9;((*YH L[U'!
M//(Q@Y..N!C+8ZG&<#D\4ZN3\2:[?Z% E];>'=0U^S#,+V/2+K3TU.T15+-<
M1VNIS:?8RVZ $WCRZK;R1H,Q0W#?*,GP_P#%/P+XCLDO+3Q!IMJ3*T#6>HW^
MGVM[%(AVE'A%Y(I^;Y5,<D@8_=)!!(!Z%152*_LY]GDW5O+YG,?E3PR[U.,,
MGER-N5L@@C.<CCD59# D@=B1G(P2.H'.<COQCWH =13#(H(![]#P1P,GH21C
MW ]LTJL&Y'3L>QY(X/0]/PR,\\4 .HH_7_/O2;AVY/. .^,]^G8]Z %HH_3_
M #[44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?(W[9
MW[+L?[4GP:NO"OA_Q6_PS^,G@77=)^*W[.?QDM;)+V_^#OQX\#&6]\ >-OL)
M*KK/AN2Y:;PY\1?"<S);>-OAYK?B?PK--9KJJW=O]:[FR1P/F !((R.X')Y'
M9N <XP*^.?B!^T/\5-'U+6=.\+?!C4Y;#3)M2AC\2ZVFK/IEY:Z?$\TVK)#8
MVMH+:P$$;S1R7.HQ&6)3+O@8"(@'*_LP?MP^#/B_\'+3Q3\68=+^#?QN\%Z_
MK'PO_:#^"]U?W.HZG\,/C9X,\NU\;>'+"4VD-_KW@Z_FDMO$_P ._%ALH;;Q
M;X'UWP]K4:P7-U/9VN]XT_;3\(::RVO@?P_J'BV5@V_4+^9] TF$[6VJBRVM
MWJ5Y(QQ^[%G:0[/,+7B.L44WX;_MB?$&]^''QCT/]MZR\,VFF^%-5TK1OAO^
MV[8^&S=O!J7@?[8ME\,_VF-/T!8VFCUSX$7U_#HGQ%#7U]>:A\(M8U6Z8-/X
M1LI%^G;>6WNX(;JTN(;JTNX(;JUN[2Z2[L[RTN85GMKVSNH&^SW-M>02Q3P7
M, :&YB:.X@E,4FV@#ZUU;]L?XJW[L-+T_P )Z#&%=52*QN]4GC+X"O\ :+R[
MC4NH!/$ !8C( 7!P=%_:P^,NCS.UUJ6D>(8I;F.XDBU;28UV*JE7M;::PFM'
MMX'PCKD3/$YE<%Q(%C^< H'].G'3/.,G.!G)/MBC'7DX.,CMD8P?7/ [X]J
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M.\CI"K>>(XG+2!901%0!\?H6D<1QI(\ISB%(Y))6( )"1(C/( #EFA678.6
M&2.ET;P;XP\12I#H7A;7]5>1D5#:Z5>O'E^!NF6%X8P#GYI9$7@\C%?JY\,/
M@;X!^%-J)=,M6UG6+B,B\\2ZV+6XU!@K1*\=DJ11VMC;%FD=HK8B=G(C>6Z
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MHNE?"^VB'BU_#)M?"<?B&Q^*<5S<^$]3GU)_#2QVNK6#-=?;]?A!_P $WO\
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MN;F165-ZV5]?Z@@25E>XTRZ0- X!\&7NG66IZ5>V.IZ?:W>B:KI]SI]Y8ZG
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M*=!M]/N[N*RN]/DM=2@::":UOQ"TT<<D;Q7%K*S0*XG@FB/#))O1RII_%?\
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MU9WMM/9WEI(#D)<0RK&\#N,@#DR*&0X1W5H=HVNHX61MTJ+\J3'<S#SD7"3
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M9I,%T+"_,VI_8KK3)9;.^NX[V2&%YD^#/'G_  <B_P#!.WP5\5;_ .']O/\
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MT 8P/3'KGG)+$@@LQ?<  /HHHH *:QQC[V.AVA689QRH;N.G'S;2Q' -.HH
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M%8!E)?:N5;[P8[E'S$8Y(!I @C(((]001^E+3=H'"_+SDX[^OY]Z=0 4444
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MD6EJ]_<RB8((;\S0MYERQ(!^>G[4WQ3\5^#/#'ASX<?"AX)/CW\>M;N_AO\
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M?E?\#?\ @L?^U]^S-^P9XJ\<_MB^./@-\=OVE_"W[<O[4G[.5[J_Q-\7Z7\
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M;BKQ]+6O?KS<V]K6/S(M_P#@M1\=_P"S_ WP]_8U\*>!OVN/#_AG_@EAJ/\
MP4,\5_';]KKQ/K_[/WQ.U[1O@]\?OBI\$/C1X(\6> ? G@75-%_X6G:ZC\/#
MX<MUT>WTSPS:>,HM;U?4]4G\,)HIU7T3XP_\%]+SP5\8/V6K7P7X,^!7B7X5
M?&C2_P!B/4?B+\/3XD_:#\3_ +3/PVB_;>L_"FH^#;KQI=>"?@/J?[-'P7N/
M#VE^*[+7]"\$?&/XQZ1X_P#BWX4TZZ\4>$- L;+5?#?]M_3WQ#_X(1?LJ?%#
M]LGP)\9O%GA'P/)^RQ\,_P!@;3/V,O!'[*NB:5XO\*6FC:MIGQYU[XMGQG)X
MN\*^-M%&J^%-9\.^)]>\&^*/ >L:/?Q^*)-6O]4UW5;Y;N>TD^P/B%_P2G_8
M+^*/Q-M?B[XP_9[\.R^-;63X/W!FT+Q#XU\*>'K_ %#]G^.UMO@MK6N^"_#/
MB/2O!WB37?AGI6GV'A[PAJ^NZ'?ZAHWARTBT.SNHM*5+)$XQ=_=7YO[VFW\V
MV^K*YI-WD^:6MY6MS-[MJ,HQ5^T8I*R221^/GP<_X*0?M/\ AZ^\&? KX#?#
MKP?\4?BM^TK_ ,%-_P#@JU\ _#FN_M2?'OXBW?A+P#_PS=XRUCQ5H%U_;7A[
MP5X@\367@5=,-QI>D?#?1M*OVT.RMK6TT+4+>P+FSZ#]G[]N+Q#^U/\ M2?\
M$3OVS-.T'Q)\+T_;B^!W[;_[/OQ@^#5CXHU'7_!UGXF^"%Y<:\-:\F.:'2;Z
MWT+QW\+O%T7A#Q)=Z9'K*^&_%,&GWLHDE>%/VI\*_L _LF>"O&/@?Q_X:^#^
MBZ9XN^''QF^.G[07@O6DU/7YKC0?B[^TF\Y^,WC"UCN-3DADN?&<<\D5U9SI
M)IUE%MBTZTM44"OGKX;_ /!+[X=_!O\ :7_9/^(OPEO=#\ ?LY?L;?!7]H+P
M3\'OV?-(TK6KR2R^*?[2/CZW\6^/?B3>^+M8\1:C+-9I82:]8:;HCZ?)<V][
MXGU:Y.J-;"VM(CEBM4DFM4[+1IW37N] <FU;5733M*:;3[M5+OYW/U(6,K_#
M@D=003Z\GCKT./;M4JC Y&#C'ZGW]^?TIU%5OO[S3NI/?:W32Q%O>YKOX5&U
MVUIUU;=_F%-+J"02?E )X) R">H&,X!)&<@8)P&7+JY_Q)?W&D:+K&JV-A-J
ME]I^G7EW::=;*7FOKN"UDEBM40,"[S^7'& 2HVDX;)VD&?$W[8?Q5EM%L?AE
MH&I1K)?VTM]XQ2V!,R6$WEKI>DSSX"6RWDT3W=Q&)/M$B0VZ>7Y+RL/S^"@
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MM2@MV;16<F6^@CMY)'#D1[8G4[Y'S0!Y/12*P8!AT.>OL<?TH)"@DYX].30
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M.8[1GZY)Z#@X.,C/.!@$$YK\)?\ @KA\3/%$W[3_ /P2T_92\5?&3QU^SO\
MLC_M5_%K]H73_P!I;XJ?#CXA:I\&O$FMZU\)OA'I?B_X(? 1_C-HUWIFL> M
M%^-GBO4?$-CK,/AW6O#WBWQ':^%AI_A[Q%I,R7,D@!^ZPF)S\AR,DC/(^8!5
MP0"7(SP 4# KYAX8L-P!N)7A,[L-R "XR5(! RC D9!((C,A5L?S.?'7]N#X
MG?LG?%&P_8E_8P_:'^ 5I\+OA'^P/\=_VZE_:/\ VZ_&/Q!_:Q7XES^"?COX
MD^'FG_LL>#/B5:?'CX7ZS+)X$O-%UC3/%'BCQ1XQ^*/C3PIX=_X1K0FTV]U'
M1KZ[OOA'PQ_P4S^-'@?]H7]K_P#:X\+:-X)\(?$']J7]GG_@@9I6E^%_B_J/
MBS5O@?\ L[^*/VS/!NKQ^(_%_C;1]-UOPAK=_P"&OAT/$-R;J.+6O!E[KDT&
MEQ:KKFFH[_9P#^U3SN0-O4G W<XS@-C&,9SD!BZ@'Y20P4\[Y2VTX!([]MV>
MV#C: 2I89)P3@;OY;M<_X*I?MZP>+Q^S9X&\8_L1^/OB_I'_  5%^&_[!%Q^
MTYI'PJ^)M_\  #QUX.^+7[-[_&B/Q1IOPQT3X_7NN:!\5O@UJ-W#X;\<^$+?
MXP^)=#U#Q+I:^%GU/P_'=W?B!-30O^"RW[0&E_\ !1GX<?LP7.M_!GX\_";7
M_CY^TE^RMX\F^&O[,OQ-^%.J:-\6?V9_@IK?CCQ*GA'XF>-_VE?&K^,/&=YX
M_P!!3P]XE\#V_P %K7P;X5TS7+#2O#GQ2^(&IZ?-X@U$ _I^$O'W>^ ,]26
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MFFRC/:P-O2O44^8!C][D$@$ CJ."3Q@@]<YSSC(IP0<Y).1@DA3Z8XQ@ 8X
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MI+2?4%DAN'T[68W=)[6^L9HO*EE,1%U9&'R(HT8.?I5(@A!!' (X4#[S%MH
M.%0$X50,@ 99N2?QG^!WQ&U7X;?$#1;NTO631-9OK/2?$%AEVL[JQNKA85N9
M8C+&OVRRDE\RVO"Q=%+I(L\06-/V820MM'!RI;<!@,,@*Z_,V%;D@$DXP<T
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MU/XICT>_\/1^(Y?B*GAQ?%KZ]_8.IZEHG]L/JYOSI.H7NG/<&SNIX9/X^/\
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M(>*]9T3Q18Q/;W$BKI]W!,)[&%3]9T4 >-/\ O@:WQ9/Q]/P4^$\GQW;1?\
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M0UK6;_2]-0+8:?=:KJ5U:V\=UJ%P)5\&? +X'?#CQAXW^(GP[^"_PH\!>/\
MXH7"7OQ+\<^#/AOX-\+>,/B'="42&?QUXFT+0].USQ9,9,RF;7[R_G65@^[
M;'LE% 'S%<?L<?LDW>B>&?#5[^RK^SE=>&_!GB'Q3XO\&>'KGX%?"^XT'PGX
MM\;.[^-/%'AS26\+26>@>(_&)DDD\4:UI-M::EX@;/\ :U[>/)Y9[R/X%_!=
M?$VD>-5^#'PL3QEH'@*7X3Z'XM'P[\'KXGT;X6RLS3?#72=?72!JNF_#RY9M
M[>#K.Z@\/E<K/I>\FO8:* /F2V_8V_9'MOAFGP6M_P!E3]FZ#X-KXM'CY?A-
M#\"_AA!\,U\<K<1W0\:?\("GA./PNOC![N))_P#A)1I2ZJDL<4_VOS55SSO@
M_P#9"\$>$?VO_C#^V=)K7B'7_B-\4_@M\*/V?M(T>]CTZV\-?#3X5_"[5/$W
MBD>&?!]M9PP7?E>*_&GBK4/$^M2ZA+*\%\EM!8/:VL!6OKVB@ Z#GC []OJ:
M*#R",XR.OI[UD7VI-9W.GP+97EP+Z66(2P0NT-J8[>><O>28VPH_E&*,LP#3
M/&BDEP" :_\ G_/YBD) ZD#OR0./7GZC\Z16W ,.A!/((.>,<$ ^O;L/6JUY
M<0VD$MU<2"&WM89KBXG=MD44$*AY6=MR@%4!92V5 5LX.,@'A'[3FMZ=I7P=
M\7V]Y?V=I<:QIPTW2X)Y8Q<7]Y//"##90EQ)))%$S2RM$C^7$V]L*,'\AH_N
MX   9@%!+;0&( 8GDL.C9YSFO7/C;\4;[XK^-9M480KHFBO=:7X;AM_-,#:>
MEQ<8U*196!>ZU%)=\I*;HHUB10KJR#R11M 4<*JJB#).U$ 55R>2 !@$_,1C
M/.: '4444 %1R(KJ59 ZD@LAVA7PP(#;GC& P5_O$DH/E(SB2B@#3T3Q'X@\
M+:E#K/AO6M3T?5(G,@N[.^N(6F 50XO+<74<-[;,H6.>QG#QW$?)'RC/Z\?
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M+JTUN^\<>'[235Y+6]N$FTZSTZ_.K/J,UE87]I:B\A"J'O/L\#W,H>-V"$J
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M.#%8VNI6DDMS.%7 :\N%@,89PQMT+) 8@[AOT4"J.@ Z=!C&!M&/0 < #@4
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M*SL\GAVT:Q\B[F1<Y'[^Z*[@!NRV<@FON"O%?@+X);P#\+_"VBS)(NHW-O\
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MMCX \.)K%I;[X;77]6EN+2WNITD96GM=,6&.X-KE3Y?VI[8S#;(ORD _)WQ
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MG.YHY9(F;(.'BE>.1.IR P9<@E3SAF4BOWTF(C24\L#$YV@98[1([ #H2=X
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MB%XQT3P_H=K/.[W]I+J5Y",0Z5I*7<8O]1N)V'[M;>)'$2I'*]Q,5CA!^9@
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M_OHXZ<]: C YR.#D$G.XDC.X!01@#"X8^I&." 2T444 %%%% !1110 4444
M%%%% !1110 4444 -;[IZ'USG&,\].?P'7I7PM^VQKE['X=\):!;FW.GWFK7
M%[JA:0&]BFLH2NF"2U203+;71>\E$LL2PN\0CW^850_=3#<I'!R.AZ?CU_\
MK=:_.7]MS14BUKP)KL2E9-1TW5-+NV!PLGV%[>YMFE 3#LGVF1$<D,HP ,=
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M%50 ,]39HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-H>FZA/"C317VJZ?;K&SW*B@#YO\6?\ !//]F#Q;K.N>)YO#?C7P_P"+M?\
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M_!SPU\7;NTBUBZ\-ZKJ/PAM_$UQX:\7?%&VTW2/%\=M?QZAXDU#Q"NF6\O\
M13\&[_P3-\)?AA)\/?"VO>!? ,G@;PI;>!?!/B?P#XI^%WB'PGX4M-#L[3P]
MX9U?X<^-](T#Q?X(U#1-(M[73I_"OB;1=+US1/LPL-0L+:X@>-?3?-0.B,&W
MOT&PC(XSQCD+D!C@A1RV!S0!_*WX&_9N_;"^#'[.WP:L?V9/"G[2W@?XL^/_
M /@CC\5M+^)L=]XB^)LH@_:6\$>.OV8&^&&DZC9>,_%,6B^!?CGI'P]\2_'S
M0?A;:Z3+X+\16VB"]\-Z)J=EI7AG0V\-:/C;]D.;Q?\ L[>)M2?P]\>_C/\
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M!X(]N]'0XP>03GKSP,<_A^7M0 V,D@Y)/W>O^XA_F2?J:?110 4444 %%%%
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? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>fin_001.jpg
<TEXT>
begin 644 fin_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !! 1@# 2(  A$! Q$!_\0
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M099CVKSV_P#$.HWD[.MQ)!&"=D<3%<#W(Y/X_I4M_KTU]I$%FP(9#^]?)_>
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MI^'- %/X/:KJ.I_VU_:%_=7?E^1L^T3-)MSYF<9)QG _*O4:^=? _P#PF/\
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M(XR>%VC/3?$6TN;[P'J5O:6\MQ._E;8HD+LV)4)P!R> 37444 <O\.K2YL?
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MA6.=T;H@((/13\I!P-N!4-Q?7FK>)I](TZ_^Q0:?&DE[+&@:5GD#;(UWJ5
M&XM@]0!CFM74-7M=-FLX)B[7%Y,(8(8UW.Y_B;']U1\S'H /H#S+P6D/C?4K
M?5KN6V34/)GL#%?3VXE;:L3I\K*A<%4.!\V''7H "Y?+J7AB*/4AJMUJ&G1R
M$WT-VBLZ1NPS*C1H#\F22I!&W(&W HHU;3-"M/L]E>2ZI.^H2?9X[8:E<N90
M>&)7S/N*I)8G@#Z@$H ZBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH Y'XG_ /).]5_[8_\ HU*\C^&'_)1-*_[;?^BGHHH
M]S\5_P#(GZW_ ->$_P#Z+:O(_@Q_R.%W_P!>#_\ HR.BB@#T7_FL'_< _P#;
MBN1^-_\ S O^WC_VG110!K_!C_D3[O\ Z_W_ /1<=:_A[_DHGC+_ +<O_11H
MHH /'G_,L_\ 8?M?_9J/B?\ \D[U7_MC_P"C4HHH \Z^#'_(X7?_ %X/_P"C
H(Z]%^)__ "3O5?\ MC_Z-2BB@#SKX,?\CA=_]>#_ /HR.BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
